FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Sebastian, J Huerta, S Blinman, T Livingston, EH AF Sebastian, J Huerta, S Blinman, T Livingston, EH TI Interleukin-10 (IL-10) results in loss of neural cell adhesion molecule (NCAM) expression in colon carcinoma. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Sch Med, Div Gen Surg,Surg Mol Biol Res Lab, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G2793 BP A676 EP A677 DI 10.1016/S0016-5085(98)82773-X PN 2 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089602773 ER PT J AU Solomon, TE Reeve, JR Grandt, D Bussjaeger, L Varga, G Walsh, JH AF Solomon, TE Reeve, JR Grandt, D Bussjaeger, L Varga, G Walsh, JH TI Different receptor subtypes mediate PYY-induced inhibition of gastric acid and pepsin secretion. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Dig Dis Div, Los Angeles, CA USA. CURE, Dig Dis Res Ctr, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G1193 BP A290 EP A291 DI 10.1016/S0016-5085(98)81183-9 PN 2 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089601183 ER PT J AU Wong, H Slice, L Zeng, N Walsh, JH AF Wong, H Slice, L Zeng, N Walsh, JH TI Internalization and recycling of galanin-1 receptors by clathrin-mediated pathway. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, DDRC, CURE, Los Angeles, CA 90073 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G4870 BP A1191 EP A1191 DI 10.1016/S0016-5085(98)84840-3 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089604838 ER PT J AU Wu, SV Yang, M Avedian, D Walsh, JH AF Wu, SV Yang, M Avedian, D Walsh, JH TI Inhibition of cell growth by CCK requires activation of cyclic AMP signaling in HEK-293 cells. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G4872 BP A1192 EP A1192 DI 10.1016/S0016-5085(98)84842-7 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089604844 ER PT J AU Young, SH Ennes, HS Mayer, EA AF Young, SH Ennes, HS Mayer, EA TI Evidence for efferent function of dorsal root ganglion (DRG) neurons onto colonic smooth muscle cells in primary culture. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Dept Med, CURE,Neuroenter Dis Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, CURE,Neuroenter Dis Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G4881 BP A1194 EP A1195 DI 10.1016/S0016-5085(98)84851-8 PN 2 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089604849 ER PT J AU Young, SH Ennes, HS Mayer, EA AF Young, SH Ennes, HS Mayer, EA TI Mechanically insensitive dorsal root ganglion cell (DRG) neurites show chemical excitability. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Dept Med,CURE,Neuroenter Dis Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Dept Physiol,CURE,Neuroenter Dis Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Brain Res Inst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G4882 BP A1195 EP A1195 DI 10.1016/S0016-5085(98)84852-X PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089604855 ER PT J AU Zaninovic, V Gukovskaya, AS Gukovsky, I Kim, S Pandol, SJ AF Zaninovic, V Gukovskaya, AS Gukovsky, I Kim, S Pandol, SJ TI Adhesion molecule ICAM-1 is present and functions in rat pancreatic acinar cells. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G2088 BP A512 EP A512 DI 10.1016/S0016-5085(98)82077-5 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089602077 ER PT J AU Zeng, N Kang, T Athmann, C Wen, Y Walsh, JH Sachs, G AF Zeng, N Kang, T Athmann, C Wen, Y Walsh, JH Sachs, G TI Identification of gastric endocrine cells as the target sites of neuropeptides in regulation of gastric secretion by semi-quantitative RT-PCR and video imaging. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, W Los Angeles VA, DDRC, CURE, Los Angeles, CA 90024 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G4887 BP A1196 EP A1196 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089604858 ER PT J AU Zong, YM Reeve, JR Walsh, JH Gong, PX Ho, FJ Solomon, TE AF Zong, YM Reeve, JR Walsh, JH Gong, PX Ho, FJ Solomon, TE TI Secretin-GLY is a major product of preprosecretin processing in rat small intestine: Identification and quantitation by HPLC and radioimmunoassay. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, CURE, Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR 15 PY 1998 VL 114 IS 4 SU S MA G4892 BP A1197 EP A1197 DI 10.1016/S0016-5085(98)84862-2 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH263 UT WOS:000073089604860 ER PT J AU Ikeuchi, T Sanpei, K Takano, H Sasaki, H Tashiro, K Cancel, G Brice, A Bird, TD Schellenberg, GD Pericak-Vance, MA Welsh-Bohmer, KA Clark, LN Wilhelmsen, K Tsuji, S AF Ikeuchi, T Sanpei, K Takano, H Sasaki, H Tashiro, K Cancel, G Brice, A Bird, TD Schellenberg, GD Pericak-Vance, MA Welsh-Bohmer, KA Clark, LN Wilhelmsen, K Tsuji, S TI A novel long and unstable CAG/CTG trinucleotide repeat on chromosome 17q SO GENOMICS LA English DT Article ID CAG REPEAT; HUMAN GENOME; EXPANSION; INSTABILITY; MECHANISM; DEMENTIA; DISEASE; GENE AB Using the direct identification of repeat expansion and cloning technique, we cloned a novel long CAG/ CTG trinucleotide repeat on chromosome 17. Using radiation hybrid panels, the CAG/CTG repeat was mapped to chromosome 17q. The CAG/CTG repeat is highly polymorphic, with a heterozygosity of 85%, and exhibits a bimodal distribution (allele S, 10-26 repeat units, and allele L, 50-92 repeat units). The CAG/CTG repeat of allele L exhibited intergenerational instabilities, which are more prominent in maternal transmission than in paternal transmission. Analyses of Northern blot and RT-PCR indicate that the repeat is transcribed. Although the size of the CAG/CTG repeat of allele L is within the range of the expanded CAG repeat of disease-causing genes, we did not detect any association of allele L with various neurodegenerative diseases, including frontotemporal dementia and parkinsonism, mapped to 17q21-q23. (C) 1998 Academic Press. C1 Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan. Hokkaido Univ, Sch Med, Dept Neurol, Sapporo, Hokkaido 060, Japan. Hop La Pitie Salpetriere, Federat Neurol, Paris, France. Hop La Pitie Salpetriere, INSERM, U289, Paris, France. VA Puget Sound Hlth Care Syst, Neurol Sect, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA. RP Tsuji, S (reprint author), Niigata Univ, Brain Res Inst, Dept Neurol, 1 Asahimachi, Niigata 951, Japan. EM tsuji@cc.niigata-u.ac.jp FU NINDS NIH HHS [NS26630, NS31153] NR 22 TC 35 Z9 35 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 J9 GENOMICS JI Genomics PD APR 15 PY 1998 VL 49 IS 2 BP 321 EP 326 DI 10.1006/geno.1998.5266 PG 6 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA ZN543 UT WOS:000073656400021 PM 9598323 ER PT J AU Kroll, MH Shandera, WX AF Kroll, MH Shandera, WX TI AIDS-associated Kaposi's sarcoma SO HOSPITAL PRACTICE LA English DT Article AB In less than two decades, the disease mechanisms have been elucidated and hypotheses for innovative treatments have been developed, Our understanding of the sarcoma's pathogenesis has led directly to general knowledge of the physiology and pathology of angiogenesis, Hence, it can be expected that new treatments for all cancer patients may someday emerge from clinical intervention trials for the AIDS-related disease. C1 Baylor Coll Med, Houston, TX 77030 USA. RP Kroll, MH (reprint author), VA Med Ctr, Houston, TX 77211 USA. NR 6 TC 4 Z9 4 U1 0 U2 0 PU MCGRAW HILL HEALTHCARE PUBLICATIONS PI MINNEAPOLIS PA 4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000 USA SN 8750-2836 J9 HOSP PRACT JI Hosp. Pract. PD APR 15 PY 1998 VL 33 IS 4 BP 85 EP + PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA ZH329 UT WOS:000073097100010 PM 9562835 ER PT J AU Pratley, RE Thompson, DB Prochazka, M Baier, L Mott, D Ravussin, E Sakul, H Ehm, MG Burns, DK Foroud, T Garvey, WT Hanson, RL Knowler, WC Bennett, PH Bogardus, C AF Pratley, RE Thompson, DB Prochazka, M Baier, L Mott, D Ravussin, E Sakul, H Ehm, MG Burns, DK Foroud, T Garvey, WT Hanson, RL Knowler, WC Bennett, PH Bogardus, C TI An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article DE type 2 diabetes mellitus; glucose tolerance; insulin secretion; insulin action; genetics ID DEPENDENT DIABETES-MELLITUS; SUSCEPTIBILITY LOCUS; QUANTITATIVE TRAITS; VARIANCE-COMPONENTS; INSULIN-RESISTANCE; GENETIC-LINKAGE; WIDE SEARCH; MUTATIONS; OBESITY; NIDDM AB Type 2 diabetes mellitus is a common chronic disease that is thought to have a substantial genetic basis. Identification of the genes responsible has been hampered by the complex nature of the syndrome. Abnormalities in insulin secretion and insulin action predict the development of type 2 diabetes and are, themselves, highly heritable traits. Since fewer genes may contribute to these precursors of type 2 diabetes than to the overall syndrome, such genes may be easier to identify. We, therefore, undertook an autosomal genomic scan to identify loci linked to prediabetic traits in Pima Indians, a population with a high prevalence of type 2 diabetes. 363 nondiabetic Pima Indians were genotyped at 516 polymorphic microsatellite markers on all 22 autosomes, Linkage analyses were performed using three methods (single-marker, nonparametric multipoint [MAPMAKER/SIBS], and variance components multipoint). These analyses provided evidence for linkage at several chromosomal regions, including 3q21-24 linked to fasting plasma insulin concentration and in vivo insulin action, 4p15-q12 linked to fasting plasma insulin concentration, 9q21 linked to 2-h insulin concentration during oral glucose tolerance testing, and 22q12-13 linked to fasting plasma glucose concentration. These results suggest loci that may harbor genes contributing to type 2 diabetes in Pima Indians. None of the linkages exceeded a LOD score of 3.6 (a 5% probability of occurring in a genome-wide scan). These findings must, therefore, be considered tentative until extended in this population or replicated in others. C1 NIDDKD, Clin Diabet & Nutr Sect, NIH, Phoenix, AZ 85016 USA. NIDDKD, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ 85016 USA. Sequana Therapeut Inc, Dept Stat Genet, La Jolla, CA 92037 USA. Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA. Indiana Univ, Sch Med, Dept Med Genet, Indianapolis, IN 46202 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC 29425 USA. RP Pratley, RE (reprint author), NIDDKD, Clin Diabet & Nutr Sect, NIH, 4212 N 16Th St, Phoenix, AZ 85016 USA. RI Hanson, Robert/O-3238-2015 OI Hanson, Robert/0000-0002-4252-7068 FU NCRR NIH HHS [1P41-RR-03655]; NIDDK NIH HHS [DK-47461] NR 43 TC 173 Z9 183 U1 0 U2 1 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR 15 PY 1998 VL 101 IS 8 BP 1757 EP 1764 DI 10.1172/JCI1850 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ZJ234 UT WOS:000073193000027 PM 9541507 ER PT J AU Bozkurt, B Kribbs, SB Clubb, FJ Michael, LH Didenko, VV Hornsby, PJ Seta, Y Oral, H Spinale, FG Mann, DL AF Bozkurt, B Kribbs, SB Clubb, FJ Michael, LH Didenko, VV Hornsby, PJ Seta, Y Oral, H Spinale, FG Mann, DL TI Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats SO CIRCULATION LA English DT Article DE heart failure; remodeling; contractility; cytokines ID CHRONIC HEART-FAILURE; SUPRAVENTRICULAR TACHYCARDIA; FACTOR CHALLENGES; CONSCIOUS DOGS; NITRIC-OXIDE; INFUSION; ENDOTHELIN; RECEPTORS; ENDOTOXIN; CYTOKINES AB Background-Although patients with heart failure express elevated circulating levels of tumor necrosis factor-alpha (TNF-alpha) in their peripheral circulation, the structural and functional effects of circulating levels of pathophysiologically relevant concentrations of TNF-alpha on the heart are not known. Methods and Results-Osmotic infusion pumps containing either diluent or TNF-alpha were implanted into the peritoneal cavity of rats. The rate of TNF-alpha infusion was titrated to obtain systemic levels of biologically active TNF-alpha comparable to those reported in patients with heart failure (approximate to 80 to 100 U/mL), and the animals were examined serially for 15 days. Two-dimensional echocardiography was used to assess changes in left ventricular (LV) structure (remodeling) and LV function. Video edge detection was used to assess isolated cell mechanics, and standard histological techniques were used to assess changes in the volume composition of LV cardiac myocytes and the extracellular matrix, The reversibility of cytokine-induced effects was determined either by removal of the osmotic infusion pumps on day 15 or by treatment of the animals with a soluble TNF-alpha antagonist (TNFR:Fc). The results of this study show that a continuous infusion of TNF-alpha led to a time-dependent depression in LV function, cardiac myocyte shortening, and LV dilation that were at least partially reversible by removal of the osmotic infusion pumps or treatment of the animals with TNFR:Fc. Conclusions-These studies suggest that pathophysiologically relevant concentrations of TNF-alpha are sufficient to mimic certain aspects of the phenotype observed in experimental and clinical models of heart failure. C1 Vet Adm Med Ctr, Dept Med, Cardiol Sect, Houston, TX 77211 USA. Baylor Coll Med, Huffington Ctr Aging, Dept Cell Biol, Houston, TX 77030 USA. Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. Texas Heart Inst, Houston, TX 77025 USA. RP Mann, DL (reprint author), VA Med Ctr, Cardiol Res 151C, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [P50-HL-06H, R29-HL-52910] NR 55 TC 541 Z9 583 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD APR 14 PY 1998 VL 97 IS 14 BP 1382 EP 1391 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA ZG811 UT WOS:000073042200010 PM 9577950 ER PT J AU Shuler, CL Allison, N Holcomb, S Harlan, M McNeill, J Robinett, G Bagby, SP AF Shuler, CL Allison, N Holcomb, S Harlan, M McNeill, J Robinett, G Bagby, SP TI Accuracy of an automated blood pressure device in stable inpatients - Optimum vs routine use SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID HYPERTENSION AB Background: Despite widespread use of the automated blood pressure (BP) device (IVAC model +200, IVAC Corporation, San Diego, Calif), there is little formal validation in the literature on its accuracy. Objective: To assess the accuracy of the IVAC 4200 device, both under standardized conditions and as routinely used by ward staff, compared with the true indirect BP measured by mercury manometer (MM). Methods: One hundred forty-five stable inpatients were randomly selected for BP measurements by 3 randomly ordered protocols: (1) MM performed by certified investigators, (2) IVAC 4200 BP performed by trained investigators (research automated [RA]), and (3) IVAC 4200 BP performed by ward personnel (ward automated [WA]). Results: For RA compared with MM ("true" indirect BP), 59% of systolic and 54% of diastolic readings were within 5 mm Hg and 83% of systolic and 86% of diastolic were within 10 mm Hg for a British Hypertension Society grade C for both. For WA compared with MM, 40% of systolic and 50% of diastolic readings were within 5 mm Hg and 70% of systolic and 80% of diastolic readings were within 10 mm Hg for British Hypertension Society grades D and C, respectively. The presence of arrhythmias and/or low K5 values (fifth phase of Korotkoff sounds <30 mm Hg) significantly increased the inaccuracy for diastolic values. Inappropriate cuff selection significantly increased inaccuracy of systolic BP (WA vs MM). Conclusions: The IVAC 4200 yields substandard estimates of systolic and diastolic BP even under standardized, thus optimum conditions. The presence of arrythmias or low K5 values and the selection of inappropriate cuff size by the ward staff also contributed to inaccuracy. C1 Dept Vet Affairs, Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Bagby, SP (reprint author), Portland Vet Affairs Med Ctr, Dept Med, 111C,3710 SW Vet Hosp Rd,POB 1034, Portland, OR 97207 USA. NR 12 TC 23 Z9 23 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 13 PY 1998 VL 158 IS 7 BP 714 EP 721 DI 10.1001/archinte.158.7.714 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA ZH209 UT WOS:000073083800005 PM 9554677 ER PT J AU Pahlavani, MA Harris, MD Richardson, A AF Pahlavani, MA Harris, MD Richardson, A TI Activation of p21(ras)/MAPK signal transduction molecules decreases with age in mitogen-stimulated T cells from rats SO CELLULAR IMMUNOLOGY LA English DT Article ID PROTEIN-TYROSINE KINASE; MURINE LYMPHOCYTES-T; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; MAP KINASES; OLD MICE; PHOSPHORYLATION; RAS; PROLIFERATION; EXPRESSION AB Signal transduction is ubiquitously involved in the initiation of physiological signals that lead to growth and proliferation of cells. The signaling cascade mediated by the mitogen-activated protein kinase (MAPK) is considered essential for T cell growth and function. Therefore, it was of interest to determine the influence of age on the induction of MAPK in mitogen-activated T cells. T cells from young (4-6 months) and old (24-26 months) rats responded to concanavalin A (Con A) stimulation by increasing MAPK, c-jun amino terminal kinase (JNK), and p21(ras) activities. The time course of induction of MAPK/JNK and p21(ras) activities was similar in T cells isolated from young and old rats. The induction of JNK activity did not change significantly with age; however, the induction of MAPK and p21(ras) activities was significantly less (50 to 65%) in T cells from old rats than in T cells from young rats. Although the relative protein levels of p42 and p44 MAPK did not change with age, the proportion of the phosphorylated p44 MAPK decreased with age. In addition, it was found that the in vitro kinase activities of the T cell receptor-associated protein tyrosine kinase Lck (p56(Lck)) and ZAP-70 but not Fyn (p59(Fyn)) were lower in T cells from old rats than in T cells from young rats. The decline in activities of these signaling molecules with age was not associated with changes in their corresponding protein levels. Thus, our results demonstrate that aging alters the activation of the signal transduction cascade that leads to T cell activation. (C) 1998 Academic Press. C1 Audie L Murphy Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. RP Pahlavani, MA (reprint author), Audie L Murphy Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [AG00677, AG14088] NR 76 TC 37 Z9 38 U1 0 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0008-8749 J9 CELL IMMUNOL JI Cell. Immunol. PD APR 10 PY 1998 VL 185 IS 1 BP 39 EP 48 DI 10.1006/cimm.1998.1274 PG 10 WC Cell Biology; Immunology SC Cell Biology; Immunology GA ZU259 UT WOS:000074178700004 PM 9636681 ER PT J AU Bartzokis, G Altshuler, LL Greider, T Curran, J Keen, B Dixon, WJ AF Bartzokis, G Altshuler, LL Greider, T Curran, J Keen, B Dixon, WJ TI Reliability of medial temporal lobe volume measurements using reformatted 3D images SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE magnetic resonance imaging; methodology; temporal horn; hippocampus; amygdala ID ALZHEIMERS-DISEASE; HIPPOCAMPAL-FORMATION; COMPUTED-TOMOGRAPHY; BRAIN STRUCTURES; LONGITUDINAL CT; MR IMAGES; SCHIZOPHRENIA; ATROPHY; ABNORMALITIES; AMYGDALA AB The study assessed whether standardizing the angle of image display and controlling for head position in three planes affects the scan-rescan reliability of medial temporal lobe volume measures when very thin (1.5 mm) slices are used. Five volunteers were scanned two times oil consecutive days. A three-dimensional MRI sequence acquired whole brain data in 1.4 mm thick coronal slices. The data were displayed as 1.5 mm thick images and were rated both in the originally acquired coronal plane, and after reformatting to correct for head tilt and display the brain in the coronal plane perpendicular to the long axis of the left anterior hippocampus. One rater measured five brain regions (temporal lobe, anterior and posterior hippocampus, amygdala, and temporal horn) on the left and right sides of the two non-reformatted and two reformatted scans to obtain inter-scan variance. Furthermore, most scans were remeasured, to obtain 'reread' variances. All data were log-transformed in order to produce comparable variability across brain regions of different sizes. For all the regions, except the temporal horn, the non-reformatted scans showed significantly larger scan-rescan variability than the reformatted scans. A typical standard deviation for a non-reformatted pair of scans was 0.10, corresponding to 26% error, while a typical value for a reformatted pair of scans was 0.04, corresponding to 10% error. For all the regions, the reread data (intra-rater reliability) gave similar results for both reformatted and non-reformatted images with similar standard deviations (typical value for reread standard deviation was 0.020, corresponding to 5% error). The data suggest that, even when very thin slices are acquired, volume measurement accuracy of gray matter structures in the temporal lobe is considerably improved by controlling for image orientation in three planes. For these structures, the sample size needed to detect a small (5%) within-subject volume change would be halved if reformatted images were used. Image contrast is an additional important factor since the reformatted T-1 weighted images used in this study, which have suboptimal CSF/brain contrast, worsened measurement accuracy in the temporal horn. (C) 1998 Elsevier Science Ireland Ltd. C1 W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90074 USA. Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA 90074 USA. Gen Elect Med Syst, Milwaukee, WI 53188 USA. RP Bartzokis, G (reprint author), W Los Angeles Vet Affairs Med Ctr, Res Serv, 11301 Wilshire Blvd,Mail Code B-151H,Bldg 210,Rm, Los Angeles, CA 90073 USA. RI Bartzokis, George/K-2409-2013 NR 60 TC 52 Z9 53 U1 2 U2 4 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD APR 10 PY 1998 VL 82 IS 1 BP 11 EP 24 DI 10.1016/S0925-4927(98)00007-9 PG 14 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ZT798 UT WOS:000074128500002 PM 9645547 ER PT J AU van Kammen, DP Petty, F Kelley, ME Kramer, GL Barry, EJ Yao, JK Gurklis, JA Peters, JL AF van Kammen, DP Petty, F Kelley, ME Kramer, GL Barry, EJ Yao, JK Gurklis, JA Peters, JL TI GABA and brain abnormalities in schizophrenia SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE ventricle-brain ratio (VBR); prefrontal sulcus; computed tomography; plasma; CSF ID GAMMA-AMINOBUTYRIC-ACID; MATTER VOLUME DEFICITS; POST-MORTEM BRAINS; PREFRONTAL CORTEX; BASAL GANGLIA; UPTAKE SITES; FUNCTIONAL ARCHITECTURE; ANTIPSYCHOTIC-DRUGS; AFFECTIVE-DISORDER; NUCLEUS-ACCUMBENS AB Some recent autopsy studies indicate that alpha-aminobutyric acid (GABA) function is decreased in brain areas that involve some of the well-described structural changes observed in schizophrenia. The current study examined the relationship between CSF and plasma GABA levels and brain structural measures in schizophrenia. Sixty-two drug-free, physically healthy male patients with schizophrenia (DSM-IIIR) were evaluated for plasma and CSF GABA, as well as brain structural measures on CT scans. Plasma levels of GABA were associated with prefrontal sulcal widening and VBRs, but not global sulcal widening in the schizophrenic patients. CSF GABA measures were not associated with brain structural measures, but were associated with age and age of onset. The significant relationship between plasma GABA, but not CSF GABA, and specific brain morphology measures in schizophrenic patients suggests that if GABA transmission is impaired in schizophrenia, it is a local, but not global, phenomenon. (C) 1998 Elsevier Science Ireland Ltd. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. VA N Texas Healthcare Syst, Dallas, TX 75216 USA. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75216 USA. RP van Kammen, DP (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM dpvk@pitt.edu FU NIMH NIH HHS [MH-41115, MH-44841] NR 86 TC 19 Z9 19 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD APR 10 PY 1998 VL 82 IS 1 BP 25 EP 35 DI 10.1016/S0925-4927(98)00006-7 PG 11 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ZT798 UT WOS:000074128500003 PM 9645548 ER PT J AU Huang, MS Adebanjo, O Moonga, BS Goldstein, S Lai, FA Lipschitz, DA Zaidi, M AF Huang, MS Adebanjo, O Moonga, BS Goldstein, S Lai, FA Lipschitz, DA Zaidi, M TI Upregulation of functional ryanodine receptors during in vitro aging of human diploid fibroblasts SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article ID INTRACELLULAR CALCIUM; INOSITOL TRISPHOSPHATE; ALZHEIMER DONORS; AGE; SENESCENCE; CHANNEL; MUSCLE; CELLS AB We demonstrate for the first time that cellular aging in vitro is accompanied by a dramatic elevation in the levels of ryanodine receptor-bearing Ca2+ channels. These channels normally reside within microsomal membranes and gate Ca2+ release from intracellular stores. We therefore measured cytosolic Ca2+ levels in 'young' (30 mean population doublings, MPDs) and 'senescent' (53 to 58 MPDs) human diploid fibroblasts (HDFs). Application of the known. ryanodine receptor modulators, caffeine or cyclic adenosine diphosphate-ribose (cADPr), triggered cytosolic Ca2+ signals in both young and senescent cells. The signal magnitude however was significantly greater in senescent compared with young HDFs. In parallel, incubation with a highly specific anti-ryanodine receptor antiserum resulted in specific immunofluorescence only in senescent HDPs. We envisage that elevated levels of functional ryanodine receptors may underlie the defective Ca2+ handling and cellular degeneration that occurs with aging. (C) 1998 Academic Press. C1 Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA. Vet Affairs Med Ctr, Ctr Osteoporosis & Skeletal Aging, Philadelphia, PA 19104 USA. Allegheny Univ Hlth Sci, Med Coll Penn Hahnemann Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. Natl Inst Med Res, MRC, London NW7 1AA, England. RP Huang, MS (reprint author), Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA. FU NIA NIH HHS [R01 AG14917-02] NR 18 TC 5 Z9 5 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 7 PY 1998 VL 245 IS 1 BP 50 EP 52 DI 10.1006/bbrc.1998.8392 PG 3 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA ZK045 UT WOS:000073279400009 PM 9535781 ER PT J AU Shuster, E AF Shuster, E TI The significance of the Nuremberg code - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Shuster, E (reprint author), Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 2 PY 1998 VL 338 IS 14 BP 996 EP 996 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA ZE776 UT WOS:000072829800027 ER PT J AU Ling, W Charuvastra, C Collins, JF Batki, S Brown, LS Kintaudi, P Wesson, DR McNicholas, L Tusel, DJ Malkerneker, U Renner, JA Santos, E Casadonte, P Fye, C Stine, S Wang, RIH Segal, D AF Ling, W Charuvastra, C Collins, JF Batki, S Brown, LS Kintaudi, P Wesson, DR McNicholas, L Tusel, DJ Malkerneker, U Renner, JA Santos, E Casadonte, P Fye, C Stine, S Wang, RIH Segal, D TI Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial SO ADDICTION LA English DT Article ID OPIOID DEPENDENCE; METHADONE-MAINTENANCE; DETOXIFICATION; PHARMACOLOGY; BLOCKADE; ABUSE AB Aims. To evaluate the safety and efficacy of an 8 mg/day sublingual dose of buprenorphine in the maintenance treatment of heroin addicts by comparison with a 1 mg/day dose over a 16-week treatment period. As a secondary objective, outcomes were determined concurrently for patients treated with two other dose levels. Design. Patients were randomized to four dosage groups and treated double-blind. Setting. Twelve outpatient opiate maintenance treatment centers throughout the United States. Participants. Two hundred and thirty-nine women and 497 men who met the DSM-III-R criteria for opioid dependence and were seeking treatment. Intervention. Patients received either 1, 4, 8 or 16 mg/day of buprenorphine and were treated in the usual clinical context, including a 1-hour weekly clinical counseling session. Measurement. Retention in treatment, illicit opioid use as determined by urine toxicology, opioid craving and global ratings by patient and staff. Safety outcome measures were provided by clinical monitoring and by analysis of the reported adverse events. Findings. Outcomes in the 8 mg group were significantly better than in the 1 mg group in all four efficacy domains. No deaths occurred in either group. The 8 mg group did not show an increase in the frequency of adverse events. Most reported adverse effects were those commonly seen in patients treated with opioids. Conclusions. The findings support the safety and efficacy of buprenorphine and suggest that an adequate dose of buprenorphine will be a useful addition to pharmacotherapy. C1 Los Angeles Addict Treatment Res Ctr, Los Angeles, CA 90025 USA. San Francisco Gen Hosp, San Francisco, CA USA. Med Coll Wisconsin, Milwaukee, WI USA. Univ Penn, Philadelphia, PA 19104 USA. US Dept Vet Affairs, Washington, DC 20420 USA. US Natl Inst Drug Abuse, Lexington, KY USA. RP Ling, W (reprint author), Los Angeles Addict Treatment Res Ctr, 10350 Santa Monica Blvd,Suite 340, Los Angeles, CA 90025 USA. OI Stine, Susan/0000-0001-5426-4448 NR 32 TC 225 Z9 229 U1 0 U2 9 PU CARFAX PUBL CO PI ABINGDON PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE SN 0965-2140 J9 ADDICTION JI Addiction PD APR PY 1998 VL 93 IS 4 BP 475 EP 486 DI 10.1046/j.1360-0443.1998.9344753.x PG 12 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA ZJ556 UT WOS:000073228600003 PM 9684386 ER PT J AU Steigh, C Glassman, PA Fajardo, F AF Steigh, C Glassman, PA Fajardo, F TI Physician and dietitian prescribing of a commercially available oral nutritional supplement SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID PROTEIN-CALORIE UNDERNUTRITION; DIETARY-SUPPLEMENT; ELDERLY PATIENTS; MALNUTRITION; MORTALITY; INTERVENTION; POPULATION; PREVALENCE AB We examined whether a policy change transferring prescribing privileges for oral nutritional supplements to dietitians resulted in fewer inappropriate outpatient prescriptions. This was a pre/post study design using a retrospective review of physician and dietitian prescribing for ambulatory patients during two separate time periods: physician prescribing, October to December, 1994; dietitian prescribing, April to June, 1995. Inappropriate prescriptions during each period were defined as those given to patients with normal nutritional status or with a contraindication to a high-energy, electrolyte-containing solution. The study was conducted in outpatient clinics at a Veterans Affairs teaching hospital. We found that dietitians gave fewer prescriptions to outpatients who were not malnourished or to outpatients who had a contraindication to receiving a supplement (11% vs 34%; P = 0.002). In addition, dietitians more often completed relevant laboratory assessments (75% vs 43%; P = 0.001: and more frequently arranged follow-up dietetic evaluations (84% vs 30%, P < 0.001) for ambulatory patients receiving supplements, We conclude that transferring nutritional supplement prescribing privileges to dietitians led to fewer inappropriate outpatient prescriptions and to more comprehensive nutritional assessments, as measured by relevant laboratory use and dietetic follow-up. Physicians more frequently prescribed supplements to outpatients who were not malnourished or who had contraindications to receiving supplements. Our results suggest that physicians would benefit from assistance with and/or education concerning oral nutritional supplements. C1 W Los Angeles Vet Affairs Med Ctr, Div Gen Internal Med 1116, Los Angeles, CA 90073 USA. RP Glassman, PA (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Gen Internal Med 1116, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 19 TC 5 Z9 6 U1 0 U2 1 PU AMER MED PUBLISHING, M W C COMPANY PI OLD BRIDGE PA 1816 ENGLISHTOWN RD, STE 101, OLD BRIDGE, NJ 08857 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 1998 VL 4 IS 4 BP 567 EP 572 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ZN869 UT WOS:000073691600006 PM 10179915 ER PT J AU Gulley, ML Nicholls, JM Schneider, BG Amin, MB Ro, JY Geradts, J AF Gulley, ML Nicholls, JM Schneider, BG Amin, MB Ro, JY Geradts, J TI Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; P16(INK4A) EXPRESSION; HUMAN CANCERS; P16 GENE; HEAD; INACTIVATION; HETEROZYGOSITY; METHYLATION AB The p16/MTS1 gene is altered by deletion, mutation, or hypermethylation in a wide variety of human cancers. As a result of deficient p16 protein, these cancers lack a critical mechanism for halting G1/S cell cycle progression. In the current study, 59 cases of nasopharyngeal carcinoma were evaluated for expression of the p16 tumor suppressor protein by immunohistochemical analysis of paraffin-embedded tissue. There was no detectable p16 in 38/59 cases (64%), which implies a very high rate of p16 inactivation in this type of cancer. On the other hand, the retinoblastoma gene product, which also regulates the G1 to S phase transition of the cell cycle, was consistently expressed in nasopharyngeal carcinomas by immunohistochemical analysis. These results implicate p16 inactivation but not Rb alteration in the stepwise progression of nasopharyngeal carcinogenesis. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Dept Pathol, San Antonio, TX 78284 USA. Univ Hong Kong, Hong Kong, Hong Kong. Louisiana State Univ, Med Ctr, New Orleans, LA USA. Stanley Scott Canc Ctr, New Orleans, LA USA. Henry Ford Hosp, Detroit, MI 48202 USA. Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA. Univ N Carolina, Chapel Hill, NC USA. RP Gulley, ML (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCI NIH HHS [P30-CA54174] NR 26 TC 44 Z9 49 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BALTIMORE PA 428 EAST PRESTON ST, BALTIMORE, MD 21202-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 1998 VL 152 IS 4 BP 865 EP 869 PG 5 WC Pathology SC Pathology GA ZF714 UT WOS:000072924700003 PM 9546345 ER PT J AU Chandrasekar, B Melby, PC Troyer, DA Colston, JT Freeman, GL AF Chandrasekar, B Melby, PC Troyer, DA Colston, JT Freeman, GL TI Temporal expression of pro-inflammatory cytokines and inducible nitric oxide synthase in experimental acute chagasic cardiomyopathy SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID TUMOR-NECROSIS-FACTOR; TRYPANOSOMA-CRUZI; FACTOR-ALPHA; CARDIOVASCULAR-RESPONSE; MYOCARDIAL-FUNCTION; CONSCIOUS DOGS; INDUCTION; ENDOTOXIN; INTERLEUKIN-1; DISEASE AB To characterize the kinetics of myocardial cytokine and inducible nitric oxide synthase (iNOS) expression in acute Chagasic cardiomyopathy, we studied a rat model of acute Trypanosoma cruzi infection, Rats were euthanized 36 hours and 5, 10, and 15 days after infection, and hearts were collected for histology, mRNA, and protein analyses, Histological analysis of myocardium showed a progressive increase in the number of amastigotes and mononuclear inflammatory cells, Organisms were first detected 5 days after intraperitoneal inoculation as isolated nests and became numerous by day 15. Northern blot analysis of total RNA revealed no signal for interleukin (IL)-1 beta or tumor necrosis factor (TNF)-alpha and a weak signal for IL-6 in control hearts, High levels of expression for the three genes mere detected in the infected animals at 36 hours after infection, Although IL-1 beta and IL-6 levels increased steadily up to 10 days, TNF-alpha levels were the highest at 5 days, remained high at 10 days, and declined thereafter, Western blot analysis showed similar results to that of mRNA expression, No signal was detected for iNOS in the controls, but both its mRNA and protein were found in the infected animals, with levels being highest at 15 days after infection, Immunohistochemistry revealed no iNOS immunoreactivity in uninfected animals, but intense iNOS staining was detected in blood vessels of infected animals, which decreased progressively with period of infection, Positive staining for iNOS in cardiomyocytes was first detected at 36 hours after infection Cat a time when there was no histological inflammatory reaction), which steadily increased, being the highest at 15 days after infection, These results indicate that, in addition to mechanical damage by T. cruzi, substantial pro-inflammatory cytokine production within the myocardium is Likely to participate in the pathophysiology of acute Chagasic cardiomyopathy. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Freeman, GL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 49 TC 55 Z9 56 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BALTIMORE PA 428 EAST PRESTON ST, BALTIMORE, MD 21202-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 1998 VL 152 IS 4 BP 925 EP 934 PG 10 WC Pathology SC Pathology GA ZF714 UT WOS:000072924700011 PM 9546353 ER PT J AU Koopmans, SJ Mandarino, L DeFronzo, RA AF Koopmans, SJ Mandarino, L DeFronzo, RA TI Time course of insulin action on tissue-specific intracellular glucose metabolism in normal rats SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE lipid metabolism; insulin resistance; glycogen synthesis; glycolysis; hepatic glucose production ID DIABETIC RATS; GLYCOGEN-SYNTHESIS; IN-VIVO; CONSCIOUS RATS; HUMAN MUSCLE; HYPERGLYCEMIA; RESISTANCE; CLAMP; LIVER; STIMULATION AB We investigated the time course of insulin action in conscious rats exposed to constant physiological hyperinsulinemia (similar to 100 mU/l) while maintaining euglycemia (similar to 100 mg/dl) for 0, 0.5, 2, 4, 8, or 12 h. [3-H-3]glucose was infused to quantitate whole body glucose disposal (rate of disappearance, R-d), glycolysis (generation of (H2O)-H-3 in plasma), hepatic glucose production (HGP), and skeletal muscle and liver glycogen synthesis ([3-H-3]glucose incorporation into glycogen and time-dependent change in tissue glycogen concentration). The basal R-d, which equals HGP, was 6.0 +/- 0.3 mg.kg(-1).min(-1). With increased duration of hyperinsulinemia from 0 to 0.5 to 2 to 4 h, R-d increased from 6.0 +/- 0.3 to 21.0 +/- 1.1 to 24.1 +/- 1.5 to 26.6 +/- 0.6 mg.kg(-1).min(-1) (P < 0.05 for 2 and 4 h vs. 0.5 h). During the first 2 h the increase in R-d was explained by parallel increases in glycolysis and glycogen synthesis. From 2 to 4 h the further increase in R-d was entirely due to an increase in glycolysis without change in glycogen synthesis. From 4 to 8 to 12 h of hyperinsulinemia, R-d decreased by 19% from 26.6 +/- 0.6 to 24.1 +/- 1.1 to 21.6 +/- 1.8 mg.kg(-1).min(-1) (P < 0.05 for 8 h vs. 4 h and 12 h vs. 8 h). The progressive decline in R-d, in the face of constant hyperinsulinemia, occurred despite a slight increase (8-14%) in glycolysis and was completely explained by a marked decrease (64%) in muscle glycogen synthesis. In contrast, liver glycogen synthesis increased fourfold, indicating an independent regulation of muscle and liver glycogen synthesis by long-term hyperinsulinemia. In the liver, during the entire 12-h period of insulin stimulation, the contribution of the direct (from glucose) and the indirect (from C-3 fragments) pathways to net glycogen formation remained constant at 77 +/- 5 and 23 +/- 5%, respectively. HGP remained suppressed throughout the 12-h period of hyperinsulinemia. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Diabet, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Affairs Hosp, San Antonio, TX 78284 USA. Leiden Univ Hosp, Dept Endocrinol & Metab Dis, NL-2333 AA Leiden, Netherlands. RP DeFronzo, RA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Diabet, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 34 TC 16 Z9 16 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD APR PY 1998 VL 274 IS 4 BP E642 EP E650 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA ZG359 UT WOS:000072993700010 PM 9575825 ER PT J AU McGlynn, EA Asch, SM AF McGlynn, EA Asch, SM TI Developing a clinical performance measure SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article; Proceedings Paper CT Conference on Prevention in Managed Care - Joining Forces for Value and Quality CY JAN 15-16, 1997 CL ATLANTA, GEORGIA DE quality assessment measurement; health care; chronic disease; task performance and analysis ID HYPERTENSION; POPULATION AB Background: Clinical performance measurement is an increasingly important way for public and private purchasers alike to compare the value of health services provided by competing health delivery systems. The widespread use of performance measures has increased the demand for development of new measures that cover previously unevaluated aspects of care. Methods: Four steps required to develop a clinical performance measure that is suitable for-making comparisons among health delivery systems are discussed: (1) choosing clinical areas to measure, (2) selecting performance indicators within each area, (3) designing specifications for consistent implementation of a measure, and (4) evaluating the scientific strength of a measure, Results: The application of these steps to developing measures of quality for hyper-tension is provided, with an emphasis on a measure of adequacy of control of blood pressure. Conclusions: Developing useful clinical performance measures requires careful attention to methodologic issues, Following the steps outlined in this paper should enhance the quality of future measurement development. (C) 1998 American Journal of Preventive Medicine. C1 RAND, Hlth Program, Santa Monica, CA 90401 USA. RAND Hlth, Ctr Res Qual & Hlth Care, Santa Monica, CA 90401 USA. W Los Angeles Vet Adm, Hlth Serv & Dev, Santa Monica, CA 90401 USA. RP McGlynn, EA (reprint author), RAND, Hlth Program, 1700 Main St, Santa Monica, CA 90401 USA. NR 12 TC 124 Z9 128 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 1998 VL 14 IS 3 SU S BP 14 EP 21 DI 10.1016/S0749-3797(97)00032-9 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA ZG459 UT WOS:000073004700005 PM 9566932 ER PT J AU Vollmer, WM Osborne, ML Buist, AS AF Vollmer, WM Osborne, ML Buist, AS TI 20-year trends in the prevalence of asthma and chronic airflow obstruction in an HMO SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article ID HEALTH MAINTENANCE ORGANIZATION; ACUTE CHILDHOOD ASTHMA; GENDER DIFFERENCES; MORTALITY; HOSPITALIZATION; CARE; POPULATION; MORBIDITY; SEVERITY; DEATHS AB Although asthma is on the rise in the United States and elsewhere, data on age-sex-specific patterns of change in various types of health care utilization are scarce. We report on 20-yr trends in the treated prevalence of asthma among members of a large health maintenance organization. Data are presented separately for each of six age-sex categories, and include both the treated prevalence of asthma as well as the treated prevalence of the broader category of chronic airflow obstruction (CAO), defined as asthma, chronic bronchitis, or emphysema. During the period 1967-1987 the treated prevalence of asthma and CAO increased significantly in all age-sex categories except males aged 65 and older. These patterns are in contrast to previous studies of this population that showed that increases in asthma hospitalizations and hospital-based episodes of care were limited primarily to young boys. Not only do these findings support other evidence of a real increase in asthma prevalence, but they also highlight the risks associated with drawing inferences about changing disease epidemiology based on a single type of health care utilization. C1 Kaiser Permanente Ctr Hlth Res, Portland, OR 97227 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Vollmer, WM (reprint author), Kaiser Permanente Ctr Hlth Res, 3800 N Kaiser Ctr Dr, Portland, OR 97227 USA. EM vollmerwi@chr.mts.kpnw.org FU NHLBI NIH HHS [HL41039] NR 35 TC 75 Z9 77 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR PY 1998 VL 157 IS 4 BP 1079 EP 1084 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA ZG643 UT WOS:000073024500012 PM 9563722 ER PT J AU Asch, S Leake, B Anderson, R Gelberg, L AF Asch, S Leake, B Anderson, R Gelberg, L TI Why do symptomatic patients delay obtaining care for tuberculosis? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article ID IMMUNODEFICIENCY-VIRUS INFECTION; SEEKING CARE; MORTALITY; DIAGNOSIS; ACCESS AB The resurgence of tuberculosis (TB) has coincided with deteriorating access to care for high-risk populations. We sought to determine what perceived access barriers delayed symptomatic TB patients from obtaining care. In order to do this, we conducted a survey in Los Angeles County, California, using a consecutive sample of patients with active TB as confirmed by the county TB control authority. The measures used in the study were a self-reported delay in seeking care of more than 60 d from symptom onset, a period sufficient to cause skin-test conversion in exposed contacts, and self-reported access barriers. The county TB registry provided supplementary clinical data. We found that one in five of the 248 symptomatic respondents (response rate: 60%) delayed obtaining care for > 60 d (mean = 74 d, SD = 216 d). During the delay, patients exposed an average of eight contacts. As compared with the rest of the sample, delay was more common in those who were unemployed (25% versus 14%), concerned about cost (27% versus 14%), anticipated prolonged waiting-room time (26% versus 14%), believed they could treat themselves (31% versus 14%), anticipated difficulty in getting an appointment (28% versus 16%), were uncertain about where to get care (33% versus 16%), and feared immigration authorities (47% versus 18%) (p < 0.05). Logistic regression revealed that uncertainty about where to get care, unemployment, and belief in the efficacy of self-treatment independently predicted delay > 60 d. Illness severity as measured by chest radiography, sputum smears, and symptoms had little impact on delay. We conclude that because access variables such as lack of employment and knowledge about where to obtain care were more closely associated with clinically significant delay than was severity of illness, these results raise concerns about the equity of access to care among TB patients. The results suggest that improving the availability of services for high-risk groups may substantially reduce TB patients' delay in obtaining care, and thus may limit the spread of the disease. C1 W Los Angeles Vet Adm Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Asch, S (reprint author), W Los Angeles Vet Adm Med Ctr, Dept Med, Mail Code 111G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 28 TC 87 Z9 88 U1 0 U2 6 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR PY 1998 VL 157 IS 4 BP 1244 EP 1248 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA ZG643 UT WOS:000073024500036 PM 9563746 ER PT J AU Duerinckx, AJ Lipton, MJ AF Duerinckx, AJ Lipton, MJ TI Noninvasive coronary artery imaging using CT and MR imaging SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Editorial Material ID BREATH-HOLD; ANGIOGRAPHY; STENOSIS; ECHO C1 Univ Chicago, Dept Radiol, Chicago, IL 60637 USA. Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Lipton, MJ (reprint author), Univ Chicago, Dept Radiol, MC 2026,5841 S Maryland Ave, Chicago, IL 60637 USA. NR 33 TC 14 Z9 14 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD APR PY 1998 VL 170 IS 4 BP 900 EP 902 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ZC706 UT WOS:000072608400012 PM 9530030 ER PT J AU Franco, L Najvar, L Gomez, BL Restrepo, S Graybill, JR Restrepo, A AF Franco, L Najvar, L Gomez, BL Restrepo, S Graybill, JR Restrepo, A TI Experimental pulmonary fibrosis induced by Paracoccidioides brasiliensis conidia, measurement of local host responses SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INTERSTITIAL LUNG-DISEASES; LOWER RESPIRATORY-TRACT; GROWTH-FACTOR; CHRONIC INFLAMMATION; UNKNOWN CAUSE; HISTOPLASMOSIS; FIBROBLASTS; CYTOKINES; SECRETION; ALPHA AB Pulmonary fibrosis was induced following inoculation of Paracoccidioides brasiliensis conidia intranasally in BALB/c mice. Fibrosis was associated with formation of granulomas, increase in lung hydroxyproline, and sustained increases in tissue tumor necrosis factor-alpha and transforming growth factor-beta. This study suggests a role for these cytokines in generation of pulmonary fibrosis associated with chronic granulomatous infectious diseases. C1 Corp Invest Biol, Medellin, Colombia. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Franco, L (reprint author), Corp Invest Biol, Medellin, Colombia. NR 36 TC 22 Z9 22 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DRIVE SUITE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 1998 VL 58 IS 4 BP 424 EP 430 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA ZK139 UT WOS:000073289300006 PM 9574786 ER PT J AU Minassian, BA DeLorey, TM Olsen, RW Philippart, M Bronstein, Y Zhang, QW Guerrini, R Van Ness, P Livet, MO Delgado-Escueta, AV AF Minassian, BA DeLorey, TM Olsen, RW Philippart, M Bronstein, Y Zhang, QW Guerrini, R Van Ness, P Livet, MO Delgado-Escueta, AV TI Angelman syndrome: Correlations between epilepsy phenotypes and genotypes SO ANNALS OF NEUROLOGY LA English DT Article ID HAPPY PUPPET SYNDROME; UNIPARENTAL DISOMY; DELETION; EEG; CHROMOSOME-15; DIAGNOSIS; 15Q11-13; CLONING; GENE AB We compared epilepsy phenotypes with genotypes of Angelman syndrome (AS), including chromosome 15q11-13 deletions (class I), uniparental disomy (class II), methylation imprinting abnormalities (class III), and mutation in the UBE3A gene (class IV). Twenty patients were prospectively selected based on clinical cytogenetic and molecular diagnosis of AS. All patients had 6 to 72 hours of closed-circuit television videotaping and digitized electroencephalogrpahic (EEG) telemetry. Patients from all genotypic classes had characteristic EEGs with diffuse bifrontally dominant high-amplitude 1- to 3-Hz notched or triphasic or polyphasic slow waves, or slow and sharp waves. Class I patients had severe intractable epilepsy, most frequently with atypical absences and myoclonias and less frequently with generalized extensor tonic seizures or flexor spasms. Epileptic spasms were recorded in AS patients as old as 41 years. Aged-matched class II, III, and IV patients had either no epilepsy or drug-responsive mild epilepsy with relatively infrequent atypical absences, myoclonias, or atonic seizures. In conclusion, maternally inherited chromosome 15q11-13 deletions produce severe epilepsy. Loss-of-function UBE3A mutations, uniparental disomy, or methylation imprint abnormalities in AS are associated with relatively mild epilepsy. Involvement of other genes in the chromosome 15q11-13 deletion, such as GABRB3, may explain severe epilepsy in AS. C1 Univ Calif Los Angeles, Comprehens Epilepsy Program, Sch Med, Dept Neurol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Div Pediat Neurol, Los Angeles, CA USA. W Los Angeles DVA Med Ctr, Neurol Serv, Los Angeles, CA USA. W Los Angeles DVA Med Ctr, Res Serv, Los Angeles, CA USA. Univ Toronto, Hosp Sick Children, Dept Pediat, Div Neurol, Toronto, ON M5G 1X8, Canada. Univ Toronto, Bloorview Epilepsy Program, Toronto, ON, Canada. Univ Pisa, Inst Child Neurol & Psychiat, Pisa, Italy. IRCCS, Stella Maris Fdn, Pisa, Italy. Univ Texas, Dept Neurol, Dallas, TX 75230 USA. Hop Enfants La Timone, Dept Child Neurol, Marseille, France. RP Delgado-Escueta, AV (reprint author), Univ Calif Los Angeles, Comprehens Epilepsy Program, Sch Med, Dept Neurol, Bldg 500,Room 3405,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NINDS NIH HHS [NS28772, NS21908] NR 29 TC 117 Z9 118 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 1998 VL 43 IS 4 BP 485 EP 493 DI 10.1002/ana.410430412 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ZF997 UT WOS:000072954400011 PM 9546330 ER PT J AU Gade-Andavolu, R MacMurray, JP Blake, H Muhleman, D Tourtellotte, W Comings, DE AF Gade-Andavolu, R MacMurray, JP Blake, H Muhleman, D Tourtellotte, W Comings, DE TI Association between the gamma-aminobutyric acid A(3) receptor gene and multiple sclerosis SO ARCHIVES OF NEUROLOGY LA English DT Article ID BENZODIAZEPINE RECEPTORS; DECARBOXYLASE; LYMPHOCYTES; DOPAMINE; NEURONS; SCREEN; GROWTH; BRAIN; LOCUS; GABA AB Background: In a prior study we observed an association between the dopamine D-2 receptor gene (DRD2) and the age of onset and/or diagnosis of multiple sclerosis (MS). We hypothesized that this effect was mediated through the dopaminergic control of the release of prolactin, a modulator of immune response. Since gamma-aminobutyric acid also modulates the release of prolactin, we examined the possible association between alleles of the GABRA3 (gamma-aminobutyric acid A, receptor) gene and MS. Design: We examined the GABRA3 alleles of 189 subjects with MS who died of their disease. They were divided into test group 1 (n=64) and retest group 2 (n=56). Each group had a separate set of controls (group 1, n=109; group 2, n=430). All subjects were white. All were tested at a dinucleotide cytosine-adenosine repeat polymorphism with 6 alleles representing 11 to 16 repeats. Results: In the first group there was a significant difference in the frequency of the GABRA3 alleles (P<.002), with the most notable difference being an increase in the frequency of the 16-repeat allele in subjects with MS and a relative decrease in the other alleles. In the replication group there was again a significant difference in the distribution of the GABRA3 alleles (P<.001), and again the greatest difference was an increase in the frequency of the 16-repeat allele in subjects with MS. For both groups combined, a significant difference in the frequency of the 16-repeat allele was noted (chi(2)=46.30; P<.001). Conclusions: These results suggest the GABRA3 gene may be a risk factor for MS. As with the DRD2 gene, the effect may be mediated through its regulation of prolactin release. C1 City Hope Natl Med Ctr, Dept Med Genet, Duarte, CA 91910 USA. Loma Linda Univ, Dept Psychiat, Loma Linda, CA 92350 USA. W Los Angeles Vet Affairs Med Ctr, Dept Neurol, Los Angeles, CA 90073 USA. RP Comings, DE (reprint author), City Hope Natl Med Ctr, Dept Med Genet, 1500 E Duarte Rd, Duarte, CA 91910 USA. NR 36 TC 10 Z9 10 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 1998 VL 55 IS 4 BP 513 EP 516 DI 10.1001/archneur.55.4.513 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA ZG859 UT WOS:000073047200011 PM 9561979 ER PT J AU Pecha, MD Able, AC Barber, DB Willingham, AC AF Pecha, MD Able, AC Barber, DB Willingham, AC TI Outcome after spontaneous spinal epidural hematoma in children: Case report and review of the literature SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Review ID EXTRADURAL HEMATOMA; HEMORRHAGE AB Objective: Spontaneous spinal epidural hematoma (SSEH) is an idiopathic accumulation of blood in the vertebral epidural space without identifiable predisposing factors. First reported in 1869, the clinical outcome in children younger than 18 years old has not been clearly delineated. Design: A comprehensive review of the English language literature revealed 26 patients younger than 18 years old with reported clinical outcomes. The 27th case is presented. Results: Complete neurologic recovery occurred in 14 of 27 (52%) patients, partial recovery in 12 of 27 (44%) patients, and death in 1 of 27 (4%) patients. Conclusion: There is an overall good prognosis for neurologic recovery in children who experience SSEH. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. C1 Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, San Antonio, TX 78284 USA. S Texas Vet Healthcare Syst, Audie L Murphy Div, Spinal Cord Injury Sect, San Antonio, TX USA. Warm Springs Baptist Rehabil Hosp, San Antonio, TX USA. RP Able, AC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 38 TC 21 Z9 22 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 1998 VL 79 IS 4 BP 460 EP 463 DI 10.1016/S0003-9993(98)90151-4 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA ZG317 UT WOS:000072989400018 PM 9552116 ER PT J AU Rider, LG Gurley, RC Pandey, JP Garcia-de la Torre, I Kalovidouris, AE O'Hanlon, TP Love, LA Hennekam, RCM Baumbach, LL Neville, HE Garcia, CA Klingman, J Gibbs, M Weisman, MH Targoff, IN Miller, FW AF Rider, LG Gurley, RC Pandey, JP Garcia-de la Torre, I Kalovidouris, AE O'Hanlon, TP Love, LA Hennekam, RCM Baumbach, LL Neville, HE Garcia, CA Klingman, J Gibbs, M Weisman, MH Targoff, IN Miller, FW TI Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy SO ARTHRITIS AND RHEUMATISM LA English DT Article ID INCLUSION-BODY MYOSITIS; SYSTEMIC LUPUS-ERYTHEMATOSUS; DEPENDENT DIABETES-MELLITUS; SIGNAL RECOGNITION PARTICLE; RHEUMATOID-ARTHRITIS; GENETIC SUSCEPTIBILITY; OLIGONUCLEOTIDE PROBES; IRANIAN JEWS; DISEASE; HLA AB Objective. To describe the clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy (IIM) and to compare these with the features of sporadic IIM. Methods. Clinical signs and symptoms, autoantibodies, HLA-DRB1 and DQA1 alleles, and GM/KM phenotypes were compared among 36 affected and 28 unaffected members of 16 unrelated families in which 2 or more blood relatives developed an IIM. In addition, findings in patients with familiar IIM were compared with those in 181 patients with sporadic IIM, The families included 3 pairs of monozygotic twins with juvenile dermatomyositis, 11 families with other siblings or relatives with polymyositis or dermatomyositis, and 3 families with inclusion body myositis. Results, The clinical features of familial IIM were similar to those of sporadic IIM, although the frequency of myositis-specific autoantibodies tvas lon cr in familial than in sporadic IIM. DRB1*0301 mas a common genetic risk factor for familial and sporadic IIM, but contributed less to the genetic risk of familial IIM (etiologic fraction 0.35 versus 0.51 in sporadic IIM), Homozygosity at the HLA-DQA1 locus was found to be a genetic risk factor unique to familial IIM (57% versus 24% of controls; odds ratio 4.2, corrected P = 0.002), Conclusion. These findings emphasize that 1) familial muscle weakness is not always due to inherited metabolic defects or dystrophies, but may be the result of the development of IIM in several members of the same family, and 2) multiple genetic factors are likely important in the etiology and disease expression of familial IIM, as is also the case for sporadic myositis, but DQA1 homozygosity is a distinct risk factor for familial IIM. C1 US FDA, Ctr Biol Evaluat & Res, Div Monoclonal Antibodies, NIH, Bethesda, MD 20892 USA. NIAMSD, NIH, Bethesda, MD 20892 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Univ Guadalajara, Guadalajara 44430, Jalisco, Mexico. Hosp Gen Occidente SS, Guadalajara, Jalisco, Mexico. US FDA, Ctr Food & Special Nutr, Washington, DC 20204 USA. Amsterdam Med Coll, Dept Pediat, Amsterdam, Netherlands. Amsterdam Med Coll, Inst Human Genet, Amsterdam, Netherlands. Univ Miami, Sch Med, Miami, FL 33152 USA. Univ Colorado, Sch Med, Denver, CO 80202 USA. Denver VA Med Ctr, Denver, CO USA. Louisiana State Univ, Sch Med, New Orleans, LA USA. So Calif Permanente Med Grp, Walnut Creek, CA USA. Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. Univ Oklahoma, Med Sci Ctr, VA Med Ctr, Oklahoma City, OK USA. Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Indiana Univ, VA Med Ctr, Indianapolis, IN 46204 USA. RP Rider, LG (reprint author), US FDA, Ctr Biol Evaluat & Res, Div Monoclonal Antibodies, NIH, Bldg 29B,Room 2G11,HFM-561,8800 Rockville Pike, Bethesda, MD 20892 USA. OI Rider, Lisa/0000-0002-6912-2458; Miller, Frederick/0000-0003-2831-9593 NR 58 TC 35 Z9 36 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD APR PY 1998 VL 41 IS 4 BP 710 EP 719 DI 10.1002/1529-0131(199804)41:4<710::AID-ART19>3.0.CO;2-K PG 10 WC Rheumatology SC Rheumatology GA ZG163 UT WOS:000072972800018 PM 9550481 ER PT J AU Waters, TM Bennett, CL Pajeau, TS Sobocinski, KA Klein, JP Rowlings, PA Horowitz, MM AF Waters, TM Bennett, CL Pajeau, TS Sobocinski, KA Klein, JP Rowlings, PA Horowitz, MM TI Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? SO BONE MARROW TRANSPLANTATION LA English DT Article DE cost-effectiveness; economics; stem cell transplantation ID COST-EFFECTIVENESS; CLINICAL-TRIALS; RECOMMENDATIONS; CHEMOTHERAPY; MEDICINE; THERAPY; HEALTH; RECALL; POLICY; CARE AB The use of blood and/or bone marrow stem cell transplantation (SCT) grew extensively in the last decade as technological advances led to improved outcomes and wider availability, The first study of SCT costs, however, was not published until 1989, This paper summarizes current knowledge about costs and cost-effectiveness of allogeneic and autologous SCT for leukemias and lymphoma, Methodological issues in cost studies such as types of costs, methods of data collection, and time horizons are discussed, and studies are evaluated with regard to these issues, Considerations specific to economic analyses of SCT are considered, including the potential impact of technological changes, learning curve effects, and inter-institutional differences. C1 Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL 60208 USA. Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA. Northwestern Univ, Lurie Canc Ctr, Chicago, IL 60611 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. Chicago Vet Adm Hlth Syst, Lakeside Div, Chicago, IL USA. Med Coll Wisconsin, Ctr Stat, Int Bone Marrow Transplant Registry Autologous Bl, Milwaukee, WI 53226 USA. Med Coll Wisconsin, Hlth Policy Inst, Milwaukee, WI 53226 USA. RP Waters, TM (reprint author), Northwestern Univ, Inst Hlth Serv Res & Policy Studies, 629 Noyes St, Evanston, IL 60208 USA. RI Bennett, Charles/C-2050-2008 FU NHLBI NIH HHS [103HR951181P000-0000] NR 30 TC 34 Z9 34 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 1998 VL 21 IS 7 BP 641 EP 650 DI 10.1038/sj.bmt.1701160 PG 10 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA ZF263 UT WOS:000072880000001 PM 9578302 ER PT J AU Yang, H Li, WP Reeve, JR Rivier, J Tache, Y AF Yang, H Li, WP Reeve, JR Rivier, J Tache, Y TI PYY-preferring receptor in the dorsal vagal complex and its involvement in PYY stimulation of gastric acid secretion in rats SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Article DE neuropeptide Y; PYY3-36; [Pro(34)]PYY; pancreatic polypeptide; Y1 receptor agonists; Y2 receptor agonists ID PEPTIDE-YY RECEPTORS; PANCREATIC-POLYPEPTIDE RECEPTOR; NEUROPEPTIDE-Y; BINDING-SITES; FUNCTIONAL EXPRESSION; ANESTHETIZED RATS; BRAIN; IDENTIFICATION; CLONING; SUBTYPE AB 1 Microinjection of peptide YY (PYY, 7-46 pmol) into the dorsal vagal complex (DVC) stimulated gastric acid secretion in urethane-anaesthetized rats. Using a variety of neuropeptide Y (NPY) and PYY derivatives, we characterized the pharmacological profile of the receptor mediating the acid secretory response to PYY. 2 [Pro(34)]rat(r)/porcine(p)PYY and [Pro(34)]human(h)PYY (23-117 pmol), microinjected unilaterally into the DVC resulted in a similar maximal increase in net acid secretion reaching 68+/-11 and 89+/-31 mu mol 90 min(-1) respectively. 3 Rat/hNPY and pNPY (47 pmol) microinjected into the DVC induced a similar net gastric acid secretion (27+/-8 and 23+/-8 mu mol 90 min(-1) respectively) and a higher dose (116 pmol) tended to reduce the response. 4 Pancreatic polypeptide (PP, 4-46pmol), [Leu(31),Pro(34)]r/hNPY (47 and 117 pmol) and the Y2 selective agonists, hPYY(3-36), PNPY5-36 and pNPY(13-36) (25-168 pmol) microinjected into the DVC failed to influence basal gastric acid secretion. 5 The rank order of potency of PYY greater than or equal to[Pro(34)]r/pPYY=[Pro(34)]hPYY>r/hNPY=pNPY to stimulate gastric acid secretion upon injection into the DVC and the ineffectiveness of PP, [Leu(31),Pro(34)]NPY and C-terminal NPY/PYY fragments suggest that a PYY-preferring receptor subtype may be involved in mediating the stimulating effect. C1 W Los Angeles Vet Affairs Med Ctr, CURE Digest Dis Res Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. RP Yang, H (reprint author), W Los Angeles Vet Affairs Med Ctr, CURE Digest Dis Res Ctr, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-50255, DK-30110]; NIMH NIH HHS [MH-00663] NR 53 TC 22 Z9 22 U1 0 U2 1 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD APR PY 1998 VL 123 IS 8 BP 1549 EP 1554 DI 10.1038/sj.bjp.0701767 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ZJ171 UT WOS:000073186600011 PM 9605560 ER PT J AU van Dijk, S Dean, DD Liu, Y Zhao, Y Chirgwin, JM Schwartz, Z Boyan, BD AF van Dijk, S Dean, DD Liu, Y Zhao, Y Chirgwin, JM Schwartz, Z Boyan, BD TI Purification, amino acid sequence, and cDNA sequence of a novel calcium-precipitating proteolipid involved in calcification of Corynebacterium matruchotii SO CALCIFIED TISSUE INTERNATIONAL LA English DT Article DE microbial calcification; proteolipid; dental calculus; amino acid sequence; cDNA nucleotide sequence ID PHOSPHOLIPID-PHOSPHATE COMPLEXES; CARTILAGE MATRIX VESICLES; POLYACRYLAMIDE-GEL ELECTROPHORESIS; SECONDARY-STRUCTURE; BRUSH-BORDER; PROTEINS; GROWTH; MEMBRANES; ION; IDENTIFICATION AB Corynebacterium matruchotii is a microbial inhabitant of the oral cavity associated with dental calculus formation. It produces membrane-associated proteolipid capable of inducing hydroxyapatite formation in vitro. This proteolipid was purified from chloroform:methanol extracts by chromatography on Sephadex LH-20 and migrated on SDS-polyacrylamide gel electrophoresis at 6-9 kDa. Removal of covalently attached acyl moieties by methanolic KOH decreased its molecular mass to approximately 5.5 kDa. The amino acid sequence of the apoproteolipid indicated a peptide of 50 amino acids, a calculated molecular weight of 5354 Da, and an isoelectric point of 4.28. Sequence analysis revealed an 8 amino acid sequence with homology to human phosphoprotein phosphatase 2A as well as several potential acylation sites and one phosphorylation site. The purified proteolipid induced calcium precipitation in vitro. Deacylation of the proteolipid by hydroxylamine treatment resulted in >50% loss of calcium-precipitating activity, suggesting that covalently attached Lipids are required. Degenerate oligonucleotide primers, based on the amino acid sequence, were used to amplify the gene for the 5.5 kDa proteolipid from total chromosomal DNA of C. matruchotii by PCR. A 166 bp cDNA was isolated and sequenced, confirming the amino acid sequence of the proteolipid. Thus, we have sequenced a unique bacterial proteolipid that is involved in the formation of dental calculus by precipitating Ca2+ and possibly in transport of inorganic phosphate, necessary for hydroxyapatite formation. C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Orthopaed, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Hebrew Univ Jerusalem, Hadassah Fac Dent Med, Dept Periodont, IL-91010 Jerusalem, Israel. RP Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. OI Dean, David/0000-0002-4512-9065 FU NIDCR NIH HHS [DE-07263, DE-05932]; NINDS NIH HHS [NSF EEC-9209612] NR 71 TC 10 Z9 10 U1 3 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0171-967X EI 1432-0827 J9 CALCIFIED TISSUE INT JI Calcif. Tissue Int. PD APR PY 1998 VL 62 IS 4 BP 350 EP 358 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ZB890 UT WOS:000072518300013 PM 9504961 ER PT J AU Colston, JT Chandrasekar, B Freeman, GL AF Colston, JT Chandrasekar, B Freeman, GL TI Expression of apoptosis-related proteins in experimental coxsackievirus myocarditis SO CARDIOVASCULAR RESEARCH LA English DT Article DE CD1; C3H.HeJ; mice; coxsackievirus; myocarditis; apoptosis; immunohistochemistry ID TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; NITRIC-OXIDE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; HUMAN MONOCYTES; BCL-2 HOMOLOG; FAS ANTIGEN; GENE; BAX; HEART AB Objective: The extent to which apoptosis contributes to myocyte cell loss during acute carditic viral infection is unknown. To assess whether apoptosis occurs in acute viral myocarditis, and how it is modulated, we studied mice inoculated with coxsackievirus B3 (CVB3). Methods: Five CD1 and C3H.HeJ (C3H) mice/group were sacrificed as saline vehicle-injected controls, and at 1, 2, and 3 weeks post-inoculation (p.i.) with 5 X 10(6) pfu CVB3. Histopathological status and terminal transferase-mediated dUTP-biotin nick end-labeling (TUNEL) assays quantified inflammation, necrosis and apoptosis in myocardium. Apoptosis-related protein immunoreactivity defined presence and location of Bax, Fas, Fas Ligand (FasL), Bcl-2. interleukin-1 beta converting enzyme (ICE), inducible nitric oxide synthase (iNOS) and the proto-oncogene p53. Results: Both strains exhibited significant histopathology at all time points. Saline-injected control animals showed no signs of inflammation and no significant difference in apoptosis-related protein immunoreactivity was observed between strains. Myocardial TUNEL-positive cells were exceedingly rare though apoptosis was present in thymic medulla and spleen follicles. Pro-apoptotic proteins Bax, Fas, and Fast were present in all groups though no clear correlation with histopathology was apparent. By contrast, the anti-apoptotic protein Bcl-2 showed mild immunoreactivity in controls, which increased following infection and correlated well with histopathological scores in both strains. Myocardial iNOS immunoreactivity displayed a similar though weaker staining pattern to Bcl-2 over the 3 week study period in both strains. Neither ICE nor p53 immunoreactivity could be demonstrated in myocardium. Conclusion: Thus, despite marked inflammatory activity, myocyte apoptosis is rare. in acute CVB3 myocarditis in CD1 and C3H.HeJ mice. (C) 1998 Elsevier Science B.V. C1 Univ Texas, Hlth Sci Ctr, Div Cardiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. RP Freeman, GL (reprint author), Univ Texas, Hlth Sci Ctr, Div Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM freeman@uthscsa.edu FU NHLBI NIH HHS [2 T32 HL07350] NR 49 TC 47 Z9 52 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD APR PY 1998 VL 38 IS 1 BP 158 EP 168 DI 10.1016/S0008-6363(97)00323-4 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ZT390 UT WOS:000074080500017 PM 9683918 ER PT J AU Yao, JK Moss, HB Kirillova, GP AF Yao, JK Moss, HB Kirillova, GP TI Determination of salivary cortisol by nonisotopic immunoassay SO CLINICAL BIOCHEMISTRY LA English DT Article ID ADOLESCENTS; SERUM C1 VA Pittsburgh Healthcare Syst, Neurochem & Psychopharmacol Lab, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Ctr Educ & Drug Abuse Res, Pittsburgh, PA USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Neurochem & Psychopharmacol Lab, 7180 Highland Dr, Pittsburgh, PA 15206 USA. FU NIDA NIH HHS [P50-DA 05605] NR 10 TC 14 Z9 14 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0009-9120 J9 CLIN BIOCHEM JI Clin. Biochem. PD APR PY 1998 VL 31 IS 3 BP 187 EP 190 DI 10.1016/S0009-9120(98)00004-6 PG 4 WC Medical Laboratory Technology SC Medical Laboratory Technology GA ZT388 UT WOS:000074080300010 PM 9629493 ER PT J AU Revankar, SG Dib, OP Kirkpatrick, WR McAtee, RK Fothergill, AW Rinaldi, MG Redding, SW Patterson, TF AF Revankar, SG Dib, OP Kirkpatrick, WR McAtee, RK Fothergill, AW Rinaldi, MG Redding, SW Patterson, TF TI Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RECURRENT ORAL CANDIDIASIS; POSITIVE PATIENTS; ALBICANS; AIDS; THERAPY AB Signs and symptoms of oropharyngeal candidiasis (OPC) were correlated with microbiology and clinical response to fluconazole in a cohort of patients with advanced human immunodeficiency virus (HIV) infection and recurrent OPC. Sixty-four HIV-infected patients with a median CD4 cell count of <50/mm(3) (range, 3-318/mm(3)) who presented with OPC were enrolled in a longitudinal study. Specimens for cultures were taken weekly until clinical resolution. Therapy with fluconazole was increased weekly as required to a maximum daily dose of 800 mg until resolution of symptoms and oral lesions. Resistant or dose-dependent susceptible yeasts, defined as a minimum inhibitory concentration of greater than or equal to 16 mu g/mL, were detected in 48 (31%) of 155 episodes. Clinical resolution with fluconazole therapy occurred in 107 (100%) of 107 episodes with susceptible yeasts vs. 44 (92%) of 48 episodes with resistant or dose-dependent susceptible strains (P = .008), Patients from whom fluconazole-resistant yeasts were isolated required longer courses of therapy and higher doses of fluconazole for response, but overall, excellent responses to fluconazole were seen in patients with advanced HIV infection. C1 Univ Texas, Hlth Sci Ctr, Dept Med Infect Dis, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Revankar, SG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCRR NIH HHS [M01-RR-01346]; NIDCR NIH HHS [1 R01 DE11381-01] NR 19 TC 45 Z9 47 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR PY 1998 VL 26 IS 4 BP 960 EP 963 DI 10.1086/513950 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA ZH279 UT WOS:000073091300029 PM 9564483 ER PT J AU Argyropoulos, G Brown, AM Peterson, R Likes, CE Watson, DK Garvey, WT AF Argyropoulos, G Brown, AM Peterson, R Likes, CE Watson, DK Garvey, WT TI Structure and organization of the human uncoupling protein 2 gene and identification of a common biallelic variant in Caucasian and African-American subjects SO DIABETES LA English DT Article ID UCP C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Garvey, WT (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 171 Ashley Ave, Charleston, SC 29425 USA. FU NCRR NIH HHS [M01-RR1070]; NIDDK NIH HHS [DK-47461] NR 9 TC 25 Z9 28 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 1998 VL 47 IS 4 BP 685 EP 687 DI 10.2337/diabetes.47.4.685 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ZD577 UT WOS:000072700500025 PM 9568704 ER PT J AU Agrawal, L Emanuele, NV Abraira, C Henderson, WG Levin, SR Sawin, CT Silbert, CK Nuttall, FQ Comstock, JP Colwell, JA AF Agrawal, L Emanuele, NV Abraira, C Henderson, WG Levin, SR Sawin, CT Silbert, CK Nuttall, FQ Comstock, JP Colwell, JA CA VA CSDM Grp TI Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM) SO DIABETES CARE LA English DT Article ID WHITE AMERICANS; FEASIBILITY TRIAL; CIGARETTE-SMOKING; GLUCOSE-TOLERANCE; UNITED-STATES; BLACK; NIDDM; COMPLICATIONS; SECRETION; SENSITIVITY AB OBJECTIVE - The Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus was conducted in NIDDM patients to determine if a significant difference in HbA(1c) could be achieved between groups receiving standard and intensive treatment. We observed differences in the response to exogenous insulin between African-Americans and other intensively treated patients. Therefore, we assessed the variations of response and correlated factors that might explain such differences. RESEARCH DESIGN AND METHODS - One hundred fifty-three men aged 40-69 years with NIDDM for less than or equal to 15 years were randomized to either the standard therapy (n = 78) or the intensive therapy (n = 75) arm. Of the 75 patients in the intensive therapy group, 57 completed the study on insulin therapy alone. Of these, 18 were African-Americans and 39 were non-African-Americans. We conducted an analysis of the data collected to determine differences in baseline characteristics, glycemic response, insulin requirement, body weight, exercise, and basal C-peptide level, factors that may explain a difference in response to insulin therapy. RESULTS - Glycemic control improved in all patients with intensive insulin therapy African-Americans achieved a greater improvement in HbA(1c) compared with non-African-Americans with a similar increment in insulin. This difference could not be explained by differences in body weight, activity, concomitant use of other medicines, or insulin-secretory capacity of the pancreas. CONCLUSIONS - We conclude that ethnic differences may exist in the response to insulin therapy. A knowledge of such differences may aid in achieving good glycemic control, especially since minorities have a greater prevalence of and burden from the microvascular complications of diabetes. C1 Edward Hines Vet Adm Hosp, Endocrinol Diabet Sect 111A, Hines, IL 60141 USA. Edward Hines Vet Adm Hosp, Med Serv, Div Metab, Hines, IL 60141 USA. Edward Hines Vet Adm Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA. Vet Adm Wadsworth Med Ctr, Special Diagnost & Treatment Ctr, Los Angeles, CA 90073 USA. VA Med Ctr, Endocrine Diabet Sect, Boston, MA USA. VA Med Ctr, Med Serv, Endocrinol Sect, Minneapolis, MN USA. VA Med Ctr, Houston, TX USA. Med Univ S Carolina, Ctr Diabet, Div Endocrinol, Charleston, SC 29425 USA. RP Agrawal, L (reprint author), Edward Hines Vet Adm Hosp, Endocrinol Diabet Sect 111A, Roosevelt Rd & 5th Ave,Box 5000,Bldg 200,Rm 1226, Hines, IL 60141 USA. NR 34 TC 15 Z9 15 U1 1 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 1998 VL 21 IS 4 BP 510 EP 515 DI 10.2337/diacare.21.4.510 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ZD293 UT WOS:000072670700008 PM 9571333 ER PT J AU Kovacs, TOG Campbell, D Haber, M Rose, P Jennings, DE Richter, J AF Kovacs, TOG Campbell, D Haber, M Rose, P Jennings, DE Richter, J TI Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE lansoprazole; gastric ulcer; maintenance therapy; ulcer recurrence ID ACID-SECRETION; COPENHAGEN-COUNTY; DUODENAL-ULCER; DISEASE; RANITIDINE; OMEPRAZOLE; PREVENTION; INHIBITION; ASPIRIN; THERAPY AB Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer. Within one month, 40% of patients receiving placebo experienced ulcer recurrence compared to 0% and 7% of patients receiving lansoprazole 15 mg and 30 mg, respectively, All placebo patients became symptomatic, experienced ulcer recurrence or withdrew from the study by month 9, As compared to placebo, a significantly (P < 0.001) higher percentage of patients treated with lansoprazole 15 mg (83%) and lansoprazole 30 mg (93%) with healed gastric ulcer disease remained healed at month 12. Of patients asymptomatic at baseline, 100% and 59% of those treated with lansoprazole 15 mg and 30 mg, respectively, remained asymptomatic at month 12. The incidence of adverse events was comparable among the treatment groups. Lansoprazole safely and effectively reduces ulcer recurrence in patients with a history of gastric ulcer disease. C1 W Los Angeles Vet Affairs Med Ctr, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. Vet Adm Med Ctr, Kansas City, MO 64128 USA. Allegheny Univ Hlth Sci, Dept Pathol, Philadelphia, PA 19102 USA. TAP Holdings, Deerfield, IL 60015 USA. Cleveland Clin Fdn, Dept Gastroenterol, Cleveland, OH 44195 USA. RP Kovacs, TOG (reprint author), W Los Angeles Vet Affairs Med Ctr, Ctr Ulcer Res & Educ, 11301 Wilshire Blvd,Bldg 115,Room 212, Los Angeles, CA 90073 USA. NR 32 TC 11 Z9 11 U1 0 U2 0 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 1998 VL 43 IS 4 BP 779 EP 785 DI 10.1023/A:1018818115047 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZH100 UT WOS:000073072100015 PM 9558034 ER PT J AU Leverenz, JB Raskind, MA AF Leverenz, JB Raskind, MA TI Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: A regional quantitative analysis SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer's disease; beta-amyloid protein; Down syndrome; hippocampus; plaques ID ALZHEIMERS-DISEASE; DOWNS-SYNDROME; SENILE PLAQUES; NEUROPATHOLOGICAL CHANGES; NEUROFIBRILLARY TANGLES; CEREBRAL-CORTEX; DEMENTIA; PROTEIN; PRECURSOR; AGE AB The presence of the neuropathological alterations of Alzheimer's disease (AD) in essentially all older Down syndrome (DS) patients suggests that the examination of younger DS patients may clarify the early pathological progression of AD. We examined the hippocampus and parahippocampal-inferior temporal gyri of 42 DS patients (ages 4 days to 38 years) for the deposition of amyloid beta protein (A beta) using bath a modified Biel-schowsky stain and immunohistochemistry for A beta protein. The parahippocampal and inferior temporal gyri demonstrated A beta staining in eases as young as 8 years of age. as age and degree of A beta deposition increased, staining included the CA-1/subiculum and dentate molecular layer followed then by the remainder of the CA hippocampal regions. The first neuritic plaques were observed in tale CA-1/subiculum despite this being a later region of A beta deposition. Although A beta staining increased with age, there was substantial variability in the severity of A beta deposition within age groups. These results suggest that within the hippocampal/parahippocampal region there is a progressive stereotypic deposition of A beta. The variable severity of A beta deposition within age groups suggests that, other factors, besides DS, may be contributing to the timing anf severity of A beta deposition. (C) 1998 Academic Press. C1 Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Leverenz, JB (reprint author), Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. FU NIA NIH HHS [AG00503, AG05136] NR 34 TC 102 Z9 106 U1 0 U2 3 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 1998 VL 150 IS 2 BP 296 EP 304 DI 10.1006/exnr.1997.6777 PG 9 WC Neurosciences SC Neurosciences & Neurology GA ZJ769 UT WOS:000073251100014 PM 9527899 ER PT J AU Brosnan, J AF Brosnan, J TI Parenting the strong willed child: The clinically proven five-week program for parents of two- to six-year-olds SO FAMILY & COMMUNITY HEALTH LA English DT Book Review C1 W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. RP Brosnan, J (reprint author), W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ASPEN PUBL INC PI FREDERICK PA 7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD APR PY 1998 VL 21 IS 1 BP 81 EP 82 PG 2 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA ZB994 UT WOS:000072529000012 ER PT J AU Jensen, DM Jutabha, R Kovacs, TOG Machicado, GA Gralnek, I Cheng, S Jensen, ME Gornbein, J AF Jensen, DM Jutabha, R Kovacs, TOG Machicado, GA Gralnek, I Cheng, S Jensen, ME Gornbein, J TI Final results of a randomized prospective study of combination banding and sclerotherapy versus sclerotherapy alone for hemostasis of bleeding esophageal varices. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, W Los Angeles Vet Adm Med Ctr, CURE, Hemostasis Res Grp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 1998 VL 47 IS 4 SU S MA 184 BP AB70 EP AB70 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZK314 UT WOS:000073306800184 ER PT J AU Jutabha, R Jensen, DM Kovacs, TOG Machicado, GA Gralnek, IM King, J Jensen, ME AF Jutabha, R Jensen, DM Kovacs, TOG Machicado, GA Gralnek, IM King, J Jensen, ME TI Initial results of a prospective study of combination banding & sclerotherapy compared to sclerotherapy alone for bleeding gastric varices. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, CURE Hemostasis Res Grp, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 1998 VL 47 IS 4 SU S MA 249 BP AB86 EP AB86 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZK314 UT WOS:000073306800248 ER PT J AU Kim, J Officer, T Graham, DY AF Kim, J Officer, T Graham, DY TI Endoscope disinfection may not always be effective: The "Y" connection is an unnecessary Achilles heel of the disinfection process SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 VA Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 1998 VL 47 IS 4 SU S MA 112 BP AB52 EP AB52 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZK314 UT WOS:000073306800113 ER PT J AU Machicado, GA Jensen, DM Kovacs, TG Jutabha, R Randall, G Gornbein, J Jensen, ME Cheng, S Fontana, L AF Machicado, GA Jensen, DM Kovacs, TG Jutabha, R Randall, G Gornbein, J Jensen, ME Cheng, S Fontana, L TI Patients with recurrent GI hemorrhage and colonic angiomas - A randomized study of endoscopic treatment with bipolar or heater probe coagulation SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 1998 VL 47 IS 4 SU S MA 304 BP AB100 EP AB100 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZK314 UT WOS:000073306800302 ER PT J AU Haake, DA Martinich, C Summers, TA Shang, ES Pruetz, JD McCoy, AM Mazel, MK Bolin, CA AF Haake, DA Martinich, C Summers, TA Shang, ES Pruetz, JD McCoy, AM Mazel, MK Bolin, CA TI Characterization of leptospiral outer membrane lipoprotein LipL36: Downregulation associated with late-log-phase growth and mammalian infection SO INFECTION AND IMMUNITY LA English DT Article ID INTERROGANS SEROVAR HARDJO; FRACTURE ELECTRON-MICROSCOPY; LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; TREPONEMA-PALLIDUM; PATHOGENIC LEPTOSPIRA; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; BOVIS INFECTION; ESCHERICHIA-COLI AB We report the cloning of the gene encoding a 36-kDa leptospiral outer membrane lipoprotein, designated LipL36. We obtained the N-terminal amino acid sequence of a staphylococcal V8 proteolytic-digest fragment in order to design an oligonucleotide probe. A Lambda-Zap II library containing EcoRI fragments of Leptospira kirschneri DNA was screened, and a 2.3-kb DNA fragment which contained the entire structural lipL36 gene was identified. Several lines of evidence indicate that LipL36 is lipid modified in a manner similar to that of LipL41, a leptospiral outer membrane lipoprotein we described in a previous study (E. S. Shang, T. A. Summers, and D. A. Haake, Infect. Immun, 64:2322-2330, 1996). The deduced amino acid sequence of LipL36 would constitute a 364-amino-acid polypeptide,vith a 20-amino-acid signal peptide, followed by an L-X-Y-C lipoprotein signal peptidase cleavage site. LipL36 is solubilized by Triton X-114 extraction of L. kirschneri; phase separation results in partitioning of LipL36 exclusively into the hydrophobic, detergent phase. LipL36 is intrinsically labeled during incubation of L. kirschneri in media containing [H-3]palmitate. Processing of LipL36 is inhibited by globomycin, a selective inhibitor of lipoprotein signal peptidase. After processing, LipL36 is exported to the outer membrane along with LipL41 and lipopolysaccharide. Unlike Lip41, there appears to be differential expression of LipL36. In early-log-phase cultures, LipL36 is one of the most abundant L. kirschneri proteins. However, LipL36 levels drop considerably beginning in mid-log phase. LipL36 expression in vivo was evaluated by examining the humoral immune response to leptospiral antigens in the hamster model of leptospirosis. Hamsters surviving challenge with culture-adapted virulent L. kirschneri generate a strong antibody response to LipL36. In contrast, sera from hamsters surviving challenge with host-adapted L. kirschneri do not recognize LipL36. These findings suggest that LipL36 expression is downregulated during mammalian infection, providing a marker for studying the mechanisms by which pathogenic Leptospira species adapt to the host environment. C1 W Los Angeles Vet Affairs Med Ctr, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA. USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA. RP Haake, DA (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. RI Pruetz, Jill/A-7202-2009 OI Pruetz, Jay/0000-0002-3155-0852 FU NCI NIH HHS [CA16042, P30 CA016042]; NIAID NIH HHS [2-T32-AI07323-06, AI-34431, R01 AI034431, R21 AI034431, R29 AI034431, T32 AI007323] NR 54 TC 81 Z9 93 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD APR PY 1998 VL 66 IS 4 BP 1579 EP 1587 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ZD630 UT WOS:000072706100043 PM 9529084 ER PT J AU Oslin, D Atkinson, RM Smith, DM Hendrie, H AF Oslin, D Atkinson, RM Smith, DM Hendrie, H TI Alcohol Related Dementia: Proposed clinical criteria SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE alcoholism; dementia; diagnosis ID SOCIAL DRINKING; ALZHEIMERS-DISEASE; COGNITIVE LOSS; CONSUMPTION; BRAIN; DIAGNOSIS; RISK; RELIABILITY; PERFORMANCE; DISORDERS AB Current diagnostic criteria for Alcohol Related Dementia (ARD) are based almost exclusively on clinical judgment. Moreover, there are no guidelines available to assist the clinician or the researcher in distinguishing Alcohol Related Dementia from other causes of dementia such as Alzheimer's Disease (AD). However, this distinction may have implications for the prognosis and treatment of patients. In this article, provisional diagnostic criteria for establishing a diagnosis of Alcohol Related Dementia are proposed for further study. The criteria are based on the available literature on the relationship between alcohol consumption and dementia and were modeled after existing diagnostic criteria for AD and Vascular Dementia. Validity of these criteria for distinguishing AD from ARD will require further study. (C) 1998 John Wiley & Sons, Ltd. C1 Univ Penn, Ralston Penn Ctr, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Indiana Univ, Sch Med, Bloomington, IN 47405 USA. RP Oslin, D (reprint author), Univ Penn, Ralston Penn Ctr, Sect Geriatr Psychiat, 3614 Chestnut St, Philadelphia, PA 19104 USA. NR 61 TC 86 Z9 87 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD APR PY 1998 VL 13 IS 4 BP 203 EP 212 DI 10.1002/(SICI)1099-1166(199804)13:4<203::AID-GPS734>3.0.CO;2-B PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA ZL443 UT WOS:000073433400004 PM 9646147 ER PT J AU Damon, SE Haugk, KL Birnbaum, RS Quinn, LS AF Damon, SE Haugk, KL Birnbaum, RS Quinn, LS TI Retrovirally mediated overexpression of insulin-like growth factor binding protein 4: Evidence that insulin-like growth factor is required for skeletal muscle differentiation SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID FACTOR IGF BINDING; MYOBLAST DIFFERENTIATION; FACTOR-II; MYOGENIC DIFFERENTIATION; CELL-DIFFERENTIATION; PRIMARY CULTURES; GENE-EXPRESSION; FACTOR-BETA; PROLIFERATION; RECEPTOR AB Recent studies have indicated that the insulin-like growth factors (IGFs) stimulate skeletal myoblast proliferation and differentiation. However, the question of whether IGFs are required for myoblast differentiation has not been resolved. To address this issue directly, we used a retroviral vector (LBP4SN) to develop a subline of mouse C2 myoblasts (C2-BP4) that constitutively overexpress IGF binding protein-4 (IGFBP-4). A control C2 myoblast subline (C2-LNL6) was also developed by using the LNL6 control retroviral vector. C2-BP4 myoblasts expressed sixfold higher levels of IGFBP-4 protein than C2-LNL6 myoblasts. (125)I-IGF-I cross linking indicated that IGFBP-4 overexpression reduced IGF access to the type-1 IGF receptor tenfold. At low plating densities, myoblast proliferation was inhibited, and myoblast differentiation was abolished in C2-BP4 cultures compared with C2-LNL6 cultures. At high plating densities in which nuclear numbers were equal in the two sets of cultures, C2-BP4 myoblast differentiation was inhibited completely. Differentiation was restored in C2-BP4 cells by treatment with high levels of exogenous IGF-I or with des(1-3)IGF-I, an analog of IGF-I with reduced affinity for IGFBPs. These findings confirm the hypothesis that positive differentiation signals from the IGFs are necessary for C2 myoblast differentiation, and they suggest that the present model of myogenic differentiation, which involves only negative external control of differentiation by mitogens, may be incomplete. (C) 1998 Wiley-Liss, Inc. C1 VA Puget Sound Hlth Care Syst, Amer Lake Div, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. FU NICHD NIH HHS [N01-HD-6-2915] NR 66 TC 36 Z9 37 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD APR PY 1998 VL 175 IS 1 BP 109 EP 120 DI 10.1002/(SICI)1097-4652(199804)175:1<109::AID-JCP12>3.0.CO;2-6 PG 12 WC Cell Biology; Physiology SC Cell Biology; Physiology GA YZ345 UT WOS:000072245100012 PM 9491786 ER PT J AU Conigliaro, J Lofgren, RP Hanusa, BH AF Conigliaro, J Lofgren, RP Hanusa, BH TI Screening for problem drinking - Impact on physician behavior and patient drinking habits SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE alcohol abuse; problem drinking; screening; brief interventions ID IDENTIFICATION TEST AUDIT; PRIMARY-CARE PATIENTS; ALCOHOL-USE; BRIEF INTERVENTIONS; CAGE QUESTIONNAIRE; PROBLEM DRINKERS; SUBSTANCE ABUSE; UNITED-STATES; PREVALENCE; DISORDERS AB OBJECTIVE: To assess the effect of a screen for problem drinking on medical residents and their patients. DESIGN: Descriptive cohort study. SETTING: Veterans Affairs Medical Clinic. PATIENTS: Patients were screened 2 weeks before a scheduled visit (n = 714). Physicians were informed if their patients scored positive. MEASUREMENTS AND MAIN RESULTS: Physician discussion of alcohol use was documented through patient interview and chart review. Self-reported alcohol consumption was recorded. Of 236 current drinkers, 28% were positive for problem drinking by the Alcohol Use Disorders Identification Test (AUDIT). Of 58 positive patients contacted at 1 month, 78% recalled a discussion about alcohol use, 58% were advised to decrease drinking, and 9% were referred for treatment. In 57 positive patient charts, alcohol use was noted in 33 (58%), and a recommendation in 14 (25%). Newly identified patients had fewer notations than patients with prior alcohol problems. Overall, 6-month alcohol consumption decreased in both AUDIT-positive and AUDIT-negative patients. The proportion of positive patients who consumed more than 16 drinks per week (problem drinking) decreased from 58% to 49%. Problem drinking at 6 months was independent of physician discussion or chart notation. CONCLUSIONS: Resident physicians discussed alcohol use in a majority of patients who screened positive for alcohol problems but less often offered specific advice or treatment. Furthermore, residents were less likely to note concerns about alcohol use in charts of patients newly identified. Finally, a screen for alcohol abuse may influence patient consumption. C1 VA Pittsburgh Hlth Care Syst, Gen Internal Med Sect, Pittsburgh, PA USA. RP Conigliaro, J (reprint author), VA Pittsburgh Hlth Care Syst 11A, Sect Gen Med, Univ Dr C, Pittsburgh, PA 15240 USA. NR 33 TC 27 Z9 28 U1 3 U2 3 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 1998 VL 13 IS 4 BP 251 EP 256 DI 10.1046/j.1525-1497.1998.00075.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ZF826 UT WOS:000072937100005 PM 9565388 ER PT J AU Conde, MV Williams, JW Mulrow, CD AF Conde, MV Williams, JW Mulrow, CD TI Targeting depression interviewing - An exercise in diagnostic reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article ID NATIONAL-COMORBIDITY-SURVEY; MAJOR DEPRESSION; UNITED-STATES; PREVALENCE; DISORDERS C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Conde, MV (reprint author), Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 10 TC 1 Z9 1 U1 1 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 1998 VL 13 IS 4 BP 262 EP 265 DI 10.1046/j.1525-1497.1998.00077.x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ZF826 UT WOS:000072937100007 PM 9565390 ER PT J AU Rheinwald, J Palanisamy, A Benwood, J Feldman, R Sauter, E AF Rheinwald, J Palanisamy, A Benwood, J Feldman, R Sauter, E TI Premalignant human keratinocytes exhibiting extended replicative lifespans and EGF-independence cultured from dysplastic oral epithelial lesions. SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 Harvard Univ, Brigham & Womens Hosp, Div Dermatol, Sch Med, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1998 VL 110 IS 4 BP 522 EP 522 PG 1 WC Dermatology SC Dermatology GA ZD914 UT WOS:000072738200330 ER PT J AU Doolittle, MH Ben-Zeev, O Briquet-Laugier, V AF Doolittle, MH Ben-Zeev, O Briquet-Laugier, V TI Enhanced detection of lipoprotein lipase by combining immunoprecipitation with Western blot analysis SO JOURNAL OF LIPID RESEARCH LA English DT Article DE affinity purified chicken anti-LPL antibody; chicken IgG Fab production; immunomatrix ID DROSOPHILA-MELANOGASTER CELLS; TRANSLOCATION; GLYCOSYLATION; PURIFICATION; EXPRESSION; DEFICIENT; PROMOTER; ENZYME AB This manuscript describes the problems inherent in combining immunoprecipitation of lipoprotein lipase (LPL) with its detection by Western blot, and how these problems can be circumvented by the preparation of suitable immunoreagents. These reagents used during the immunoprecipitation step, include Fab fragments of the primary antibody (chicken anti-bovine LPL), and a covalently linked immunomatrix of the secondary antibody (rabbit anti-chicken Igc). The use of these reagents in conjunction with Western blot detection virtually eliminates the problem of non-relevant protein detection when analyzing LPL from complex biological samples. Moreover, this approach can be adapted to detect any protein with the same inherent problems as LPL, such as hepatic lipase. C1 W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Doolittle, MH (reprint author), W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NHLBI NIH HHS [HL28481] NR 20 TC 10 Z9 10 U1 1 U2 1 PU LIPID RESEARCH INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD APR PY 1998 VL 39 IS 4 BP 934 EP 942 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA ZF025 UT WOS:000072855200020 PM 9555956 ER PT J AU Knowlton, AA Kapadia, S Torre-Amione, G Durand, JB Bies, R Young, J Mann, DL AF Knowlton, AA Kapadia, S Torre-Amione, G Durand, JB Bies, R Young, J Mann, DL TI Differential expression of heat shock proteins in normal and failing human hearts SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE heat shock proteins; hsp27; hsp60; hsp70; hsp72; hsp90; cardiomyopathy; heart failure ID TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; DILATED CARDIOMYOPATHY; FACTOR RECEPTORS; STRESS PROTEIN; MESSENGER-RNA; APOPTOSIS; RABBIT; HSP70; GENE AB Background: heat shock proteins (hsp) constitute an endogenous stress response that protects cells from injury. Most work on these important proteins has focused on the immediate response to acute stress in cell culture systems and mammalian models of heart disease. Little is known about the expression of the hsps in human hearts. We were interested in whether there was increased expression of the hsps in heart failure, a setting of chronic, sustained stress. Five different hsps were examined: hsp27, hsp60, hsp72, hsc70 and hsp90. Methods and results: three groups of explanted hearts were studied: dilated cardiomyopathy (DCM), ischemic cardiomyopathy (IHD), and normal controls. Western-blotting with a standard curve of purified protein on each blot was used to quantify the expression of the hsps. Hsp27 was increased almost two-fold in DCM compared to normal hearts, and was significantly greater than in IHD hearts. Levels of hsp60 were doubled in both DCM and MD hearts (P<0.05). Hsp72, hsc70 and hsp90 were not significantly changed. Conclusions: this study shows for the first time that differential changes in hsp levels occur in end-stage heart failure. Since hsps can render cells resistant to apoptosis, and are associated with the mitochondria and the cytoskeleton, which are known to be abnormal in heart failure, these studies may lead to new insights into the pathogenesis of cardiac decompensation. (C) 1998 Academic Press Limited. C1 VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Cleveland Clin, Cleveland, OH 44106 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. RP Knowlton, AA (reprint author), VA Med Ctr, 151C,2002 Holcombe, Houston, TX 77030 USA. OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [HL92510] NR 45 TC 116 Z9 122 U1 1 U2 5 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD APR PY 1998 VL 30 IS 4 BP 811 EP 818 DI 10.1006/jmcc.1998.0646 PG 8 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA ZK958 UT WOS:000073384700010 PM 9602430 ER PT J AU Sayers, ST Khan, N Ahmed, Y Shahid, R Khan, T AF Sayers, ST Khan, N Ahmed, Y Shahid, R Khan, T TI Preparation of brain-derived neurotrophic factor- and neurotrophin-3-secreting Schwann cells by infection with a retroviral vector SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE gene therapy; brain-derived neurotrophic factor (BDNF); neurotrophin-3 (NT-3); retroviral vector; Schwann cells; spinal cord injury ID NERVE GROWTH-FACTOR; RAT SPINAL-CORD; FACTOR MESSENGER-RNA; HUMAN-GENE-THERAPY; MOLECULAR-CLONING; FACTOR FAMILY; AXONAL GROWTH; MOTOR NEURONS; EXPRESSION; BDNF AB One reason that the central, nervous system of adult mammals does not regenerate after injury is that neurotrophic factors are present only in low concentrations in these tissues. Recent studies have shown that the application of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) acts to encourage the regrowth of motor and sensory fibers after spinal cord injury. Other studies have reported that the regrowth of axons after injury was enhanced by the implantation of Schwann cells, which normally secrete BDNF and NTT-3. The purpose of the present study was to genetically modify Schwann cells to secrete increased amounts of BDNF or NT-3 by infection with a retroviral vector. Retroviral vectors were constructed by the Ligation of BDNF or NT-3 cDNA to the LXSN vector. Viruses were generated from the plasmid forms of the vectors by transient transfection of PA317 amphotrophic retroviral packaging cells. Viruses were harvested and used to infect the human Schwann cell line designated NF-1T. Northern blot analysis of poly (At) RNA prepared from Schwann cells that were infected with BDNF- or NT3-containing virus showed the presence of BDNF or NTT-3 mRNA. An enzyme-linked immunosorbent assay (ELISA) for BDNF and NT-3 was performed on media the cells were grown in, and on cellular extracts prepared from the BDNF- and NT3-infected Schwann cells. The ELISA results demonstrated that the Schwann cells were secreting increased levels of immunologically active BDNF or NT-3. Immunocytochemical staining of these cells revealed the presence of these two neurotrophic factors located in perinuclear granules. These neurotrophic factor-secreting Schwann cells are currently being evaluated for their efficacy in the treatment of spinal cord injury. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Rehabil Res & Dev Ctr, Hines, IL 60141 USA. Loyola Univ, Med Ctr, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA. RP Sayers, ST (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Rehabil Res & Dev Ctr, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 58 TC 21 Z9 26 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD APR PY 1998 VL 10 IS 2 BP 143 EP 160 DI 10.1007/BF02737125 PG 18 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 104BZ UT WOS:000074993500007 PM 9699155 ER PT J AU Eisenberg, LS Dirks, DD Takayanagi, S Martinez, AS AF Eisenberg, LS Dirks, DD Takayanagi, S Martinez, AS TI Subjective judgments of clarity and intelligibility for filtered stimuli with equivalent speech intelligibility index predictions SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE subjective judgments; category rating; clarity; intelligibility ID PAIRED-COMPARISON JUDGMENTS; SOUND QUALITY JUDGMENTS; HEARING-AID SELECTION; MAGNITUDE ESTIMATION; CONTINUOUS DISCOURSE; FREQUENCY RESPONSES; ARTICULATION INDEX; LISTENERS; RELIABILITY; SENSITIVITY AB The purpose of this investigation was to determine whether subjective judgments of clarity or intelligibility would be rated equally among conditions in which speech was equated for predicted intelligibility (using the Speech Intelligibility Index, SII) but varied in bandwidth. Twenty listeners with normal hearing rated clarity and intelligibility for sentence material (Hearing In Noise Test) in speech-shaped noise at six paired low- and high-pass Filtered conditions in which SII was equated for each pair. For three paired conditions, predicted intelligibility increased as SII increased monotonically (0.3, 0.4, 0.5). In the remaining paired conditions, SII continued to increase monotonically (0.6, 0.7, 0.8) but predicted intelligibility was held at a maximal level (greater than or equal to 95%). Predicted intelligibility was estimated from the transfer function relating SII to speech recognition scores determined in preliminary experiments. Differences in ratings between paired low-and high-pass filtered sentences did not reach statistical significance for either clarity or intelligibility, indicating that the spectral differences at equivalent Sits did not influence the judgments for either of the two dimensions. For conditions in which predicted intelligibility increased, both clarity and intelligibility ratings increased in a similar manner. For conditions in which predicted intelligibility was maximized, intelligibility ratings remained the same statistically across conditions while clarity ratings changed modestly. Although high correlations were observed between clarity and intelligibility ratings, intelligibility ratings were consistently higher than clarify ratings For comparable conditions. The results indicated that listeners with normal hearing produced clarity and intelligibility ratings for the same speech material and experimental conditions that were highly related but differed in magnitude. Caution is required when substituting clarity For intelligibility. C1 Univ Calif Los Angeles, Sch Med, Div Head & Neck Surg, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Linguist, Los Angeles, CA 90024 USA. W Los Angeles Vet Adm Med Ctr, Los Alamos, NM USA. RP Eisenberg, LS (reprint author), House Ear Inst, 2100 W 3rd St,5th Floor, Los Angeles, CA 90057 USA. EM leisenberg@hei.org FU NIDCD NIH HHS [T32 DC00029-07, 5 K08 DC 00083-05] NR 45 TC 32 Z9 32 U1 3 U2 5 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD APR PY 1998 VL 41 IS 2 BP 327 EP 339 PG 13 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA ZH627 UT WOS:000073130500009 PM 9570586 ER PT J AU Rabeneck, L Palmer, A Knowles, JB Seidehamel, RJ Harris, CL Merkel, KL Risser, JMH Akrabawi, SS AF Rabeneck, L Palmer, A Knowles, JB Seidehamel, RJ Harris, CL Merkel, KL Risser, JMH Akrabawi, SS TI A randomized controlled trial evaluating nutrition counseling with or without oral supplementation in malnourished HIV-infected patients SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PARENTERAL-NUTRITION; MEGESTROL-ACETATE; BODY-COMPOSITION; VIRUS INFECTION; AIDS; CACHEXIA; ENERGY; MASS AB Objective To evaluate the effects of nutrition counseling with or without oral supplementation in malnourished patients infected with the human immunodeficiency virus (HIV). Design Randomized controlled trial. Subjects HIV-infected men (n=118) who were less than 90% of usual weight for height or who had lost more than 10% of body weight. Intervention Nutrition counseling alone (control group) vs nutrition counseling plus enteral supplementation (supplement group) for 6 weeks. AU patients were instructed to consume a diet that exceeded estimated total energy expenditure by 960 kcal/day. Main outcome measures Weight, skinfold thickness, fat-free mass, grip strength, quality of life, and cognitive function (Buschke test). Statistical analyses Differences in baseline variables and outcomes were evaluated using analysis of variance or the Wilcoxon rank sum test. Results Ninety-nine men completed at least 4 weeks of treatment, 49 in the supplement group and 50 in the control group. Half the patients in each treatment group achieved at least 80% of their energy target. No differences in weight, skinfold thickness measurements, or quality of life were observed. Compared with the control group, the supplement group had larger increases in fat-free mass and grip strength, although the differences did not reach statistical significance. Applications In the short term, nutrition counseling with or without oral supplementation can achieve a substantial increase in energy intake in about 50% of malnourished HIV-infected patients. Although further study is needed to evaluate long-term effects, these findings suggest that nutrition counseling has an important role in the management of malnourished HIV-infected patients. C1 Dept Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Mead Johnson Nutr Grp, Evansville, IN USA. RP Rabeneck, L (reprint author), Vet Adm Med Ctr, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 18 TC 44 Z9 45 U1 0 U2 0 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD APR PY 1998 VL 98 IS 4 BP 434 EP 438 DI 10.1016/S0002-8223(98)00099-6 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA ZG012 UT WOS:000072955900016 PM 9550167 ER PT J AU Perkowski, LC Stroup-Benham, CA Markides, KS Lichtenstein, MJ Angel, RJ Guralnik, JM Goodwin, JS AF Perkowski, LC Stroup-Benham, CA Markides, KS Lichtenstein, MJ Angel, RJ Guralnik, JM Goodwin, JS TI Lower-extremity functioning in older Mexican Americans and its association with medical problems SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID PERFORMANCE-BASED MEASURES; NON-HISPANIC WHITES; PHYSICAL PERFORMANCE; DIABETIC-RETINOPATHY; ELDERLY PEOPLE; RISK-FACTORS; DISABILITY; HEALTH; DISEASE; PREDICTORS AB OBJECTIVE: To describe lower-extremity functioning in community-dwelling older Mexican Americans and to examine its relationship with medical problems. DESIGN: Cross-sectional analyses of survey and performance-based data obtained in a population-based study employing area probability sampling. SETTING: Households within selected census tracts of five Southwestern states: Arizona, California, Colorado, New Mexico, and Texas. PARTICIPANTS: A total of 2873 Mexican Americans aged 65 years and older. MEASUREMENTS: A multidimensional questionnaire assessing demographic, sociocultural, and health variables. Standardized tests of lower-extremity physical functioning included measures of standing balance, repeated chair stands, walking, and an overall summary measure. RESULTS: Regression analyses revealed that being more than age 75 and female, having arthritis diabetes, visual impairments, or being obese or underweight were all significantly associated with performance on both individual and summary tests of lower-extremity functioning. In separate regression analyses, the total number of medical conditions was also associated with performance. CONCLUSIONS: The likelihood of predicting performance or inability to complete tests of lower-extremity functioning was greatest for those aged 80 and older, those with arthritis or diabetes, and those with three or more medical conditions. Because of the high prevalence of diabetes in Mexican Americans, documentation of the association of diabetes with performance-based tests of lower-extremity functioning may help guide early interventions targeted to prevent progression to more severe limitations or disability. C1 Univ So Calif, Sch Med, Div Med Educ, Los Angeles, CA 90033 USA. Univ Texas, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77550 USA. Univ Texas, Med Branch, Ctr Aging, Galveston, TX 77550 USA. Univ Texas, Hlth Sci Ctr, Div Geriatr & Gerontol, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. Univ Texas, Dept Sociol, Austin, TX 78712 USA. NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA. RP Perkowski, LC (reprint author), Univ So Calif, Sch Med, Div Med Educ, 1975 Zonal Ave, KAM 211A, Los Angeles, CA 90033 USA. FU NIA NIH HHS [R01-AG10939] NR 62 TC 34 Z9 35 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 1998 VL 46 IS 4 BP 411 EP 418 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ZG164 UT WOS:000072973100002 PM 9560061 ER PT J AU Coleman, EA Wagner, EH Grothaus, LC Hecht, J Savarino, J Buchner, DM AF Coleman, EA Wagner, EH Grothaus, LC Hecht, J Savarino, J Buchner, DM TI Predicting hospitalization and functional decline in older health plan enrollees: Are administrative data as accurate as self-report? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT AGS Annual Meeting CY MAY, 1997 CL ATLANTA, GEORGIA ID COMPREHENSIVE GERIATRIC ASSESSMENT; RANDOMIZED TRIAL; ADMISSION; RISK; ADULTS; OUTCOMES; QUESTIONNAIRE; MANAGEMENT; CRITERIA; VALIDITY AB OBJECTIVE: To compare the predictive accuracy of two validated indices, one that uses self-reported variables and a second that uses variables derived from administrative data sources, to predict future hospitalization. To compare the predictive accuracy of these same two indices for predicting future functional decline. DESIGN: A longitudinal cohort study with 4 years of follow-up. SETTING: A large staff model HMO in western Washington State. PARTICIPANTS: HMO Enrollees 65 years and older (n = 2174) selected at random to participate in a health promotion trial and who completed a baseline questionnaire. MEASUREMENT: Predicted probabilities from the two indices were determined for study participants for each of two outcomes: hospitalization two or more times in 4 years and functional decline in 4 years, measured by Restricted Activity Days. The two indices included similar demographic charac teristics, diagnoses, and utilization predictors. The probabilities from each index were entered into a Receiver Operating Characteristic (ROC) curve program to obtain the Area Under the Curve (AUG) for comparison of predictive accuracy. RESULTS: For hospitalization, the AUC of the self-report and administrative indices were .696 and .694, respectively (difference between curves, P = .828). For functional decline, the AUC of the two indices were .714 and .691, respectively (difference between curves, P = .144). CONCLUSIONS: Compared with a self-report index, the administrative index affords wider population coverage, freedom from nonresponse bias, lower cost, and similar predictive accuracy. A screening strategy utilizing administrative data sources may thus prove more valuable for identifying high risk older health plan enrollees for population-based interventions designed to improve their health status. C1 Univ Washington, Harborview Med Ctr, Div Gerontol & Geriatr Med, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98104 USA. Univ Washington, Dept Med, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, NW HSR&D Field Program, Seattle, WA USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. RP Coleman, EA (reprint author), Univ Washington, Harborview Med Ctr, Div Gerontol & Geriatr Med, Robert Wood Johnson Clin Scholars Program, Box 359755,325 9th Ave,HH565, Seattle, WA 98104 USA. NR 39 TC 55 Z9 56 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 1998 VL 46 IS 4 BP 419 EP 425 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ZG164 UT WOS:000072973100003 PM 9560062 ER PT J AU Liu, YJ Stagni, G Walden, JG Shepherd, AMM Lichtenstein, MJ AF Liu, YJ Stagni, G Walden, JG Shepherd, AMM Lichtenstein, MJ TI Thioridazine dose-related effects on biomechanical force platform measures of sway in young and old men SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID NURSING-HOME RESIDENTS; ANTIPSYCHOTIC DRUG-USE; RISK-FACTORS; AGED WOMEN; BALANCE; FALLS; TRIAZOLAM; MOBILITY; SCALE; TRIAL AB OBJECTIVE: Thioridazine (TDZ) is associated with an increased risk of falls. The purpose of this study was to determine whether (1) thioridazine increases Biomechanics Force Platform (BFP) measures of sway in a dose-related manner, (2) there is a difference in sway between young and old men, (3) there is a correlation between sway and orthostatic changes in BP and HR. DESIGN: Seven younger (aged 20-42) and five older (aged 70-76) healthy male volunteers received, in a randomized order double-blind design, a single oral dose of 0, 25, and 50 mg of TDZ on three separate days at least 7 days apart and 75 mg on the fourth day of the study. Sway and blood pressure were measured for 24 hours. SETTING: A general clinical research center. MEASUREMENTS: Biomechanics force platform measures of postural sway were measured as the movement of the center of pressure. The elliptical area (EA) and average velocity (AV) were calculated with eyes open and eyes closed. Blood pressure and heart rate were measured for 5 minutes supine and 5 minutes standing. RESULTS: Thioridazine increases BFP sway in a dose-dependent manner. EA increased from 0.56 (SD =.51) cm(2) for placebo to 0.88 (SD = 1.09) cm(2) for 75 mg TDZ. AV increased from 1.07 (SD =.27) cm/sec, placebo, to 1.43 (SD =.55) cm/sec, 75 mg TDZ. Older men swayed more than younger men. Changes followed the expected time course for TDZ. EA and AV were associated with HR and BP, e.g., SEP versus In(EA) and In(AV) (r = -0.21 and r = -0.22, respectively; P<.0001). CONCLUSIONS: Thioridazine increases validated measures of fall risk dose dependently in young and old men. This may explain the effects of neuroleptic drugs on fall risk in older people. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Div Clin Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, Spinal Cord Injury Ctr, Dept Surg, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, Geriatr Res Educ & Clin Ctr 182, San Antonio, TX USA. RP Shepherd, AMM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Div Clin Pharmacol, 7703 Floyd Curl Dr,5-4 MCD, San Antonio, TX 78284 USA. FU NCRR NIH HHS [MO1-RR-01346] NR 40 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 1998 VL 46 IS 4 BP 431 EP 437 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ZG164 UT WOS:000072973100005 PM 9560064 ER PT J AU Lichtenstein, MJ Hazuda, HP AF Lichtenstein, MJ Hazuda, HP TI Cross-cultural adaptation of the hearing handicap inventory for the elderly-screening version (HHIE-S) for use with Spanish-speaking Mexican Americans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID TEST-RETEST RELIABILITY; OLDER ADULTS; IMPAIRMENT; VALIDATION AB OBJECTIVE: To cross-culturally adapt the Hearing Handicap Inventory for the Elderly-Screening Version (HHIE-S) for use with older Spanish-speaking Mexican Americans. SUBJECTS AND SETTING: Two different samples were used. First, a convenience sample of 100 older community-dwelling Mexican American men and women in San Antonio, Texas, was used to test technical equivalence of the Spanish and English language versions of the HHIE-S. Second, a neighborhood-based sample of older Mexican Americans was used to establish conceptual (n = 433) and criterion equivalence (n = 381) of the two HHIE-S language versions. METHODS: Independent forward and back translations were done to create a Spanish language version of the HHIE-S. In the convenience sample, subjects were administered the English and Spanish HHIE-S in random order on separate days. In the neighborhood sample, the HHIE-S was given on one occasion in the language of the subject's preference. Depressive symptoms were assessed using the Geriatric Depression scale to see if the two language versions of the HHIE-S were similarly associated with depression (conceptual equivalence). Hearing impairment was assessed using the Welch-Allyn Audioscope(TM) to see if the two language versions were similarly associated with an audiometric measure for hearing loss (criterion equivalence). RESULTS: In the convenience sample, the overall mean (SD) Spanish and English HHIE-S scores were 6.2 (8.7) and 6.2 (9.3), respectively (P = 1.00). Total scores of the English and Spanish versions were highly correlated (r =.89), and regression analysis indicated that the two language versions gave nearly identical results. In the neighborhood-based sample, men had higher HHIE-S scores than women (OR 2.0, 95% CI = 1.3-3.5). Having depressive symptoms (OR 3.2, 95% CI = 1.9-5.5) or hearing impairment (OR 6.1, 95% CI = 3.5-10.5) was associated with higher HHIE-S scores. After adjustment for gender, depressive symptoms, and/or hearing impairment, the language of interview was not associated with HHIE-S score. CONCLUSION: We have developed and tested a Spanish translation of the HHIE-S that yields equivalent results to those obtained with the English version in bilingual Mexican Americans. The Spanish HHIE-S presented here is suitable for clinical use and research studies involving older Mexican Americans. C1 Audie L Murphy Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Div Geriatr & Gerontol, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Div Clin Epidemiol, San Antonio, TX USA. RP Lichtenstein, MJ (reprint author), Audie L Murphy Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU AHRQ HHS [HS-07397]; NCRR NIH HHS [MO1-RR-01346]; NIA NIH HHS [R01-AG10444] NR 25 TC 19 Z9 22 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 1998 VL 46 IS 4 BP 492 EP 498 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ZG164 UT WOS:000072973100016 PM 9560075 ER PT J AU Grandaliano, G Choudhury, GG Poptic, E Woodruff, K Barnes, JL Abboud, HE AF Grandaliano, G Choudhury, GG Poptic, E Woodruff, K Barnes, JL Abboud, HE TI Thrombin regulates PDGF expression in bovine glomerular endothelial cells SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GROWTH-FACTOR; MESANGIAL CELLS; PROSTACYCLIN PRODUCTION; FIBRIN DEPOSITION; INVITRO; RELEASE; GLOMERULONEPHRITIS; ISOFORMS; GENE AB The proteolytic enzyme thrombin is produced during activation of the coagulation pathway. Intraglomerular fibrin deposition and thrombosis are common pathologic features of several glomerular diseases, including transplant rejection. The effect of thrombin on platelet-derived growth factor (PDGF) production and DNA synthesis in well characterized bovine glomerular endothelial cells (G/endo) was studied. DNA synthesis was measured as the amount of [H-3]thymidine incorporated into acid-insoluble material. PDGF released in the supernatant was measured by Western blotting and by a radioreceptor assay. PDGF mRNA expression was analyzed by solution hybridization, using human genomic PDGF B-chain (c-sis) and A-chain cDNA probes. G/endo constitutively secrete PDGF activity in serum-free medium. Thrombin stimulates PDGF production and increases the expression of mRNA that hybridizes with labeled B-chain but not A-chain probe, whereas epidermal growth factor and transforming growth factor-ct stimulate the expression of PDGF A-chain mRNA. In addition, thrombin stimulates DNA synthesis with a peak effect at 24 h, Unlike endothelial cells from other microvascular beds, G/endo did not respond to any of the three PDGF isoforms BE, AB, or AA. These data demonstrate that bovine G/endo produce PDGF and that thrombin stimulates de novo synthesis of PDGF from these cells. Because mesangial, but not bovine, G/endo express PDGF receptors, PDGF released by G/endo is Likely to modulate mesangial cell functions such as proliferation and matrix production by means of a paracrine mechanism. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Abboud, HE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. RI Grandaliano, Giuseppe/G-2963-2012 FU NIDDK NIH HHS [DK 33665, DK 43988, DK 50190] NR 42 TC 17 Z9 18 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD APR PY 1998 VL 9 IS 4 BP 583 EP 589 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA ZE284 UT WOS:000072776600007 PM 9555660 ER PT J AU Kraut, JA Hiura, J Shin, JM Smolka, A Sachs, G Scott, D AF Kraut, JA Hiura, J Shin, JM Smolka, A Sachs, G Scott, D TI The Na+-K+-ATPase beta 1 subunit is associated with the HK alpha 2 protein in the rat kidney SO KIDNEY INTERNATIONAL LA English DT Article DE renal H+-K+-ATPase; H+-K+-ATPase beta subunit; Na+-K+-ATPase beta(1) subunit ID FUNCTIONAL EXPRESSION; GASTRIC H,K-ATPASE; DISTAL COLON; ALPHA-SUBUNIT; H+; H+,K+-ATPASE; TRANSPORT; OUABAIN; TUBULE; CELLS AB The Na-K-ATPase beta 1 subunit. acts as the beta subunit for the HK alpha(2) protein in the rat kidney. The colonic H+-K+-ATPase is a member of the P-type ATPases, and has been shown to contribute to potassium transport by the mammalian kidney; and colon. The P-type ATPases often consist of an alpha subunit that contains the catalytic site and a beta subunit that participates In regulation of enzyme activity; and targeting of the enzyme to the plasma membrane. The cDNA of the alpha subunit (HK alpha(2)) has been cloned and the HK alpha(2) protein has been isolated from the rat kidney and colon. However, a unique beta subunit for the colonic H+-K+-ATPase has not been described. To determine if one of the known beta subunits present in the kidney might act as the beta subunit for the colonic H+-K+-ATPase, microsomes enriched in the colonic H+-K+-ATPase were isolated using an HK alpha(2)-specific antibody (AS 31.7) and the Minimac magnetic separation system. Immunoblots of rat kidney microsomal protein isolated with antibody AS 31.7 were probed with antibodies directed against the gastric HK beta subunit. Na+-K+-ATPase alpha 1, and Na+-K+-ATPase beta 1 subunits. A band of the appropriate size was detected with Na+-K+-ATPase beta(1)-specific antibodies, but not those directed against HK beta(1). These data suggest that Na+-K+-ATPase beta(1) could be the beta subunit for the colonic H+-K+-ATPase in the kidney. C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Div Nephrol 691 111L, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med,W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Med Univ S Carolina, Div Med, Columbia, SC USA. RP Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Div Nephrol 691 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK43138] NR 32 TC 35 Z9 35 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD APR PY 1998 VL 53 IS 4 BP 958 EP 962 DI 10.1046/j.1523-1755.1998.00841.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA ZD423 UT WOS:000072683700018 PM 9551404 ER PT J AU McHorney, CA AF McHorney, CA TI Methodological inquiries in health status assessment SO MEDICAL CARE LA English DT Editorial Material ID QUALITY-OF-LIFE; MENTAL-HEALTH; DOUBLE-BLIND; DEPRESSION; OUTCOMES C1 Univ Wisconsin, Sch Med, Madison, WI 53706 USA. William S Middleton Mem Vet Hosp, Hlth Serv Res & Dev Program, Madison, WI USA. RP McHorney, CA (reprint author), Univ Wisconsin, Sch Med, Madison, WI 53706 USA. NR 28 TC 11 Z9 11 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 1998 VL 36 IS 4 BP 445 EP 448 DI 10.1097/00005650-199804000-00001 PG 4 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA ZF245 UT WOS:000072878200001 PM 9544585 ER PT J AU Ubel, PA Spranca, MD DeKay, ML Hershey, JC Asch, DA AF Ubel, PA Spranca, MD DeKay, ML Hershey, JC Asch, DA TI Public preferences for prevention versus cure: What if an ounce of prevention is worth only an ounce of cure? SO MEDICAL DECISION MAKING LA English DT Article DE rationing; allocation; person tradeoff; public survey; ethics ID HEALTH-CARE; TRADE-OFF AB Background. The belief that small preventive efforts bring large benefits may explain why many people say they value prevention above all other types of health care. However, it often takes a great deal of preventive medicine to prevent a bad outcome. This study explores whether people value prevention or cure more when each brings the same magnitude of benefit and examines whether preferences for prevention or cure vary according to the severity of the disability of the patients who can receive the preventive or curative intervention. Methods. 289 prospective jurors were presented with a policy dilemma involving how best to allocate funds to benefit people with varying levels of disability. Each project was said to influence the functional ability of 100 nursing home residents, either by improving their level of function or by preventing their level of function from declining. Results. When given a choice between preventive and curative interventions, more subjects preferred the preventive intervention (37% vs 21%, p = 0.002). However, when the strength of people's preferences was taken into account, the preference for preventive interventions was not statistically significant (p = 0.135). With both preventive and curative interventions, the subjects preferred helping patients with more severe disabilities (p < 0.005 for both comparisons). This preference for helping more severely disabled patients did not differ for prevention and cure (p = 0.663). Conclusion. When the magnitude of benefit was held constant, the subjects slightly preferred prevention over cure. In addition, they preferred directing limited resources toward those with greater disabilities, regardless of whether those resources were targeted toward prevention or cure. These findings suggest that previously stated preferences for prevention over cure may result from a belief that small efforts at prevention will be repaid by large reductions in the later need for cure. C1 Univ Penn, Sch Med, Ctr Bioeth, Div Gen Internal Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Rand Corp, Santa Monica, CA USA. Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. Univ Penn, Wharton Sch, Pittsburgh, PA USA. RP Ubel, PA (reprint author), Univ Penn, Sch Med, Ctr Bioeth, Div Gen Internal Med, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA. NR 10 TC 32 Z9 32 U1 0 U2 2 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD APR-JUN PY 1998 VL 18 IS 2 BP 141 EP 148 PG 8 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA ZG626 UT WOS:000073022700002 PM 9566447 ER PT J AU Asch, DA Hershey, JC DeKay, ML Pauly, MV Patton, JP Jedrziewski, MK Frei, F Giardine, R Kant, JA Mennuti, MT AF Asch, DA Hershey, JC DeKay, ML Pauly, MV Patton, JP Jedrziewski, MK Frei, F Giardine, R Kant, JA Mennuti, MT TI Carrier screening for cystic fibrosis: Costs and clinical outcomes SO MEDICAL DECISION MAKING LA English DT Article DE cost-effectiveness; cystic fibrosis; decision making; economics; ethics; genetics; health policy; health screening; methodology; modeling ID PRENATAL-DIAGNOSIS; SPONTANEOUS-ABORTION; PREGNANCIES; ULTRASOUND; WILLINGNESS; ATTITUDES; BENEFITS; ENZYMES; GENE; PAY AB Objectives. To evaluate the costs and clinical effects of 16 alternative strategies for cystic fibrosis (CF) carrier screening in the reproductive setting; and to test the sensitivity of the results to assumptions about cost and detection rate, stakeholder perspective, DNA test specificity, chance of nonpaternity, and couples' reproductive plans. Method. Cost-effectiveness analysis. Results. A sequential screening strategy had the lowest cost per CF birth avoided. In this strategy, the first partner was screened with a standard test that identifies 85% of carriers. The second partner was screened with an expanded test if the first partner's screen was positive. This strategy identified 75% of anticipated CF births at a cost of $367,000 each. This figure does not include the lifetime medical costs of caring for a patient with CF, and it assumes that couples who identify a pregnancy at risk will choose to have prenatal diagnosis and termination of affected pregnancies. The cost per CF birth identified is approximately half this figure when couples plan two children. Conclusions. The cost-effectiveness of CF carrier screening depends greatly on couples' reproductive plans. CF carrier screening is most cost-effective when it is performed sequentially, when the information is used for more than one pregnancy, and when the intention of the couple is to identify and terminate affected pregnancies. These conclusions are important for policy considerations regarding population-based screening for CF, and may also have important implications for screening for less common diseases. C1 Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Ctr Bioeth, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. Univ Rochester, Simon Sch Business, Rochester, NY 14627 USA. Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. RP Asch, DA (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM asch@wharton.upenn.edu FU NHGRI NIH HHS [R01-1HG00616, R01-1HG00621] NR 36 TC 17 Z9 18 U1 0 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD APR-JUN PY 1998 VL 18 IS 2 BP 202 EP 212 PG 11 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA ZG626 UT WOS:000073022700008 PM 9566453 ER PT J AU Clausen, BE Bridges, SL Lavelle, JC Fowler, PG Gay, S Koopman, WJ Schroeder, HW AF Clausen, BE Bridges, SL Lavelle, JC Fowler, PG Gay, S Koopman, WJ Schroeder, HW TI Clonally-related immunoglobulin V-H domains and nonrandom use of D-H gene segments in rheumatoid arthritis synovium SO MOLECULAR MEDICINE LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIABLE REGION GENES; HUMAN-ANTIBODY REPERTOIRE; HIGH ENDOTHELIAL VENULES; HEAVY-CHAIN DIVERSITY; PERIPHERAL B-CELLS; GERM-LINE GENES; SOMATIC MUTATION; NUCLEOTIDE-SEQUENCES; PREFERENTIAL UTILIZATION AB Background: Synovia of patients with long-standing rheumatoid arthritis (RA) are typically infiltrated with B lymphocytes and plasma cells that secrete large amounts of immunoglobulin. The CDR3 of an immunoglobulin heavy chain is composed of the V-H-D-H-J(H) join, with interposed N region addition, and thus defines clonal relatedness. Furthermore, the CDR3 lies at the center of the antigen binding site, so its length and composition influence antigen binding. We sought definitive evidence of an antigen-driven B cell response (i.e., clones derived from the same V-H, D-H, and J(H) gene segments with shared somatic mutations) in RA synovial mRNA transcripts, and to characterize CDR3 intervals at the target of inflammation in this autoimmune disease. Materials and Methods: We screened a cDNA library generated from unselected cells from the knee joint of a 62-year-old white female with long-standing RA. This technique does not have the potential bias of selecting for antibodies that express a particular reactivity such as rheumatoid factor. C gamma recombinants were sequenced and progenitor V-H, D-H, and J(H) gene segments were assigned and somatic mutations determined by comparison to germline sequences. Analyses of D-H reading frame utilization and hydropathy characteristics of CDR3s were performed. Results: Two of 67 recombinants were derived from the same V-H (V3-11) and J(H) gene segments, demonstrated shared mutations, and contained nearly identical V-H- D-H-J(H) joins, including N region addition. Three other recombinants contained identical sequence throughout the variable domain. We also found preferential utilization of a limited number of V-H and D-H gene segments and marked preference for a D-H reading frame encoding predominantly hydrophilic residues. Conclusions: Analysis of expressed heavy chain variable domains strongly supports the hypothesis that the B cell response in RA synovium is at least in part antigen driven and oligoclonal. C1 Univ Alabama, Div Dev & Clin Immunol, Wallace Tumor Inst 378, Birmingham, AL 35294 USA. Univ Alabama, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Schroeder, HW (reprint author), Univ Alabama, Div Dev & Clin Immunol, Wallace Tumor Inst 378, Birmingham, AL 35294 USA. EM harry.schroeder@ccc.uab.edu RI CLAUSEN, Bjorn/A-8229-2010 OI CLAUSEN, Bjorn/0000-0002-2484-7842 FU NIAID NIH HHS [AI18958]; NIAMS NIH HHS [AR01867, AR03555] NR 81 TC 14 Z9 15 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 1076-1551 J9 MOL MED JI Mol. Med. PD APR PY 1998 VL 4 IS 4 BP 240 EP 257 PG 18 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA ZP317 UT WOS:000073740200005 PM 9606177 ER PT J AU Schwartz, MW AF Schwartz, MW TI Orexins and appetite: The big picture of energy homeostasis gets a little bigger SO NATURE MEDICINE LA English DT Editorial Material ID NEUROPEPTIDE-Y; HYPERPHAGIA; OBESITY C1 Univ Washington, Dept Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Schwartz, MW (reprint author), Univ Washington, Dept Med, Seattle, WA 98108 USA. RI Schwartz, Michael/H-9950-2012 NR 14 TC 14 Z9 14 U1 1 U2 2 PU NATURE AMERICA INC PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD APR PY 1998 VL 4 IS 4 BP 385 EP 386 DI 10.1038/nm0498-385 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA ZF531 UT WOS:000072906800024 PM 9546775 ER PT J AU Mendez, MF Cherrier, MM AF Mendez, MF Cherrier, MM TI The evolution of alexia and simultanagnosia in posterior cortical atrophy SO NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY LA English DT Article DE alexia; simultanagnosia; posterior cortical atrophy; dementia ID ALZHEIMERS-DISEASE; BALINTS-SYNDROME; VISUAL AGNOSIA; PURE ALEXIA; WORD-FORM; DEMENTIA; DYSLEXIA; PATIENT; DEFECT AB Early alexia and higher visual impairments characterize Posterior cortical atrophy (PCA), a progressive dementing syndrome most often caused by Alzheimer disease. Posterior cortical atrophy is rare, and the nature of the visual impairments in PCA are unclear. The authors observed two patients who had an insidiously progressive reading difficulty characterized by letter-by-letter reading and otherwise intact cognitive functions. Over time, these patients developed "ventral simultanannosia" with preserved detection of multiple stimuli but inability to interpret whole scenes. Subsequently, they progressed to Balint syndrome with "dorsal simultanagnosia," optic ataxia, and oculomotor apraxia. Structural imaging was normal, but functional imaging revealed posterior cortical dysfunction. On a letter reading task, both patients had a word superiority effect, and on a whole word reading task, they could not read most words with missing or crosshatched letters. An inability to assess whole scenes progressed to an inability to detect more than one stimulus in an array. These findings suggest an evolution of PCA with progressive difficulty in visual integration beginning with letters, progressing to whole scenes, and culminating in Balint syndrome. These changes may reflect an extension of the pathophysiology of PCA from the extrastriate visual cortex to its occipitotemporal and occipitoparietal connections. C1 W Los Angeles Vet Affairs Med Ctr, Neurobehav Unit 116AF, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), W Los Angeles Vet Affairs Med Ctr, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 35 TC 31 Z9 32 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-878X J9 NEUROPSY NEUROPSY BE JI Neuropsychiatr. Neuropsychol. Behav. Neurol. PD APR PY 1998 VL 11 IS 2 BP 76 EP 82 PG 7 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 173JB UT WOS:000078976400004 PM 9652488 ER PT J AU Baker, RR Lichtenberg, PA Moye, J AF Baker, RR Lichtenberg, PA Moye, J TI A practice guideline for assessment of competency and capacity of the older adult SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article AB This article identifies the need for a conceptual and practical model for conducting psychological assessments for competency and capacity in the older adult as part of a legal determination of competency. The role of practice guidelines in responding to this need is discussed, and a practice guideline is described to assist practitioners in responding to requests for such assessments. C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Rehabil Inst Michigan, Detroit, MI USA. Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA. Brockton W Roxbury Vet Affairs Med Ctr, Brockton, MA USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Baker, RR (reprint author), S Texas Vet Hlth Care Syst, San Antonio, TX USA. RI Moye, Jennifer/F-2240-2017 OI Moye, Jennifer/0000-0002-3434-347X NR 21 TC 10 Z9 10 U1 0 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD APR PY 1998 VL 29 IS 2 BP 149 EP 154 DI 10.1037//0735-7028.29.2.149 PG 6 WC Psychology, Multidisciplinary SC Psychology GA ZD922 UT WOS:000072739000010 ER PT J AU Rasmussen, DD AF Rasmussen, DD TI Effects of chronic nicotine treatment and withdrawal on hypothalamic proopiomelanocortin gene expression and neuroendocrine regulation SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE nicotine; proopiomelanocortin; endorphins; hypothalamus; mRNA; withdrawal ID MESSENGER-RNA LEVELS; BETA-ENDORPHIN; CIGARETTE-SMOKING; ARCUATE NUCLEUS; ABSTINENCE SYNDROME; CONDITIONED TOLERANCE; INSITU HYBRIDIZATION; DOPAMINE RELEASE; MEDIAN-EMINENCE; RAT AB Considerable evidence suggest that some responses to smoking and nicotine are mediated by forebrain beta-endorphinergic opioid mechanisms. It has also been demonstrated that nicotine stimulates rat tuberoinfundibular dopaminergic activity. Since we have proposed that interactions between mediobasohypothalamic (MBH) dopaminergic and beta-endorphinergic mechanisms have a key role in neuroendocrine integration, we investigated the effects of chronic nicotine treatment and withdrawal on: (1) MBH concentrations of proopiomelanocortin (POMC, precursor for beta-endorphin biosynthesis) mRNA; (2) MBH concentrations of tyrosine hydroxylase (TH, rate limiting enzyme in catecholamine biosynthesis) mRNA; (3) corresponding, serum prolactin, corticosterone, luteinizing hormone (LH), and testosterone concentrations. POMC and TH mRNA levels were measured by RNase protection/solution hybridization assay; serum hormone levels were measured by radioimmunoassay. Adult male rats received subcutaneous injections of either nicotine or saline during the dark period of each day on an increasing frequency (1-3 injections/day) and dosage (0.4-0.5 mg nicotine/kg body weight) schedule over 4 weeks. The rats were sacrificed after 4 weeks treatment and at 1. 3, 7, 14 and 21 days withdrawal. Chronic daily nicotine administration induced significant changes in serum corticosterone, serum prolactin, MBH TH mRNA, and MBH POMC mRNA concentrations that tended to persist through day 3 of withdrawal; serum prolactin and MBH POMC mRNA concentrations were suppressed whereas serum corticosterone and MBH TH mRNA concentrations were stimulated. None of the parameters were significantly different from control levels following 7 or more days of withdrawal from nicotine, except for a significant decrease of MBH POMC mRNA concentrations on day 21. Chronic daily nicotine or withdrawal did not significantly alter serum LH or testosterone concentrations. These results suggest that chronic nicotine inhibited POMC gene expression and thus, probably, biosynthesis of beta-endorphin and other opiomelanocortins. We hypothesize that suppression of forebrain beta-endorphin synthesis in response to long-term nicotine exposure produces a chronically opioid deficient condition which may play an important role in maintaining nicotine self-administration and in mediating some changes during the nicotine withdrawal syndrome. (C) 1998 Elsevier Science Ltd. All rights reserved. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98195 USA. RP Rasmussen, DD (reprint author), VA Med Ctr, Res Serv 151, Amer Lake, Tacoma, WA 98493 USA. EM drasmuss@u.washington.edu NR 67 TC 34 Z9 36 U1 2 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD APR PY 1998 VL 23 IS 3 BP 245 EP 259 PG 15 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 100KA UT WOS:000074814300003 PM 9695129 ER PT J AU Kaufman, KR Gerner, R AF Kaufman, KR Gerner, R TI Lamotrigine toxicity secondary to sertraline SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE lamotrigine; sertraline; toxicity; metabolism; glucuronidation; epilepsy ID EPIDERMAL NECROLYSIS; ANTICONVULSANT; METABOLISM; VALPROATE AB Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants. We investigated initial drug-drug interactions between lamotrigine and sertraline. We report on case histories of two epileptic patients who were initially on lamotrigine and to whom sertraline was added to control psychiatric features. In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity. In case 2, a 25 mg reduction in the total daily dose of sertraline resulted in halving of the lamotrigine blood level even though the lamotrigine dosage was increased by 33%. This shows that sertraline has potent interactions with lamotrigine metabolism. The authors hypothesize that inhibition of glucuronidation is responsible. Clinicians are advised to observe for symptoms of toxicity and to do serial blood levels to monitor this interaction. C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, New Brunswick, NJ 08901 USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90024 USA. RP Kaufman, KR (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, 125 Paterson St,Clin Acad Bldg,Suite 2200, New Brunswick, NJ 08901 USA. NR 12 TC 63 Z9 63 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD APR PY 1998 VL 7 IS 2 BP 163 EP 165 DI 10.1016/S1059-1311(98)80074-5 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ZN974 UT WOS:000073702700014 PM 9627209 ER PT J AU Hansen, KE Arnason, J Bridges, AJ AF Hansen, KE Arnason, J Bridges, AJ TI Autoantibodies and common viral illnesses SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE autoantibodies; viral infection; parvovirus; hepatitis A, B, C; human immunodeficiency virus ID ACQUIRED IMMUNODEFICIENCY SYNDROME; PARVOVIRUS B19 INFECTION; A VIRUS-INFECTION; ANTICARDIOLIPIN ANTIBODIES; LUPUS ANTICOAGULANT; RHEUMATOID-FACTOR; HEPATITIS-C; MONONUCLEOSIS; CRYOGLOBULINEMIA; AUTOIMMUNITY AB Objectives: To review the literature about common autoantibodies produced in association with viral infection. Methods: Medline review of the medical literature published in English. Results: Common viral infections are often associated with low-titer, polyspecific autoantibodies. However, high-titer antinuclear antibodies, double-stranded DNA antibodies, anticardiolipin antibodies, and other subtype antibodies may be found. Hepatitis C and B virus, human immunodeficiency virus, and parvovirus B19 appear to be associated with autoantibodies more commonly than other viruses. Conclusions: Transient autoantibodies resulting from viral infections are not uncommon. Clinical and laboratory follow-up over time will help distinguish between connective tissue disease and self-limited illness. Copyright (C) 1998 by W.B. Saunders Company. C1 Univ Wisconsin Hosp & Clin, Ctr Clin Sci H6 367, Madison, WI 53792 USA. William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Bridges, AJ (reprint author), Univ Wisconsin Hosp & Clin, Ctr Clin Sci H6 367, 600 Highland Ave, Madison, WI 53792 USA. NR 39 TC 46 Z9 49 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0049-0172 J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD APR PY 1998 VL 27 IS 5 BP 263 EP 271 DI 10.1016/S0049-0172(98)80047-4 PG 9 WC Rheumatology SC Rheumatology GA ZJ120 UT WOS:000073181500001 PM 9572708 ER PT J AU Deutsch, JC AF Deutsch, JC TI Normal digestive physiology and the evaluation of digestive function SO SEMINARS IN ONCOLOGY LA English DT Review ID EXOCRINE PANCREATIC FUNCTION; BILE-ACID MALABSORPTION; FEEDBACK-REGULATION; BREATH TEST; SECRETION; CHOLECYSTOKININ; ABSORPTION; FAT; RELEASE C1 Univ Colorado, Hlth Sci Ctr, Div Gastroenterol, Denver, CO 80262 USA. Denver Vet Affairs Hosp, Denver, CO USA. RP Deutsch, JC (reprint author), Univ Colorado, Hlth Sci Ctr, Div Gastroenterol, 4200 E 9th Ave,Box B-158, Denver, CO 80262 USA. NR 31 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0093-7754 J9 SEMIN ONCOL JI Semin. Oncol. PD APR PY 1998 VL 25 IS 2 SU 6 BP 4 EP 11 PG 8 WC Oncology SC Oncology GA ZT176 UT WOS:000074056800002 PM 9625377 ER PT J AU Bessesen, DH Faggioni, R AF Bessesen, DH Faggioni, R TI Recently identified peptides involved in the regulation of body weight SO SEMINARS IN ONCOLOGY LA English DT Review ID OB/OB MICE; LEPTIN; OBESE; GENE; MUTATION; HUMANS; TUBBY C1 Denver Hlth Med Ctr, Denver, CO 80204 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Bessesen, DH (reprint author), Denver Hlth Med Ctr, Mail Code 4000,777 Bancock St, Denver, CO 80204 USA. FU NIDDK NIH HHS [DK49448, DK40990, DK47311] NR 27 TC 13 Z9 15 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0093-7754 J9 SEMIN ONCOL JI Semin. Oncol. PD APR PY 1998 VL 25 IS 2 SU 6 BP 28 EP 32 PG 5 WC Oncology SC Oncology GA ZT176 UT WOS:000074056800005 PM 9625380 ER PT J AU Hunt, LM Valenzuela, MA Pugh, JA AF Hunt, LM Valenzuela, MA Pugh, JA TI Porque me toco a mi? Mexican American diabetes patients' causal stories and their relationship to treatment behaviors SO SOCIAL SCIENCE & MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-Applied-Anthropology CY MAR 29-APR 02, 1995 CL ALBUQUERQUE, NEW MEXICO SP Soc Appl Anthropol DE diabetes; Locus of Control; causal model; behavioral factors; patient perspective; Mexican Americans ID CHRONIC ILLNESS; HEALTH BELIEFS; EDUCATION; MELLITUS; LOCUS; MANAGEMENT; IDEOLOGY; SCALES; ADULTS; FOCUS AB This paper reports findings from an ethnographic study of self-care behaviors and illness concepts among Mexican-American non-insulin dependent diabetes mellitus (NIDDM) patients. Open-ended interviews were conducted with 49 NIDDM patients from two public hospital outpatient clinics in South Texas. They are self-identified Mexican-Americans who have had NIDDM for at least 1 yr, and have no major impairment due to NIDDM. Interviews focused on their concepts and experiences in managing their illness and their self-care behaviors. Clinical assessment of their glucose control was also extracted from their medical records. The texts of patient interviews were content analyzed through building and refining thematic matrixes focusing on their causal explanations and treatment behaviors. We found patients' causal explanations of their illness often are driven by an effort to connect the illness in a direct and specific way to their personal history and their past experience with treatments. While most cite biomedically accepted causes such as heredity and diet, they elaborate these concepts into personally relevant constructs by citing Provoking Factors, such as behaviors or events. Their causal models are thus both specific to their personal history and consistent with their experiences with treatment success or failure. Based on these findings, we raise a critique of the Locus of Control Model of treatment behavior prevalent in the diabetes education literature. Our analysis suggests that a sense that one's own behavior is important to the disease onset may reflect patients' evaluation of their experience with treatment outcomes, rather than determining their level of activity in treatment. (C) 1998 Elsevier Science Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX 78284 USA. Univ Texas, Dept Social Sci, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Hunt, LM (reprint author), Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX 78284 USA. OI Pugh, Jacqueline/0000-0003-4933-141X FU AHRQ HHS [1-UO1-HSO7397] NR 61 TC 91 Z9 94 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD APR PY 1998 VL 46 IS 8 BP 959 EP 969 DI 10.1016/S0277-9536(97)10014-4 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA ZD022 UT WOS:000072643000003 PM 9579748 ER PT J AU Goldstein, IB Bartzokis, G Hance, DB Shapiro, D AF Goldstein, IB Bartzokis, G Hance, DB Shapiro, D TI Relationship between blood pressure and subcortical lesions in healthy elderly people SO STROKE LA English DT Article DE blood pressure; elderly; heart rate; magnetic resonance imaging ID WHITE-MATTER LESIONS; RISK-FACTORS; HYPERTENSIVE PATIENTS; STROKE; VOLUME AB Background and Purpose-The relationship between blood pressure (BP) and heart rate (HR) and MRI assessments of subcortical T2 hyperintensities was evaluated in healthy elderly men and women. Methods-Casual and 24-hour ambulatory BPs and HR measurements were taken of 144 elderly individuals, aged 55 to 79 years. Subjects had no evidence of previous health disorders. MRT scans of white matter, subcortical gray matter, and insular subcortex were coded for severity of hyperintensities. Results-Mean casual BP for the group was 120/72 mm Hg. With age and sex accounted for, individuals with the highest severity rating of white matter hyperintensities had higher casual, awake, and sleep systolic BPs; higher awake diastolic BPs; greater awake systolic BP variability; and a smaller nocturnal fall in systolic and diastolic BPs than individuals with less severe ratings, Higher severity ratings for subcortical gray matter hyperintensities were associated with elevations in casual, awake, and asleep systolic BPs and a smaller HR drop during sleep. Subjects with higher ratings for the insular subcortex had higher systolic and diastolic BPs (casual, awake, and asleep), greater HR variability during sleep, and a smaller nocturnal fall in HR, Conclusions-Casual and 24-hour ambulatory BPs and some ambulatory HR measures are associated with subcortical lesions of the brain. Longitudinal studies are needed to further explore the relationship between white matter lesions and cardiovascular measures, as well as the significance of these lesions for cerebrovascular disease in healthy elderly subjects. C1 Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA USA. RP Goldstein, IB (reprint author), Univ Calif Los Angeles, Dept Psychiat, 760 Westwood Plaza, Los Angeles, CA 90024 USA. EM irisg@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIA NIH HHS [AG-11595] NR 30 TC 76 Z9 78 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 1998 VL 29 IS 4 BP 765 EP 772 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA ZF529 UT WOS:000072906600005 PM 9550509 ER PT J AU Goodkin, R Laska, LL AF Goodkin, R Laska, LL TI Vascular and visceral injuries associated with lumbar disc surgery: Medicolegal implications SO SURGICAL NEUROLOGY LA English DT Review DE lumbar disc surgery; ventral perforation; vascular/visceral injury; medicolegal implications ID ARTERIOVENOUS-FISTULA; INTERVERTEBRAL-DISK; URETERAL INJURY; OUTCOME ANALYSIS; COMPLICATIONS; DISCECTOMY; SECONDARY; LAMINECTOMY; ANATOMY AB Symptomatic perforation of the anterior annulus fibrosus/anterior longitudinal ligament during surgery for herniated lumbar disc disease is one of the more solemn and sobering complications experienced by neurosurgeons or orthopedic surgeons. This complication frequently results in the death of the patient. Its occurrence is probably more common than the medical community would expect. The authors report 21 cases since 1985 in which an injury to an intra-abdominal vessel or viscera occurred. In all cases litigation resulted and a settlement or verdict was rendered. A review of the literature is presented and the medicolegal implications of symptomatic ventral perforations of the annulus fibrosus/anterior longitudinal ligament are discussed. (C) 1998 by Elsevier Science Inc. C1 Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Tennessee State Univ, Coll Business, Nashville, TN 37203 USA. RP Goodkin, R (reprint author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA. NR 124 TC 58 Z9 62 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0090-3019 J9 SURG NEUROL JI Surg. Neurol. PD APR PY 1998 VL 49 IS 4 BP 358 EP 370 DI 10.1016/S0090-3019(97)00372-8 PG 13 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA ZE443 UT WOS:000072793100001 PM 9537654 ER PT J AU Hsu, JH Brent, GA AF Hsu, JH Brent, GA TI Thyroid hormone receptor gene knockouts SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID EMBRYONIC STEM-CELLS; C-ERBA-ALPHA; V-ERBA; MESSENGER-RNAS; DIFFERENTIAL EXPRESSION; GENERALIZED RESISTANCE; RESPONSE ELEMENT; GENOMIC LOCUS; BETA-GENE; STRUCTURAL-ANALYSIS AB The thyroid hormone receptor genes, TR alpha and TR beta, differ in developmental expression and tissue distribution. TR beta knockout mice have goiter, elevated thyroid hormone and TSH levels, and a functional auditory defect. In contrast, mice with TR alpha 1/alpha 2 inactivation have thyroid hypoplasia, low serum thyroid hormone levels, growth arrest and delayed small intensive maturation. Mice with selective TR alpha 1 inactivation have apparent normal growth and development, but have bradycardia and reduced body temperature. The dramatic differences between these mice with TR beta and TR alpha gene inactivations indicate the differential functional of these genes. The influence of these gene inactivations on thyroid-stimulating hormone regulation is central to the resulting phenotypes. C1 Univ Calif Los Angeles, Sch Med, Dept Med, Mol Endocrinol Lab,W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Mol Endocrinol Lab,W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. RP Hsu, JH (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, Mol Endocrinol Lab,W Los Angeles VA Med Ctr, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 96 TC 41 Z9 42 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD APR PY 1998 VL 9 IS 3 BP 103 EP 112 DI 10.1016/S1043-2760(98)00026-5 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ZU314 UT WOS:000074184300003 PM 18406250 ER PT J AU Shuster, E AF Shuster, E TI The Nuremberg Code: Hippocratic ethics and human rights SO LANCET LA English DT Article C1 Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Shuster, E (reprint author), Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM Shuster.Evelyne@Forum.va.gov NR 28 TC 29 Z9 32 U1 3 U2 9 PU LANCET LTD PI LONDON PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD MAR 28 PY 1998 VL 351 IS 9107 BP 974 EP 977 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA ZE227 UT WOS:000072770900046 PM 9734958 ER PT J AU Sachdev, D Chirgwin, JM AF Sachdev, D Chirgwin, JM TI Order of fusions between bacterial and mammalian proteins can determine solubility in Escherichia coli SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article ID PORCINE PEPSINOGEN; PROCATHEPSIN-D; EXPRESSION; RHODANESE; MITOCHONDRIAL; STABILIZATION; MUTAGENESIS; MUTATIONS AB We made fusions between Escherichia coli maltose-binding protein (MBP) and the mammalian aspartic proteinases pepsinogen or procathepsin D. When MBP was at the N-terminus, the fusions were soluble in E. coli. When the order was reversed, the chimeric proteins formed inclusion bodies. The data suggest that the solubility of fusion proteins is controlled by whether the protein domains emerging first from the ribosome normally fold into soluble or insoluble states. The soluble MBP-aspartic proteinase fusions were stable but proteolytically inactive. MBP-pepsinogen, however, was efficiently renatured from 8 M urea in vitro, suggesting that the E. coli cytoplasm does not support folding of the mammalian partner protein to the native state. Thus, inclusion body formation may be the consequence, rather than the cause, of non-native folding in vivo, and in E. coli soluble proteins may fold into states different from those reached in vitro. (C) 1998 Academic Press. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, Res Serv, San Antonio, TX 78284 USA. RP Chirgwin, JM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCI NIH HHS [P01 CA 40035] NR 32 TC 42 Z9 45 U1 0 U2 3 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAR 27 PY 1998 VL 244 IS 3 BP 933 EP 937 DI 10.1006/bbrc.1998.8365 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA ZF658 UT WOS:000072919100059 PM 9535771 ER PT J AU Fitzgibbon, WR Ploth, DW AF Fitzgibbon, WR Ploth, DW TI Bradykinin acts via luminal B-2 receptors to decrease distal nephron Na absorption in rats. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 20 PY 1998 VL 12 IS 5 SU S MA 3972 BP A685 EP A685 PN 2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HD UT WOS:000076006500358 ER PT J AU Xu, YC Bunegin, M Jin, DC Abboud, HE AF Xu, YC Bunegin, M Jin, DC Abboud, HE TI Apoptosis of glomerular cells is an early manifestation of immunecomplex-mediated glomerulonephritis in the rat SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 20 PY 1998 VL 12 IS 5 SU S MA 4615 BP A796 EP A796 PN 2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HD UT WOS:000076006500997 ER PT J AU Singh, BN AF Singh, BN TI Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article; Proceedings Paper CT Symposium on Can Antiarrhythmic Drugs Survive Survival Trials CY AUG 26, 1997 CL STOCKHOLM, SWEDEN ID VENTRICULAR INTRACELLULAR POTENTIALS; CARDIAC-ARRHYTHMIAS; INTRAVENOUS AMIODARONE; MYOCARDIAL-INFARCTION; SUDDEN-DEATH; DOUBLE-BLIND; ATRIAL; MUSCLE; TACHYARRHYTHMIAS; REPOLARIZATION AB Numerous developments in our knowledge of arrhythmias during the past decade or so have had a major influence on antiarrhythmic drug therapy. It has become increasingly evident that arrhythmias merit treatment not only for the relief of symptoms, with improvement in quality of life, but also for the prolongation of survival by decreasing arrhythmic deaths. No longer can mere suppression of arrhythmias, symptomatic or asymptomatic, be equated with prolonged survival. We now know that antiarrhythmic drugs that act by blocking sodium channels can increase mortality and that the most important determinants of arrhythmia mortality are the degree and nature of ventricular dysfunction. To these considerations must be added the advances in nonpharmacologic approaches to controlling cardiac arrhythmias. There has been a shift to the use of implantable devices and of drugs with alternative modes of action, such as beta blockers and class III drugs (e.g., sotalol, amiodarone). However, the side-effect profiles of these 2 classes of compounds have led to the synthesis and characterization of agents that act simply by blocking greater than or equal to 1 membrane ion channels, The isolated block of the rapid component of the delayed rectifier potassium current (I-Kr) has been associated with patent antifibrillatory activity in the atria, with a neutral (e.g., with dofetilide) or deleterious (with d-sotalol) effect on mortality in postinfarct survivors. Therefore, the focus now is on compounds that can block > 1 ion channel (e.g., tedisamil and azimilide). Azimilide is the first of the class III agents that blocks both components of the delayed rectifier potassium current. The drug's overall action is associated with a spectrum of electrophysiologic properties that hold promise in the control of atrial and ventricular arrhythmias, with potential for improving survival in patients at risk for cardiac arrest. (C) 1998 by Excerpta Medica, Inc. C1 W Los Angeles Vet Affairs Med Ctr, Div Cardiol 111E, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RP Singh, BN (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Cardiol 111E, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 75 TC 40 Z9 40 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAR 19 PY 1998 VL 81 IS 6A SI SI BP 3D EP 13D DI 10.1016/S0002-9149(98)00147-7 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ZE882 UT WOS:000072841100002 PM 9537217 ER PT J AU Simon, SL Domier, C Rawson, R Ling, W AF Simon, SL Domier, C Rawson, R Ling, W TI Cognitive consequences of methamphetamine abuse on tests of frontal lobe function. SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Medicat Dev Unit, Los Angeles, CA 90073 USA. Matrix Inst Addict, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD MAR 18 PY 1998 VL 10 SU S BP 64 EP 64 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA ZJ263 UT WOS:000073196500183 ER PT J AU Arbuckle, MR Harley, JB James, JA AF Arbuckle, MR Harley, JB James, JA TI Anti-Sm B/B ' antibodies in SLE patient sera initially target PPPGMRPP SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Oklahoma, Oklahoma Med Res Fdn, Oklahoma City, OK USA. US Dept Vet Affairs, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 3531 BP A608 EP A608 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006403525 ER PT J AU Bersohn, MM Carmack, C AF Bersohn, MM Carmack, C TI Sodium-calcium exchange activity in atria and ventricles of rabbit and rat hearts SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 593 BP A102 EP A102 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006400595 ER PT J AU Das, M Dempsey, EC Stenmark, KR AF Das, M Dempsey, EC Stenmark, KR TI Selective subpopulations of pulmonary artery adventitial fibroblasts exhibit unique proliferative and apoptotic capabilities. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Colorado, Hlth Sci Ctr, CVP Lab, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dev Biol Lab, Denver, CO 80262 USA. Denver VAMC, Denver, CO 80262 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 1971 BP A339 EP A339 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006401967 ER PT J AU Durant, W Liao, L Peyton, KJ Schafer, AI AF Durant, W Liao, L Peyton, KJ Schafer, AI TI Thrombin stimulates vascular smooth muscle cell polyamine synthesis by inducing cationic amino acid transporter and ornithine decarboxylase gene expression. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Houston VAMC, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 612 BP A105 EP A105 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006400613 ER PT J AU Janech, MG Fitzgibbon, WR Miller, DH Lacy, ER Ploth, DW AF Janech, MG Fitzgibbon, WR Miller, DH Lacy, ER Ploth, DW TI Effect of dilution on renal excretory function of the Atlantic stingray, Dasyatis sabina. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Univ Charleston, Charleston, SC 29424 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 2458 BP A423 EP A423 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006402452 ER PT J AU Kroning, R Lichtenstein, AK Nagami, GT AF Kroning, R Lichtenstein, AK Nagami, GT TI Inhibition of cisplatin toxicity and uptake in renal tubule epithelial cells by L-cysteine. SO FASEB JOURNAL LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 669 BP A115 EP A115 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006400670 ER PT J AU Linnemeyer, PA Seaman, WE AF Linnemeyer, PA Seaman, WE TI Expression of functional NK-complex receptors on mouse uterine decidual NK cells during pregnancy. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco VAMC, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 3491 BP A601 EP A601 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006403487 ER PT J AU Nakamura, MC Linnemeyer, PA Seaman, WE AF Nakamura, MC Linnemeyer, PA Seaman, WE TI Expression and function of chimeric NKR-P1/Ly-49 receptors on RNK-16 natural killer cells. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. San Francisco VAMC, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 3499 BP A602 EP A602 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006403494 ER PT J AU Ruff, LJ Dempsey, EC AF Ruff, LJ Dempsey, EC TI Bryostatin-1 attenuates hypoxic growth of bovine pulmonary artery smooth muscle cells in vitro. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Colorado, Hlth Sci Ctr, CVP Res Lab, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO 80262 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 1970 BP A339 EP A339 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006401964 ER PT J AU Tottempudi, P Reyland, ME Das, M Hoagland, KD Dempsey, EC AF Tottempudi, P Reyland, ME Das, M Hoagland, KD Dempsey, EC TI Regulation of protein kinase C-alpha gene expression in bovine pulmonary artery smooth muscle cells. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Denver VAMC, Denver, CO 80262 USA. Univ Colorado, CVP Res Lab, Hlth Sci Ctr, Denver, CO 80262 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 17 PY 1998 VL 12 IS 4 SU S MA 2753 BP A474 EP A474 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 121HC UT WOS:000076006402748 ER PT J AU Mader, SL Alley, PA AF Mader, SL Alley, PA TI Age-related changes in adenylyl cyclase activity in rat aorta membranes SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE aging; adenylyl cyclase; vascular; beta-adrenergic receptors ID VASCULAR SMOOTH-MUSCLE; BETA-ADRENERGIC RESPONSIVENESS; CYCLIC-AMP METABOLISM; PROTEIN; RELAXATION; RECEPTOR; BINDING; ADRENOCEPTOR; SYSTEM; CELLS AB Blood vessels from aged animals and humans have impaired relaxation and cAMP production to beta-adrenergic stimulation. Direct activators of adenylyl cyclase (AC) such as forskolin are not affected. We hypothesized that analogous findings would occur in membrane preparations. Aortic media membrane preparations from Fischer 344 rats of four age groups (6 weeks to 24 months) were studied. Basal AC activity increased significantly with age. Forskolin-stimulated activity compared to basal tended to be greater in the 6-week and 6-month preparations compared to the 12- and 24-month preparations. AC activity was assessed in the presence of the G protein activators (GTP, GppNHp, NaF). There was no age-related decrease in responsiveness. The receptor agonists isoproterenol (beta-adrenergic), and PGE-1 (prostaglandin), were studied. There was no significant age-related change in responsiveness over basal activity to either of these agonists. There was a slight, but significant increase in the isoproterenol responsiveness over GTP responsiveness in the 6-week-old animals which also approached significance in the 6-month-old animals, but was not seen in the 12- and 24-month-old animals. These data suggest that using a membrane system to assess age-related changes in beta-adrenergic responsiveness in vascular smooth muscle does not retain the robust differences seen in whole vessels. (C) 1998 Published by Elsevier Science Ireland Ltd. All rights reserved. C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97207 USA. RP Mader, SL (reprint author), Oregon Hlth Sci Univ, Portland VA Med Ctr, POB 1035 11V, Portland, OR 97207 USA. EM mader@portland.va.gov NR 22 TC 10 Z9 10 U1 1 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing. Dev. PD MAR 16 PY 1998 VL 101 IS 1-2 BP 111 EP 118 DI 10.1016/S0047-6374(97)00168-1 PG 8 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA ZF487 UT WOS:000072902400009 PM 9593317 ER PT J AU Moffitt, TE Brammer, GL Caspi, A Fawcett, JP Raleigh, M Yuwiler, A Silva, P AF Moffitt, TE Brammer, GL Caspi, A Fawcett, JP Raleigh, M Yuwiler, A Silva, P TI Whole blood serotonin relates to violence in an epidemiological study SO BIOLOGICAL PSYCHIATRY LA English DT Article DE serotonin; violence; aggression; platelet ID FLUID 5-HYDROXYINDOLEACETIC ACID; DISRUPTIVE BEHAVIOR DISORDERS; HUMAN PLATELET SEROTONIN; IMPULSIVE FIRE SETTERS; CEREBROSPINAL-FLUID; AGGRESSIVE-BEHAVIOR; MONOAMINE METABOLITES; PERSONALITY-DISORDERS; HEALTHY-VOLUNTEERS; AUTISTIC DISORDER AB Background: Clinical and animal studies suggest that brain serotonergic systems may regulate aggressive behavior; however, the serotonin/violence hypothesis has not been assessed at the epidemiological level. For study of an epidemiological sample we examined blood serotonin, because certain physiological and behavioral findings suggested that it might serve as an analog marker for serotonergic function. Methods: Whole blood serotonin was measured in a representative birth cohort of 781 21-year-old women (47%) and men (53%). Violence was measured using cumulative court conviction records and participants' self-reports. Potential intervening factors addressed were: gender, age, diurnal variation, diet, psychiatric medications, illicit drug history, season of phlebotomy, plasma tryptophan, platelet count, body mass, suicide attempts, psychiatric diagnoses, alcohol, tobacco, socioeconomic status, IQ, and overall criminal offending. Results: Whole blood serotonin related to violence among men but not women. Violent men's mean blood serotonin level was 0.48 SD above the male population norm and 0.56 SD above the mean of nonviolent men. The finding was specific to violence, as opposed to general crime, and it was robust across two different methods of measuring violence. Together, the intervening variables accounted for 25% of the relation between blood serotonin and violence. Conclusions: To our knowledge, this is the first demonstration that an index of serotonergic function is related to violence in the general population. (C) 1998 Society of Biological Psychiatry. C1 Inst Psychiat, London SE5 8AF, England. Univ Wisconsin, Madison, WI USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Otago, Sch Pharm, Dunedin, New Zealand. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Otago, Sch Med, Dunedin, New Zealand. RP Moffitt, TE (reprint author), Inst Psychiat, 111 Denmark Hill, London SE5 8AF, England. RI caspi, avshalom/D-5294-2011; Moffitt, Terrie/D-5295-2011 OI Moffitt, Terrie/0000-0002-8589-6760 FU NIMH NIH HHS [MH-45070, MH-49414] NR 91 TC 79 Z9 84 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1998 VL 43 IS 6 BP 446 EP 457 DI 10.1016/S0006-3223(97)00340-5 PG 12 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ZB552 UT WOS:000072484000009 PM 9532350 ER PT J AU Huang, M Stolina, M Sharma, S Mao, JT Zhu, L Miller, PW Wollman, J Herschman, H Dubinett, SM AF Huang, M Stolina, M Sharma, S Mao, JT Zhu, L Miller, PW Wollman, J Herschman, H Dubinett, SM TI Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production SO CANCER RESEARCH LA English DT Article ID BRONCHOALVEOLAR LAVAGE FLUID; SYNTHASE MESSENGER-RNA; CLASS-I EXPRESSION; SWISS 3T3 CELLS; PROSTAGLANDIN E(2); T-CELLS; COLORECTAL-CANCER; BRONCHOGENIC-CARCINOMA; ANTITUMOR IMMUNITY; EPITHELIAL-CELLS AB Tumor-derived prostaglandin E-2 (PGE(2)) modifies cytokine balance and inhibits host immunity, We hypothesized that a high level of PGE(2) production by lung tumor cells is dependent on tumor cyclooxygenase (COX)-2 expression, We found that PGE(2) production by A549 non-small cell lung cancer (NSCLC) cells was elevated up to 50-fold in response to interleukin (IL)-1 beta, Reversal of IL-1 beta-induced PGE(2) production in A549 cells was achieved by specific pharmacological or antisense oligonucleotide inhibition of COX-2 activity or expression, In contrast, specific COX-1 inhibition was not effective, Consistent with these findings, IL-1 beta induced COX-2 mRNA expression and protein production in A549 cells, Specific inhibition of COX-2 abrogated the capacity of IL-1 beta-stimulated A549 cells to induce IL-10 in lymphocytes and macrophages, Furthermore, specific inhibition of A549 COX-2 reversed the tumor-derived PGE(2)-dependent inhibition of macrophage IL-12 production when whole blood was cultured in tumor supernatants, Our results indicate that lung tumor-derived PGE(2) plays a pivotal role in promoting lymphocyte and macrophage IL-10 induction while simultaneously inhibiting macrophage IL-12 production, Immunohistochemistry of human NSCLC tissues obtained from lung cancer resection specimens revealed cytoplasmic staining for COX-2 within tumor cells, This is the first description of functional COX-2 expression by NSCLC cells and the definition of a pathway whereby tumor COX-2 expression and a high level of PGE(2) production mediate profound alteration in cytokine balance in the lung cancer microenvironment. C1 Univ Calif Los Angeles, Sch Med,W Los Angeles Vet Affairs Med Ctr, Dept Med,Div Pulm & Crit Care Med, Pulm Immunol Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Biol Chem & Mol & Med Pharmacol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, Sch Med,W Los Angeles Vet Affairs Med Ctr, Dept Med,Div Pulm & Crit Care Med, Pulm Immunol Lab, 111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCI NIH HHS [CA09120, CA71818]; NIGMS NIH HHS [GM24797] NR 84 TC 374 Z9 394 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAR 15 PY 1998 VL 58 IS 6 BP 1208 EP 1216 PG 9 WC Oncology SC Oncology GA ZB892 UT WOS:000072518500025 PM 9515807 ER PT J AU Smith, NL Reiber, GE Psaty, BM Heckbert, SR Siscovick, DS Ritchie, JL Every, NR Koepsell, TD AF Smith, NL Reiber, GE Psaty, BM Heckbert, SR Siscovick, DS Ritchie, JL Every, NR Koepsell, TD TI Temporal trends in unstable angina treatment: 1990-1995 SO CIRCULATION LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 3 PY 1998 VL 97 IS 8 MA P11 BP 821 EP 821 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YY916 UT WOS:000072200800062 ER PT J AU Kasarabada, ND Anglin, MD Khalsa-Denison, E Paredes, A AF Kasarabada, ND Anglin, MD Khalsa-Denison, E Paredes, A TI Variations in psychosocial functioning associated with patterns of progression in cocaine-dependent men SO ADDICTIVE BEHAVIORS LA English DT Article ID DRUG-USE; ABUSERS AB This study examined the relationship between patterns of progression of cocaine use and psychosocial functioning in a sample of cocaine-dependent men who were veterans. Four patterns of progression were examined: mild-severe, moderate-severe, mild-moderate-severe, and severe only. Analysis of variance and post hoc analysis with Duncan grouping revealed significant differences among cocaine users with different patterns of progression in terms of negativism, problem index for situations involving unpleasant emotions, problem index for situations involving urges, depression, somatic anxiety, and medical problems in the family. However, there were no significant differences on sensation seeking, confidence to resist taking cocaine in different situations, obsessive compulsiveness, somatization, attention deficit, and social adjustment. Cocaine users with a severe-only pattern of progression were significantly more dysfunctional than those with mild-moderate-severe progression in terms of negativism, problem index for situations involving unpleasant emotions, depression, and somatic anxiety. Cocaine users with mild-moderate-sever progression had significantly less somatic anxiety than those with mild-severe progression and had less negativism and a lower problem index for urges than those with moderate-severe progression. Logistic regression analysis revealed unique behavioral variables associated with different patterns of progression The implications of these findings for treatment are discussed. (C) 1998 Elsevier Science Ltd. C1 Univ Calif Los Angeles, Drug Abuse Res Ctr, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Kasarabada, ND (reprint author), Univ Calif Los Angeles, Drug Abuse Res Ctr, 1100 Glendon Ave,Suite 763, Los Angeles, CA 90024 USA. EM naga@ucla.edu FU NIDA NIH HHS [DAOO146, DAO4268, DAO7699] NR 27 TC 11 Z9 13 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD MAR-APR PY 1998 VL 23 IS 2 BP 179 EP 189 DI 10.1016/S0306-4603(97)00078-6 PG 11 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA ZC169 UT WOS:000072547700004 PM 9573422 ER PT J AU Shanoudy, H Raggi, P Gasperetti, C Soliman, A Ramachandran, K Ammerman, GE Russell, DC AF Shanoudy, H Raggi, P Gasperetti, C Soliman, A Ramachandran, K Ammerman, GE Russell, DC TI Detection of coronary vasospasm by posthyperventilation technetium-99m sestamibi single-photon emission computed tomography imagine in patients with coronary artery disease SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID PRINZMETALS VARIANT ANGINA; MYOCARDIAL SCINTIGRAPHY; SPASM; HYPERVENTILATION; PECTORIS AB Forced hyperventilation is simple, safe to perform, and can be used as a provocative test for coronary vasospasm. This study assesses whether a vasospastic component of angina might be detected in patients with angiographically "nonobstructive" coronary artery disease by posthyperventilation technetium-99m (Tc-99m) sestamibi single-photon emission computed tomography (SPECT) cardiac imaging, Eleven patients with angiographically nonobstructive coronary artery disease underwent Tc-99m sestamibi SPECT imaging at rest and after forced hyperventilation. Vessel diameters were measured by quantitative angiography before and after forced hyperventilation, and posthyperventilation SPECT images were compared with dipyridamole Tc-99m sestamibi stress images, Forced hyperventilation resulted in a 15% reduction in coronary artery diameter in stenotic segments (p < 0.01), and a 17% reduction in adjacent nonstenotic segments (p < 0.001). Myocardial uptake of Tc-99m sestamibi in segments perfused by vessels with angiographically nonobstructive stenoses was reduced 24% following forced hyperventilation (p < 0.001) compared with only 4% following dipyridamole (p < 0.02), These findings suggest that posthyperventilation Tc-99m sestamibi SPECT imaging in patients with angina pectoris and nonobstructive coronary artery disease may be useful in identifying a vasospastic component of angina. (C) 1998 by Excerpta Medico, Inc. C1 Dept Vet Affairs Med Ctr, Cardiol Sect, Salem, MA USA. Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. RP Russell, DC (reprint author), William S Middleton Mem Vet Hosp, Cardiol Sect 111CA, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 23 TC 5 Z9 5 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAR 1 PY 1998 VL 81 IS 5 BP 573 EP 577 DI 10.1016/S0002-9149(97)00969-7 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ZA900 UT WOS:000072413300008 PM 9514452 ER PT J AU Lavretsky, H Sultzer, D AF Lavretsky, H Sultzer, D TI A structured trial of risperidone for the treatment of agitation in dementia SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 149th Annual Meeting of the American-Psychiatric-Association CY MAY 04-09, 1996 CL NEW YORK, NEW YORK SP Amer Psychiat Assoc ID ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; NEUROLEPTIC TREATMENT; RATING-SCALE; AGGRESSION; PSYCHOSIS; SCHIZOPHRENIA; DISTURBANCES; HALOPERIDOL; MECHANISMS AB Fifteen patients with dementia and agitated behavior were treated in a 9-week structured trial of risperidone. Agitation remitted in all patients, and aggressive behaviors improved early in the course of treatment. The modal optimal risperidone dose was 0.5 mg/day. Extrapyramidal symptoms developed at some point during the trial in eight patients, and cognitive skills declined in three patients. These results indicate that risperidone is effective for treatment of agitation in elderly patients with dementia, although adverse extrapyramidal or cognitive effects may occur, even with low doses. C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Mental Hlth Serv, Geriatr Psychiat Program, Los Angeles, CA USA. RP Lavretsky, H (reprint author), Univ Calif Los Angeles, NPI, Dept Psychiat, 760 Westwood Plaza, Los Angeles, CA 90024 USA. RI Lavretsky, Helen/M-5711-2015 OI Lavretsky, Helen/0000-0001-9990-5085 FU NIA NIH HHS [AG 10123]; NIMH NIH HHS [MH00910] NR 57 TC 39 Z9 40 U1 1 U2 2 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD SPR PY 1998 VL 6 IS 2 BP 127 EP 135 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA ZJ524 UT WOS:000073224800006 PM 9581208 ER PT J AU Molinari, V Kunik, ME Mulsant, B Rifai, AH AF Molinari, V Kunik, ME Mulsant, B Rifai, AH TI The relationship between patient, informant, social worker, and consensus diagnoses of personality disorder in elderly depressed inpatients SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID COLLABORATIVE RESEARCH-PROGRAM; NIMH TREATMENT; RELIABILITY; CONCORDANCE; INTERVIEWS; PREVALENCE AB Two psychiatrists simultaneously administered the Personality Assessment Form (PAF) to 20 depressed geropsychiatric inpatients and to 20 of their relatives (informants). a social worker also completed PAF ratings, and a consensus conference independently assigned an Axis II diagnosis. For patient interviews, categorical and dimensional interrater reliability indices for cluster and total personality disorders (PDs) were generally marginal. For informant interviews, categorical interrater reliability indices for cluster and total PDs were also marginal, but dimensional reliability was high. Consistent with previous research, agreement between categorical scores yielded by the four assessment methods was poor, but agreement between dimensional scores was generally better. It appears that patients, family members, and staff maintain different perspectives on patients' personality that, if overlapping, may provide useful diagnostic data. C1 Baylor Coll Med, Psychol Serv 116B, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Molinari, V (reprint author), Baylor Coll Med, Psychol Serv 116B, Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIMH NIH HHS [MH 49786, MH 30915, MH 52247] NR 29 TC 12 Z9 12 U1 1 U2 3 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD SPR PY 1998 VL 6 IS 2 BP 136 EP 144 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA ZJ524 UT WOS:000073224800007 PM 9581209 ER PT J AU Jarvik, ME Olmstead, RE Schneider, NG Iwamoto-Schaap, PN Madsen, DC AF Jarvik, ME Olmstead, RE Schneider, NG Iwamoto-Schaap, PN Madsen, DC TI Sweeteners and cigarette craving: Glucose, aspartame, sorbitol SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article ID WITHDRAWAL; SMOKING; NICOTINE; SYMPTOMS; SMOKERS AB Objective: To determine whether reported cigarette craving can be relieved with glucose versus other sweeteners. Methods: In Study I (a dose-response, partial crossover design), glucose was compared to the non-nutritive sweetener aspartame on degree of urges to smoke over a brief (3 hour) withdrawal period, Study II compared glucose to sorbitol in a smoking cessation clinic where smokers also received nicotine gum and behavioral intervention, Results: In Study I, cigarette craving increased significantly over time for all subjects (p<.001) but was unaffected by either sweetener. However, in Study II, sorbitol significantly decreased craving while glucose increased it (p<.05), Conclusion: The inconsistent pattern of findings suggests any effect of sweet food consumption on craving for cigarettes is likely to be moderated by many variables. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Jarvik, ME (reprint author), W Los Angeles Vet Affairs Med Ctr, 691-B151D,T-350, Los Angeles, CA 90073 USA. NR 10 TC 9 Z9 9 U1 0 U2 0 PU PNG PUBLICATIONS PI STAR CITY PA PO BOX 4593, STAR CITY, WV 26504-4593 USA SN 1087-3244 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PD MAR-APR PY 1998 VL 22 IS 2 BP 130 EP 140 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA YY502 UT WOS:000072153900006 ER PT J AU Norman, RA Tataranni, PA Pratley, R Thompson, DB Hanson, RL Prochazka, M Baier, L Ehm, MG Sakul, H Foroud, T Garvey, WT Burns, D Knowler, WC Bennett, PH Bogardus, C Ravussin, E AF Norman, RA Tataranni, PA Pratley, R Thompson, DB Hanson, RL Prochazka, M Baier, L Ehm, MG Sakul, H Foroud, T Garvey, WT Burns, D Knowler, WC Bennett, PH Bogardus, C Ravussin, E TI Autosomal genomic scan for loci linked to obesity and energy metabolism in Pima Indians SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID BODY-MASS INDEX; DEPENDENT DIABETES-MELLITUS; NECROSIS-FACTOR-ALPHA; OB GENE REGION; FAT MASS; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; MARKERS FLANKING; EXTREME OBESITY; COMPLEX TRAITS AB An autosomal genomic scan to search for linkage to obesity and energy metabolism was completed in Pima Indians, a population prone to obesity. Obesity was assessed by percent body fat (by hydrodensitometry) and fat distribution (the ratio of waist circumference to thigh circumference). Energy metabolism was measured in;a respiratory chamber as 24-h metabolic rate, sleeping metabolic rate, and 24-h respiratory quotient (24RQ), an indicator of the ratio of carbohydrate oxidation to fat oxidation. Five hundred sixteen microsatellite markers with a median spacing of 6.4 cM were analyzed, in 362 siblings who had measurements of body composition and in 220 siblings who had measurements of energy metabolism. These comprised 451 sib pairs in 127 nuclear families, for linkage analysis to obesity, and 236 sib pairs in 82 nuclear families, for linkage analysis to energy metabolism. Pointwise and multipoint met:hods for regression of sib-pair differences in identity by descent, as well as a sibling-based variance-components method, were used to detect linkage. LOD scores greater than or equal to 2 were found at 11q21-q22, for percent body fat (LOD = 2.1; P = .001), at 11q23-q24, for 24-h energy expenditure (LOD = 2.0; P = .001), and at 1p31-p21 (LOD = 2.0) and 20q11.2 (LOD = 3.0; P = .0001), for 24RQ, by pointwise and multipoint analysts. With the variance-components method, the highest LOD score (LOD = 2.3 P = .0006) was found at 18q21, for percent body fat, and at 1p31-p21 (LOD = 2.8; P = .0003), for 24RQ. Possible candidate genes include LEPR (leptin receptor), at 1p31, and ASIP (agouti-signaling protein), at 20q11.2. C1 NIDDKD, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ 85016 USA. Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA. Sequana Therapeut Inc, Dept Stat Genet, La Jolla, CA USA. Indiana Univ, Sch Med, Dept Med Genet, Indianapolis, IN 46202 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Ravussin, E (reprint author), NIDDKD, Phoenix Epidemiol & Clin Res Branch, NIH, Room 541,4212 N 16th St, Phoenix, AZ 85016 USA. EM eric_ravussin@nih.gov RI Hanson, Robert/O-3238-2015 OI Hanson, Robert/0000-0002-4252-7068 FU NCRR NIH HHS [1 P41 RR03655]; NIDDK NIH HHS [DK-47461] NR 59 TC 157 Z9 157 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD MAR PY 1998 VL 62 IS 3 BP 659 EP 668 DI 10.1086/301758 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA ZF407 UT WOS:000072894400020 PM 9497255 ER PT J AU Hamawaki, M Coffman, TM Lashus, A Koide, M Zile, MR Oliverio, MI DeFreyte, G Cooper, G Carabello, BA AF Hamawaki, M Coffman, TM Lashus, A Koide, M Zile, MR Oliverio, MI DeFreyte, G Cooper, G Carabello, BA TI Pressure-overload hypertrophy is unabated in mice devoid of AT(1A) receptors SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE renin-angiotensin system; aortic stenosis; gene expression; ventricular function ID CONVERTING-ENZYME-INHIBITION; LEFT-VENTRICULAR HYPERTROPHY; ANGIOTENSIN-II RECEPTOR; CARDIAC-HYPERTROPHY; BLOOD-PRESSURE; RAT-HEART; EXPRESSION; RAMIPRIL; GROWTH; ANTAGONIST AB Mechanisms controlling cardiac growth are under intense investigation. Among these, the renin-angiotensin system has received great interest. In the current study, we tested the hypothesis that the renin-angiotensin system was not an obligate factor in cardiac hypertrophy. We examined the left, ventricular hypertrophic response to a pressure overload in mice devoid of the AT(1A) receptor the putative major effector of the growth response of the renin-angiotensin system. Aortic banding produced similar transband gradients in wild-type and AT(1A) knockout mice. The left ventricular mass-to-body weight ratio increased from 3.44 +/- 0.08 to 5.62 +/- 0.25 in wild-type ascending aortic-banded mice. The response in the knockout mice was not different (from 2.97 +/- 0.13 to 5.24 +/- 0.37). We conclude that the magnitude of cardiac hypertrophy is not affected by the absence of the AT(1A) receptor and its signaling pathway and that this component of the renin-angiotensin system is not necessary in cardiac hypertrophy. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs, Charleston, SC 29403 USA. Durham Med Ctr, Nephrol Sect, Durham, NC 27705 USA. RP Carabello, BA (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. NR 25 TC 49 Z9 52 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR PY 1998 VL 274 IS 3 BP H868 EP H873 PG 6 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA YZ791 UT WOS:000072292000016 PM 9530198 ER PT J AU Anderson, RJ Ray, CJ AF Anderson, RJ Ray, CJ TI Potential autocrine and paracrine mechanisms of recovery from mechanical injury of renal tubular epithelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE renal cell injury; growth factors ID FIBROBLAST GROWTH-FACTOR; ENDOTHELIAL-CELLS; RAT-KIDNEY; FACTOR-I; PDGF-B; NECROSIS; REGENERATION; PROTEIN; ULTRASTRUCTURE; PROLIFERATION AB The present studies were done to clarify potential pathways of the nephrogenic repair process. Media removed from mechanically injured vascular smooth muscle cells and LLC-PK(1) renal tubular epithelial cells significantly stimulated [(3)H]thymidine uptake and cell number in quiescent LLC-PK(1) cells, demonstrating the existence of potential autocrine and paracrine pathways of nephrogenic repair. The effect of mechanical injury resulting in release of one or more growth factors into culture media was also found in the opossum kidney OK renal tubular cell line. The nonspecific peptide growth factor antagonist suramin inhibited the effect of media from injured LLC-PK(1) cells to stimulate [(3)H]thymidine uptake in quiescent LLC-PK(1) cells. Exposure of quiescent LLC-PK(1) cells to six growth factors, including acidic and basic fibroblastic growth factors (aFGF and bFGF), platelet-derived growth factors AA and BE (PDGF-AA and PDGF-BB), endothelin-2, and hepatocyte growth factor, reproduced the biological responses seen when quiescent LLC-PK(1) cells were exposed to media from injured cells. Immunoblotting and enzyme-linked immunosorbent assay experiments demonstrated the presence of aFGF, bFGF, and PDGF-BB but not other candidate growth factors in the media from injured LLC-PK(1) cells. A neutralizing antibody directed against bFGF attenuated the effect of media from injured cells to stimulate [(3)H]thymidine uptake in serum-starved LLC-PK(1) cells. These results demonstrate that mechanical injury to renal tubular epithelial cells results in release of aFGF, bFGF, and PDGF-BB into the media and suggests that bFGF may be involved in an autocrine fashion to promote recovery from injury. C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Anderson, RJ (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med, POB B180,4200 E 9th Ave, Denver, CO 80262 USA. NR 39 TC 10 Z9 10 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAR PY 1998 VL 274 IS 3 BP F463 EP F472 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA ZB651 UT WOS:000072493900005 PM 9530262 ER PT J AU Leaf, DA Yusin, M Gallik, D Kleinman, MT AF Leaf, DA Yusin, M Gallik, D Kleinman, MT TI Exercise-induced oxidative stress in patients during thallium stress testing SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE myocardial ischemia; oxidative stress; lipid peroxidation ID ANGIOPLASTY; RELEASE AB Background: Free radical injury is implicated in the pathogenesis of coronary artery disease, including atherogenesis and reperfusion/injury. Strenuous physical exercise can cause oxidative stress by several mechanisms, including reperfusion/injury, We hypothesize that exercise-induced lipid peroxidation is greater among those with than these without exercise-induced myocardial ischemia. Methods: The effect of physical exercise stress testing on plasma malonaldehyde (MDA) levels was compared between patients with (Group A, N = 8) and without (Group B) exercise-induced myocardial ischemia by thallium imaging. Analysis: Two-way ANOVA was used to compare plasma MDA levels pre- and post-exercise, and paired t-test comparisons were conducted for percent MDA changes between Group A and Group B patients. Results: Two-way ANOVA revealed a significant (P = 0.002) directional difference in response to exercise between the groups' mean plasma MDA levels (Group A increased by 46 +/- 12.7 percent, Group B decreased by 16.8 +/- 4.6 percent). Conclusions: Differences in exercise-induced lipid peroxidation between patients with and without thallium documentation of myocardial ischemia have important implications in the development of clinical markers of coronary artery disease and further research related to atherogenesis. C1 W Los Angeles Vet Affairs Med Ctr, Div Gen Internal Med, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Div Cardiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Irvine, Dept Community & Environm Med, Irvine, CA 92717 USA. RP Leaf, DA (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Gen Internal Med, 111G,Wilshire & Sawtelle, Los Angeles, CA 90073 USA. NR 8 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAR PY 1998 VL 315 IS 3 BP 185 EP 187 DI 10.1097/00000441-199803000-00007 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA ZB883 UT WOS:000072517600007 PM 9519931 ER PT J AU Klaustermeyer, WB Kraske, GK Lee, KG Klaustermeyer, WB Kurohara, ML AF Klaustermeyer, WB Kraske, GK Lee, KG Klaustermeyer, WB Kurohara, ML TI Allergic and immunologic profile of symptomatic Persian Gulf war veterans SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article ID HEALTH; STORM AB Background: Persian Gulf War veterans have been enrolled in the Veterans Administration Persian Gulf Health Registry for evaluation of unexplained symptoms and illnesses. The allergy and immunology division at the West Los Angeles Veterans Administration Medical Center evaluated 20 consecutive symptomatic Persian Gulf War veterans. Objective: The purpose of this study was to examine the immunologic profiles of symptomatic Persian Gulf War Veterans. Methods: A detailed history was obtained that included duties/responsibilities, length of time in the Persian Gulf, location, and exposures during the Gulf War. A complete physical examination was performed, with extensive laboratory testing and immediate and delayed hypersensitivity skin testing. Data from these Persian Gulf War Veterans were compared with a control population consisting of 44 non-Persian Gulf War veterans enrolled in our allergy and immunology clinic. Presenting allergic symptoms, presence of atopy, and total serum IgE levels were compared. Results: Persian Gulf study patients and registry patients had a broad spectrum of nonspecific symptoms as compared with allergy clinic control patients who had dermatologic and respiratory symptoms. Persian Gulf study patients with allergy symptoms had a higher mean IgE level (88.7 IU/mL) than Persian Gulf study patients without allergy symptoms (47.5 IU/mL). Persian Gulf study patients with positive skin tests had a higher mean IgE level (161.5 IU/mL) than Persian Gulf study patients with negative skin tests (22.3 IU/mL). Laboratory data showed no significant immune abnormalities. Conclusion: Our study showed that 20 Persian Gulf veterans with a multitude of nonspecific symptoms had no immune abnormality. Mean IgE levels and eosinophil counts correlated with atopic state and reported allergy symptoms. C1 W Los Angeles Vet Affairs Med Ctr, Allergy & Immunol Sect, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Med Serv, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Klaustermeyer, WB (reprint author), W Los Angeles Vet Affairs Med Ctr, Allergy & Immunol Sect, 111R,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 11 TC 6 Z9 6 U1 0 U2 0 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD MAR PY 1998 VL 80 IS 3 BP 269 EP 273 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA ZE352 UT WOS:000072784000010 PM 9532977 ER PT J AU Shea, JA Berlin, JA Bachwich, DR Staroscik, RN Malet, PF McGuckin, M Schwartz, JS Escarce, JJ AF Shea, JA Berlin, JA Bachwich, DR Staroscik, RN Malet, PF McGuckin, M Schwartz, JS Escarce, JJ TI Indications for and outcomes of cholecystectomy - A comparison of the pre and postlaparoscopic eras SO ANNALS OF SURGERY LA English DT Article ID LAPAROSCOPIC CHOLECYSTECTOMY; EXPERIENCE; METAANALYSIS AB Purpose Examine changing patient characteristics and surgical outcomes for patients undergoing cholecystectomy al five community hospitals in 1989 and 1993. Procedures In a retrospective chart review, data were gathered regarding gallstone disease severity, type of admission, patient age, number of comorbidities, American Society of Anesthesiologists (ASA) Physical Status Classification, length of stay, and multiple outcomes of surgery. Main Findings The volume of nonincidental cholecystectomies increased 26%, from 1611 in 1989 to 2031 in 1993. Nearly ail of the increase occurred among patients with uncomplicated cholelithiasis and with elective admissions, in 1993, lengths of stay were significantly shorter and percentages of complications were significantly lower for infectious, cardiac, pulmonary, and gastrointestinal complications when controlling for patient case-mix characteristics. There were more major intraoperative complications (unintended wounds or injuries to the common bile duct, bowel, blood vessel(s), or other organs) in 1993. Conclusions Different types of patients underwent cholecystectomy in 1993 compared with patients in 1989, which supports the hypothesis of changing thresholds. Statements supporting the safety of cholecystectomy in the laparoscopic era were borne out when controlling for differences in patient characteristics. C1 Univ Penn, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Shea, JA (reprint author), Univ Penn, Div Gen Internal Med, Dept Med, Ralston House 318,3615 Chestnut St, Philadelphia, PA 19104 USA. FU AHRQ HHS [HS06481] NR 26 TC 55 Z9 67 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAR PY 1998 VL 227 IS 3 BP 343 EP 350 DI 10.1097/00000658-199803000-00005 PG 8 WC Surgery SC Surgery GA ZC704 UT WOS:000072608200005 PM 9527056 ER PT J AU Cantrell, M Norman, DC AF Cantrell, M Norman, DC TI Skin and soft-tissue infections in the elderly SO BAILLIERES CLINICAL INFECTIOUS DISEASES LA English DT Article DE cellulitis; diabetic foot ulcer; osteomyelitis; erysipelas; pressure sore; infections ID PRESSURE SORES; DIABETIC FOOT; OSTEOMYELITIS; ULCERS; CELLULITIS; STRATEGIES; DIAGNOSIS AB The skin is a basic first-line barrier to infection. Unfortunately, ageing results in substantial changes in skin histology and function which reduce the effectiveness of the integument as a critically important host defence. Age-associated loss of dermal thickness and subcutaneous mass and reduced glandular secretion make the skin less resistant to shearing forces. Furthermore, ageing makes the skin relatively acellular and avascular, reducing the response to injury. There is a reduction in Langerhans' cells, which are the local tissue antigen-presenting cells, which may further compromise local immune response. These and other factors commonly observed in the geriatric population, such as loss of mobility, frequent presence of lower extremity oedema and poor nutrition, may account for the relatively common occurrence of skin and soft-tissue infections in the elderly. In this chapter we will cover only those infections of the skin that are either seen more frequently in geriatric patients or present unique or difficult management problems. These include erysipelas, cellulitis, acute diabetic foot infections and pressure sore infections. C1 W Los Angeles VA Med Ctr, Nursing Home Care Unit, Los Angeles, CA 90075 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles VA Med Ctr, Los Angeles, CA 90075 USA. RP Cantrell, M (reprint author), W Los Angeles VA Med Ctr, Nursing Home Care Unit, Los Angeles, CA 90075 USA. NR 41 TC 3 Z9 3 U1 1 U2 2 PU BAILLIERE TINDALL PI LONDON PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX SN 1071-6564 J9 BAILLIERE CLIN INF D JI Baillieres Clin. Infect. Dis. PD MAR PY 1998 VL 5 IS 1 BP 71 EP 81 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 128AG UT WOS:000076382600006 ER PT J AU Moses, A Nelson, J Bagby, GC AF Moses, A Nelson, J Bagby, GC TI The influence of human immunodeficiency virus-1 on hematopoiesis SO BLOOD LA English DT Review ID EPSTEIN-BARR-VIRUS; MARROW STROMAL CELLS; COLONY-STIMULATING FACTOR; HUMAN-BONE-MARROW; SARCOMA-ASSOCIATED HERPESVIRUS; TUMOR-NECROSIS-FACTOR; NON-HODGKINS-LYMPHOMA; CAPILLARY ENDOTHELIAL-CELLS; POLYMERASE CHAIN-REACTION; CD34(+) PROGENITOR CELLS C1 Oregon Hlth Sci Univ, Oregon Canc Ctr, Div Hematol & Med Oncol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Bagby, GC (reprint author), Oregon Hlth Sci Univ, Oregon Canc Ctr, Div Hematol & Med Oncol, L580,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. FU NIDDK NIH HHS [DK49887] NR 189 TC 197 Z9 201 U1 0 U2 5 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0006-4971 J9 BLOOD JI Blood PD MAR 1 PY 1998 VL 91 IS 5 BP 1479 EP 1495 PG 17 WC Hematology SC Hematology GA YY237 UT WOS:000072127000001 PM 9473211 ER PT J AU Bauer, TR Schwartz, BR Liles, WC Ochs, HD Hickstein, DD AF Bauer, TR Schwartz, BR Liles, WC Ochs, HD Hickstein, DD TI Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34(+) cells derived from a patient with leukocyte adhesion deficiency type 1 SO BLOOD LA English DT Article ID APE LEUKEMIA-VIRUS; MONOCLONAL-ANTIBODIES; RESPIRATORY BURST; HUMAN NEUTROPHILS; FLOW-CYTOMETRY; CROSS-LINKING; SUBUNIT; GLYCOPROTEIN; EXPRESSION; ACTIVATION AB Leukocyte adhesion deficiency or LAD is a congenital immunodeficiency disease characterized by recurrent bacterial infections in which the leukocytes from affected children fail to adhere to endothelial cells and migrate to the site of infection due to heterogeneous defects in the leukocyte integrin CD18 subunit. To assess the feasibility of human gene therapy of LAD, we transduced granulocyte colony-stimulating factor (G-CSF)-mobilized, CD34(+) peripheral blood stem cells derived from a patient with the severe form of LAD using supernatant from the retroviral vector PG13/LgCD18. The highest transduction frequencies (31%) were found after exposure of the cells to retroviral vector on a substrate of recombinant fibronectin fragment CH-296 in the presence of growth factors interleukin-3 (IL-3), IL-6, and stem cell factor. When the phenotype of the transduced cells was monitored by fluorescence-activated cell sorting following in vitro differentiation with growth factors G-CSF and granulocyte-macrophage CSF (GM-CSF), CD11a surface expression was detected immediately after transduction. CD11b and CD11c were expressed at low levels immediately following transduction, but increased over 3 weeks in culture, Adhesion of the transduced cells was nearly double that of nontransduced cells in a cell adhesion assay using human umbilical vein endothelial cells. Transduced cells also demonstrated the ability to undergo a respiratory burst in response to opsonized zymosan, a CD11/CD18-dependent ligand. These experiments show that retrovirus-mediated gene transfer of the CD18 subunit complements the defect in LAD CD34(+) cells resulting in CD11/CD18 surface expression, and that the differentiated myelomonocytic cells derived from the transduced LAD CD34(+) cells display CD11/CD18-mediated adhesion function. These results indicate that ex vivo gene transfer of CD18 into LAD CD34(+) cells, followed by re-infusion of the transduced cells, may represent a therapeutic approach to LAD. (C) 1998 by The American Society of Hematology. C1 VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Div Oncol, Seattle, WA USA. Univ Washington, Sch Med, Div Hematol, Seattle, WA USA. Univ Washington, Sch Med, Div Allergy & Infect Dis, Seattle, WA USA. Univ Washington, Sch Med, Div Pediat, Seattle, WA USA. Univ Washington, Sch Med, Div Mol Med, Seattle, WA USA. RP Bauer, TR (reprint author), VA Puget Sound Hlth Care Syst, Med Res Serv, GMR 151,1660 S Columbian Way, Seattle, WA 98108 USA. FU NHLBI NIH HHS [HL53515, HL54881]; NIDDK NIH HHS [DK48456] NR 27 TC 25 Z9 25 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0006-4971 J9 BLOOD JI Blood PD MAR 1 PY 1998 VL 91 IS 5 BP 1520 EP 1526 PG 7 WC Hematology SC Hematology GA YY237 UT WOS:000072127000005 PM 9473215 ER PT J AU Sinha, S Kaseta, J Santner, SJ Demers, LM Bremmer, WJ Santen, RJ AF Sinha, S Kaseta, J Santner, SJ Demers, LM Bremmer, WJ Santen, RJ TI Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE aromatase inhibitors; estradiol; estrogens; letrozole; medical ovariectomy; premenopausal; uterus ID BREAST-CANCER; ESTROGEN; AMINOGLUTETHIMIDE; BIOSYNTHESIS; INHIBITORS; LETROZOLE; WOMEN AB Aromatase catalyzes the rate limiting step that converts androgens to estrogens. Postmenopausal women with hormone dependent breast cancer respond to first generation aromatase inhibitors such as aminoglutethimide with a marked suppression of circulating estradiol levels. In contrast, premenopausal women appear to be resistant to first generation aromatase inhibitors. The inability to block ovarian aromatase results from the low affinity of first generation inhibitors for the active site of the enzyme. Under these circumstances, the high substrate levels in the premenopausal ovary compete effectively with these inhibitors and do not allow binding of inhibitor to the active site of the enzyme. Second and third generation aromatase inhibitors with higher affinity for aromatase have now been developed and potentially could block ovarian aromatase. To test this possibility, we administered CGS 20267 (letrozole), a highly potent aromatase inhibitor, to cycling female rats. A dose dependent inhibition of uterine weight occurred with maximum effects produced by the 5 mg/kg/day dosage. During a period of 4 weeks, uterine weight was reduced to levels induced by ovariectomy. Ovarian tissue estradiol levels were inhibited by approximately 80%. As a reflection of inhibition of ovarian aromatase activity, the levels of androstenedione in the ovary increased by an order of magnitude. Both LH and FSH plasma levels increased but not to those observed after ovariectomy. The rise in gonadotropin levels induced a statistically significant but relatively small increase in ovarian weights. These results demonstrate the ability to persistently block ovarian aromatase activity in cycling rats with a potent aromatase inhibitor. This study provides a rationale for clinical trials of potent aromatase inhibitors in pre-menopausal women with breast cancer. C1 Univ Virginia, Hlth Sci Ctr, Ctr Canc, Dept Med, Charlottesville, VA 22908 USA. Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA. Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA. Wayne State Univ, Karmanos Canc Inst, Dept Internal Med, Detroit, MI 48201 USA. Univ Washington, Sch Med, Dept Med, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. RP Santen, RJ (reprint author), Univ Virginia, Hlth Sci Ctr, Ctr Canc, Dept Med, Box 334, Charlottesville, VA 22908 USA. NR 15 TC 34 Z9 39 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD MAR PY 1998 VL 48 IS 1 BP 45 EP 51 DI 10.1023/A:1005937900788 PG 7 WC Oncology SC Oncology GA ZA208 UT WOS:000072340000005 PM 9541188 ER PT J AU Shah, IA Jayram, L Gani, OS Fox, IS Stanley, TM AF Shah, IA Jayram, L Gani, OS Fox, IS Stanley, TM TI Papillary serous carcinoma of the peritoneum in a man - A case report SO CANCER LA English DT Article DE papillary serous carcinoma; peritoneum; man; immunocytochemistry ID DIFFUSE MALIGNANT MESOTHELIOMA; PULMONARY ADENOCARCINOMA; PLEURAL MESOTHELIOMA; PSEUDOMESOTHELIOMATOUS CARCINOMA; EPITHELIAL MESOTHELIOMA; MONOCLONAL-ANTIBODIES; LUNG ADENOCARCINOMA; BORDERLINE TUMORS; LEU M1; DIAGNOSIS AB BACKGROUND. Papillary serous carcinoma of the peritoneum (PSCP) is a rare primary peritoneal tumor, described exclusively in women. It is believed to arise from the secondary mullerian system, which is comprised of the pelvic and lower abdominal mesothelial lining and subjacent (subcoelomic) mesenchyme in women. Both mesotheliomas and PSCP arise from the coelomic epithelium, but are clinicopathologically and biologically distinct entities. METHODS. The authors report clinicopathologic findings in a man, age 74 years, who died 3 months after-the diagnosis of an extensive malignant abdominal disease. RESULTS, The routine histologic and immunocytochemical studies of tumor tissue, obtained during the patient's lifetime and at autopsy, validated the unique occurrence of PSCP in a man. CONCLUSIONS. This case illustrates that PSCP can occur in a man and that this diagnosis may be considered in the differential diagnosis of papillary serous tumors of the peritoneum in male patients. Although rare, PSCP is a diagnostically distinct entity the treatment of which is similar to ovarian serous tumors rather than mesotheliomas. (C) 1998 American Cancer Society. C1 Vet Affairs Med Ctr, Dept Pathol & Lab Med, Phoenix, AZ 85012 USA. W Los Angeles Vet Affairs Med Ctr, Pathol & Electron Microscopy Unit, Los Angeles, CA 90073 USA. RP Shah, IA (reprint author), Vet Affairs Med Ctr, Dept Pathol & Lab Med, 650 E Indian Sch Rd, Phoenix, AZ 85012 USA. NR 48 TC 32 Z9 33 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0008-543X J9 CANCER JI Cancer PD MAR 1 PY 1998 VL 82 IS 5 BP 860 EP 866 DI 10.1002/(SICI)1097-0142(19980301)82:5<860::AID-CNCR9>3.0.CO;2-N PG 7 WC Oncology SC Oncology GA YY439 UT WOS:000072146700009 PM 9486574 ER PT J AU Liu, RG Oberley, TD Oberley, LW AF Liu, RG Oberley, TD Oberley, LW TI Effects of endothelial nitric oxide synthase gene expression on the tumor biology of human oral carcinoma SCC-25 cells SO CELL GROWTH & DIFFERENTIATION LA English DT Article ID ACTIVATED MACROPHAGES; HEPATOMA-CELLS; TARGET-CELLS; SOLID TUMOR; L-ARGININE; CYTOTOXICITY; CYTOSTASIS; INHIBITION; INDUCTION; PRODUCT AB Stable transfection of endothelial nitric oxide synthase (eNOS) cDNA in human oral carcinoma SCC-25 cells was performed, Two eNOS-expressing clones were isolated, and both were shown to have increased eNOS expression as assayed by Northern and Western analyses, Furthermore, a nitrite assay indicated that nitric oxide production in eNOS-transfected cells was increased, The growth rate and plating efficiency of eNOS-transfected cells in vitro were lower than that of the wild-type parental or vector control-transfected cells as assayed by growth curves, [H-3]thymidine incorporation, and standard plating efficiency assays in L-arginine-rich medium. However, when these cancer cells were inoculated into nude mice, tumor size of eNOS-transfected cells was smaller during the first 25 days but increased later as compared to tumor size of parental and vector control-transfected cells, It is not clear whether the later increase in tumor size was due to an increase in SCC-25 cancer cell proliferation, normal stromal cell proliferation, or both. These results show significant effects of overexpression of eNOS on tumor growth in vitro and in vivo. C1 Univ Iowa, Med Labs B180, Radiat Res Lab, Iowa City, IA 52242 USA. Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53705 USA. William S Middleton Mem Vet Hosp, Pathol Serv, Madison, WI 53705 USA. RP Oberley, LW (reprint author), Univ Iowa, Med Labs B180, Radiat Res Lab, Iowa City, IA 52242 USA. FU NCI NIH HHS [CA 66081, CA 41267]; NIDCR NIH HHS [DE 10758] NR 31 TC 16 Z9 18 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 1044-9523 J9 CELL GROWTH DIFFER JI Cell Growth Differ. PD MAR PY 1998 VL 9 IS 3 BP 239 EP 246 PG 8 WC Cell Biology SC Cell Biology GA ZB255 UT WOS:000072452700005 PM 9543390 ER PT J AU Lam, S Kennedy, T Unger, M Miller, YE Gelmont, D Rusch, V Gipe, B Howard, D LeRiche, JC Coldman, A Gazdar, AF AF Lam, S Kennedy, T Unger, M Miller, YE Gelmont, D Rusch, V Gipe, B Howard, D LeRiche, JC Coldman, A Gazdar, AF TI Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy SO CHEST LA English DT Article DE autofluorescence; bronchoscopy; early detection; lung neoplasm ID OCCULT LUNG-CANCER; IMAGING TECHNIQUES; SPUTUM CYTOLOGY; EARLY-STAGE; CARCINOMA; CHEMOPREVENTION; PROGRESSION; DYSPLASIA; PROGRAM; THERAPY AB Background: In the treatment of lung cancer, the best outcome is achieved when the lesion is discovered in the intraepithelial (preinvasive) stage. However, intraepithelial neoplastic lesions are difficult to localize by conventional white-light bronchoscopy (WLB). Objective: To determine if autofluorescence bronchoscopy, when used as an adjunct to WLB, could improve the bronchoscopist's ability to locate and remove biopsy specimens from areas suspicious of intraepithelial neoplasia as compared with WLB alone. Method: A multicenter clinical trial was conducted in seven institutions in the United States and Canada. WLB followed by fluorescence examination with the light-induced fluorescence endoscopy (LIFE) device was performed in 173 subjects known or suspected to have lung cancer. Biopsy specimens were taken from all areas suspicious of moderate dysplasia or worse on WLB and/or LIFE examination. In addition, random biopsy specimens were also taken from other parts of the bronchial tree, Results: The relative sensitivity of WLB+LIFE vs WLB alone was 6.3 for intraepithelial neoplastic lesions and 2.71 when invasive carcinomas were also included. The positive predictive value was 0.33 and 0.39 and the negative predictive value was 0.89 and 0.83, respectively, for WLB+LIFE and WLB alone. Conclusion: Autofluorescence bronchoscopy, when used as an adjunct to standard WLB, enhances the bronchoscopist's ability to localize small neoplastic lesions, especially intraepithelial lesions that may have significant implication in the management of lung cancer in the future.. C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Presbyterian St Lukes Med Ctr, Denver, CO USA. Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Penn Hosp, Philadelphia, PA 19107 USA. Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Calif Los Angeles, Los Angeles, CA USA. St Marys Hosp, Evansville Canc Ctr, Evansville, IN USA. British Columbia Canc Res Ctr, Dept Pathol, Vancouver, BC V5Z 1L3, Canada. British Columbia Canc Res Ctr, Dept Epidemiol, Vancouver, BC V5Z 1L3, Canada. Univ Texas, SW Med Ctr, Dept Pathol, Hamon Canc Ctr, Dallas, TX USA. RP Main Floor,2775 Heather St, Vancouver, BC V5Z 3J5, Canada. FU NCI NIH HHS [P50-CA58187] NR 40 TC 394 Z9 405 U1 1 U2 5 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 1998 VL 113 IS 3 BP 696 EP 702 DI 10.1378/chest.113.3.696 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA ZB867 UT WOS:000072516000024 PM 9515845 ER PT J AU Wang, SI Parsons, R Ittmann, M AF Wang, SI Parsons, R Ittmann, M TI Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas SO CLINICAL CANCER RESEARCH LA English DT Article ID ALLELIC LOSS; CHROMOSOME-10; HETEROZYGOSITY; PROGRESSION; CANCER; REGIONS; LOCI AB A novel tumor suppressor gene, PTEN, which encodes a dual-specificity protein phosphatase, has recently been identified on chromosome 10q23. We have previously shown that both alleles of this gene are inactivated in three of four prostate cancer cell lines tested, To evaluate the role of inactivation of this gene in primary stage B prostate cancers, 60 cases were analyzed using Southern blotting with PTEN probes and microsatellites on 10q23. Eight of 60 cases had homozygous deletions by Southern blotting, In three of these cases, homozygous deletion was confirmed by apparent retention of heterozygosity at PTEN with loss of heterozygosity at telomeric and centromeric loci, In the remaining five cases, microsatellite analysis was consistent with homozygous deletion. Loss of heterozygosity at PTEN was found in only two cases both by microsatellite analysis and quantitative Southern blotting, No small mutations within PTEN exons were found in any tumors exhibiting alterations an 10q23, Thus, inactivation of the PTEN gene by homozygous deletion occurs in approximately 10-15% of primary stage B prostate carcinomas. C1 Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA. Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. Univ Houston, Dept Vet Affairs Med Ctr, Res Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. RP Wang, SI (reprint author), Columbia Univ Coll Phys & Surg, Dept Pathol, P&S Bldg,Room 14-453,630 W 168th St, New York, NY 10032 USA. EM rep15@columbia.edu NR 21 TC 149 Z9 161 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAR PY 1998 VL 4 IS 3 BP 811 EP 815 PG 5 WC Oncology SC Oncology GA ZC038 UT WOS:000072533300034 PM 9533551 ER PT J AU Goetz, MB AF Goetz, MB TI Editorial response: Are corticosteroids useful adjunctive agents in the treatment of disseminated Mycobacterium avium complex infection associated with human immunodeficiency virus infection? SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID NECROSIS-FACTOR-ALPHA; AIDS PATIENTS; HIV-INFECTION; GLUCOCORTICOIDS; THERAPY; TYPE-1; MACROPHAGES; REPLICATION; EXPRESSION; DISEASE C1 W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RP Goetz, MB (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI Goetz, Matthew/0000-0003-4542-992X NR 31 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR PY 1998 VL 26 IS 3 BP 687 EP 688 DI 10.1086/514598 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA YZ745 UT WOS:000072287400025 PM 9524845 ER PT J AU Nimmagadda, A O'Brien, WA Goetz, MB AF Nimmagadda, A O'Brien, WA Goetz, MB TI The significance of vitamin A and carotenoid status in persons infected by the human immunodeficiency virus SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID BETA-CAROTENE; A-DEFICIENCY; HIV-INFECTION; TYPE-1 INFECTION; DIETARY-INTAKE; MILD VITAMIN; CARDIOVASCULAR-DISEASE; MICRONUTRIENT INTAKE; RESPIRATORY-DISEASE; INCREASED MORTALITY AB Hyporetinemia is associated with increased childhood morbidity and mortality that is reversible with vitamin A supplementation. Although vitamin A deficiency is otherwise rare in developed countries, the prevalence of hyporetinemia in human immunodeficiency virus (HIV)-infected persons is up to 29%. Hyporetinemic HIV-infected patients have a 3.5-5-fold increased risk of death. Furthermore, HIV-infected patients with very low or very high intake of vitamin A and beta-carotene (a vitamin A precursor) have greater rates of disease progression than do patients with intermediate intake. In developing countries up to 60% of HIV-infected pregnant women are hyporetinemic. In such women the relative risk of perinatal HIV transmission may be increased more than fourfold. These data indicate that vitamin A deficiency is common in HIV-infected patients in the developed world and strongly suggest that vitamin A supplementation may be especially useful in adjunctive therapy for HIV-infected pregnant women who reside in the developing world. C1 W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RP Goetz, MB (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Med, 111F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI Goetz, Matthew/0000-0003-4542-992X NR 83 TC 18 Z9 19 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR PY 1998 VL 26 IS 3 BP 711 EP 718 DI 10.1086/514565 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA YZ745 UT WOS:000072287400030 PM 9524850 ER PT J AU Fudala, PJ Yu, E Macfadden, W Boardman, C AF Fudala, PJ Yu, E Macfadden, W Boardman, C TI Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article; Proceedings Paper CT 97th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics CY MAR 20-22, 1996 CL ORLANDO, FLORIDA SP Amer Soc Clin Pharmcol & Therapeut DE buprenorphine; naloxone; opioid-dependence; treatment ID METHADONE-MAINTAINED VOLUNTEERS; ACUTE PHYSICAL-DEPENDENCE; PRECIPITATED WITHDRAWAL; HUMANS; MAINTENANCE; EXPOSURE; ABUSE AB The present study, conducted as part of the development of a buprenorphine/naloxone combination product, was designed to evaluate the individual and combined effects of intravenously administered buprenorphine and naloxone. This in-patient trial used a randomized, double-blind: crossover design. Ten opioid-dependent male subjects were stabilized and maintained on morphine, lj mg given intramuscularly four times daily. Then, at 48- to 72-h intervals, subjects received one of the following by intravenous injection: (1) placebo, (2) morphine 15 mg, (3) buprenorphine 2 mg, (4) buprenorphine 2 mg/naloxone 0.5 mg, and (5) naloxone 0.5 mg. Both naloxone and buprenorphine/naloxone produced significant (P < 0.005) opioid withdrawal effects compared to placebo as assessed with the CINA scale, an instrument which utilizes subject-and observer-reported, as well as physiological parameters. The combination of buprenorphine with naloxone in a 4:1 ratio produced opioid antagonist-like effects which should limit its potential for intravenous abuse by opioid addicts. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved. C1 Univ Penn, Sch Med, Dept Psychiat, Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. NIDA, Medicat Dev Div, Rockville, MD USA. RP Fudala, PJ (reprint author), Univ Penn, Sch Med, Dept Psychiat, Dept Vet Affairs Med Ctr, Bldg 15,Univ & Woodland Ave, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [YO1-DA30011] NR 36 TC 69 Z9 71 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAR 1 PY 1998 VL 50 IS 1 BP 1 EP 8 DI 10.1016/S0376-8716(98)00008-8 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA ZG913 UT WOS:000073052600001 PM 9589267 ER PT J AU Motomura, K Brent, GA AF Motomura, K Brent, GA TI Mechanisms of thyroid hormone action - Implications for the clinical manifestation of thyrotoxicosis SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA LA English DT Article ID MESSENGER-RIBONUCLEIC-ACID; BETA-ADRENERGIC RECEPTORS; BROWN ADIPOSE-TISSUE; DEVELOPING RAT-BRAIN; GENE-EXPRESSION; RETINOIC ACID; RESPONSE ELEMENTS; MOLECULAR-BASIS; POSTTRANSCRIPTIONAL REGULATION; FUNCTIONAL-CHARACTERIZATION AB Thyroid hormone acts predominantly by combining with high affinity nuclear receptors and modifying gene expression. There are two thyroid hormone receptor genes, alpha and beta, with multiple isoforms that are differentially expressed developmentally and in adult tissues. Thyroid hormone-regulated genes have been identified in a number of tissues, and their expression is altered in thyrotoxicosis. Correlations between the clinical manifestations of thyrotoxicosis and modified gene expression can be made in some tissues. C1 Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Div Endocrinol & Metab, Sch Med,Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Div Endocrinol & Metab, Sch Med,Dept Med, Los Angeles, CA 90073 USA. Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 852, Japan. RP Brent, GA (reprint author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Div Endocrinol & Metab, Sch Med,Dept Physiol, 11301 Wilshire Blvd,111D, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK43714] NR 96 TC 20 Z9 22 U1 1 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8529 J9 ENDOCRIN METAB CLIN JI Endocrinol. Metabol. Clin. North Amer. PD MAR PY 1998 VL 27 IS 1 BP 1 EP + DI 10.1016/S0889-8529(05)70294-2 PG 24 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ZB936 UT WOS:000072523200002 PM 9534024 ER PT J AU Brown, KE Kinter, MT Oberley, TD Freeman, ML Frierson, HF Ridnour, LA Tao, Y Oberley, LW Spitz, DR AF Brown, KE Kinter, MT Oberley, TD Freeman, ML Frierson, HF Ridnour, LA Tao, Y Oberley, LW Spitz, DR TI Enhanced gamma-glutamyl transpeptidase expression and selective loss of CuZn superoxide, dismutase in hepatic iron overload SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE CuZn superoxide dismutase; glutathione; hemochromatosis; 4-hydroxynonenal; lipid peroxidation; free radical ID ISOLATED RAT HEPATOCYTES; GLUTATHIONE S-CONJUGATE; LIPID-PEROXIDATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; HUMAN LIVER; METABOLISM; HEMOCHROMATOSIS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; INACTIVATION AB Liver injury caused by iron overload is presumed to involve lipid peroxidation and the formation of products such as 4-hydroxynonenal (4HNE), which has been implicated in hepatic fibrogenesis. Cellular antioxidants that modulate the formation and detoxification of compounds such as 4HNE may represent important protective mechanisms involved in the response to iron overload, This study examines the relationship between 4HNE, collagen content, and antioxidant defenses in the livers of rats fed carbonyl iron for 10 weeks. Iron-loading resulted in significant increases in iron (8.8-fold), 4HNE(1.7-fold), and hydroxyproline (1.5-fold). Total glutathione content was unchanged by iron, but gamma-glutamyl transpeptidase activity (GGT) increased sixfold and CuZn superoxide dismutase (CuZnSOD) activity decreased >90%. GGT colocalized with iron deposition and was associated with increased GGT mRNA. Decreased CuZnSOD activity was paralleled by a reduction in CuZnSOD protein on Western blot and immunohistochemistry, but no decrease in CuZnSOD mRNA. Glutathione S-transferase (GST) and Mn superoxide dismutase (Mn SOD) activities were also significantly increased by iron loading. These results demonstrate that iron overload significantly alters the expression of antioxidant enzymes associated with glutathione (GGT and GST) and superoxide metabolism (CuZnSOD and MnSOD). Furthermore, the localized induction of GGT may enhance detoxification of lipid peroxidation-derived aldehydes via glutathione-dependent pathways in iron-loaded hepatocytes. These alterations in antioxidant defenses may represent an adaptive response, limiting accumulation 4HNE, and thus, stimulation of collagen synthesis, accounting for the mild fibrogenic response seen in this model of iron overload. (C) 1998 Elsevier Science Inc. C1 St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, St Louis, MO 63110 USA. John Cochran VAMC, Med Serv, Gastroenterol Sect, St Louis, MO USA. Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA. Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA. Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Hosp, Lab Serv, Pathol Sect, Madison, NJ USA. Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA. Washington Univ, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO USA. RP Brown, KE (reprint author), St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, Box 15250, St Louis, MO 63110 USA. EM brown.kyle_e@st-louis.va.gov OI Freeman, Michael/0000-0003-1881-366X; Kinter, Michael/0000-0001-7409-8918 FU NCI NIH HHS [CA38079]; NHLBI NIH HHS [HL42057]; NIDDK NIH HHS [DK03907] NR 54 TC 51 Z9 52 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAR 1 PY 1998 VL 24 IS 4 BP 545 EP 555 DI 10.1016/S0891-5849(97)00284-0 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA ZE226 UT WOS:000072770800005 PM 9559866 ER PT J AU Netscher, D Alford, EL Wigoda, P Cohen, V AF Netscher, D Alford, EL Wigoda, P Cohen, V TI Free composite myo-osseous flap with serratus anterior and rib: Indications in head and neck reconstruction SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE myo-osseous flap; serratus anterior; rib; head and neck reconstruction ID MANDIBULAR RECONSTRUCTION; BONE; DEFECTS; MUSCLE AB Background. Although the microvascular transfer of the serratus/rib myo-osseous composite flap has been previously described, the indications for its use in head and neck reconstruction have not been fully explored. Slender and easily contoured, rib bone offers reconstructive advantages over other hone sources under certain circumstances. The serratus/rib myo-osseous flap can provide vascularized muscle, bone, and cartilage; in combination with the latissimus dorsi muscle, the serratus/rib flap provides additional soft-tissue bulk on a single thoracodorsal vascular pedicle unrestricted by orientation requirements of the bone. Many orientations of bone and sofi tissue are possible. Methods. We describe, through three illustrative cases, the indications for this Rap, which might include bony, cartilaginous, and soft-tissue requirements in the retromolar trigone region, large calvarial defects, and large composite full-thickness cheek and mandibular defects. Conclusions. The serratus/rib composite myo-osseous flap reliably provides vascularized bone of relatively delicate composition which offers advantages in certain reconstructive circumstances, In addition, when combined with latissimus dorsi muscle on a single Vascular pedicle, it supplies additional soft-tissue bulk which can be positioned without being constrained by the hone placement. Finally, this is a useful "backup" supply of vascularized bone when other sources cannot be used due to, for example, inability to use fibula in the face of severe peripheral vascular disease and inability to use iliac crest if this has been previously used as a donor site for nonvascularized free grafts (as in secondary reconstructions). (C) 1998 John Wiley & Sons, Inc. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Otorhinolaryngol & Communicat Sci, Houston, TX 77030 USA. Univ Texas, SW Med Ctr, Dept Plast Surg, Dallas, TX USA. RP Netscher, D (reprint author), Baylor Coll Med, Div Plast Surg, 6560 Fannin,Suite 800, Houston, TX 77030 USA. NR 19 TC 21 Z9 23 U1 0 U2 0 PU JOHN WILEY & SONS INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD MAR PY 1998 VL 20 IS 2 BP 106 EP 112 DI 10.1002/(SICI)1097-0347(199803)20:2<106::AID-HED2>3.0.CO;2-6 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA YV240 UT WOS:000071803400002 PM 9484940 ER PT J AU Gulley, ML Burton, MP Allred, DC Nicholls, JM Amin, MB Ro, JY Schneider, BG AF Gulley, ML Burton, MP Allred, DC Nicholls, JM Amin, MB Ro, JY Schneider, BG TI Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma SO HUMAN PATHOLOGY LA English DT Article DE nasopharyngeal carcinoma; Epstein-Barr virus; p53 ID NF-KAPPA-B; PREINVASIVE LESIONS; GENE; EXPRESSION; MUTATIONS; PROTEIN; CANCER; TRANSACTIVATOR; PROLIFERATION; INDUCTION AB Eight-three cases of nasopharyngeal carcinoma were evaluated for the presence of Epstein-Barr virus (EBV) infection in tumor cells by in situ hybridization to EBER1 transcripts, and for p53 expression by immunostains using the D07 antibody which detects native and mutant forms of the p53 protein. A highly significant association was found between EBV infection and p53 overexpression (P = .0004), with 77% of cases coexpressing both markers, This newly discovered association suggests that EBV is not an innocent bystander with respect to p53 accumulation. One possible mediator of the interaction between EBV and p53, viral BZLF1, was not colocalized. with p53 in these tumors, suggesting that BZLF1 is not the factor responsible for p53 accumulation. From an epidemiological standpoint, this series of cancers represents an international cohort in which cases from an endemic part of the world (Hong Kong) were examined alongside cases from the United Slates, where the disease is 50-fold less prevalent. The cancers from Hong Kong tended to be less differentiated and more frequently associated with EBV, suggesting that biological differences might underlie epidemiological variations in turner prevalence. Finally, we examined 18 potential;premalignant lesions of the surface epithelium of the nasopharynx. Although our numbers are small, our data suggest that p53 accumulation might precede EBV infection in the transition from metaplasia to carcinoma in situ. Further studies are needed to dissect the stepwise progression of nasopharyngeal carcinogenesis. Copyright (C) 1998 by W.B. Saunders Company. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Dept Pathol, San Antonio, TX 78284 USA. Wilford Hall USAF Med Ctr, Dept Pathol, San Antonio, TX 78236 USA. Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong. Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA. Univ Texas, Md Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA. RP Gulley, ML (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCI NIH HHS [P30-CA54174] NR 41 TC 52 Z9 57 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD MAR PY 1998 VL 29 IS 3 BP 252 EP 259 DI 10.1016/S0046-8177(98)90044-2 PG 8 WC Pathology SC Pathology GA YZ606 UT WOS:000072270900009 PM 9496828 ER PT J AU Shang, ES Skare, JT Exner, MM Blanco, DR Kagan, BL Miller, JN Lovett, MA AF Shang, ES Skare, JT Exner, MM Blanco, DR Kagan, BL Miller, JN Lovett, MA TI Isolation and characterization of the outer membrane of Borrelia hermsii SO INFECTION AND IMMUNITY LA English DT Article ID VARIABLE MAJOR PROTEINS; ANTIGENIC VARIATION; RELAPSING FEVER; GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE; HAEMOPHILUS-INFLUENZAE; TREPONEMA-PALLIDUM; ESCHERICHIA-COLI; IMMUNOGLOBULIN-D; SURFACE PROTEIN; BURGDORFERI AB The outer membrane of Borrelia hermsii has been shown by freeze-fracture analysis to contain a low density of membrane-spanning outer membrane proteins which have not yet been isolated or identified, In this study, we report the purification of outer membrane resides (OMV) from B. hem?sii HS-I and the subsequent identification of their constituent outer membrane proteins. The B. hermsii outer membranes were released by vigorous vortexing of whole organisms in low-pH, hypotonic citrate buffer and isolated by isopycnic sucrose gradient centrifugation. The isolated OMV exhibited porin activities ranging from 0.2 to 7.2 nS, consistent with their outer membrane origin. Purified OMV were shown to be relatively free of inner membrane contamination by the absence of measurable beta-NADH oxidase activity and the absence of protoplasmic cylinder-associated proteins observed by Coomassie blue staining. Approximately 60 protein spots (some of which are putative isoelectric isomers) with 25 distinct molecular weights were identified as constituents of the OMV enrichment. The majority of these proteins were also shown to he antigenic with sera from B. hermsii-infected mice. Seven of these antigenic proteins were labeled with [H-3]palmitate, including the surface-exposed glycerophosphodiester phosphodiesterase, the variable major proteins 7 and 33, and proteins of 15, 17, 38, 42, and 67 kDa, indicating that they are lipoprotein constituents of the outer membrane. In addition, immunoblot analysis of the OMV probed with antiserum to the Borrelia garinii surface-exposed p66/Oms66 porin protein demonstrated the presence of a p66 (Oms66) outer membrane homolog. Treatment of intact B. hermsii with proteinase IC resulted ire the partial proteolysis of the Oms66/p66 homolog, indicating that it is surface exposed. This identification and characterization of the OMV proteins should aid in further studies of pathogenesis and immunity of tick-borne relapsing fever. C1 Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Inst Neuropsychiat, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. Texas A&M Univ, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Shang, ES (reprint author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave,CHS 43-239, Los Angeles, CA 90095 USA. EM eshang@microimmun.medsch.ucla.edu FU NIAID NIH HHS [R01 AI029733, AI-37312, F32 AI009117, T32 AI007323, AI-29733, AI-21352, R01 AI037312] NR 44 TC 19 Z9 19 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAR PY 1998 VL 66 IS 3 BP 1082 EP 1091 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA YY565 UT WOS:000072160900029 PM 9488399 ER PT J AU Rossen, RD Birdsall, HH Mann, DL AF Rossen, RD Birdsall, HH Mann, DL TI The enemy within: Immunologic responses to cardiac tissue SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Review ID STREPTOCOCCAL M-PROTEIN; VIRAL MYOCARDITIS; LYMPHOCYTIC MYOCARDITIS; ENDOMYOCARDIAL BIOPSY; TRYPANOSOMA-CRUZI; CYCLOSPORINE-A; DISEASE; MICE; CARDIOMYOPATHY; MECHANISMS C1 Houston Vet Affairs Med Ctr, Dept Allergy & Immunol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Dept Cardiol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA. Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA. RP Rossen, RD (reprint author), Houston Vet Affairs Med Ctr, Dept Allergy & Immunol, Bldg 109,Rm 147,2002 Holcombe Blvd, Houston, TX 77030 USA. OI Mann, Douglas /0000-0002-2516-0145 NR 72 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 1056-9103 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD MAR PY 1998 VL 7 IS 3 BP 129 EP 144 PG 16 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ZF690 UT WOS:000072922300009 ER PT J AU Frye, MA Ketter, TA Altshuler, LL Denicoff, K Dunn, RT Kimbrell, TA Cora-Locatelli, G Post, RM AF Frye, MA Ketter, TA Altshuler, LL Denicoff, K Dunn, RT Kimbrell, TA Cora-Locatelli, G Post, RM TI Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Review DE clozapine; bipolar disorder; neuroleptics ID MIDBRAIN DOPAMINE NEURONS; MANIC-DEPRESSIVE ILLNESS; PSYCHOTIC MOOD DISORDERS; CAUDATE NUCLEI VOLUMES; FOS PROTEIN EXPRESSION; LONG-TERM TREATMENT; SCHIZOPHRENIC-PATIENTS; SCHIZOAFFECTIVE DISORDER; TARDIVE-DYSKINESIA; RISPERIDONE TREATMENT AB Traditional neuroleptics are often utilized clinically for the management of bipolar disorder. Although effective as antimanic agents, their mood stabilizing properties are less clear. Additionally, their acute clinical side effect profile and long term risk of tardive dyskinesia, particularly in mood disorder patients, portend significant liability. This review focuses on the use of atypical antipsychotics in the treatment of bipolar disorder focusing on clozapine as the prototypical agent. Although, preclinical research and clinical experience suggest that the atypical antipsychotics are distinctly different from typical antipsychotics, they themselves are heterogeneous in profiles of neuropharmacology, clinical efficacy, and tolerability. The early clinical experience of clozapine as a potential mood stabilizer suggests greater antimanic than antidepressant properties. Conversely, very preliminary clinical experience with risperidone suggests greater antidepressant than antimanic properties and some liability for triggering or exacerbating mania. Olanzapine and sertindole are under investigation in psychotic mood disorders. The foregoing agents and future drugs with atypical neuroleptic properties should come to play an increasingly important role, compared to the older classical neuroleptics, in the acute and long term management of bipolar disorder. (C) 1998 Elsevier Science B.V. C1 NIMH, Biol Psychiat Branch, Bethesda, MD 20892 USA. Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Frye, MA (reprint author), NIMH, Biol Psychiat Branch, Bethesda, MD 20892 USA. EM maf@helix.nih.gov NR 147 TC 93 Z9 97 U1 3 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAR PY 1998 VL 48 IS 2-3 BP 91 EP 104 DI 10.1016/S0165-0327(97)00160-2 PG 14 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ZC526 UT WOS:000072589200001 PM 9543198 ER PT J AU Bell, NH AF Bell, NH TI Renal and nonrenal 25-hydroxyvitamin D 1 alpha-hydroxylases and their clinical significance SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Review ID CULTURED ALVEOLAR MACROPHAGES; GROWTH FACTOR-I; CIRCULATING 1-ALPHA,25-DIHYDROXYVITAMIN-D; PARATHYROID-HORMONE; SERUM CONCENTRATION; CALCITROIC ACID; DIETARY CALCIUM; D METABOLISM; 1,25-DIHYDROXYVITAMIN-D3; SARCOIDOSIS C1 Med Univ S Carolina, Dept Med, Med Ctr, Ralph H Johnson Dept Vet Affairs, Charleston, SC 29401 USA. RP Bell, NH (reprint author), Med Univ S Carolina, Dept Med, Med Ctr, Ralph H Johnson Dept Vet Affairs, 109 Bee St, Charleston, SC 29401 USA. NR 42 TC 42 Z9 43 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAR PY 1998 VL 13 IS 3 BP 350 EP 353 DI 10.1359/jbmr.1998.13.3.350 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YZ967 UT WOS:000072313100002 PM 9525334 ER PT J AU Devlin, RD Reddy, SV Savino, R Ciliberto, G Roodman, GD AF Devlin, RD Reddy, SV Savino, R Ciliberto, G Roodman, GD TI IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)(2)D-3, on osteoclast-like cell formation in normal human bone marrow cultures SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article; Proceedings Paper CT 18th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 07-11, 1996 CL SEATTLE, WASHINGTON SP Amer Soc Bone & Mineral Res ID INTERLEUKIN-6 PRODUCTION; GIANT-CELLS; RESORPTION; TUMORS; ANTAGONISTS; DISEASE; INVITRO AB A potent interleukin-6 (IL-6) antagonist (Sant 5), which binds tightly to the IL-6 alpha receptor but has impaired gp130 heterodimerization, has been developed recently by site-directed mutagenesis of human IL-6. We report here that Sant 5 inhibits IL-6-stimulated osteoclast-like multinucleated cell (MNC) formation in human marrow cultures but also inhibits the stimulatory effects of IL-1 or tumor necrosis factor alpha (TNF-alpha in these cultures, We further show that a neutralizing antibody to IL-6 also inhibits the stimulatory effects of IL-1 or TNF-alpha in these cultures. In contrast, Sant 5 had no effect on parathyroid hormone related protein (PTHrP) or 1,25-dihydroxyvitamin D-3 stimulated MNC formation in human marrow cultures, Transfection of a human marrow stromal cell line, which normally induces osteoclast formation through production of IL-6, with the Sant 5 cDNA driven by a cytomegalovirus (CMV) promoter blocked the capacity of these cells to stimulate osteoclast-like cell formation, These Sant 5 transfected cells and conditioned media from these cells also inhibited the stimulatory effects of the parent cell line on MNC formation, These data suggest that IL-6 mediates the effects of IL-1 and TNF on human osteoclast formation, but in contrast to murine systems, does not mediate the effects of PTHrP, These data further demonstrate that stromal cells transfected with the Sant 5 cDNA can constitutively produce high levels of the IL-6 antagonist and inhibit osteoclast formation in vitro. C1 Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX USA. Ist Ric Biol Mol, Dept Genet, Rome, Italy. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Roodman, GD (reprint author), 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. OI Savino, Rocco/0000-0002-4046-1472 FU NIA NIH HHS [AG 39529]; NIADDK NIH HHS [AM 35188]; NIAMS NIH HHS [AR 41336] NR 17 TC 50 Z9 56 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAR PY 1998 VL 13 IS 3 BP 393 EP 399 DI 10.1359/jbmr.1998.13.3.393 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YZ967 UT WOS:000072313100007 PM 9525339 ER PT J AU Namnoum, AB Merriam, GR Moses, AM Levine, MA AF Namnoum, AB Merriam, GR Moses, AM Levine, MA TI Reproductive dysfunction in women with Albright's hereditary osteodystrophy SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID STIMULATORY-G-PROTEIN; NUCLEOTIDE REGULATORY PROTEIN; GS-ALPHA-GENE; ADENYLYL-CYCLASE; ACTIVATING MUTATIONS; DEFICIENT ACTIVITY; CA2+ MOBILIZATION; PARENTAL ORIGIN; BINDING PROTEIN; PSEUDOHYPOPARATHYROIDISM AB Most individuals with Albright's hereditary osteodystrophy (AHO) have deficient expression or function of G(s alpha), the alpha subunit of the guanine nucleotide binding protein that stimulates adenylyl cyclase, and are resistant to parathyroid hormone (PTH) and other hormones that act via stimulation of adenylyl cyclase. To determine the incidence and etiology of ovarian dysfunction in women with AHO, we examined the reproductive history and hypothalamic-pituitary-ovarian axis in 17 affected women aged 17-43 yr. All patients had typical PTH resistance and an approximately 50% reduction in erythrocyte G(s alpha) activity. (0.43 +/- 0.03 vs. 0.92 +/- 0.08 for normal control subjects, P < 0.001). Fourteen of the 17 patients (76%) were oligomenorrheic or amenorrheic, more than half had delayed or incomplete sexual development, and only two had a history of earlier pregnancy. Most women were mildly hypoestrogenic, with normal to slightly elevated serum gonadotropin levels. Computer analysis of 24 degrees LH measurement showed that the frequency of LH peaks/24 h in AHO women varied widely, but as a group they were not statistically different from a group of normal women studied in the early follicular phase. Administration of 100 mu g synthetic GnRH produced normal FSH and LH responses. We conclude that reproductive dysfunction is common in women with AHO and probably represents partial resistance to gonadotropins. C1 Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA. Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21287 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Div Reprod Endocrinol, Seattle, WA 98195 USA. State Univ Hosp, Dept Med, Syracuse, NY 13210 USA. RP Levine, MA (reprint author), Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, 863 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA. EM mlevine@welchlink.welch.jhu.edu OI Levine, Michael/0000-0003-0036-7809 FU NCRR NIH HHS [RR-00052]; NIDDK NIH HHS [DK-34281] NR 34 TC 36 Z9 37 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 1998 VL 83 IS 3 BP 824 EP 829 DI 10.1210/jc.83.3.824 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ZA804 UT WOS:000072403500022 PM 9506735 ER PT J AU Sutton, DA Slifkin, M Yakulis, R Rinaldi, MG AF Sutton, DA Slifkin, M Yakulis, R Rinaldi, MG TI US case report of cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (R-mackenziei): Criteria for identification, therapy, and review of other known dematiaceous neurotropic taxa SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CENTRAL NERVOUS-SYSTEM; XYLOHYPHA-BANTIANA; CLADOSPORIUM-TRICHOIDES; BRAIN-ABSCESS; EXOPHIALA-DERMATITIDIS; WANGIELLA-DERMATITIDIS; CELL TYPE; INFECTION; PATIENT; PHEOHYPHOMYCOSIS AB We report a case of cerebral phaeohyphomycosis in a 36-year-old male caused by the neurotropic fungus Ramichloridium obovoideum (Matushima) de Hoog 1977 (Ramichloridium mackenziei Campbell et Al-Hedaithy 1993). This man resided in the Middle East, where the fungus appears to be endemic and, possibly, geographically restricted, since all previous reports of brain abscesses due to this organism have been for patients indigenous to this area. As a servant of the Saudi Arabian royal family, he appeared in the United States seeking treatment for chronic weight loss, fatigue, decreased memory, and a more recent 2-week history of right-hand weakness which worsened to involve the entire right upper extremity. On the day prior to his admission, he had a focal motor seizure with rotation of the head and eyes to the right, followed by secondary generalization. A computerized tomogram showed a ring-enhancing hypodense lesion in the left parietal subcortical region with associated edema and mass effect. Diagnosis of a fungal etiology was made following a parietal craniotomy and excisional biopsy by observation of septate, dematiaceous hyphal elements 2 to 3 mu m in width on hematoxylin-and-eosin-stained sections from,within areas of inflammation and necrosis. Culture of the excised material grew out a dematiaceous mould which was subsequently identified as R. obovoideum. At two months postsurgery and with a regimen of 200 mg of itraconazole twice a day, the patient was doing well and returned to Saudi Arabia. His condition subsequently deteriorated, however, and following a 7-month course of itraconzole, he expired. We use this case to alert clinicians and personnel in clinical mycology laboratories of the pathogenicity of this organism and its potential occurrence in patients with central nervous system signs and symptoms who have resided in the Middle East and to review and/or compare R. obovoideum with other neurotropic, dematiaceous taxa and similar nonneurotropic, dematiaceous species. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. Allegheny Gen Hosp, Dept Lab Med, Pittsburgh, PA 15212 USA. RP Sutton, DA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 53 TC 52 Z9 53 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 1998 VL 36 IS 3 BP 708 EP 715 PG 8 WC Microbiology SC Microbiology GA YX389 UT WOS:000072035100020 PM 9508300 ER PT J AU Hunt, LM Pugh, J Valenzuela, M AF Hunt, LM Pugh, J Valenzuela, M TI How patients adapt diabetes self-care recommendations in everyday life SO JOURNAL OF FAMILY PRACTICE LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-Applied-Anthropology CY MAR 29-APR 02, 1995 CL ALBUQUERQUE, NEW MEXICO SP Soc Appl Anthropol DE diabetes mellitus, type 2; patient acceptance of health care; poverty; self-care; Hispanic Americans ID HYPOGLYCEMIA; EDUCATION; MANAGEMENT; MELLITUS; SYMPTOMS AB BACKGROUND. Our study explored behavioral factors affecting what patients with type 2 diabetes do for self-care and why they do it. The findings were used to develop clinical recommendations to improve intervention strategies. METHODS. Interviewers, using open-ended questions, explored patients' own perceptions and assessments of self-care behaviors. The fifty-one subjects were self-identified Mexican Americans who had type 2 diabetes for at least 6 months, and had no major impairment as a result of this diabetes. Texts of patient interviews were analyzed by building and refining matrixes to display and compare central themes regarding treatment strategies and their contexts. RESULTS. All patients were trying to control their diabetes, but none of them followed recommendations completely. Instead, they adapted self-care behaviors to the exigencies of everyday life. Key factors influencing patients' treatment choices were: (1) the belief in the power of modern medicine; (2) the desire to act and feel "normal"; (3) the desire to avoid physical symptoms; and (4) limited economic resources. CONCLUSIONS. As patients apply treatment recommendations in the context of their everyday lives, they continually must make many small decisions affecting self-care behavior. The specific contexts of patients' lives, including their economic, educational, and cultural circumstances, determine how the generalized principles of type 2 diabetes management are implemented, Clinical strategies must be responsive to these circumstances in order to enable patients to make appropriate decisions when adapting their self-care behaviors to their own situations. C1 Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Mexican Amer Med Treatment Effectiveness Res Ctr, San Antonio, TX 78284 USA. Univ Texas, Dept Social Sci, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Hunt, LM (reprint author), Univ Texas, Hlth Sci Ctr, Sch Nursing, 7700 Floyd Curl Dr, San Antonio, TX 78284 USA. OI Pugh, Jacqueline/0000-0003-4933-141X FU AHRQ HHS [1-UO1-HSO7397] NR 36 TC 68 Z9 68 U1 0 U2 6 PU APPLETON & LANGE PI E NORWALK PA 25 VAN ZANT ST, E NORWALK, CT 06855 USA SN 0094-3509 J9 J FAM PRACTICE JI J. Fam. Pract. PD MAR PY 1998 VL 46 IS 3 BP 207 EP 215 PG 9 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA ZB691 UT WOS:000072497900012 PM 9519018 ER PT J AU Berkwits, M Inui, TS AF Berkwits, M Inui, TS TI Making use of qualitative research techniques SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article C1 Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Berkwits, M (reprint author), Ralston House 3W,3615 Chestnut St, Philadelphia, PA 19104 USA. NR 12 TC 32 Z9 33 U1 1 U2 3 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 1998 VL 13 IS 3 BP 195 EP 199 DI 10.1046/j.1525-1497.1998.00054.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ZC325 UT WOS:000072565900008 PM 9541377 ER PT J AU Mendez, MF Doss, RC Cherrier, MM AF Mendez, MF Doss, RC Cherrier, MM TI Use of the cognitive estimations test to discriminate frontotemporal dementia from Alzheimer's disease SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article ID FRONTAL-LOBE DEGENERATION; MEMORY; SCALE AB This study investigated the cognitive estimations test (CET) in patients with frontotemporal dementia (FTD) and Alzheimer's disease (AD). The CET consists of questions which reflect judgment and reasoning. FTD patients, who have predominant frontotemporal atrophy, may give more extreme estimates on the CET compared to AD patients, who have greater temporoparietal pathology. The CET was administered to 31 FTD and 31 AD patients of comparable dementia severity plus 31 normal elderly controls. Both dementia groups gave significantly more extreme estimates on the CET than did the controls, and, contrary to expectations, AD patients gave more extreme estimates than did FTD patients. Extreme CET scores correlated with poor savings and calculations scores on neuropsychological tests. In conclusion, the CET may be particularly impaired in AD because it reflects impaired memory and numerical ability as well as disturbed judgment and reasoning. The CET may also be helpful in discriminating some patients in moderate stages of AD from those with FTD. C1 W Los Angeles VA Med Ctr, Neurobehav Unit 691116AF, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. St Paul Ramsey Med Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), W Los Angeles VA Med Ctr, Neurobehav Unit 691116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 26 TC 17 Z9 17 U1 0 U2 0 PU DECKER PERIODICALS INC PI HAMILTON PA 4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD SPR PY 1998 VL 11 IS 1 BP 2 EP 6 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA ZZ678 UT WOS:000074755600001 PM 9686745 ER PT J AU Thompson, JT Rackley, MS Menick, DR O'Brien, TX AF Thompson, JT Rackley, MS Menick, DR O'Brien, TX TI Co-regulation of Nkx2-5 transcriptional activation in cardiac hypertrophy. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 1998 VL 46 IS 3 SU S BP 202A EP 202A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA ZK545 UT WOS:000073335300072 ER PT J AU Kahn, T AF Kahn, T TI Hypernatremia with edema. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 CUNY Mt Sinai Sch Med, Bronx Vet Adm Med Ctr, Nephrol Sect, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 1998 VL 46 IS 3 SU S BP 221A EP 221A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA ZK545 UT WOS:000073335300188 ER PT J AU Stehman-Breen, CO Lindberg, J Sherrard, DJ AF Stehman-Breen, CO Lindberg, J Sherrard, DJ TI Racial differences in bone mineral density among end stage renal disease patients. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 VA Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 1998 VL 46 IS 3 SU S BP 223A EP 223A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA ZK545 UT WOS:000073335300197 ER PT J AU Gilkeson, GS Molano, I AF Gilkeson, GS Molano, I TI Decreased autoantibody production in TDT deficient autoimmune mice SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 1998 VL 46 IS 3 SU S BP 229A EP 229A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA ZK545 UT WOS:000073335300234 ER PT J AU Oates, JC Reily, CM Christensen, EF Gilkeson, GS AF Oates, JC Reily, CM Christensen, EF Gilkeson, GS TI The role of nitric oxide in systemic lupus erythematosus. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Ralph H Johnson Vet Adm Med Ctr, Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 1998 VL 46 IS 3 SU S BP 229A EP 229A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA ZK545 UT WOS:000073335300233 ER PT J AU Huang, Y Nussbaum, N Jaffa, AA Lopes-Virella, MF AF Huang, Y Nussbaum, N Jaffa, AA Lopes-Virella, MF TI Oxidized LDL-containing immune complexes stimulate mitogen-activated protein (MAP) kinase in macrophages. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 1998 VL 46 IS 3 SU S BP 232A EP 232A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA ZK545 UT WOS:000073335300255 ER PT J AU Das, D Orengo, CA Kunik, ME Molinari, V Workman, RH AF Das, D Orengo, CA Kunik, ME Molinari, V Workman, RH TI Cognitive decline in patients on an acute geropsychiatric unit SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article AB The authors compared patients in a geropsychiatric unit who showed marked cognitive decline during hospitalization with those who did not. Patients who declined in cognitive function were older, were more likely to have a diagnosis of dementia, and were more anergic on admission. These patients were also discharged to move restrictive living environments. The subgroup of demented patients who declined in cognitive function were also older and improved less on anxiety and depression. C1 Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. RP Orengo, CA (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, 1 Baylor Plaza, Houston, TX 77030 USA. NR 9 TC 3 Z9 3 U1 0 U2 0 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 1998 VL 10 IS 2 BP 205 EP 209 PG 5 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA ZN416 UT WOS:000073643700010 PM 9608410 ER PT J AU O'Brien, CP Childress, AR Ehrman, R Robbins, SJ AF O'Brien, CP Childress, AR Ehrman, R Robbins, SJ TI Conditioning factors in drug abuse: can they explain compulsion? SO JOURNAL OF PSYCHOPHARMACOLOGY LA English DT Article DE addiction; conditioning; craving; dependence ID CUE EXPOSURE TREATMENT; ALCOHOL DEPENDENCE; NUCLEUS-ACCUMBENS; CONTROLLED TRIAL; OPIATE ADDICTS; COCAINE ABUSE; SMOKING CUES; REACTIVITY; TOLERANCE; BEHAVIOR AB There is a good deal of clinical evidence suggesting that compulsion to resume drug taking is an important part of the addiction syndrome. The symptoms comprising motivation to resume drug use, namely craving and compulsion, have been studied experimentally in human subjects. While much work remains to be done, there is evidence showing that these symptoms are influenced by learning. The research has been guided by animal studies demonstrating that drug effects can be conditioned. Much attention has been directed toward demonstrating the existence of drug conditioning in human addicts and exploring the neurological structures that may underlie such learned responses,We do not yet know the relative importance of learning in the overall phenomenon of relapse, and treatments based on conditioning principles are still under investigation. C1 Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP O'Brien, CP (reprint author), Univ Penn, Vet Affairs Med Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [P50 DA 5186, R0 1 DA 000586] NR 63 TC 407 Z9 412 U1 2 U2 15 PU SAGE PUBLICATIONS LTD PI LONDON PA 6 BONHILL STREET, LONDON, ENGLAND EC2A 4PU SN 0269-8811 J9 J PSYCHOPHARMACOL JI J. Psychopharmacol. PD MAR PY 1998 VL 12 IS 1 BP 15 EP 22 DI 10.1177/026988119801200103 PG 8 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA ZH321 UT WOS:000073096300003 PM 9584964 ER PT J AU Moe, KE Prinz, PN Larsen, LH Vitiello, MV Reed, SO Merriam, GR AF Moe, KE Prinz, PN Larsen, LH Vitiello, MV Reed, SO Merriam, GR TI Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID CLINICAL RESEARCH-CENTER; FACTOR-I; TRANSDERMAL ESTROGEN; BINDING-PROTEIN; GH SECRETION; AGING MEN; SLEEP; SEX; ESTRADIOL; AGE AB Studies of estrogen effects on growth hormone (GH) and its pulsatile release in postmenopausal women have typically utilized estrogen replacement therapy (ERT) of relatively short duration (days to weeks). The purpose of this study was to compare GH measures from healthy postmenopausal women who were on oral ERT for 3 years or more (n = 24; mean ERT duration = 16.1 years) with women not on ERT (NERT; n = 40). Blood samples were drawn remotely every 20 min for 24 h and then analyzed for mean 24-h GH, mean GR during sleep, and mean 24-h insulin-like growth factor-I (IGF-I). GH peak analyses were also performed. Mean 24-h GH and GH during sleep were significantly higher and IGF-I was significantly lower in ERT women compared with NERT women. In addition, use of long-term ERT was associated with more GH peaks relative to women not on ERT; hut no change in GH peak amplitude or area. GH was not related to age in either group. GH was strongly and negatively correlated with measures of adiposity in NERT women hut not in ERT women. in conclusion, long-term oral ERT is associated with increased circulating GH and decreased IGF-I levels, even after many gears of treatment. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Amer Lake Div, Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Tacoma, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Moe, KE (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA. FU NIA NIH HHS [AG10943, AG12915]; NIMH NIH HHS [MH33688] NR 46 TC 20 Z9 20 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 1998 VL 53 IS 2 BP B117 EP B124 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ZB926 UT WOS:000072522200006 PM 9520907 ER PT J AU Klaustermeyer, WB Kinney, JL AF Klaustermeyer, WB Kinney, JL TI Nomograms to follow recovery rate in status asthmaticus in a veteran population SO MILITARY MEDICINE LA English DT Article ID BRONCHIAL-ASTHMA; CONTROLLED TRIAL; METHYLPREDNISOLONE; PREDNISOLONE; THERAPY AB Data from 12 Department of Veterans Affairs patients hospitalized for status asthmaticus were analyzed to determine the rate and degree of response to therapy, The time to achieve recovery was directly related to the level of baseline obstruction at the time of hospital admission, The recovery rate was constant and could be described by a single second-degree polynomial regression equation. Nomograms were constructed showing this rate of improvement of pulmonary function over time at four levels of baseline pulmonary obstruction. C1 W Los Angeles Vet Affairs Med Ctr, Allergy & Immunol Sect, Med Serv, Los Angeles, CA 90073 USA. RP Klaustermeyer, WB (reprint author), W Los Angeles Vet Affairs Med Ctr, Allergy & Immunol Sect, Med Serv, 11301 Wilshire Blvd,111R, Los Angeles, CA 90073 USA. NR 20 TC 1 Z9 1 U1 0 U2 0 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD MAR PY 1998 VL 163 IS 3 BP 177 EP 179 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA ZA537 UT WOS:000072374300012 PM 9542860 ER PT J AU Cannova, JV AF Cannova, JV TI Multiple giant cell tumors in a patient with Gulf War syndrome SO MILITARY MEDICINE LA English DT Article AB "Persian Gulf syndrome" refers to a group of clinical findings found in military personnel who served in the Persian Gulf War. The most commonly reported symptoms include chronic fatigue, headache, and neurologic disorders, Recently, new information has linked Whipple's disease and Ki-1 anaplastic large cell lymphoma to this syndrome, Presented here is an unusual case of multiple giant cell tumors of the hand in a patient with documented Persian Gulf syndrome. The epidemiologic significance between these true entities is unclear, because this is a single reported case, However, the practical message is clear. Physicians must meticulously evaluate patients who are veterans of the Persian Gulf conflict to further our understanding and confirm the existence of this syndrome. C1 Ralph H Johnson Vet Adm Med Ctr, Dept Surg, Div Plast Surg, Charleston, SC 29401 USA. RP Cannova, JV (reprint author), Ralph H Johnson Vet Adm Med Ctr, Dept Surg, Div Plast Surg, 109 Bee St, Charleston, SC 29401 USA. NR 5 TC 4 Z9 4 U1 0 U2 1 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD MAR PY 1998 VL 163 IS 3 BP 184 EP 185 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA ZA537 UT WOS:000072374300014 PM 9542862 ER PT J AU Hubble, JP Kurth, JH Glatt, SL Kurth, MC Schellenberg, GD Hassanein, RES Lieberman, A Koller, WC AF Hubble, JP Kurth, JH Glatt, SL Kurth, MC Schellenberg, GD Hassanein, RES Lieberman, A Koller, WC TI Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia SO NEUROEPIDEMIOLOGY LA English DT Article DE Parkinson's disease; dementia; cytochrome P-450; pesticides ID ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; EDUCATION; PREVALENCE; AGE; ALLELE; DEBRISOQUINE; ASSOCIATION; ONSET; FREQUENCIES AB We had previously examined environmental, sociodemographic and clinical variables as predictors for Parkinson's disease with dementia (PD + D) and found that lower educational attainment, greater motor impairment and advanced age at disease onset were more common in PD + D than in subjects with Parkinson's disease without dementia (PD - D), We now explore the hypothesis that genetic traits coupled with nongenetic factors may raise the risk of development of PD + D, The study cohort of 43 PD + D and 51 PD - D subjects was analyzed examining environmental, sociodemographic and clinical variables along with 3 candidate gene markers: poor debrisoquine metabolizer allele (CYP 2D6 29B+), monoamine oxidase B allele 1, and apolipoprotein E epsilon 4 allele, Variables were initially entered into a multivariate model singly. Again lower education, age at onset and motor impairment appeared as predictors of PD + D while other variables (including allele status) failed to emerge as significant individual risk factors for dementia, We then examined environmental and genetic variables analyzed in tandem to look for potential variable interactions. Subjects who had pesticide exposure and at least I copy of the CYP 2D6 29B+ allele had 83 % predicted probability of PD + D (stepwise logistic regression model: p = 0.0491), This case-control study provides preliminary evidence that a gene-toxin interaction may play an etiological role in PD + D, Further assessment of the role of these putative risk factors in incident dementia in PD is indicated. C1 Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA. Univ Kansas, Med Ctr, Dept Biometry, Kansas City, KS 66103 USA. Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Hubble, JP (reprint author), Ohio State Univ Hosp, Dept Neurol, 1654 Upham Dr,463 Means Hall, Columbus, OH 43210 USA. FU NIA NIH HHS [AG0513C, AG10182] NR 52 TC 30 Z9 30 U1 2 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PD MAR-APR PY 1998 VL 17 IS 2 BP 96 EP 104 DI 10.1159/000026159 PG 9 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA ZK331 UT WOS:000073309000007 PM 9592786 ER PT J AU Cummings, JL AF Cummings, JL TI Metrifonate: Overview of safety and efficacy SO PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT Symposium on New Advances in the Treatment of Alzheimers Disease CY JUL 12, 1997 CL DALLAS, TX ID ALZHEIMERS-DISEASE; CONTROLLED TRIAL; DOUBLE-BLIND; INHIBITOR AB Metrifonate is a cholinesterase inhibitor with a long-lasting inhibition that raises brain acetylcholine levels. It is well-absorbed and has limited binding to serum proteins. In preliminary studies of its utility in the treatment of Alzheimer disease's (AD), it led to improvements of cognition or reduced the rate of decline of cognition compared with placebo. It also benefited the global function of these patients. Side effects include nausea, cramping, and diarrhea. Metrifonate has promise as a well-tolerated treatment of the symptoms of AD. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Reed Neurol Res Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Neuropsychiat & Neurobehav Unit, Los Angeles, CA 90073 USA. RP Cummings, JL (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Reed Neurol Res Ctr, 710 Westwood Plaza, Los Angeles, CA 90095 USA. FU NIA NIH HHS [AG10123] NR 24 TC 14 Z9 14 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD MAR-APR PY 1998 VL 18 IS 2 SU S BP 43 EP 46 PN 2 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 111LG UT WOS:000075438400003 PM 9543464 ER PT J AU Letran, JL Brawer, MK AF Letran, JL Brawer, MK TI Management of radiation failure for localized prostate cancer SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Review DE prostate cancer; radiation failure; salvage prostatectomy; cryoablation; androgen deprivation therapy ID SALVAGE RADICAL PROSTATECTOMY; GUIDED PERCUTANEOUS CRYOABLATION; EXTERNAL BEAM IRRADIATION; STAGE C ADENOCARCINOMA; TERM FOLLOW-UP; CRYOSURGICAL ABLATION; KERATIN IMMUNOREACTIVITY; I-125 IMPLANTATION; ANTIGEN LEVELS; NEEDLE-BIOPSY AB Due to the historically large number of patients with localized prostate cancer (CAP) treated by radiation therapy, an increasing number of patients are presenting local failure. The currently available concepts regarding its definition as well as management options are reviewed. The literature regarding radiation failure for localized prostate cancer was reviewed. Emphasis was made on articles concerning definition of radiation failure, patient evaluation and restaging and definitive as well as palliative management options. There is definitely a subset of patients with locally recurrent prostate cancer without evidence of metastasis that could potentially benefit from aggressive local therapy A treatment algorithm is proposed but it should be emphasized that treatment options should be individualized to suit the need of a particular patient. C1 Univ Washington, Sect Urol 112UR, Dept Urol, VA Puget Sound Hlth Care Syst,Med Ctr, Seattle, WA 98108 USA. RP Brawer, MK (reprint author), Univ Washington, Sect Urol 112UR, Dept Urol, VA Puget Sound Hlth Care Syst,Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 90 TC 6 Z9 6 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD MAR PY 1998 VL 1 IS 3 BP 119 EP 127 DI 10.1038/sj.pcan.4500225 PG 9 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 115RA UT WOS:000075677900005 ER PT J AU Williams, W Weiss, TW Edens, A Johnson, M Thornby, JI AF Williams, W Weiss, TW Edens, A Johnson, M Thornby, JI TI Hospital utilization and personality characteristics of veterans with psychiatric problems SO PSYCHIATRIC SERVICES LA English DT Article ID INPATIENT SERVICES; CARE AB Objective: The relationship between hospital utilization and psychometric, demographic, and diagnostic data was examined among veterans with psychiatric problems, Methods: Data were obtained from the records of 500 psychiatric inpatients admitted to a Veterans Affairs medical center between 1984 and 1987 and followed for four years. All patients completed the Minnesota Multiphasic Personality Inventory, the California Personality Inventory, the Millon Clinical Multiaxial Inventory, and the Psychological Inventory of Personality and Symptoms. Stepwise linear regression analysis was used to predict the number and length of inpatient stays, and Cox and logistic regression analyses predicted rehospitalization. Results: Higher rates of psychiatric hospital utilization were found among patients who were unmarried, who had disabilities connected with their military service, who had lower levels of adaptive functioning, and who were diagnosed as having posttraumatic stress disorder, drug or alcohol use disorder; or passive-aggressive or antisocial personality disorder Higher utilization was also found among those whom psychometric data characterized as less responsible and more compulsive, The data also predicted the length of subsequent medical hospitalization and identified patients who stayed out of the hospital longer and who were not rehospitalized, Conclusions: Hospital utilization was found to he a function of psychiatric diagnosis, marital status, and various personality factors, Factors relating to social disadvantage also played a role, Axis I diagnoses, particularly substance use disorders, were as important as, if not more important than, axis II diagnoses in predicting utilization. C1 Houston Vet Affairs Med Ctr, Psychol Serv 116B, Houston, TX 77030 USA. Merck & Co Inc, W Point, PA USA. Baylor Coll Med, Houston, TX 77030 USA. St Thomas Univ, Houston, TX USA. RP Williams, W (reprint author), Houston Vet Affairs Med Ctr, Psychol Serv 116B, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 20 TC 15 Z9 15 U1 1 U2 2 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA SN 1075-2730 J9 PSYCHIATR SERV JI Psychiatr. Serv. PD MAR PY 1998 VL 49 IS 3 BP 370 EP 375 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ZA509 UT WOS:000072370400015 PM 9525799 ER PT J AU Hendrick, V Altshuler, LL Suri, R AF Hendrick, V Altshuler, LL Suri, R TI Hormonal changes in the postpartum and implications for postpartum depression SO PSYCHOSOMATICS LA English DT Review ID CARDIFF PUERPERAL MOOD; POSTNATAL DEPRESSION; THYROID-DYSFUNCTION; CEREBROSPINAL-FLUID; LATE PREGNANCY; PREVALENCE; PLASMA; STRESS; WOMEN; TRIIODOTHYRONINE AB The months following childbirth are a time of heightened vulnerability to depressive mood changes. Because of the abrupt and dramatic changes occurring in hormone levels after delivery, many studies have examined the role of hormonal factors in postpartum depression. The authors review the literature on potential hormonal etiologies in postpartum depression, in particular for progesterone, estrogen, prolactin, cortisol, oxytocin, thyroid, and vasopressin. While evidence for an etiologic role is lacking for most hormones, changes in certain hormonal axes may contribute to depressive mood changes in some women following childbirth. C1 Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. RP Hendrick, V (reprint author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, 300 Med Plaza,Suite 1544, Los Angeles, CA 90095 USA. NR 57 TC 111 Z9 116 U1 2 U2 16 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAR-APR PY 1998 VL 39 IS 2 BP 93 EP 101 PG 9 WC Psychiatry; Psychology SC Psychiatry; Psychology GA ZJ929 UT WOS:000073267900002 PM 9584534 ER PT J AU Renner, SW AF Renner, SW TI The red blood cell utilization review experience SO TRANSFUSION SCIENCE LA English DT Article ID COLORECTAL-CANCER SURGERY; FROZEN PLASMA USE; EDUCATION-PROGRAM; TRANSFUSION; AUDITS; CARE; APPROPRIATENESS; PHYSICIANS; REDUCTION; MEDICINE AB The Joint Commission on Accreditation of Healthcare Organizations catalyzed peer-review of blood transfusion and gave it new form in 1984. This process became mostly comprehensive, retrospective, bi-level, and chart-based with an initial screening phase followed by physician- review. Studies were identified and evaluated to test the efficacy of this process, which has recently come under question. In two-thirds of the studies, transfusions were judged appropriate in over 90% of cases.In most hospitals reporting, there were no inappropriate transfusions. It is concluded that the process often results in too few inappropriate cases to readily identify opportunities for improvement. (C) 1998 Elsevier Science Ltd. All rights reserved. C1 W Los Angeles Vet Affairs Med Ctr, Dept Lab Med & Pathol, Los Angeles, CA 90073 USA. RP Renner, SW (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Lab Med & Pathol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 39 TC 2 Z9 2 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0955-3886 J9 TRANSFUS SCI JI Transfus. Sci. PD MAR PY 1998 VL 19 IS 1 BP 83 EP 90 DI 10.1016/S0955-3886(98)00013-7 PG 8 WC Hematology SC Hematology GA ZV874 UT WOS:000074350400014 PM 10182185 ER PT J AU Arita, S Nagai, T Ochiai, M Sakamoto, Y Smith, CV Shevlin, L Mullen, Y AF Arita, S Nagai, T Ochiai, M Sakamoto, Y Smith, CV Shevlin, L Mullen, Y TI Pravastatin prevents primary nonfunction of canine islet autografts SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 6th Congress of the International-Pancreas-and-Islet-Transplant-Association CY SEP 24-27, 1997 CL MILAN, ITALY SP Int Pancreas & Islet Transplant Assoc C1 W Los Angeles Vet Affairs Med Ctr, Human Islet Program, Dept Surg, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Surg, Human Islet Program, Los Angeles, CA 90024 USA. RP Mullen, Y (reprint author), W Los Angeles Vet Affairs Med Ctr, Human Islet Program, Dept Surg, 11301 Wilshire Blvd,Bldg 304,E1-206, Los Angeles, CA 90073 USA. NR 1 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD MAR PY 1998 VL 30 IS 2 BP 411 EP 411 DI 10.1016/S0041-1345(97)01331-6 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA ZD159 UT WOS:000072657300093 PM 9532104 ER PT J AU Arita, S Kasraie, A Une, S Ohtsuka, S Atiya, A Shevlin, L Mullen, Y AF Arita, S Kasraie, A Une, S Ohtsuka, S Atiya, A Shevlin, L Mullen, Y TI Pravastatin and low-dose cyclosporine treatment prevent islet allograft rejection in mice SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 6th Congress of the International-Pancreas-and-Islet-Transplant-Association CY SEP 24-27, 1997 CL MILAN, ITALY SP Int Pancreas & Islet Transplant Assoc C1 W Los Angeles Vet Affairs Med Ctr, Dept Surg, Human Islet Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Surg, Human Islet Program, Los Angeles, CA 90024 USA. RP Mullen, Y (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Surg, Human Islet Program, Bldg 304,El-206,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 1 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD MAR PY 1998 VL 30 IS 2 BP 522 EP 522 DI 10.1016/S0041-1345(97)01386-9 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA ZD159 UT WOS:000072657300147 PM 9532158 ER PT J AU Ochiai, M Arita, S Nagai, T Sakamoto, Y Smith, CV Shevlin, L Mullen, Y AF Ochiai, M Arita, S Nagai, T Sakamoto, Y Smith, CV Shevlin, L Mullen, Y TI Islet toxicity of FK506 measured in canine autografts SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 6th Congress of the International-Pancreas-and-Islet-Transplant-Association CY SEP 24-27, 1997 CL MILAN, ITALY SP Int Pancreas & Islet Transplant Assoc C1 W Los Angeles Vet Affairs Med Ctr, Dept Surg, Islet Transplant Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Surg, Islet Transplant Program, Los Angeles, CA 90024 USA. RP Mullen, Y (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Surg, Islet Transplant Program, E1-206,Bldg 304,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 1 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD MAR PY 1998 VL 30 IS 2 BP 663 EP 663 DI 10.1016/S0041-1345(97)01453-X PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA ZD159 UT WOS:000072657300214 PM 9532224 ER PT J AU Chandrasekar, B Streitman, JE Colston, JT Freeman, GL AF Chandrasekar, B Streitman, JE Colston, JT Freeman, GL TI Inhibition of nuclear factor kappa B attenuates proinflammatory cytokine and inducible nitric-oxide synthase expression in postischemic myocardium SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Article DE reperfusion injury; NF-kappa B; proinflammatory cytokine; inducible nitric-oxide synthase; TGF-beta 1; diethyldithiocarbamate ID TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; SMOOTH-MUSCLE CELLS; TRANSCRIPTION FACTOR; FACTOR-ALPHA; MESSENGER-RNA; INFARCT SIZE; L-ARGININE; FACTOR TNF; DIETHYLDITHIOCARBAMATE AB We have previously reported that induction of nuclear factor-kappa B (NF-kappa B) occurs in a biphasic manner in postischemic myocardium. Because interleukin-l (IL-1), IL-6, tumor necrosis factor-alpha (TNF-alpha), and inducible nitric-oxide synthase (iNOS) contain kappa B-response elements, and since transforming growth factor-beta 1 (TGF-beta 1) down-modulates both cytokine and iNOS expression, we studied their temporal expression during myocardial ischemia/reperfusion (I/R). Northern and Western analyses showed low levels of IL-6 and no signal for IL-1 beta, TNF-alpha and iNOS under basal conditions. Their expression rose significantly over sham-operated controls by 1 h reperfusion, and persisted high for various periods. Under basal conditions, low levels of TGF-beta 1 were detected, which rose significantly at 3 h reperfusion, and remained high until 24 h reperfusion. Administration of diethyldithiocarbamate (DDC) inhibited induction of NF-kappa B and concomitantly the expression of IL-1 beta, IL-6, TNF-alpha as well as iNOS. However, expression of TGF-beta was not altered. Our results indicate that ischemia/reperfusion induces NF-kappa B, and upregulates kappa B-response genes. Administration of DDC inhibits NF-kappa B levels, and attenuates expression of inflammatory cytokines and iNOS. (C) 1998 Elsevier Science B.V. C1 Univ Texas, Hlth Sci Ctr, Div Cardiol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Freeman, GL (reprint author), Univ Texas, Hlth Sci Ctr, Div Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM freeman@uthscsa.edu NR 57 TC 86 Z9 102 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD FEB 27 PY 1998 VL 1406 IS 1 BP 91 EP 106 DI 10.1016/S0925-4439(97)00062-8 PG 16 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA ZE880 UT WOS:000072840900011 PM 9545547 ER PT J AU Roach, J Choi, SJ Schaub, RL Leach, RJ Roodman, GD Reddy, SV AF Roach, J Choi, SJ Schaub, RL Leach, RJ Roodman, GD Reddy, SV TI Further characterization of the murine collagenase (type IVB) gene promoter and analysis of mRNA expression in murine tissues SO GENE LA English DT Article DE osteoclast; collagenase; promoter; transcription factor ID TRANSGENIC MICE; GELATINASE-B; CELL-LINES; MOUSE; 92-KDA; OSTEOCLAST; MACROPHAGES AB The collagenase B type IV (Co14B) gene is highly expressed in the osteoclast, the primary bone-resorbing cell. However, factors that regulate expression of the Co14B gene are not well characterized. A murine P1 genomic clone containing a 94kb sequence insert which contains the Co14B gene was isolated. A 4 kb EcoR1 DNA fragment containing the 5' flanking sequence of the gene was further subcloned and restriction mapped. Putative transcription factors such as SRY, Lyf-1, and GATA1 and 2, binding motifs were identified by sequence analysis in this promoter region. Enhancer and suppressor regions were mapped by transient expression of Co14B gene promoter deletion mutant-luciferase reporter gene constructs in HepG2 cells. Co14B mRNA expression in different murine tissues was analyzed by reverse transcription-polymerase chain reaction and demonstrated high levels of expression in bone, clavaria, spleen and thymus. This promoter provides a valuable tool for targeting gene expression to the osteoclast. (C) 1998 Elsevier Science B.V. C1 Univ Texas, Hlth Sci Ctr, Dept Med & Hematol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Reddy, SV (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med & Hematol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 17 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1119 J9 GENE JI Gene PD FEB 27 PY 1998 VL 208 IS 2 BP 117 EP 122 DI 10.1016/S0378-1119(97)00609-4 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA ZD054 UT WOS:000072646200002 PM 9524243 ER PT J AU Hamner, MB Gold, PB AF Hamner, MB Gold, PB TI Plasma dopamine beta-hydroxylase activity in psychotic and non-psychotic post-traumatic stress disorder SO PSYCHIATRY RESEARCH LA English DT Article DE post-traumatic stress disorder; psychotic symptoms; dopamine beta-hydroxylase; Vietnam combat veterans ID EMOTIONALLY-DISTURBED BOYS; DEPRESSED-PATIENTS; SYMPTOMS; SCHIZOPHRENIA; UNIPOLAR AB Recognition and treatment of comorbid chronic psychotic symptoms in post-traumatic stress disorder (PTSD) has become of increasing clinical interest. Altered dopamine beta-hydroxylase (DBH) activity has been reported in mood disorders. Plasma DBH is reduced in major depression with psychosis and elevated in bipolar disorder with psychosis compared with their respective non-psychotic diagnostic groups. DBH is likely a trait marker with interindividual variations secondary to genetic polymorphism. We therefore evaluated DBH activity in PTSD patients with and without psychotic features and compared these groups with age- and gender-matched control subjects. Vietnam combat veterans with PTSD (n = 19) (including patients with and without psychotic features) and normal control subjects (n = 22) had plasma DBH enzyme activity assayed photometrically. DBH was significantly higher in patients with PTSD with psychotic features than in patients without psychotic features (80.6 +/- 13.4 vs. 42.1 +/- 7.3 mM/min, P < 0.01) and was also higher than normal control subjects (46.12 +/- 4.93, P < 0.01). Plasma DBH activity may differentiate psychotic and non-psychotic subtypes of PTSD. The observed changes are, interestingly, opposite to those seen in psychotic depression but comparable to psychotic bipolar disorder. Since DBH is a genetic marker, this may reflect individual vulnerabilities to develop psychosis in the context of trauma. (C) 1998 Elsevier Science Ireland Ltd. C1 Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA. RP Hamner, MB (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hamnermarkb@charlestonva.gov NR 35 TC 40 Z9 42 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD FEB 27 PY 1998 VL 77 IS 3 BP 175 EP 181 DI 10.1016/S0165-1781(98)00002-X PG 7 WC Psychiatry SC Psychiatry GA ZE602 UT WOS:000072811000005 PM 9707300 ER PT J AU Tumani, H Tourtellotte, WW Peter, JB Felgenhauer, K AF Tumani, H Tourtellotte, WW Peter, JB Felgenhauer, K CA Optic Neuritis Study Grp TI Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE cerebrospinal fluid; blood-CSF barrier; intrathecal IgG; viral-specific antibodies; MRI; multiple sclerosis; optic neuritis treatment/prognosis ID CENTRAL NERVOUS-SYSTEM; HUMORAL IMMUNE-RESPONSE; CEREBROSPINAL-FLUID; IGG SYNTHESIS; NEUROLOGICAL DISORDERS; IMMUNOGLOBULIN-G; TREATMENT TRIAL; BRAIN; BARRIER; EXPERIENCE AB The diagnostic significance of intrathecally synthesized IgG and virus-specific antibodies to measles, rubella and varicella-zoster (MRZ) in cerebrospinal fluid (CSF) remains controversial in cases of acute optic neuritis (AON). This study evaluates the prognostic value of baseline CSF and serum markers in AON, and correlates them with magnetic resonance imaging (MRI) and progression to multiple sclerosis (MS). Paired CSF and serum samples from 36 AON patients, 26 MS patients and 22 controls were analyzed for albumin, Igc, oligoclonal IgG (OI), MRZ antibodies, and blood-CSF barrier function; baseline MRI scanning of the head was also performed. The most sensitive parameter for detection of intrathecal inflammation in AON was OI (75%), Baseline MRI scans revealed abnormalities in 46% of the 28 patients with AON. Fifty percent of AON patients developed MS over the following 4 years. Ninety four percent of patients progressing to MS were positive for either OI, MRI or both. Of the AON patients initially positive for MRI and intrathecally-produced MRZ antibodies, 86% developed MS after 4 years. Only 17% of AON patients with negative results for OI and MRI developed MS. Six patients with abnormal OI but normal MRT progressed to MS. CSF and serum analyses, together with MRI, are the methods of choice for prognostic evaluation of patients with AON. (C) 1998 Elsevier Science B.V. C1 Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Specialty Labs Inc, Santa Monica, CA USA. RP Tumani, H (reprint author), Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany. EM htumani@med.uni-goettingen.de NR 35 TC 31 Z9 31 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD FEB 18 PY 1998 VL 155 IS 1 BP 44 EP 49 DI 10.1016/S0022-510X(97)00272-4 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ZD996 UT WOS:000072746600006 PM 9562321 ER PT J AU Swanson, TH Krahl, SE Liu, YZ Drazba, JA Rivkees, SA AF Swanson, TH Krahl, SE Liu, YZ Drazba, JA Rivkees, SA TI Evidence for physiologically active axonal adenosine receptors in the rat corpus callosum SO BRAIN RESEARCH LA English DT Article DE action potential; cyclopentyladenosine; caffeine ID GAMMA-AMINOBUTYRIC ACID; MONOCLONAL-ANTIBODIES DISTINGUISH; MYELINATED NERVE-FIBERS; GABA-A RECEPTORS; HIPPOCAMPAL-FORMATION; UPTAKE SITES; SPINAL-CORD; ADENOSINE-A1-RECEPTOR BINDING; DEPOLARIZING ACTION; GLUTAMATE RELEASE AB Several neurotransmitter receptors have been identified on axons, and emerging evidence suggests that central axonal conduction may be modulated by neurotransmitters. We have recently demonstrated the presence of extra-synaptic adenosine Al receptors along rat hippocampal axons. We now present immunocytochemical evidence for Al receptors on rat corpus callosum axons and show that these receptors actively modulate axon physiology. Using rat brain coronal slices, we stimulated the corpus callosum and recorded the evoked extracellular compound action potential. The lipid-soluble, Al-specific adenosine receptor agonist cyclopentyladenosine, dose-dependently decreased the compound action potential amplitude, an effect reversed by the specific Al antagonist 8-cyclopentyl-1,3-dipropylxanthine. These data provide the first direct evidence that axonal Al adenosine receptors modulate axon physiology in the adult mammalian brain. Influencing axonal transmission is a potentially powerful mechanism of altering information processing in the nervous system. (C) 1998 Elsevier Science B.V. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA. Yale Univ, Sch Med, Dept Pediat Endocrinol, New Haven, CT USA. Med Coll Ohio, Dept Anat, Toledo, OH 43699 USA. Med Coll Ohio, Dept Neurobiol, Toledo, OH 43699 USA. Med Coll Ohio, Dept Med, Toledo, OH 43699 USA. RP Swanson, TH (reprint author), Med Coll Ohio, Ruppert Hlth Ctr, Dept Anat & Neurobiol, Room 1450,3120 Glendale Ave, Toledo, OH 43614 USA. NR 81 TC 29 Z9 29 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD FEB 16 PY 1998 VL 784 IS 1-2 BP 188 EP 198 DI 10.1016/S0006-8993(97)01323-1 PG 11 WC Neurosciences SC Neurosciences & Neurology GA ZC505 UT WOS:000072586800021 PM 9518606 ER PT J AU Berkwits, M AF Berkwits, M TI What's wrong with this picture? SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID ANGIODYSPLASIA; ASSOCIATION C1 Univ Penn, Med Ctr, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Berkwits, M (reprint author), Univ Penn, Med Ctr, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 15 PY 1998 VL 128 IS 4 BP 323 EP 324 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA YX170 UT WOS:000072013400023 PM 9471945 ER PT J AU Garnovskaya, MN Mukhin, Y Raymond, JR AF Garnovskaya, MN Mukhin, Y Raymond, JR TI Rapid activation of sodium-proton exchange and extracellular signal-regulated protein kinase in fibroblasts by G protein-coupled 5-HT1A receptor involves distinct signalling cascades SO BIOCHEMICAL JOURNAL LA English DT Article ID BETA-GAMMA-SUBUNIT; DOMINANT-NEGATIVE MUTANT; STIMULATES NA-H; GROWTH-FACTOR; TYROSINE-KINASE; NA+/H+ EXCHANGER; PHOSPHOINOSITIDE 3-KINASE; SELECTIVE INHIBITOR; 5-HYDROXYTRYPTAMINE(1A) RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE AB These experiments tested the hypothesis that signalling elements involved in the activation of the extracellular signal-regulated protein kinase (ERK) mediate rapid activation of sodium-proton exchange (NHE) in fibroblasts when both signals are initiated by a single G protein-coupled receptor, the 5-HT1A receptor. Similarities between the two processes were comparable concentration-response curves and time-courses, and overlapping sensitivity to some pharmacological inhibitors of:tyrosine kinases (staurosporine and genistein), and phosphoinositide 3'-kinase (wortmannin and LY204002). Activation of NHE was much more sensitive to the phosphatidylcholine-specific phospholipase inhibitor (D609) than was ERK. Neither pathway was sensitive to manoeuvres designed to block PKC. In contrast, Src or related kinases appear to be required to activate ERK, but not NHE. Transfection of cDNA constructs encoding inactive mutant phosphoinositide 3'-kinase, Grb2, Sos, Ras, and Raf molecules were successful in attenuating ERK, but had essentially no effect upon NHE activation. Finally, PD98059, an inhibitor of mitogen activated/extracellular signal regulated kinase kinase, blocked ERK but not NHE activation. Thus, in CHO fibroblast cells, activation by the 5-HT1A receptor of ERK and NHE share a number of overlapping features. However, our studies do not support a major role for ERK, when activated by the 5-HT1A receptor, as a short-term upstream regulator of NHE activity. C1 Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. FU NIDDK NIH HHS [DK52448]; NINDS NIH HHS [NS30927] NR 63 TC 39 Z9 39 U1 0 U2 1 PU PORTLAND PRESS PI LONDON PA 59 PORTLAND PLACE, LONDON, ENGLAND W1N 3AJ SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD FEB 15 PY 1998 VL 330 BP 489 EP 495 PN 1 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA ZB154 UT WOS:000072441800067 PM 9461547 ER PT J AU Lu, J Chuntharapai, A Beck, J Bass, S Ow, A De Vos, AM Gibbs, V Kim, KJ AF Lu, J Chuntharapai, A Beck, J Bass, S Ow, A De Vos, AM Gibbs, V Kim, KJ TI Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: The role of domains 1 and 2 SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HUMAN GROWTH-HORMONE; HUMAN INTERFERON-ALPHA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; COMPLEX; BETA; EXPRESSION; CLONING; MUTAGENESIS; DISTINCT AB We have performed a structure-function analysis of extracellular domain regions of the human IFN-alpha receptor (hIFNAR1) using mAbs generated by immunizing mice with a soluble hIFNAR1-IgG. Five mAbs described in this study recognize different epitopes as determined by a competitive binding ELISA and by alanine substitution mutant analyses of the hIFNAR1-IgG. Two mAbs, 2E1 and 4A7, are able to block IFN-stimulated gene factor 3 (ISGF3) formation and inhibit the antiviral cytopathic effect induced by several IFN-alpha (IFN-alpha 2/1, -alpha 1, -alpha 2, -alpha 5, and -alpha 8). None of these anti-IFNAR1 mAbs were able to block activity of IFN-beta. mAb 4A7 binds to a domain 1-hIFNAR1-IgG but not to a domain 2-hIFNAR1-IgG, which suggests that its binding region is located in domain 1, The binding of the most potent blocking mAb, 2E1, requires the presence of domain 1 and domain 2, The most critical residue for 2E1 binding is a lysine residue at position 249, which is in domain 2. These findings suggest that both domain 1 and domain 2 are necessary to form a functional receptor and that a region in domain 2 is important. IFN-beta recognizes regions of the hIFNAR complex that are distinct from those important for the IFN-alpha. C1 Genentech Inc, Dept Antibody & Bioassay Technol, S San Francisco, CA 94080 USA. San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. RP Kim, KJ (reprint author), Genentech Inc, Dept Antibody & Bioassay Technol, S San Francisco, CA 94080 USA. EM jin@gene.com FU PHS HHS [R2948748] NR 41 TC 33 Z9 34 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 15 PY 1998 VL 160 IS 4 BP 1782 EP 1788 PG 7 WC Immunology SC Immunology GA ZN995 UT WOS:000073704800030 PM 9469437 ER PT J AU Peters, NS Coromilas, J Hanna, MS Josephson, ME Costeas, C Wit, AL AF Peters, NS Coromilas, J Hanna, MS Josephson, ME Costeas, C Wit, AL TI Characteristics of the temporal and spatial excitable gap in anisotropic reentrant circuits causing sustained ventricular tachycardia SO CIRCULATION RESEARCH LA English DT Article DE anisotropy; reentry; excitable gap ID MYOCARDIAL-INFARCTION PERIOD; ISOLATED CARDIAC-MUSCLE; EPICARDIAL BORDER ZONE; OPEN-CHEST DOGS; ATRIAL-FIBRILLATION; RESETTING RESPONSE; CONSCIOUS DOGS; FIXED OBSTACLE; SPIRAL WAVES; ARRHYTHMIAS AB The excitable gap of a reentrant circuit has both temporal (time during the cycle length that the circuit is excitable) and spatial (length of the circuit that is excitable at a given time) properties. We determined the temporal and spatial properties of the excitable gap in reentrant circuits caused by nonuniform anisotropy, Myocardial infarction was produced in canine hearts by ligation of the left anterior descending coronary artery, Four days later, reentrant circuits were mapped in the epicardial border-zone of the infarcts with a multielectrode array during sustained ventricular tachycardia induced by programmed stimulation. During tachycardia, premature impulses were initiated by stimulation at sites around and in the reentrant circuits, and their conduction characteristics in the circuit were mapped. All circuits had a temporal excitable gap in at least part of the circuit, which allowed premature impulses to enter the circuit. Completely and partially excitable segments of the temporal gap were identified by measuring conduction velocity of the premature impulses; conduction was equal to the native reentrant wave front in completely excitable regions and slower than the reentrant wave front in partially excitable regions. In some circuits, a temporal gap existed throughout the circuit, permitting the entire circuit to be reset over a range of premature premature coupling intervals, although the size of the gap varied at different sites. In other circuits, the gap became so small at local sites that even though premature impulses could enter the circuit, the circuit could not be reset. Premature impulses could terminate reentry in circuits that could be reset or not. We also found a significant spatial gap, which was identified by determining the distance between the head of the circulating wave front, which could be located on the activation map, and its tail, which was the site most distal from the head as located by the site of entry of the premature wave front into the circuit. The spatial gap could also vary in different parts of the circuit. Therefore, nonuniform anisotropic reentrant circuits have both a temporal and spatial excitable gap with fully and partially excitable components that change in different parts of the circuit. C1 St Marys Hosp, Dept Cardiol, London W2 1NY, England. Univ London Imperial Coll Sci & Technol, Sch Med, London, England. Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA. Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. Harvard Univ, Beth Israel Hosp, Dept Med, Boston, MA 02215 USA. Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Peters, NS (reprint author), St Marys Hosp, Dept Cardiol, Praed St, London W2 1NY, England. FU NHLBI NIH HHS [HL-30557, R37 HL-31393] NR 44 TC 41 Z9 42 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7330 EI 1524-4571 J9 CIRC RES JI Circ.Res. PD FEB 9 PY 1998 VL 82 IS 2 BP 279 EP 293 PG 15 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA YV683 UT WOS:000071852300016 PM 9468199 ER PT J AU New, AS Gelernter, J Yovell, Y Trestman, RL Nielsen, DA Silverman, J Mitropoulou, V Siever, LJ AF New, AS Gelernter, J Yovell, Y Trestman, RL Nielsen, DA Silverman, J Mitropoulou, V Siever, LJ TI Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: A preliminary study SO AMERICAN JOURNAL OF MEDICAL GENETICS LA English DT Article DE serotonin; genetics; personality disorders; polymorphism ID SEROTONIN TRANSPORTER GENE; PERSONALITY-DISORDER; VIOLENT OFFENDERS; FIRE SETTERS; POLYMORPHISM; ALCOHOLISM; RFLP AB To assess the relationship between two phenotypes in an extremely well-characterized population of personality disorder patients-impulsive aggression and prolactin response to fenfluramine-and tryptophan hydroxylase (TPH) genotype, TPH genotype (at an intronic polymorphic site) and prolactin response to fenfluramine were assessed in 40 Caucasian patients with personality disorder. Impulsive aggression was assessed by using the Buss-Durkee Hostility Inventory (BDHI). Twenty-one male patients with the "LL" genotype had higher BDHI scores than men with the "UL" or the "UU" genotype. No relationship between genotype and prolactin response to fenfluramine was found. It was concluded that impulsive-aggressive behavior in male personality disorder patients may be associated with the TPH genotype. (C) 1998 Wiley-Liss, Inc. C1 Bronx Vet Adm Med Ctr, Psychiat Serv 116A, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. W Haven VA Med Ctr, Psychiat Serv 116A, W Haven, CT USA. Yale Univ, Sch Med, Dept Psychiat, Div Mol Psychiat, New Haven, CT USA. NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA. RP New, AS (reprint author), Bronx Vet Adm Med Ctr, Psychiat Serv 116A, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. RI Nielsen, David/B-4655-2009 FU NCRR NIH HHS [5 M01-RR00071]; NIMH NIH HHS [K02-MH01387, R01-MH42827] NR 29 TC 98 Z9 102 U1 4 U2 11 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0148-7299 J9 AM J MED GENET JI Am. J. Med. Genet. PD FEB 7 PY 1998 VL 81 IS 1 BP 13 EP 17 DI 10.1002/(SICI)1096-8628(19980207)81:1<13::AID-AJMG3>3.0.CO;2-O PG 5 WC Genetics & Heredity SC Genetics & Heredity GA YZ567 UT WOS:000072267000003 PM 9514581 ER PT J AU Weg, JG Anzueto, A Balk, RA Wiedemann, HP Pattishall, EN Schork, A Wagner, LA AF Weg, JG Anzueto, A Balk, RA Wiedemann, HP Pattishall, EN Schork, A Wagner, LA TI The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID END-EXPIRATORY PRESSURE; EXTRACORPOREAL CO2 REMOVAL; INVERSE RATIO VENTILATION; ACUTE LUNG INJURY; MECHANICAL VENTILATION; PULMONARY BAROTRAUMA; MICROVASCULAR INJURY; SYNDROME ARDS; TIDAL VOLUME; FAILURE AB Background In patients with the acute respiratory distress syndrome, pneumothorax and other air leaks - any extrusion of air outside the tracheobronchial tree - have been attributed to high ventilatory pressures or volumes and linked to increased mortality. Methods We analyzed data from a prospective trial of aerosolized synthetic surfactant in 725 patients with the acute respiratory distress syndrome induced by sepsis. We compared the ventilatory pressures and volumes in the patients without any air leaks (the highest values during the five-day study) with the pressures and volumes in those with pneumothorax or with any air leaks (the highest values during the 16- and 24-hour periods before the complication developed). Results Fifty patients (6.9 percent) had pneumothorax, and 77 (10.6 percent) had pneumothorax or other air leaks. There were no significant differences between patients with air leaks and those without air leaks in any pressure or volume examined. Overall mortality at 30 days was 40.0 percent (95 percent confidence interval, 36.4 to 43.6); among the patients with pneumothorax, it was 46.0 percent (95 percent confidence interval, 32.2 to 59.8), and among those without pneumothorax, it was 39.3 percent (95 percent confidence interval, 35.6 to 43.0; P=0.35). The mortality rate was 45.5 percent (95 percent confidence interval, 34.4 to 56.6) in the group with any air leaks and 39.0 percent (95 percent confidence interval, 35.3 to 42.8) in the group without air leaks (P=0.28). Conclusions In patients with sepsis-induced acute respiratory distress syndrome who were receiving mechanical ventilation with conventional pressures and volumes, there were no significant correlations between high ventilatory pressures or volumes and the development of pneumothorax or other air leaks. Pneumothorax or other air leaks were not associated with a significantly increased mortality rate. (C) 1998, Massachusetts Medical Society. C1 Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA. Cleveland Clin, Cleveland, OH 44106 USA. Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA. Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. RP Weg, JG (reprint author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care, B1H245,Box 0024,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. OI Wiedemann, Herbert/0000-0002-4587-4401 NR 42 TC 87 Z9 88 U1 0 U2 4 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 5 PY 1998 VL 338 IS 6 BP 341 EP 346 DI 10.1056/NEJM199802053380601 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA YV426 UT WOS:000071822200001 PM 9449726 ER PT J AU Pellegrin, KL Arana, GW AF Pellegrin, KL Arana, GW TI Why the triple-threat approach threatens the viability of academic medical centers SO ACADEMIC MEDICINE LA English DT Editorial Material ID COSTS C1 Med Univ S Carolina, Dept Psychiat & Behav Sci, Med Ctr, Coll Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Pellegrin, KL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Med Ctr, Coll Med, 171 Ashley Ave, Charleston, SC 29425 USA. NR 9 TC 7 Z9 7 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD FEB PY 1998 VL 73 IS 2 BP 123 EP 125 DI 10.1097/00001888-199802000-00008 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA YX199 UT WOS:000072016300010 PM 9484183 ER PT J AU Andrade, FH Anzueto, A Napier, W Levine, S Lawrence, RA Jenkinson, SG Maxwell, LC AF Andrade, FH Anzueto, A Napier, W Levine, S Lawrence, RA Jenkinson, SG Maxwell, LC TI Effects of selenium deficiency on diaphragmatic function after resistive loading SO ACTA PHYSIOLOGICA SCANDINAVICA LA English DT Article DE diaphragm; glutathione; glutathione peroxidase; reactive oxygen species; selenium ID FREE-RADICALS; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; N-ACETYLCYSTEINE; REACTIVE OXYGEN; SKELETAL-MUSCLE; RESPIRATORY-FAILURE; RAT DIAPHRAGM; FATIGUE; EXERCISE AB Diaphragmatic fatigue has been associated with increased production of reactive oxygen species. Among the defences against reactive oxygen species is the glutathione redox system. The selenium-dependent enzyme glutathione peroxidase is an important component of this system. Thus, we hypothesized that selenium deficiency would lower glutathione peroxidase activity and render the diaphragm more susceptible to a mild exertional protocol. Sprague-Dawley rats were fed a selenium-deficient or control diet for 12 weeks then divided into four experimental groups: (1) unloaded, basic diet with selenium supplementation (control); (2) unloaded, selenium-deficient diet, (3) loaded, basic diet with selenium supplementation; and (4) loaded, selenium-deficient diet. Diaphragmatic in vitro contractile properties, glutathione peroxidase activity and glutathione content were measured. During inspiratory resistive loading, the animals breathed against an inspiratory resistor at 70% of maximal airway pressure until the target pressure was not achieved for five consecutive breaths. Selenium deficiency resulted in a significant decrease in diaphragmatic glutathione peroxidase activity, without changes in total glutathione content. Neither selenium deficiency nor inspiratory resistive loading alone impaired diaphragmatic contractility. Selenium deficiency in conjunction with inspiratory resistive loading resulted in a significant decrease in diaphragmatic twitch and tetanic force, with a downward shift in the force/frequency curve. These data suggest that selenium deficiency lowers diaphragmatic glutathione peroxidase activity, and when these animals are subjected to the oxidative stress of resistive loading, there is an impairment in muscle function. We conclude that a functional glutathione peroxidase is necessary to protect the diaphragm against the effects of resistive loading. C1 Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Pulm Dis Sect 111E, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78284 USA. Baylor Coll Med, Dept Physiol, Houston, TX 77030 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. S Texas Vet Hosp Div, San Antonio, TX USA. RP Anzueto, A (reprint author), Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Pulm Dis Sect 111E, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. RI Andrade, Francisco/F-1258-2011 OI Andrade, Francisco/0000-0002-2460-5798 NR 30 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL SCIENCE LTD PI OXFORD PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND SN 0001-6772 J9 ACTA PHYSIOL SCAND JI Acta Physiol. Scand. PD FEB PY 1998 VL 162 IS 2 BP 141 EP 148 PG 8 WC Physiology SC Physiology GA YY623 UT WOS:000072166800004 PM 9550226 ER PT J AU Aleynik, SI Leo, MA Aleynik, MK Lieber, CS AF Aleynik, SI Leo, MA Aleynik, MK Lieber, CS TI Increased circulating products of lipid peroxidation in patients with alcoholic liver disease SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE alcohol; liver disease; 4-hydroxynonenal; F-2-isoprostanes; lipid peroxidation ID CHROMATOGRAPHY-MASS-SPECTROMETRY; PROSTANOIDS F2-ISOPROSTANES; OXIDATIVE DAMAGE; RAT-LIVER; ETHANOL; 4-HYDROXYALKENALS; F-2-ISOPROSTANES; MECHANISM; INDEX AB F-2-isoprostanes (F-2-IP) and 4-hydroxynonenal (4-HNE), peroxidation products of polyunsaturated fatty acids (PUFA), are considered the most reliable indicators of endogenous lipid peroxidation in vivo, To determine to what extent these are also altered in patients with alcoholic liver disease, plasma free and esterified F-2-IP as well as 4-HNE were measured by GC/MS in 49 fasting subjects who underwent diagnostic percutaneous needle biopsies of the liver, Compared to patients with mild steatosis and no fibrosis, free F-2-IP and 4-HNE were strikingly increased in individuals with alcoholic hepatitis, There was also a significant but lesser rise of 4-HNE in patients with perivenular fibrosis. An increase of F-2-IP was also found in subjects with transition to, or complete, alcoholic cirrhosis, with a comparable trend for 4-HNE, By contrast, in patients who were drinking heavily up to 48 hr before admission, F-2-IP were not abnormal, but they increased later (p < 0.005), Contrasting with plasma free F-2-IP, esterified F-2-IP were not significantly changed with fibrosis, Thus, whereas circulating esterified F-2-IP were unchanged in patients with alcoholic liver disease, there was an increase in free F-2-IP as well as 4-HNE during recovery from intoxication, The increase was not a result of accompanying hepatitis C but a function of the stage of alcoholic liver injury, possibly reflecting enhanced lipid peroxidation as well as interference with biliary excretion and/or hepatic esterification. C1 Bronx Vet Affairs Med Ctr, Ctr Alcohol Res & Treatment, Bronx, NY 10468 USA. Mt Sinai Sch Med, Bronx, NY USA. RP Lieber, CS (reprint author), Bronx Vet Affairs Med Ctr, Ctr Alcohol Res & Treatment, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. FU NIAAA NIH HHS [AA 05934, AA 07275, AA 11115] NR 30 TC 76 Z9 78 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD FEB PY 1998 VL 22 IS 1 BP 192 EP 196 DI 10.1097/00000374-199802000-00026 PG 5 WC Substance Abuse SC Substance Abuse GA ZA165 UT WOS:000072335500028 PM 9514306 ER PT J AU Cunningham, WE Shapiro, MF Hays, RD Dixon, WJ Visscher, BR George, WL Ettl, MK Beck, CK AF Cunningham, WE Shapiro, MF Hays, RD Dixon, WJ Visscher, BR George, WL Ettl, MK Beck, CK TI Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID OF-LIFE; MEDICAL OUTCOMES; RELIABILITY; INFECTION; VALIDITY; INDEX; TRIAL; AIDS AB PURPOSE: To assess the severity of constitutional symptoms in persons with human immunodeficiency virus (HIV) infection, and their relationship to health-related quality of life (HRQOL). PATIENTS AND METHODS: Two hundred five HIV-infected patients (93% male, 26% African American, 28% Latino, 39% white, 7% other ethnicity) with diarrhea, fever, or weight loss were studied at a county hospital and a Veterans Administration hospital in southern California. Consenting subjects were administered a battery that included 11 scales measuring various aspects of health-related quality of life and detailed questions about six constitutional symptoms or symptom complexes (myalgias, exhaustion, anorexia/nausea/vomiting, night sweats, fever, and weight loss) as well as about other manifestations of HIV disease. RESULTS: Constitutional symptoms except weight loss were all strongly related to all measures of quality of life. On 0 (worst) to 100 (best) point scales, mean scores ranged from 34 (for individuals having all five symptoms other than weight loss) to 78 (for those with none) for physical function, 43 to 79 for emotional well-being, and 36 to 73 for social function. Adjustment for helper T-lymphocyte counts, duration of illness, and demographic characteristics did not diminish these associations. CONCLUSION: The presence, number, and severity of constitutional symptoms in HIV disease is strongly related to health-related quality of life in symptomatic HIV-infected individuals. Identifying and treating these very common symptoms has the potential to improve quality of life in these patients. (C) 1998 by Excerpta Medica, Inc. C1 Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Ctr Hlth Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA. W Los Angeles VA Hosp, Los Angeles, CA USA. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. Rand Corp, Santa Monica, CA USA. RP Cunningham, WE (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Ctr Hlth Sci, Rm 31-254A,10833 Le Conte Ave, Los Angeles, CA 90095 USA. RI Hays, Ronald/D-5629-2013 FU AHRQ HHS [HS-066775-S1, HS-06775] NR 25 TC 84 Z9 84 U1 1 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD FEB PY 1998 VL 104 IS 2 BP 129 EP 136 DI 10.1016/S0002-9343(97)00349-5 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA ZA187 UT WOS:000072337700004 PM 9528730 ER PT J AU Olsen, TW Aaberg, SY Geroski, DH Edelhauser, HF AF Olsen, TW Aaberg, SY Geroski, DH Edelhauser, HF TI Human sclera: Thickness and surface area SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article AB PURPOSE: To assess the mean thickness and surface area of human sclera. METHODS: Fifty-five formalin-fixed eye bank eyes were hemisected from anterior to posterior. Cross;sectional slides were taken to include a millimeter scale ruler in each photograph. Slide photographs were projected and the scleral silhouette sketched. Mean scleral thickness measurements with standard deviation were obtained. Twenty-five human eye bank eyes were used to determine total scleral surface area by either a computerized tracing method (17 globes) or volumetric calculations (eight globes) using fluid displacement. RESULTS: Mean scleral thickness +/- SD was 0.53 +/- 0.14 mm at the corneoscleral limbus, significantly decreasing to 0.39 +/- 0.17 mm near the equator, and increasing to 0.9 to 1.0 mm near the optic nerve. The mean total scleral surface area by surface area computerized tracings was 16.3 +/- 1.8 cm(2) and, by the volume displacement method, was 17.0 +/- 1.5 cm(2). CONCLUSIONS: Scleral thickness and surface area measurements from cadaver eyes are important for ophthalmic surgeons and have implications for transscleral diffusion. C1 Univ Wisconsin, Clin Sci Ctr F4336, Madison, WI 53792 USA. Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA. William S Middleton Mem Vet Hosp, Madison, WI USA. RP Olsen, TW (reprint author), Univ Wisconsin, Clin Sci Ctr F4336, 600 Highland Ave, Madison, WI 53792 USA. FU NEI NIH HHS [P30 EY06360] NR 6 TC 174 Z9 176 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD FEB PY 1998 VL 125 IS 2 BP 237 EP 241 DI 10.1016/S0002-9394(99)80096-8 PG 5 WC Ophthalmology SC Ophthalmology GA YV845 UT WOS:000071869100014 PM 9467451 ER PT J AU Silverstein, JH AF Silverstein, JH TI Anesthetic alterations of the neuroendocrine response to insulin/hypoglycemia in Fischer 344 rats. SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 Bronx Vet Affairs Med Ctr, Anesthesia Sect, Bronx, NY USA. Mt Sinai Sch Med, Dept Anesthesiol Surg Geriatr & Adult Dev, New York, NY USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD FEB PY 1998 VL 86 IS 2S SU S MA S503 PG 1 WC Anesthesiology SC Anesthesiology GA YV675 UT WOS:000071851500502 ER PT J AU Zaugg, M Tagliente, T Silverstein, JH AF Zaugg, M Tagliente, T Silverstein, JH TI Effect of perioperative atenolol on the release of neuropeptide Y to major surgical stress SO ANESTHESIA AND ANALGESIA LA English DT Meeting Abstract C1 Mt Sinai Med Ctr, Dept Anesthesiol, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Dept Anesthesiol, New York, NY USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD FEB PY 1998 VL 86 IS 2S SU S MA S120 PG 1 WC Anesthesiology SC Anesthesiology GA YV675 UT WOS:000071851500120 ER PT J AU Badgett, RG O'Keefe, M Henderson, MC AF Badgett, RG O'Keefe, M Henderson, MC TI Clinical experience and evidence-based medicine - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Univ Texas, Hlth Sci Ctr, Audie L Murphy Vet Adm Hosp, San Antonio, TX 78284 USA. RP Badgett, RG (reprint author), Univ Texas, Hlth Sci Ctr, Audie L Murphy Vet Adm Hosp, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. OI Badgett, Robert/0000-0003-2888-3303 NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 1998 VL 128 IS 3 BP 245 EP 245 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA YU303 UT WOS:000071703200019 ER PT J AU Baillie, GM Sherer, JT Weart, CW AF Baillie, GM Sherer, JT Weart, CW TI Insulin and coronary artery disease: Is syndrome X the unifying hypothesis? SO ANNALS OF PHARMACOTHERAPY LA English DT Review DE insulin; coronary artery disease; syndrome X ID DEPENDENT DIABETES-MELLITUS; ADIPOSE-TISSUE DISTRIBUTION; ISCHEMIC-HEART-DISEASE; MIDDLE-AGED MEN; GLUCOSE-TOLERANCE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; CIGARETTE-SMOKING; PLASMA-INSULIN AB OBJECTIVE: TO review data supporting the hypothesis that syndrome X plays a major role in the pathogenesis of coronary artery disease (CAD), and the effects of lifestyle factors and pharmacologic interventions on insulin, other metabolic parameters, and outcomes. DATA SOURCES: MEDLINE (January 1966-August 1997) and Current Contents database searches identified applicable English-language experimental trials, epidemiologic studies, reviews, and editorials. STUDY SELECTION AND DATA EXTRACTION: Studies that were included addressed the role of insulin resistance and hyperinsulinemia in the pathogenesis of CAD or the effects of lifestyle factors and pharmacologic interventions on metabolic parameters and outcomes. DATA SYNTHESIS: The main characteristics of syndrome X are hyperinsulinemia and insulin resistance. These result in secondary syndrome X features, including hyperglycemia, increased very-low-density lipoprotein concentrations, decreased high-density lipoprotein cholesterol, and hypertension. Insulin resistance is worsened by obesity, and insulin has been shown to contribute to the development of hypertension. Other studies demonstrate that smoking adversely affects glucose and insulin concentrations. Animal studies have linked hyperinsulinemia and atherogenesis. These animal data have been confirmed by several large prospective and population studies that have identified associations between hyperinsulinemia and CAD. CONCLUSIONS: Strong evidence links insulin resistance and hyperinsulinemia to CAD. Lifestyle modifications play an important role in decreasing cardiovascular risk, and clinicians should strongly encourage such changes. Clinicians must also carefully consider the effects of antihypertensive, antihyperglycemic, and antidyslipidemic agents on patients' metabolic profiles when choosing appropriate therapeutic regimens. However, outcome data on many potentially beneficial agents, including calcium antagonists, alpha(1)-adrenergic antagonists, angiotensin-converting enzyme inhibitors, metformin, acarbose, and troglitazone, are not yet available. C1 Med Univ S Carolina, Dept Pharm Practice, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Baillie, GM (reprint author), Med Univ S Carolina, Dept Pharm Practice, 171 Ashley Ave, Charleston, SC 29425 USA. NR 124 TC 25 Z9 27 U1 0 U2 0 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD FEB PY 1998 VL 32 IS 2 BP 233 EP 247 DI 10.1345/aph.13398 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YW202 UT WOS:000071908700012 PM 9496410 ER PT J AU Nunes, EV Quitkin, FM Donovan, SJ Deliyannides, D Ocepek-Welikson, K Koenig, T Brady, R McGrath, PJ Woody, G AF Nunes, EV Quitkin, FM Donovan, SJ Deliyannides, D Ocepek-Welikson, K Koenig, T Brady, R McGrath, PJ Woody, G TI Imipramine treatment of opiate-dependent patients with depressive disorders - A placebo-controlled trial SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article; Proceedings Paper CT College-on-Problems-of-Drug-Dependence Annual Meeting CY JUN, 1996 CL SCOTTSDALE, ARIZONA SP Coll Problems Drug Dependence ID METHADONE-MAINTAINED PATIENTS; 2.5-YEAR FOLLOW-UP; STRUCTURED CLINICAL INTERVIEW; DSM-III-R; COCAINE DEPENDENCE; MAINTENANCE PATIENTS; DRUG-ABUSE; OPIOID ADDICTS; DOUBLE-BLIND; DESIPRAMINE AB Background: The literature is inconclusive on the role of antidepressant medications in treating drug dependence. Studies have either not focused on depressed patients or have selected patients with depressive disorders based on cross-sectional symptoms rather than a syndromal diagnosis. A clinical trial of an antidepressant was, therefore, conducted on drug-dependent patients with syndromal depression. Methods: Patients receiving methadone hydrochloride maintenance treatment were selected if they met the criteria for a DSM-III-R depressive disorder that was chronologically primary, had persisted during a past abstinent period or was long-standing, and persisted during at least I month of stable methadone treatment. Subjects were randomized to a 12-week, double-blind, placebo-controlled trial of imipramine hydrochloride. A favorable response was defined as a Clinical Global Impression scale score for depression of 2 ("much improved") or 1 ("very much improved") and at least a 75% reduction in self-reported drug or alcohol use or abstinence. Results: One hundred thirty-seven patients were randomized, and 84 completed a minimum adequate trial of at least 6 weeks. Among the 84 adequately treated patients, 57% (24/42) receiving imipramine were rated as responders compared with 7% (3/42) receiving placebo (P <.001). On measures of mood, there was a robust effect of imipramine, Imipramine was superior to placebo on some self-reported measures of substance use and craving, and mood improvement was associated with improvement in self-reported substance use. However, few patients achieved urine-confirmed abstinence. Conclusions: Imipramine was an effective antidepressant in patients receiving methadone who were selected via syndromal criteria for depressive illness, Imipramine patients whose mood improves; however, this effect was less robust. C1 New York State Psychiat Inst, Depress Evaluat Serv, Unit 35, New York, NY 10032 USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA. Bridge Plaza Treatment & Rehabil Serv, New York, NY USA. Long Isl Jewish Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA. Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. RP Nunes, EV (reprint author), New York State Psychiat Inst, Depress Evaluat Serv, Unit 35, 722 W 168th St, New York, NY 10032 USA. RI McGrath, Patrick/I-6410-2013 OI McGrath, Patrick/0000-0001-7217-7321 FU NIDA NIH HHS [K02 DA00288, K20 DA00154, R18 DA06140] NR 66 TC 112 Z9 114 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD FEB PY 1998 VL 55 IS 2 BP 153 EP 160 DI 10.1001/archpsyc.55.2.153 PG 8 WC Psychiatry SC Psychiatry GA YV744 UT WOS:000071858400008 PM 9477929 ER PT J AU Aranha, GV AF Aranha, GV TI The international medical graduate in US academic general surgery SO ARCHIVES OF SURGERY LA English DT Article AB Objectives: To identify graduates of medical schools outside of the United States who are on academic general surgical faculties in the United States and to determine their contribution to surgery in the United States. Design: A questionnaire was sent to the departments of general surgery of 128 medical schools and clinics with independent surgical training programs. Setting: All the departments of surgery affiliated with medical schools and clinics in the United States. Participants: All department chairpersons of the general surgical services in the United States. Main Outcome Measure: To identify graduates of foreign medical schools who had their training in the United States, their area of expertise, and their present positions. Results: One hundred twenty-two (95.3%) of the 128 medical schools and clinics replied to the questionnaire. Of the 122, 108 (88.5%) had at least 1 international medical graduate (IMG) on their faculty; 572 IMGs were identified on the surgical faculty, of which 538 were men and 34 were women. These individuals represent 72 countries or colonies and most continents and regions of the world. Fourteen are or have been department chairpersons. Asia, with 172 medical graduates, contributed the highest number of graduates, followed by North, Central, and South America, with 136 total, and Europe, with 123. India, followed by Canada, South Africa, the United Kingdom, and the People's Republic of China, accounts for a large number of the individuals. The states with the most IMGs were California, 78; New York, 75; and Illinois, 42. Conclusions: International medical graduates account for 10% of the academic surgical faculty in the United States. These graduates come from all countries and regions of the world. International medical graduates occupy faculty positions commensurate with experience. Fourteen are or have been department chairpersons. Since 1960. there has been an increasing number of appointments of IMGs to faculty of the departments of surgery. The results of this survey suggest that the experience of the IMG in US surgery has been quite favorable. C1 Loyola Univ, Stritch Sch Med, Sect Surg Oncol, Dept Surg, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Aranha, GV (reprint author), Loyola Univ, Stritch Sch Med, Sect Surg Oncol, Dept Surg, EMS 110-3236,2160 S 1st Ave, Maywood, IL 60153 USA. NR 3 TC 12 Z9 12 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD FEB PY 1998 VL 133 IS 2 BP 130 EP 133 DI 10.1001/archsurg.133.2.130 PG 4 WC Surgery SC Surgery GA YX656 UT WOS:000072063200002 PM 9484722 ER PT J AU Roodman, GD AF Roodman, GD TI Osteoclast differentiation and activity SO BIOCHEMICAL SOCIETY TRANSACTIONS LA English DT Article; Proceedings Paper CT Colloquium on Molecular and Cellular Biology of the Bone at the 663rd Meeting of the Biochemical-Society CY SEP 03-05, 1997 CL UNIV GALWAY, GALWAY, IRELAND SP Biochem Soc HO UNIV GALWAY ID ESTROGEN TARGET-CELLS; HUMAN MARROW CULTURES; GROWTH-FACTOR-BETA; BONE-RESORPTION; OSTEOTROPIC HORMONES; CONGENITAL OSTEOPETROSIS; PARATHYROID-HORMONE; CALCITONIN RECEPTOR; NITRIC-OXIDE; INTERLEUKIN-6 C1 Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, San Antonio, TX 78284 USA. RP Roodman, GD (reprint author), Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NCI NIH HHS [CA-40035]; NIA NIH HHS [AG13625]; NIAMS NIH HHS [AR39529] NR 58 TC 4 Z9 4 U1 0 U2 1 PU PORTLAND PRESS PI LONDON PA 59 PORTLAND PLACE, LONDON, ENGLAND W1N 3AJ SN 0300-5127 J9 BIOCHEM SOC T JI Biochem. Soc. Trans. PD FEB PY 1998 VL 26 IS 1 BP 7 EP 13 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YZ064 UT WOS:000072216700002 PM 10909749 ER PT J AU Amin, F Hashmi, A Stroe, AE Adebogun, O Densmore, D Knott, PJ AF Amin, F Hashmi, A Stroe, AE Adebogun, O Densmore, D Knott, PJ TI Reproducibility of plasma catecholamine metabolites in normal subjects SO BIOLOGICAL PSYCHIATRY LA English DT Article DE plasma; catecholamine; metabolite; reproducibility; homovanillic acid; 3-methoxy-4-hydroxyphenylglycol AB Background: Plasma homovanillic acid (HVA) and methoxy-hydroxy-phenylglycol (MHPG) are often used in repeated measurement designs to assess dopamine and norepinephrine metabolism in clinical research. However, only limited data on the reproducibility of these metabolites are currently available. Methods: Plasma HVA and MHPG were measured in normal volunteers on five nonconsecutive mornings under fasting conditions and restricted smoking and physical activity. Results: Intraclass correlation coefficients (ICC) for plasma HVA and MHPG across 5 days were determined to be 0.85 and 0.79, respectively. ICC improved to 0.90 for HVA and 0.91 for MHPG when the average of the first 2 days was examined against the average of the last 2 days. Conclusions: Results suggested that under controlled conditions plasma HVA and MHPG measurements have good reproducibility. Published by the Society of Biological Psychiatry 1998. C1 Houston VA Med Ctr, Psychiat Serv 116A, Dept Psychiat, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Bronx VAMC, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. RP Amin, F (reprint author), Houston VA Med Ctr, Psychiat Serv 116A, Dept Psychiat, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 6 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 1 PY 1998 VL 43 IS 3 BP 233 EP 235 DI 10.1016/S0006-3223(97)00378-8 PG 3 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA YY699 UT WOS:000072174800011 PM 9494706 ER PT J AU Longmore, GD You, Y Molden, J Liu, KD Mikami, A Lai, SY Pharr, P Goldsmith, MA AF Longmore, GD You, Y Molden, J Liu, KD Mikami, A Lai, SY Pharr, P Goldsmith, MA TI Redundant and selective roles for erythropoietin receptor tyrosines in erythropoiesis in vivo SO BLOOD LA English DT Article ID HEMATOPOIETIC PROGENITOR CELLS; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; STAT5 ACTIVATION; ERYTHROID-CELLS; DIFFERENTIATION; INTERLEUKIN-2; DOMAIN; PROLIFERATION; EXPRESSION AB Cytokine receptors have been shown in cell culture systems to use phosphotyrosine residues as docking sites for certain signal transduction intermediates, Studies using various cellular backgrounds have yielded conflicting information about the importance of such residues, The present studies were undertaken to determine whether or not tyrosine residues within the erythropoietin receptor (EPOR) are essential for biologic activity during hematopoiesis in vivo. A variant of the EPOR was constructed that contains both a substitution (R129C) causing constitutive receptor activation as well as replacement of all eight cytoplasmic tyrosines by phenylalanines (cEPORYF). A comparison between animals exposed to recombinant retroviruses expressing cEPOR and cEPORYF showed that efficient red blood cell (RBC) development in vivo is dependent on the presence of tyrosine residues in the cytoplasmic domain of the EPOR. In addition, an inefficient EPOR tyrosine independent pathway supporting RBC development was detected. Tyrosine add-back mutants showed that multiple individual tyrosines have the capacity to restore full erythropoietic potential to the EPOR as determined in whole animals. The analysis of primary erythroid progenitors transduced with the various cEPOR tyrosine mutants and tyrosine add-backs showed that only tyrosine 343 (Y1) and tyrosine 479 (Y8) were capable of supporting immature burst-forming unit-erythroid progenitor development. Thus, this receptor is characterized by striking functional redundancy of tyrosines in a biologically relevant context. However, selective tyrosine residues may be uniquely important for early signals supporting erythroid development. (C) 1998 by The American Society of Hematology. C1 Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA. Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA. Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Goldsmith, MA (reprint author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA. FU NCI NIH HHS [CA75315]; NIGMS NIH HHS [GM54531] NR 38 TC 32 Z9 33 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0006-4971 J9 BLOOD JI Blood PD FEB 1 PY 1998 VL 91 IS 3 BP 870 EP 878 PG 9 WC Hematology SC Hematology GA YT777 UT WOS:000071644000018 PM 9446647 ER PT J AU Garrido, SM Chauncey, TR AF Garrido, SM Chauncey, TR TI Neuroleptic malignant syndrome following autologous peripheral blood stem cell transplantation SO BONE MARROW TRANSPLANTATION LA English DT Article DE neuroleptic malignant syndrome; autotransplant ID SYMPTOMS AB Neuroleptic malignant syndrome (NMS) is a rare disorder characterized by hyperthermia, elevated creatine phosphokinase, extrapyramidal effects, autonomic instability, altered level of consciousness and leukocytosis associated with neuroleptic and other psychotropic medications, There are no cases of NMS reported following stem cell transplantation. We describe two patients receiving autotransplants who developed NMS. With the common use of neuroleptic and other related psychotropic medications in the peri-transplant period and the associated physiologic stress of the procedure, we believe that NMS may be unrecognized and account for significant morbidity in this setting. C1 VA Puget Sound Hlth Care Syst, Div Oncol 111, Marrow Transplant Unit, Seattle, WA 98118 USA. Univ Washington, Sch Med, Div Oncol, Seattle, WA 98195 USA. RP Chauncey, TR (reprint author), VA Puget Sound Hlth Care Syst, Div Oncol 111, Marrow Transplant Unit, 1660 S Columbian Way, Seattle, WA 98118 USA. NR 11 TC 6 Z9 6 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD FEB PY 1998 VL 21 IS 4 BP 427 EP 428 DI 10.1038/sj.bmt.1701093 PG 2 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA YZ430 UT WOS:000072253300018 PM 9509981 ER PT J AU Barnes, CJ Cameron, IL Hardman, WE Lee, M AF Barnes, CJ Cameron, IL Hardman, WE Lee, M TI Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis SO BRITISH JOURNAL OF CANCER LA English DT Article DE colon cancer; proliferation; apoptosis; non-steroidal anti-inflammatory drugs; lymphoid nodules; 1,2-dimethylhydrazine ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPEROXIDE-H SYNTHASE-1; LYMPHOID NODULES; DIFFERENTIAL INHIBITION; COLORECTAL-CANCER; ASPIRIN; EXPRESSION; PROSTAGLANDINS; ADENOCARCINOMAS; PARAMETERS AB Sustained use of non-steroidal anti-inflammatory drugs (NSAIDs) may, prevent colorectal cancer. However, the optimal drug, period of efficacy and mechanism(s) of action are unknown, Experiments were undertaken to determine which of several NSAIDs would modulate colon crypt cell proliferation or apoptosis when given during the initiation phase of 1,2-dimethylhydrazine (DMH)-induced rat colon cancer, Colon crypts located both away from and over an aggregate of lymphoid nodules (ALN) were examined, Rats were injected with aspirin, indomethacin, nabumetone, sodium salicylate, 16,16-dimethyl prostaglandin E-2 or saline for 3 days and DMH or DMH vehicle on day 4 of each week for 8 weeks, then killed 3 days after the last DMH injection. At the time of killing, DMH had significantly increased crypt cell proliferation but not apoptosis. There was significantly more cell proliferation and apoptosis in crypts over the ALN than away from the ALN, Aspirin and salicylate increased proliferation and apoptosis in crypts over the ALN, Finally, the distributional peaks of cell proliferation and apoptosis were shifted significantly closer together after DMH. Thus, DMH increases proliferation and alters the distribution of proliferating and apoptotic cells in colon crypts early in carcinogenesis, Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in carcinogen-initiated cells. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Gastroenterol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Vet Affairs Med Ctr, San Antonio, TX 78284 USA. RP Barnes, CJ (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Gastroenterol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCI NIH HHS [P30 CA 54174] NR 44 TC 68 Z9 69 U1 0 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0007-0920 J9 BRIT J CANCER JI Br. J. Cancer PD FEB PY 1998 VL 77 IS 4 BP 573 EP 580 DI 10.1038/bjc.1998.93 PG 8 WC Oncology SC Oncology GA YX517 UT WOS:000072048500010 PM 9484814 ER PT J AU January, B Seibold, A Allal, C Whaley, BS Knoll, BJ Moore, RH Dickey, BF Barber, R Clark, RB AF January, B Seibold, A Allal, C Whaley, BS Knoll, BJ Moore, RH Dickey, BF Barber, R Clark, RB TI Salmeterol-induced desensitization, internalization and phosphorylation of the human beta(2)-adrenoceptor SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Article DE salmeterol; beta(2)-adrenoceptor; desensitization; internalization; phosphorylation ID BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; ACTING BETA-2-ADRENOCEPTOR AGONIST; CYCLIC-AMP ACCUMULATION; ADENYLATE-CYCLASE; MILD ASTHMA; STIMULATION; KINASE; FORMOTEROL; DURATION AB 1 Partial agonists of the beta(2)-adrenoceptor which activate adenylyl cyclase are widely used as bronchodilators for the relief of bronchoconstriction accompanying many disease conditions, including bronchial asthma. The bronchodilator salmeterol has both a prolonged duration of action in bronchial tissue and the ability to reassert this activity following the temporary blockade of human beta(2)-adrenoceptors with antagonist. 2 We have compared the activation and desensitization of human beta(2)-adrenoceptor stimulation of adenylyl cyclase induced by salmeterol, adrenaline and salbutamol in a human lung epithelial line, BEAS-2B, expressing beta(2)-adrenoceptor levels of 40-70 fmol mg(-1), and in human embryonic kidney (HEK) 293 cell lines expressing 2-10 pmol mg(-1). The efficacy observed for the stimulation of adenylyl cyclase by salmeterol was only congruent to 10% of that observed for adrenaline in BEAS-2B cells expressing low levels of beta(2)-adrenoceptor, but similar to adrenaline in HEK 293 cells expressing very high levels of receptors. Salmeterol pretreatment of these cells induced a rapid and stable activation of adenylyl cyclase activity which resisted extensive washing and beta(2)-adrenoceptor antagonist blockade, consistent with binding to a receptor exosite and/or to partitioning into membrane lipid. 3 The desensitization and internalization of beta(2)-adrenoceptors induced by the partial agonists salmeterol and salbutamol were considerably reduced relative to the action of adrenaline. Consistent with these observations, the initial rate of phosphorylation of the receptor induced by salmeterol and salbutamol was much reduced in comparison to adrenaline. 4 Our data suggest that the reduction in the rapid phase of desensitization of beta(2)-adrenoceptors after treatment with salmeterol or salbutamol is caused by a decrease in the rate of beta(2)-adrenoceptor kinase (beta ARK) phosphorylation and internalization. In contrast, the fate of cyclic AMP-dependent protein kinase (PKA)-mediated phosphorylation by these partial agonists appears to be similar to adrenaline. C1 Univ Texas, Hlth Sci Ctr, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77225 USA. Baylor Coll Med, VA Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Dept Cell Biol, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Dept Mol Physiol & Biophys, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. RP Clark, RB (reprint author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol Pharmacol & Physiol, POB 20708, Houston, TX 77225 USA. FU NCRR NIH HHS [RR-07710]; NIGMS NIH HHS [GM-31208] NR 46 TC 56 Z9 56 U1 0 U2 2 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD FEB PY 1998 VL 123 IS 4 BP 701 EP 711 DI 10.1038/sj.bjp.0701658 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YY053 UT WOS:000072107500015 PM 9517390 ER PT J AU Furukawa, H Kusne, S Sutton, DA Manez, R Carrau, R Nichols, L Abu-Elmagd, K Skedros, D Todo, S Rinaldi, MG AF Furukawa, H Kusne, S Sutton, DA Manez, R Carrau, R Nichols, L Abu-Elmagd, K Skedros, D Todo, S Rinaldi, MG TI Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SECTION LONGIBRACHIATUM; GENUS TRICHODERMA; SINUSES; VIRIDE; PERITONITIS; INFECTION; REVISION; NOSE AB We describe a case of acute invasive sinusitis due to an unusual moniliaceous fungus, Trichoderma longibrachiatum Rifai 1969 (a member of the class Hyphomycetes), in a small bowel and liver transplant recipient treated with tacrolimus (FK-506) and prednisone. The patient was successfully treated with surgical debridements and amphotericin B followed by oral itraconazole. C1 Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Div Transplantat Med, Dept Surg, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Kusne, S (reprint author), Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Div Transplantat Med, Dept Surg, 3515 5th Ave, Pittsburgh, PA 15213 USA. NR 22 TC 32 Z9 32 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5801 S ELLIS AVENUE, CHICAGO, IL 60637 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 1998 VL 26 IS 2 BP 487 EP 489 DI 10.1086/516317 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA YW499 UT WOS:000071941900039 PM 9502475 ER PT J AU Swartz, BE Goldensohn, ES AF Swartz, BE Goldensohn, ES TI Timeline of the history of EEG and associated fields SO ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY LA English DT Article C1 W Los Angeles Vet Affairs Med Ctr, Epilepsy Ctr, Los Angeles, CA 90073 USA. Montefiore Med Ctr, Albert Einstein Sch Med, Bronx, NY 10467 USA. RP Swartz, BE (reprint author), W Los Angeles Vet Affairs Med Ctr, Epilepsy Ctr, W127B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 80 TC 32 Z9 35 U1 0 U2 6 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0013-4694 J9 ELECTROEN CLIN NEURO JI Electroencephalogr. Clin. Neurophysiol. PD FEB PY 1998 VL 106 IS 2 BP 173 EP 176 PG 4 WC Engineering, Biomedical; Clinical Neurology SC Engineering; Neurosciences & Neurology GA ZC075 UT WOS:000072537000013 PM 9741779 ER PT J AU Pekary, AE Hershman, JM Berg, L AF Pekary, AE Hershman, JM Berg, L TI Tumor necrosis factor, ceramide, transforming growth factor-beta(1), and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells SO ENDOCRINOLOGY LA English DT Article ID RAT-THYROID CELLS; I IODOTHYRONINE DEIODINASE; PROTEIN-KINASE-C; FACTOR-ALPHA; FACTOR-BETA; SIGNAL-TRANSDUCTION; IODIDE TRANSPORT; POSSIBLE INVOLVEMENT; CELLULAR SENESCENCE; ANCHORED PROTEINS AB Iodide uptake, which is necessary for thyroid hormone synthesis, can be inhibited by aging, withdrawal of TSH, or increased tumor necrosis factor (TNF) and transforming growth factor (TGF)-beta(1) levels resulting from the nonthyroid illness syndrome. TNF induces receptor-mediated activation of sphingomyelinase, which converts sphingomyelin to ceramide, a mediator of TNF actions. Thyroid follicular cells transport iodide from blood into the follicular lumen against an iodide gradient by means of coupled transport of Na+ ions and I- ions via the Na+/I- symporter (NIS). An inward Na+ gradient is maintained by Na+/K+-ATPase. The recent cloning and sequencing of the rat NIS complementary DNA has made possible studies on the mechanism by which TSH, aging, and cytokines regulate I- uptake by thyroid cells. Young (<20 passages) and aged (>40 passages) FRTL-5 cells grown with or without TSH were treated with various concentrations of TNF, TGF-beta(1) sphingomyelinase, or ceramide. NIS messenger RNA (mRNA) levels in aged cells were only 2% of those in young cells. Withdrawal of TSH from young cells reduced NIS mRNA levels by more than 90%. TNF reduced NIS mRNA levels in young cells grown with TSH at t(1/2) = 0.62 days, a cycloheximide inhibitable effect. Similar treatments with TGF-beta(1), sphingomyelinase, or ceramide reduced NIS mRNA by 70-90%. Ceramide reduced I-125(-)-uptake by 50%. The addition of TNF increased both the sphingomyelin and ceramide levels 3- to 5-fold in young and old cells. We conclude that 1) the decline in iodide uptake due to aging, a fall in serum TSH or an increase in TNF or TGF-beta(1) is mediated primarily by a reduction in thyroid NIS expression; and 2) that receptor-mediated activation of sphingomyelinase is an important, protein synthesis-dependent, intracellular pathway for inhibition of NIS expression by TNF. C1 Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Endocrinol Res Lab, Los Angeles, CA 90073 USA. RP Hershman, JM (reprint author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Endocrinol Res Lab, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershman@ucla.edu NR 57 TC 71 Z9 78 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 1998 VL 139 IS 2 BP 703 EP 712 DI 10.1210/en.139.2.703 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YR396 UT WOS:000071491000038 PM 9449644 ER PT J AU Kanner, AM Bourgeois, BFD Hasegawa, H Hutson, P AF Kanner, AM Bourgeois, BFD Hasegawa, H Hutson, P TI Rapid switchover to carbamazepine using pharmacokinetic parameters SO EPILEPSIA LA English DT Article DE carbamazepine; rapid switchover; pharmacokinetic cross-tolerance; pharmacodynamic cross-tolerance ID TONIC CLONIC SEIZURES; PHENYTOIN; PRIMIDONE; VALPROATE; EPILEPSY; CHILDREN; PLASMA; ADULTS; DISCONTINUATION; MONOTHERAPY AB Purpose: The standard practice of switching patients to carbamazepine (CBZ) involves initiating a low dose and raising it by small increments until the desired dose is reached, to avoid intolerable adverse effect (AE). In a pilot study, a protocol using single-dose kinetic studies was developed to switch patients to CBZ through rapid-dose increments and to manage concurrent rapid taper of the previous antiepileptic drugs (AEDs) without causing AE. The purpose of this prospective study was (a) to reassess whether a rapid switch-over to CBZ could be done with minimal or no AE and without causing an increase in seizures (b) to determine whether the maintenance-dose of CBZ predicted at the time of the single dose kinetic study can yield the desired concentration at steady state (C-ss); and (c) to determine the degree to which the calculated maintenance dose of CBZ will need to be adjusted after the previous AED has been discontinued for a four-week period, Methods: Twenty-five patients taking phenytoin (PHT) and/or phenobarbital (PB) and/or primidone (PRM) underwent a rapid switchover to CBZ following a 10 mg/kg single-dose kinetic study (day 1) which allowed calculation of a maintenance dose necessary to yield a mean C-ss of 10.2 (+/-2.2) men, On day 2, patients received a CBZ dose equivalent to 10 mg/kg + 200 mg; thereafter, they underwent daily dose increments of 200 mg until the calculated maintenance dose was reached. Dose increments were modified in the case of AE. Concurrent tapering of the previous AED was started as of day 1: PHT by 100 mg/day, while PB and PRM were stopped on day 1; PB was restarted before patients were to be discharged from the hospital if a PB serum concentration above 10 mg/l was identified at that time. Pharmacokinetic data and occurrence of AE were compared between the two groups at the time of the single-dose kinetic study, al the completion of the switchover to CBZ and 4 weeks after discontinuation of the previous AED. Results: All patients completed the switchover to CBZ within a mean lime period of 6 days (+/-2), reaching a mean maintenance dose of 1,639 mg/day (+/-370) Which yielded a mean C-ss of 11.3 (+/-3.2) mg/l. The maintenance dose had to be lowered by 20.4% (+/-8.3) in 59% of patients within the four-week period following discontinuation of at least one of the previous AEDs. None of the patients experienced an increase in seizure frequency relative to baseline, Fifteen (60%) patients had no AE: five (20%) experienced AE of mild severity. AE rated as moderately severe (n = 4) or severe in = 1) occurred ill patients with a static encephalopathy: (p = 0.02. Fisher's exact test) and among patients greater than or equal to 55 years (p = 0.017, Fisher's exact test). Conclusions: A rapid switch-over to CBZ from PHT, PB, or PRM can be carried out safely with no, or minimal, AE in young adults, unless they suffer from static encephalopathy. C1 Rush Med Coll, Dept Neurol Sci, Chicago, IL 60612 USA. Rush Med Coll, Rush Epilepsy Ctr, Chicago, IL 60612 USA. Washington Univ, Dept Neurol, St Louis, MO USA. Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. Univ Wisconsin, Sch Med, Dept Neurol, Madison, WI 53706 USA. William S Middleton Mem Vet Hosp, Serv Neurol, Madison, WI USA. RP Kanner, AM (reprint author), Rush Presbyterian St Lukes Med Ctr, Rush Epilepsy Ctr, 1653 W Congress Pkwy, Chicago, IL 60612 USA. NR 32 TC 3 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD FEB PY 1998 VL 39 IS 2 BP 194 EP 200 DI 10.1111/j.1528-1157.1998.tb01358.x PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA YU668 UT WOS:000071741900010 PM 9578000 ER PT J AU Nelson, EC McHorney, CA Manning, WG Rogers, WH Zubkoff, M Greenfield, S Ware, JE Tarlov, AR AF Nelson, EC McHorney, CA Manning, WG Rogers, WH Zubkoff, M Greenfield, S Ware, JE Tarlov, AR TI A longitudinal study of hospitalization rates for patients with chronic disease: Results from the medical outcomes study SO HEALTH SERVICES RESEARCH LA English DT Article DE prepaid health plans; managed care; fee-for-service plans; resource utilization; system comparisons ID FEE-FOR-SERVICE; PREPAID GROUP-PRACTICE; HEALTH-MAINTENANCE ORGANIZATIONS; RHEUMATOID-ARTHRITIS; MANAGED CARE; PRACTICE SETTINGS; ELDERLY PATIENTS; SYSTEMS; SPECIALTIES; HYPERTENSION AB Objective. To prospectively compare inpatient and outpatient utilization rates between prepaid (PPD) and fee-for-service (FFS) insurance coverage for patients with chronic disease. Data Source/Study Setting. Data from the Medical Outcomes Study, a longitudinal observational study of chronic disease patients conducted in Boston, Chicago, and Los Angeles. Study Design. A four-year prospective study of resource utilization among 1,681 patients under treatment for hypertension, diabetes, myocardial infarction, or congestive heart failure in the practices of 367 clinicians. Data Collection/Extraction Methods. Insurance payment system (PPD or FFS), hospitalizations, and office visits were obtained from patient reports. Disease and severity indicators, sociodemographics, and self-reported functional status were used to ac?just for patient mix and to compute expected utilization rates. Principal Findings. Compared to FFS, PPD patients had 31 percent fewer observed hospitalizations before adjustment for patient differences (p = .005) and 15 percent fewer hospitalizations than expected after adjustment (p = .078). The observed rate of FFS hospitalizations exceeded the expected rate by 9 percent. These results are not explained by system differences in patient mix or trends in hospital use over four years. Half of the PPD/FFS difference in hospitalization rate is due to intrinsic characteristics of the payment system itself. Conclusions. PPD patients with chronic medical conditions followed prospectively eve:: four years, after extensive patient-mix adjustment, had 15 percent fewer hospitalizations than their FFS counterparts owing to differences intrinsic to the insurance reimbursement system. C1 Dartmouth Hitchcock Med Ctr, Presidents Off, Lebanon, NH 03756 USA. Univ Wisconsin, Dept Prevent Med, Madison, WI 53706 USA. Univ Wisconsin, Dept Med, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Hosp, Madison, WI 53705 USA. Univ Minnesota, Sch Publ Hlth, Inst Hlth Serv Res, Minneapolis, MN 55455 USA. New England Med Ctr, Hlth Inst, Boston, MA 02111 USA. Dartmouth Med Sch, Dept Family & Community Med, Hanover, NH USA. New England Med Ctr, Primary Care Outcomes Res Inst, Boston, MA 02111 USA. RP Nelson, EC (reprint author), Dartmouth Hitchcock Med Ctr, Presidents Off, 1 Med Ctr Dr, Lebanon, NH 03756 USA. NR 32 TC 20 Z9 21 U1 0 U2 0 PU HEALTH ADMINISTRATION PRESS PI MELROSE PARK PA C/O FOUNDATION AMER COLL HEALTHCARE EXECUTIVES 1951 CORNELL AVE, MELROSE PARK, IL 60160 USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 1998 VL 32 IS 6 BP 759 EP 774 PG 16 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA YY654 UT WOS:000072170200004 PM 9460485 ER PT J AU Vandenbark, AA Chou, YK Whitham, R Bourdette, DN Offner, H AF Vandenbark, AA Chou, YK Whitham, R Bourdette, DN Offner, H TI Effects of vaccination with T cell receptor-peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide SO IMMUNOLOGY AND CELL BIOLOGY LA English DT Article DE cross-reactivity; experimental autoimmune encephalomyelitis; multiple sclerosis; myelin basic protein; regulatory T cells; T cell receptor peptides ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; V-BETA-6.1 CDR2 PEPTIDES; MULTIPLE-SCLEROSIS; LEWIS RATS; AUTOREGULATION; IMMUNIZATION; IMMUNITY; INCLUDE; GENES AB Immunization of Lewis rats with guinea-pig myelin basic protein (Gp-MBP) induced T cell responses to primary and secondary encephalitogenic determinants, as well as to a third non-encephalitogenic epitope, residues 55-69. This sequence is of interest due to its protective activity against experimental autoimmune encephalomyelitis. Protection involved induction of MBP-55-69-specific T cells expressing cross-reactive TCR BV8S6 genes that activated regulatory T cells specific for TCR BV8S2 determinants expressed on encephalitogenic T cells. We here present and discuss new evidence suggesting a possible immunological crossreactivity between the protective Gp-MBP-55-69 peptide and the regulatory BV8S2-39-59 peptide. This crossreactivity, which may also occur between the human MBP-55-74 peptide and the BV12S2-38-58 sequence, has potentially important implications for human diseases such as multiple sclerosis. C1 Portland VA Med Ctr, Res Serv, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Vet Affairs Med Ctr, Neurol Serv, Portland, OR USA. RP Vandenbark, AA (reprint author), Portland VA Med Ctr, Res Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97201 USA. FU NINDS NIH HHS [NS23444, NS23221] NR 26 TC 5 Z9 6 U1 0 U2 0 PU BLACKWELL SCIENCE PI CARLTON PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA SN 0818-9641 J9 IMMUNOL CELL BIOL JI Immunol. Cell Biol. PD FEB PY 1998 VL 76 IS 1 BP 83 EP 90 DI 10.1046/j.1440-1711.1998.00720.x PG 8 WC Cell Biology; Immunology SC Cell Biology; Immunology GA ZB780 UT WOS:000072507300010 PM 9553780 ER PT J AU Liberman, RP AF Liberman, RP TI International perspectives on skills training for the mentally disabled SO INTERNATIONAL REVIEW OF PSYCHIATRY LA English DT Editorial Material ID SCHIZOPHRENIC-PATIENTS; MANAGEMENT C1 W Los Angeles Vet Affairs Med Ctr, Res Ctr Schizophrenia & Psychiat Rehabil, Los Angeles, CA 90073 USA. RP Liberman, RP (reprint author), Univ Calif Los Angeles, Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 14 TC 17 Z9 17 U1 1 U2 3 PU CARFAX PUBL CO PI ABINGDON PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE SN 0954-0261 J9 INT REV PSYCHIATR JI Int. Rev. Psych. PD FEB PY 1998 VL 10 IS 1 BP 5 EP 8 DI 10.1080/09540269875014 PG 4 WC Psychiatry SC Psychiatry GA ZM783 UT WOS:000073575400001 ER PT J AU Canver, CC Heisey, DM Nichols, RD Cooler, SD Kroncke, GM AF Canver, CC Heisey, DM Nichols, RD Cooler, SD Kroncke, GM TI Long-term survival benefit of internal thoracic artery grafting is negligible in a patient with bad ventricle SO JOURNAL OF CARDIOVASCULAR SURGERY LA English DT Article DE thoracic arteries transplantation; heart surgery, methods; stroke volume; coronary artery bypass mortality; ventricular function, left ID MAMMARY-ARTERY; OPERATIVE MORTALITY; EJECTION FRACTION; BYPASS; SURGERY; MODEL; IMPACT AB Background. Although the internal thoracic artery (ITA) graft is well known for its benefit of enhancing patient longevity after coronary artery bypass grafting (CABG), whether its superior patency is associated with improved patient survival at all levels of left ventricular function is unknown. The purpose of this study was to determine whether the use of ITA grafting during CABG confers improved survival benefit to patients with impaired preoperative left ventricular function. Methods. A retrospective chart review was performed in 966 patients who had undergone isolated primary CABG between 1984 and 1995. The study population included 320 patients with only venous conduits (no-ITA group) and 646 patients with at least one ITA conduit (ITA group). A Cox partial likelihood approach was used to model the instantaneous mortality risk ratios as functions of ITA use and preoperative ejection fraction (EF). The forward stepwise regression model specifically examined the following potential confounders in the risk analyses: year of operation, patient age, weight, body surface area, graft location, number of grafts, perfusion time, ischemia time and Veterans Administration preoperative cardiac surgical risk estimates. Results. Early (30-day) mortality in the ITA group (0.5%) was lower than the no-ITA group (4.1%) (p=0.0004). While 91% of the ITA group patients were still alive, only 70% of the no-ITA group patients were long-term survivors (p=0.0001). The ITA risk ratios for the increasing proportions of EF were not the same. In patients with E less than or equal to 0.40, the ITA risk ratio, 2.96, was significantly different (p=0.0001). It was only for EF >0.46, a significant survival benefit due to an ITA graft could be detected. The ITA-EF relationship was not confounded by the inclusion of those potential confounding variables in the model. Conclusions. Patient survival after CABG using an ITA graft may be affected by the level of preoperative EF. The internal thoracic artery-specific patient survival benefit appears to be less in a patient with poor left ventricular function. C1 Univ Wisconsin, William S Middleton Mem Vet Hosp, Sch Med, Sect Cardiothorac Surg, Madison, WI 53706 USA. RP Canver, CC (reprint author), Univ Wisconsin, Sch Med, Div Cardiothorac Surg, Clin Sci Ctr H4 352, 600 Highland Ave, Madison, WI 53706 USA. NR 20 TC 3 Z9 3 U1 0 U2 0 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0021-9509 J9 J CARDIOVASC SURG JI J. Cardiovasc. Surg. PD FEB PY 1998 VL 39 IS 1 BP 57 EP 63 PG 7 WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Surgery GA ZC472 UT WOS:000072582700011 PM 9537537 ER PT J AU Gentilini, A Feliers, D Pinzani, M Woodruff, K Abboud, S AF Gentilini, A Feliers, D Pinzani, M Woodruff, K Abboud, S TI Characterization and regulation of insulin-like growth factor binding proteins in human hepatic stellate cells SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article; Proceedings Paper CT National Annual Meeting of the American-Federation-of-Clinical-Research CY MAY 03-06, 1996 CL WASHINGTON, D.C. SP Amer Federat Clin Res ID FAT-STORING CELLS; CHRONIC LIVER-DISEASE; I IGF-I; HUMAN FIBROBLASTS; RAT HEPATOCYTES; STROMAL CELLS; NONPARENCHYMAL CELLS; PRIMARY CULTURES; GENE-EXPRESSION; ITO-CELL AB Cultured hepatic stellate cells (HSCs), the cell type primarily involved in the progression of liver fibrosis, secrete insulin-like growth factor-I (IGF-I) and IGF binding protein (IGFBP) activity. IGF-I exerts a mitogenic effect on HSCs, thus potentially contributing to the fibrogenic process in an autocrine fashion, However, IGF-I action is modulated by the presence of specific IGFBPs that may inhibit and/or enhance its biologic effects. Therefore, we examined IGFBP-1 through IGFBP-6 mRNA and protein expression in HSCs isolated from human liver and activated in culture. Regulation of IGFBPs in response to IGF-I and other polypeptide growth factors involved in the hepatic fibrogenic process was also assessed. RNase protection assays and ligand blot analysis demonstrated that HSCs express IGFBP-2 through IGFBP-6 mRNAs and release detectable levels of IGFBP-2 through IGFBP-5. Because IGF-I, platelet-derived growth factor-BB (PDGF-BB), and transforming growth factor-beta (TGF-beta) stimulate HSC proliferation and/or matrix production, we tested their effect on IGFBPs released HSCs. IGF-I induced IGFBP-3 and IGFBP-5 proteins in a time-dependent manner without an increase in the corresponding mRNAs. IGFBP-4 protein levels decreased in response to IGF-I. IGF-beta stimulated IGFBP-3 mRNA and protein but decreased IGFBP-5 mRNA and protein. In contrast, PDGF-BB failed to regulate IGFBPs compared with controls. Recombinant human IGFBP-3 (rhlGFBP-3) was then tested for its effect on IGF-1-induced mitogenesis in HSCs. rhlGFBP-3 inhibited IGF-I-stimulated DNA synthesis in a dose-dependent manner, with a peak effect observed at 25 nM IGFBP-3. Because TGF-beta is highly expressed in cirrhotic river tissue, we determined whether IGFBP-3 mRNA expression is increased in liver biopsies obtained from patients with an active fibroploliferative response due to viral-induced chronic active hepatitis. In the majority of these samples, IGFBP-3 mRNA was increased compared with normal controls. These findings indicate that human HSCs, in their activated phenotype, constitutively produce IGFBPs. IGF-I and TGF-beta differentially regulate IGFBP-3, IGFBP-4, and IGFBP-5 expression, which, in turn, may modulate the in vitro and in vivo action of IGF-I. (C) 1998 Wiley-Liss, Inc. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Univ Florence, Ist Med Interna, Florence, Italy. RP Abboud, S (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NIAMS NIH HHS [AR42306] NR 55 TC 30 Z9 33 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9541 EI 1097-4652 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD FEB PY 1998 VL 174 IS 2 BP 240 EP 250 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA YP019 UT WOS:000071233100011 PM 9428810 ER PT J AU Roder, ME Porte, D Schwartz, RS Kahn, SE AF Roder, ME Porte, D Schwartz, RS Kahn, SE TI Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID JAPANESE-AMERICAN MEN; INSULIN-SECRETION; CHLORPROPAMIDE THERAPY; INTACT PROINSULIN; GLUCOSE-TOLERANCE; C-PEPTIDE; NIDDM; HYPERGLYCEMIA; RESISTANCE; HYPERPROINSULINEMIA AB An increased proportion of fasting proinsulin (PI) relative to immunoreactive insulin (IRI; increased PI/IRI) occurs in noninsulin-dependent diabetes mellitus (NIDDM). To determine whether the magnitude of the increase in PI/IRI is an indicator of the degree of reduced B cell secretory capacity, we measured fasting plasma glucose, PI, IRI, and PI/IRI and related them to maximal B cell secretory capacity (AIRmax) in 9 subjects with NIDDM [age, 61 +/- 3 yr; body mass index (BMI), 27.5 +/- 1.3 kg/m(2); duration of NIDDM, 10.8 +/- 1.8 yr; mean +/- SEM and in 10 healthy subjects matched for age and BMI (age,61 +/- 6 yr; BMI, 27.9 +/- 1.5 kg/m(2)). AIRmax was quantified as the incremental insulin response to iv arginine at maximal glycemic potentiation (plasma glucose >25 mmol/L). Mean fasting plasma glucose was 13.7 +/- 1.4 mmol/L (range, 7.5-18.3 mmol/L) in NIDDM subjects and 5.0 +/- O.1 mmol/L in the controls. Fasting PI was higher in NIDDM (33.1 +/- 5.2) than in controls (9.4 +/- 2.5 pmol/L; P < 0.01), but IRI levels were similar (93.4 +/- 10.9 vs. 82.8 +/- 23.4 pmol/L; P = NS). The PI/IRI ratio was significantly elevated in NIDDM compared to control subjects (35.9 +/- 4.1% vs. 12.8 +/- 0.8%; P < 0.01). After elevation of the glucose level to 30.3 +/- 0.4 mmol/L (NIDDM) and 30.3 +/- 0.5 mmol/L (controls), AIRmax was quantified as 622 +/- 71 pmol/L in NIDDM and 1997 +/- 315 pmol/L in controls, (P < 0.001). The PI/IRI ratio correlated inversely with AIRmax in the NIDDM patients (r = -0.76; P < 0.01). We conclude that the magnitude of the elevation in fasting PI/IRI is related to the reduction in AIRmax. Thus, the fasting PI/IRI ratio appears to be a marker of the degree of reduced AIRmax in NIDDM. C1 Harborview Med Ctr, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Harborview Med Ctr, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Geriatr Med, Seattle, WA 98108 USA. Harborview Med Ctr, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gerontol, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. RP Roder, ME (reprint author), Univ Copenhagen, Rigshosp, Dept Nephrol & Endocrinol P, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark. EM mroder@login.dknet.dk OI Kahn, Steven/0000-0001-7307-9002 FU NIA NIH HHS [AG-08673]; NIDDK NIH HHS [DK-12829, DK-17047] NR 39 TC 134 Z9 145 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 1998 VL 83 IS 2 BP 604 EP 608 DI 10.1210/jc.83.2.604 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YV437 UT WOS:000071823900051 PM 9467581 ER PT J AU Stelnicki, EJ Komuves, LG Kwong, AO Holmes, D Klein, P Rozenfeld, S Lawrence, HJ Adzick, NS Harrison, M Largman, C AF Stelnicki, EJ Komuves, LG Kwong, AO Holmes, D Klein, P Rozenfeld, S Lawrence, HJ Adzick, NS Harrison, M Largman, C TI HOX homeobox genes exhibit spatial and temporal changes in expression during human skin development SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE dermis; epidermis; gene regulation; homeodomain ID GROWTH-FACTOR RECEPTOR; DIFFERENTIAL EXPRESSION; HAIR FOLLICLE; DNA-BINDING; VERTEBRATE DEVELOPMENT; MICE; EPIDERMIS; PROTEINS; FETAL AB The spatial and temporal deployment of HOX homeobox genes along the spinal axis and in limb buds during fetal development is a key program, in embryonic pattern formation. Although we have previously reported that several of the HOX homeobox genes are expressed during murine skin development, there is no information about developmental expression of HOX genes in human skin. We have now used reverse transcriptase polymerase chain reaction, in conjunction with a set of degenerate oligonucleotide primers, to identify a subset of HOX genes that are expressed during human fetal skin development. In situ hybridization analyses demonstrated that there were temporal and spatial shifts in expression of these genes. Strong HOXA4 expression was detected in the basal cell layers of 10 wk fetal epidermis and throughout the epidermis and dermis of 17 wk skin, whereas weak signal was present in the granular layer of newborn and adult skin. The expression patterns of HOXA5 and HOXA7 were similar, but their expression was weaker, In sib hybridization analysis also revealed strong HOXC4 and weaker HOXB7 expression throughout fetal development, whereas HOXB4 was expressed at barely detectable levels, Differential HOX gene expression was also observed in developing hair follicles, and sebaceous and sweat glands, None of the HOX genes examined were detected in the adult dermis. C1 VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. VA Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Washington, Med Ctr, Dept Surg, St Louis, MO USA. Childrens Hosp, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. RP Largman, C (reprint author), VA Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. FU NICHD NIH HHS [HD-25505] NR 45 TC 87 Z9 92 U1 0 U2 7 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD FEB PY 1998 VL 110 IS 2 BP 110 EP 115 DI 10.1046/j.1523-1747.1998.00092.x PG 6 WC Dermatology SC Dermatology GA YT480 UT WOS:000071608100002 PM 9457903 ER PT J AU Schlesinger, N Gowin, KM Baker, DG Beutler, AM Hoffman, BI Schumacher, HR AF Schlesinger, N Gowin, KM Baker, DG Beutler, AM Hoffman, BI Schumacher, HR TI Acute gouty arthritis is seasonal SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE gout; seasons ID WEATHER AB Objective, Information regarding effect of weather conditions on gout is sparse, We conducted a study in the USA to examine whether gout is seasonal, Methods. We reviewed synovial fluid (SF) analyses from our laboratory during 1990-1995 and identified 359 patients who had acute gouty attacks. All fluids of patients with acute gout had intracellular monosodium urate crystals and SF leukocyte counts > 2000/mm(3) or more than 10 leukocytes per high power field (HPF). Retrospective chart review of all patients was performed to confirm a clinical picture of acute gout. A control group included 76 patients with acute pseudogout whose SF were analyzed during the same period and who had intracellular calcium pyrophosphate crystals and inflammatory leukocyte counts as in patients with gout, Results. Acute gout was most common during the spring; n = 115 (32%). Ninety (25%) patients had acute gout attacks in the fall; 81 (23%) had acute attacks during the summer; 73 (20%) had acute attacks in the winter. One-way analysis of variance (ANOVA) was used to compare the overall frequency of acute gout during the months and seasons, Using ANOVA, there was no overall statistically significant difference in the incidence of gout per season (p = 0.07), although it approached statistical significance. Acute gouty attacks were more common in the spring compared with winter (p = 0.002) and summer (p = 0.015), There was a trend but no statistically significant difference compared with fall. Winter was the season in which the fewest acute gouty cases were seen, although it was not statistically significant. No seasonal difference was seen in the pseudogout group. There was no correlation between either mean monthly temperature or humidity and the incidence of acute gouty attacks. Conclusion. Acute gout attacks are significantly more common in the spring, No seasonal variation was seen in patients with acute pseudogout attacks. C1 Allegheny Univ Hosp, Dept Med, Div Rheumatol, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Arthrit Immunol Ctr, Philadelphia, PA USA. RP Schlesinger, N (reprint author), Med Clin Houston, 1707 Sunset Blvd, Houston, TX 77005 USA. NR 9 TC 25 Z9 25 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD FEB PY 1998 VL 25 IS 2 BP 342 EP 344 PG 3 WC Rheumatology SC Rheumatology GA YU558 UT WOS:000071729900028 PM 9489831 ER PT J AU Schlesinger, N Baker, DG Schumacher, HR AF Schlesinger, N Baker, DG Schumacher, HR TI Persian Gulf War myalgia syndrome - Reply SO JOURNAL OF RHEUMATOLOGY LA English DT Letter C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Allegheny Univ Hosp, Philadelphia, PA USA. Arthrit Immunol Ctr, Philadelphia, PA USA. RP Schlesinger, N (reprint author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD FEB PY 1998 VL 25 IS 2 BP 389 EP 389 PG 1 WC Rheumatology SC Rheumatology GA YU558 UT WOS:000071729900040 ER PT J AU Ferry, DR O'Rourke, RA Blaustein, AS Crawford, MH Deedwania, PC Carson, PE Pepine, CJ Thomas, RG Hlatky, MA Leppo, JA Iwane, MK Kleiger, RE Zoble, RG Dai, H Chow, BK Lavori, PW Boden, WE AF Ferry, DR O'Rourke, RA Blaustein, AS Crawford, MH Deedwania, PC Carson, PE Pepine, CJ Thomas, RG Hlatky, MA Leppo, JA Iwane, MK Kleiger, RE Zoble, RG Dai, H Chow, BK Lavori, PW Boden, WE CA VANQWISH Trial Res Investigators TI Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM PROGNOSIS; ST-SEGMENT ELEVATION; CIGARETTE-SMOKING; ELECTROCARDIOGRAPHIC CHANGES; NATURAL-HISTORY; EVOLUTION; REPERFUSION; PREDICTORS; EXTENSION AB Objectives. The Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial was designed to compare outcomes of patients with a non-Q wave myocardial infarction (NQMI) who were randomized prospectively to an early "invasive" strategy versus an early "conservative" strategy. The primary objective was to compare early and late outcomes between the two strategies using a combined trial end point (all-cause mortality or nonfatal infarction) during at least 1 year of follow-up. Background. Because of the widely held view that survivors of NQMI are at high risk for subsequent cardiac events, management of these patients has become more aggressive during the last decade. There is a paucity of data from controlled trials to support such an approach, however. Methods. Appropriate patients with a new NQMI were randomized to an early "invasive" strategy (routine coronary angiography followed by myocardial revascularization, if feasible) versus an early "conservative" strategy (noninvasive, predischarge stress testing with planar thallium scintigraphy and radionuclide ven triculography), where the use of coronary angiography and myocardial revascularization was guided by the development of ischemia (clinical course or results of noninvasive tests, or both). Results. A total of 920 patients were randomized (mean follow-up 23 months, range 12 to 44). The mean patient age was 61 +/- 10 years; 97% were male; 38% had ST segment depression at study entry; 30% had an anterior NQMI; 54% were hypertensive; 26% had diabetes requiring insulin; 43% were current smokers; 43% had a previous acute myocardial infarction; and 45% had antecedent angina within 3 weeks of the index NQMI. Conclusions. Baseline characteristics were compatible with a moderate to high risk group of patients with an NQMI. (C) 1998 by the American College of Cardiology. C1 Jerry L Pettis Mem Vet Adm Med Ctr, Loma Linda, CA 92354 USA. Loma Linda Univ, Sch Med, Loma Linda, CA USA. Vet Affairs Med Ctr, San Antonio, TX USA. Vet Affairs Med Ctr, Houston, TX 77030 USA. Vet Affairs Med Ctr, Albuquerque, NM USA. Vet Affairs Med Ctr, Fresno, CA USA. Vet Affairs Med Ctr, Washington, DC 20422 USA. Vet Affairs Med Ctr, Gainesville, FL 32608 USA. Vet Affairs Cooperat Studies Program, Coordinating Ctr, Palo Alto, CA USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Univ Massachusetts, Med Ctr, Dept Nucl Med, Worcester, MA USA. Univ Massachusetts, Med Ctr, Dept Med, Worcester, MA USA. Stat Collaborat Inc, Washington, DC USA. Vet Affairs Med Ctr, Tampa, FL USA. Vet Affairs Hlth Care Network Upstate New York, Syracuse, NY USA. SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA. RP Boden, WE (reprint author), Dept Vet Affairs Med Ctr, Med Serv, 800 Irving Ave, Syracuse, NY 13210 USA. EM boden.william_e@syracuse.va.gov NR 47 TC 24 Z9 24 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB PY 1998 VL 31 IS 2 BP 312 EP 320 DI 10.1016/S0735-1097(97)00486-5 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA YV175 UT WOS:000071796900012 PM 9462573 ER PT J AU Kaufer, DI Cummings, JL Christine, D Bray, T Castellon, S Masterman, D MacMillan, A Ketchel, P DeKosky, ST AF Kaufer, DI Cummings, JL Christine, D Bray, T Castellon, S Masterman, D MacMillan, A Ketchel, P DeKosky, ST TI Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory caregiver distress scale SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 8th Annual Meeting of the American-Neuropsychiatric-Association CY FEB 02-04, 1997 CL ORLANDO, FLORIDA SP Amer Neuropsychiat Assoc ID NURSING-HOME PLACEMENT; BEHAVIORAL SYMPTOMS; PSYCHIATRIC-SYMPTOMS; RATING-SCALE; DEMENTIA; PSYCHOPATHOLOGY; TROUBLESOME; DIAGNOSIS; DELUSIONS; TACRINE AB OBJECTIVES: To develop an adjunct scale to the Neuropsychiatric Inventory (NPI) for assessing the impact of neuropsy chiatric symptoms in Alzheimer's disease (AD) patients on caregiver distress, DESIGN: Cross-sectional descriptive and correlational study. SETTING: University out-patient memory disorders clinics. PARTICIPANTS: Eighty-five AD subjects and their caregivers (54 spouses, 31 children). MEASUREMENTS: The NPI and NPI Caregiver Distress Scale (NPI-D) were used to assess neuropsychiatric symptoms in AD patients and related caregiver distress, respectively. Criterion validity of the NPI-D tvas examined(N = 69) by comparison with an abridged version of the Relatives' Stress Scale (RSS'), a general measure of sari giver stress, using item clusters that had previously been correlated to behavioral disturbances in demented patients. Test-retest in = 20) and inter-rater reliability (n = 16) of the NPI-D were also assessed. RESULTS: Test-retest and interrater reliability of the NPT-D were both adequate, Overall, caregiver NPI-D distress ratings were correlated significantly with the RSS' (r = .60, P < .001), RSS' ratings correlated strongly with NPI scores (r .64, P < .001), even after controlling for degree of cognitive impairment based on the Mini-Mental State Exam (MMSE) score (r = .61). MMSE scores showed a moderate correlation to RSS' ratings (-.30, P = .02), but this association was markedly attenuated when controlling for the degree of neuropsychiatric disturbance based on the NPI score (r = -.14). NPI-D ratings for 9 of 10 NPI symptom domains correlated most strongly with either NPI symptom severity or total (frequency X severity) scores. Agitation, dysphoria, irritability, delusions, and apathy were the symptoms most often reported to be severely distressing to caregivers. CONCLUSIONS: The NPI-D provides a reliable and valid measure of subjective caregiver distress in relation to neuropsychiatric symptoms measured by the NPI. Neuropsychiatric alterations are more strongly associated than cognitive symptoms to caregiver distress. The NPI-D may be useful in both clinical and research settings for assessing the contribution to caregiver distress of neuropsychiatric symptoms in AD patients. C1 Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Behav Neurosci Sect, Psychiat Serv, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Nursing Serv, Los Angeles, CA USA. RP Kaufer, DI (reprint author), 4 West,MUH,200 Lothrop St, Pittsburgh, PA 15213 USA. FU NIA NIH HHS [AG10123, AG10533] NR 42 TC 270 Z9 280 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 1998 VL 46 IS 2 BP 210 EP 215 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA YW198 UT WOS:000071908300015 PM 9475452 ER PT J AU Berenson, JR Vescio, RA Said, J AF Berenson, JR Vescio, RA Said, J TI Multiple myeloma: the cells of origin - A two-way street SO LEUKEMIA LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Society-of-Hematology CY DEC 05-09, 1997 CL SAN DIEGO, CALIFORNIA SP Amer Soc Hematol DE multiple myeloma; immunoglobulin genes; Kaposi's sarcoma-associated herpes virus ID SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN BONE-MARROW; PERIPHERAL-BLOOD; KAPOSIS-SARCOMA; B-CELL; DNA-SEQUENCES; ANTIGENIC SELECTION; MALIGNANT-CELLS; GENE SEGMENT; PLASMA-CELLS AB Multiple myeloma results from an interplay between the manoclonal malignant plasma cells and supporting nonmalignant cells in the bone marrow. Recent studies suggest that the final transforming event in this B cell disorder occurs at a late stage of B cell differentiation based on the characteristics of the immunoglobulin genes expressed by the malignant clone as well as surface markers present on the tumor cells. Recently, an increasing pathogenic role in this malignancy by the nonmalignant cells in the bone marrow has been suggested by several studies. Specific infection of these supporting cells by the recently identified Kaposi's sarcoma-associated herpes virus (KSHV) suggests a novel mechanism by which this nonmalignant population may lead to the development of this B cell malignancy and support its growth. C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Berenson, JR (reprint author), Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd 111H, Los Angeles, CA 90073 USA. NR 98 TC 14 Z9 14 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD FEB PY 1998 VL 12 IS 2 BP 121 EP 127 DI 10.1038/sj.leu.2400947 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA ZB085 UT WOS:000072434200004 PM 9519771 ER PT J AU Sachdev, D Chirgwin, JM AF Sachdev, D Chirgwin, JM TI Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin SO PROTEIN EXPRESSION AND PURIFICATION LA English DT Article ID HUMAN CATHEPSIN-D; PROCATHEPSIN-D; ESCHERICHIA-COLI; PORCINE PEPSINOGEN; EXPRESSION VECTOR; IN-VITRO; ACTIVATION; PURIFICATION; SPECIFICITY; MUTAGENESIS AB When the mammalian aspartic proteinases, procathepsin D or pepsinogen, are expressed in Escherichia coli both accumulate in inclusion bodies. While pepsinogen is efficiently refolded in vitro, recovery of procathepsin D is limited by insolubility. We expressed procathepsin D and pepsinogen in E. coli, with E. coli maltose-binding protein (MBP) or thioredoxin (trx) fused to their C-termini (aspartic proteinase-MBP or aspartic proteinase-trx), The fusion proteins were still found in inclusion bodies. However, the recovery of soluble procathepsin D-MBP and procathepsin D-trx after refolding was facilitated by the bacterial fusion partners. Maltose-binding protein was more efficient than thioredoxin in increasing the recovery of soluble protein. The vector, pET23bMBPH(6), can be used for general expression of heterologous proteins in E. coli. The vector includes a histidine tag at the C-terminus of MBP to allow one-step purification of the fusion proteins under denaturing conditions. After purification, the protein of interest can be cleaved from MBP with factor Xa protease and separated from the MBP partner. Refolded pepsinogen-MBP and pepsinogen-trx were enzymatically active, but procathepsin D-MBP and procathepsin D-trx were soluble but largely inactive. The results show that the limited recovery of activity upon refolding of procathepsin D is not the consequence of competing aggregation. Thus, the fusions do not necessarily facilitate native refolding, but they do enhance the recovery of soluble protein. Such fusions could provide a system to study, in soluble form, folding states which are otherwise inaccessible because of aggregation and precipitation. (C) 1998 Academic Press. C1 Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Res Serv, San Antonio, TX 78284 USA. RP Chirgwin, JM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 44 TC 71 Z9 78 U1 0 U2 9 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-5928 J9 PROTEIN EXPRES PURIF JI Protein Expr. Purif. PD FEB PY 1998 VL 12 IS 1 BP 122 EP 132 DI 10.1006/prep.1997.0826 PG 11 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA YY157 UT WOS:000072119000017 PM 9473466 ER PT J AU Nickerson, CAE Jasper, JD Asch, DA AF Nickerson, CAE Jasper, JD Asch, DA TI Comfort level, financial incentives, and consent for organ donation SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT 33rd Annual Congress of the Japan-Society-for-Transplantation CY SEP 16-18, 1997 CL OSAKA, JAPAN SP Japan Soc Transplantat ID TRANSPLANTATION; ATTITUDES; MARKET; EDUCATION; ETHICS C1 Vet Affairs Med Ctr, Sect 111GM, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Operat & Informat Management, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. RP Nickerson, CAE (reprint author), Vet Affairs Med Ctr, Sect 111GM, Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 35 TC 6 Z9 6 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD FEB PY 1998 VL 30 IS 1 BP 155 EP 159 DI 10.1016/S0041-1345(97)01218-9 PG 5 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA ZA145 UT WOS:000072333400050 PM 9474988 ER PT J AU Kiatboonsri, C Resnick, SC Chan, KM Barbers, RG Marboe, CC Khonsary, A Santiago, SM Sharma, OP AF Kiatboonsri, C Resnick, SC Chan, KM Barbers, RG Marboe, CC Khonsary, A Santiago, SM Sharma, OP TI The detection of recurrent sarcoidosis by FDG-PET in a lung transplant recipient SO WESTERN JOURNAL OF MEDICINE LA English DT Article ID POSITRON EMISSION TOMOGRAPHY; PULMONARY SARCOIDOSIS C1 Univ So Calif, Div Pulm & Crit Care Med, Los Angeles, CA USA. Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA. W Los Angeles Vet Affairs Med Ctr, Pulm & Crit Care Sect, W Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Nucl Med Sect, W Los Angeles, CA USA. RP Chan, KM (reprint author), Henry Ford Hosp, Div Pulm & Crit Care Med, 2799 W Grand Blvd, Detroit, MI 48202 USA. NR 7 TC 11 Z9 11 U1 0 U2 0 PU CARDEN JENNINGS PUBL CO LTD PI CHARLOTTESVILLE PA BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903 USA SN 0093-0415 J9 WESTERN J MED JI West. J. Med. PD FEB PY 1998 VL 168 IS 2 BP 130 EP 132 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA YX309 UT WOS:000072027300013 PM 9499753 ER PT J AU Rabkin, JM Orloff, SL Reed, MH Wheeler, LJ Corless, CL Benner, KG Flora, KD Rosen, HR Olyaei, AJ AF Rabkin, JM Orloff, SL Reed, MH Wheeler, LJ Corless, CL Benner, KG Flora, KD Rosen, HR Olyaei, AJ TI Biliary tract complications of side-to-side without T tube versus end-to-end with or without T tube choledochocholedochostomy in liver transplant recipients SO TRANSPLANTATION LA English DT Article; Proceedings Paper CT 23rd Annual Meeting of the American-Society-of-Transplant-Surgeons CY MAY 10-16, 1997 CL CHICAGO, ILLINOIS SP Amer Soc Transplant Surgeons ID HEPATIC-ARTERY THROMBOSIS; BILE-DUCT; MANAGEMENT; ANASTOMOSIS; DRAINAGE; THERAPY; RECONSTRUCTION; CONDUIT AB Background, Biliary anastomotic complications remain a major cause of morbidity in liver transplant recipients, ranging between 10% and 50% in large clinical series, An end-to-end choledochocholedochostomy with or without T tube (CDCD EE with T tube and CDCD EE w/o T tube) and a Roux-en Y choledochojejunostomy have been standard methods for biliary drainage, Methods. The objectives of this retrospective study were to: (1) evaluate the incidence of biliary tract complications using a new method of side-to-side choledochocholedochostomy without T tube (CDCD SS w/o T tube) and (2) compare the results of CDCD SS w/o T tube with those of CDCD EE with T tube and CDCD EE w/o T tube, From September 1991 through June 1996, 279 orthotopic liver transplants were performed in 268 patients and followed through December 1996 (minimum of 6 months' follow-up). A total of 227 CDCD anastomoses in 220 patients were studied (7 retransplants >30 days): CDCD EE with T tube (n=124), CDCD EE w/o T tube (n=44), and CDCD SS w/o T tube (n=59). Results. Sixty-nine biliary complications were observed in 220 patients (30%). Anastomotic and/or T-tube leaks were seen in 43 patients (19%), and anastomotic strictures were found in 26 patients (12%). Forty patients (18%) required percutaneous or endoscopic stent placement (6%) or surgical interventions (12%). CDCD EE with T tube had the highest incidence of biliary leak requiring rehospitalization but the lowest anastomotic stricture and intervention rate and the lowest B-month mortality rate, Conclusions, CDCD EE with T tube was superior to CDCD EE or CDCD SS w/o T tube despite the increased number of rehospitalizations. CDCD SS w/o T tube did not offer significant advantages over conventional biliary anastomotic techniques. C1 Oregon Hlth Sci Univ, Dept Surg, Sect Liver Transplantat, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Med, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Rabkin, JM (reprint author), Sect Liver Pancreas Transplantat, 3181 SW Sam Jackson Pk Rd,L590, Portland, OR 97201 USA. NR 35 TC 56 Z9 60 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD JAN 27 PY 1998 VL 65 IS 2 BP 193 EP 199 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA YU164 UT WOS:000071688700008 PM 9458013 ER PT J AU Wen, Y Edelman, JL Kang, T Zeng, NX Sachs, G AF Wen, Y Edelman, JL Kang, T Zeng, NX Sachs, G TI Two functional forms of vascular endothelial growth factor receptor-2 Flk-1 mRNA are expressed in normal rat retina SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TYROSINE KINASE; PERMEABILITY FACTOR; CELL GROWTH; EPITHELIAL-CELLS; MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; HYPOXIC INDUCTION; FACTOR FAMILY; FACTOR VEGF; ANGIOGENESIS AB Vascular endothelial growth factor (VEGF) is an important mediator of ocular neovascularization by exerting its endothelial specific mitogenic effects through high affinity tyrosine kinase receptors. By screening a rat retina cDNA library, we have isolated a clone encoding the full-length prototypic form of the rat VEGF receptor-2/FLk-1, as well as a short form of the mRNA that encodes the complete seven N-terminal immunoglobulin-like extracellular ligand-binding domains, transmembrane region, NH2-terminal half of the intracellular kinase domain, and kinase insert domain but does not encode the COOH-terminal half of the intracellular kinase domain and carboxyl-terminal region. Both forms of mRNA are detected in rat retina, although the short form is expressed at a lower level. VEGF induced a biphasic increase of cytoplasmic calcium with both forms in RR 293 transfected cells, indicating that both forms of the VEGF receptor-2/Flk-1 are functional and that the COOH-terminal half of the intracellular kinase domain and carboxyl region of VEGF receptor-2/Flk-1 are not strictly necessary for either Ligand binding or this biological activity. C1 W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90073 USA. Allergan, Irvine, CA 92713 USA. RP Sachs, G (reprint author), W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Dept Med, 11301 Wilshire Blvd,Bldg 113,Room 324, Los Angeles, CA 90073 USA. NR 45 TC 51 Z9 52 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 23 PY 1998 VL 273 IS 4 BP 2090 EP 2097 DI 10.1074/jbc.273.4.2090 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YT367 UT WOS:000071595200037 PM 9442048 ER PT J AU Carson, JL Duff, A Berlin, JA Lawrence, VA Poses, RM Huber, EC O'Hara, DA Noveck, H Strom, BL AF Carson, JL Duff, A Berlin, JA Lawrence, VA Poses, RM Huber, EC O'Hara, DA Noveck, H Strom, BL TI Perioperative blood transfusion and postoperative mortality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID MORBIDITY; DISEASE; SYSTEM; RISK AB Context.-The risks of blood transfusion have been studied extensively but the benefits and the hemoglobin concentration at which patients should receive a transfusion have not. Objective.-To determine the effect of perioperative transfusion on 30- and 90-day postoperative mortality. Design.-Retrospective cohort study. Setting.-A total of 20 US hospitals between 1983 and 1993. Participants.-A total of 8787 consecutive hip fracture patients, aged 60 years or older, who underwent surgical repair. Main Outcome Measures.-Primary outcome was 30-day postoperative mortality; secondary outcome was 90-day postoperative mortality. The "trigger" hemoglobin level was defined as the lowest hemoglobin level prior to the first transfusion during the time period or, for patients in the nontranfused group, as the lowest hemoglobin level during the time period. Results.-Overall 30-day mortality was 4.6% (n=402; 95% confidence interval [CI], 4.1%-5.0%); overall 90-day mortality was 9.0% (n=788; 95% CI, 8.4%-9.6%). A total of 42% of patients (n=3699) received a postoperative transfusion. Among patients with trigger hemoglobin levels between 80 and 100 g/L (8.0 and 10.0 g/dL), 55.6% received a transfusion, while 90.5% of patients with hemoglobin levels less than 80 g/L (8.0 g/dL) received postoperative transfusions. Postoperative transfusion did not influence 30- or 90-day mortality after adjusting for trigger hemoglobin level, cardiovascular disease, and other risk factors for death: for 30-day mortality, the adjusted odds ratio (OR) was 0.96 (95% CI, 0.74-1.26); for 90-day mortality, the adjusted hazard ratio was 1.08 (95% CI, 0.90-1.29). Similarly, 30-day mortality after surgery did not differ between those who received a preoperative transfusion and those who did not (adjusted OR, 1.23; 95% CI, 0.81-1.89). Conclusions.-Perioperative transfusion in patients with hemoglobin levels 80 g/L (8.0 g/dL) or higher did not appear to influence the risk of 30- or 90-day mortality in this elderly population, At hemoglobin concentrations of less than 80 g/L (8.0 g/dL), 90.5% of patients received a transfusion, precluding further analysis of the association of transfusion and mortality. C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, New Brunswick, NJ 08903 USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Anesthesia, New Brunswick, NJ 08903 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, Div Gen Med, San Antonio, TX USA. Univ Texas, Dept Med, San Antonio, TX 78285 USA. Brown Univ, Sch Med, Dept Med, Div Gen Internal Med, Providence, RI 02912 USA. Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA. Virginia Commonwealth Univ, Med Coll Virginia, Div Gen Internal Med, Richmond, VA 23298 USA. RP Carson, JL (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, 125 Paterson St, New Brunswick, NJ 08903 USA. EM carson@umdnj.edu FU AHRQ HHS [1R01HS07322] NR 27 TC 258 Z9 262 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 21 PY 1998 VL 279 IS 3 BP 199 EP 205 DI 10.1001/jama.279.3.199 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA YR124 UT WOS:000071460700029 PM 9438739 ER PT J AU Martinez, V Wang, LX Mayer, E Tache, Y AF Martinez, V Wang, LX Mayer, E Tache, Y TI Proximal colon distention increases fos expression in the lumbosacral spinal cord and activates sacral parasympathetic NADPHd-positive neurons in rats SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE nitric oxide; visceral afferents; pain; immediate-early genes; sacral parasympathetic nucleus ID NITRIC-OXIDE SYNTHASE; NOXIOUS COLORECTAL DISTENSION; PROTEIN-LIKE IMMUNOREACTIVITY; DORSAL-ROOT GANGLIA; C-FOS; PELVIC NERVE; PREGANGLIONIC NEURONS; HORSERADISH-PEROXIDASE; ELECTRICAL-STIMULATION; INHIBITORY CONTROLS AB Fos expression induced by nociceptive mechanical distention of the proximal colon was examined in the lumbosacral spinal cord in freely moving rats equipped with a chronic balloon in the proximal colon. Fos protein in lumbosacral neurons was detected immunocytochemically, and colocalization with nicotinamide adenine dinucleotide phosphate diaphorase (NADPHd) activity was determined histochemically at 1 hour after distention. Distention of the proximal colon (10 ml, 30 seconds on/off for 10 minutes, about 90 mm Hg) increased the number of Fos-positive cells in the lumbar 6 (L6) and sacral 1 and 2 (S1, S2) segments, whereas no change was observed in the L1-L5 and S3 segments compared with the sham distended group or with animals that received no treatment. In L6-S2 segments, Fos-positive neurons were increased by two-fold in laminae I-VII (mainly in laminae I and outer II) and area X (surrounding the central canal) and by nine-fold in the sacral parasympathetic nucleus. Results of time course studies indicate that the maximal increase in Fos expression observed at 1 hour after distention returns to basal levels within 4 hours, In the S1 seg-ment, distention of the proximal colon increased the percentage of NADPHd/Fos-positive neurons selectively in the parasympathetic nucleus by 40% compared with less than 4% in the sham distention group; the number and pattern of NADPHd-stained cells were not modified. These results indicate that noxious distention of the proximal colon for a short duration in awake rats selectively activates neurons in the L6-S2 segments of the dorsal horn mainly in laminae involved in nociceptive and autonomic processing. The marked activation of NADPHd-positive neurons in the sacral parasympathetic nucleus suggests a possible role of nitric oxide in the visceroautonomic reflexes induced by distention of the proximal colon. (C) 1998 Wiley-Liss, Inc. C1 W Los Angeles Vet Affairs Med Ctr, Digest Dis Res Ctr, CURE, Dept Med, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Digest Dis Res Ctr, CURE, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Martinez, V (reprint author), W Los Angeles Vet Affairs Med Ctr, Digest Dis Res Ctr, CURE, Dept Med, Bldg 115,Room 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [R01 DK-33061, DK-41302]; NIMH NIH HHS [K05 MH-00663] NR 62 TC 29 Z9 29 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD JAN 19 PY 1998 VL 390 IS 3 BP 311 EP 321 PG 11 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA YP877 UT WOS:000071325000001 PM 9455894 ER PT J AU Oren, DA Terman, M AF Oren, DA Terman, M TI Tweaking the human circadian clock with light SO SCIENCE LA English DT Article ID RHYTHMS C1 US Dept Vet Affairs, W Haven, CT 06516 USA. Yale Univ, Sch Med, W Haven, CT 06516 USA. New York State Psychiat Inst, New York, NY 10032 USA. Columbia Univ, New York, NY 10032 USA. RP Oren, DA (reprint author), US Dept Vet Affairs, W Haven, CT 06516 USA. FU NIMH NIH HHS [MH-42931] NR 21 TC 36 Z9 36 U1 3 U2 4 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD JAN 16 PY 1998 VL 279 IS 5349 BP 333 EP 334 DI 10.1126/science.279.5349.333 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA YT158 UT WOS:000071570800030 PM 9454328 ER PT J AU Singh, N Gayowski, T Wannstedt, CF Shakil, AO Wagener, MM Fung, JJ Marino, IR AF Singh, N Gayowski, T Wannstedt, CF Shakil, AO Wagener, MM Fung, JJ Marino, IR TI Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial SO TRANSPLANTATION LA English DT Article ID HUMAN-LEUKOCYTE INTERFERON; VIRUS-INFECTION; CYTOMEGALO-VIRUS; RECOMBINANT; REJECTION; ALLOGRAFT; THERAPY AB Background In a randomized, controlled trial, we sought to determine whether prophylaxis with interferon-alpha for 6 months had an impact on rate, severity, and timing of onset of recurrent hepatitis C virus (HCV hepatitis in liver transplant recipients and to assess whether interferon use was associated with re jection in liver transplant recipients. Methods. Twenty-four consecutive liver transplant recipients with HCV were randomized after transplantation to receive either interferon alpha (3 million Il three times weekly) for 6 months or no prophylaxis; median follow-up was 874 days. Results. Recurrent HCV hepatitis (histopathologically proven) developed in 50% (6 of 12) of the interferon-alpha patients versus 42% (5 of 12) of the control patients (P=NS). Severity of recurrence (as assessed by Knodell score on liver biopsies) also did not differ between the two groups (mean 4.0 for interferon-alpha patients versus 3.5 for control patients, P=NS), Interferon alpha, however, significantly delayed the timing of occurrence of HCV hepatitis; recurrent HCV hepatitis developed a median of 408 days after transplant in the interferon-alpha group versus 193 days in the control group (P=0.05). No difference in graft or patient survival was demonstrated in the two groups. Rejection episodes, treated with corticosteroids, occurred in 50% (6 of 12) of patients in the interferon-alpha group versus 42% (5 of 12) in the control group (P=NS). Corticosteroid resistant rejection (requiring OKT3) occurred in only one study patient (in the control group). Conclusions. Interferon-alpha in liver transplant recipients for 6 months delayed the occurrence of HCV hepatitis, but did not decrease the incidence nor the severity of HCV hepatitis after transplantation. Interferon-alpha use was not associated with a higher incidence of rejection compared with the control patients. C1 Vet Affairs Med Ctr, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA. RP Singh, N (reprint author), VA Pittsburgh Hlth Care Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. RI Fung, John/A-2679-2012 NR 24 TC 117 Z9 119 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD JAN 15 PY 1998 VL 65 IS 1 BP 82 EP 86 DI 10.1097/00007890-199801150-00016 PG 5 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA YR654 UT WOS:000071516900015 PM 9448149 ER PT J AU Koch, PJ Kastowsky, M Bradaczek, H Brandenburg, K AF Koch, PJ Kastowsky, M Bradaczek, H Brandenburg, K TI Improvement of x-ray powder-diffraction patterns of Salmonella minnesota deep rough mutant bacterial lipopolysaccharide induced by heating plus hydration SO THIN SOLID FILMS LA English DT Article DE hydration of bilayers; membrane structure and order; Salmonella minnesota R595 deep rough mutant lipopolysaccharide (Re-LPS); self-aggregated membrane; X-ray powder-diffraction ID PHASE-BEHAVIOR; CONFORMATION; MEMBRANES; NEUTRON AB The effects of different sample treatments on the X-ray powder-diffraction patterns of Salmonella minnesota R595 deep rough mutant bacterial lipopolysaccharides (LPS) were investigated. Samples were obtained by slow evaporation of aqueous solutions or suspensions of sodium, lithium and natural salt form lipids. Samples were treated by hydration in moist air, heating to 60 degrees C and heating plus hydration. While after heating of samples no changes in diffraction patterns were observed, other treatments resulted in the improvement of peak intensities and sharpness of reflections. Heating plus hydration gave the most significant effects. For one natural salt form LPS sample the treatments resulted in almost doubling of the number of observable: reflections with the highest order found at 2 theta = 36 degrees. It is discussed that the effects of treatments are most probably related to perfection of the lateral and the stacking order in the samples, rather than an improved mosaic spread. The simplicity of our sample treatment:, make them suitable fur application to other than lipopolpsaccharide samples, especially for samples prepared by the Langmuir-Blodgett method. (C) 1998 Elsevier Science S.A. C1 Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany. William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. Forschungsinst Borstel, D-23845 Borstel, Germany. RP Koch, PJ (reprint author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany. NR 16 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCIENCE SA PI LAUSANNE PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND SN 0040-6090 J9 THIN SOLID FILMS JI Thin Solid Films PD JAN 14 PY 1998 VL 312 IS 1-2 BP 313 EP 319 DI 10.1016/S0040-6090(97)00952-8 PG 7 WC Materials Science, Multidisciplinary; Materials Science, Coatings & Films; Physics, Applied; Physics, Condensed Matter SC Materials Science; Physics GA ZN334 UT WOS:000073635500053 ER PT J AU Reardon, LC Macpherson, DS AF Reardon, LC Macpherson, DS TI Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors - How much should we worry? SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CONGESTIVE-HEART-FAILURE; CHRONIC-RENAL-FAILURE; DIABETIC HYPERTENSIVE PATIENTS; LIFE-THREATENING HYPERKALEMIA; RANDOMIZED CONTROLLED TRIAL; COMBINED THERAPY; ENALAPRIL; CAPTOPRIL; LISINOPRIL; SAFETY AB Background: Hyperkalemia is a potentially life-threatening complication resulting from the use of angiotensin-converting enzyme (ACE) inhibitors; data to guide the intensity of monitoring for or responding to hyperkalemia in outpatients are limited. Methods: Case-control methodological procedures were used to identify risk factors for hyperkalemia. Outpatients prescribed ACE inhibitors during 1992 and 1993 at a Veterans affairs medical center general medicine clinic were identified. Case patients had a potassium level higher than 5.1 mmol/L on the day of clinic visit while using an ACE inhibitor; controls had a potassium level lower than 5.0 mmol/L on the day of clinic visit while using an ACE inhibitor and had no elevated potassium level during the study period. Predictor variables measured included type and dosage of ACE inhibitor; serum chemistries; comorbidities; concurrent drug use; and age. Case patients were followed up for 1 year after the index episode of hyperkalemia. Follow-up variables included changes in therapy with ACE inhibitor, maximum potassium for each change, and mortality. Results: Of 1818 patients using ACE inhibitors, 194 (11%) developed hyperkalemia. Results of laboratory studies indicating a serum urea nitrogen level higher than 6.4 mmol/L (18 mg/dL), creatinine level higher than 136 mu mol/L (1.5 mg/dL), congestive heart failure, and long-acting ACE inhibitors were independently associated with hyperkalemia; concurrent use of loop or thiazide diuretic agent was associated with reduced risk. After 1 year of follow-up, 15 (10%) of 146 case patients remaining on a regimen of an ACE inhibitor developed severe hyperkalemia (potassium level > 6.0 mmol/L). a serum urea nitrogen level higher than 8.9 mmol/L (25 mg/dL) and age more than 70 years were independently associated with subsequent severe hyperkalemia. Conclusions: Mild hyperkalemia is common in medical outpatients using ACE inhibitors, especially in those with renal insufficiency or congestive heart failure. However, once hyperkalemia is identified during the use of ACE inhibitors, subsequent severe hyperkalemia is uncommon in patients younger than 70 years with normal renal function. C1 Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA 15240 USA. RP Macpherson, DS (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Univ Dr C, Pittsburgh, PA 15240 USA. NR 55 TC 125 Z9 130 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JAN 12 PY 1998 VL 158 IS 1 BP 26 EP 32 DI 10.1001/archinte.158.1.26 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA YQ742 UT WOS:000071418700004 PM 9437375 ER PT J AU O'Brien, CP AF O'Brien, CP TI Drug abuse and therapy - Response SO SCIENCE LA English DT Letter C1 Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP O'Brien, CP (reprint author), Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD JAN 9 PY 1998 VL 279 IS 5348 BP 160 EP 161 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA YQ636 UT WOS:000071408100010 ER PT J AU Zareparsi, S Kay, J Camicioli, R Kramer, P Nutt, J Bird, T Litt, M Payami, H AF Zareparsi, S Kay, J Camicioli, R Kramer, P Nutt, J Bird, T Litt, M Payami, H TI Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease SO LANCET LA English DT Article C1 Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Zareparsi, S (reprint author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. FU NIA NIH HHS [AG0817] NR 5 TC 35 Z9 35 U1 0 U2 2 PU LANCET LTD PI LONDON PA 42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD JAN 3 PY 1998 VL 351 IS 9095 BP 37 EP 38 DI 10.1016/S0140-6736(05)78089-2 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA YP205 UT WOS:000071253100021 PM 9433434 ER PT J AU Yao, L Johnson, C Gentili, A Lee, JK Seeger, LL AF Yao, L Johnson, C Gentili, A Lee, JK Seeger, LL TI Stress injuries of bone: Analysis of MR imaging staging criteria SO ACADEMIC RADIOLOGY LA English DT Article DE bones, injuries; bones, MR; fractures; fractures, stress ID FRACTURES; CLASSIFICATION AB Rationale and Objectives. The authors examined the prognostic value of magnetic resonance (MR) imaging in stress injuries of bone. Materials and Methods. Clinical follow-up data were collected in 35 patients who underwent MR imaging because of suspected stress fractures. MR findings were correlated with total duration of symptoms, the time to return to sports activity, and findings at follow-up radiography. Results. The MR imaging finding of a "fracture" or "fatigue" line or a cortical signal intensity abnormality was predictive of a longer symptomatic period, whereas muscle edema was predictive of a shorter symptomatic period. A published grading system could be used in only 24 patients; the MR imaging grade of injury did not show correlation with clinical outcome. Conclusion. The MR imaging finding of either a medullary line or a cortical abnormality appears to indicate a more severe stress injury of bone. A previously published MR imaging grading system for stress injuries of the tibia was not prognostic in this more heterogeneous patient group. C1 Georgetown Univ, Med Ctr, Dept Radiol, Washington, DC 20007 USA. Univ Florida, Hlth Sci Ctr, Dept Radiol, Jacksonville, FL 32209 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Samaritan Hosp, Dept Radiol, Troy, NY USA. Univ Calif Los Angeles, Dept Radiol Sci, Los Angeles, CA 90024 USA. RP Yao, L (reprint author), Georgetown Univ, Med Ctr, Dept Radiol, 3800 Reservoir Rd NW, Washington, DC 20007 USA. RI Gentili, Amilcare/G-1238-2013 OI Gentili, Amilcare/0000-0002-5623-7512 NR 13 TC 46 Z9 46 U1 0 U2 5 PU ASSOC UNIV RADIOLOGISTS PI OAK BROOK PA 2021 SPRING RD, STE 600, OAK BROOK, IL 60521 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD JAN PY 1998 VL 5 IS 1 BP 34 EP 40 DI 10.1016/S1076-6332(98)80009-3 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ZH425 UT WOS:000073107700006 PM 9442205 ER PT J AU Liu, Y Brooks, BR Taniguchi, N Hartmann, HA AF Liu, Y Brooks, BR Taniguchi, N Hartmann, HA TI CuZnSOD and MnSOD immunoreactivity in brain stem motor neurons from amyotropic lateral sclerosis patients SO ACTA NEUROPATHOLOGICA LA English DT Article DE ALS; CuZnSOD; MnSOD; immunoantibodies; brain stem motor neurons ID SUPEROXIDE-DISMUTASE ACTIVITY; CENTRAL-NERVOUS-SYSTEM; CU/ZN-SUPEROXIDE; ALZHEIMERS-DISEASE; MUTATIONS; DEGENERATION; MECHANISMS; CATALASE; DECREASE; MUTANT AB Motor neurons from the brain stems of amyotrophic lateral sclerosis (ALS) and control patients were examined with immunoantibodies to CuZn-superoxide dismutase (CuZnSOD) and Mn-superoxide dismutase (MnSOD). We found that there was a marked staining for CuZnSOD in all the motor nuclei, the hypoglossus, ambiguus, facialis and trigeminus from the ALS patients, but not in the controls. The same neurons from the ALS patients also stained very intensely for MnSOD, whereas the neurons from the control patients stained weakly or not at all. Loss of neurons was also a very consistent finding and was noted in all the motor nuclei from the ALS patients, There was a proliferation of glial cells which stained strongly both for CuZnSOD and for MnSOD accompanying the loss of the neurons. These results indicated that there was an apparent increase of superoxide dismutase immunoreactivity in motor neurons of ALS patients. We conclude that CuZnSOD and MnSOD immunoreactivity is increased in motor neurons and glia in the brain stems of patients with ALS, specific for the terminal phase of this disease. C1 Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA. Univ Wisconsin, Sch Med, Dept Neurol, Madison, WI 53706 USA. William S Middleton Mem Vet Hosp, Neurol Serv, Great Lakes Vet Integrated Serv Network, Madison, WI USA. Osaka Univ, Dept Biochem, Osaka, Japan. RP Hartmann, HA (reprint author), Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA. NR 52 TC 17 Z9 17 U1 0 U2 1 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD JAN PY 1998 VL 95 IS 1 BP 63 EP 70 PG 8 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA YM855 UT WOS:000071108400008 PM 9452823 ER PT J AU Cacciola, JS Alterman, AI Rutherford, MJ McKay, JR McLellan, AT AF Cacciola, JS Alterman, AI Rutherford, MJ McKay, JR McLellan, AT TI The early course of change in methadone maintenance SO ADDICTION LA English DT Article ID ADDICTION SEVERITY INDEX; ABUSE AB Aims. This study examined the functional and substance use status of methadone maintenance (MM) patients at treatment entry and 2 and 7 months later Design. Two groups of subjects were identified for longitudinal follow-up, those in continuous MM treatment and those who left treatment. Setting. The study was conducted at the Philadelphia Veterans Affairs Medical Center MM Program. Participants. Subjects were 157 men admitted to treatment. Measurements. Change was evaluated using the Addiction Severity Index and urinalysis results. Findings. Both groups of subjects reported significant reductions in drug use and increases in psychosocial functioning from admission to month 2, but demonstrated no significant changes from months 2 to 7. Subjects who left treatment, however, had more heroin use and criminal activity at all evaluation points than subjects who remained in treatment. Urinalysis data also suggested that subjects who left treatment were using drugs more frequently while in treatment than were those subjects who remained continuously enrolled in MM. Finally, subjects who left treatment spent more time in restricted environments (e.g. inpatient treatment, jail) at follow-up. Conclusions. Services may need to be enhanced to foster continuing progress in patients who remain in MM treatment and to retain those patients with more severe problems who leave treatment early. C1 Philadelphia Vet Affairs Med Ctr, PENN VA Ctr Studies Addict, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Cacciola, JS (reprint author), PENN TRC, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [DA-01586, DA-05858] NR 19 TC 17 Z9 20 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0965-2140 J9 ADDICTION JI Addiction PD JAN PY 1998 VL 93 IS 1 BP 41 EP 49 DI 10.1046/j.1360-0443.1998.931415.x PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA YT683 UT WOS:000071631800005 PM 9624710 ER PT S AU Frazer, A Daws, LC AF Frazer, A Daws, LC BE Martin, GR Eglen, RM Hoyer, D Hamblin, MW Yocca, F TI Serotonin transporter function in vivo: Assessment by chronoamperometry SO ADVANCES IN SEROTONIN RECEPTOR RESEARCH: MOLECULAR BIOLOGY, SIGNAL TRANSDUCTION, AND THERAPEUTICS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Advances in Serotonin Receptor Research - Molecular Biology, Signal Transduction, and Therapeutics CY OCT 08-10, 1997 CL SAN FRANCISCO, CALIFORNIA SP Serotonin Club, Int Union Pharmacol, Roche Biosci, Palo Alto, Bristol Myers Squibb, Wallingford, DuPont Merck Pharmaceut Co, Wilmington, F Hoffmann La Roche, Basel, Lilly Res Labs, Indianapolis, Novartis Pharma AG, Basel, Pfizer Cent Res, Groton, SmithKline Beecham, Harlow, Glaxo Wellcome, Stevenage, Merck Res Labs, Harlow, Pierre Fabre, Castres ID FREELY MOVING RATS; IN-VIVO; INVIVO VOLTAMMETRY; NUCLEUS-ACCUMBENS; DOPAMINE UPTAKE; UPTAKE BLOCKERS; BIOPHASE CONCENTRATION; UPTAKE INHIBITORS; CAUDATE-PUTAMEN; RAPHE NUCLEI AB Local application of selective serotonin reuptake inhibitors, fluloxamine and citalopram, prolonged the clearance of exogenously administered serotonin (5-HT) in both the dentate gyrus and CA3 region of the dorsal hippocampus, as measured using in, vivo chronoamperometry. These effects were abolished in rats pretreated with 5,7-dihydroxytryptamine. The NE uptake inhibitors, desipramine and protriptyline, did not alter the 5-HT signal in the CA3 region, but prolonged the clearance of 5-HT in the dentate gyrus; this effect was absent in rats pretreated with 6-hydroxydopamine. From these data, it is inferred that both the SERT and NET contribute to the active clearance of exogenously applied 5-HT in the dentate gyrus. In another experiment, cyanopindolol, an antagonist of the serotonin terminal autoreceptor, also prolonged the clearance of 5-HT from the CA3 region, These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of 5-HT uptake through an effect on the serotonin transporter. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78250 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA. Univ Adelaide, Dept Clin & Expt Pharmacol, Adelaide, SA 5005, Australia. RP Frazer, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78250 USA. EM frazer@uthscsa.edu FU NIMH NIH HHS [MH27094] NR 48 TC 12 Z9 12 U1 1 U2 8 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-170-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1998 VL 861 BP 217 EP 229 DI 10.1111/j.1749-6632.1998.tb10193.x PG 13 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy GA BM29R UT WOS:000078304800027 PM 9928259 ER PT J AU Chey, WD Murthy, UK Linscheer, W Barish, C Riff, D Rubin, H Safdi, M Schwartz, H Shah, U Wruble, L El-Zimaity, HMT AF Chey, WD Murthy, UK Linscheer, W Barish, C Riff, D Rubin, H Safdi, M Schwartz, H Shah, U Wruble, L El-Zimaity, HMT TI The Chemtrak Hp Chek fingerstick whole blood serology test for the detection of Helicobacter pylori infection SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID NONULCER DYSPEPSIA; ACCURACY; DIAGNOSIS AB Objective: To evaluate a new whole blood serology test (Hp Chek; ChemTrak) that detects IgG antibodies to Helicobacter pylori. Methods: The study was conducted at 10 sites within the United States. Patients undergoing upper endoscopy for dyspepsia were recruited for enrollment. Those treated for H. pylori infection within a year of endoscopy and those who had regularly used proton pump inhibitors, bismuth compounds, or antibiotics within a month of endoscopy were not eligible. During endoscopy, specimens were obtained from the corpus and antrum for histological examination, which was performed by a single experienced pathologist, The Hp Chek was tested using whole blood and serum. Serum was also tested with a reference enzyme-linked immunosorbent assay (ELISA) at a centralized location. Test characteristics for the Hp Chek and ELISA were calculated using histology as the "gold standard." Results: Two hundred eighty-seven patients (140 women and 147 men; mean age 53 +/- 6 yr) were enrolled. The Hp Chek was easy to perform and yielded results 9 min after inoculation of the test cassette with whole blood or serum. When the Hp Chek used with whole blood was compared with histology as the gold standard, the sensitivity was 88%, specificity 85%, positive predictive value 83%, negative predictive value 90%, and percent agreement 86%. There were no statistically significant differences among the results obtained with the Hp Chek using whole blood, the E-fp Chek using serum, or reference ELISA, Conclusions: The Hp Chek whole blood serology test was easy to perform and rapid and yielded performance characteristics comparable to those of a reference ELISA or the Hp Chek used with serum. (C) 1998 by Am. Coll. of Gastroenterology. C1 Univ Michigan, Ann Arbor, MI 48109 USA. VA Med Ctr, Syracuse, NY USA. VA Med Ctr, Raleigh, NC USA. VA Med Ctr, Anaheim, CA USA. VA Med Ctr, Beverly Hills, CA USA. VA Med Ctr, Cincinnati, OH USA. VA Med Ctr, Miami, FL USA. VA Med Ctr, Leonardstown, MD 20650 USA. VA Med Ctr, Memphis, TN USA. VA Med Ctr, Houston, TX USA. RP Chey, WD (reprint author), 3912 Taubman Ctr,Box 0362, Ann Arbor, MI 48109 USA. NR 19 TC 13 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 1998 VL 93 IS 1 BP 16 EP 19 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ZB488 UT WOS:000072477000006 PM 9448166 ER PT J AU Graybill, JR Vazquez, J Darouiche, RO Morhart, R Greenspan, D Tuazon, C Wheat, LJ Carey, J Leviton, I Hewitt, RG MacGregor, RR Valenti, W Restrepo, M Moskovitz, BL AF Graybill, JR Vazquez, J Darouiche, RO Morhart, R Greenspan, D Tuazon, C Wheat, LJ Carey, J Leviton, I Hewitt, RG MacGregor, RR Valenti, W Restrepo, M Moskovitz, BL TI Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CLOTRIMAZOLE TROCHES; FLUCONAZOLE; RESISTANCE; ALBICANS; CANDIDOSIS; INFECTION; AZOLES; AIDS; HIV AB PURPOSE: Oropharyngeal candidasis (thrush) is the most common opportunistic infection in individuals who are positive for the human immunodeficiency virus (HIV) and those who have progressed to AIDS. Itraconazole has a broad in vitro spectrum of activity, including a wide variety of Candida species. Our study determined the relative efficacy of a new oral solution formulation of itraconazole and fluconazole tablets in the treatment of oropharyngeal candidiasis. PATIENTS AND METHODS: This was a prospective randomized, third-party-blind, multicenter trial conducted at 12 centers in the United States. One hundred seventy-nine HIV-positive patients with mycologically documented oropharyngeal candidiasis were treated with itraconazole oral solution 200 mg/day for 7 or 14 days, or fluconazole tablets 100 mg/day for 14 days. Severity of disease was scored clinically before treatment and at clinical evaluations on days 3, 7, 14, 21, 35, and 42. Semiquantitative cultures of mouth washings were also obtained on these days. RESULTS: Both 14-day and 7-day regimens of itraconazole oral solution were equivalent to fluconazole for most efficacy parameters. The clinical response rate was 97% after 14 days of itraconazole and 87% after 14 days of fluconazole. Itraconazole oral solution given for 7 days was also equivalent to fluconazole treatment for 14 days. Approximately one half of patients in all three groups relapsed by 1 month after completion of treatment. There were few adverse reactions to either drug. CONCLUSION: Itraconazole oral solution is well tolerated and offers an alternative at least as effective as fluconazole in the treatment of oropharyngeal candidiasis. (C) 1998 by Excerpta Medica, Inc. C1 Audie L Murphy Mem Vet Hosp, Div Infect Dis, San Antonio, TX 78284 USA. Wayne State Univ, Dept Internal Med, Detroit, MI 48202 USA. VA Med Ctr, Infect Dis Sect, Houston, TX USA. DVA Med Ctr, Dent Res Unit, Miami, FL USA. Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA. George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA. Infect Dis Res Clin, Indianapolis, IN USA. ACTU, Div Infect Dis, Cleveland, OH USA. Montefiore Hosp, Dept Med, Div Infect Dis, Bronx, NY USA. Erie Cty Med Ctr, Buffalo, NY USA. Univ Penn, Philadelphia, PA 19104 USA. Community Hlth Network, Rochester, NY USA. Janssen Pharmaceut, Titusville, NJ USA. RP Graybill, JR (reprint author), Audie L Murphy Mem Vet Hosp, Div Infect Dis, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. NR 29 TC 60 Z9 62 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 1998 VL 104 IS 1 BP 33 EP 39 DI 10.1016/S0002-9343(97)00307-0 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA YT744 UT WOS:000071640700006 PM 9528717 ER PT J AU Ubel, PA Goold, S AF Ubel, PA Goold, S TI Does bedside rationing violate patients' best interests? An exploration of "moral hazard" SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID PRACTICE GUIDELINES; COST-CONTAINMENT; HEALTH-CARE; PHYSICIANS; DECISIONS; SELECTION; DOCTORS; TRIAL C1 Univ Penn, Ctr Bioeth, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Div Gen Internal Med, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Div Gen Internal Med, Ann Arbor, MI USA. Univ Michigan, Program Soc & Med, Ann Arbor, MI USA. RP Ubel, PA (reprint author), Univ Penn, Ctr Bioeth, Sch Med, Div Gen Internal Med, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA. OI Goold, Susan Dorr/0000-0002-0258-9774 NR 29 TC 9 Z9 9 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 1998 VL 104 IS 1 BP 64 EP 68 DI 10.1016/S0002-9343(97)00172-1 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA YT744 UT WOS:000071640700010 PM 9528721 ER PT J AU Potter, DA Moreno, A Luther, MF Eddy, CA Siler-Khodr, TM King, TS Schenken, RS AF Potter, DA Moreno, A Luther, MF Eddy, CA Siler-Khodr, TM King, TS Schenken, RS TI Effects of follicular-phase cocaine administration on menstrual and ovarian cyclicity in rhesus monkeys SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the Society-for-Gynecologic-Investigation CY MAR 19-23, 1996 CL PHILADELPHIA, PENNSYLVANIA SP Soc Gynecol Invest, NIH DE cocaine; follicular phase; menstrual cyclicity ID ANTERIOR-PITUITARY HORMONES; ESTROUS CYCLICITY; ABUSE; PROLACTIN; RAT AB OBJECTIVE: The purpose of this study was to evaluate the effects of daily follicular-phase cocaine administration on menstrual cyclicity, gonadotropin and ovarian steroid levels, ovulation rates, and corpus luteum function in cycling rhesus monkeys. STUDY DESIGN: Thirteen normally cycling, drug-naive adult rhesus monkeys were randomized to receive daily intravenous injections of either 4 mg/kg cocaine or an equal volume of saline solution. Treated animals were yoked to pair-fed controls to minimize differences in caloric intake. Daily blood samples were obtained through indwelling catheters for measurement of serum gonadotropin and ovarian steroid levels. Daily vaginal swabs were obtained to determine the onset of menses. Laparoscopy was performed 2 days after the midcycle estrogen peak to check for ovulation. Daily caloric intakes and pretreatment and posttreatment weights were recorded. RESULTS: All six of the control monkeys had laparoscopically confirmed ovulation compared with one of seven in the cocaine-treated group (p < 0.004). Cycle length was normal in five of six controls versus one of seven cocaine-treated monkeys. Estradiol levels were significantly higher in the controls versus the cocaine-treated monkeys (p = 0.01) during the first 14 days of the treatment cycle. There were no differences in basal plasma gonadotropin levels between groups. Luteal-phase lengths and luteal-phase plasma progesterone levels were similar in the controls and the single ovulatory cocaine-treated monkey. There were no significant differences in weight change or caloric intake between the two groups. CONCLUSIONS: Daily follicular-phase cocaine administration disrupts menstrual cyclicity and folliculogenesis independent of weight loss, caloric intake, and basal gonadotropin levels. C1 Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Dept Res & Dev, San Antonio, TX 78284 USA. RP Schenken, RS (reprint author), Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NIDA NIH HHS [DA08295] NR 26 TC 21 Z9 21 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 1998 VL 178 IS 1 BP 118 EP 125 DI 10.1016/S0002-9378(98)70637-4 PN 1 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA YU977 UT WOS:000071776100021 PM 9465814 ER PT J AU Kiraly, A Suto, G Guth, PH Tache, Y AF Kiraly, A Suto, G Guth, PH Tache, Y TI Peripheral mediators involved in gastric hyperemia to vagal activation by central TRH analog in rats SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE nitric oxide; atropine; histamine; capsaicin; N-G-nitro-L-arginine methyl ester; thyrotropin-releasing hormone; blood pressure; acetylcholine; N-G-monomethyl-L-arginine; pyrilamine; gastric vascular resistance ID THYROTROPIN-RELEASING-HORMONE; MUCOSAL BLOOD-FLOW; NITRIC-OXIDE SYNTHASE; NERVOUS-SYSTEM ACTION; ARGININE METHYL-ESTER; DORSAL MOTOR NUCLEUS; STIMULATION; HISTAMINE; PENTAGASTRIN; ARTERIOLES AB Mechanisms mediating the increase in gastric mucosal blood flow (GMBF) induced by the stable thyrotropin-releasing hormone (TRH) analog RX-77368 injected intracis ternally at a gastric acid secretory dose (30 ng) were investigated using hydrogen gas clearance in urethananesthetized rats. The histamine H-1 receptor antagonist pyrilamine (intravenously), capsaicin (subcutaneously, -10 days), and N-G-nitro-L-arginine methyl ester (L-NAME, intracisternally) failed to impair the 150% rise in GMBF induced by intracisternal injection of RX-77368. By contrast, atropine (subcutaneously) and N-G-monomethyl-L-arginine (intravenously) completely inhibited the increase in GMBF evoked by intracisternal RX-77368. L-NAME (intravenously) blocked the intracisternal RX-77368-induced increase in GMBF in capsaicin-pretreated rats, and the L-NAME effect was reversed by intravenous L- but not D-arginine. These findings indicate that vagal efferent activation induced by TRH analog injected intracisternally at a gastric acid secretory dose increases GMBF through atropine-sensitive mechanisms stimulating L-arginine-nitric oxide pathways, whereas HL receptors and capsaicin-sensitive afferent fibers do not play a role. C1 W Los Angeles Vet Affairs Med Ctr, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), W Los Angeles Vet Affairs Med Ctr, CURE, Digest Dis Res Ctr, 11301 Wilshire Blvd,Bldg 115,Rm 203, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-41301, DK-30110]; NIMH NIH HHS [MH-00663] NR 42 TC 13 Z9 13 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JAN PY 1998 VL 274 IS 1 BP G170 EP G177 PG 8 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA YR449 UT WOS:000071496400021 PM 9458786 ER PT J AU Freeman, GL Colston, JT Zabalgoitia, M Chandrasekar, B AF Freeman, GL Colston, JT Zabalgoitia, M Chandrasekar, B TI Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the American-College-of-Cardiology CY MAR 16-19, 1997 CL ANAHEIM, CALIFORNIA SP Amer Coll Cardiol DE myocardial contraction; coxsackievirus; inducible nitric oxide synthase; mice ID TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; FACTOR-ALPHA; CARDIAC MYOCYTES; COXSACKIEVIRUS-B3 MYOCARDITIS; MURINE MODEL; HEART; CARDIOMYOPATHY; INDUCTION; INTERLEUKIN-1 AB We assessed two strains of mice [CD-1 and C3H.HeJ (C3H)] with different responses to cox-sackievirus B3 (CVB3) infection at 7, 14, and 21 days after inoculation with 10(5) pfu of CVBS. CD-1 mice developed inflammatory lesions at 7 days that nearly recovered by 21 days; C3H mice demonstrated persistence of infiltrates. Although there were differences in the baseline fractional shortening, it was further reduced at 7 and 14 days in both strains. It recovered in CD-1 mice but remained depressed at 21 days in C3H mice. Interleukin-6 and tumor necrosis factor-alpha transcripts were increased in both strains at 7 days. Levels dropped to near control in CD-1 mice at 21 days but remained elevated in C3H mice. Interleukin-1 beta was minimally elevated in CD-1 mice but increased progressively in C3H mice. mRNA for the inducible form of NO synthase (NOS was increased at 7 days in the CD-1 mice, returning to baseline by 14 days; it rose progressively in C3H mice, with a fivefold increase at 21 days. We conclude that mice infected with CVB3 show increased expression of proinflammatory cytokines as well as iNOS associated with reduced contractile performance. In more susceptible mice, contractile depression and cytokine and iNOS expression are more pronounced. C1 Univ Texas, Hlth Sci Ctr, Div Cardiol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Freeman, GL (reprint author), Univ Texas, Hlth Sci Ctr, Div Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NHLBI NIH HHS [2 T32 HL-07350] NR 37 TC 35 Z9 37 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JAN PY 1998 VL 274 IS 1 BP H249 EP H258 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA YT006 UT WOS:000071554600030 PM 9458874 ER PT J AU Jagielo, PJ Quinn, TJ Qureshi, N Schwartz, DA AF Jagielo, PJ Quinn, TJ Qureshi, N Schwartz, DA TI Grain dust-induced lung inflammation is reduced by Rhodobacter sphaeroides diphosphoryl lipid A SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE endotoxin; lipopolysaccharide inhibition; asthma ID RHODOPSEUDOMONAS-SPHAEROIDES; NONTOXIC LIPOPOLYSACCHARIDE; ENDOTOXIN; INDUCTION AB To further determine the importance of endotoxin in grain dust-induced inflammation of the lower respiratory tract, we evaluated the efficacy of pentaacylated diphosphoryl lipid A derived from the lipopolysaccharide of Rhodobacter sphaeroides (RsDPLA) as a partial agonist of grain dust-induced airway inflammation. RsDPLA is a relatively inactive compound compared with lipid A derived from Escherichia coli (LPS) and has been demonstrated to act as a partial agonist of LPS-induced inflammation. To assess the potential stimulatory effect of RsDPLA in relation to LPS, we incubated THP-1 cells with RsDPLA (0.001-100 mu g/ml), LPS (0.02 mu g endotoxin activity/ml), or corn dust extract (CDE; 0.02 mu g endotoxin activity/ml). Incubation with RsDPLA revealed a tumor necrosis factor (TNF)-alpha stimulatory effect at 100 mu g/ml. In contrast, incubation with LPS or CDE resulted in TNF-alpha release at 0.02 mu g/ml. Pretreatment of THP-1 cells with varying concentrations of RsDPLA before incubation with LPS or CDE (0.02 mu g endotoxin activity/ml) resulted in a dose-dependent reduction in the LPS-or CDE-induced release of TNF-alpha with concentrations of RsDPLA of up to 10 mu g/ml but not at 100 mu g/ml. To further understand the role of endotoxin in grain dust-induced airway inflammation, we utilized the unique LPS inhibitory property of RsDPLA to determine the inflammatory response to inhaled CDE in mice in the presence of RsDPLA. Ten micrograms of RsDPLA intratracheally did not cause a significant inflammatory response compared with intratracheal saline. However, pretreatment of mice with 10 mu g of RsDPLA intratracheally before exposure to CDE (5.4 and 0.2 mu g/m(3)) or LPS (7.2 and 0.28 mu g/m(3)) resulted in significant reductions in the lung lavage concentrations of total cells, neutrophils, and specific proinflammatory cytokines compared with mice pretreated with sterile saline. These results confirm the LPS-inhibitory effect of RsDPLA and support the role of endotoxin as the principal agent in grain dust causing airway inflammation. C1 Univ Iowa, Coll Med, Dept Internal Med, Pulm Dis Crit Care & Occupat Med Div, Iowa City, IA 52242 USA. Univ Wisconsin, William S Middleton Mem Vet Hosp, Dept Bacteriol, Madison, WI 53705 USA. RP Schwartz, DA (reprint author), Univ Iowa, Coll Med, Dept Internal Med, Pulm Dis Crit Care & Occupat Med Div, Iowa City, IA 52242 USA. FU NIEHS NIH HHS [ES-06537, ES-00203]; NIOSH CDC HHS [OH-00134-02] NR 19 TC 20 Z9 20 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JAN PY 1998 VL 274 IS 1 BP L26 EP L31 PG 6 WC Physiology; Respiratory System SC Physiology; Respiratory System GA YT173 UT WOS:000071572600004 PM 9458797 ER PT J AU Smith, PR Mackler, SA Weiser, PC Brooker, DR Ahn, YJ Harte, BJ McNulty, KA Kleyman, TR AF Smith, PR Mackler, SA Weiser, PC Brooker, DR Ahn, YJ Harte, BJ McNulty, KA Kleyman, TR TI Expression and localization of epithelial sodium channel in mammalian urinary bladder SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE amiloride-sensitive sodium channel; sodium transport ID SENSITIVE NA+ CHANNEL; MEDULLARY COLLECTING DUCT; APICAL MEMBRANE; IMMUNOCYTOCHEMICAL LOCALIZATION; HOMOLOGOUS SUBUNITS; ALPHA-SUBUNITS; GAMMA-SUBUNITS; BETA-SUBUNITS; CLONING; TRANSPORT AB The mammalian urinary bladder exhibits transepithelial Na(+) absorption that contributes to Na(+) gradients established by the kidney. Electrophysiological studies have demonstrated that electrogenic Na(+) absorption across the urinary bladder is mediated in part by amiloride-sensitive Na(+) channels situated within the apical membrane of the bladder epithelium. We have used a combination of in situ hybridization, Northern blot analysis, and immunocytochemistry to examine whether the recently cloned epithelial Na(+) channel (ENaC) is expressed in the rat urinary bladder. In situ hybridization and Northern blot analyses indicate that alpha-, beta-, and gamma-rat ENaC (rENaC) are expressed in rat urinary bladder epithelial cells. Quantitation of the levels of alpha-, beta-, and gamma-rENaC mRNA expression in rat urinary bladder, relative to p-actin mRNA expression, indicates that, although comparable levels of alpha- and beta-rENaC subunits are expressed in the urinary bladder of rats maintained on standard chow, the level of gamma-rENaC mRNA expression is 5- to 10-fold lower than alpha- or beta-rENaC mRNA. Immunocytochemistry, using an antibody directed against alpha-rENaC, revealed that ENaCs are predominantly localized to the luminal membrane of the bladder epithelium. Together, these data demonstrate that ENaC is expressed in the mammalian urinary bladder and suggest that amiloride-sensitive Na(+) transport across the apical membrane of the mammalian urinary bladder epithelium is mediated primarily by ENaC. C1 Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA. Allegheny Univ Hlth Sci, Dept Physiol, Philadelphia, PA 19129 USA. RP Kleyman, TR (reprint author), Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. FU NIDDK NIH HHS [DK-51391, DK-46705, DK-07006] NR 45 TC 50 Z9 50 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 1998 VL 274 IS 1 BP F91 EP F96 PG 6 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA YR534 UT WOS:000071504900011 PM 9458827 ER PT J AU Sivarajan, M AF Sivarajan, M TI Analgesic nephropathy, a form of chronic renal disease - Reply SO ANESTHESIOLOGY LA English DT Letter C1 VA Puget Sound Hlth Care Syst, Dept Anesthesiol 112A, Seattle, WA 98108 USA. RP Sivarajan, M (reprint author), VA Puget Sound Hlth Care Syst, Dept Anesthesiol 112A, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD JAN PY 1998 VL 88 IS 1 BP 274 EP 275 DI 10.1097/00000542-199801000-00045 PG 2 WC Anesthesiology SC Anesthesiology GA YQ733 UT WOS:000071417800046 ER PT J AU Mitler, MM Guilleminault, C Harsh, JR Hirshkowitz, M Becker, PM Jamieson, AO Jewel, CE Bogan, RK James, DS Sutton, JT Corser, B Mayleben, DW Bernard, SH Dinner, DS Emsellem, H Knight, E Chase, C Erwin, CW Krystal, AD Radtke, RA Farrow, S Odynski, T Pinto, J Steljes, D Feldman, NT O'Brien, M Fredrickson, PA Kaplan, J Lin, SC Burger, C Fry, JM Black, J Green, PM Schmitigal, L Gross, PT Dignan, S Harsh, J Hartwig, G Haynes, JB Hageman, M Porter-Shirley, K Hertz, G Moore, CA Iyer, V Mahowald, MM Ullevig, C Hayduk, R Erman, MK Pascualy, R Stolz, S Parman, D Richter, RW Gruenau, SP Webster, JAJ Ristanovic, RK Bergen, D Kanner, A Dyonzak, J Rogers, AE Aldrich, MS Rosenberg, R Richardson, T Lee, J Sahota, PK Dexter, JD Burger, RC Sangal, RB Sangal, JAM Belisle, C Schmidt, HS Parisot, PA Schmidt-Nowara, WW Jessup, C Schwartz, JRL Schwartz, ER Veit, C Blakely, L Scrima, L Miller, BR Shettar, SM May, RS Wilkerson, KE Stafford, C Grogan, WA Tearse, R Thein, SG Colontonio, L Vern, BA Mercer, PJ Merritt, SL Walsleben, JA O'Malley, MB Rapoport, DM Winokur, A Szuba, MD Civil, RH Dobbins, TW Kribbs, NB Laughton, WB Nelson, MT Wang, LX AF Mitler, MM Guilleminault, C Harsh, JR Hirshkowitz, M Becker, PM Jamieson, AO Jewel, CE Bogan, RK James, DS Sutton, JT Corser, B Mayleben, DW Bernard, SH Dinner, DS Emsellem, H Knight, E Chase, C Erwin, CW Krystal, AD Radtke, RA Farrow, S Odynski, T Pinto, J Steljes, D Feldman, NT O'Brien, M Fredrickson, PA Kaplan, J Lin, SC Burger, C Fry, JM Black, J Green, PM Schmitigal, L Gross, PT Dignan, S Harsh, J Hartwig, G Haynes, JB Hageman, M Porter-Shirley, K Hertz, G Moore, CA Iyer, V Mahowald, MM Ullevig, C Hayduk, R Erman, MK Pascualy, R Stolz, S Parman, D Richter, RW Gruenau, SP Webster, JAJ Ristanovic, RK Bergen, D Kanner, A Dyonzak, J Rogers, AE Aldrich, MS Rosenberg, R Richardson, T Lee, J Sahota, PK Dexter, JD Burger, RC Sangal, RB Sangal, JAM Belisle, C Schmidt, HS Parisot, PA Schmidt-Nowara, WW Jessup, C Schwartz, JRL Schwartz, ER Veit, C Blakely, L Scrima, L Miller, BR Shettar, SM May, RS Wilkerson, KE Stafford, C Grogan, WA Tearse, R Thein, SG Colontonio, L Vern, BA Mercer, PJ Merritt, SL Walsleben, JA O'Malley, MB Rapoport, DM Winokur, A Szuba, MD Civil, RH Dobbins, TW Kribbs, NB Laughton, WB Nelson, MT Wang, LX CA US Modafinil Narcolepsy Multicenter Study Grp TI Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy SO ANNALS OF NEUROLOGY LA English DT Article; Proceedings Paper CT 121st Annual Meeting of the American-Neurological-Association CY OCT 13-16, 1996 CL MIAMI, FLORIDA SP Amer Neurol Assoc ID SLEEP LATENCY TEST; INDUCED WAKEFULNESS; AMPHETAMINE; MICE; RAT; CAT AB Narcolepsy is a central nervous system disorder characterized by excessive daytime sleepiness and cataplexy. This placebo-controlled, double-blind, randomized, parallel-group, 18-center study assessed the efficacy and safety of modafinil, a new wake-promoting drug for treating sleepiness in narcolepsy. Subjects with narcolepsy (n = 283) received daily modafinil, 200 or 400 mg, or placebo, for 9 weeks, followed by an open-label treatment period. Subjective sleepiness was measured with the Epworth Sleepiness Scale. Objective sleepiness was assessed with the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test. Level of illness was measured with the Clinical Global Impression of Change. Modafinil significantly reduced all measures of sleepiness and was associated with significant improvements in level of illness. Medication-related adverse experiences were few, dose-dependent, and mostly rated mild to moderate. Modafinil taken once daily was a very well tolerated and effective wake-promoting agent in the treatment of excessive daytime somnolence associated with narcolepsy. Modafinil demonstrated an excellent safety profile for up to 40 weeks of open-label treatment and efficacy was maintained, suggesting that tolerance will not develop with long-term use. Modafinil is a pharmacologically and clinically promising compound for the treatment of pathological daytime somnolence. C1 Presbyterian Med Ctr, Sleep Med Inst, Dallas, TX USA. Baptist Med Ctr, Columbia, SC USA. Christ Hosp, Cincinnati Reg Sleep Ctr, Cincinnati, OH 45219 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Neurol Ctr, Chevy Chase, MD USA. Duke Univ, Med Ctr, Durham, NC USA. Sleep Clin Nevada, Las Vegas, NV USA. Palms Pasadena Hosp, St Petersburg, FL USA. Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Sleep Disorders Ctr, Philadelphia, PA 19129 USA. Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. Kalamazoo Neurol PC, Kalamazoo, MI USA. Lahey Clin Fdn, Burlington, MA USA. Forrest Gen Hosp, Hattiesburg, MS USA. St Thomas Hosp, Sleep Disorders Ctr, Nashville, TN USA. Winthrop Univ Hosp, Mineola, NY 11501 USA. VA Med Ctr, Houston, TX USA. Univ Louisville, Res Fdn Inc, Louisville, KY 40292 USA. Hennepin Cty Med Ctr, Minnesota Reg Sleep Disorders Ctr, Minneapolis, MN 55415 USA. Scripps Res Inst, La Jolla, CA USA. Providence Sleep Disorders Ctr, Seattle, WA USA. St Johns Hosp, Tulsa, OK USA. Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Northside Hosp, Atlanta, GA USA. Univ Missouri, Columbia, MO USA. Sleep Disorders Inst, Troy, MI USA. Ohio Sleep Med Inst, Dublin, OH USA. Univ New Mexico Hosp, Albuquerque, NM USA. Integris SW Med Ctr, Sleep Disorders Ctr Oklahoma, Oklahoma City, OK USA. Sleep Alertness Disorder Ctr, Aurora, CO USA. UAB Stn, Ctr Psychiat Med, Birmingham, AL USA. Crozer Chester Med Ctr, Upland, PA USA. Sacred Heart Hosp, Sacred Heart Sleep Disorders Ctr, Eugene, OR USA. Pacific Res Network, San Diego, CA USA. Univ Illinois, Chicago, IL USA. NYU, Bellevue Hosp Ctr, Med Ctr, Sleep Disorders Ctr, New York, NY 10016 USA. Hosp Univ Penn, Philadelphia, PA 19104 USA. RP Fry, JM (reprint author), Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Sleep Disorders Ctr, 3200 Henry Ave, Philadelphia, PA 19129 USA. RI Krystal, Andrew/J-7109-2013 OI Krystal, Andrew/0000-0002-6702-781X NR 33 TC 239 Z9 240 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JAN PY 1998 VL 43 IS 1 BP 88 EP 97 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YR531 UT WOS:000071504600011 ER PT J AU Graybill, JR Najvar, LK Fothergill, A Hardin, T Rinaldi, M Lambros, C Regen, SL AF Graybill, JR Najvar, LK Fothergill, A Hardin, T Rinaldi, M Lambros, C Regen, SL TI KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID METHYL-ESTER; LEUKOENCEPHALOPATHY; CELLS AB KY-62 is a water-soluble analog of amphotericin B. In vitro testing of five clinical isolates of Candida albicans showed KY-62 to have potency similar to that of amphotericin B. KY-62 was administered to mice infected intravenously with C. albicans. In vivo, KY-62 was effective in immunocompetent mice, with potency similar to that of amphotericin B. KY-62 was well tolerated up to 30 mg/kg of body weight per dose, an amount that would be lethal with amphotericin B. KY-62 was less effective in mice rendered neutropenic with 5-fluorouracil. The addition of flucytosine had little effect. KY-62 may have potential for clinical development. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. S TExas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Lehigh Univ, Bethlehem, PA 18015 USA. NIAID, Bethesda, MD 20892 USA. RP Graybill, JR (reprint author), Audie L Murphy Mem Vet Hosp, Div Infect Dis 111F, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIAID NIH HHS [N01-AI-25141] NR 25 TC 10 Z9 10 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 1998 VL 42 IS 1 BP 147 EP 150 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA YP659 UT WOS:000071301100023 PM 9449275 ER PT J AU Graybill, JR Najvar, LK Montalbo, EM Barchiesi, FJ Luther, MF Rinaldi, MG AF Graybill, JR Najvar, LK Montalbo, EM Barchiesi, FJ Luther, MF Rinaldi, MG TI Treatment of histoplasmosis with MK-991 (L-743,872) SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CANDIDA-ALBICANS; ANTIFUNGAL AGENT; AMPHOTERICIN-B; CELL-WALL; PNEUMOCANDIN; FLUCONAZOLE; ITRACONAZOLE; PREVENTION; L-733560 AB BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts, MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis. C1 S Texas Vet Hlth Care Syst, Audie Murphy Div 111F, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. RP Graybill, JR (reprint author), S Texas Vet Hlth Care Syst, Audie Murphy Div 111F, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. NR 19 TC 50 Z9 50 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 1998 VL 42 IS 1 BP 151 EP 153 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA YP659 UT WOS:000071301100024 PM 9449276 ER PT J AU Uthman, BM Rowan, AJ Ahmann, PA Leppik, IE Schachter, SC Sommerville, KW Shu, V AF Uthman, BM Rowan, AJ Ahmann, PA Leppik, IE Schachter, SC Sommerville, KW Shu, V TI Tiagabine for complex partial seizures - A randomized, add-on, dose-response trial SO ARCHIVES OF NEUROLOGY LA English DT Article ID UPTAKE INHIBITOR; PHARMACOKINETICS AB Objective: To determine the efficacy and tolerability of tiagabine, a new antiepileptic drug(AED) that inhibits gamma-aminobutyric acid (GABA) uptake, at 3 dose levels vs placebo as adjunctive therapy in patients with intractable complex partial seizures (CPS). Design: Randomized, double-blind, placebo-controlled study with a parallel-group, add-on design, starting with a 12-week unblinded baseline phase followed by a 20-week double-blind treatment phase. Setting: Twenty-one US medical centers. Patients: Patients (N = 297) aged 12 to 77 years, previously diagnosed as having CPS and receiving stable regimens of 1 to 3 hepatic enzyme-inducing AEDs; dival-proex sodium or valproic acid was allowed in combination with any of these drugs. Interventions: Placebo or tiagabine 4 times a day at 16, 32, or 56 mg daily. Main Outcome Measures: Median change in 4-week CPS frequency and adverse events. Results: Median decreases in if-week CPS frequency for the 32-mg (-2.2) and 56-mg (-2.8) tiagabine groups were significantly greater than for the placebo (-0.7) group (P = .03 and P < .03, respectively); 20% and 29% of patients in the 32- and 56-mg groups had a 50% or greater reduction in the frequency of CPS vs 4% in the placebo group (P = .002 and P < .001, respectively). Adverse effects were similar for placebo and tiagabine except for a significantly greater incidence of dizziness in the 32-mg tiagabine group, tremor in the 32- and 56-mg groups, abnormal thinking (usually mental lethargy or difficulty concentrating) in the SG-mg group, and depressed mood in the 16- and 56-mg groups. Conclusions: Tiagabine is efficacious and well tolerated as adjunctive therapy for CPS; there is a clear dose-response relationship. C1 Vet Affairs Med Ctr, Neurol Serv 127, Gainesville, FL 32608 USA. Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA. Univ Florida, Coll Med, Inst Brain, Gainesville, FL USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. Marschfield Clin, Marshfield, WI USA. MINCEP Epilepsy Ctr, Minneapolis, MN USA. Univ Minnesota, Minneapolis, MN 55455 USA. Beth Israel Hosp, Boston, MA 02215 USA. Abbott Labs, N Chicago, IL 60064 USA. RP Uthman, BM (reprint author), Vet Affairs Med Ctr, Neurol Serv 127, 1601 SW Archer Rd, Gainesville, FL 32608 USA. NR 11 TC 114 Z9 115 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JAN PY 1998 VL 55 IS 1 BP 56 EP 62 DI 10.1001/archneur.55.1.56 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA YR191 UT WOS:000071469900006 PM 9443711 ER PT J AU Passaro, E Howard, TJ Sawicki, MP Watt, PC Stabile, BE AF Passaro, E Howard, TJ Sawicki, MP Watt, PC Stabile, BE TI The origin of sporadic gastrinomas within the gastrinoma triangle - A theory SO ARCHIVES OF SURGERY LA English DT Article ID LYMPH-NODES; CELLS AB Sporadic gastrinomas are found predominantly within the gastrinoma triangle (85%), frequently within lymph nodes in the triangle (40%) and often multiple (40%). In addition, they are homologous with pancreatic polypeptidomas and express pancreatic polypeptide. We hypothesized that, if gastrinomas were of ventral pancreatic bud origin, several (7) predictions could be made. The data from the investigation of these predictions have supported the theory. We postulate that sporadic gastrinomas in the triangle arise from stem cells from the ventral pancreatic bud that become dispersed and incorporated into lymph tissue and the duodenal wall during the ventral bud's embryonic dorsal rotation within the area of the triangle. C1 W Los Angeles Vet Affairs Med Ctr, Surg Serv, Los Angeles, CA 90073 USA. Richard L Roudebush Vet Affairs Med Ctr, Los Angeles, CA USA. Harbor Univ Calif Los Angeles, Med Ctr, Dept Surg, Los Angeles, CA USA. RP Passaro, E (reprint author), W Los Angeles Vet Affairs Med Ctr, Surg Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 13 TC 24 Z9 24 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD JAN PY 1998 VL 133 IS 1 BP 13 EP 16 DI 10.1001/archsurg.133.1.13 PG 4 WC Surgery SC Surgery GA YQ717 UT WOS:000071416200002 PM 9438752 ER PT J AU Dunn, RB Walter, JS Lucero, Y Weaver, F Langbein, E Fehr, L Johnson, P Riedy, L AF Dunn, RB Walter, JS Lucero, Y Weaver, F Langbein, E Fehr, L Johnson, P Riedy, L TI Follow-up assessment of standing mobility device users SO ASSISTIVE TECHNOLOGY LA English DT Article DE spinal cord injury; standing wheelchair; standing frame ID SPINAL-CORD INJURIES; PARAPLEGIC PATIENTS; AMBULATION AB The use of standing devices by spinal cord-injured subjects was investigated through a national survey of a sample of individuals who returned their manufacturer's warranty card to two companies. We obtained a 32% response rate (99/310). The majority of respondents were male (87%) with a median age between 41 and 50 years. Seventy-seven percent were paraplegic and 21% were quadriplegic. Forty percent had between 1 and 5 years experience with their device, and 84% of those responding were currently using their standing device. Forty-one percent used their standing device one to six times a week; two-thirds stood between 30 minutes and 1 hour for each use. Less than 10% of subjects experienced any side effects, such as nausea or headaches, from standing. Twenty-one percent of subjects reported being able to empty their bladder more completely. There was also a favorable response by some individuals on the effects of the standing devices on bowel regularity, reduction of urinary tract infections, leg spasticity, and number of bed sores. Finally, 79% of subjects highly recommended use of standing devices to other people with spinal cord injury, The positive responses of individuals using standing devices is a strong recommendation for the assistive technology community to make these devices more available to individuals with spinal cord injury. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Rehabil Res & Dev Ctr, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Serv, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. Loyola Med Ctr, Dept Internal Med, Maywood, IL USA. RP Dunn, RB (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv 151, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 28 TC 21 Z9 21 U1 0 U2 4 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 1998 VL 10 IS 2 BP 84 EP 93 PG 10 WC Rehabilitation SC Rehabilitation GA 154JL UT WOS:000077885700003 PM 10339284 ER PT J AU Burton, MP Schneider, BG Brown, R Escamilla-Ponce, N Gulley, ML AF Burton, MP Schneider, BG Brown, R Escamilla-Ponce, N Gulley, ML TI Comparison of histologic stains for use in PCR analysis of microdissected, paraffin-embedded tissues SO BIOTECHNIQUES LA English DT Article ID AMPLIFICATION AB We evaluated the effect of six different histologic stains on the productivity of PCR amplification of DNA isolated from paraffin-embedded tissue samples. The tissue was collected from glass slides by microdissection techniques, whereby tiny portions of tissue are visually identified through a microscope and selectively resected for subsequent DNA extraction and PCR amplification. We found that the success of PCR amplification depended on the type of histologic stain that was used to facilitate microscopic visualization of the undeparaffinized tissue section. The best results were obtained with methyl green and nuclear fast red, while Wright's stain yielded less PCR product. Two other stains, Evans blue and light-green SF yellowish (also known as the counterstain for geomori methenamine silver stain) yielded sufficient PCR products; however, their staining characteristics did not afford satisfactory visualization of nuclear chromatin to discriminate between benign and malignant cells. Our most significant finding was that a commonly used histologic stain, hematoxylin, failed to produce DNA templates that could be consistently amplified by PCR. In conclusion, it is prudent to avoid hematoxylin stains when preparing tissues as starting material for PCR. Among the remaining five strains that were evaluated, the best choice depends on the differential staining characteristics of the cells to be dissected. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Louisiana State Univ, Med Ctr, New Orleans, LA USA. RP Gulley, ML (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCI NIH HHS [R29 CA63308] NR 8 TC 59 Z9 65 U1 0 U2 3 PU EATON PUBLISHING CO PI NATICK PA 154 E. CENTRAL ST, NATICK, MA 01760 USA SN 0736-6205 J9 BIOTECHNIQUES JI Biotechniques PD JAN PY 1998 VL 24 IS 1 BP 86 EP + PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YQ698 UT WOS:000071414300018 PM 9454959 ER PT J AU Heinrich, MC Hoatlin, ME Zigler, AJ Silvey, KV Bakke, AC Keeble, WW Zhi, Y Reifsteck, CA Grompe, M Brown, MG Magenis, RE Olson, SB Bagby, GC AF Heinrich, MC Hoatlin, ME Zigler, AJ Silvey, KV Bakke, AC Keeble, WW Zhi, Y Reifsteck, CA Grompe, M Brown, MG Magenis, RE Olson, SB Bagby, GC TI DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function SO BLOOD LA English DT Article ID HUMAN HEMATOPOIETIC-CELLS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; INDUCED APOPTOSIS; CYCLE CHECKPOINT; GENE FACC; COMPLEMENTATION; PHASE; POLYPEPTIDE; CAFFEINE AB Cells from individuals with Fanconi anemia (FA) arrest excessively in the G2/M cell cycle compartment after exposure to low doses of DNA cross linking agents. The relationship of this abnormality to the fundamental genetic defect in such cells is unknown, but many investigators have speculated that the various FA genes directly regulate cell cycle checkpoints. We tested the hypothesis that the protein encoded by the FA group C complementing gene (FAG) functions to control a cell cycle checkpoint and that cells from group C patients (FA[C]) have abnormalities of cell cycle regulation directly related to the genetic mutation. We found that retroviral transduction of FA(C) lymphoblasts with wild-type FAC cDNA resulted in normalization of the cell cycle response to low-dose mitomycin C (MMC). However, when DNA damage was quantified in terms of cytogenetic damage or cellular cytotoxicity, we found similar degrees of G2/M arrest in response to equitoxic amounts of MMC in FA(C) cells as well as in normal lymphoblasts. Similar results were obtained using isogenic pairs of uncorrected, FAC or mock-corrected (neo only) FA(C) cell lines. To test the function of other checkpoints we examined the effects of hydroxyurea (HU) and ionizing radiation on cell cycle kinetics of FA(C) and normal lymphoblasts as well as with isogenic pairs of uncorrected, FAG-corrected, or mock-corrected FA(C) cell lines. In all cases the cell cycle response of FA(C) and normal lymphoblasts to these two agents were identical. Based on these studies we conclude that the aberrant G2/M arrest that typifies the response of FA(C) cells to low doses of cross-linking agents does not represent an abnormal cell cycle response but instead represents a normal cellular response to the excessive DNA damage that results in FA(C) cells following exposure to low doses of cross-linking agents. (C) 1998 by The American Society of Hematology. C1 Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Dept Med, Portland, Dorset, England. Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, Dorset, England. Oregon Hlth Sci Univ, Dept Pediat, Portland, Dorset, England. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Heinrich, MC (reprint author), 151B 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. FU NCI NIH HHS [CA36306]; NHLBI NIH HHS [1PO1HL48546, HL48546] NR 77 TC 51 Z9 51 U1 1 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0006-4971 J9 BLOOD JI Blood PD JAN 1 PY 1998 VL 91 IS 1 BP 275 EP 287 PG 13 WC Hematology SC Hematology GA YN358 UT WOS:000071160100033 PM 9414295 ER PT J AU Scremin, OU Shih, TM Li, MG Jenden, DJ AF Scremin, OU Shih, TM Li, MG Jenden, DJ TI Mapping of cerebral metabolic activation in three models of cholinergic convulsions SO BRAIN RESEARCH BULLETIN LA English DT Article DE cholinesterase inhibitors; epilepsy; cerebral glucose utilization; pilocarpine; physostigmine; soman ID MUSCARINIC RECEPTOR SUBTYPES; LITHIUM PILOCARPINE MODEL; SOMAN-INDUCED SEIZURES; REGIONAL GLUCOSE USE; STATUS EPILEPTICUS; ACETYLCHOLINESTERASE INHIBITION; HYPERTENSIVE RESPONSE; BLOOD-FLOW; RAT-BRAIN; PHYSOSTIGMINE AB Glucose utilization of four cerebral cortex and 35 subcortical regions (CGU) was analyzed in three models of cholinergic seizures induced by the following compounds: 1) soman (pinacolylmethylphosphonofluoridate) an organophosphorus cholinesterase inhibitor, 100 mu g/kg SC after pretreatment with pyridostigmine 26 mu g/kg IM (n = 6); 2) physostigmine, a carbamate cholinesterase inhibitor, 1.31 mg/kg infused IV over 75 min (n = 6); and 3) pilocarpine, a direct cholinergic agonist, 30 mg/kg SC (n = 6), Physostigmine and pilocarpine were preceded by 3 mmol/kg LiCl IP 20 hrs earlier, Animals injected with saline SC (n = 6) were used as controls, Step-wise discriminant analysis successfully classified 100% of the cases into the four experimental groups with data from only six regions, Pyridostigmine-soman induced the most widespread and greatest increases in CGU. More restricted and lower levels of activation were observed with Li-pilocarpine while Li-physostigmine induced significant increases in CGU only in globus pallidus, entopeduncular nucleus, and substantia nigra, These three regions, which are functionally related, were also activated in the other two models of cholinergic convulsions and may represent the initial step in cholinergic activation of the CNS, Li-pilocarpine failed to activate most of the brainstem and the superior colliculus. All cortical regions were activated by Li-pilocarpine and pyridostigmine-soman, while they were inhibited by Li-physostigmine. This phenomenon may be due in part to the lack of activation with physostigmine of the basal forebrain nuclei (lateral septum, medial septum, vertical and horizontal limbs of the diagonal band, and substantia innominata) resulting in a decreased drive of cortical metabolism. (C) 1998 Elsevier Science Inc. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90073 USA. USA, Med Res Inst Chem Def, Neurotoxicol Branch, Aberdeen Proving Ground, MD 21010 USA. RP Scremin, OU (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Bldg 115,Room 317, Los Angeles, CA 90073 USA. NR 41 TC 9 Z9 9 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0361-9230 J9 BRAIN RES BULL JI Brain Res. Bull. PY 1998 VL 45 IS 2 BP 167 EP 174 DI 10.1016/S0361-9230(97)00334-1 PG 8 WC Neurosciences SC Neurosciences & Neurology GA YN851 UT WOS:000071214500009 PM 9443835 ER PT J AU Li, ZH Carraro, R Gregerman, RI Lau, DCW AF Li, ZH Carraro, R Gregerman, RI Lau, DCW TI Adipocyte differentiation factor (ADF): A protein secreted by mature fat cells that induces preadipocyte differentiation in culture SO CELL BIOLOGY INTERNATIONAL LA English DT Article DE preadipocytes; fat cells; adipocyte differentiation factor; cytokines; paracrine factor; obesity; diabetes ID TUMOR-NECROSIS-FACTOR; AMINO-ACID-SEQUENCE; GROWTH FACTOR-I; ADIPOSE-TISSUE ISLETS; PRECURSOR CELLS; GENE-EXPRESSION; INITIAL CHARACTERIZATION; ADIPOGENIC ACTIVITY; MOLECULAR-CLONING; INHIBITORY FACTOR AB A factor that is released into the culture medium of mature adipocytes and promotes the differentiation (adipogenic conversion) of preadipocytes has been partially characterized. The factor acts in a dose-dependent manner on preadipocytes to produce up to a four-fold increase in triacylglycerol (triglyceride) content and a nine-fold increase in glycerol-3-phosphate dehydrogenase (GPDH) activity, a marker of the late phase of differentiation of preadipocytes, The material appears to be a protein, since it has a molecular weight (Superose-12 gel exclusion chromatography) of about 53 kDa, an isoelectric point (pl) of 4.7-4.9, and is inactivated by the proteases papain and chymotrypsin and extremes of pH (2 and 12), Considerations of molecular weight, isoelectric point, stability to specific proteases, and especially to the action of chemical agents [the adipogenic activity is not affected by either an oxidizing (KIO4) or a reducing agent (DTT)], lead to the conclusion that the differentiation factor is distinct from known cytokines, The authors suggest that the protein be designated adipocyte differentiation factor (ADF). ADF in vivo may act as a cytokine paracrine agent to regulate the differentiation of preadipocytes. (C) 1998 Academic Press. C1 Ottawa Civic Hosp, Div Endocrinol & Metab, Ottawa, ON K1Y 4E9, Canada. Univ Ottawa, Dept Med, Ottawa, ON, Canada. Univ Ottawa, Loeb Res Inst, Ottawa, ON, Canada. Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain. Dept Vet Affairs, S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78284 USA. RP Lau, DCW (reprint author), Ottawa Civic Hosp, Div Endocrinol & Metab, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada. EM gregerman@uthscsa.edu NR 93 TC 8 Z9 12 U1 0 U2 2 PU ACADEMIC PRESS LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1065-6995 J9 CELL BIOL INT JI Cell Biol. Int. PY 1998 VL 22 IS 4 BP 253 EP 270 DI 10.1006/cbir.1998.0237 PG 18 WC Cell Biology SC Cell Biology GA 174WF UT WOS:000079058800001 PM 10101042 ER PT J AU Weiss, GR Poggesi, I Rocchetti, M DeMaria, D Mooneyham, T Reilly, D Vitek, LV Whaley, F Patricia, E Von Hoff, DD O'Dwyer, P AF Weiss, GR Poggesi, I Rocchetti, M DeMaria, D Mooneyham, T Reilly, D Vitek, LV Whaley, F Patricia, E Von Hoff, DD O'Dwyer, P TI A phase I and pharmacokinetic study of tallimustine [PNU152241 (FCE 24517)] in patients with advanced cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID ANTITUMOR-ACTIVITY; NITROGEN-MUSTARD; DISTAMYCIN-A; DNA; FCE-24517; RESISTANT; BINDING; AGENTS AB Tallimustine [PNU 152241 (FCE 24517)] is a synthetic derivative of the DNA minor groove binder distamycin A, in which the NH2-terminal formyl group is substituted by benzoyl mustard, In this Phase I clinical trial, patients with advanced solid tumors received i.v. bolus injections of tallimustine daily for 3 consecutive days, Patients were treated at six dosage levels of 33.3 mu g/m(2)/day to 250 (mu g/m(2)/day for 3 consecutive days, with courses of therapy repeated every 28 days, Detailed pharmacokinetic blood sampling was performed during the first 3 days of the first course of tallimustine, The plasma samples were analayzed by high-performance liquid chromatography with UV detection, Forty-eight eligible patients were treated at all six dosage levels, The dominant dose-related toxicity of tallimustine was neutropenia, becoming dose limiting at 250 mu g/m(2)/day. At this dosage level, one patient experienced febrile neutropenia, and a second patient died on study of indeterminate cause, Thrombocytopenia was not observed, and only 10 patients developed anemia <8.0 gm/dl, Sporadic elevation of liver enzymes or bilirubin was observed but was not dose related. Pharmacokinetic analysis gave reliable results for 33 patients, For most patients, analysis of the data best fit a three-exponential model, Dose-related increases in areas under the concentration-time curve and end-of-infusion concentrations were observed, There was no significant plasma accumulation of tallimustine over the 3 days of administration, The terminal half-life of tallimustine in individual patients ranged from 6.83 to 39.02 h following the last dose, In summary, the recommended Phase II dosage for tallimustine is 200 mu g/m(2)/day for 3 consecutive days every 28 days, Neutropenia is the principal toxicity of this agent at this dosage and schedule. C1 Univ Texas, Hlth Sci Ctr, Div Med Oncol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Sect, San Antonio, TX USA. Pharmacia & Upjohn, Nerviano, Italy. Fox Chase Canc Ctr, Fox Chase, PA USA. Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA. RP Weiss, GR (reprint author), Univ Texas, Hlth Sci Ctr, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 18 TC 31 Z9 31 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JAN PY 1998 VL 4 IS 1 BP 53 EP 59 PG 7 WC Oncology SC Oncology GA YT599 UT WOS:000071623200008 PM 9516952 ER PT J AU Craig, WA AF Craig, WA TI Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ACUTE OTITIS-MEDIA; GRAM-NEGATIVE BACILLI; STREPTOCOCCUS-PNEUMONIAE; THERAPEUTIC EFFICACY; KLEBSIELLA-PNEUMONIAE; PEAK CONCENTRATION; INFECTION MODELS; THIGH-INFECTION; ANTIBIOTICS; INVIVO C1 William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI 53705 USA. RP Craig, WA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 64 TC 1590 Z9 1649 U1 11 U2 74 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN PY 1998 VL 26 IS 1 BP 1 EP 10 DI 10.1086/516284 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA YR235 UT WOS:000071474500001 PM 9455502 ER PT J AU Bisnett, T Anzueto, A Andrade, FH Rodney, GG Napier, WR Levine, SM Maxwell, LC Mureeba, P Derdak, SD Grisham, MB Jenkinson, SG AF Bisnett, T Anzueto, A Andrade, FH Rodney, GG Napier, WR Levine, SM Maxwell, LC Mureeba, P Derdak, SD Grisham, MB Jenkinson, SG TI Effect of nitric oxide synthase inhibitor on diaphragmatic function after resistive loading SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR AND INTEGRATIVE PHYSIOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-Experimental-Biology on Structure and Function in Comparative Physiology - a Tribute to Pierre Laurent CY MAR 25-26, 1996 CL UNIV LANCASTER, LANCASTER, ENGLAND SP Soc Expt Biol, Anim Respirat & Osmoregulat Grp HO UNIV LANCASTER DE nitric oxide; N-omega-nitro-L-arginine-methyl-ester; diaphragmatic fatigue; resistive loading ID SKELETAL-MUSCLE; REACTIVE OXYGEN; RAT DIAPHRAGM; INVITRO; FLOW AB We studied the effect of a nitric oxide synthase inhibitor, N-omega-Nitro-L-arginine-methyl-ester (L-NAME), on in vitro diaphragmatic function both at rest (control) or after inspiratory resistive loading (IRL). Sprague-Dawley rats were anesthetized, instrumented, and then the following experimental groups: (1) controls; (2) L-NAME (100 mg/kg/body weight intravenously alone); (3) IRL alone; and (4) L-NAME + IRL. The IRL protocol consisted of applying a variable resistor to the inspiratory limb of a two-way valve at 70% of maximal airway pressure until apnea. After the experiment, the animals were sacrificed and diaphragmatic strips were obtained for activity of constitutive nitric oxide synthase (cNOS) and measurements of in vitro contractile properties: tetanic (Po) and twitch tensions (Pt). cNOS activity was significantly decreased in the L-NAME and L- NAME + IRL groups (P less than or equal to 0.05) as compared with control and IRL groups. L-NAME alone did not affect Po or Pt. However, in both IRL groups, with and without was a significant decrease in Po and Pt. This reduction was comparable in both groups. In summary, our data showed that L-NAME resulted in a significant decrease cNOS activity, bur. in vitro contractility was impaired, COMP BIOCHEM PHYSIOL 119A;1:185-190, 1998. (C) 1998 Elsevier Science Inc. C1 Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Pulm Dis Sect 111E, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78284 USA. Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA. Louisiana State Univ, Shreveport, LA 71105 USA. RP Anzueto, A (reprint author), Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Pulm Dis Sect 111E, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. RI Andrade, Francisco/F-1258-2011 OI Andrade, Francisco/0000-0002-2460-5798 NR 26 TC 11 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 1095-6433 J9 COMP BIOCHEM PHYS A JI Comp. Biochem. Physiol. A-Mol. Integr. Physiol. PD JAN PY 1998 VL 119 IS 1 BP 185 EP 190 DI 10.1016/S1095-6433(97)00420-0 PG 6 WC Biochemistry & Molecular Biology; Physiology; Zoology SC Biochemistry & Molecular Biology; Physiology; Zoology GA ZZ685 UT WOS:000074756400022 PM 11253784 ER PT J AU Reddy, SV Roodman, GD AF Reddy, SV Roodman, GD TI Control of osteoclast differentiation SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION LA English DT Review DE osteoclast; differentiation; hormones; cytokines; stromal cells; bone resorption; transcription factors ID COLONY-STIMULATING FACTOR; HUMAN MARROW CULTURES; GROWTH-FACTOR-BETA; CALCITONIN RECEPTOR ISOFORMS; PARATHYROID-HORMONE BINDING; GIANT-CELL TUMORS; BONE-RESORPTION; IN-VITRO; OSTEOBLASTIC CELLS; INHIBITS FORMATION AB The osteoclast is the primary bone-resorbing cell and is derived from the monocyte/macrophage lineage, Bipotent osteoclast precursors, which can form both osteoclasts and monocyte-macrophages, proliferate and differentiate to become unipotent post-mitotic committed osteoclast precursors. These post-mitotic committed precursors fuse to form the multinucleated osteoclast, which is then activated to resorb bone. A variety of soluble and membrane-bound factors play a critical role in regulating osteoclast formation, including growth factors, systemic hormones, and cells in the marrow microenvironment, such as osteoblasts and marrow stromal cells. Cell-to-cell interactions are important in both the formation and activity of the osteoclast. Recent molecular biological studies have identified transcription factors, such as c-fos and PU.I, which are required for osteoclast differentiation. In this review, we discuss the phenotypic changes that are induced as the cells mature from bipotent early precursors to mature osteoclasts; factors that have been identified that are involved in this process; and the role of marrow stromal cells and osteoblasts in osteoclast differentiation. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, San Antonio, TX 78284 USA. Audie L Murphy Vet Adm Hosp, San Antonio, TX 78284 USA. FU NCI NIH HHS [CA-40035]; NIA NIH HHS [AG-13625]; NIAMS NIH HHS [AR39529] NR 114 TC 55 Z9 58 U1 0 U2 1 PU BEGELL HOUSE INC PI NEW YORK PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892 USA SN 1045-4403 J9 CRIT REV EUKAR GENE JI Crit. Rev. Eukaryot. Gene Expr. PY 1998 VL 8 IS 1 BP 1 EP 17 PG 17 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA ZZ684 UT WOS:000074756300001 PM 9673448 ER PT J AU Fass, R Fullerton, S Naliboff, B Hirsh, T Mayer, EA AF Fass, R Fullerton, S Naliboff, B Hirsh, T Mayer, EA TI Sexual dysfunction in patients with irritable bowel syndrome and non-ulcer dyspepsia SO DIGESTION LA English DT Article DE libido; visceral hyperalgesia; quality of life ID PITUITARY-ADRENAL AXIS; FIBROMYALGIA; DISEASE; WOMEN AB The prevalence and type of sexual dysfunction in patients with functional gastrointestinal (GI) disorders involving the upper (functional dyspepsia) or lower GI tract (irritable bowel syndrome) were studied in 683 patients seen at a tertiary referral center and a comparison group of 247 community volunteers. Associations between sexual dysfunction and type and severity of GI symptoms, and psychological symptoms were examined. All subjects were evaluated with a validated bowel syndrome questionnaire, which included questions about sexual function. Psychological symptom severity was assessed by SCL-90R, The prevalence of self-reported sexual dysfunction in patients with functional GI disorders was 43.3% and did not differ by gender, age stratification or disease subtype: irritable bowel syndrome (IBS); non-ulcer dyspepsia (NUD), and IBS+NUD, In the comparison subjects without IBS symptoms and those with IBS symptoms but not seeking health care (IBS non-patients), the reported sexual dysfunction prevalence was significantly lower (16.1 and 24.4 %, respectively, p < 0.005). Decreased sexual drive was the symptom most commonly reported by both male (36.2%) and female (28.4%) patients. Dyspareunia was reported by 16.4% of females and 4% of males with IBS, but was rarely observed in patients with NUD. Report of sexual dysfunction was positively associated with perceived GI symptom severity, but not with psychological symptom severity. Sexual dysfunction should be incorporated into the quality-of-life assessment of patients with functional GI disorders and addressed in future outcome studies. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Digest Dis Res Ctr, CURE,Neuroenter Dis Program, Los Angeles, CA 90024 USA. RP Mayer, EA (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 115,CURE, Los Angeles, CA 90073 USA. NR 28 TC 46 Z9 46 U1 2 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0012-2823 J9 DIGESTION JI Digestion PD JAN-FEB PY 1998 VL 59 IS 1 BP 79 EP 85 DI 10.1159/000007471 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA YU105 UT WOS:000071682200011 PM 9468103 ER PT J AU Moser, AJ Karam, JA Giurgiu, DI Weber, PA Abedin, ZR Roslyn, JJ Abedin, MZ AF Moser, AJ Karam, JA Giurgiu, DI Weber, PA Abedin, ZR Roslyn, JJ Abedin, MZ TI Elevated biliary calmodulin during gallstone formation - The role of bile acids SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE gallstones; calmodulin; bile acids; phospholipids; secretion; prairie dog ID CYSTIC-FIBROSIS; GALLBLADDER ABSORPTION; CHOLESTEROL GALLSTONES; SECRETION; CALCIUM; RADIOIMMUNOASSAY; PHOSPHORYLATION; PROTEIN; DISEASE; DOG AB Hepatic bile synthesis is altered during experimental gallstone formation. In response to cholesterol, there is a hydrophobic shift in hepatic bile acid synthesis and hypersecretion of phospholipids. These changes decrease the vesicular capacity for cholesterol and favor crystallization. The mechanism for these changes in hepatic bile formation is unknown. Calmodulin (CaM), a Ca2+ receptor protein involved in cellular secretion, regulates gallbladder transport and may play an important role in alterations of hepatic bile formation during cholelithiasis. We hypothesized that biliary CaM activity is altered during gallstone formation and may be associated with changes in bile acid and phospholipid synthesis. Prairie dogs were fed either control (N = 22) or 1.2% cholesterol-enriched (N = 26) diets for one to six weeks. Cholecystectomy was performed; the common bile duct was cannulated, and hourly bile samples were collected. CaM was measured in bile and gallbladder tissues by radioimmunoassay. Bile samples were analyzed for cholesterol, phospholipids, total bile acids, total protein, calcium, and individual bile acid composition. Compared to controls, gallstone animals had elevated hepatic bile levels of CaM, phospholipids, and cholesterol. Hydrophobic bile acid synthesis was also stimulated, with increased levels of taurochenodeoxycholic acid (TCDCA) and decreased taurocholic acid (TCA). Gallbladder bile demonstrated similar changes. Although gallbladder bile CaM levels were increased, tissue levels were unchanged, suggesting that increased CaM concentration is a hepatic phenomenon. Hepatic bile CaM activity correlated linearly with TCDCA concentration (r = 0.64, P < 0.004) and phospholipid hypersecretion (r = 0.53, P < 0.03). The relationship between biliary CaM and increased concentrations of TCDCA and phospholipids suggests a role for CaM in alterations of hepatocyte secretion that may promote gallstone formation. C1 Allegheny Univ Hlth Sci, Dept Surg, Philadelphia, PA 19129 USA. Philadelphia VA Med Ctr, Res Serv, Philadelphia, PA USA. Philadelphia VA Med Ctr, Surg Serv, Philadelphia, PA USA. RP Abedin, MZ (reprint author), Allegheny Univ Hlth Sci, Dept Surg, 3300 Henry Ave, Philadelphia, PA 19129 USA. NR 47 TC 3 Z9 3 U1 1 U2 1 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 1998 VL 43 IS 1 BP 170 EP 177 DI 10.1023/A:1018852810678 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA YX136 UT WOS:000072010000027 PM 9508521 ER PT J AU Reid, MS Mickalian, JD Delucchi, KL Hall, SM Berger, SP AF Reid, MS Mickalian, JD Delucchi, KL Hall, SM Berger, SP TI An acute dose of nicotine enhances cue-induced cocaine craving SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE nicotine; cocaine; cue-induced; craving; relapse ID FREELY MOVING RATS; CIGARETTE-SMOKING; TRANSDERMAL NICOTINE; DEPENDENT PATIENTS; ABUSE PATIENTS; D-AMPHETAMINE; HUMANS; PERFORMANCE; REACTIVITY; TOBACCO AB The present study examined whether the active component in tobacco, nicotine, can modulate cocaine craving in patients with a history of smoking crack cocaine when exposed to crack cocaine related environmental cues. Twenty patients, all cigarette smokers, were randomly assigned to nicotine (two 22 mg transdermal patches) or placebo in a single-dose, placebo-controlled, crossover, double-blind study. Craving and anxiety were measured before and after cocaine cues with visual analog scales for desire to use cocaine and mood. Skin conductance and skin temperature were recorded before and during cocaine cues. Following exposure to cocaine cues, all patients reported an increase in cocaine craving and anxiety relative to the pre-cue measures. Cue exposure also produced an increase in skin conductance and decrease in skin temperature. The cue-induced increase in cocaine craving was strongly enhanced by nicotine, while the increase in anxiety was slightly augmented. Cue-induced skin conductance and temperature responses were unaffected by nicotine. These findings show that cue-induced cocaine craving is enhanced by nicotine. This occurred in the absence of any tobacco smoking-related cues, suggesting that nicotine may have direct psychopharmacological effects on conditioned cocaine craving. (C) 1998 Elsevier Science Ireland Ltd. C1 NYU, New York Vet Affairs Med Ctr, Dept Psychiat, New York, NY 10010 USA. Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. RP Reid, MS (reprint author), NYU, New York Vet Affairs Med Ctr, Dept Psychiat, 423 E 23rd St, New York, NY 10010 USA. EM msreid@itsa.ucsf.edu OI Delucchi, Kevin/0000-0003-2195-9627 FU NIDA NIH HHS [1R18DA06097, P50 DA09253, T32 DA07250] NR 40 TC 91 Z9 92 U1 1 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 1998 VL 49 IS 2 BP 95 EP 104 DI 10.1016/S0376-8716(97)00144-0 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA ZC149 UT WOS:000072544800003 PM 9543646 ER PT J AU Tom, T Cummings, JL AF Tom, T Cummings, JL TI Depression in Parkinson's disease - Pharmacological characteristics and treatment SO DRUGS & AGING LA English DT Review ID CATECHOL-O-METHYLTRANSFERASE; ELECTROCONVULSIVE-THERAPY; MAJOR DEPRESSION; L-DOPA; PSYCHIATRIC-SYMPTOMS; CEREBROSPINAL-FLUID; LOCUS COERULEUS; OFF PHENOMENON; BINDING-SITES; MEDICALLY ILL AB Parkinson's disease (PD) is a common neurological illness and various degrees of depression frequently complicate its course. Risk factors for developing depression with PD include right-sided hemiparkinsonism, akinesia, increased severity of disability, anxiety and psychosis. Onset of parkinsonism at a younger age, female gender and the use of levodopa are arguable risk factors. Depression may be difficult to diagnose in patients with PD because the signs of the 2 disorders overlap. In addition, patients with atypical PD more commonly have depression than patients with classical PD presentations. Antidepressant response to antiparkinsonian treatment has been limited. Enhancement of catecholamine levels in the CNS by selegiline (deprenyl), a monoamine oxidase (MAO) type B inhibitor, has shown potential antidepressant as well as neuroprotective effects. Other MAO inhibitors have shown antidepressant efficacy in animal models but have not been well tolerated by patients with PD. A catechol-O-methyltransferase (COMT) inhibitor combined with an MAO inhibitor might synergistically maximise the levels of catecholamines in the CNS. Antidepressant medications used in patients without PD include tricyclic antidepressants (TCAs) and selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), but only TCAs have been carefully studied for their antidepressant effects in PD. Electroconvulsive therapy has proven efficacy as antidepressant therapy in patients with PD, and transcranial magnetic stimulation has provided temporary-relief of depression under experimental conditions. Adverse effects of polypharmacy in the attempted treatment of depression in patients with PD are common in the elderly. A 'serotonin syndrome' has occurred frequently enough to preclude the coadministration of selegiline with SSRIs or TCAs, and multiple interactions between antiparkinsonian and antidepressant medications further complicate treatment strategies in patients with PD. An algorithmic approach to the pharmacological treatment of depression is described in this article. C1 Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Neuropsychiat & Neurobehav Unit, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Cummings, JL (reprint author), Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA. FU NIA NIH HHS [P30 AG010123] NR 139 TC 62 Z9 65 U1 3 U2 7 PU ADIS INTERNATIONAL LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PD JAN PY 1998 VL 12 IS 1 BP 55 EP 74 DI 10.2165/00002512-199812010-00006 PG 20 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA YR568 UT WOS:000071508300006 PM 9467687 ER PT J AU Goodfriend, TL Egan, BM Kelley, DE AF Goodfriend, TL Egan, BM Kelley, DE TI Aldosterone in obesity SO ENDOCRINE RESEARCH LA English DT Article; Proceedings Paper CT 8th Conference on the Adrenal Cortex CY JUN 13-16, 1998 CL ORFORD, CANADA SP Univ Laval, Univ Montreal, McGill Univ, Univ Sherbrooke, Univ Toronto, Univ Sherbrooke, Ctr Res, Univ Montreal, Ctr Res, Univ Laval, Ctr Res, Duglas Hosp Res Ctr, Med Res Council Canada, Merck Frosst, Bayer, BiochemPharma ID BLOOD-PRESSURE; WEIGHT-REDUCTION; HYPERTENSIVE PATIENTS; FATTY-ACIDS; RESTRICTION; INSULIN; SODIUM AB Plasma aldosterone levels were measured in adults whose body mass index ranged from lean to obese. Blood was drawn while subjects rested supine for 30-90 minutes. Aldosterone was higher in obese subjects, but could not be explained by renin or K+. The best predictors of plasma aldosterone were abdominal obesity measured as waist/hip ratio or by CT scan, and insulin resistance measured by insulin or oral glucose tolerance tests, or euglycemic clamp. In one cohort, these correlations were limited to women; in the other, they were also found in men. In the women with a strong correlation between aldosterone and visceral fat, aldosterone also correlated with cortisol and DHEA-S. The data are consistent with an effect of visceral fat on adrenal steroidogenesis. Visceral adipocytes have a high rate of triglyceride turnover, and their circulation drains directly to the liver. In an experiment based on these characteristics, rat hepatocytes responded to fatty acids by releasing an unidentified secretagogue that stimulated aldosterone production by rat adrenal glomerulosa cells. The clinical data suggest that aldosterone participates in hypertension associated with the "Insulin Resistance Syndrome". The adrenal in viscerally obese subjects may be driven by a secretagogue released from the liver by fatty acids from abdominal adipocytes. C1 Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. Univ Wisconsin, Dept Med, Madison, WI USA. Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA. Med Univ S Carolina, Dept Pharmacol, Div Clin Pharmacol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Clin Pharmacol, Charleston, SC 29425 USA. Univ Pittsburgh, Dept Med, Div Endocrinol & Metab, Pittsburgh, PA USA. RP Goodfriend, TL (reprint author), Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. NR 19 TC 110 Z9 114 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 USA SN 0743-5800 J9 ENDOCR RES JI Endocr. Res. PY 1998 VL 24 IS 3-4 BP 789 EP 796 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 150ZW UT WOS:000077697300082 PM 9888579 ER PT S AU Qureshi, N Jarvis, B Takayama, K Sattar, N Hofman, J Stutz, P AF Qureshi, N Jarvis, B Takayama, K Sattar, N Hofman, J Stutz, P BE Levin, J Pollack, M Yokochi, T Nakano, M TI Natural and synthetic LPS and lipid A analogs or partial structures that antagonize or induce tolerance to LPS SO ENDOTOXIN AND SEPSIS: MOLECULAR MECHANISMS OF PATHOGENESIS, HOST RESISTANCE, AND THERAPY SE PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH LA English DT Article; Proceedings Paper CT 4th Conference of the International-Endotoxin-Society CY OCT 22-27, 1996 CL NAGOYA, JAPAN SP Int Endotoxin Soc ID TUMOR-NECROSIS-FACTOR; RHODOPSEUDOMONAS-SPHAEROIDES ATCC-17023; LIPOPOLYSACCHARIDE LPS; ENDOTOXIN ANTAGONIST; LETHAL ENDOTOXEMIA; A PRECURSOR; FATTY-ACIDS; GLUCOCORTICOIDS; ACTIVATION; INHIBITION C1 William S Middleton Mem Vet Adm Med Ctr, Mycobacteriol Res Lab, Madison, WI 53705 USA. Coll Agr & Life Sci, Dept Bacteriol, Madison, WI 53706 USA. Acad Sci Czech Republic, Prague 4, Czech Republic. Sandoz GmbH, A-1235 Vienna, Austria. RP Qureshi, N (reprint author), William S Middleton Mem Vet Adm Med Ctr, Mycobacteriol Res Lab, Madison, WI 53705 USA. FU NIGMS NIH HHS [GM-50870] NR 29 TC 3 Z9 3 U1 0 U2 0 PU WILEY-LISS, INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0361-7742 BN 0-471-19432-8 J9 PROG CLIN BIOL RES JI Prog.Clin.Biol.Res. PY 1998 VL 397 BP 289 EP 300 PG 12 WC Biology; Immunology; Medicine, Research & Experimental; Microbiology SC Life Sciences & Biomedicine - Other Topics; Immunology; Research & Experimental Medicine; Microbiology GA BL23U UT WOS:000074779900028 PM 9575570 ER PT J AU Meyer, JS Terayama, Y Konno, S Akiyama, H Margishvili, GM Mortel, KF AF Meyer, JS Terayama, Y Konno, S Akiyama, H Margishvili, GM Mortel, KF TI Risk factors for cerebral degenerative changes and dementia SO EUROPEAN NEUROLOGY LA English DT Article; Proceedings Paper CT International Symposium on the Challenge of Cerebrovascular Aging - the Therapeutic Value of Almitrine-Raubasine CY MAY 10, 1997 CL SHANGHAI, PEOPLES R CHINA DE normal human aging; risk factors; cognitive decline; dementia; longitudinal analysis; cerebral atrophy and degenerative change; neuroimaging ID COMPUTED TOMOGRAPHIC ANALYSIS; ESTROGEN REPLACEMENT THERAPY; WHITE MATTER LUCENCIES; SCAN LEUKO-ARAIOSIS; ALZHEIMERS-DISEASE; BLOOD-FLOW; VASCULAR DEMENTIA; NEUROLOGIC FINDINGS; BRAIN; ATROPHY AB It is concluded that the most important determinants for cerebral neurodegenerative changes and cognitive decline during aging are neuronal shrinkage and/or loss, which are accelerated by certain risk factors: e.g. TIAs, hypertension, heart disease, hyperlipidemia, smoking, heavy alcohol consumption, male gender, low educational status, family history of cerebrovascular disease and absence of estrogen replacement therapy among women. Some of these risk factors are remediable by therapeutic interventions, including prevention of TIAs and medications that control hypertension, heart disease, hyperlipidemia and estrogen replacement in postmenopausal women, as well as abstention from abuse of tobacco and alcohol. Cerebral neurodegenerative changes measured by neuroimaging appear to be premorbid markers for depleted neuronal and synaptic reserves which predispose to the onset of dementias of both VAD and DAT types. Normal subjects at risk for cognitive decline include those with TIAs, hypertension and heart disease since these risk factors measurably accelerate cerebral atrophy, ventricular enlargement, leukoaraiosis, and decline in cortical perfusion. C1 Baylor Coll Med, VA Med Ctr, Cerebrovasc Res Labs, Dept Neurol, Houston, TX 77030 USA. RP Meyer, JS (reprint author), Baylor Coll Med, VA Med Ctr, Cerebrovasc Res Labs, Dept Neurol, 2002 Holcombe Blvd 151A, Houston, TX 77030 USA. OI Akiyama, Hisanao/0000-0003-4491-6064 NR 52 TC 21 Z9 21 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 J9 EUR NEUROL JI Eur. Neurol. PY 1998 VL 39 SU 1 BP 7 EP 16 DI 10.1159/000052064 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ZA243 UT WOS:000072343700003 PM 9516069 ER PT J AU Meyer, JS AF Meyer, JS TI Summary and conclusions SO EUROPEAN NEUROLOGY LA English DT Editorial Material C1 Baylor Coll Med, Cerebrovasc Res Lab, VA Med Ctr, Dept Neurol, Houston, TX 77030 USA. RP Meyer, JS (reprint author), Baylor Coll Med, Cerebrovasc Res Lab, VA Med Ctr, Dept Neurol, 2002 Holcombe Blvd 151A, Houston, TX 77030 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 J9 EUR NEUROL JI Eur. Neurol. PY 1998 VL 39 SU 1 BP 45 EP 47 DI 10.1159/000052070 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ZA243 UT WOS:000072343700009 ER PT J AU Bech, P Peuskens, JCJR Marder, SR Chouinard, G Hoybergs, OJ Huttunen, MO Blin, O Claus, A AF Bech, P Peuskens, JCJR Marder, SR Chouinard, G Hoybergs, OJ Huttunen, MO Blin, O Claus, A TI Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics SO EUROPEAN PSYCHIATRY LA English DT Article DE meta-analysis schizophrenia; risperidone; efficacy; tolerability ID NEGATIVE SYMPTOMS; HALOPERIDOL; METAANALYSIS; CLOZAPINE; SCALE; DRUGS AB Data from six randomised, controlled, comparative studies of risperidone and conventional neuroleptics (haloperidol, zuclopenthixol and perphenazine) in the treatment of 911 patients with chronic schizophrenia were analysed to estimate the benefits and risks of treatment. Efficacy and risk of treatment were assessed by means of the Positive and Negative Syndrome Scale (PANSS) and the Extrapyramidal Symptom Rating Scale (ESRS). An effect size (difference between treatments) was calculated from the PANSS and ESRS scores. The effect size of antipsychotic effect favoured risperidone (sizes ranged from 0.22 to 0.37 on the PANSS subscales), and the effect size of safety also favoured risperidone (sizes ranged from 0.18 to 0.36 on the ESRS). An analysis of the proportions of patients requiring antiparkinsonian medication produced an effect size of 0.37 (20% of risperidone patients and 38% of patients receiving a conventional neuroleptic required antiparkinsonian medication). These data indicate that risperidone is a more effective antipsychotic than the conventional agents and causes less severe extrapyramidal symptoms. (C) 1998 Elsevier, Paris. C1 Frederiksborg Gen Hosp, Psychiat Res Unit, Hillerod Sygehus, DK-3400 Hillerod, Denmark. Univ Ctr St Jozef, Kortenberg, Belgium. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Hosp Louis H Lafontaine, Montreal, PQ, Canada. Molde Hosp, Dept Psychiat, Molde, Norway. Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland. Hop Enfants La Timone, Marseille, France. Univ Psychiat Hosp St Camillus, Birbeek, Belgium. RP Bech, P (reprint author), Frederiksborg Gen Hosp, Psychiat Res Unit, Hillerod Sygehus, DK-3400 Hillerod, Denmark. NR 26 TC 8 Z9 8 U1 0 U2 3 PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS CEDEX 15 PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 1998 VL 13 IS 6 BP 310 EP 314 DI 10.1016/S0924-9338(98)80049-7 PG 5 WC Psychiatry SC Psychiatry GA 134PH UT WOS:000076751400005 PM 19698646 ER PT J AU Makinodan, T AF Makinodan, T TI Studies on the influence of age on immune response to understand the biology of immunosenescence SO EXPERIMENTAL GERONTOLOGY LA English DT Article ID AGING ANIMALS; BONE-MARROW; IMMUNOLOGICAL DEFICIENCIES; T-CELLS; MICE; RESTORATION; 2-MERCAPTOETHANOL; DIFFERENTIATION; RESPONSIVENESS; DECLINE C1 Univ Calif Los Angeles, VA Med Ctr, GRECC, Ctr Asians & Pacific Islanders,MEDTEP,RAND, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Makinodan, T (reprint author), W Los Angeles Vet Affairs Med Ctr, API, MEDTEP Ctr, RAND,VA,UCLA, 11301 Wilshire Blvd,Bldg 115,Room 328, Los Angeles, CA 90073 USA. NR 35 TC 12 Z9 12 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JAN-MAR PY 1998 VL 33 IS 1-2 BP 27 EP 38 DI 10.1016/S0531-5565(97)00058-2 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA YN224 UT WOS:000071145500005 PM 9467714 ER PT J AU Scott, DR Weeks, D Hong, C Postius, S Melchers, K Sachs, G AF Scott, DR Weeks, D Hong, C Postius, S Melchers, K Sachs, G TI The role of internal urease in acid resistance of Helicobacter pylori SO GASTROENTEROLOGY LA English DT Article ID HYDROGEN-ION CONCENTRATION; PROTON MOTIVE FORCE; CAMPYLOBACTER-PYLORI; GNOTOBIOTIC PIGLETS; NEGATIVE MUTANT; ULCER DISEASE; MUCUS LAYER; LOW PH; OMEPRAZOLE; GASTRITIS AB Background & Aims: The relative role of internal urease for acid protection of Helicobacter pylori is unknown, The aim of this study was to determine the comparative importance of internal and external urease under acidic conditions, Methods: The pH optimum and measured Michaelis constant for urea of external urease and urease in intact bacteria at different medium pH (pH(out)) were measured using (CO2)-C-14 release from C-14-urea, The effect of urea on membrane potential and bacterial cytoplasmic pH was measured at different fixed pH(out). S-35-methionine labeling and sodium dodecyl sulfate-polyacrylamide gel electrophoresis of labeled proteins in the organism and medium measured protein synthesis at different pH(out) and mechanisms of urease externalization. Results: External urease had activity between pH 5.0 and 8.5 and internal urease between pH(out) 2.5 and 6.5, and its Michaelis constant at pH(out) 2.5 was 300 mmol/L but at pH(out) 4.5 was 0.5 mmol/L, similar to free urease, The addition of 5 mmol/L urea to bacteria at fixed pH(out) from 3.0 to 6.0 elevated potential to about -105 mV and periplasmic pH to about pH 6.2, Protein synthesis occurred mainly between pH 6.5 and 8.0, and urease activity resulted in increased protein synthesis at acidic pH, The labeling pattern of intrabacterial and released protein was similar. Conclusions: Intracellular urease activity is regulated by external pH, defends against gastric acidity by increasing periplasmic pH and membrane potential, and stimulates protein synthesis at acidic pH. External urease is produced mostly by cell lysis. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. BYK Gulden Lomberg GmbH, Dept Biol Mol, D-7750 Constance, Germany. RP Sachs, G (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 113,Room 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK 40615, DK 41301] NR 59 TC 189 Z9 197 U1 1 U2 10 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 1998 VL 114 IS 1 BP 58 EP 70 DI 10.1016/S0016-5085(98)70633-X PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA YN909 UT WOS:000071220900012 PM 9428219 ER PT J AU Barnes, CJ Cameron, IL Lee, M AF Barnes, CJ Cameron, IL Lee, M TI Immunohistochemical localization of prostaglandin endoperoxide G/H synthase isozymes in the normal rat colon epithelium and in 1,2-dimethylhydrazine-induced colon tumours SO GI CANCER LA English DT Article DE prostaglandin synthase; colon cancer; immunohistochemistry; rats ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2 GENE-EXPRESSION; ASPIRIN; CANCER; ADENOCARCINOMAS; ADENOMAS; TUMORS AB Objectives Prostaglandin endoperoxide G/H synthase (PGHS) is a potential target for colon cancer chemoprevention. The aims of this study were to determine if the localization of PGHS isozymes is altered early in 1,2-dimethylhydrazine (DMH)-induced rat colon tumorigenesis and to characterize PGHS isozyme localization in DMH-induced colon tumours. Methods Male Sprague-Dawley rats were injected once a week for 8 weeks with the colon carcinogen DMH or vehicle and then sacrificed at 9 or 30 weeks. Immunohistochemical detection of PGHS isozymes was performed in normal appearing colonic mucosa and colon tumours. Results At both time points, in normal appearing colon, PGHS-1 was localized in vascular endothelial cells, smooth muscle cells, and specific cells in the lamina propria, while PGHS-2 localization was limited to a few scattered cells at the periphery of lymphatic modules. However, both isozymes were localized to carcinoma and stromal cells of DMH-induced colon tumours. Conclusions PGHS-1 is the predominant isozyme in the rat colon, and PGHS-2 is selectively upregulated in DMH-induced colon tumours. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Gastroenterol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Vet Affairs Med Ctr, San Antonio, TX 78284 USA. RP Barnes, CJ (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Gastroenterol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1064-9700 J9 GI CANCER JI GI Cancer PY 1998 VL 2 IS 4 BP 329 EP + PG 6 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA 123RN UT WOS:000076138300009 ER PT J AU Ubel, PA Loewenstein, G Scanlon, D Kamlet, M AF Ubel, PA Loewenstein, G Scanlon, D Kamlet, M TI Value measurement in cost-utility analysis: Explaining the discrepancy between rating scale and person trade-off elicitations SO HEALTH POLICY LA English DT Article DE cost-effectiveness analysis; utility; person trade-off; rating scale ID HEALTH-CARE; PREFERENCES; OUTCOMES; STATES; OREGON; QALYS AB Previous studies have shown a discrepancy between common utility elicitation methods, such as rating scale (RS) elicitations, and person trade-off (PTO) elicitations. This discrepancy has generally been felt to be due to the fact that RS elicitations ask people to compare conditions to each other in terms of numbers on a visual rating scale, while PTO elicitations ask people to think in terms of numbers of people needing to be treated. However, there are three other cognitive differences between PTO and RS elicitations that might contribute to the discrepancy: In PTO elicitations, as opposed to RS elicitations: (1) people are asked to think about how conditions affect people other than themselves; (2) people are asked to think about the benefit of treating conditions; and (3) people are asked to chose who to treat among patients with different conditions. In this study, we attempt to determine whether any of these three cognitive differences contribute to the discrepancy between RS and PTO utility elicitations. We randomized prospective jurors to receive one of several survey versions in which we manipulated the RS and PTO elicitations to reduce the differences between them, while preserving their underlying structure. In the RS-self survey, we asked subjects to rate a health condition on a scale from 0 to 100 as if they had the condition. In the RS-other survey, we asked people to rate the health condition as if someone else had it. In the RS-cure survey, we asked subjects to rate the benefits of curing someone else of the health condition. In the PTO-comparison survey, we asked people to determine equivalent numbers of people needing to be cured of two conditions in order to produce equal benefits. In the PTO-choice survey, we presented people with a budget constraint and asked them to determine equivalent numbers of people needing to be cured of two conditions to help decide which group should be treated within the budget constraint. Two hundred and twenty two subjects completed surveys. Median utilities for health conditions were higher in the two PTO elicitations than in the three RS elicitations. There were no differences in utilities across the two PTO surveys, nor across the three RS surveys. In addition, the PTO elicitations allowed people to make finer distinctions among non-life threatening conditions than did the RS elicitations. The discrepancy between RS and PTO elicitations cannot be explained by shifting subjects attentions from themselves to others, nor from conditions to the benefit of treating conditions. Instead, the discrepancy occurs because of the general format of RS and PTO elicitations. (C) 1998 Published by Elsevier Science Ireland Ltd. C1 Vet Affairs Med Ctr, Philadelphia, PA USA. Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. Penn State Univ, Dept Hlth Policy & Adm, University Pk, PA 16802 USA. Carnegie Mellon Univ, H John Heinz III Sch Publ Policy & Management, Pittsburgh, PA 15213 USA. RP Ubel, PA (reprint author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA. NR 18 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0168-8510 J9 HEALTH POLICY JI Health Policy PD JAN PY 1998 VL 43 IS 1 BP 33 EP 44 DI 10.1016/S0168-8510(97)00077-8 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA YZ153 UT WOS:000072225600003 PM 10178799 ER PT J AU Gulley, ML Zhang, Q Gascoyne, RD DuPont, BR Banks, PM Cho, CG Huang, JM Montalvo, EA AF Gulley, ML Zhang, Q Gascoyne, RD DuPont, BR Banks, PM Cho, CG Huang, JM Montalvo, EA TI Translocations of 11q13 in mantle cell lymphoma fail to disrupt the S mu bp-2 gene SO HEMATOPATHOLOGY AND MOLECULAR HEMATOLOGY LA English DT Article DE mantle cell lymphoma; S mu bp-2; 11q13; Epstein-Barr virus; BZLF1 ID DNA-BINDING PROTEIN; CYCLIN D1 GENE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; BCL-1 LOCUS; BREAKPOINTS; REARRANGEMENTS; OVEREXPRESSION; CHROMOSOME-11; MALIGNANCIES AB We recently cloned a gene whose protein product binds to the Epstein-Barr virus BZLF1 gene promoter. The same gene has been previously cloned by another group who named it S mu bp-2 because its protein product binds to the S mu motif of the immunoglobulin heavy chain gene where it is postulated to function in immunoglobulin class switching. In the current study, we confirm that the S mu bp-2 gene is located on chromosome 11q13, a locus known to be altered by translocation in 50-70% of mantle cell lymphomas. We used Southern blot analysis to determine whether the S mu bp-2 gene was structurally rearranged in any of 25 mantle cell lymphomas. We found no evidence of rearrangement in any of these lymphomas including 18 that were proven to contain t(11;14) by cytogenetic analysis. These data suggest that structural alteration of the S mu bp-2 gene is not an underlying mechanism of tumorigenesis in mantle cell lymphomas. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78284 USA. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. RP Gulley, ML (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 29 TC 0 Z9 0 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 USA SN 1082-8893 J9 HEMATOPATHOL MOL HEM JI Hematopathol. Mol. Hematol. PY 1998 VL 11 IS 1 BP 1 EP 11 PG 11 WC Hematology; Pathology SC Hematology; Pathology GA YM690 UT WOS:000071090300001 ER PT J AU Poorkaj, P Sharma, V Anderson, L Nemens, E Alonso, ME Orr, H White, J Heston, L Bird, TD Schellenberg, GD AF Poorkaj, P Sharma, V Anderson, L Nemens, E Alonso, ME Orr, H White, J Heston, L Bird, TD Schellenberg, GD TI Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene SO HUMAN MUTATION LA English DT Article DE Alzheimer's disease; presenilin 1; dementia; mutations; presenilin 2; STM2; S182 ID APOLIPOPROTEIN-E; IN-VIVO; PROTEIN; LOCUS; IDENTIFICATION; POLYMORPHISM; EXPRESSION; KINDREDS; TOPOLOGY AB Mutations in the presenilin genes (PS-1 and PS-2) cause early onset autosomal dominant Alzheimer's disease (AD). Eight early-onset, autopsy-documented familial AD kindreds were screened for mutations in PS-1, and seven different mutations were identified. Three of these were new mutations (G209V A426P, and E120D), two were previously reported mutations in new families, and three mutations were confirmed in previously published families. Two of these new mutations are found within predicted transmembrane domains (TMDs 4, 7, and 8). The A426P mutation is the most C-terminal PS-1 mutation identified to date. (C) 1998 Wiley-Liss, Inc. C1 Vet Affairs Puget Sound Hlth Care Syst, GRECC 182B, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. Ingenex Inc, Menlo Park, CA USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico. Univ Minnesota, Dept Lab Med, Minneapolis, MN 55455 USA. Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA. Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. RP Schellenberg, GD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC 182B, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIA NIH HHS [AG05136, R01 AG1176] NR 36 TC 36 Z9 38 U1 1 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1998 VL 11 IS 3 BP 216 EP 221 DI 10.1002/(SICI)1098-1004(1998)11:3<216::AID-HUMU6>3.0.CO;2-F PG 6 WC Genetics & Heredity SC Genetics & Heredity GA YZ386 UT WOS:000072249200006 PM 9521423 ER PT J AU Melby, PC Yang, YZ Cheng, J Zhao, WG AF Melby, PC Yang, YZ Cheng, J Zhao, WG TI Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani SO INFECTION AND IMMUNITY LA English DT Article ID TRANSFORMING GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; IFN-GAMMA; INTERFERON-GAMMA; ANTIMICROBIAL ACTIVITY; ACTIVATED MACROPHAGES; MURINE LEISHMANIASIS; TH1 CELLS; EXPRESSION; INTERLEUKIN-12 AB Infection with the protozoan Leishmania donovani can cause serious visceral disease or subclinical infection in humans, To better understand the pathogenesis of this dichotomy, we have investigated the host cellular immune response to cutaneous or visceral infection in a murine model. Mice infected in the skin del eloped no detectable visceral parasitism, whereas intravenous inoculation resulted in hepatosplenomegaly and an increasing visceral parasite burden, Spleen cells from mice with locally controlled cutaneous infection showed strong parasite-specific proliferative and gamma interferon (IFN-gamma) responses, but spleen cells from systemically infected mice were unresponsive to parasite antigens, The in situ expression of IFN-gamma, interleukin-4 (IL-4), IL-10, IL-12, and inducible nitric oxide synthase (iNOS) mRNAs was determined in the spleen, draining lymph node (LN), and cutaneous site of inoculation, There was considerably greater expression of IPN-gamma and IL-12 p40 mRNAs in the LN draining a locally controlled cutaneous infection than in the spleen following systemic infection, Similarly, there was a high level of IFN-gamma production by LN cells following subcutaneous infection but no IFN-gamma production by spleen cells following systemic infection, Splenic IL-4 expression was transiently increased early after systemic infection, but splenic IL-IO transcripts increased throughout the course of visceral infection, IL-4 and IL-10 mRNAs were also increased in the LN following cutaneous infection, iNOS mRNA was detected earlier in the LN draining a cutaneous site of infection compared to the spleen following systemic challenge, Thus, locally controlled cutaneous infection was associated with antigen-specific spleen cell responsiveness and markedly increased levels of IFN-gamma, IL-12, and iNOS mRNA in the draining LN. Progressive splenic parasitism was associated with an early IL-4 response, markedly increased IL-10 but minimal IL-12 expression, and delayed expression of iNOS. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Med Serv, San Antonio, TX 78284 USA. RP Melby, PC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 44 TC 88 Z9 93 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 1998 VL 66 IS 1 BP 18 EP 27 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA YP559 UT WOS:000071290000004 PM 9423834 ER PT J AU Kunik, ME Puryear, L Orengo, CA Molinari, V Workman, RH AF Kunik, ME Puryear, L Orengo, CA Molinari, V Workman, RH TI The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE dementia; agitation; behavioral disturbance; geropsychiatry; psychotropic agent; side-effect profile ID ALZHEIMERS-DISEASE; VALPROATE; DISORDERS; AGITATION AB Behavioral disturbances are commonly encountered in elderly demented patients. The records of all patients admitted to a geropsychiatric inpatient unit within a 2-year period who had a primary diagnosis of dementia and an accompanying behavioral disturbance treated with divalproex sodium were reviewed. Of the 13 patients identified, all tolerated divalproex sodium without significant side-effects. General psychiatric symptoms, overall agitation, physical aggression and non-aggressive physical agitation decreased significantly, but verbal agitation did not. Divalproex sodium is well tolerated and may be effective in ameliorating certain behavioral disturbances in elderly demented patients with agitation. (C) 1998 John Wiley & Sons, Ltd. C1 Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Houston VAMC, Geriatr Psychiat Serv, Houston, TX USA. RP Kunik, ME (reprint author), Dept Psychiat, 1 Baylor Plaza, Houston, TX 77030 USA. NR 16 TC 42 Z9 43 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JAN PY 1998 VL 13 IS 1 BP 29 EP 34 DI 10.1002/(SICI)1099-1166(199801)13:1<29::AID-GPS726>3.0.CO;2-Z PG 6 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA YT707 UT WOS:000071635000006 PM 9489578 ER PT J AU Williams, JW Bhogte, M Flinn, JF AF Williams, JW Bhogte, M Flinn, JF TI Meeting the needs of primary care physicians: A guide to content for programs on depression SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article; Proceedings Paper CT Symposium on Effective Educational Techniques for Primary Care Providers - Application to the Management of Psychiatric Disorders CY JUN 27-29, 1997 CL DARTMOUTH COLL, HANOVER, NEW HAMPSHIRE SP Solvay Pharm HO DARTMOUTH COLL DE primary health care; depressive disorders; education; medical; physician's practice patterns; attitude of health personnel ID RANDOMIZED CLINICAL-TRIAL; LATE-LIFE DEPRESSION; GENERAL-PRACTITIONERS; ANTIDEPRESSANT TREATMENT; MENTAL-DISORDERS; MAJOR DEPRESSION; FAMILY MEDICINE; RECOGNITION; PREVALENCE; ILLNESS AB Objective: The purpose of this article is to identify literature-based content for the design of educational programs on depression for practicing primary care physicians. Methods: A MEDLINE search was conducted of English-language medical literature published from 1982 through July 1997 for studies describing primary care physicians' knowledge, skills, practice patterns, and perceived barriers related to care of depressed patients. Studies focusing exclusively on residency training and those describing physician practices outside North America were excluded. Of 377 articles identified, forty met inclusion and exclusion criteria. Results: Recommendations for educational content were identified from the literature review. For recognition, educators should prioritize communication skills and strategies for the use of depression questionnaires. For diagnosis, practice interpreting symptoms in the medically ill, strategies for efficient diagnosis, and systematic approaches to assessing suicide risk should be emphasized. For treatment, greater attention to the therapeutic alliance, staged therapy, and strategies for improving medication adherence are indicated. Conclusions: There is a moderately well developed literature describing self-perceived and observed gaps in the current care for depression in primary care. Addressing the entire list of needs would take more time than practicing physicians are likely to have. An important challenge for educators is to design flexible programs based on individualized needs assessment or, when not possible, to prioritize the most generalizable needs. C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Williams, JW (reprint author), Ambulatory Care 11C-6,7400 Merton Minter Blvd, San Antonio, TX 78284 USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 61 TC 8 Z9 8 U1 2 U2 2 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 1998 VL 28 IS 1 BP 123 EP 136 PG 14 WC Psychiatry SC Psychiatry GA ZQ605 UT WOS:000073884800008 PM 9617652 ER PT J AU Williams, J Mulrow, C Chiquette, E Aguilar, C Noel, P Cornell, J AF Williams, J Mulrow, C Chiquette, E Aguilar, C Noel, P Cornell, J TI Newer pharmacotherapies for depression in primary care: A literature synthesis SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 1998 VL 28 IS 4 BP 405 EP 406 PG 2 WC Psychiatry SC Psychiatry GA 178YX UT WOS:000079297700033 ER PT J AU Grann, A Wallner, K AF Grann, A Wallner, K TI Prostate brachytherapy in patients with inflammatory bowel disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostatic carcinoma; brachytherapy; inflammatory bowel disease; Crohn's; ulcerative colitis AB Purpose: There are minimal data to support the perceived contraindication of radiation therapy in patients with inflammatory bowel disease (IBD). Because of widespread concern about the possibility of radiation-related morbidity in IBD patients, the posttreatment course for 6 patients with a history of LED who were treated with I-125 prostate implantation for early stage prostate cancer are reported here. Materials and Methods: Six patients with a prior history of IBD and Stage T1c-T2c prostatic carcinoma underwent I-125 prostate brachytherapy from 1991-1996. Three patients had Crohn's disease and three had ulcerative colitis. The treatment plans were designed to treat the preimplant prostatic margin, as defined on planning CT scan, to 150 Gy. No special effort was made to minimize the rectal surface dose. Detailed records were available for all patients, and all patients were interviewed for this report, Follow-up ranged from 1 to 6 years (median: 3.7 years). Results: None of the 6 patients experienced unusual or significant gastrointestinal side effects following implantation. All 6 patients remain free of GI complications. The rectal surface area that received > 100 Gy was kept below 10 mm(2) in all patients, in accordance with previously published guidelines, Conclusions: Based on the limited information available, it appears that prostate brachytherapy is safe in patients with a history of LED. (C) 1998 Elsevier Science Inc. C1 Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Brachytherapy Serv, New York, NY 10021 USA. RP Wallner, K (reprint author), Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Radiat Oncol Serv, 1660 S Columbian Way 174, Seattle, WA 98108 USA. NR 10 TC 22 Z9 23 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 1998 VL 40 IS 1 BP 135 EP 138 DI 10.1016/S0360-3016(97)00583-X PG 4 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA YN393 UT WOS:000071164200021 PM 9422569 ER PT J AU Haskell, CM Mendoza, E Pisters, KMW Fossella, FV Figlin, RA AF Haskell, CM Mendoza, E Pisters, KMW Fossella, FV Figlin, RA TI Phase II study of intravenous adenosine 5 '-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE ATP; adenosine 5 '-triphosphate; non-small cell lung cancer ID EXTRACELLULAR ATP; CLINICAL-TRIALS; TUMOR-CELLS; GROWTH AB Fifteen patients with Stage IIIB or IV non-small cell lung cancer gave informed consent to receive three or more 96-hour infusions of ATP at a dose of 50 mcg/kg/min or higher to determine whether ATP has antineoplastic activity against this tumor type and to better define the spectrum of toxicity for ATP given as a single agent. There were no objective complete or partial responses observed. The median survival of the overall group was 187 days and the median time to tumor progression was 113 days. The major toxic side effects were chest pain and dyspnea, leading to the cessation of treatment in 5 patients. We conclude that ATP at this dose and schedule of administration is an inactive agent in patients with advanced non-small cell lung cancer. C1 W Los Angeles Vet Affairs Med Ctr, Ctr Canc, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Houston, TX 77030 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. RP Haskell, CM (reprint author), W Los Angeles Vet Affairs Med Ctr, Ctr Canc, 11301 Wilshire Blvd,111-N, Los Angeles, CA 90073 USA. NR 16 TC 39 Z9 40 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1998 VL 16 IS 1 BP 81 EP 85 DI 10.1023/A:1006018610986 PG 5 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA 114AM UT WOS:000075587000011 PM 9740548 ER PT J AU Frosch, DL Shoptaw, S Jarvik, ME Rawson, RA Ling, W AF Frosch, DL Shoptaw, S Jarvik, ME Rawson, RA Ling, W TI Interest in smoking cessation among methadone maintained outpatients SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article ID TREATING CIGARETTE-SMOKING; NICOTINE DEPENDENCE; ADDICTIVE BEHAVIORS; TOBACCO USE; ALCOHOL; CANCER; MORTALITY; CLIENTS; HEALTH AB The prevalence of cigarette smoking among opiate abusers is extremely high and tobacco related diseases are a major factor associated with morbidity and mortality for this group. Yet, many treatment providers remain reluctant to address smoking cessation with their clients due in part to the belief that substance abusers are not interested in quitting smoking. The present study examined self-reported interest in smoking cessation among methadone maintenance clients (N = 120) in four clinics in Los Angeles. Fifty-eight percent of subjects rated themselves as 'Somewhat' or 'Very Interested' in a smoking cessation program. Overall subjects appeared to accurately perceive the personal risks from tobacco smoking. In conclusion we find that clients in methadone maintenance treatment programs evidence a high level of interest in quitting smoking and may well be suited for a highly structured smoking cessation intervention. C1 Matrix Ctr, Santa Fe, NM USA. Los Angeles Addict Treatment Res Ctr, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. RP Frosch, DL (reprint author), 10350 Santa Monica Blvd,330, Los Angeles, CA 90025 USA. FU NIDA NIH HHS [R18 DA-06185, P50 DA-09260] NR 34 TC 48 Z9 49 U1 0 U2 2 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 1998 VL 17 IS 2 BP 9 EP 19 PG 11 WC Substance Abuse SC Substance Abuse GA ZH303 UT WOS:000073093900002 PM 9567223 ER PT J AU Shoptaw, S Reback, CJ Frosch, DL Rawson, RA AF Shoptaw, S Reback, CJ Frosch, DL Rawson, RA TI Stimulant abuse treatment as HIV prevention SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article ID INTRAVENOUS-DRUG-USERS; AIDS-RELATED KNOWLEDGE; SUBSTANCE USE; RISK BEHAVIORS; BISEXUAL MEN; COCAINE DEPENDENCE; SEXUAL-BEHAVIOR; HOMOSEXUAL MEN; SAN-FRANCISCO; SAFER SEX AB Individuals who use illicit stimulants, primarily cocaine and methamphetamine, engage in substantial amounts of HIV-related sexual risk behaviors when under the influence. This paper presents the idea that reductions in stimulant use consequent to drug treatment makes stimulant drug treatment an important HIV prevention tool for this high-risk population. Data are presented to describe many of the HIV-related sexual risks reported by out-of-treatment methamphetamine users and by cocaine and methamphetamine abusers at treatment entry and six months post treatment entry. Overall, our findings demonstrate that following initiation of a treatment episode, stimulant abusers demonstrate significant and relevant reductions in HIV-related sexual behaviors, primarily by reducing the number of sexual partners. Rea sons for why stimulant treatment corresponds to HIV transmission risk reductions and suggestions for implementing prevention messages in treatment settings are offered. C1 Matrix Ctr, Friends Res Inst Inc, Los Angeles, CA 90025 USA. Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Rawson, RA (reprint author), Matrix Ctr, Friends Res Inst Inc, 10350 Santa Monica Blvd,Suite 330, Los Angeles, CA 90025 USA. OI Shoptaw, Steven/0000-0002-3583-0026 FU NIDA NIH HHS [R44 DA08786]; PHS HHS [H204213] NR 48 TC 43 Z9 46 U1 4 U2 7 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 1998 VL 17 IS 4 BP 19 EP 32 PG 14 WC Substance Abuse SC Substance Abuse GA 142FP UT WOS:000077189700003 PM 9848029 ER PT J AU Ashofteh, A Lau, BSF Setoda, D Ling, W AF Ashofteh, A Lau, BSF Setoda, D Ling, W TI Identifying methadone abuse in patients receiving LAAM SO JOURNAL OF ADDICTIVE DISEASES LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, MDRU, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 1998 VL 17 IS 2 MA 34A BP 170 EP 170 PG 1 WC Substance Abuse SC Substance Abuse GA ZH303 UT WOS:000073093900046 ER PT J AU Bush, R Sanchez, H Geisler, D AF Bush, R Sanchez, H Geisler, D TI Baba ghanoush anaphylaxis due to a "hidden" food allergen. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 William S Middleton Mem Vet Adm Hosp, Madison, WI USA. Univ Wisconsin, Madison, WI 53706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1998 VL 101 IS 1 MA 134 BP S31 EP S31 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA YW339 UT WOS:000071924800135 ER PT J AU Crawford, WW Castle, SC Klaustermeyer, WB AF Crawford, WW Castle, SC Klaustermeyer, WB TI Clinical markers of cell-mediated immunity and atopy in elderly outpatients SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1998 VL 101 IS 1 MA 1036 BP S250 EP S250 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA YW339 UT WOS:000071924801032 ER PT J AU Sanchez, H Geisler, D Bush, R AF Sanchez, H Geisler, D Bush, R TI Detection of peanut proteins in foods by immunoblot-polymerase chain reaction (PCR) assay. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 Univ Wisconsin, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1998 VL 101 IS 1 MA 999 BP S241 EP S241 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA YW339 UT WOS:000071924800995 ER PT J AU Sanchez, H Geisler, D Bush, R AF Sanchez, H Geisler, D Bush, R TI Identification of Alt a 2 in native and recombinant Alternaria preparations. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 Univ Wisconsin, Madison, WI 53706 USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1998 VL 101 IS 1 MA 360 BP S86 EP S86 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA YW339 UT WOS:000071924800360 ER PT J AU Yusin, JS Crawford, WW Clements, PJ Klaustermeyer, WB AF Yusin, JS Crawford, WW Clements, PJ Klaustermeyer, WB TI Hemolytic uremic syndrome thrombotic thrombocytopenic purpura (HUS/TTP) associated renal failure in a patient with scleroderma: A case report SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1998 VL 101 IS 1 MA 506 BP S122 EP S122 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA YW339 UT WOS:000071924800506 ER PT J AU Morrell, MJ Badr, MS AF Morrell, MJ Badr, MS TI Effects of NREM sleep on dynamic within-breath changes in upper airway patency in humans SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE respiratory control; breathing; sleep apnea; obstruction ID TOTAL PULMONARY RESISTANCE; LUNG-VOLUME; APNEA; WAKEFULNESS; COLLAPSIBILITY; HYPERCAPNIA; VENTILATION; VELOPHARYNX; RESPIRATION; OCCLUSION AB The purpose of our study was to compare inspiratory-and expiratory-related changes in retropalatal cross-sectional area (CSA) during wakefulness to those during non-rapid-eye-movement (NREM) sleep. We studied 18 subjects in whom the severity of sleep-disordered breathing varied. Relative changes in CSA were visualized by using fiber-optic endoscopy. For each breath analyzed (wakefulness n = 4-13; sleep n = 7-16), the CSA was measured at fixed points within inspiration and expiration (0, 25, 50, and 100% of the inspiratory and expiratory duration); these measurements were expressed as a percentage of the CSA that occurred at the start of inspiration. During wakefulness, there was a statistically significant increase in the retropalatal CSA (compared with the start of inspiration) only during early expiration (group mean: expiration, 0% = 112.6 +/- 3.2 (SE) %; 25% = 122.8 +/- 6.2%; 50% = 110.6 +/- 3.8%). In contrast, during sleep, significant changes in CSA occurred during both inspiration and expiration (group mean: inspiration, 25% = 75.3 +/- 6.0%; 50% = 66.7 +/- 7.7%; 75% = 64.6 +/- 8.1%; expiration, 0% = 126.8 +/- 11.8%; 25% = 125.3 +/- 6.9%). The expiratory-related increase in CSA was followed by narrowing such that at end expiration the caliber of the airway was returned to that occurring at the beginning of inspiration (group mean at end expiration = 98.6 +/- 3.1%). The largest changes in CSA occurred in the subjects with an increased body mass index (BMI). We conclude that, during NREM sleep, significant changes in CSA occur during both inspiration and expiration and that the magnitude of these changes is significantly influenced by BMI. C1 William S Middleton Mem Vet Hosp, Dept Med, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Dept Prevent Med, John Rankin Lab Pulm Med, Madison, WI 53705 USA. RP Morrell, MJ (reprint author), Imperial Coll, Sch Med, Natl Heart Lung Inst, St Dunstans Rd, London W6 8RP, England. EM m.morrell@cxwms.ac.uk FU PHS HHS [53443] NR 36 TC 34 Z9 34 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 1998 VL 84 IS 1 BP 190 EP 199 PG 10 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA YR127 UT WOS:000071461000025 PM 9451635 ER PT J AU Kurihara, N Ishizuka, S Tatsumi, J Arai, F Ikeda, K Roodman, GD AF Kurihara, N Ishizuka, S Tatsumi, J Arai, F Ikeda, K Roodman, GD TI 23(S)25(R)-1,25-dihydroxyvitamin D-3-lactone, a naturally occurring metabolite of 1,25-dihydroxyvitamin D-3, inhibits osteoclast-like cell formation in human bone marrow cultures SO JOURNAL OF BONE AND MINERAL METABOLISM LA English DT Article DE 1,25(OH)(2)D-3; 1,25(OH)(2)D-3-lactone; osteoclast-like cell ID MULTINUCLEATED CELLS; 1-ALPHA,25-DIHYDROXYVITAMIN D3-26,23-LACTONE; BIOLOGICAL-ACTIVITY; PHENOTYPE; DIASTEREOISOMERS; PRECURSORS AB We have used a human bone marrow culture system that forms multinucleated cells (MNCs), 50% of which express the osteoclast phenotype, to examine the 23(S)25(R)-1,25-dihydroxyvitamin D-3-26,23-lactone (1,25-D-3-lactone) on osteoclast-like cell formation. The 1,25-D-3-lactone is a vitamin D-3 metabolite that has recently been detected in human serum under physiological conditions at concentrations of approximately 131 pg/ml (3 x 10(-10) M) and can inhibit bone resorption induced by 1,25-dihvdroxyvitamin D-3 (1,25-D-3) in vivo and in vitro. We examined the effects of the 1,25-D-3-lactone on the formation of MNC that cross-reacted with 23C6 monoclonal antibody (23C6-positive MNC), which preferentially binds to osteoclasts. All metabolites of 1,25-D-3 except the 1,25-D-3-lactone increased both total and 23C6-positive MNC formation in a dose-dependent manner. In contrast. the 1,25 D-3-lactone inhibited both total and 23C6-positive MNC formation, whether the cultures were treated with 1,25-D-3, parathyroid hormone, or interleukin-1 beta, all potent stimulators of MNC formation. This inhibitory action of 1,25-D-3-lactone on MNC formation was very similar to the inhibitory effects of calcitonin. These data suggest that (1) 1,25-D-3-lactone is a potent natural inhibitor of formation of cells with the osteoclast phenotype at physiological concentrations and (2) the inhibition of these cells by 1,25-D-3-lactone may not result solely from its competitive binding to the 1,25-D-3 receptor. C1 Meikai Univ, Dept Periodontol, Sakado, Saitama 3500283, Japan. Audie L Murphy Mem Vet Hosp, Res Serv, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. Teijin Inst Biomed Res, Hino, Tokyo 191, Japan. RP Kurihara, N (reprint author), Meikai Univ, Dept Periodontol, 1-1 Keyakidai, Sakado, Saitama 3500283, Japan. RI Arai, Fumio/J-5241-2013 OI Arai, Fumio/0000-0003-1936-4907 NR 20 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113, JAPAN SN 0914-8779 J9 J BONE MINER METAB JI J. Bone Miner. Metab. PY 1998 VL 16 IS 1 BP 5 EP 10 DI 10.1007/s007740050021 PG 6 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA 135AW UT WOS:000076778100002 ER PT J AU VanRemmen, H Williams, MD Yang, H Walter, CA Richardson, A AF VanRemmen, H Williams, MD Yang, H Walter, CA Richardson, A TI Analysis of the transcriptional activity of the 5'-flanking region of the rat catalase gene in transiently transfected cells and in transgenic mice SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID GLUTATHIONE-PEROXIDASE GENE; AMINO-ACID-SEQUENCE; SUPEROXIDE-DISMUTASE; NUCLEOTIDE-SEQUENCE; ANTIOXIDANT ENZYMES; MAMMALIAN-CELLS; DNA; EXPRESSION; LIVER; CDNA AB Transiently transfected cell lines and transgenic mice were used to study the transcriptional activity of the 5'-flanking region of the catalase gene, Fragments of the 5'-flanking region of the rat catalase gene ranging in length from 3,421 base pairs (bp) to 69 bp were fused to the chloramphenicol acetyltransferase (CAT) reporter gene, and the transcriptional activity of the reporter gene was measured following transient transfection in three cell lines: a human hepatoma cell line (HepG2), a porcine kidney epithelial cell line (LLCPK1), and a human glioma cell line (U-138 MG). The 3,421-bp fragment of the 5'-flanking region resulted in a high level of expression of the reporter gene in all three cell lines. Shorter fragments of the 5'-flanking region resulted in a decrease in the level of CAT reporter expression that varied among the three cell lines, implying the presence of tissue-specific regulatory sites. To study the tissue-specific regulation of the catalase promoter, transgenic mice containing the 3,421-bp 5'-flanking sequence attached to the CAT reporter gene were produced, and CAT expression was measured in various tissues of three independent transgenic lines. CAT activ- ity was consistently high in muscle tissue (heart, skeletal muscle, and diaphragm) and low in most other tissues studied, particularly in liver and kidney. In contrast, the endogenous expression of catalase is low in muscle and high in liver and kidney; thus, the tissue-specific expression of the reporter gene driven by the 3,421-bp fragment of the 5'-flanking region of the catalase gene was not similar to the expression of the endogenous catalase gene. (C) 1998 Wiley-Liss, Inc. C1 S TEXAS VET HLTH CARE SYST,CTR GERIATR RES EDUC & CLIN,AUDIE L MURPHY DIV,SAN ANTONIO,TX. UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284. FU NIA NIH HHS [AG01548] NR 35 TC 22 Z9 22 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 1998 VL 174 IS 1 BP 18 EP 26 DI 10.1002/(SICI)1097-4652(199801)174:1<18::AID-JCP3>3.0.CO;2-J PG 9 WC Cell Biology; Physiology SC Cell Biology; Physiology GA YH655 UT WOS:A1998YH65500003 PM 9397152 ER PT J AU Awumey, EMK Mitra, DA Hollis, BW Kumar, R Bell, NH AF Awumey, EMK Mitra, DA Hollis, BW Kumar, R Bell, NH TI Vitamin D metabolism is altered in Asian Indians in the southern United States: A clinical research center study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID D-ENDOCRINE SYSTEM; D DEFICIENCY; PLASMA 25-HYDROXYVITAMIN-D; IMMIGRANT POPULATION; NUTRITIONAL RICKETS; WHITE-CHILDREN; BONE; BLACK; RADIOIMMUNOASSAY; OSTEOMALACIA AB Asian Indians who immigrate to northern Europe have lower serum 25-hydroxyvitamin D [25(OH)D] than Caucasians, and they develop vitamin D deficiency, rickets, and osteomalacia. We investigated vitamin D metabolism, the effects of 25(OH)D, on vitamin D metabolism and activity of 25(OH)D-24-hydroxylase, the rate-limiting enzyme for degradation of 25(OK)D, from cultured skin fibroblasts of Asian Indians and compared them with cultured skin fibroblasts of Caucasians in the southern United States. Normal subjects, ages 20-40 yr, were admitted to a metabolic ward for 2.5 days and given a daily diet containing 400 mg calcium and 900 mg phosphorus. Serum vitamin D, serum 25(OH)D, urinary calcium, and urinary phosphorus were significantly lower, whereas serum immunoreactive intact parathyroid hormone (PTH) and serum 1,25-dihydroxy vitamin D [1,25(OH)(2)D] were significantly higher in Asian Indians than in Caucasians. Administration of 25(OH)D-3 increased serum 25(OH)D and urinary calcium but did not change serum PTH or serum 1,25(OK)(2)D in Asian Indians. In cultured skin fibroblasts, E-max and V-max of 25(OH)D-24-hydroxylase activity were significantly higher in Asian Indians. In summary, in Asian Indians serum vitamin D and 25(OH)D are markedly reduced, altered vitamin D metabolism is only partially reversed by 25(OH)D-3, and 25(OH)D-24-hydroxylase activity in cultured skin fibroblasts is markedly increased. Thus, Asian Indians residing in the U.S. are at risk for developing vitamin D deficiency, rickets, and osteomalacia. C1 Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29401 USA. Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. RP Bell, NH (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA. RI Osborne, Nicholas/N-4915-2015 OI Osborne, Nicholas/0000-0002-6700-2284 FU NCRR NIH HHS [MO1 RR0170]; NIAMS NIH HHS [R01 AR 36066]; NIDDK NIH HHS [R01 DK025409, DK 25409] NR 39 TC 102 Z9 104 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 1998 VL 83 IS 1 BP 169 EP 173 DI 10.1210/jc.83.1.169 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YP375 UT WOS:000071270600031 PM 9435436 ER PT J AU Revankar, SG Kirkpatrick, WR McAtee, RK Fothergill, AW Redding, SW Rinaldi, MG Patterson, TF AF Revankar, SG Kirkpatrick, WR McAtee, RK Fothergill, AW Redding, SW Rinaldi, MG Patterson, TF TI Interpretation of trailing endpoints in antifungal susceptibility testing by the national committee for clinical laboratory standards method SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CANDIDA-ALBICANS; CHROMOGENIC AGAR; FLUCONAZOLE; RESISTANCE AB Trailing endpoints remain a problem in antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards (NCCLS) method, For isolates for which trailing endpoints are found, MICs of less than or equal to 1 mu g/ml at 24 h and of >64 mu g/ml at 48 h are usually observed. In a study of human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis, we identified three patients with multiple serial isolates for which trailing endpoints were observed,vith fluconazole. At 24 h, MICs were generally less than or equal to 1 mu g/ml by both broth macro-and microdilution methods, However, at 48 h, MICs were >64 mu g/ml, while the organism remained Susceptible by agar dilution testing with fluconazole, Most episodes of oropharyngeal candidiasis with trailing-endpoint isolates responded to doses of fluconazole as low as 100 mg/day. Two patients had both susceptible and trailing-endpoint isolates by NCCLS broth macro-and microdilution testing; these isolates were found to be the same strain by pulsed-field gel electrophoresis using restriction fragment length polymorphisms, Another patient had two different strains, one for which trailing endpoints were observed and one which was susceptible at 48 h, Trailing endpoints may be seen,vith selected isolates of a strain or may be a characteristic finding for most or all isolates of a strain, In addition, with isolates for which trailing endpoints are observed, reading the endpoint for the NCCLS method at 24 h may be more appropriate. C1 Univ Texas, Hlth Sci Ctr, Dept Med Infect Dis, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. RP Revankar, SG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NCRR NIH HHS [M01 RR001346, MO1-RR-01346]; NIDCR NIH HHS [1 RO1 DE11381-01, R01 DE011381] NR 15 TC 74 Z9 79 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 1998 VL 36 IS 1 BP 153 EP 156 PG 4 WC Microbiology SC Microbiology GA YM068 UT WOS:000071024700031 PM 9431939 ER PT J AU Meltzer, HY Casey, DE Garver, DL Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Measuring outcome in schizophrenia: Differences among the atypical antipsychotics SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID DOUBLE-BLIND; OLANZAPINE TRIAL; RISPERIDONE; PLACEBO; HALOPERIDOL; CLOZAPINE; QUALITY; SCALE; LIFE; MULTICENTER AB The advent of the atypical antipsychotics marked a new era in the history of the treatment of psychotic disorders. To evaluate the published literature about the available atypical antipsychotics-clozapine, risperidone, olanzapine, and quetiapine-and select the most appropriate treatment for specific patients, physicians need to understand the outcome measures used in clinical studies, the pharmacologic differences that explain varying side effect profiles, and pharmacoeconomic assessments that are used in the decision-making process. While the atypical antipsychotics have established efficacy in the overall treatment of schizophrenia, they may differ in their effects on factors such as cognitive function, overall quality of life, adverse events, and hospitalization status. Each of these factors should be considered when weighing treatment options for an individual patient. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Ann Arbor, MI USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 40 TC 35 Z9 36 U1 1 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 3 EP 9 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700001 ER PT J AU Cummings, JL AF Cummings, JL TI Alzheimer's disease management - Introduction SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material ID PREVALENCE C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Neurobehav & Neuropsychiat Program, Los Angeles, CA 90073 USA. RP Cummings, JL (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. NR 3 TC 4 Z9 4 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 13 BP 4 EP 5 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120VJ UT WOS:000075977800001 PM 9771824 ER PT J AU Small, GW Leiter, F AF Small, GW Leiter, F TI Neuroimaging for diagnosis of dementia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 149th Annual Meeting of the American-Psychiatric-Association CY MAY 04-09, 1996 CL NEW YORK, NEW YORK SP Amer Psychiat Assoc ID POSITRON EMISSION TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; E TYPE-4 ALLELE; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; EPSILON-4 ALLELE; DEPRESSION; RISK; LIFE AB Although many clinicians consider neuroimaging studies as optional for the differential diagnosis of dementia, clinical experience suggests that they can improve diagnostic accuracy. Data are limited, however, on sensitivity, specificity, and cost-effectiveness of various neuroimaging techniques. The author reviews advantages and disadvantages of neuroimaging techniques for the differential diagnosis of dementia and describes strategies used for early detection of Alzheimer's disease, including combining positron emission tomography scanning with genetic risk assessment. Such approaches could provide a means for in vivo therapeutic monitoring of brain function during experimental antidementia treatment trials. C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Aging, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Small, GW (reprint author), Univ Calif Los Angeles, Inst Neuropsychiat, 760 Westwood Plaza, Los Angeles, CA 90024 USA. FU NIA NIH HHS [1T32 AG00245, 1RO1 AG13308]; NIMH NIH HHS [1RO1 MH52453] NR 32 TC 24 Z9 26 U1 2 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 11 BP 4 EP 7 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 115LE UT WOS:000075665700002 PM 9731543 ER PT J AU Raskind, MA AF Raskind, MA TI The clinical interface of depression and dementia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Late Life Depression - Complex Problems, New Strategies CY MAY 20, 1997 CL SAN DIEGO, CALIFORNIA ID ALZHEIMERS-DISEASE; TRIAL AB The interface between depression and dementia is complex and has been studied primarily in Alzheimer's disease. This article discusses several aspects of this intriguing area of clinical research, including depressive pseudodementia and the possibility that depression may be a risk factor for the expression of Alzheimer's disease in later life and that depression may occur as a prodrome for this most common dementing disorder. In addition, the treatment challenges faced by clinicians when depression complicates the course of Alzheimer's disease are addressed. It is likely that a combination of behavioral treatment and use of antidepressant medication will, provide the optimal management of depression in Alzheimer's disease. C1 VA Puget Sound Hlth Care Syst, Mental Hlth Serv 116, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv 116, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 22 TC 30 Z9 32 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 10 BP 9 EP 12 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 111NF UT WOS:000075443400003 PM 9720476 ER PT J AU Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Clinical development of atypical antipsychotics: Research design and evaluation SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID BLIND OLANZAPINE TRIAL; SCHIZOPHRENIC-PATIENTS; PARALLEL-GROUP; HALOPERIDOL; PLACEBO; RISPERIDONE; MULTICENTER; QUETIAPINE; CHLORPROMAZINE; CLOZAPINE AB Clinical trials support the efficacy and safety of new drugs on the market. They provide the United States Food and Drug Administration with the information needed to approve an Investigational New Drug application and are the basis for package inserts provided by the manufacturers that guide clinicians in the use of a new drug. Because clinical trials are vital to the effective and safe use of new drugs, it is important to understand who participates in them, what questions are answered by clinical trials, and what questions are raised. The reader who asks the proper questions about issues such as methodology, affiliations of the investigators, statistical analyses performed, location of study centers, and study populations will derive the most information from the report of a clinical trial. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 25 TC 0 Z9 0 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 10 EP 16 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700002 ER PT J AU Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Adverse effects of the atypical antipsychotics SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID BLIND OLANZAPINE TRIAL; SCHIZOPHRENIC PATIENTS; CLOZAPINE; HALOPERIDOL; RISPERIDONE; PLACEBO; DRUGS; SERTINDOLE; DOPAMINE; MULTICENTER AB Adverse effects of antipsychotics often lead to noncompliance. Thus, clinicians should address patients' concerns about adverse effects and attempt to choose medications that will improve their patients' quality of life as well as overall health. The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics. Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain. The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only). Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely-to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 57 TC 5 Z9 8 U1 2 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 17 EP 22 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700003 ER PT J AU Marder, SR AF Marder, SR TI Facilitating compliance with antipsychotic medication SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SCHIZOPHRENIC-PATIENTS; SUBSTANCE-ABUSE; PSYCHIATRIC-SYMPTOMS; TARDIVE-DYSKINESIA; CLOZAPINE; RISPERIDONE; ADHERENCE; RELAPSE; IMPACT AB Noncompliance with medication is common among patients who have schizophrenia and is a leading cause of rehospitalization in this population. Both standard and subjective risk-factor assessments have been used to identify patients who are likely to refuse or discontinue treatment. Noncompliant patients who have schizophrenia commonly have been treated with potent D-2 dopamine-receptor antagonists and therefore may have experienced extrapyramidal side effects. The newer antipsychotics (i.e., serotonin-dopamine antagonists) are efficacious in reducing the symptoms of schizophrenia without associated dysphoria and motor side effects. Clozapine and other newer antipsychotics may improve certain aspects of cognition. The improved psychiatric state and cognitive function may facilitate "involved compliance" as a result of increased insight, awareness, and judgment. These cognitive faculties allow patients to appreciate their improved state and take steps to maintain it. The periodic visits for blood monitoring mandated for clozapine therapy also facilitate the formation of a therapeutic alliance that allows the clinician to monitor compliance. Facilitating involved compliance this way among patients who have schizophrenia may reduce the cost of this disorder to society. C1 W Los Angeles Vet Affairs Med Ctr, Psychiat Dept 116A, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Marder, SR (reprint author), W Los Angeles Vet Affairs Med Ctr, Psychiat Dept 116A, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 57 TC 75 Z9 78 U1 4 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 3 BP 21 EP 25 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA ZE878 UT WOS:000072840700004 PM 9541334 ER PT J AU Peskind, ER AF Peskind, ER TI Pharmacologic approaches to cognitive deficits in Alzheimer's disease SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on New Strategies for Treating Alzheimer's Disease CY AUG 02, 1997 CL CHICAGO, ILLINOIS SP Bayer Corp ID ESTROGEN REPLACEMENT THERAPY; CONTROLLED TRIAL; DOUBLE-BLIND; CHOLINERGIC NEURONS; SELECTIVE LOSS; L-DEPRENYL; DEMENTIA; TACRINE; MEMORY; PHYSOSTIGMINE AB This article reviews placebo-controlled studies addressing drug efficacy for the cognitive deficits of Alzheimer's disease. Efforts to compensate for the presynaptic cholinergic deficiency in Alzheimer's disease by pharmacologically inhibiting acetylcholine degradation have been successful in several clinical trials. Two cholinesterase inhibitors are available for Alzheimer's disease, and others most likely will soon be available. Cholinesterase inhibitors represent the only therapy currently approved for the treatment of Alzheimer's disease. The antioxidant drugs alpha-tocopherol (vitamin E) and selegiline have been demonstrated marginally superior to placebo for slowing functional deterioration in patients with moderately advanced Alzheimer's disease. Epidemiologic studies suggest protective effects against Alzheimer's disease from postmenopausal estrogen replacement and nonsteroidal antiinflammatory drugs. Placebo-controlled studies prospectively evaluating the hypotheses generated by these epidemiologic studies are ongoing. C1 VA Puget Sound Hlth Care Syst, Mental Hlth Serv 116, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Mental Illness Res & Educ & Clin Ctr, MIRECC, Seattle, WA 98195 USA. RP Peskind, ER (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv 116, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 46 TC 22 Z9 22 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 9 BP 22 EP 27 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 113HP UT WOS:000075545200004 PM 9720483 ER PT J AU Cummings, JL Masterman, DL AF Cummings, JL Masterman, DL TI Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Alzheimer's Disease Management - Algorithmic Strategies for Diagnosis and Treatment CY MAY 17, 1997 CL SAN DIEGO, CALIFORNIA SP Amer Psychiat Assoc ID CONTROLLED TRIAL; RATING-SCALE; PSYCHIATRIC-SYMPTOMS; EXTRAPYRAMIDAL SIGNS; PRIMARY DEMENTIA; NURSING-HOMES; DOUBLE-BLIND; DELUSIONS; PSYCHOSIS; TACRINE AB Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and neurologic manifestations. Behavioral changes should be assessed as part of a comprehensive evaluation of the effects of cholinergic treatment of Alzheimer's disease. The psychometric properties, origin, source of behavioral information, content, and administration requirements of tools used to assess behavior in Alzheimer's disease affect the type of information garnered and the conclusions that can be derived. Assessment of drug-related behavioral changes can be affected by spontaneous remission of neuropsychiatric symptoms, differing baseline severity of behavioral abnormalities, uncertain magnitude of expected treatment effects, and by the influence of disease stages, concurrent medications, and comorbid conditions. Cholinergic therapies ameliorate behavioral alteration in Alzheimer's disease, and changes in behavior should be monitored when such therapy is initiated. C1 Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Neurobehav & Neuropsychiat Program, Los Angeles, CA 90073 USA. RP Cummings, JL (reprint author), Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA. FU NIA NIH HHS [AG10123] NR 80 TC 21 Z9 22 U1 4 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 13 BP 23 EP 30 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120VJ UT WOS:000075977800004 PM 9771827 ER PT J AU Meltzer, HY Casey, DE Garver, DL Lasagna, S Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Lasagna, S Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Assessment of EPS and tardive dyskinesia in clinical trials SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID DOUBLE-BLIND; ANTIPSYCHOTIC-DRUGS; OLANZAPINE TRIAL; SCHIZOPHRENIA; HALOPERIDOL; RISPERIDONE; PLACEBO; CLOZAPINE; SYMPTOMS; MULTICENTER AB The incidence of acute extrapyramidal symptoms (EPS)-akathisia, dystonia, and parkinsonism-associated with traditional antipsychotics varies, but most researchers agree that neuroleptic-induced EPS occur in 50% to 75% of patients who take conventional antipsychotics. Atypical antipsychotics were developed to widen the therapeutic index and to reduce EPS. Although the mechanisms are unclear, the risk of EPS is less with the novel antipsychotics than with conventional drugs, and agents that produce low levels of acute EPS are likely to produce less tardive dyskinesia. Nevertheless; clinicians should exercise caution when comparing data from investigations of the novel antipsychotics and, until long-term data become available, should administer the new drugs at doses below the EPS-producing level. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 27 TC 0 Z9 0 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 23 EP 27 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700004 ER PT J AU Meltzer, HY Casey, DE Garver, DL Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Assessing the effects of atypical antipsychotics on negative symptoms SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID DOUBLE-BLIND; SCHIZOPHRENIC-PATIENTS; REFRACTORY SCHIZOPHRENIA; NEUROLEPTIC TREATMENT; RISPERIDONE; HALOPERIDOL; PLACEBO; OLANZAPINE; CLOZAPINE; TRIAL AB Attempts to clarify the domains of schizophrenia gained importance when the atypical antipsychotics joined the armamentarium of schizophrenia treatments because of evidence that these agents art: superior to conventional antipsychotics for the treatment of negative symptoms. Negative symptoms can be divided into 3 components: (1) deficit or primary enduring negative symptoms that may or may not respond to treatment, (2) primary nonenduring negative symptoms, and (3) secondary negative symptoms that are associated with positive symptoms, extrapyramidal symptoms, depression, and environmental deprivation. The atypical antipsychotics have generally been found to be more effective than conventional antipsychotics against the totality of negative symptoms, but their effects on specific components are still under study. Sophisticated statistical tools such as path analysis have been used in investigations of the direct and indirect effects of atypical antipsychotics on negative symptoms, but these tools have limitations. Future study is needed to identify specific components of negative symptoms that may respond preferentially to one or another of the atypical antipsychotics. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 47 TC 7 Z9 7 U1 4 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 28 EP 34 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700005 ER PT J AU Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Evaluating the effects of antipsychotics on cognition in schizophrenia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID NEGATIVE SYMPTOMS; CLOZAPINE; DYSFUNCTION; RISPERIDONE; IMPROVEMENT; DEFICITS; DECLINE; AGENTS; MEMORY AB Cognitive deficits are an integral feature of schizophrenia and have a deleterious effect on the ability of schizophrenic patients to work and function in a social environment. Drugs that bring about substantial cognitive improvement represent a major contribution in improving the quality of life in schizophrenia. Recent studies have suggested that the atypical antipsychotics may be more useful than conventional agents for improving cognition. There is evidence that scores on neuropsychological assessments have improved after treatment with clozapine, risperidone, and quetiapine. Future research is needed to characterize and quantify the cognitive effects of the atypical antipsychotics. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 22 TC 2 Z9 2 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 35 EP 40 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700006 ER PT J AU Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID PSYCHOTIC MOOD DISORDERS; SCHIZOAFFECTIVE DISORDER; NEGATIVE SYMPTOMS; RISPERIDONE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; SCALE; MANIA AB Depression in schizophrenia may be partially responsible for the increased suicide rate in schizophrenic patients, which is more than 20 times higher than that found in the general population. Affective disorders in patients with schizophrenia are associated with a poor outcome, an increased risk of relapse, and a high rate of suicide. There is evidence that atypical antipsychotics may contribute to a reduction in suicidality, and although the new drugs are marketed for the treatment of schizophrenia, their novel psychopharmacologic effects suggest the possibility of other therapeutic applications. Recent studies of the efficacy of the novel antipsychotics found that these agents may produce an antidepressant effect in schizophrenia and may be used as either an adjunctive medication or an alternative to mood stabilizers in patients with affective disorders. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 28 TC 1 Z9 1 U1 4 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 41 EP 45 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700007 ER PT J AU Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R AF Meltzer, HY Casey, DE Garver, DL Lasagna, L Marder, SR Masand, PS Miller, D Pickar, D Tandon, R CA Collaborative Working Grp Clinical Trial Evalua TI Treatment of special populations with the atypical antipsychotics SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Closed Symposium Clinical Trial Evaluations and Outcome Measures in Psychiatry CY NOV 21, 1997 CL CHICAGO, ILLINOIS ID RISPERIDONE; SCHIZOPHRENIA; CLOZAPINE; DISORDERS; PSYCHOSIS; SYMPTOMS; EFFICACY AB Atypical antipsychotics have become the treatment of choice for patients experiencing a first episode of schizophrenia. In addition, they are often prescribed for conditions such as bipolar disorder and dementia. While clinical trials have not yet established the efficacy of the atypical antipsychotics for these uses, a number of reports offer preliminary evidence that the atypical antipsychotics may be beneficial for affective disorders, substance abuse disorder, senile dementia, and pathologic aggression. Atypical agents may be particularly effective and tolerable in elderly patients who are especially susceptible to the adverse effects of conventional antipsychotic medication. Lower dosages are more necessary for the elderly than for younger adults. Current evidence suggests that clozapine is the most effective atypical antipsychotic for neuroleptic-resistant patients. Risperidone, olanzapine, and quetiapine may also be effective in a subset of these patients. C1 Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Psychiat Serv, Portland, OR USA. Vet Affairs N Texas Med Ctr, Dallas, TX USA. Tufts Univ, Boston, MA 02111 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. SUNY Hlth Sci Ctr, Dept Psychiat, Syracuse, NY 13210 USA. Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. NIMH, Intramural Res Program, Bethesda, MD 20892 USA. Univ Michigan, Med Ctr, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Meltzer, HY (reprint author), Vanderbilt Univ, Sch Med, Dept Psychiat, Div Psychopharmacol, 1601 23rd Ave S,Suite 306, Nashville, TN 37212 USA. RI Meltzer, Herbert/E-8131-2013 NR 35 TC 1 Z9 1 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1998 VL 59 SU 12 BP 46 EP 52 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 120FD UT WOS:000075943700008 ER PT J AU Van Dijk, S Griffiths, GR Everett, MM Liu, Y You, SH Dean, DD Schwartz, Z Boyan, BD AF Van Dijk, S Griffiths, GR Everett, MM Liu, Y You, SH Dean, DD Schwartz, Z Boyan, BD TI Role of alkaline phosphatase and proteolipid in mineralization of E-coli. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Hebrew Univ Jerusalem, Jerusalem, Israel. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1998 VL 77 SI A MA 35 BP 110 EP 110 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA YU125 UT WOS:000071684800035 ER PT J AU Burgess, JO Douglas, AS AF Burgess, JO Douglas, AS TI Microleakage of root filled teeth. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 LSUMC, Sch Dent, New Orleans, LA USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1998 VL 77 SI A MA 1105 BP 244 EP 244 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA YU125 UT WOS:000071684801109 ER PT J AU Mikulik, RW Alder, ME McAnear, JT AF Mikulik, RW Alder, ME McAnear, JT TI CT titanium attenuation varies with implant alignment, symmetry, and quantity. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1998 VL 77 SI A MA 1309 BP 269 EP 269 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA YU125 UT WOS:000071684801302 ER PT J AU Summitt, JB Miller, B Buikema, DJ Chan, DCN AF Summitt, JB Miller, B Buikema, DJ Chan, DCN TI Shear bond strength of Amalgambond Plus cold and at room temperature. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1998 VL 77 SI A MA 1345 BP 274 EP 274 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA YU125 UT WOS:000071684801340 ER PT J AU Mcguire, A Moonga, B Rifkin, B AF Mcguire, A Moonga, B Rifkin, B TI Tetracyclines promote osteoclast apoptosis. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 NYU, Coll Dent, New York, NY USA. Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1998 VL 77 SI B MA 726 BP 722 EP 722 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA ZK546 UT WOS:000073335400723 ER PT J AU Durgin, JD Valente, TJ Clark, RA AF Durgin, JD Valente, TJ Clark, RA TI Calreticulin: Down-regulation and transcription factors. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Audie L Murphy Mem Vet Hosp, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 14A EP 14A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700074 ER PT J AU Darville, T Andrews, CW Williams, DM AF Darville, T Andrews, CW Williams, DM TI Tumor necrosis factor-alpha (TNA-alpha) as a mediator of host defense in chlamydial genital tract infection. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA. Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA. Audie L Murphy Mem Vet Hosp, Div Infect Dis, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 39A EP 39A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700203 ER PT J AU Williams, JW Mulrow, CD Dhanda, R Lee, S AF Williams, JW Mulrow, CD Dhanda, R Lee, S TI The course of depression in primary care. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 48A EP 48A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700253 ER PT J AU Doherty, DK Liu, YJ Kellogg, DL AF Doherty, DK Liu, YJ Kellogg, DL TI Endothelin B-2 receptors contribute to resting vascular tone in humans. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Angelo, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 59A EP 59A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700309 ER PT J AU Roesler, JM Livingston, EH Moatamed, F AF Roesler, JM Livingston, EH Moatamed, F TI Paradoxical differences in immunostaining between two separate anti-NCAM/CD56 antibodies in paraffin-embedded issues. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Mol Biol Lab,Dept Surg, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 66A EP 66A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700345 ER PT J AU Lueck, KL Mendez, MF Perryman, KM AF Lueck, KL Mendez, MF Perryman, KM TI Eye movements during reading in Alzheimer's disease SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Neurobehav Unit, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 82A EP 82A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700430 ER PT J AU Gait, S Merriam, GR AF Gait, S Merriam, GR TI Changes in ovarian growth hormone receptor mRNA during development and follicular maturation in rats. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. Univ Washington, Tacoma, WA USA. VA Puget Sound Hlth Care Syst, Tacoma, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 84A EP 84A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700443 ER PT J AU Chen, S McDougall, S Iida-Klein, A Lee, S Hahn, TJ AF Chen, S McDougall, S Iida-Klein, A Lee, S Hahn, TJ TI Regulation of chondrocyte PTH/PTHrP receptor expression by ECM. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles VAMC, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 85A EP 85A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700448 ER PT J AU Schleyer, AM McDonell, MB Fihn, SD AF Schleyer, AM McDonell, MB Fihn, SD TI Relationship between depression and impaired functional status in chronic obstructive pulmonary disease (COPD). SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 89A EP 89A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700468 ER PT J AU Kashefi, C Sawicki, MP AF Kashefi, C Sawicki, MP TI Mutational analysis of the von Hippel-Lindau gene in pancreatic endocrine tumors. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Dept Surg, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 103A EP 103A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700548 ER PT J AU Wang, EH Ebrahimi, SA Wu, AY Sawicki, MP AF Wang, EH Ebrahimi, SA Wu, AY Sawicki, MP TI Mutation of the menin gene in sporadic pancreatic endocrine tumors. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Dept Surg, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 103A EP 103A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700549 ER PT J AU Ko, FC Hahn, TJ McDougall, S Peters, JH AF Ko, FC Hahn, TJ McDougall, S Peters, JH TI Rat chondrocytes adhere avidly to the alternatively spliced V segment of fibronectin. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles VAMC, GRECC, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 141A EP 141A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700752 ER PT J AU Lim, T Lee, S Chen, S Iida-Klein, A McDougall, S Hahn, TJ AF Lim, T Lee, S Chen, S Iida-Klein, A McDougall, S Hahn, TJ TI The alpha v beta 3 vitronectin receptor: Second messenger generation and cell phenotype regulation in mammalian chondrocytes. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles VAMC, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 141A EP 141A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700751 ER PT J AU Prigeon, RL D'Alessio, DA Porte, D AF Prigeon, RL D'Alessio, DA Porte, D TI A precise method for assay of tritiated glucose. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 146A EP 146A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700778 ER PT J AU Lee, JC Stolina, M Sharma, S Lin, Y Dubinett, SM AF Lee, JC Stolina, M Sharma, S Lin, Y Dubinett, SM TI Tumor cyclooxygenase-2 dependent modulation of antitumor immunity in non-small cell lung cancer. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Dept Med,Jonsson Comprehens Canc Ctr, Pulm Immunol Lab,Div Pulm & Crit Care Med, Los Angeles, CA 90024 USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 149A EP 149A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700798 ER PT J AU Nagata, Y Stevens, DL Bryant, AE Guth, PH Finegold, S Chen, RYZ AF Nagata, Y Stevens, DL Bryant, AE Guth, PH Finegold, S Chen, RYZ TI Microcirculatory derangements induced by clostridial exotoxin in rat skeletal muscle. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Vet Affairs Med Ctr, Boise, ID USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 161A EP 161A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700862 ER PT J AU Sebastian, J Blinman, T Lopez, M Livingston, EH AF Sebastian, J Blinman, T Lopez, M Livingston, EH TI Downregulation of interleukin-10 in transformed colonic epithelial cells following co-culture with endothelial cells. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Div Gen Surg, Los Angeles, CA 90034 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 1998 VL 46 IS 1 BP 169A EP 169A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YU124 UT WOS:000071684700908 ER PT J AU Yao, JK Reddy, RD van Kammen, DP AF Yao, JK Reddy, RD van Kammen, DP TI Plasma-specific glutathione peroxidase and symptom severity in schizophrenia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 1998 VL 70 SU 1 BP S66 EP S66 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA YY627 UT WOS:000072167200264 ER PT J AU Alexander, MJ DeSalles, AAF Tomiyasu, U AF Alexander, MJ DeSalles, AAF Tomiyasu, U TI Multiple radiation-induced intracranial lesions after treatment for pituitary adenoma - Case report SO JOURNAL OF NEUROSURGERY LA English DT Article DE radiation-induced tumor; ependymoma; meningioma; cavernous malformation; pituitary adenoma ID CRYPTIC VASCULAR MALFORMATIONS; CRANIAL IRRADIATION; EPENDYMOMAS; MENINGIOMAS; NEOPLASMS; THERAPY AB This 53-year-old man presented with a syncopal episode 31 years after undergoing craniotomy and external-beam radiation for a pituitary macroadenoma. A gadolinium-enhanced magnetic resonance (MR) image of the brain demonstrated a 2.5-cm enhancing mass in the right caudate region that had not been seen on previous studies. A stereotactically guided biopsy procedure was performed to obtain specimens from the mass, which were consistent with ependymoma. The MR image also revealed two additional lesions that appeared to be within the radiation fields: a right temporal meningioma and a left frontal cavernous malformation. A review of the literature found three previous reports in which ependymomas presented after radiation therapy. C1 Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Med Ctr, Dept Pathol, Los Angeles, CA USA. RP Alexander, MJ (reprint author), Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Box 956901, Los Angeles, CA 90095 USA. OI Alexander, Michael/0000-0003-0280-809X NR 33 TC 49 Z9 50 U1 1 U2 2 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD JAN PY 1998 VL 88 IS 1 BP 111 EP 115 DI 10.3171/jns.1998.88.1.0111 PG 5 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA YN287 UT WOS:000071151800016 PM 9420081 ER PT J AU Rolandelli, RH Koruda, MJ Fukuchi, SG Rombeau, JL Stein, TP AF Rolandelli, RH Koruda, MJ Fukuchi, SG Rombeau, JL Stein, TP TI The effect of glutamine- and alanine-enriched total parenteral nutrition on postburn proteolysis in the rat SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY LA English DT Article DE glutamine; alanine; burn; hypermetabolism; catabolism; muscle proteolysis ID SMALL-INTESTINE; MAXIMAL ACTIVITIES; METABOLISM; GLUCOSE; GLUCONEOGENESIS; ENZYMES; MUCOSA; BURN; GUT AB This study compared the effects of total parenteral nutrition (TPN) supplemented with either glutamine (GLN) or alanine (ALA) on postburn proteolysis in the mt. Thirty adult Sprague-Dawley rats underwent catheterization of the superior vena cava and placement of a swivel apparatus. One group (CONTROL, N = 18) was then returned to their cages while the remaining animals (BURN, N = 12) received a full-thickness scald burn (approximately 20% BSA). CONTROL and BURN rats were then randomly assigned to receive TPN supplemented with either GLN or ALA. TPN consisted of dextrose (250 Kcal/Kg BW/day) and crystalline amino acids (0.9 gN/kg BW/day) composed of all essential amino acids, histidine, arginine, glycine, and either ALA or GLN (1.2 g/100 mg). TPN was administered for 3 days after the burn. Urinary 3-methyl histidine (3MH) and nitrogen excretions were determined, and blood amino acids were measured. Both BURN groups had significantly higher 3MH excretion and blood levels of branched chain amino acids (BCAA) and alanine than both CONTROL groups. In both BURN and CONTROL groups, GLN-TPN did not significantly affect 3MH excretion or the blood levels of BCAA or alanine compared with ALA-TPN. In BURN animals, GLN-TPN resulted in significantly higher urinary nitrogen excretion than ALA-TPN resulting in lower nitrogen retention. Compared with ALA-TPN, GLN-TPN produced greater urinary nitrogen losses and did not reduce protein catabolism. (C) Elsevier Science Inc. 1998. C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ N Carolina, Chapel Hill, NC 27515 USA. Univ Med & Dent New Jersey, Camden, NJ USA. Univ N Carolina, Chapel Hill, NC USA. RP Rolandelli, RH (reprint author), Allegheny Univ Hosp, Hahnemann Div, Mail Stop 413,Broad & Vine St, Philadelphia, PA 19102 USA. NR 20 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0955-2863 J9 J NUTR BIOCHEM JI J. Nutr. Biochem. PD JAN PY 1998 VL 9 IS 1 BP 28 EP 30 DI 10.1016/S0955-2863(97)00163-0 PG 3 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA YQ396 UT WOS:000071382600005 ER PT J AU Harris, RA Valenzuela, CF Brozowski, S Chuang, L Hadingham, K Whiting, PJ AF Harris, RA Valenzuela, CF Brozowski, S Chuang, L Hadingham, K Whiting, PJ TI Adaptation of gamma-aminobutyric acid type A receptors to alcohol exposure: Studies with stably transfected cells SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID PROTEIN-KINASE-C; OPERATED CHLORIDE CHANNELS; CHRONIC ETHANOL TREATMENT; HUMAN GABA(A) RECEPTORS; A RECEPTORS; SUBUNIT; EXPRESSION; ALTERS; PHOSPHORYLATION; PHARMACOLOGY AB We studied the adaptation of gamma-aminobutyric acid type A (GABA(A)) receptor function to chronic ethanol exposure in cells stably transfected with the following GABA(A) receptor subunits: alpha-1 beta-2 gamma-2L, alpha-1 beta-2 gamma-2S, alpha-1 beta-3 gamma-2S, alpha-1 beta-1, alpha-5 beta-3 gamma-3 and alpha-6 beta-3 gamma-2S. Chronic exposure to ethanol resulted in a decrease in muscimol-stimulated 36Cl(-) flux and a decrease in modulation of that flux by ethanol, flunitrazepam, methyl-6,7-4-dimethoxy-4-ethyl-beta-carboline-3-carboxylate and pregnanolone without any change in the modulation by pentobarbital or zinc. Direct activation of the GABA(A) receptor by pentobarbital was enhanced by chronic ethanol treatment. Reduction of the action of muscimol, ethanol and flunitrazepam differed in the duration and amount of ethanol required to see an effect. Reduction of the action of ethanol of alpha-1 beta-2 gamma-2L cells occurred within 15 min and was near-maximal for 25 mM ethanol, whereas reduction of the actions of muscimol and flunitrazepam actions required hours of exposure and higher concentrations of ethanol. Chronic ethanol exposure produced a reduction in the E-max value for the action of muscimol for ail six subunit combinations, but quantification of surface receptors by immunolabeling showed no change in GABA(A) receptor density. The differences in alcohol sensitivity and time courses for different effects of ethanol indicate multiple mechanisms of adaptation of GABA(A) receptors. Use of stably transfected cells rules out "subunit substitution" as a mechanism for these changes and points to post-translational changes (e.g., phosphorylation, receptor assembly) as the most likely mechanisms. These in vitro findings are compared with results from in vivo studies. C1 Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO 80262 USA. Merck Sharp & Dohme Neurosci Res Labs, Harlow, Essex, England. RP Harris, RA (reprint author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, C236,4200 E 9th Ave, Denver, CO 80262 USA. EM Adron.Harris@UCHSC.edu FU NIAAA NIH HHS [AA06399, AA03527] NR 44 TC 22 Z9 23 U1 0 U2 0 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JAN PY 1998 VL 284 IS 1 BP 180 EP 188 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YQ672 UT WOS:000071411700024 PM 9435176 ER PT J AU Lieber, CS AF Lieber, CS TI Hepatic and other medical disorders of alcoholism: From pathogenesis to treatment SO JOURNAL OF STUDIES ON ALCOHOL LA English DT Review ID CHRONIC ETHANOL-CONSUMPTION; DOPAMINE-D2 RECEPTOR GENE; ALDEHYDE DEHYDROGENASE-ACTIVITIES; DENSITY-LIPOPROTEIN SUBFRACTIONS; FIRST-PASS METABOLISM; ACID-BINDING PROTEIN; VITAMIN-A DEPLETION; FAT-STORING CELLS; LIVER-DISEASE; BLOOD-ALCOHOL AB The medical risks of moderate and excessive alcohol consumption are reviewed. Current knowledge of metabolism of alcohol, including effects of moderate amounts, on hepatic metabolism and toxicity is summarized, with an evaluation of the relationship between the level of consumption and its effects on nutrients (including retinoids, carotenoids and folate), liver disease and other medical complications of alcoholism, including cardiovascular diseases and cancer. Putative benefits are also considered. Promising therapeutic approaches evolving from newly gained insight in the pathogenesis of medical complications of alcoholism are outlined. C1 MT SINAI SCH MED, DEPT MED, NEW YORK, NY USA. MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY USA. RP Lieber, CS (reprint author), BRONX VET ADM MED CTR, GI LIVER ALCOHOL PROGRAM, 130 W KINGSBRIDGE RD, BRONX, NY 10468 USA. FU NIAAA NIH HHS [AA05934, AA07275, AA11115] NR 195 TC 48 Z9 50 U1 4 U2 7 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 0096-882X J9 J STUD ALCOHOL JI J. Stud. Alcohol PD JAN PY 1998 VL 59 IS 1 BP 9 EP 25 PG 17 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA YL441 UT WOS:A1998YL44100002 PM 9498311 ER PT J AU Duerinckx, AJ Kenagy, JJ Grant, EG AF Duerinckx, AJ Kenagy, JJ Grant, EG TI Planning and cost analysis of digital radiography services for a network of hospitals (the Veterans Integrated Service Network) SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID ATM; PACS; TELERADIOLOGY; RADIOLOGY AB This study analysed the design and cost of a picture archiving and communications system (PACS), computerized radiography (CR) and a wide-area network for teleradiology. The Desert Pacific Healthcare Network comprises 10 facilities, including four tertiary medical centres and one small hospital. Data were collected on radiologists' workloads, and patient and image flow within and between these medical centres. These were used to estimate the size and cash flows associated with a system-wide implementation of PACS, CR and teleradiology services. A cost analysis model was used to estimate the potential cost savings in a filmless radiology environment. ATM technology was selected as the communications medium between the medical centres. A strategic plan and business plan were successfully developed. The cost model predicted the cost-effectiveness of the proposed PACS/CR configuration within four to six years, if the base costs were kept low. The experience gained in design and cost analysis of a PACS/teleradiology network will serve as a model for similar projects. C1 Univ Calif Los Angeles, Serv Radiol, W Los Angeles Vet Affairs Med Ctr, Ctr Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90024 USA. Vet Integrated Serv Network, Desert Pacific Healthcare Network, Long Beach, CA USA. RP Duerinckx, AJ (reprint author), Univ Calif Los Angeles, Serv Radiol, W Los Angeles Vet Affairs Med Ctr, Ctr Med, Mail Route W114,MRI Bld 507,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ajd@ucla.edu NR 22 TC 10 Z9 10 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 1998 VL 4 IS 3 BP 172 EP 178 DI 10.1258/1357633981932163 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 119QH UT WOS:000075907400008 PM 10321046 ER PT J AU Weinberger, LE Sreenivasan, S Markowitz, E AF Weinberger, LE Sreenivasan, S Markowitz, E TI Extended civil commitment for dangerous psychiatric patients SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article AB Mental health clinicians are increasingly held civilly liable for the dangerous acts of their psychiatric patients. One area of liability is the negligent release of involuntarily committed patients who engage in dangerous acts after their hospital discharge, All states have provisions for extended involuntary commitment for mentally ill dangerous patients. We examined extended civil commitment petitions in Los Angeles County, California, and found that the great majority were rejected, While the standard for extended civil commitment in California includes verbal threats of substantial physical harm, deputy district attorneys tended to reject petitions initiated by clinicians when verbal threats were the sole criterion of dangerousness. This tendency by deputy district attorneys can be quite confusing for clinicians, Mental health professionals' liability has sensitized them to the legal implications of patients' verbal threats of harm; attorneys do not incur the same legal liability and are not so sensitized. C1 Univ So Calif, Inst Psychiat Law & Behav Sci, Los Angeles, CA 90086 USA. Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 90086 USA. W Los Angeles Vet Affairs Med Ctr, Dept Psychol, Los Angeles, CA 90073 USA. RP Weinberger, LE (reprint author), Univ So Calif, Inst Psychiat Law & Behav Sci, POB 86125, Los Angeles, CA 90086 USA. NR 12 TC 8 Z9 8 U1 0 U2 0 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 0091-634X J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 1998 VL 26 IS 1 BP 75 EP 87 PG 13 WC Law; Psychiatry SC Government & Law; Psychiatry GA ZF352 UT WOS:000072888900008 PM 9554712 ER PT J AU Beahrs, JO AF Beahrs, JO TI Quantifying psychological victimization: Scientific uncertainty, legal necessity SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; EMPLOYMENT DISCRIMINATION CLAIMS; PERSONALITY; DIAGNOSIS; TRAUMA; IMPACT; SCALE AB Quantifying psychological victimization presents a formidable conundrum for psychiatry and the law. On the one hand, the task is fundamentally uncertain, due to causal complexity that includes disparity between projected image and inner reality, context dependence, volition, and conflicting interests. On the other hand, the task is necessary for just determination in such areas of law as disability assessment, victim impact, compensation, and psychological crimes such as harassment. A multiaxial protocol is proposed to meet this problematic charge. The five dimensions of this protocol are (1) gross estimate of victimization, including severity of the stressor, the degree of resulting impairment, and variably, the degree of the victim's nonresponsibility; (2) reliability; (3) other conditions; (4) conflicts of interest; and (5) evaluator bias. Intuitive estimates are used widely here instead of operationalized criteria, to enhance flexibility and widen relevance. Evaluators are asked to determine and explain the weighting that should be given to different factors and to give a self-statement of their own biases. C1 Portland VA Med Ctr, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Beahrs, JO (reprint author), Portland VA Med Ctr, V-7-MHCV,POB 1035, Portland, OR 97207 USA. NR 69 TC 1 Z9 1 U1 0 U2 2 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 0091-634X J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 1998 VL 26 IS 2 BP 201 EP 214 PG 14 WC Law; Psychiatry SC Government & Law; Psychiatry GA ZY242 UT WOS:000074600500003 PM 9664256 ER PT J AU Payne, TH Savarino, J AF Payne, TH Savarino, J TI Development of a clinical event monitor for use with the Veterans Affairs Computerized Patient Record System and other data sources SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB We are developing an event monitor to operate with the Veterans Affairs Computerized Patient Record System (CPRS). The event monitor is designed to receive messages when important patient events such as posting of new results, patient movement, and orders occur. Our design separates the event monitor from CPRS itself, using communication via a network connection to receive HL7 messages, to access other data needed to run rules, and to communicate with providers by message display, electronic mail and other mechanisms. Results from operation of the event monitor using patient data in our test account show that a wide variety of data can be accessed by the event monitor with acceptable response times. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Payne, TH (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 11 TC 1 Z9 1 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1998 SU S BP 145 EP 149 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3156 UT WOS:000171768600026 ER PT J AU Zacks, MP Hersh, WR AF Zacks, MP Hersh, WR TI Developing search strategies for detecting high quality reviews in a hypertext test collection SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Objective To identify search strategies for retrieving high quality review studies about etiology, prognosis, therapy, and diagnosis from World Wide Web (WWW) medical documents. Design Observational study of the performance of search strategies based on terms found in high quality review articles in a collection of hypertext medical documents from the WWW. Measurements The sensitivity and specificity of search strategies for review articles in general and with a specific focus were determined by comparison to a manual review of a collection of hypertext medical documents. Results A total of 1058 hypertext medical documents from seven governmental and academic WWW sites were included in the study collection. About 169,66 of the documents in the collection met the criteria for high quality review documents. Search strategies for review documents were identified that had 87% sensitivity and 95% specificity. Compared to simple strategies combining the term "review" and the article focus, more complex strategies based on terms found in high quality studies were more sensitive in identifying review articles of a given focus. These more complex strategies had a sensitivity of 83% for diagnosis, 85% for therapy, 79% for prognosis, and 88% for etiology, while the simple strategies had a sensitivity of 88%, 74%, 38%, and 46%, respectively. In addition, the more complex strategies were more specific for high quality review articles on diagnosis and therapy. Conclusion Search strategies can be identified that enhance retrieval of review documents and review documents of specific focus from a collection of WWW hypertext medical documents. C1 Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA. Portland VA Med Ctr, Dept Med, Portland, OR USA. RP Zacks, MP (reprint author), Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA. OI Hersh, William/0000-0002-4114-5148 NR 7 TC 1 Z9 1 U1 0 U2 3 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1998 SU S BP 663 EP 667 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3156 UT WOS:000171768600129 ER PT J AU Anderson, SM McDonell, MB Canody, CC Schreiner, SJ Fihn, SD AF Anderson, SM McDonell, MB Canody, CC Schreiner, SJ Fihn, SD TI Multi-hospital data mart for quality improvement in ambulatory care SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Meeting Abstract AB We have used SQL databases, PC based software tools, high volume network printers, and optical scanning technology to build an information system for a clinical trial that tracks the ambulatory care of over 60,000 patients at seven VA hospitals. The system presents patient information to providers at General Internal Medicine (GIM) clinic visits for 26,800 patients assigned to the intervention group. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1998 SU S BP 967 EP 967 PG 1 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3156 UT WOS:000171768600191 ER PT J AU Lang, WP Borgnakke, WS Richards, PS Nyquist, LV Shipman, BL Bradley, DR Marshall, JG Ronis, DL AF Lang, WP Borgnakke, WS Richards, PS Nyquist, LV Shipman, BL Bradley, DR Marshall, JG Ronis, DL TI Dentists' use and opinions of MEDLINE SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Meeting Abstract C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Toronto, Toronto, ON, Canada. US Dept Vet Affairs, Ann Arbor, MI USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1998 SU S BP 1033 EP 1033 PG 1 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3156 UT WOS:000171768600257 ER PT J AU Paul, RV Wackym, PS Budisavljevic, MN AF Paul, RV Wackym, PS Budisavljevic, MN TI Destabilization of natriuretic peptide C-receptor mRNA by phorbol myristate acetate SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; CLEARANCE RECEPTOR; MESSENGER-RNA; RAT; PROLIFERATION; GROWTH; STIMULATION; EXPRESSION; MEDIATION AB Natriuretic peptide C receptor (NPR-C) expression in rat mesangial cells is downregulated by platelet-derived growth factor (PDGF) and the protein kinase C agonist phorbol myristate acetate (PMA). This study shows that PDGF and PMA diminish NPR-C mRNA abundance and that PMA does so by accelerating the degradation of the transcript. Exposure to PMA (0.1 mu M) decreased mesangial cell NPR-C mRNA levels by more than 50% within 3 h and I-125-atrial natriuretic peptide binding by approximately 50% within 6 h. Disappearance of NPR-C transcripts after PMA treatment was more than twice as rapid as that seen after inhibition of RNA transcription with actinomycin D. Treatment with PDGF A/B (10 ng/ml) also produced downregulation of NPR-C mRNA, but the rate of transcript disappearance was similar to that seen after actinomycin D. Coincubation with actinomycin D inhibited the rapid disappearance of NPR-C mRNA with PMA. NPR-C mRNA levels increased four-to eightfold within 6 h after treatment with the protein synthesis inhibitor cycloheximide, but simultaneous treatment with PMA or PDGF still decreased the level of NPR-C mRNA despite the presence of cycloheximide. These results indicate that NPR-C expression is rapidly regulated by changes in the rate of catabolism of its mRNA through a protein kinase C-activated mechanism that depends on transcription. Treatment with cycloheximide induces NPR-C mRNA, but downregulation of this mRNA by either PDGF or PMA does not depend on synthesis of new protein. C1 Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Med Serv, Charleston, IL USA. RP Paul, RV (reprint author), Med Univ S Carolina, Div Nephrol, 171 Ashley Ave, Charleston, SC 29425 USA. NR 26 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 1998 VL 9 IS 1 BP 26 EP 32 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA YN605 UT WOS:000071186700004 PM 9440083 ER PT J AU Bremner, JD Krystal, JH Putnam, FW Southwick, SM Marmar, C Charney, DS Mazure, CM AF Bremner, JD Krystal, JH Putnam, FW Southwick, SM Marmar, C Charney, DS Mazure, CM TI Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) SO JOURNAL OF TRAUMATIC STRESS LA English DT Article DE dissociation; trauma; PTSD; psychometrics ID POSTTRAUMATIC-STRESS-DISORDER; MULTIPLE PERSONALITY-DISORDER; SYMPTOMS; RELIABILITY; EXPERIENCES; INTERVIEW; VALIDITY; VETERANS AB The purpose of this study was to develop an instrument for the measurement of present-state dissociative symptoms, the Clinician Administered Dissociative States Scale (CADSS). Reported here are interrater reliability and internal consistency of the CADSS, validity as assessed by comparisons with other instruments for the assessment of dissociation, and sensitivity of the CADSS to discriminate patients with dissociative disorders from patients with other psychiatric disorders nad healthy subjects. lnitial analyses indicated good interrater reliability and construct validity for the CADSS. Scores opt the CADSS discriminated patients with dissociative disorders from the other groups. C1 Yale Psychiat Inst, New Haven, CT 06520 USA. W Haven VA Med Ctr, W Haven, CT USA. Natl Ctr Posttraumat Stress Disorder, Div Clin Neurosci, W Haven, CT 06516 USA. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. NIMH, Bethesda, MD 20892 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Bremner, JD (reprint author), Yale Psychiat Inst, POB 208038,Yale Stn, New Haven, CT 06520 USA. RI Bremner, James/B-1632-2013 NR 33 TC 260 Z9 260 U1 1 U2 6 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD JAN PY 1998 VL 11 IS 1 BP 125 EP 136 DI 10.1023/A:1024465317902 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA YU729 UT WOS:000071748400009 PM 9479681 ER PT J AU Gray, SL Sager, M Lestico, MR Jalaluddin, M AF Gray, SL Sager, M Lestico, MR Jalaluddin, M TI Adverse drug events in hospitalized elderly SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID MEDICAL PATIENTS; TRIAL; AGE AB Background. The study objectives were (a) to describe the occurrence, types, and preventability of adverse drug events (ADEs) in hospitalized patients 70 years of age and older; (b) to examine the association between potential risk factors and ADEs; and (c) to examine the relationship of an ADE occurrence and hospital length of stay (LOS) and functional decline. Method. Consecutive general medical admissions (II = 157) of community-dwelling persons were prospectively monitored daily for ADE occurrence. Admission assessment included demographic factors, cognition, preadmission medication use, and functional status. Discharge assessment included functional status, LOS, discharge diagnoses, and medication use during the hospitalization. Results. Twenty-three patients (14.6%) experienced 28 probable ADEs, of which 54.2% (13/24) were judged to be potentially preventable. Patients experiencing an ADE had a significantly lower mean Mini-Mental State Examination score (23.6 +/- 4.3 vs 25.5 +/- 3.6, p=.039) and were prescribed significantly more new inpatient medications (4.0 +/- 2.3 vs 2.6 +/- 1.7, p = .01) compared to non-ADE patients. Age, gender, functional status prior to admission, percent with more than four active diagnoses, or number of preadmission medications were not associated with ADE status. Upon discharge, 50.0% of ADE patients experienced a decline in one or more activities of daily living (ADLs), compared with 24.1% of non-ADE patients (p = .017). ADE patients had a longer LOS (8.7 +/- 4.9 vs 6.6 +/- 3.0 days, p = .022) compared to non-ADE patients. Conclusions, ADEs were associated with number of new inpatient medications and admission cognitive status, but not demographic, disease, or physical function variables. Patients experiencing an ADE were more likely to experience a longer LOS and to decline in ADL function. ADEs may be one factor contributing to functional decline during hospitalization. Future research in this area should include larger samples and multivariable analyses controlling for potential confounders. C1 Univ Washington, Sch Pharm, Seattle, WA 98195 USA. Univ Wisconsin, Dept Med, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI USA. St Marys Hosp, Med Ctr, Dept Pharm, Madison, WI 53715 USA. Univ Wisconsin, Dept Prevent Med, Madison, WI 53706 USA. RP Gray, SL (reprint author), Univ Washington, Sch Pharm, Box 357630, Seattle, WA 98195 USA. NR 25 TC 73 Z9 73 U1 3 U2 4 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 1998 VL 53 IS 1 BP M59 EP M63 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA YU395 UT WOS:000071712800020 PM 9467435 ER PT J AU Agrawal, PK Bush, CA Qureshi, N Takayama, K AF Agrawal, PK Bush, CA Qureshi, N Takayama, K TI NMR spectral investigations - Part 48. H-1 and C-13 NMR assignments of a lipopolysaccharide obtained from the deep rough mutant of Escherichia coli D31m4 SO MAGNETIC RESONANCE IN CHEMISTRY LA English DT Article DE NMR; H-1 NMR; C-13 NMR; rough LPS; E-coli ID NUCLEAR-MAGNETIC-RESONANCE; PERFORMANCE LIQUID-CHROMATOGRAPHY; COMPLETE STRUCTURAL DETERMINATION; DESORPTION MASS-SPECTROMETRY; HEPTOSE-LESS MUTANT; LIPID-A BACKBONE; CAPSULAR POLYSACCHARIDE; SALMONELLA-MINNESOTA; ENTEROBACTERIAL LIPOPOLYSACCHARIDES; 3-DEOXY-D-MANNO-OCTULOSONIC ACID AB The hexamethyl derivative of lipopolysaccharide (LPS), obtained by diazomethane methylation of LPS extracted from a deep mutant of Escherichia coli D31m4, followed by high-performance liquid chromatographic purification, was subjected to home-and heteronuclear two-dimensional NMR spectroscopy (DQF-COSY, HOHAHA, NOESY, HMQC and HMBC) to achieve H-1 and C-13 NMR assignments, particularly of the sugar backbone. These studies confirmed two each of glucosamine (GlcN), 3-deoxy-D-manno-octulosonic acid (Kdo), phosphate, beta-hydroxymyristate and beta-acyloxymyristate and the structure of the tetrasaccharide as alpha-Kdo(p)-(2 --> 4)-alpha-Kdo(p)-(2 --> 6)-beta-D-Glc(p)N-(1 --> 6)alpha-D-Glc(p)N, bisphosphorylated at the I and 4' positions. (C) 1998 John Wiley & Sons Ltd. C1 Cent Inst Med & Aromat Plants, Lucknow 226015, Uttar Pradesh, India. Univ Maryland, Dept Chem & Biochem, Baltimore, MD 21228 USA. William S Middleton Mem Vet Hosp, Mycobacteriol Res Lab, Madison, WI 53705 USA. Univ Wisconsin, Coll Agr & Life Sci, Dept Bacteriol, Madison, WI 53706 USA. RP Agrawal, PK (reprint author), Cent Inst Med & Aromat Plants, Lucknow 226015, Uttar Pradesh, India. NR 46 TC 3 Z9 3 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0749-1581 J9 MAGN RESON CHEM JI Magn. Reson. Chem. PD JAN PY 1998 VL 36 IS 1 BP 1 EP 7 DI 10.1002/(SICI)1097-458X(199801)36:1<1::AID-OMR164>3.0.CO;2-J PG 7 WC Chemistry, Multidisciplinary; Chemistry, Physical; Spectroscopy SC Chemistry; Spectroscopy GA YR824 UT WOS:000071533900001 ER PT J AU Asch, DA Christakis, NA Ubel, PA AF Asch, DA Christakis, NA Ubel, PA TI Conducting physician mail surveys on a limited budget - A randomized trial comparing $2 bill versus $5 bill incentives SO MEDICAL CARE LA English DT Article DE cost effectiveness; data collection; epidemiology; financial incentives ID RESPONSE RATES AB OBJECTIVES. The effects of incentive size on physicians' response rates to a mail survey were determined. METHODS. One thousand US primary care physicians were assigned randomly to receive a survey with either a $5 bill or a $2 bill as an incentive. For each of the two incentive groups, the overall response rate for three mailing waves, the total cost, and the total cost per usable response were measured. RESULTS. The response rate among those receiving the $5 bill (61%) was 32% higher than the response rate among those receiving the $2 bill (46%); overall costs were slightly higher in the $5 group, but the cost per response for each group was similar ($15.46 versus $14.93). For the same cost, a higher response rate could have been achieved in the $2 group if costs saved from foregoing the third mailing were instead used to increase the incentive for a portion of the subjects. CONCLUSIONS. A $5 bill incentive yielded a higher response rate among the physicians in this study than did a $2 bill incentive. Moreover, the powerful effect of the incentive size, combined with the consequent decline in the costs of subsequent mailing waves, suggests that resources in a fixed survey budget are allocated more efficiently to increasing the initial incentive rather than to providing a third wave to nonresponders. C1 Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. Univ Chicago, Dept Sociol, Chicago, IL 60637 USA. RP Asch, DA (reprint author), 317 Ralston Penn Ctr, Div Gen Internal Med, 3615 Chestnut St, Philadelphia, PA 19104 USA. RI Christakis, Nicholas/B-6690-2008; Christakis, Nicholas/C-3205-2009 NR 13 TC 79 Z9 78 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 1998 VL 36 IS 1 BP 95 EP 99 DI 10.1097/00005650-199801000-00011 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA YN567 UT WOS:000071181500011 PM 9431335 ER PT J AU DeKay, ML Asch, DA AF DeKay, ML Asch, DA TI Is the defensive use of diagnostic tests good for patients, or bad? SO MEDICAL DECISION MAKING LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-for-Judgment-and-Decision-Making CY NOV 11-13, 1995 CL LOS ANGELES, CALIFORNIA SP Soc Judgment & Decis Making DE decision analysis; decision threshold; defensive medicine; diagnostic testing; expected utility; malpractice liability ID HINDSIGHT BIAS; DECISION-MAKING; UNCERTAINTY; PROBABILITY; HEURISTICS; JUDGMENT AB Physicians sometimes order diagnostic tests to reduce the risk of malpractice liability. The authors develop an expected-utility model that links a rational physician's concerns about malpractice liability to increases in the use of diagnostic tests and use this model to assess the effects of defensive testing on patients' interests. To do so, they adapt the threshold approach to clinical decision making to incorporate the physician's interests, focusing on 1) the effect of the physician's expected liability risks and 2) the effect of any expected liability reduction due to diagnostic testing. Surprisingly, the mere existence of liability risks is often sufficient to widen the range of disease probabilities for which diagnostic testing is the preferred clinical strategy. If testing reduces the physician's expected liability risks, the testing range is widened further. For some disease probabilities, testing is preferred by the physician even though it is not in the patient's best interests. When tests are performed in such instances, utility is transferred from the patient to the physician and the physician's insurer. Although the defensive use of diagnostic tests improves clinical outcomes for some patients, it worsens clinical outcomes for others. Moreover, defensive testing worsens the expected outcomes of all patients whose clinical strategies are changed. Physicians should realize that defensive testing necessarily reduces the overall quality of patient care. C1 Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA. Carnegie Mellon Univ, H John Heinz III Sch Publ Policy & Management, Pittsburgh, PA 15213 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP DeKay, ML (reprint author), Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA. EM dekay@andrew.cmu.edu; asch@wharton.upenn.edu NR 25 TC 59 Z9 59 U1 0 U2 5 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-MAR PY 1998 VL 18 IS 1 BP 19 EP 28 DI 10.1177/0272989X9801800105 PG 10 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA YQ612 UT WOS:000071405300005 PM 9456202 ER PT J AU DeKay, ML Asch, DA AF DeKay, ML Asch, DA TI Offensive testing - The balancing act, the evil twin, and the pure play SO MEDICAL DECISION MAKING LA English DT Article ID BLOOD ACID-BASE; PROGNOSTIC INFORMATION C1 Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA. Carnegie Mellon Univ, H John Heinz III Sch Publ Policy & Management, Pittsburgh, PA 15213 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP DeKay, ML (reprint author), Ralston Penn Ctr, 3615 Chestnut St,317, Philadelphia, PA 19104 USA. NR 11 TC 2 Z9 2 U1 0 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-MAR PY 1998 VL 18 IS 1 BP 35 EP 36 DI 10.1177/0272989X9801800109 PG 2 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA YQ612 UT WOS:000071405300009 PM 9456206 ER PT S AU Duerinckx, AJ Gentili, A El-Saden, S Harmon, C Kenagy, JJ Edward, EG AF Duerinckx, AJ Gentili, A El-Saden, S Harmon, C Kenagy, JJ Edward, EG BE Horii, SC Blaine, GJ TI First six months of clinical usage of an ATM network between two Veterans Affairs Medical Centers. SO MEDICAL IMAGING 1998 - PACS DESIGN AND EVALUATION: ENGINEERING AND CLINICAL ISSUES SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT PACS Design and Evaluation Conference CY FEB 24-26, 1998 CL SAN DIEGO, CA SP SPIE, Amer Assoc Physicists Med, Amer Physiol Soc, US FDA, Ctr Devices & Radiol Hlth, Soc Imaging Sci & Technol, Natl Elect Mfg Assoc, Diag Imaging & Therapy Syst Div, Radiol Informat Syst Consortium, Radiol Soc N Amer, Soc Comp Applicat Radiol AB Purpose/Background Asynchronous transfer mode (ATM) network technology has recently been used for high speed transmission of radiological images between hospitals and inside hospitals. However, the number of clinical sites which routinely use this technology is limited. The purpose of this study was to analyze the very early impact of an ATM link between a large tertiary referral center and small peripheral clinic on cost and clinical practice. Methodology A ATM link using 155 bps (OC3) technology was installed between the West Los Angeles VA Medical Center and the Sepulveda VA, outpatient facility which provides full service radiological services. The West Los Angeles VA Medical Center is a large tertiary referral center with subspecialist radiologist. The clinical impact of this ATM link between a large full-scale DICOM-3 compliant PACS system at the West LA VA on a smaller PACS system at the Sepulveda VA was evaluated. Results The ability to freely exchange complicated MRI and CT studies between a tertiary referral center and a clinic could have a direct impact on patient care. Over the last six months, all and CT studies from Sepulveda VA were readily available via the ATM connection to all radiologists at the West LA VA. On average the workload at the Sepulveda VA in CT and MRI was about one tenth of the same workload at West LA VA, thus creating interesting possibilities for sharing or radiologist resources. Conclusions Although our preliminary data and work loads have been too limited to draw any final conclusions yet, we feel that future results will show that the ability to provide immediate and fast interactive consultation between general radiologists in a larg outpatient facility and sub-specialists at a tertiary referral center can have an impact upon the quality of patient care. C1 W Los Angeles Vet Affairs Med Ctr, Serv Radiol, Los Angeles, CA 90073 USA. RP Duerinckx, AJ (reprint author), W Los Angeles Vet Affairs Med Ctr, Serv Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Gentili, Amilcare/G-1238-2013 OI Gentili, Amilcare/0000-0002-5623-7512 NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-2784-5 J9 P SOC PHOTO-OPT INS PY 1998 VL 3339 BP 388 EP 399 DI 10.1117/12.319792 PG 12 WC Engineering, Biomedical; Medical Informatics; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Medical Informatics; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BL49R UT WOS:000075701600041 ER PT S AU Duerinckx, AJ Harmon, C Crook, M Grant, EG AF Duerinckx, AJ Harmon, C Crook, M Grant, EG BE Horii, SC Blaine, GJ TI Integrating DICOM conformant imaging equipment with a PACS. SO MEDICAL IMAGING 1998 - PACS DESIGN AND EVALUATION: ENGINEERING AND CLINICAL ISSUES SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT PACS Design and Evaluation Conference CY FEB 24-26, 1998 CL SAN DIEGO, CA SP SPIE, Amer Assoc Physicists Med, Amer Physiol Soc, US FDA, Ctr Devices & Radiol Hlth, Soc Imaging Sci & Technol, Natl Elect Mfg Assoc, Diag Imaging & Therapy Syst Div, Radiol Informat Syst Consortium, Radiol Soc N Amer, Soc Comp Applicat Radiol AB Purpose/Background As medical centers purchase commercial PACS to integrate with their imaging equipment, the fact that each component is often purchased at different times and with differing levels of DICOM conformance may become a problem. When the PACS is installed, major incompatibilities are often discovered between DICOM conformant pieces of equipment. Commercial PACS vendors are sometimes reluctant to take responsibility for the final integration of these components. The purpose of this paper is to document the nature and extent of these problem at one medical center, to report on how we are trying to solve them, and recommendations for the future. Methods A large commercial PACS (IMPAX(TM), Bayer Corporation, Agfa division) installed at the West Los Angeles VA medical Center was recently upgraded to be DICOM 3.0 conformant. Recently purchased DICOM conformant CT and MRI units and an older CT were already present. The problems in interfacing and integrating these imaging modalities with the upgraded DICOM- compliant PACS were investigated. Both software and hardware incompatibilities and human factors in bringing the different commercial vendors together were analyzed. Results Major hardware and software incompatibilities were discovered. The use of DICOM-gateways is not always able to solve problems of incompatibility. The typical lag time between discovery of a problem and provision of a solution was 4 to 5 months. For more severe problems and also for a few of the lesser problems, resolution took over a year and is still ongoing. Repeated requests had to be made to the vendors to get together with us and solve these problems. C1 W Los Angeles Vet Affairs Med Ctr, Serv Radiol, Los Angeles, CA 90073 USA. RP Duerinckx, AJ (reprint author), W Los Angeles Vet Affairs Med Ctr, Serv Radiol, Los Angeles, CA 90073 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 0-8194-2784-5 J9 P SOC PHOTO-OPT INS PY 1998 VL 3339 BP 540 EP 555 DI 10.1117/12.319813 PG 16 WC Engineering, Biomedical; Medical Informatics; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Medical Informatics; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BL49R UT WOS:000075701600059 ER PT S AU Meyer, KE Altamore, R Chapko, M Miner, M McGann, M Hill, E Van Duesen-Lucas, C Bates, M Weir, C Lincoln, T AF Meyer, KE Altamore, R Chapko, M Miner, M McGann, M Hill, E Van Duesen-Lucas, C Bates, M Weir, C Lincoln, T BE Cesnik, B McCray, AT Scherrer, JR TI The need for a thoughtful deployment strategy: Evaluating clinicians' perceptions of critical deployment issues SO MEDINFO '98 - 9TH WORLD CONGRESS ON MEDICAL INFORMATICS, PTS 1 AND 2 SE STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS LA English DT Proceedings Paper CT 9th World Congress on Medical Informatics: Global Health Networking - A Vision for the Next Millennium (MEDINFO 98) CY 1998 CL SEOUL, SOUTH KOREA SP Int Med Informat Assoc DE evaluation studies; attitude to computers; planning techniques; user computer interface; medical record systems computerized; management information systems; information systems; computing systems AB This paper presents data collected from 899 clinicians across three Department of Veterans Affairs (VA) medical centers where existing terminal-based architecture was being replaced with client-sewer architecture Surveys were conducted with physicians (n=184), nurses (n=355) and other clinicians (n=360) gathering user characteristics and their perceptions of five deployment issues (e.g. adequacy of technical and institutional support and perceptions of the soon-to-be-implemented clinical workstation). Mean scores for the five deployment issues for all clinicians indicates perceptions are somewhat neutral. However when data is analyzed according to job classification, significant (p=0.05) differences in perceptions were noted among groups of clinicians (e.g, physicians and registered nurses). Results of analyzing data grouped by VA site (n=3) indicates significant (p=0.05) differences exist among sites in clinicians' perceptions of the deployment issues. A thoughtful deployment strategy including an in-depth assessment of clinician users by job classification and by location may produce important information, critical to the successful deployment of new technologies, in very large health management institutions. C1 VA Puget Sound Hlth Care Syst, GRECC, NW Ctr Cooperat Studies Hlth Serv, Seattle, WA 98108 USA. RP Meyer, KE (reprint author), VA Puget Sound Hlth Care Syst, GRECC, NW Ctr Cooperat Studies Hlth Serv, MS 182B,1660 S Columbian Way, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU I O S PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0926-9630 BN 90-5199-407-9 J9 ST HEAL T PY 1998 VL 52 BP 854 EP 858 PG 5 WC Medical Informatics SC Medical Informatics GA BM09G UT WOS:000077613500167 PM 10384582 ER PT J AU Minshew, NJ Goldstein, G AF Minshew, NJ Goldstein, G TI Autism as a disorder of complex information processing SO MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS LA English DT Review DE autism; neurobehavioral models; information processing; cognitive profiles ID PERVASIVE DEVELOPMENTAL DISORDERS; LEARNING-IMPAIRED CHILDREN; BRAIN-STEM; ELECTROPHYSIOLOGIC INDICATION; DIAGNOSTIC INTERVIEW; INFANTILE-AUTISM; LANGUAGE; INDIVIDUALS; TOMOGRAPHY; BEHAVIOR AB Numerous neurobehavioral models for autism have been proposed in the decades since a neurologic origin gained acceptance. Research related to these models has resulted in substantial progress in the characterization of the neurocognitive basis of autism. The culmination of considerable research has resulted in support for a neurobehavioral model of autism as a disorder of complex information processing systems. This is a multiple primary cognitive deficit model proposing that the pattern of deficits within and across domains in autism is a reflection of complex information processing demands. This article will first provide an overview of the evolution of neurobehavioral models in autism and then present findings leading to the conceptualization of this model for autism, (C) 1998 Wiley-Liss, Inc. C1 Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Minshew, NJ (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St,Bellefield Towers,Suite 430, Pittsburgh, PA 15213 USA. EM minshewnj@msx.upmc.edu NR 43 TC 85 Z9 87 U1 1 U2 10 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 1080-4013 J9 MENT RETARD DEV D R JI Ment. Retard. Dev. Disabil. Res. Rev. PY 1998 VL 4 IS 2 BP 129 EP 136 DI 10.1002/(SICI)1098-2779(1998)4:2<129::AID-MRDD10>3.0.CO;2-X PG 8 WC Clinical Neurology; Neurosciences; Pediatrics; Psychiatry SC Neurosciences & Neurology; Pediatrics; Psychiatry GA 106EX UT WOS:000075117900010 ER PT J AU Sepulveda, AR Ota, H Gutierrez, O Kim, JG Genta, RM Graham, DY AF Sepulveda, AR Ota, H Gutierrez, O Kim, JG Genta, RM Graham, DY TI Variation in cellular phenotypes of gastric cancer from three different geographic regions. SO MODERN PATHOLOGY LA English DT Meeting Abstract C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Hosp San Juan de Dios, Bogota, Colombia. Korea Univ, Coll Med, Guru Hosp, Seoul 136701, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 1998 VL 11 IS 1 BP 70A EP 70A PG 1 WC Pathology SC Pathology GA YV140 UT WOS:000071793400413 ER PT J AU Gulley, ML Nicholls, JM Schneider, BG Amin, MB Ro, JY Geradts, J AF Gulley, ML Nicholls, JM Schneider, BG Amin, MB Ro, JY Geradts, J TI Frequent loss of p16 expression in nasopharyngeal carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Univ Hong Kong, Hong Kong, Peoples R China. Louisiana State Univ, Med Ctr, Baton Rouge, LA 70803 USA. Henry Ford Hosp, Detroit, MI 48202 USA. Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA. Univ N Carolina, Chapel Hill, NC 27515 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 1998 VL 11 IS 1 BP 119A EP 119A PG 1 WC Pathology SC Pathology GA YV140 UT WOS:000071793400712 ER PT J AU Amrikachi, M Finch, CJ Crump, D Krishnan, B Saleh, G Shahab, I AF Amrikachi, M Finch, CJ Crump, D Krishnan, B Saleh, G Shahab, I TI Actinobacillusactinomycetemcomitans-Actinomyces species associate lymphadenopathy mimicking lymphoma. SO MODERN PATHOLOGY LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 1998 VL 11 IS 1 BP 143A EP 143A PG 1 WC Pathology SC Pathology GA YV140 UT WOS:000071793400854 ER PT J AU Canalejo, A Hernandez, A Almaden, Y Concepcion, MT Felsenfeld, A Torres, A Rodriguez, M AF Canalejo, A Hernandez, A Almaden, Y Concepcion, MT Felsenfeld, A Torres, A Rodriguez, M TI The effect of a high phosphorus diet on the parathyroid cell cycle SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article; Proceedings Paper CT 2nd International Symposium on Advances in Renal Osteodystrophy CY MAR 20-21, 1997 CL OVIEDO, SPAIN DE apoptosis; calcium; cell cycle; parathyroid hormone; parathyroid hyperplasia; phosphorus ID CHRONIC-RENAL-FAILURE; MESSENGER-RNA; VITAMIN-D; IN-VITRO; HORMONE; RATS; CALCITRIOL; PHOSPHATE; PTH; HYPERCALCEMIA AB High extracellular phosphorus directly increases parathyroid hormone (PTH) secretion and gene transcription. The present study evaluates the effect of high phosphorus diet on the parathyroid cell cycle in rats with normal renal function. Rats were divided into two groups, receiving either a high phosphorus diet (HPD, P=1.2%) or a normal phosphorus diet (NPD, P=0.6%). The dietary calcium content was 0.6% in both diets. Rats were pair fed and sacrified on days 0, 1, 5, 10 and 15 after initiation of the diet. The parathyroid glands were removed and parathyroid cells dispersed for evaluation of cell cycle and apoptosis by flow cytometry. Serum calcium, phosphorus, PTH and calcitriol were measured. As compared with NPD, the ingestion of a HPD resulted in an increased number of cells in the S phase of the cell cycle from day 1 to 10 (1.2+/-0.09% vs 0.6+/-0.04% for day 1, 1.2+/-0.11% vs 0.6+/-0.06% for day 5 and 1.0+/-0.09% vs 0.5+/-0.04% for day 10, P<0.01). By day 15, the percentage of cells in the S phase in NPD and HPD were not different. In the rats fed the HPD, serum PTH increased significantly from day 5 through 15 (P<0.01). Parathyroid cell apoptosis was minimal and unaffected by the diet. At day 15, the parathyroid gland size in HPD was increased by 27% as compared with NPD (P<0.05). This increase should be attributed to cell proliferation since parathyroid cell size remained unchanged. Serum calcitriol and calcium were not significantly different in the two groups. In HPD, an increase in serum phosphorus was observed only on day 1. The results show that an HPD results in the stimulation of the parathyroid cell cycle independently of changes in calcium and calcitriol. C1 Hosp Univ Reina Sofia, Unidad Invest, Serv Nefrol, E-14004 Cordoba, Spain. Hosp Univ Tenerife, Serv Nefrol, Unidad Invest, Tenerife, Spain. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Rodriguez, M (reprint author), Hosp Univ Reina Sofia, Unidad Invest, Serv Nefrol, C Avda Menendez Pidal S-N, E-14004 Cordoba, Spain. RI Rodriguez, teresa/H-5452-2011; Canalejo, Antonio/L-8407-2014 OI Canalejo, Antonio/0000-0003-2098-8960 NR 16 TC 9 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PY 1998 VL 13 SU 3 BP 19 EP 22 DI 10.1093/ndt/13.suppl_3.19 PG 4 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA ZH222 UT WOS:000073085500006 PM 9568815 ER PT J AU Frazao, JM Chesney, RW Coburn, JW AF Frazao, JM Chesney, RW Coburn, JW CA 1 Alpha D2 Study Grp TI Intermittent oral 1 alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article; Proceedings Paper CT 2nd International Symposium on Advances in Renal Osteodystrophy CY MAR 20-21, 1997 CL OVIEDO, SPAIN DE haemodialysis; 1 alpha-hydroxyvitamin D-2; intact PTH; secondary hyperparathyroidism; therapeutic trial; vitamin D ID DOSE INTRAVENOUS CALCITRIOL; PARATHYROID-HORMONE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; PROSPECTIVE TRIAL; BONE-DISEASE; VITAMIN-D; CALCIUM; RATS; SECRETION AB Calcitriol and alfacalcidol are useful in suppressing parathyroid hormone (PTH) in haemodialysis patients, but hypercalcaemia and hyperphosphataemia are frequent, The vitamin D analogue, 1 alpha-hydroxyvitamin D-2 (1 alpha D-2), has a higher therapeutic index in animal models. Previously, 1 alpha D-2, 4 mu g/day or 4 mu g/haemodialysis, lowered iPTH to the target range in 87.5% of 24 haemodialysis patients with moderate to severe secondary hyperparathyroidism (plasma iPTH, 359-1521 pg/ml). The incidences of hypercalcaemia (serum Ca > 2.8 mM) or hyperphosphataemia (serum P > 2.23 mM) were low. Later, 10 of these patients were re-treated with 1 alpha D-2, initial dose, 10 mu g, thrice weekly with haemodialysis. The iPTH was suppressed as readily, and there was no greater incidence of hypercalcaemia and hyperphosphataemia. Based on these data, a large, multicentre study is ongoing in California and Tennessee/Mississippi, using 1 alpha D-2 in haemodialysis patients with iPTH > 400 pg/ml. In this and the earlier studies, only calcium-based phosphate binders were used to control serum phosphorus. The initial dose, 10 mu g thrice weekly with haemodialysis, is adjusted to maintain a target iPTH within the range of 150 300 mu g/ml; the final dose range is 2.5-20 mu g per haemodialysis. The protocol includes 8 weeks of wash-out with no vitamin D, 16 weeks of open label treatment period with 1 alpha D-2, and finally 8 weeks of randomized double blinded treatment with either continued 1 alpha D-2 or placebo. Forty two patients from California and 38 from Tennessee/Mississippi have completed 16 weeks of open label treatment. In California, iPTH declined from 832 +/- 95 pg/ml at baseline to 222 +/- 71 pg/ml at the nadir and to 477 +/- 117 pg/ml at week 16 of the treatment. In Tennessee/Mississippi, the iPTH declined from 977 +/- 65 pg/ml to 286 +/- 42 pg/ml at the lowest point and to 493 +/- 79 at the end of the treatment. Plasma iPTH reached or fell below the target range in 84% of the 80 patients completing open treatment. Asymptomatic hypercalcaemia (serum Ca > 2.8 mM) increased episodes/100 weeks during wash-out to 3.6 episodes/100 treated weeks in California and from 0 to 3.7 episodes in Tennessee/Mississippi. In California and Tennessee, the episodes of hyperphosphataemia (serum P > 2.2 mM) increased from 5.0 and 5.0 epiodes per 100 patient/week during wash-out to 10.1 and 10.9 episodes/100 treatment weeks, respectively, with 1 alpha D-2 treatment. There were no adverse events in association with 1 alpha D-2 treatment. Thus, oral 1 alpha D-2 is safe and highly effective for the treatment of secondary hyperparathyroidism. C1 W Los Angeles Vet Affairs Med Ctr, Nephrol Sect W111L, Wadsworth Div, Med & Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pediat, Memphis, TN 38163 USA. Bone Care Int Inc, Madison, WI USA. RP Coburn, JW (reprint author), W Los Angeles Vet Affairs Med Ctr, Nephrol Sect W111L, Wadsworth Div, Med & Res Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Frazao, Joao/J-9811-2013 OI Frazao, Joao/0000-0002-8081-5474 NR 32 TC 35 Z9 36 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PY 1998 VL 13 SU 3 BP 68 EP 72 DI 10.1093/ndt/13.suppl_3.68 PG 5 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA ZH222 UT WOS:000073085500017 PM 9568825 ER PT J AU Craft, S Peskind, E Schwartz, MW Schellenberg, GD Raskind, M Porte, D AF Craft, S Peskind, E Schwartz, MW Schellenberg, GD Raskind, M Porte, D TI Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease - Relationship to severity of dementia and apolipoprotein E genotype SO NEUROLOGY LA English DT Article ID NERVOUS-SYSTEM; MEMORY; BRAIN; RECEPTORS AB Patients with Alzheimer's disease (AD) have elevations of fasting plasma insulin that are hypothesized to be associated with disrupted brain insulin metabolism. We examined paired fasted plasma and CSF insulin levels in 25 patients with AD and 14 healthy age-matched adults and determined whether insulin levels were related to severity of dementia and apolipoprotein E-epsilon 4 homozygosity, a known genetic risk factor for AD, The AD patients had lower CSF insulin, higher plasma insulin, and a reduced CSF-to-plasma insulin ratio when compared with healthy adults, The differences were greater for patients with more advanced AD, Patients who were not apolipoprotein E-epsilon 4 homozygotes had higher plasma insulin levels and reduced CSF-to-plasma ratios, whereas epsilon 4 homozygotes with AD had normal values. Both plasma and CSF insulin levels are abnormal in AD, and there are metabolic differences among apolipoprotein E genotypes. C1 VA Puget Sound Hlth Care Syst, GRECC 182B, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. RP Craft, S (reprint author), VA Puget Sound Hlth Care Syst, GRECC 182B, 1660 S Columbian Way, Seattle, WA 98108 USA. RI Schwartz, Michael/H-9950-2012 FU NIA NIH HHS [AG-05136, AG-08419, AG-10880] NR 26 TC 331 Z9 337 U1 0 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1998 VL 50 IS 1 BP 164 EP 168 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA YR353 UT WOS:000071486900030 PM 9443474 ER PT J AU Stein, DJ Buchsbaum, MS Hof, PR Siegel, BV Shihabuddin, L AF Stein, DJ Buchsbaum, MS Hof, PR Siegel, BV Shihabuddin, L TI Greater metabolic rate decreases in hippocampal formation and proisocortex than in neocortex in Alzheimer's disease SO NEUROPSYCHOBIOLOGY LA English DT Article DE positron emission tomography; Brodmann cortical areas; deoxyglucose; dementia; neurofibrillary tangles ID POSITRON EMISSION TOMOGRAPHY; NEUROFIBRILLARY TANGLE DENSITIES; QUANTITATIVE-ANALYSIS; TEMPORAL-LOBE; PATHOLOGICAL-CHANGES; COMPUTED-TOMOGRAPHY; GLUCOSE-UTILIZATION; VULNERABLE SUBSET; PYRAMIDAL NEURONS; BRAIN METABOLISM AB Neuropathological studies of Alzheimer's disease (AD) have found pathological changes in some cytoarchitectural regions and relative sparing in others. Positron emission tomography (PET) studies have also shown selective decreases in glucose metabolic rates but have generally focused on whole brain lobes or geometrically derived regions of interest. In this report, a template of Brodmann areas, derived from a whole brain histological section atlas, was used to analyze PET findings from 34 AD patients and 16 control subjects matched for age, sex, and educational level. AD patients had lowest glucose metabolic rates in limbic areas of the temporal lobe and other proisocortical areas higher rates in frontal lobe and unimodal association areas, and relative sparing of parietal/occipital lobes and motor/sensory cortices. Analysis of variance revealed larger effect sizes when AD and control subjects were compared on metabolic rate for cortical type than for lobe. These findings, which parallel neuropathological studies of regional distribution of neurofibrillary tangles in AD, suggest that vulnerability is greatest in cortical areas that are in closer synaptic contact with limbic areas. C1 Univ Stellenbosch, Dept Psychiat, ZA-7505 Tygerberg, South Africa. Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY USA. Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. Dept Vet Affairs Med Ctr, Psychiat Serv, Bronx, NY USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. RP Buchsbaum, MS (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, Box 1505,1 Gustave L Levy Pl, New York, NY 10029 USA. RI Stein, Dan/A-1752-2008 OI Stein, Dan/0000-0001-7218-7810 FU NIA NIH HHS [AG05138] NR 57 TC 36 Z9 36 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-282X J9 NEUROPSYCHOBIOLOGY JI Neuropsychobiology PY 1998 VL 37 IS 1 BP 10 EP 19 DI 10.1159/000026471 PG 10 WC Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA YP776 UT WOS:000071314000003 PM 9438267 ER PT J AU Newton, TF Cook, IA Holschneider, DP Rosenblatt, MR Lindholm, JEVZ Jarvik, MM AF Newton, TF Cook, IA Holschneider, DP Rosenblatt, MR Lindholm, JEVZ Jarvik, MM TI Quantitative EEG effects of nicotine replacement by cigarette smoking SO NEUROPSYCHOBIOLOGY LA English DT Article DE nicotine; quantitative EEG; alpha band ID CAFFEINE AB The effects of cigarette smoking on the central nervous system can be assessed directly using the electroencephalogram (EEG), Nicotine withdrawal and subsequent replacement have been studied, but have produced conflicting effects on brain electrical activity, We studied the effect of smoking 2 cigarettes at subjects' own pace in 20 subjects. EEG was recorded using the EEGSYS program in the eyes-closed awake state using a bipolar montage. Delta power decreased in central-posterior head regions. Theta power and power in the lower half of the alpha band decreased. Beta power and power in the upper half of the alpha band increased significantly over frontotemporal head regions. Examination of spectra underlying the usual frequency bands revealed that many effects of smoking on EEG power probably resulted from a shift of the overall power spectrum toward higher frequencies, rather than resulting from alterations in activity in specific frequency bands. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Newton, TF (reprint author), W Los Angeles Vet Affairs Med Ctr, W116A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI newton, thomas/0000-0002-3198-5901 NR 14 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-282X J9 NEUROPSYCHOBIOLOGY JI Neuropsychobiology PY 1998 VL 37 IS 2 BP 112 EP 116 DI 10.1159/000026488 PG 5 WC Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA ZG725 UT WOS:000073033100013 PM 9566277 ER PT S AU Grosvenor, W Feigin, AM Spielman, AI Finger, TE Wood, MR Hansen, A Kalinoski, DL Teeter, JH Brand, JG AF Grosvenor, W Feigin, AM Spielman, AI Finger, TE Wood, MR Hansen, A Kalinoski, DL Teeter, JH Brand, JG BE Murphy, C TI The arginine taste receptor - Physiology, biochemistry, and immunohistochemistry SO OLFACTION AND TASTE XII: AN INTERNATIONAL SYMPOSIUM SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT International Symposium on Olfaction and Taste XII CY JUL 07-12, 1997 CL SAN DIEGO, CALIFORNIA SP Int Commiss Olfact & Taste, NIH, NIA, NIDOCD, NIDR, NICHHD, Natl Sci Fdn, San Diego Univ, Univ California San Diego, Ajinomoto US Inc, Coca Cola Co, Firmenich SA, Glaxo Wellcome Res & Dev Ltd, Int Flavors & Fragrances Inc, Johnson & Johnson, Kirin Brewery Co Ltd, Nutrisweet Kelco C0, Olfactory Res Fund, Pherin Corp, Proctor & Gamble Co, Abbott Labs, Ross Prod Div, Soc Res Umami Taste, Unilever ID CHANNEL CATFISH; ICTALURUS-PUNCTATUS; SITES; BUDS AB The amino acid, L-arginine (L-Arg), is a potent taste stimulus for the channel catfish, Ictalurus punctatus. Receptor binding studies demonstrated a high-affinity binding of L-Arg to putative taste receptor sites. This binding could be inhibited by preincubation of the tissue in the lectins Phaseolus vulgaris agglutinin (PHA) and Ricinus communis agglutinin I(RCA I). Neurophysiological studies demonstrated that the L-Arg receptor is a stimulus-gated ion channel type receptor whose conductance was stimulated by L-Arg and inhibited by D-arginine (D-Arg), To purify the receptor we subjected CHAPS solubilized partial membrane preparation from barbel epithelium to RCA I lectin affinity chromatography, The bound proteins were eluted with D-galactose, When these proteins were reconstituted into lipid bilayers, L-Arg activated single channel currents with conductances between 45 and 85 pS, Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) of the eluted protein showed a distinct band at similar to 83 kDa, Polyclonal antibodies raised against this 83-kDa band in guinea pigs reacted with numerous small (similar to 1 mu m) sites within the taste pore of every taste bud when applied to fixed nonpermeabilized barbels, This observation suggests that the antibodies recognize an externally-facing epitope of the putative Arg receptor, The antibodies also inhibited L-Arg-stimulated currents in reconstitution studies. Sephacryl S-300 HR chromatography of the eluant from the affinity column showed a high molecular weight peak (>700 kDa) which was recognized by the antibodies. Reconstitution of the protein from this peak into a lipid bilayer resulted in L-Arg-stimulated channels that could be inhibited by D-Arg. This high molecular weight component may be aggregates of the arginine taste receptor. C1 Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. NYU, Coll Dent, New York, NY USA. Univ Colorado, Hlth Sci Ctr, Dept Struct & Cellular Biol, Rocky Mt Taste & Smell Ctr, Denver, CO USA. Univ Hamburg, Inst Zool, D-2000 Hamburg, Germany. Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Brand, JG (reprint author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA. OI Finger, Thomas/0000-0001-5923-5099 FU NIDCD NIH HHS [P01-DC00244, DC00356, DC01838] NR 10 TC 4 Z9 4 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-139-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1998 VL 855 BP 134 EP 142 DI 10.1111/j.1749-6632.1998.tb10555.x PG 9 WC Biochemistry & Molecular Biology; Food Science & Technology; Multidisciplinary Sciences; Neurosciences; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Food Science & Technology; Science & Technology - Other Topics; Neurosciences & Neurology; Nutrition & Dietetics GA BM29Q UT WOS:000078304300014 PM 9929594 ER PT J AU Dailey, RA Gray, JF Rubin, MG Hildebrand, PL Swanson, NA Wobig, JL Wilson, DJ Speelman, P AF Dailey, RA Gray, JF Rubin, MG Hildebrand, PL Swanson, NA Wobig, JL Wilson, DJ Speelman, P TI Histopathologic changes of the eyelid skin following trichloroacetic acid chemical peel SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT Fall Meeting of the ASOPRS CY 1995 CL ATLANTA, GEORGIA SP ASOPRS DE trichloroacetic acid; eyelid peel; complications; necrosis AB The use of trichloroacetic acid (TCA) as a periorbital and eyelid peel for skin rejuvenation is gaining significant acceptance among oculoplastic surgeons, dermatologists, and other surgery groups. In spite of the current enthusiasm, there remain potentially serious complications resulting from any periorbital peel. Cases of cicatricial ectropion have been reported in phenol-peeled patients, and lower eyelid ectropion has reportedly occurred in patients undergoing deep eyelid peel in conjunction with a blepharoplasty (1,2). To avoid this complication, it is necessary to better understand the depth of the wound produced by different strengths and combinations of peeling agents applied to living eyelid tissue and, more important, to determine the concentrations of TCA that are likely to lead to cicatricial ectropion when applied in a consistent fashion. We chose upper-eyelid skin because it is easier to obtain for histopathologic study than lower-eyelid skin and, in our experience, is more sensitive to hypertrophic changes after chemical peeling or carbon dioxide laser resurfacing. We applied TCA to the preseptal skin of 10 patients 48 h before standard upper-eyelid blepharoplasty. The acid was applied to produce a "frost," using varying concentrations of acid, ranging from 20 to 50%. The treated skin removed at the time of blepharoplasty was reviewed in a masked fashion by a dermatopathologist to determine the depth of necrosis. We found that superficial peels with necrosis involving 30% of the epidermis were produced by the lowest-concentration combination of TCA applied (20% followed by 0%). As the strength increased, so did the depth of peel. The combination of 50% followed by a second application of 50% produced the deepest peel, with necrosis into the papillary dermis. This finding would indicate that the chance of developing cicatricial ectropion with any of the tested combinations of TCA should be very remote. C1 Portland Vet Affairs Med Ctr, Oculoplast Serv, Portland, OR USA. RP Dailey, RA (reprint author), Oregon Hlth Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97201 USA. NR 15 TC 14 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0740-9303 J9 OPHTHALMIC PLAST REC JI Ophthalmic Plast. Reconstr. Surg. PD JAN PY 1998 VL 14 IS 1 BP 9 EP 12 DI 10.1097/00002341-199801000-00003 PG 4 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA YY516 UT WOS:000072155300003 PM 9513236 ER PT B AU Gerrity, TR AF Gerrity, TR BE Nelson, R Gelish, A Mun, SK TI A federal research strategy for improving military health in future deployments SO PACIFIC MEDICAL TECHNOLOGY SYMPOSIUM, PROCEEDINGS LA English DT Proceedings Paper CT Pacific Medical Technology Symposium (PACMEDTek) CY AUG 17-21, 1998 CL HONOLULU, HI SP Tripler Army Med Ctr AB The federal government has a commitment to cave for the health of the men and women who put themselves in harm 's way to protect the vital interests of the Nation As we have learned from the Gulf War and other conflicts, the federal government must be able to rapidly respond to the health concerns of service member, veterans, and their family members. In response to this need the National Science and Technology Council has developed a comprehensive strategic plan that encompasses deployment health, records, research, and risk communications. The research component of the broader plan identifies several areas of research capability and capacity that need to be enhanced within the federal research sector in order to provide the type of rapid response that will be called for in the future. The goals, objectives, and strategies articulated by the plan focus heavily on epidemiological research (exposure and outcomes) and risk factor research (e.g. the health consequences of low level exposures of chemical warfare agents) that needs to be undertaken or enhanced. C1 US Dept Vet Affairs, Off Res & Dev, Washington, DC USA. RP Gerrity, TR (reprint author), US Dept Vet Affairs, Off Res & Dev, Washington, DC USA. NR 2 TC 0 Z9 0 U1 0 U2 1 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA BN 0-8186-8667-7 PY 1998 BP 270 EP 273 DI 10.1109/PACMED.1998.769920 PG 2 WC Computer Science, Interdisciplinary Applications; Medical Informatics SC Computer Science; Medical Informatics GA BN33G UT WOS:000081642800047 ER PT J AU Pitner, JK Long, LD Meyer, RP Pennypacker, LC AF Pitner, JK Long, LD Meyer, RP Pennypacker, LC TI Phenytoin toxicity in an older patient with slow metabolism and atypical presentation SO PHARMACOTHERAPY LA English DT Article ID PHARMACOKINETIC DRUG-INTERACTIONS; PROTEIN-BINDING; AGE; DIPHENYLHYDANTOIN; CLEARANCE; ILLNESS; PLASMA AB Phenytoin toxicity occurred in an older man who received a dosage of 300 mg/day. The patient developed high serum phenytoin concentrations from this common adult dosage, with symptoms of functional decline and altered mental status. These behaviors were perceived as sun-downing and were treated with haloperidol. A long hospitalization was required. C1 Ralph H Johnson VAMC, Div Geriatr & Extended Care, Charleston, SC 29401 USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Pitner, JK (reprint author), Ralph H Johnson VAMC, Div Geriatr & Extended Care, Mail Grp 11G,109 Bee St, Charleston, SC 29401 USA. NR 35 TC 5 Z9 5 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER BOX 806 171 HARRISON AVE, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JAN-FEB PY 1998 VL 18 IS 1 BP 218 EP 225 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YT660 UT WOS:000071629300024 PM 9469697 ER PT S AU DiGiovine, CP Cooper, RA DiGiovine, MM Boninger, ML Robertson, RN AF DiGiovine, CP Cooper, RA DiGiovine, MM Boninger, ML Robertson, RN BE Chang, HK Zhang, YT TI Digital filtering of kinematics of racing wheelchair propulsion SO PROCEEDINGS OF THE 20TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOL 20, PTS 1-6: BIOMEDICAL ENGINEERING TOWARDS THE YEAR 2000 AND BEYOND SE PROCEEDINGS OF ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY LA English DT Proceedings Paper CT 10th Annual International Conference of the IEEE-Engineering-in-Medicine-and-Biology-Society CY OCT 29-NOV 01, 1998 CL HONG KONG, PEOPLES R CHINA SP IEEE Engn Med & Biol Soc AB The purpose of this study was to examine the residual analysis technique described by Winter [1] in the digital filtering of the kinematics of racing wheelchair propulsion. Specifically, the selection of the type and cut-off frequency of the digital filter were examined. The residual analysis was performed on the second metacarpophalangeal joint (2MP) marker. Four different types of digital filters were examined: a 2(nd), a 4(th), and, 10(th) order Butterworth, as well as a 10(th) order Chebyshev type I with a passband ripple of 0.001 dB. The residual analysis was useful in determining the appropriate cut-off frequency for each individual filter. The cut-off frequency was between 7 and 8 Hz in the x-direction, between 9 and 10 Hz in the y-direction, and 7 Hz in the z-direction, depending on the type and order of the filter implemented. The residual analysis was not useful in determining the appropriate type of filter. Knowledge regarding the magnitude and phase characteristics of the filter, as well as the type of data to be filtered, should be used to determine the most appropriate type of filter. C1 VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, Pittsburgh, PA 15206 USA. RP DiGiovine, CP (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Lab, 7180 Highland Dr,151R-1, Pittsburgh, PA 15206 USA. EM cpdst11+@pitt.edu RI DiGiovine, Carmen/E-2982-2011 OI Boninger, Michael/0000-0001-6966-919X NR 11 TC 1 Z9 1 U1 0 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1094-687X BN 0-7803-5164-9 J9 P ANN INT IEEE EMBS PY 1998 VL 20 BP 2714 EP 2716 PN 1-6 PG 3 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Medical Informatics; Medical Laboratory Technology; Clinical Neurology; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Engineering; Medical Informatics; Medical Laboratory Technology; Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA BM59Y UT WOS:000079210400741 ER PT S AU Siegel, GJ Chauhan, NB Lee, JM AF Siegel, GJ Chauhan, NB Lee, JM BE Fisher, A Hanin, I Yoshida, M TI Age-related Na,K-ATPase mRNA expression and Alzheimer's disease SO PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES SE ADVANCES IN BEHAVIORAL BIOLOGY LA English DT Proceedings Paper CT 4th International Conference on Progress in Alzheimer's and Parkinson's Diseases CY MAY 18-23, 1997 CL ELAT, ISRAEL SP Israel Inst Biol Res, Alzheimers Assoc Ronald & Nancy Regan Res Inst, Appl Genet, Bayer AG, Hoechst Marion Roussel Inc, Mitokor, Loyola Univ Chicago,Stritch Sch Med,Inst Neurosci & Aging, Novartis Pharma AG, Snow Brand Milk Prod Co Ltd C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Mol & Cellular Neurosci Lab, Hines, IL 60141 USA. RP Siegel, GJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Mol & Cellular Neurosci Lab, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0099-9962 BN 0-306-45903-5 J9 ADV BEHAV BIOL PY 1998 VL 49 BP 113 EP 119 PG 7 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA BL91N UT WOS:000077133000017 ER PT J AU Olsen, TW Sternberg, P Capone, A Martin, DF Lim, JI Grossniklaus, HE Aaberg, TM AF Olsen, TW Sternberg, P Capone, A Martin, DF Lim, JI Grossniklaus, HE Aaberg, TM TI Macular hole surgery using thrombin-activated fibrinogen and selective removal of the internal limiting membrane SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article; Proceedings Paper CT 67th Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 21-26, 1996 CL FT LAUDERDALE, FLORIDA SP Assoc Res Vis & Ophthalmol DE autologous cryoprecipitate; bovine thrombin; fibrin sealants; macular hole; pars plana vitrectomy ID AUTOLOGOUS PLATELET CONCENTRATE; PARS-PLANA VITRECTOMY; TRANSFORMING GROWTH-FACTOR-BETA-2; CLINICOPATHOLOGICAL CORRELATION; VITREOUS SURGERY AB Purpose: To evaluate a tissue sealant (autologous cryoprecipitate activated with bovine thrombin) as an adjuvant in macular hole surgery. Methods: Sixty-nine patients with stage 2, 3, or 4 full-thickness macular hole were enrolled consecutively in a prospective pilot study. Anatomic closure of the macular holes with a single operation was the primary outcome. Fifty-eight patients had pre- and postoperative standardized measurements including best refracted visual acuity, reading speed, and contrast sensitivity. Group A patients (45) had primary macular holes; Group B patients (13) had recurrent macular holes or macular holes with "other" retinal pathology. Surgical technique was standardized and membrane dissections were optional. Results: The anatomic closure rate was 80% with a minimum of 6 months follow-up. Mean improvement in visual acuity for Group A (2.9 +/- 0.4 lines) was significantly better than for Group B (0.8 +/- 0.5 lines; P = 0.008). Eyes that underwent internal limiting membrane (ILM) dissections had an anatomic closure rate of 96% (23/24),compared with 71% (32/45) in "non-ILM" cases (P = 0.034). Adverse reactions included sterile hypopyon (10%), intraretinal hemorrhage (9%), pigmentary hyperplasia (3%), and retinal detachment (3%). Conclusion: Tissue sealants should be evaluated as an adjuvant in macular hole surgery in a randomized clinical trial. inflammatory reactions may occur in some patients, Internal limiting membrane dissection may improve anatomic closure rates without adversely affecting the visual acuity. C1 Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA. Univ Wisconsin, Madison, WI 53706 USA. Univ So Calif, Doheny Eye Inst, Los Angeles, CA USA. William S Middleton Mem Vet Hosp, Los Angeles, CA USA. RP Aaberg, TM (reprint author), Emory Univ, Dept Ophthalmol, 1365B Clifton Rd NE, Atlanta, GA 30322 USA. NR 25 TC 86 Z9 93 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PY 1998 VL 18 IS 4 BP 322 EP 329 PG 8 WC Ophthalmology SC Ophthalmology GA 110HG UT WOS:000075374900005 PM 9730174 ER PT J AU Palevsky, PM AF Palevsky, PM TI Hypernatremia SO SEMINARS IN NEPHROLOGY LA English DT Review ID NEPHROGENIC DIABETES-INSIPIDUS; VASOPRESSIN V2-RECEPTOR GENE; CENTRAL-NERVOUS-SYSTEM; WATER CHANNELS; SECRETION; OSMOREGULATION; VOLUME; BRAIN; DEHYDRATION; POPULATION C1 Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Room 4N173,Univ Dr Div, Pittsburgh, PA 15240 USA. NR 52 TC 34 Z9 34 U1 1 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9295 J9 SEMIN NEPHROL JI Semin. Nephrol. PD JAN PY 1998 VL 18 IS 1 BP 20 EP 30 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA YQ953 UT WOS:000071441800003 PM 9459286 ER PT J AU Antes, LM Kujubu, DA Fernandez, PC AF Antes, LM Kujubu, DA Fernandez, PC TI Hypokalemia and the pathology of ion transport molecules SO SEMINARS IN NEPHROLOGY LA English DT Review ID EPITHELIAL SODIUM-CHANNEL; PERIODIC PARALYSIS HYPOPP; RENAL POTASSIUM CHANNELS; BARTTERS-SYNDROME; SKELETAL-MUSCLE; GENETIC-HETEROGENEITY; COLLECTING DUCT; BETA-SUBUNIT; MISSENSE MUTATION; LIDDLES SYNDROME C1 Dept Vet Affairs Med Ctr, Renal Sect, Philadelphia, PA 19104 USA. RP Fernandez, PC (reprint author), Dept Vet Affairs Med Ctr, Renal Sect, 111J,Univ & Woodland Ave, Philadelphia, PA 19104 USA. FU NIDDK NIH HHS [DK-07006, DK-09575] NR 92 TC 9 Z9 11 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 J9 SEMIN NEPHROL JI Semin. Nephrol. PD JAN PY 1998 VL 18 IS 1 BP 31 EP 45 PG 15 WC Urology & Nephrology SC Urology & Nephrology GA YQ953 UT WOS:000071441800004 PM 9459287 ER PT J AU Singh, R El-Saden, S Cohen, SN Grant, EG Ryan, P Arashebon, A Al-Shanaa, M AF Singh, R El-Saden, S Cohen, SN Grant, EG Ryan, P Arashebon, A Al-Shanaa, M TI Intracranial vascular assessment in patients with cerebrovascular disease: Can non-invasive methods replace conventional angiography? SO STROKE LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Neurol Serv 127, Los Angeles, CA 90073 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1998 VL 29 IS 1 MA 62 BP 284 EP 284 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA YQ726 UT WOS:000071417100118 ER PT S AU Lee, CM Aspnes, LE Chung, SS Weindruch, R Aiken, JM AF Lee, CM Aspnes, LE Chung, SS Weindruch, R Aiken, JM BE Harman, D Holliday, R Meydani, M TI Influences of caloric restriction on age-associated skeletal muscle fiber characteristics and mitochondrial changes in rats and mice SO TOWARDS PROLONGATION OF THE HEALTHY LIFE SPAN: PRACTICAL APPROACHES TO INTERVENTION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Towards Prolongation of the Healthy Life Span - Practical Approaches to Intervention CY AUG 15-18, 1997 CL ADELAIDE, AUSTRALIA SP 7th Congress Int Assoc Biomed Gerontol ID CYTOCHROME-C-OXIDASE; CONTRACTILE PROPERTIES; DEGENERATIVE DISEASES; OXIDATIVE STRESS; DNA DELETIONS; AD-LIBITUM; LIFE-SPAN; MYOPATHY; MORPHOLOGY; LONGEVITY AB The effect of caloric restriction (CR) initiated in adult rats (17 months of age) on the abundance of deleted mitochondrial genomes, mitochondrial enzymatic abnormalities, and fiber number was examined in mt skeletal muscle. Vastus lateralis muscle from young (3-4 months) ad libitum-fed, old (30-32 months) restricted (35% and 50% CR, designated CR35 and CR50, respectively), and old ad libitum-fed rats (29 months) was studied, CR preserved fiber number and fiber-type composition in the CR50 rats, In the old rats from all groups, individual fibers were found with either no detectable cytochrome-c oxidase activity (COX-), hyperactive for succinate dehydrogenase activity (SDH++), or both COX- and SDH++. Muscle from the CR50 rats contained significantly few er COX- and SDH++ fibers than did the muscle from the CR35 rats. CR50 rats also had significantly low er numbers of mtDNA deletion products in two (adductor longus and soleus) of the four muscles examined compared to CR35 rats. These data indicate that CR begun in late middle age can retard age-associated fiber loss and fiber-type changes as well as loser the number of skeletal muscle fibers exhibiting mitochondrial enzyme abnormalities. CR can also decrease the accumulation of deleted mitochondrial genomes. C1 Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA. Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. Univ Wisconsin, Dept Med, Madison, WI 53706 USA. Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Aiken, JM (reprint author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1655 Linden Dr, Madison, WI 53706 USA. FU NIA NIH HHS [R01 AG10536, R01 AG11604] NR 48 TC 43 Z9 45 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-108-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1998 VL 854 BP 182 EP 191 DI 10.1111/j.1749-6632.1998.tb09901.x PG 10 WC Geriatrics & Gerontology; Multidisciplinary Sciences SC Geriatrics & Gerontology; Science & Technology - Other Topics GA BM29P UT WOS:000078303400017 PM 9928429 ER PT S AU Zeng, NX Kang, T Lyu, RM Wong, H Wen, Y Walsh, JH Sachs, G Pisegna, JR AF Zeng, NX Kang, T Lyu, RM Wong, H Wen, Y Walsh, JH Sachs, G Pisegna, JR BE Forssmann, WG Said, SI TI The pituitary adenylate cyclase activating polypeptide type 1 receptor (PAC(1)-R) is expressed on gastric ECL cells: Evidence by immunocytochemistry and RT-PCR SO VIP, PACAP, AND RELATED PEPTIDES: THIRD INTERNATIONAL SYMPOSIUM SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 3rd International Symposium on VIP, PACAP, and Related Peptides CY SEP 17-20, 1997 CL FREIBURG, GERMANY SP Amylin Pharmaceut, San Diego, Bayer AG, Wuppertal, Boehringer Mannheim GmBh, Mannheim, Dr Falk Pharma Gmbh, Hannover, Hoechst Marion Roussel, Frankfurt, Hoechst Marion Roussel Inc, Cincinnati, Immunodiagnostik GmBh, Bensheim, Itoham Foods Inc, Ibaraki, Madaus AG, Koln, Neosystem, Strasbourg, Peninsula Labs Inc, Belmont, Perkin Elmer, Appl Biosyst GmBh, Wetterstadt, Schering AG, Berlin, Solvay Pharmaceut GmBh, Hannover, Tap Holdings Inc, Deerfield, Wherl Gmbh, Wolfenbuttel ID VASOACTIVE-INTESTINAL-PEPTIDE; SIGNAL-TRANSDUCTION; RAT-BRAIN; FUNCTIONAL EXPRESSION; TISSUE DISTRIBUTION; SPLICE VARIANTS; PACAP RECEPTOR; BINDING-SITES; SMOOTH-MUSCLE; SECRETION AB The current study was undertaken to determine the presence and distribution of PAC(1)-Rs within the gastric mucosa, Polyclonal antibodies to the carboxyl terminus of the rat PAC(1)-R were generated and shown to be specific against the PAC(1)-R expressed in NIH 3T3 cells. Western blot analysis using isolated (approximate to 85% pure) ECL cell membranes identified a 48 kD protein consistent with the calculated molecular mass of the cloned PAC(1)-R. RT/PCR performed using specific primers for the PAC(1)-R confirmed the presence of splice variants of the rat PAC(1)-R, but not VPAC(1)-R or VPAC(1)-R, These data provide the first direct evidence for the existence of functional PACAP Type I receptors on ECL cells of the gastric mucosa and suggest a potential role for PACAP in the stimulation of gastric acid secretion and in the regulation of the growth of ECL cells. C1 UCLA DDRC, CURE VA, W Los Angeles Vet Adm Med Ctr, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. RP Pisegna, JR (reprint author), UCLA DDRC, CURE VA, W Los Angeles Vet Adm Med Ctr, Digest Dis Res Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 31 TC 27 Z9 27 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-153-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1998 VL 865 BP 147 EP 156 DI 10.1111/j.1749-6632.1998.tb11173.x PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary Sciences; Pharmacology & Pharmacy; Physiology SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology - Other Topics; Pharmacology & Pharmacy; Physiology GA BM29V UT WOS:000078306200017 PM 9928007 ER PT J AU Zanis, DA McLellan, AT Belding, MA Moyer, G AF Zanis, DA McLellan, AT Belding, MA Moyer, G TI A comparison of three methods of measuring the type and quantity of services provided during substance abuse treatment SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE treatment services; record abstraction; validity; self-report; treatment quality ID OPIATE AB This study examined three data collection methods of quantifying and categorizing treatment services provided in a publicly funded methadone program. All three approaches were research technician implemented: (1) bi-weekly patient interview with the Treatment Services Review (TSR); (2) weekly counselor interview by the Counselor Services Interview (CSI); and (3) data abstraction from clinical patient records (REC). Fifty patients were followed over 28 days using each method to assess the services : received/provided within the program. Five service domains were assessed: medical, employment, alcohol/drug, family, and psychiatric. Correlations were calculated among the three methods of data collection across each of the Eve service domains. Overall, low to moderate correlations were found with the highest rates of agreement detected between the TSR and the REC in the employment domain (0.48) and the REC and CSI in the family domain (0.48). Post hoc focus groups with the counselors and patients found that: (I) counseling sessions rarely focused on specific problem domains; (2) counselors and patients disagreed about the quality of treatment services; and (3) counselors 'rounded-up' time spent counseling. These findings suggest that measuring treatment service delivery varies markedly based on who provides the information (e.g. patient or treatment staff) and what procedures are used for data collection (e.g. chart abstraction or self-report). (C) 1997 Elsevier Science Ireland Ltd. C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Zanis, DA (reprint author), Univ Penn, Bldg 7 Mail Code 116-D,Univ & Woodland Aves, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [DA-05186] NR 13 TC 19 Z9 19 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 30 PY 1997 VL 49 IS 1 BP 25 EP 32 DI 10.1016/S0376-8716(97)00135-X PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA YT259 UT WOS:000071581800004 PM 9476696 ER PT J AU Daws, LC Toney, GM Davis, DJ Gerhardt, GA Frazer, A AF Daws, LC Toney, GM Davis, DJ Gerhardt, GA Frazer, A TI In vivo chronoamperometric measurements of the clearance of exogenously applied serotonin in the rat dentate gyrus SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE serotonin transporter; selective serotonin reuptake inhibitors; fluvoxamine; in vivo chronoamperometry; dentate gyrus; 5,7-dihydroxytryptamine ID PULSE VOLTAMMETRY INVIVO; NUCLEUS-ACCUMBENS; DORSAL STRIATUM; DOPAMINE UPTAKE; FRONTAL-CORTEX; BRAIN MICRODIALYSIS; PREFRONTAL CORTEX; UPTAKE INHIBITORS; FIBER ELECTRODES; CAUDATE-PUTAMEN AB The present study evaluated high-speed chronoamperometry as a method for measuring the clearance of serotonin (5-HT) from extracellular space in vivo. Male Sprague-Dawley rats were anaesthetized and a Nafion-coated, carbon fiber electrode, attached to a multibarrel pipette, was lowered into the subgranular layer of the dentate gyrus, a region which receives dense serotonergic innervation, or the corpus callosum, a fiber tract relatively devoid of the 5-HT transporter (SERT). Serotonin, pressure ejected into these regions, produced replicable electrochemical signals. The amplitude and time course of the signals were significantly prolonged in the corpus callosum compared to the dentate gyrus. Similarly, signals produced by locally applied 5-HT in the dentate gyrus of rats following destruction of hippocampal serotonergic innervation with 5,7-dihydroxytryptamine (5,7-DHT), were significantly enhanced compared to those observed in control animals. The time course of the 5-HT signal was significantly prolonged by local application of the selective 5-HT reuptake inhibitor, fluvoxamine, into the dentate gyrus. By contrast, fluvoxamine did not modify the clearance of 5-HT when locally applied into the dentate gyrus of 5,7-DHT lesioned rats or into the corpus callosum of intact rats. Taken together, these data demonstrate that in intact rats, the SERT contributes to the clearance of exogenously applied 5-HT from the extracellular space. Under the experimental conditions used in this study, high-speed chronoamperometry proved to be a reliable method for directly measuring extracellular 5-HT and appears to be a valuable tool for the study of 5-HT clearance by the SERT in vivo. (C) 1997 Elsevier Science B.V. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Neurosci Training Program, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Rocky Mt Ctr Sensor Technol, Denver, CO 80262 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Daws, LC (reprint author), Univ Adelaide, Dept Clin & Expt Pharmacol, Adelaide, SA 5005, Australia. FU NIMH NIH HHS [MH29094]; NINDS NIH HHS [NS09199] NR 53 TC 33 Z9 33 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 J9 J NEUROSCI METH JI J. Neurosci. Methods PD DEC 30 PY 1997 VL 78 IS 1-2 BP 139 EP 150 DI 10.1016/S0165-0270(97)00144-1 PG 12 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA YV689 UT WOS:000071852900015 PM 9497010 ER PT J AU Conrad, CC Walter, CA Richardson, A Hanes, MA Grabowski, DT AF Conrad, CC Walter, CA Richardson, A Hanes, MA Grabowski, DT TI Cadmium toxicity and distribution in metallothionein-I and -II deficient transgenic mice SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH LA English DT Article ID MOUSE; HEPATOTOXICITY; TOLERANCE; PRETREATMENT; LETHALITY; INDUCTION; GENES; RATS AB To date, numerous correlative studies have implicated metallothionein in the detoxification of heavy metals and in the regulation of metal distribution within an organism. In the present study cadmium-binding proteins (metallothionein equivalents), cadmium acute toxicity, and cadmium distribution in tissues and subcellular fractions were compared in metallothionein-I and -II deficient (MT-/-) mice and the parental strain carrying intact metallothionein genes (M+/+) to determine if the absence of metallothionein altered any of these parameters. In an uninduced state, M-/- mice expressed lower levels of cadmium-binding proteins relative to MT+/+ mice in several tissues. Administration of zinc enhanced the levels of cadmium-binding proteins in liver, small intestine kidney, pancreas, and male sex organs, but not in cecum or brain of MT+/+ mice compared to zinc pretreated M-/- mice. The cadmium LD50 was similar for MT-/-, MT+/+, and zinc-pretreated MT-/- mice (15-17 mu mol CdCl2/kg body weight delivered ip). However, zinc-pretreated MT+/+ mice had a cadmium LD50 of 58-63 mu mol CdCL2/kg body weight. Over two-thirds of cadmium was found in liver, cecum, small intestine, and kidney in both MT+/+ and MT-/- mice; therefore, metallothionein levels do not appear to play a major role in the tissue distribution of cadmium. However, after zinc pretreatment, MT+/+ mice accumulated more cadmium in the liver and less in other tissues, whereas the amount of cadmium in the liver was not altered by zinc pretreatment in MT-/- mice. In general, the cytosolic/particulate ratio of cadmium was significantly higher in tissues of noninduced MT+/+ mice relative to MT-/- mice. This difference was accentuated after zinc pretreatment. Together these results indicate that basal levels of metallothionein do not protect from the acute toxicity of a single ip cadmium challenge. Furthermore, it does not appear that the cytosolic compartmentalization of cadmium is correlated with reduced toxicity. C1 UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284. S TEXAS VET HLTH CARE SYST,GERIATR RES EDUC & CLIN CTR,SAN ANTONIO,TX. UNIV TEXAS,HLTH SCI CTR,DEPT LAB ANIM RESOURCES,SAN ANTONIO,TX 78284. FU NCI NIH HHS [CA61335]; NIEHS NIH HHS [ES06277] NR 30 TC 18 Z9 23 U1 1 U2 9 PU TAYLOR & FRANCIS PI BRISTOL PA 1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598 SN 0098-4108 J9 J TOXICOL ENV HEALTH JI J. Toxicol. Environ. Health PD DEC 26 PY 1997 VL 52 IS 6 BP 527 EP 543 PG 17 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA YJ719 UT WOS:A1997YJ71900003 PM 9397184 ER PT J AU Casini, G Rickman, DW Sternini, C Brecha, NC AF Casini, G Rickman, DW Sternini, C Brecha, NC TI Neurokinin 1 receptor expression in the rat retina SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE substance P; amacrine cells; bipolar cells; GABA; dopamine ID IMMUNOREACTIVE AMACRINE CELLS; GABA-LIKE IMMUNOREACTIVITY; DECARBOXYLASE-LIKE IMMUNOREACTIVITIES; VASOACTIVE INTESTINAL POLYPEPTIDE; P-LIKE IMMUNOREACTIVITY; C-LIKE IMMUNOREACTIVITY; CONE BIPOLAR CELLS; SUBSTANCE-P; RABBIT RETINA; GANGLION-CELLS AB Tachykinin (TK) peptides influence neuronal activity in the inner retina of mammals. The aim of this investigation was to determine the cellular localization of the neurokinin 1 receptor (NK1), whose preferred ligand is the TK peptide substance P (SP), in the rat retina. These studies used a polyclonal antiserum directed to the C-terminus of rat NK1. The majority of NK1-immunoreactive (IR) cells were located in the proximal inner nuclear layer (INL), and very rarely they were found in the distal INL. Some small and large NK1-IR somata were present in the ganglion cell layer. NK1-IR processes were densely distributed across the inner plexiform layer (IPL) with a maximum density over lamina 2 of the IPL. Immunoreactive processes also crossed the INL and ramified in the outer plexiform layer where they formed a sparse meshwork. NK1-IR processes were rarely observed in the optic nerve fiber layer. Double-label immunofluorescence studies with different histochemical markers for bipolar cells indicated that NK1 immunoreactivity was not present in bipolar cells. Together, these observations indicate that NK1 immunoreactivity is predominantly expressed by amacrine, displaced amacrine, interplexiform, and some ganglion cells. Double-label immunofluorescence experiments were also performed to characterize NK1-containing amacrine cells. Sixty-one percent of the gamma-aminobutyric acid (GABA)-IR cells, 71% of the large tyrosine hydroxylase (TH)-IR cells, and 100% of the small TH-IR cells contained NK1 immunoreactivity. In addition, most (91%) of the NK1-IR cells had GABA immunoreactivity. In contrast, vasoactive intestinal polypeptide-, TK-, choline acetyltransferase-, and parvalbumin-IR amacrine cells did not express NK1 immunoreactivity. Overall, the present findings suggest that SP acts directly upon several cell populations, including GABA-containing amacrine cells and ganglion cells, to influence visual information processing in the inner retina. (C) 1997 Wiley-Liss, Inc. C1 W LOS ANGELES VET AFFAIRS MED CTR,CURE,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,SCH MED,DIGEST DIS RES CTR,CURE,DEPT NEUROBIOL,BRAIN RES INST,LOS ANGELES,CA 90095. UNIV CALIF LOS ANGELES,SCH MED,DIGEST DIS RES CTR,CURE,DEPT MED,BRAIN RES INST,LOS ANGELES,CA 90095. UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90095. FU NEI NIH HHS [R01 EY004067, EY 04067, R56 EY004067, R01 EY004067-15]; NIDDK NIH HHS [P30 DK041301] NR 71 TC 25 Z9 25 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD DEC 22 PY 1997 VL 389 IS 3 BP 496 EP 507 PG 12 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA YJ244 UT WOS:A1997YJ24400010 PM 9414009 ER PT J AU Levine, S Kaiser, L Leferovich, J Tikunov, B AF Levine, S Kaiser, L Leferovich, J Tikunov, B TI Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID MYOSIN HEAVY-CHAIN; HUMAN SKELETAL-MUSCLE; MYOFIBRILLAR PROTEIN-TURNOVER; FIBER TYPES; ELECTROPHORETIC SEPARATION; SINGLE FIBERS; SLOW MYOSIN; NORMAL MEN; FATIGUE; EXERCISE AB Background In patients with severe chronic obstructive pulmonary disease, the diaphragm undergoes physiologic adaptations characterized by an increase in energy expenditure and relative resistance to fatigue. We hypothesized that these physiologic characteristics would be associated with structural adaptations consisting of an increased proportion of less-fatigable slow-twitch muscle fibers and slow isoforms of myofibrillar proteins. Methods We obtained biopsy specimens of the diaphragm from 6 patients with severe chronic obstructive pulmonary disease (mean [+/-SE] forced expiratory volume in one second, 33+/-4 percent of the predicted value; residual volume, 259+/-25 percent of the predicted value) and 10 control subjects. The proportions of the various isoforms of myosin heavy chains, myosin light chains, troponin, and tropomyosin were determined by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis. We also used immunocytochemical techniques to determine the proportions of the various types of muscle fibers. Results The diaphragm-biopsy specimens from the patients had higher percentages of slow myosin heavy chain I (64+/-3 vs. 45+/-2 percent, P<0.001), and lower percentages of fast myosin heavy chains IIa (29+/-3 vs. 39+/-2 percent, P=0.01) and IIb (8+/-1 vs. 17+/-1 percent, P<0.001) than the diaphragms of the controls. Similar differences were noted when immunohistochemical techniques were used to compare the percentages of these fiber types in the two groups. In addition, the patients had higher percentages of the slow isoforms of myosin light chains, troponins, and tropomyosin, whereas the controls had higher percentages of the fast isoforms of these proteins. Conclusions Severe chronic obstructive pulmonary disease increases the slow-twitch characteristics of the muscle fibers in the diaphragm, an adaptation that increases resistance to fatigue. (C) 1997, Massachusetts Medical Society. C1 ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,CRIT CARE DIV,PHILADELPHIA,PA 19104. UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104. UNIV PENN,DIV THORAC SURG,PHILADELPHIA,PA 19104. RP Levine, S (reprint author), ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,DIV PULM,UNIV & WOODLAND AVES,PHILADELPHIA,PA 19104, USA. NR 44 TC 203 Z9 211 U1 0 U2 3 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 18 PY 1997 VL 337 IS 25 BP 1799 EP 1806 DI 10.1056/NEJM199712183372503 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA YL855 UT WOS:A1997YL85500003 PM 9400036 ER PT J AU Jonsson, EG Mirsky, AF Johannesson, T Wahlstrom, J Bieliauskas, LA van Kammen, DP Sedvall, GC AF Jonsson, EG Mirsky, AF Johannesson, T Wahlstrom, J Bieliauskas, LA van Kammen, DP Sedvall, GC TI No cytogenetical abnormalities in a set of schizophrenic quadruplets SO BIOLOGICAL PSYCHIATRY LA English DT Letter ID GENAIN QUADRUPLETS; TRIPLETS; FAMILY C1 Karolinska Hosp, Dept Clin Neurosci, Psychiat Sect, SE-17176 Stockholm, Sweden. NIMH, Sect Clin & Expt Neuropsychol, Bethesda, MD 20892 USA. East Hosp, Dept Clin Genet, Gothenburg, Sweden. VA Med Ctr, Psychol Serv, Ann Arbor, MI USA. Univ Michigan, Hosp Med, Dept Psychiat, Neuropsychol Program, Ann Arbor, MI 48109 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RP Jonsson, EG (reprint author), Karolinska Hosp, Dept Clin Neurosci, Psychiat Sect, SE-17176 Stockholm, Sweden. NR 16 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 1997 VL 42 IS 12 BP 1186 EP 1187 DI 10.1016/S0006-3223(97)00393-4 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA YM224 UT WOS:000071042200016 PM 9426891 ER PT J AU Yin, AH Miraglia, S Zanjani, ED AlmeidaPorada, G Ogawa, M Leary, AG Olweus, J Kearney, J Buck, DW AF Yin, AH Miraglia, S Zanjani, ED AlmeidaPorada, G Ogawa, M Leary, AG Olweus, J Kearney, J Buck, DW TI AC133, a novel marker for human hematopoietic stem and progenitor cells SO BLOOD LA English DT Article ID HUMAN-BONE-MARROW; TERM REPOPULATING ABILITY; RECEPTOR TYROSINE KINASE; PERIPHERAL-BLOOD; UMBILICAL-CORD; B-CELLS; EXPRESSION; CD34; DIFFERENTIATION; TRANSPLANTATION AB AC133 is one of a new panel of murine hybridoma lines producing monoclonal IgG antibodies (mAbs) to a novel stem cell glycoprotein antigen with a molecular weight of 120 kD. AC133 antigen is selectively expressed on Cd34(bright) hematopoietic stem and progenitor cells (progenitor's) derived from human fetal liver and bone marrow, add blood. It is: not detectable on other blood cells, cultured human umbilical vein endothelial cells (HUVECs), fibroblast cell lines, or the myeloid leukemia cell line KG1a by standard flow cytometric procedures. All of the noncommitted CD34(+) cell population, as well as the majority of CD34(+) cells committed to the granulocytic/monocytic pathway. are stained with AC133 antibody. In vitro clonogenicity assays have demonstrated that the CD34(+)AC133(+) double-positive population from adult bone marrow contains the majority of the CFU-GM, a proportion of the CFU-Mix, and a minor population of BFU-E. The CD34(dim) and AC133(-) population has been shown to contain the remaining progenitor cells. AC133-selected cells engraft successfully in a fetal sheep transplantation model, and human cells harvested from chimeric fetal sheep bone marrow have been shown to successfully engraft secondary recipients, providing evidence for the long-term repopulating potential of AC133(+) cells. A cDNA coding for AC133 antigen has been isolated, which codes for a polypeptide consisting of 865 amino acids (aa) with a predicted site of 97 kD. This antigen is modeled as a 5-transmembrane molecule, a structure that is novel among known cell surface structures. AC133 antibody provides an alternative to CD34 for the selection and characterization of cells necessary for with short- and long-term engraftment, in transplant situations, for studies of ex vivo expansion strategies, and for gene therapy. (C) 1997 by The American Society of Hematology. C1 AMCELL CORP,SUNNYVALE,CA 94089. UNIV NEVADA,VET ADM MED CTR,RENO,NV 89557. MED UNIV S CAROLINA,RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29425. BECTON DICKINSON IMMUNOCYTOMETRY SYST,SAN JOSE,CA. UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294. RI Olweus, Johanna/G-8008-2015 OI Olweus, Johanna/0000-0002-1898-3100 FU NHLBI NIH HHS [HL52955, HL49042]; NIAID NIH HHS [AI35940] NR 58 TC 1165 Z9 1280 U1 4 U2 38 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD DEC 15 PY 1997 VL 90 IS 12 BP 5002 EP 5012 PG 11 WC Hematology SC Hematology GA YJ908 UT WOS:A1997YJ90800040 PM 9389720 ER PT J AU Moss, HB Yao, JK AF Moss, HB Yao, JK TI Basal plasma beta-endorphin in prepubertal sons of alcoholics and drug addicts: lack of association with problem behaviors SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE beta-endorphin; children; drug abuse; alcoholism ID HIGH-RISK; ETHANOL; NALTREXONE; CORTISOL; CHILDREN; ACTH; CONSUMPTION; DEPENDENCE; MORPHINE; NALOXONE AB Several reports have speculated that variations in beta-endorphin functioning may actually proceed the development of alcoholism and other drug use disorders, and is consequently a genetic mechanism of some etiologic importance. The goal of this investigation was to determine whether differences in basal plasma beta-endorphin concentrations could be confirmed in prepubertal children naive to alcohol and drugs, yet at parental risk for alcoholism, or drug dependence. Consequently, we have examined fasting basal plasma beta-endorphin concentrations in a sample of prepubertal sons of alcoholic fathers and compared them to both our existing sample of sons of drug dependent fathers and normal control boys. In addition, we examined the relationship between plasma beta-endorphin concentrations and maternal reports of problem behaviors posited to be related to the liability for alcoholism or drug abuse. The results reveal no differences in fasting basal plasma beta-endorphin concentrations. Although the at-risk groups differ significantly from normal boys having elevated scale scores for internalizing and externalizing problem behaviors, no association between plasma beta-endorphin and these behavioral risk factors could be found. Overall, the results fail to support an inherited 'opioid deficiency hypothesis' for the development of alcoholism or drug dependence. (C) 1997 Elsevier Science Ireland Ltd. C1 Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Ctr Educ & Drug Abuse Res, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. RP Moss, HB (reprint author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Ctr Educ & Drug Abuse Res, 3811 OHara St, Pittsburgh, PA 15213 USA. FU NIDA NIH HHS [P50-DA 05605, K05-DA 00308] NR 34 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 15 PY 1997 VL 48 IS 3 BP 221 EP 225 DI 10.1016/S0376-8716(97)00128-2 PG 5 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA YM892 UT WOS:000071112200011 PM 9449021 ER PT J AU Fitzsimmons, TJ McRoberts, JA Tachiki, KH Pandol, SJ AF Fitzsimmons, TJ McRoberts, JA Tachiki, KH Pandol, SJ TI Acyl-coenzyme A causes Ca2+ release in pancreatic acinar cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; COA ESTERS; RYANODINE RECEPTORS; EXOCRINE PANCREAS; CALCIUM; OSCILLATIONS; POOL; ACTIVATION; MECHANISM AB The regulation of cytosolic Ca2+ is important for a variety of cell functions. One non-inositol 1,4,5-trisphosphate (IP3) compound that may regulate Ca2+ is palmitoyl-coenzyme A (CoA), a fatty acid-CoA that is reported to cause Ca2+ release from intracellular stores of oocytes, myocytes, and hepatocytes. To study the role of palmitoyl-CoA in the pancreatic acinar cell, rat pancreatic acini were isolated by collagenase digestion, permeablized with streptolysin O, and the release of Ca2+ from internal stores was measured with fura-2. Palmitoyl-CoA released Ca2+ from internal stores (EC50 = 14 mu M). The palmitoyl-CoA-sensitive pool was distinct from, and overlapping with the IP3-sensitive Ca2+ pool. The effects of submaximal doses of IP3 or cyclic ADP-ribose plus palmitoyl-CoA were additive. Fatty acid-CoA derivatives with carbon chain lengths of 16-18 were the most potent and efficacious. Ryanodine and caffeine or elevated resting [Ca2+] sensitized the Ca2+ pool to the actions of palmitoyl-CoA. Fatty acid-CoA levels in pancreatic acini were measured by extraction with 2-propanol/acetonitrile, followed by separation and quantification using reverse phase high performance liquid chromatography, and were found to be 10.17 +/- 0.93 nmol/mg protein. These data suggest the presence of an IP3-insensitive palmitoyl-CoA-sensitive Ca2+ store in pancreatic acinar cells and suggest that palmitoyl-CoA may be needed for Ca2+-induced Ca2+ release. C1 UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA 90073. RP Fitzsimmons, TJ (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,11301 WILSHIRE BLVD 151,BLDG 258,RM 340,LOS ANGELES,CA 90073, USA. FU NIDDK NIH HHS [DK 33010] NR 28 TC 25 Z9 25 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 12 PY 1997 VL 272 IS 50 BP 31435 EP 31440 DI 10.1074/jbc.272.50.31435 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YL419 UT WOS:A1997YL41900035 PM 9395476 ER PT J AU Rettig, MB Said, JW Sun, R Vescio, RA Berenson, JR AF Rettig, MB Said, JW Sun, R Vescio, RA Berenson, JR TI Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma - Response SO SCIENCE LA English DT Editorial Material ID POLYMERASE CHAIN-REACTION; LYMPHOCYTES-B; HEPARIN; PLASMA; CELLS; VIRUS; BLOOD; DNA C1 UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095. UNIV CALIF LOS ANGELES,DIV HEMATOL & ONCOL,LOS ANGELES,CA 90095. RP Rettig, MB (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,DIV HEMATOL & ONCOL,11301 WILSHIRE BLVD,111-H,LOS ANGELES,CA 90073, USA. NR 15 TC 5 Z9 5 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 SN 0036-8075 J9 SCIENCE JI Science PD DEC 12 PY 1997 VL 278 IS 5345 BP 1972 EP 1973 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA YL002 UT WOS:A1997YL00200047 ER PT J AU Brooks, PJ Kleopoulos, SP Funabashi, T Mobbs, CV Pfaff, DW AF Brooks, PJ Kleopoulos, SP Funabashi, T Mobbs, CV Pfaff, DW TI Widespread expression and estrogen regulation of PPEIA-3' nuclear RNA in the rat brain SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE transcription termination; RNA processing; intron; vestibular complex; cerebellar nuclei ID SMALL NUCLEOLAR RNAS; MESSENGER-RNA; INSITU HYBRIDIZATION; HETERONUCLEAR RNA; GENE; TRANSCRIPTION; LOCALIZATION; ELONGATION AB We previously identified a novel nuclear RNA species derived from the preproenkephalin (PPE) gene. This transcript, which we have named PPEIA-3' RNA, hybridizes with probes directed at a region of PPE intron A downstream of an alternative germ-cell transcription start site, but does not contain PPE protein coding sequences. We now report that estrogen treatment of ovariectomized rats increases the expression of conventional PPE heteronuclear RNA, and also induces the expression of PPEIA-3' RNA, apparently in separate cell populations within the ventromedial nucleus of the hypothalamus. Further, we show that cells expressing PPEIA-3' are found in several neuronal groups in the rat forebrain and brainstem, with a distinct topographical distribution. High densities of PPEIA3' containing cells are found in the reticular thalamic nucleus, the basal forebrain, the vestibular complex, the deep cerebellar nuclei, and the trapezoid body, a pattern that parallels the distribution of atypical nuclear RNAs described by other groups. These results suggest that this diverse neuronal population shares a common set of nuclear factors responsible for the expression and retention of this atypical RNA transcript. The implication of these results for cell-specific gene transcription and regulation in the brain and the possible relationship of PPEIA-3' RNA and other atypical nuclear RNAs is discussed. C1 MT SINAI SCH MED,FISHBERG CTR NEUROBIOL,NEW YORK,NY 10128. MT SINAI SCH MED,BRONX VET AFFAIRS MED CTR,NEW YORK,NY 10128. YOKOHAMA CITY UNIV,SCH MED,DEPT PHYSIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN. ROCKEFELLER UNIV,NEUROBIOL & BEHAV LAB,NEW YORK,NY 10021. RP Brooks, PJ (reprint author), NIAAA,MOL NEUROBIOL SECT,NEUROGENET LAB,NIH,12501 WASHINGTON AVE,ROCKVILLE,MD 20852, USA. NR 32 TC 2 Z9 2 U1 1 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD DEC 9 PY 1997 VL 94 IS 25 BP 14037 EP 14041 DI 10.1073/pnas.94.25.14037 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA YK825 UT WOS:A1997YK82500121 PM 9391148 ER PT J AU Mummidi, S Ahuja, SS McDaniel, BL Ahuja, SK AF Mummidi, S Ahuja, SS McDaniel, BL Ahuja, SK TI The human CC chemokine receptor 5 (CCR5) gene - Multiple transcripts with 5 '-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ACTIVATING-FACTOR RECEPTOR; MESSENGER-RNA; HIV-1 INFECTION; FUNCTIONAL-CHARACTERIZATION; GENOMIC ORGANIZATION; MOLECULAR-CLONING; EXPRESSION; IDENTIFICATION; MIP-1-ALPHA; MIP-1-BETA AB Human CC chemokine receptor 5 (CCR5), mediates the activation of cells by the chemokines macrophage inflammatory protein-la; macrophage inflammatory protein-1 beta, and RANTES, and serves as a fusion cofactor for macrophage-tropic strains of human immunodeficiency virus type 1. To understand the molecular mechanisms that regulate human CCR5 gene expression, we initiated studies to determine its genomic and mRNA organization, Previous studies have identified a single CCR5 mRNA isoform whose open reading frame is intronless, We now report the following novel findings, 1) Complex alternative splicing and multiple transcription start sites give rise to several distinct CCR5 transcripts that differ in their 5'-untranslated regions (UTR), 2) The gene is organized into four exons and two introns, Exons 2 and 3 are not interrupted by an intron, Exon 4 and portions of exon 3 are shared by all isoforms, Exon 4 contains the open reading frame, 11 nucleotides of the 5'-UTR and the complete 3'-UTR. 3) The transcripts appear to be initiated from two distinct promoters: an upstream promoter (P-U), upstream of exon 1, and a downstream promoter (P-D), that includes the "intronic" region between exons 1 and 3, 4) P-U and P-D lacked the canonical TATA or CAAT motifs, and are AT-rich, 5) P-D demonstrated strong constitutive promoter activity, whereas P-U was a weak promoter in all three leukocyte cell environments tested (THP-1, Jurkat, and K562), 6) We provide evidence for polymorphisms in the noncoding sequences, including the regulatory regions and 5'-UTRs, The structure of CCR5 was strikingly reminiscent of the overall structure of other chemokine/chemoattractant receptors, underscoring an important evolutionarily conserved function for a prototypical gene structure. This is the first description of functional pro meters for any CC chemokine receptor gene, and we speculate that the complex pattern of splicing events and dual promoter usage may function as a versatile mechanism to create diversity and flexibility in the regulation of CCR5 expression. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. RP Ahuja, SK (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 NR 54 TC 125 Z9 128 U1 2 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 5 PY 1997 VL 272 IS 49 BP 30662 EP 30671 DI 10.1074/jbc.272.49.30662 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YT745 UT WOS:000071640800014 PM 9388201 ER PT J AU Berkwits, M Gluckman, SJ AF Berkwits, M Gluckman, SJ TI Seeking an expert interpretation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID DIAGNOSIS C1 VET AFFAIRS MED CTR,PHILADELPHIA,PA. UNIV PENN,MED CTR,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104. UNIV PENN,MED CTR,DIV INFECT DIS,PHILADELPHIA,PA 19104. NR 9 TC 0 Z9 0 U1 0 U2 0 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 4 PY 1997 VL 337 IS 23 BP 1682 EP 1684 DI 10.1056/NEJM199712043372308 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA YJ871 UT WOS:A1997YJ87100008 PM 9385129 ER PT J AU Richardson, A AF Richardson, A TI Animal models of aging SO AGING-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article ID FISCHER-344 RATS; LONGEVITY; STRAINS C1 S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Richardson, A (reprint author), S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. NR 10 TC 1 Z9 1 U1 1 U2 1 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 0394-9532 J9 AGING-CLIN EXP RES JI Aging-Clin. Exp. Res. PD DEC PY 1997 VL 9 IS 6 BP 439 EP 441 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA ZA202 UT WOS:000072339200016 PM 9553631 ER PT J AU Shoptaw, S Frosch, D Rawson, RA Ling, W AF Shoptaw, S Frosch, D Rawson, RA Ling, W TI Cocaine abuse counseling as HIV prevention SO AIDS EDUCATION AND PREVENTION LA English DT Article ID INTRAVENOUS-DRUG-USERS; RISK REDUCTION; CRACK; PREDICTORS; BEHAVIORS; INFECTION; WOMEN; SEX AB The current study evaluated the efficacy of cocaine abuse counseling alone as a strategy to reduce HIV-related sexual risk behaviors. Participants were 232 cocaine-abusing or dependent individuals who received up to 26 weeks of Matrix counseling but no formal HIV-prevention interventions, One hundred fifty-seven (67.6%) participants completed assessments at admission, during treatment, and at 6 months following admission. Participants located for follow-up were significantly more likely to be Caucasian, to be better educated, and to complete longer treatment episodes than those not located. Main study findings indicated a statistically significant association between safer sex behavior and completion of a cocaine abuse counseling episode (chi(2)(2, n = 157) = 6.25, p < .05). Participants who completed counseling were more likely to change to safer sex or maintain safer sex over the 6-month period than participants who terminated counseling prematurely. The primary method for reducing sexual risk involved overall decreases in reported numbers of partners (Partners(baseline) = 532, SD = 6.25; Partners(6 Months) = 2.47, SD = 2.62; F(1, 132) = 36.32, p < .001) among this group of mostly heterosexual (89.9%), Caucasian (69.0%), crack cocaine users (65.6%). We concluded that cocaine abuse counseling is a powerful intervention for reducing HIV-related sexual behaviors in this group at high risk for exposure to HIV. Study findings suggested that efforts to evaluate HIV prevention programs must also account for the effect of drug counseling. C1 Los Angeles Addict Treatment Res Ctr, Los Angeles, CA 90025 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Shoptaw, S (reprint author), Los Angeles Addict Treatment Res Ctr, 10350 Santa Monica Blvd,Suite 340, Los Angeles, CA 90025 USA. FU NIDA NIH HHS [R18 DA-06185] NR 21 TC 13 Z9 14 U1 4 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD DEC PY 1997 VL 9 IS 6 BP 511 EP 520 PG 10 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA YQ926 UT WOS:000071438500003 PM 9451479 ER PT J AU Peskind, ER Leverenz, J Farlow, MR Ito, RK Provow, SA Siegel, RS Cleveland, M Morgan, CH Pandian, MR Corbin, S Nochlin, D Schellenberg, GD Raskind, MA Wagner, SL AF Peskind, ER Leverenz, J Farlow, MR Ito, RK Provow, SA Siegel, RS Cleveland, M Morgan, CH Pandian, MR Corbin, S Nochlin, D Schellenberg, GD Raskind, MA Wagner, SL TI Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; beta-amyloid; cerebrospinal fluid; soluble beta-amyloid protein precursor (s beta PP) ID HEREDITARY CEREBRAL-HEMORRHAGE; ADRDA WORK GROUP; CLINICAL-DIAGNOSIS; DUTCH TYPE AB The authors compared concentrations of soluble beta-amyloid protein precursor (s beta PP) in cerebrospinal fluid (CSF) in 45 patients diagnosed with probable Alzheimer disease (AD) and 26 normal older control volunteers. Soluble beta-amyloid protein precursor concentrations were measured in 125 CSF samples using an enzyme-linked immunosorbent assay. All subjects had Mini-Mental State Examination (MMSE) and Clinical Dementia Rating Scale (CDRS) scores and assessment of disease duration. The s beta PP concentrations in CSF in the probable AD group (mean +/- SD = 493 +/- 268 mu g/L) were decreased significantly compared with the age-matched control group (mean = 831 +/- 302 mu g/L; p < 0.0001). In the probable AD group, MMSE scores correlated positively with s beta PP concentrations (correlation coefficient r = 0.53,p < 0.0001), and CDRS ratings and disease duration correlated inversely with s beta PP concentrations (r = -0.59,p < 0.0001 and r = -0.479,p = 0.0006, respectively). Although the decrease in CSF s beta PP from levels found in healthy elderly controls was significant in AD subjects, there was substantial overlap. In AD, CSF s beta PP was most reduced in patients in later stages of the disease. The s beta PP concentrations reflect disease severity, but utility in differential diagnosis has not been determined. C1 VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. Nichols Inst, San Juan Capistrano, CA USA. Salk Inst Biotechnol Ind Associates Inc, La Jolla, CA USA. RP Peskind, ER (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIA NIH HHS [AGO5136, AG06781, AG10133] NR 29 TC 10 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD DEC PY 1997 VL 11 IS 4 BP 201 EP 206 PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA YN294 UT WOS:000071152500004 PM 9437437 ER PT J AU Sultzer, DL Gray, KF Gunay, I Berisford, MA Mahler, ME AF Sultzer, DL Gray, KF Gunay, I Berisford, MA Mahler, ME TI A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 148th Annual Meeting of the American-Psychiatric-Association CY MAY 20-26, 1995 CL MIAMI BEACH, FL SP Amer Psychiat Assoc ID ALZHEIMERS-DISEASE; AGGRESSIVE-BEHAVIOR; NURSING-HOME; NEUROLEPTIC TREATMENT; PSYCHIATRIC-SYMPTOMS; COGNITIVE DECLINE; MENTAL-DISORDERS; RATING-SCALE; COMPLICATIONS; DISTURBANCES AB The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia. Twenty-eight elderly patients with dementia and agitated behaviors were randomly assigned to double-blind treatment with either trazodone (50-250 mg/day) or haloperidol (1-5 mg/day) for 9 weeks. There was no significant difference in improvement between the medication groups. Adverse effects, however, were more common in the group treated with haloperidol. Improvement in individual areas suggested that repetitive, verbally aggressive, and oppositional behaviors responded preferentially to trazodone, whereas symptoms of excessive motor activity and unwarranted accusations responded preferentially to haloperidol These results indicate that moderate doses of trazodone and haloperidol are equally effective for treatment of overall agitated behaviors inpatients with dementia, but specific symptoms may respond preferentially to a particular agent. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. RP Sultzer, DL (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,PSYCHIAT SERV,BEHAV NEUROSCI SECT,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA. FU NIA NIH HHS [AG10123]; NIMH NIH HHS [MH00910] NR 55 TC 100 Z9 104 U1 2 U2 6 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD WIN PY 1997 VL 5 IS 1 BP 60 EP 69 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA VZ642 UT WOS:A1997VZ64200008 PM 9169246 ER PT J AU Chen, J Cohn, RA Lin, SC Cortes, AE Alvarado, JA AF Chen, J Cohn, RA Lin, SC Cortes, AE Alvarado, JA TI Endoscopic photocoagulation of the ciliary body for treatment of refractory glaucomas SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID ND-YAG CYCLOPHOTOCOAGULATION; UNCONTROLLED GLAUCOMA; LASER CYCLOPHOTOCOAGULATION; TRANSSCLERAL NEODYMIUM; NEOVASCULAR GLAUCOMA; CYCLOCRYOTHERAPY; MANAGEMENT; ABLATION; LENS AB PURPOSE: To evaluate the safety and efficacy of endoscopic cyclophotocoagulation in the treatment of refractory glaucomas. METHODS: The preoperative and postoperative courses of 68 eyes of 68 patients who underwent endoscopic cyclophotocoagulation at our institution were retrospectively reviewed. Study patients had diverse forms of glaucoma, and most had failed maximal medical therapy as well as failed filtration or transscleral cyclodestructive procedures, or both. Endoscopic cyclophotocoagulation treat ment encompassed 180 to 360 degrees of the ciliary body circumference and was performed through a limbal incision (56 eyes, 12 of which underwent concurrent cataract extraction) or pars plana incision (12 eyes). A second laser treatment was required in five eyes (7%). RESULTS: During the mean follow-up period of 12.9 months, mean +/- SD intraocular pressure decreased from 27.7 +/- 10.3 mm Mg preoperatively to 17.0 +/- 6.7 mm Hg at the final postoperative visit (P <.0001), for a mean reduction of 10.7 mm Mg and a mean percent decrease of 34%. Sixty-one eyes (90%) achieved an intraocular pressure less than or equal to 21 mm Mg. Using this definition of success, Kaplan-Meier analysis predicted a successful outcome in 94% of patients after 1 year and 82% after 2 years. The mean number of glaucoma medications used by each patient was reduced from 3.0 +/- 1.3 preoperatively to 2.0 +/- 1.3 postoperatively (P <.0001). Best-corrected visual acuity was stable or improved in 64 eyes (94%), with four (6%) losing 2 or more lines of Snellen acuity. No case of hypotony (intraocular pressure <5 mm Mg) or phthisis was observed. CONCLUSION: These early results suggest that endoscopic cyclophotocoagulation is a safe and effective therapeutic modality for refractory glaucomas. C1 UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143. SAN FRANCISCO VET ADM MED CTR,SAN FRANCISCO,CA. FU NEI NIH HHS [EY02068, EY02162] NR 26 TC 85 Z9 92 U1 0 U2 1 PU OPHTHALMIC PUBL CO PI CHICAGO PA 77 WEST WACKER DR, STE 660, CHICAGO, IL 60601 SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD DEC PY 1997 VL 124 IS 6 BP 787 EP 796 PG 10 WC Ophthalmology SC Ophthalmology GA YJ923 UT WOS:A1997YJ92300009 PM 9402825 ER PT J AU Mundinger, TO Verchere, CB Baskin, DG Boyle, MR Kowalyk, S Taborsky, GJ AF Mundinger, TO Verchere, CB Baskin, DG Boyle, MR Kowalyk, S Taborsky, GJ TI Galanin is localized in sympathetic neurons of the dog liver SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE norepinephrine; hepatic glucose production; hepatic blood flow ID NERVE-STIMULATION; NEUROPEPTIDE-Y; CELIAC GANGLION; NORADRENALINE; EXPRESSION; PANCREAS; NEUROTRANSMITTER; NOREPINEPHRINE; SEQUENCE; RELEASE AB Stimulation of canine hepatic nerves releases the neuropeptide galanin from the liver; therefore, galanin may be a sympathetic neurotransmitter in the dog liver. To test this hypothesis, we used immunocytochemistry to determine if galanin is localized in hepatic sympathetic nerves and we used hepatic sympathetic denervation to verify such localization. Liver sections from dogs were immunostained for both galanin and the sympathetic enzyme marker tyrosine hydroxylase (TH). Galanin-like immunoreactivity (GALIR) was colocalized with TH in many axons of nerve trunks as well as individual nerve fibers located both in the stroma of hepatic blood vessels and in the liver parenchyma. Neither galanin- nor TH-positive cell bodies were observed. Intraportal 6-hydroxydopamine (6-OHDA) infusion, a treatment that selectively destroys hepatic adrenergic nerve terminals, abolished the GALIR staining in parenchymal neurons but only moderately diminished the GALIR staining in the nerve fibers around blood vessels. To confirm that 6-OHDA pretreatment proportionally depleted galanin and norepinephrine in the liver, pre measured both the liver content and the hepatic nerve-stimulated spillover of galanin and norepinephrine from the liver Pretreatment with 6-OHDA reduced the content and spillover of both galanin and norepinephrine by >90%. Together, these results indicate that galanin in dog liver is primarily colocalized with norepinephrine in sympathetic nerves and may therefore function as a hepatic sympathetic neurotransmitter. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA. RP Mundinger, TO (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [DK-12829, DK-50154, DK-17047] NR 31 TC 12 Z9 14 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD DEC PY 1997 VL 273 IS 6 BP E1194 EP E1202 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA YM202 UT WOS:000071040000020 PM 9435536 ER PT J AU Abrass, CK Berfield, AK Andress, DL AF Abrass, CK Berfield, AK Andress, DL TI Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE insulin-like growth factor I; glomerulus; chemotaxis; rat ID BREAST-CANCER CELLS; FACTOR-I; EXTRACELLULAR-MATRIX; IGF-I; ENDOTHELIAL-CELLS; MESSENGER-RNA; RAT-KIDNEY; EXPRESSION; INTEGRIN; ADHESION AB Insulin-like growth factor I (IGF-I) binding protein-5 (IGFBP-5) is produced by mesangial cells (MCs) and likely functions to modulate glomerular IGF-I activity. Although IGFBP-6 may be inhibitory for IGF-stimulated MC activity, preliminary studies suggested that IGFBP-5 acts directly on MCs. To investigate this further, we evaluated the effects of IGFBP-5 on rat MC migration. We found that the carboxy-truncated fragment, IGFBP-5-(1-169), inhibited IGF-I-stimulated migration, but intact IGFBP-6 simulated migration when IGF-I was not present. Demonstration that (125)I-labeled IGFBP-5 directly binds to MCs further supports an independent role for IGFBP-5. Because heparin inhibited MC binding of (125)I-IGFBP-5, we tested the heparin binding peptide, IGFBP-5-(201-218), for stimulatory activity. IGFBP-5(201-218) stimulated MC migration, and this effect was inhibited by heparin. Because the disintegrin, kistrin, blocked IGF-I-induced migration but not migration induced by IGFBP-5-(201-218), the migratory induction mechanism for the two peptides is different. These data indicate that separate, specific regions of IGFBP-5 are responsible for interactive effects with IGF-I as well as direct effects on MC activity. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nephrol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Seattle, WA 98108 USA. RP Abrass, CK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nephrol, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 54 TC 51 Z9 51 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD DEC PY 1997 VL 273 IS 6 BP F899 EP F906 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA YM642 UT WOS:000071085200007 PM 9435678 ER PT J AU Jaffa, AA Miller, BS Rosenzweig, SA Naidu, PS Velarde V Mayfield, RK AF Jaffa, AA Miller, BS Rosenzweig, SA Naidu, PS Velarde, V Mayfield, RK TI Bradykinin induces tubulin phosphorylation and nuclear translocation of MAP kinase in mesangial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE tyrosine phosphorylation; immunocytochemistry; B(2)-kinin receptor ID ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; GLOMERULAR HYPERTROPHY; PROGRESSIVE GLOMERULOSCLEROSIS; SIGNAL-TRANSDUCTION; RENAL-DISEASE; GROWTH-FACTOR; RAT; INJURY AB Glomerular hypertension and glomerular hypertrophy act early and synergistically to promote glomerular injury in diabetes. We have previously shown that increased renal kinin production contributes to the glomerular hemodynamic abnormalities associated with diabetes. Glomerulosclerosis, characterized by mesangial cell proliferation and matrix expansion, is the final pathway leading to renal failure. The signal(s) initiating mesangial cell proliferation is ill defined. In the present study, we utilized immunofluorescence, immunoprecipitation, and immunoblotting techniques to identify substrates that are tyrosine phosphorylated in response to bradykinin action in mesangial cells. Immunofluorescence microscopy of mesangial cells stained with anti-phosphotyrosine (anti-PY) antibodies following bradykinin treatment (10(-9)-10(-6) M) revealed a dose-dependent increase in the labeling of cytoplasmic and nuclear proteins. Immunoprecipitation with anti-PY, followed by immunoblot revealed bradykinin-induced tyrosyl phosphorylation of tubulin and mitogen-activated protein kinase (MAPK). Confocal microscopy of mesangial cells stained for MAPK indicated that bradykinin stimulation resulted in translocation of MAPK from the cytoplasm to the nucleus by 2 h. These data demonstrate that bradykinin action results in the tyrosine phosphorylation of cellular proteins in mesangial cells and suggest a role for tubulin and MAPK in the signaling cascade of bradykinin leading to altered mesangial function. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Jaffa, AA (reprint author), Med Univ S Carolina, Dept Med Endocrinol Diabet Med Genet, 171 Ashley Ave, Charleston, SC 29425 USA. FU NHLBI NIH HHS [HL-07260]; NIDDK NIH HHS [DK-46543] NR 44 TC 20 Z9 20 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD DEC PY 1997 VL 273 IS 6 BP F916 EP + PG 9 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA YM642 UT WOS:000071085200009 PM 9435680 ER PT J AU McIntyre, RC Eisenach, JH Pearlman, NW Ridgeway, CE Liechty, RD AF McIntyre, RC Eisenach, JH Pearlman, NW Ridgeway, CE Liechty, RD TI Intrathyroidal parathyroid glands can be a cause of failed cervical exploration for hyperparathyroidism SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 49th Annual Meeting of the Southwestern-Surgical-Congress CY APR 13-16, 1997 CL RANCHO MIRAGE, CA SP SW Surg Congress ID REOPERATION; SURGERY; OPERATIONS; PERSISTENT; FAILURE; ANATOMY AB BACKGROUND: The incidence of intrathyroidal parathyroid glands remains controversial. The purpose of this study was to determine the incidence in a series of patients with hyperparathyroidism. METHODS: Three hundred nine patients underwent parathyroidectomy. Patients were divided into two groups: uniglandular disease versus hyperplasia. RESULTS: Eighteen of 309 patients (6%) had abnormal intrathyroidal parathyroid glands. The incidence was 3% (7 of 222) in patients with uniglandular disease versus 15% (11 of 73) in those with hyperplasia. With a mean follow-up of 54 months, 12 patients are eucalcemic, 5 have persistent hypocalcemia, and 1 has recurrent hypercalcemia. There were no recurrent laryngeal nerve injuries. CONCLUSIONS: These data suggest that an intrathyroidal adenoma is an uncommon cause of failure, whereas abnormal intrathyroidal parathyroid tissue may be a more common cause of failure in patients with hyperplasia. (C) 1997 by Excerpta Medica, Inc. C1 UNIV COLORADO, HLTH SCI CTR, DIV GASTROINTESTINAL TUMOR & ENDOCRINE SURG, DENVER, CO 80262 USA. UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA. UNIV COLORADO, HLTH SCI CTR, DIV ENDOCRINOL DIABET & METAB, DENVER, CO 80262 USA. DENVER VET AFFAIRS HOSP, DENVER, CO USA. RP McIntyre, RC (reprint author), UNIV COLORADO, HLTH SCI CTR, DEPT SURG, 4200 E 9TH AVE, BOX C-313, DENVER, CO 80262 USA. NR 25 TC 18 Z9 19 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD DEC PY 1997 VL 174 IS 6 BP 750 EP 754 DI 10.1016/S0002-9610(97)00190-6 PG 5 WC Surgery SC Surgery GA YK920 UT WOS:A1997YK92000037 PM 9409611 ER PT J AU Mulrow, C Langhorne, P Grimshaw, J AF Mulrow, C Langhorne, P Grimshaw, J TI Integrating heterogeneous pieces of evidence in systematic reviews SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CORONARY HEART-DISEASE; TRIALS; METAANALYSIS; PRAVASTATIN; METHODOLOGY AB Researchers preparing systematic reviews often encounter various types of evidence, which can generally be categorized as direct or indirect. The former directly relates an exposure, diagnostic strategy, or therapeutic intervention to the occurrence of a principal health outcome. Evidence is indirect if two or more bodies of evidence are required to relate the exposure, diagnostic strategy, or intervention to the principal health outcome. Heterogeneity of data sources complicates integration of both direct and indirect evidence. Participants in different studies may have a wide spectrum of baseline risk and sociodemographic and cultural characteristics. A variety of formulations and intensities of exposures, diagnostic strategies, and interventions, as well as diversity in the selection and definition of control groups, may be encountered. Outcome measures may be different, and similar outcomes may be measured or reported differently. Heterogeneity of study designs and of methodologic features and quality within a given design may be found. The effective integration of direct and indirect evidence requires development of explicit models that serve as analytic frameworks for linking the important pieces of evidence. A model can be viewed as a series of subquestions, with each important subquestion warranting a systematic review. Several subjective and quantitative methods can then be used to integrate the evidence. Tabular displays of major findings and strength of evidence for each subquestion can help reviewers, patients, and providers to integrate the differing research findings and draw reasonable conclusions. Various quantitative techniques, such as decision analysis and the confidence profile method, are also available. No single integration approach is clearly superior, none obviates uncertainty, and all underscore the role of careful judgment in integrating evidence. C1 GLASGOW ROYAL INFIRM, GERIATR MED SECT, GLASGOW G4 0SF, LANARK, SCOTLAND. UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78285 USA. UNIV ABERDEEN, ABERDEEN, SCOTLAND. RP AUDIE L MURPHY MEM VET ADM MED CTR, 7400 MERTON MINTER BLVD 11C6, SAN ANTONIO, TX 78284 USA. RI Grimshaw, Jeremy/D-8726-2013 OI Grimshaw, Jeremy/0000-0001-8015-8243 NR 48 TC 55 Z9 56 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 1 PY 1997 VL 127 IS 11 BP 989 EP 995 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA YJ080 UT WOS:A1997YJ08000006 PM 9412305 ER PT J AU Bosso, JA Hardin, TC AF Bosso, JA Hardin, TC TI Added qualifications for pharmacy specialists: Another perspective SO ANNALS OF PHARMACOTHERAPY LA English DT Editorial Material C1 MED UNIV S CAROLINA,COLL MED,CHARLESTON,SC 29425. S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX. RP Bosso, JA (reprint author), MED UNIV S CAROLINA,COLL PHARM,DIV CLIN PHARM SCI,171 ASHLEY AVE,CHARLESTON,SC 29425, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD DEC PY 1997 VL 31 IS 12 BP 1535 EP 1536 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YL275 UT WOS:A1997YL27500018 PM 9416396 ER PT J AU Netscher, D Cohen, V AF Netscher, D Cohen, V TI Ulnar nerve compression at the wrist secondary to anomalous muscles: A patient with a variant of abductor digiti minimi SO ANNALS OF PLASTIC SURGERY LA English DT Article AB Three patients with aberrant muscles passing through Guyon's canal are described. Each of the three patients experienced, among other symptoms, dysesthesias on the volar aspects of the little and ring fingers, The anomalous muscle in two of these patients arose from the antebrachial fascia just proximal to Guyon's canal, traveled through the canal, and inserted with the abductor digiti minimi muscle. This anomaly was bilateral in both patients. In the third patient the abductor digiti minimi muscle originated radially from the transverse carpal ligament, and this variant too was bilateral. Symptoms in each of the 3 patients resolved following surgery. Ulnar nerve compression at Guyon's canal is discussed and the literature is reviewed. Although anomalous muscles occur frequently in this location, the anatomic variant found in patient 3 has not yet been described in the literature. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Houston, TX USA. RP Netscher, D (reprint author), 6560 Fannin,Suite 800, Houston, TX 77030 USA. NR 21 TC 16 Z9 19 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0148-7043 J9 ANN PLAS SURG JI Ann. Plast. Surg. PD DEC PY 1997 VL 39 IS 6 BP 647 EP 651 DI 10.1097/00000637-199712000-00017 PG 5 WC Surgery SC Surgery GA YM861 UT WOS:000071109000018 PM 9418928 ER PT J AU Reue, K Cohen, RD Schotz, MC AF Reue, K Cohen, RD Schotz, MC TI Evidence for hormone-sensitive lipase mRNA expression in human monocyte/macrophages SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE lipases; foam cells; monocytes/macrophages; THP-1 macrophages ID DEPENDENT PROTEIN-KINASE; J774 MACROPHAGES; MESSENGER-RNA; ESTER HYDROLASE; FOAM CELLS; MONOCYTE; PHOSPHORYLATION; METABOLISM AB The role of hormone-sensitive lipase (HSL) in the hydrolysis of adipose tissue triacylglycerol to provide free fatty acids for energy requirements has been well established. However, the role of HSL in other tissues, including macrophages, is not well understood. The demonstration that HSL is capable of hydrolyzing cholesteryl esters at approximately the same rate as triacylglycerol raised the possibility that HSL activity in macrophages may influence the accumulation of cholesteryl esters in foam cells of atherosclerotic lesions. We and others have previously demonstrated that HSL mRNA is expressed in murine peritoneal macrophages and macrophage cell lines; however, it was previously reported chat HSL mRNA is absent in human monocyte-derived macrophages, suggesting that a species difference may exist. To clarify this point, we have further examined the issue of HSL mRNA expression in human macrophages. In the current study. we demonstrate that HSL mRNA is detectable in human monocyte derived macrophages and in the THP-1 human monocyte cell line using reverse transcription coupled to polymerase chain reaction (RT-PCR). Specific amplification of cDNA derived from mRNA was ensured by using primers that span an intron within the human HSL gene, and the identity of PCR products as HSL was confirmed by hybridization to HSL cDNA and by DNA sequencing. Using a semiquantitative PCR assay, we establish that HSL mRNA levels in monocyte/macrophages are approximately 1/40 the levels in human adipose tissue. These results indicate that further studies addressing the role of HSL in macrophage metabolism and its potential role in development of foam cells in human atherosclerotic lesions are warranted. C1 W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Reue, K (reprint author), W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, Bldg 113,Room 312,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 24 TC 32 Z9 34 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD DEC PY 1997 VL 17 IS 12 BP 3428 EP 3432 PG 5 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA YZ025 UT WOS:000072212600009 PM 9437189 ER PT J AU LopesVirella, MF Binzafar, N Rackley, S Takei, A LaVia, M Virella, G AF LopesVirella, MF Binzafar, N Rackley, S Takei, A LaVia, M Virella, G TI The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor SO ATHEROSCLEROSIS LA English DT Article DE LDL receptor; antibody; macrophage ID LOW-DENSITY-LIPOPROTEIN; CIRCULATING IMMUNE-COMPLEXES; MONOCYTE-DERIVED MACROPHAGES; IMMUNOGLOBULIN-G; IGG-FC; BINDING; METABOLISM; ACTIVATION; KINASE; PHOSPHORYLATION AB The incubation of human macrophages with antigen-antibody complexes prepared with rabbit anti-LDL and human LDL (LDL-IC) is followed by ingestion of those immune complexes (IC), massive cholesterol ester accumulation; cytokine release and overexpression of the LDL receptor. The massive accumulation of cholesterol esters and overexpression of the native LDL receptor are specifically induced by immune complexes containing native or modified LDL, but not by any other type of IC. We report the results of a series of experiments aimed at defining the receptor preferentially involved in LDL-IC uptake. Flow cytometry studies using CD16, CD32 and CD64 monoclonal antibodies showed a sharp reduction on the expression of CD64 (Fc gamma RI) both by human monocyte-derived macrophages and THP-I cells after incubation with LDL-IC, suggesting preferential engagement of this type of Fc receptor. Blocking experiments with aggregate-free IgG1 and CD32 monoclonal antibody confirmed that blocking Fc gamma RI prevented both LDL-IC uptake and the upregulation of LDL receptors on THP-I cells. In contrast, blocking Fc gamma RII did not affect either the uptake of LDL-IC or the expression of LDL receptors on the same cells. The preferential engagement of Fc gamma R-I by LDL-IC suggests a biological difference of LDL-IC relative to other types of IC and opsonized particles. The precise molecular mechanism(s) responsible for the paradoxical upregulation of LDL receptor after the uptake of LDL-IC remain to be elucidated. (C) 1997 Elsevier Science Ireland Ltd. C1 MED UNIV S CAROLINA,DEPT MED,DIV METAB ENDOCRINOL & NUTR,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425. RP LopesVirella, MF (reprint author), RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,109 BEE ST,CHARLESTON,SC 29403, USA. FU NHLBI NIH HHS [HL46815] NR 32 TC 71 Z9 74 U1 1 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD DEC PY 1997 VL 135 IS 2 BP 161 EP 170 DI 10.1016/S0021-9150(97)00157-3 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YL300 UT WOS:A1997YL30000002 PM 9430365 ER PT J AU Nickerson, CAE AF Nickerson, CAE TI A note on "A concordance correlation coefficient to evaluate reproducibility" SO BIOMETRICS LA English DT Article DE accuracy; analysis of variance; concordance; intraclass correlation; precision; reliability; repeatability; reproducibility ID INTRACLASS CORRELATION-COEFFICIENTS; ASSESSING AGREEMENT AB Lin (1989, Biometrics 45, 255-268) objected to the use of the intraclass correlation coefficient as a way to evaluate the reproducibility of measurements between two trials of an assay or instrument and developed an alternative called the concordance correlation coefficient. It is noted that intraclass correlation refers not to a single coefficient but to a group of coefficients and that Lin's alternative is nearly identical to a subset of the coefficients in this group. C1 Vet Affairs Med Ctr, Sect 111GM, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Operat & Informat Management, Philadelphia, PA 19104 USA. RP Nickerson, CAE (reprint author), Vet Affairs Med Ctr, Sect 111GM, Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 13 TC 64 Z9 64 U1 4 U2 24 PU INTERNATIONAL BIOMETRIC SOC PI WASHINGTON PA 808 17TH ST NW SUITE 200, WASHINGTON, DC 20006-3910 USA SN 0006-341X J9 BIOMETRICS JI Biometrics PD DEC PY 1997 VL 53 IS 4 BP 1503 EP 1507 DI 10.2307/2533516 PG 5 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA YN246 UT WOS:000071147700028 ER PT J AU Said, JW Rettig, MR Heppner, K Vescio, RA Schiller, G Ma, HJ Belson, D Savage, A Shintaku, IP Koeffler, HP Asou, H Pinkus, G Pinkus, J Schrage, M Green, E Berenson, JR AF Said, JW Rettig, MR Heppner, K Vescio, RA Schiller, G Ma, HJ Belson, D Savage, A Shintaku, IP Koeffler, HP Asou, H Pinkus, G Pinkus, J Schrage, M Green, E Berenson, JR TI Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma SO BLOOD LA English DT Article ID PRIMARY EFFUSION LYMPHOMA; APLASTIC-ANEMIA; DNA-SEQUENCES; KSHV; VIRUS; INTERLEUKIN-6; CELLS AB We have recently demonstrated the presence of Kaposi's sarcoma-associated herpesvirus (KSHV) in cultured bone marrow (BM) stromal dendritic cells from all patients with myeloma studied. To show that these findings were not an artifact of tissue culture, we performed in situ hybridization (ISH) and polymerase chain reaction (PCR) to detect KSHV in BM core biopsies. Using ISH to open reading frame-72 (ORF 72), we localized KSHV to BM dendritic cells in 17 of 20 patients with myeloma, 2 patients with plasmacytosis associated with the acquired immunodeficiency syndrome, and 1 case of aplastic anemia. In contrast, BM from normal subjects (n = 4) and patients with lymphoma and leukemia (n = 21) did not contain KSHV. PCR amplification with KSHV primers demonstrated product in fresh BM biopsy samples from 6 of 7 myeloma patients, whereas three normal marrows contained no amplified product. These findings suggest that KSHV, possibly through alterations in the BM microenvironment and production of viral interleukin-6 (vIL-6), may stimulate and maintain abnormal plasma cell proliferation in myeloma and related disorders. (C) 1997 by The American Society of Hematology. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90024. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115. CEDARS SINAI MED CTR,LOS ANGELES,CA 90048. UNIV CALIF LOS ANGELES,SCH MED,W LOS ANGELES VET AFFAIRS MED CTR,DIV HEMATOL ONCOL,LOS ANGELES,CA 90073. FU NCI NIH HHS [U01 CA 66533-02] NR 28 TC 139 Z9 143 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD DEC 1 PY 1997 VL 90 IS 11 BP 4278 EP 4282 PG 5 WC Hematology SC Hematology GA YH762 UT WOS:A1997YH76200005 PM 9373238 ER PT J AU Ko, CW Gooley, T Schoch, HG Myerson, D Hackman, RC Shulman, HM Sale, GE Lee, SP McDonald, GB AF Ko, CW Gooley, T Schoch, HG Myerson, D Hackman, RC Shulman, HM Sale, GE Lee, SP McDonald, GB TI Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis SO BONE MARROW TRANSPLANTATION LA English DT Article; Proceedings Paper CT 95th Annual Meeting of the American-Gastroenterological-Association CY MAY 14-17, 1995 CL SAN DIEGO, CALIFORNIA SP Amer Gastroenterol Assoc, Astra AB, Goteborg DE acute pancreatitis; bone marrow transplant; corticosteroids; graft-versus-host disease; hematopoietic stem cell transplantation; malignant disease ID GALLBLADDER SLUDGE; HOST-DISEASE; ACUTE GRAFT; CYCLOSPORINE; RECIPIENTS; PATHOLOGY; COMPLICATIONS; INFECTION; THERAPY AB Pancreatitis has been described as an infrequent complication of marrow transplantation, This study investigated the prevalence of pancreatitis at autopsy in marrow transplant patients and determined risk factors for its development, We reviewed consecutive autopsy reports from 1991 to 1993. Medical records and laboratory reports were reviewed for analysis of clinical variables, Autopsy findings and clinical variables were correlated with the autopsy diagnosis of pancreatitis, Pancreatitis was found in 51 of 184 (28%) patients at autopsy, Of those with pancreatitis, 35% had abdominal pain, 10% had measurements of serum pancreatic enzymes, and 20% had abdominal imaging studies in the week prior to death, By univariable analysis, risk factors associated with development of pancreatitis included clinical grades 3 and 4 GVHD, GVHD at autopsy, liver GVHD at autopsy, major infection at autopsy, and increasing days of survival, By multivariable analysis, independent risk factors for its development included any GVHD at autopsy, increasing length of survival after transplantation, and major infection at autopsy, We conclude that pancreatitis is a common but often subclinical complication of marrow transplantation, Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with cyclosporine and prednisone. C1 Fred Hutchinson Canc Res Ctr, Sect SC114, Gastroenterol Hepatol Sect, Seattle, WA 98104 USA. Fred Hutchinson Canc Res Ctr, Clin Stat Sect, Seattle, WA 98104 USA. Fred Hutchinson Canc Res Ctr, Pathol Sect, Seattle, WA 98104 USA. Univ Washington, Sch Med, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA. RP Ko, CW (reprint author), Fred Hutchinson Canc Res Ctr, Sect SC114, Gastroenterol Hepatol Sect, 1124 Columbia St, Seattle, WA 98104 USA. FU NCI NIH HHS [CA 157704, CA 1802, CA 47748] NR 33 TC 27 Z9 27 U1 0 U2 2 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD DEC PY 1997 VL 20 IS 12 BP 1081 EP 1086 DI 10.1038/sj.bmt.1701024 PG 6 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA YT108 UT WOS:000071564700011 PM 9466282 ER PT J AU Fink, JB AF Fink, JB TI Flawed paradigms drive aerosol device selection SO CHEST LA English DT Editorial Material ID METERED-DOSE INHALERS; SEVERE ASTHMA RP Fink, JB (reprint author), US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,DIV PULM & CRIT CARE MED,HINES,IL 60141, USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD DEC PY 1997 VL 112 IS 6 BP 1447 EP 1449 DI 10.1378/chest.112.6.1447-a PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA YK959 UT WOS:A1997YK95900002 PM 9404735 ER PT J AU Pilling, J Cutaia, M AF Pilling, J Cutaia, M TI The antiphospholipid antibody syndrome - A vascular disease with pulmonary manifestations SO CHEST LA English DT Editorial Material ID LUPUS ANTICOAGULANT; THROMBOSIS C1 VET AFFAIRS MED CTR,PULM SECT,PHILADELPHIA,PA. RP Pilling, J (reprint author), BROWN UNIV,VET AFFAIRS MED CTR,PULM SECT,PROVIDENCE,RI 02912, USA. NR 15 TC 3 Z9 3 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD DEC PY 1997 VL 112 IS 6 BP 1451 EP 1453 DI 10.1378/chest.112.6.1451 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA YK959 UT WOS:A1997YK95900004 PM 9404737 ER PT J AU Glynn, SM Mueser, KT AF Glynn, SM Mueser, KT TI Commentary on "Applying research on family education about mental illness to development of a relatives group consultation model" SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Editorial Material ID SCHIZOPHRENIC-PATIENTS; SOCIAL-INTERVENTION; CONTROLLED TRIAL; FOLLOW-UP; PSYCHOEDUCATION; IMPACT C1 W Los Angeles VA Med Ctr, Brentwood Div B151J, Los Angeles, CA 90073 USA. Dartmouth Med Sch, New Hampshire Dartmouth Psychiat Res Ctr, Hanover, NH USA. RP Glynn, SM (reprint author), W Los Angeles VA Med Ctr, Brentwood Div B151J, Wilshire & Sawtelle Blvd, Los Angeles, CA 90073 USA. NR 13 TC 0 Z9 0 U1 0 U2 1 PU HUMAN SCI PRESS INC PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0010-3853 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD DEC PY 1997 VL 33 IS 6 BP 571 EP 574 DI 10.1023/A:1025061022142 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA YN477 UT WOS:000071172500010 ER PT J AU Havoonjian, HH Luftman, DB Menaker, GM Moy, RL AF Havoonjian, HH Luftman, DB Menaker, GM Moy, RL TI External ultrasonic tumescent liposuction - A preliminary study SO DERMATOLOGIC SURGERY LA English DT Article AB BACKGROUND. External ultrasonic tumescent liposuction represents a new application of ultrasound energy to the standard tumescent liposuction procedure. Hoping to retain the in vivo properties of ultrasonic delivery while avoiding the growing number of invasive complications, external ultrasonic tumescent liposuction is a new technique with the potential of improving traditional tumescent liposuction therapy. OBJECTIVE. The purpose of this preliminary study was to evaluate the role of external ultrasonic tumescent liposuction as an adjunct to traditional tumescent liposuction. METHODS. Ten patients underwent standard tumescent liposuction with the addition of 10 minutes of preoperative ultrasound therapy applied to one-half of their targeted treatment regions. Both objective and subjective parameters were assessed during the subsequent side-by-side evaluations. RESULTS. Six of the 10 cases had a measurable increase in the amount of supernatant fat extracted per unit of aspirate volume fi om those regions pretreated with ultrasound energy. In five of the 10 cases, the operating physician noted slightly easier cannula maneuverability through adipose tissue on the ultrasound side. Roughly half of the patients had an improved postoperative course, with less swelling/edema, less bruising or ecchymoses, move skin retraction, and less postoperative pain/discomfort. CONCLUSION. The favorable results of this preliminary study warrant further investigation and research into external ultrasonic tumescent liposuction as an adjunct to the traditional tumescent liposuction procedure. (C) 1997 by the American Society for Dermatologic Surgery, Inc. C1 Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Luftman, DB (reprint author), 100 UCLA Med Plaza,Suite 590, Los Angeles, CA 90024 USA. NR 9 TC 19 Z9 19 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD DEC PY 1997 VL 23 IS 12 BP 1201 EP 1206 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA YN439 UT WOS:000071168700016 PM 9426669 ER PT J AU Jaffa, AA Vio, C Velarde, V LeRoith, D Mayfield, RK AF Jaffa, AA Vio, C Velarde, V LeRoith, D Mayfield, RK TI Induction of renal kallikrein and renin gene expression by insulin and IGF-I in the diabetic rat SO DIABETES LA English DT Article; Proceedings Paper CT American-Diabetes-Association Annual Meeting and Scientific Sessions CY JUN 11-14, 1994 CL NEW ORLEANS, LA SP Amer Diabet Assoc ID GROWTH-FACTOR-I; ANGIOTENSIN SYSTEM; BINDING-PROTEINS; MESSENGER-RNA; MELLITUS; KIDNEY; PRORENIN; PLASMA; HYPERFILTRATION; GLOMERULOPATHY AB The renal kallikrein-kinin system and the renin-angiotensin system are implicated in the pathogenesis of diabetic nephropathy. We have shown that renal kallikrein and renin gene expression are altered by diabetes. To investigate the cellular mechanisms responsible for these changes, we examined the effects of acute insulin and insulin-like growth factor I (IGF-I) treatment on renal kallikrein-kinin and renin-angiotensin system components. Three weeks after induc tion of diabetes, we measured renal kallikrein and renin mRNA levels, renal kallikrein and renal renin activity, and plasma renin activity in control and diabetic rats and diabetic rats treated with insulin or IGF-I for 2 or 5 h. In diabetic rats, kallikrein and renin mRNA levels were reduced >50% compared with control rats. Renal tissue kallikrein levels and plasma renin activity were decreased, whereas renal renin content was unchanged. Insulin increased kallikrein and renin mRNA levels after 2 h. IGF-I, at a dosage that stimulated kallikrein mRNA levels in control rats, had no effect on renal kallikrein and renin content or mRNA levels in diabetic rats. However, infusion of a fivefold higher IGF-I dosage resulted in a two-to threefold increase in kallikrein and renin mRNA levels in 2 h. These data suggest that 1) diabetes suppresses kallikrein and renin gene expression, and these abnormalities are reversed by insulin or IGF-I; and 2) the diabetic state produces resistance to IGF-I induction of kallikrein and renin gene expression. These changes in regulated synthesis of kallikrein and renin in the kidney may underlie renal vascular changes that develop in diabetes. C1 RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,DEPT MED,CHARLESTON,SC. RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,DEPT PHARMACOL,CHARLESTON,SC. CATHOLIC UNIV,DEPT PHYSIOL,SANTIAGO,CHILE. NIDDKD,DIABET BRANCH,BETHESDA,MD 20892. OI Vio, Carlos/0000-0003-1850-5958 FU NIDDK NIH HHS [DK-46543] NR 32 TC 18 Z9 19 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0012-1797 J9 DIABETES JI Diabetes PD DEC PY 1997 VL 46 IS 12 BP 2049 EP 2056 DI 10.2337/diabetes.46.12.2049 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YH805 UT WOS:A1997YH80500021 PM 9392495 ER PT J AU Avery, EE Baker, LD Asthana, S AF Avery, EE Baker, LD Asthana, S TI Potential role of muscarinic agonists in Alzheimer's disease SO DRUGS & AGING LA English DT Review ID AMYLOID BETA-PROTEIN; CHOLINERGIC HYPOTHESIS; ACETYLCHOLINE-RECEPTORS; SENILE DEMENTIA; CLINICAL-TRIALS; PC12M1 CELLS; PHYSOSTIGMINE; MEMORY; ARECOLINE; OXOTREMORINE AB Alzheimer's disease (AD) is a common neurodegenerative disorder and a leading cause of death among the elderly, Recent advances in our understanding of the neurobiology of AD have provided scientific groundwork for the development of potentially more effective and less toxic treatment strategies for the disease, Some of the neuropathological hallmarks of AD include early and extensive degeneration of cortically projecting cholinergic neurons in the basal forebrain, and a reduced number of muscarinic acetylcholine receptors, Of note, neocortical muscarinic receptors of the M-1 subtype are relatively preserved in the brains of patients with AD, whereas the presynaptic receptors, which are of the M-2 subtype, are reduced in number, Therefore, activation of relatively intact postsynaptic mechanisms by muscarinic M-1 receptor-specific agonists could theoretically be more efficacious in the treatment of AD compared with agents (e.g. acetylcholinesterase inhibitors) that predominantly act on dysfunctional presynaptic terminals. The administration of muscarinic agonists can demonstrably enhance cognition and significantly improve some of the disturbing behaviours in patients with AD. Recent advances in our knowledge of the molecular biology of muscarinic receptors, together with a better understanding of signal transduction pathways in AD, are likely to result in the development of receptor-specific muscarinic agonists that are more efficacious and less toxic, Moreover, preliminary evidence concerning the effects of muscarinic agonists on the processing of amyloid precursor protein and the formation of neurofibrillary tangles suggests that these agents might favourably alter the pathobiology of AD. C1 GRECC 182 B,VET AFFAIRS PUGET SOUND HEALTHCARE SYST,AMER LAKE DIV,TACOMA,WA 98493. UNIV WASHINGTON,SCH MED,SEATTLE,WA. NR 92 TC 58 Z9 60 U1 0 U2 1 PU ADIS INTERNATIONAL LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PD DEC PY 1997 VL 11 IS 6 BP 450 EP 459 PG 10 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA YK734 UT WOS:A1997YK73400004 PM 9413702 ER PT J AU Mader, SL AF Mader, SL TI Falling in old age: Preventing and management, 2nd edition SO GERONTOLOGIST LA English DT Book Review C1 Portland VA Med Ctr, Rehabil & Long Term Care Div, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Rehabil & Long Term Care Div, Portland, OR 97201 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 1997 VL 37 IS 6 BP 837 EP 838 PG 2 WC Gerontology SC Geriatrics & Gerontology GA YM417 UT WOS:000071061400022 ER PT J AU Mader, SL AF Mader, SL TI Balance disorders: A case-study approach SO GERONTOLOGIST LA English DT Book Review C1 Portland VA Med Ctr, Rehabil & Long Term Care Div, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Rehabil & Long Term Care Div, Portland, OR 97201 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 1997 VL 37 IS 6 BP 837 EP 838 PG 2 WC Gerontology SC Geriatrics & Gerontology GA YM417 UT WOS:000071061400023 ER PT J AU Mader, SL AF Mader, SL TI Preventing patient falls SO GERONTOLOGIST LA English DT Book Review C1 Portland VA Med Ctr, Rehabil & Long Term Care Div, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Rehabil & Long Term Care Div, Portland, OR 97201 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 1997 VL 37 IS 6 BP 837 EP 838 PG 2 WC Gerontology SC Geriatrics & Gerontology GA YM417 UT WOS:000071061400021 ER PT J AU Rabeneck, L AF Rabeneck, L TI Surrogates, survival, and subversion SO HEPATOLOGY LA English DT Editorial Material C1 DEPT VET AFFAIRS MED CTR,HOUSTON,TX. HLTH SERV RES & DEV FIELD PROGRAM,HOUSTON,TX. BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030. NR 4 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD DEC PY 1997 VL 26 IS 6 BP 1678 EP 1679 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA YK772 UT WOS:A1997YK77200043 PM 9398015 ER PT J AU Foy, DW Ruzek, JI Glynn, SM Riney, SJ Gusman, FD AF Foy, DW Ruzek, JI Glynn, SM Riney, SJ Gusman, FD TI Trauma focus group therapy for combat-related PTSD SO IN SESSION-PSYCHOTHERAPY IN PRACTICE LA English DT Article DE combat-related PTSD; exposure therapy; manualized treatment; group therapy; relapse prevention; cognitive restructuring; coping skills AB Although individual therapy involving imaginal experiencing of the traumatic event has been found to be effective in treating PTSD, there is evidence that few trauma therapists actually use the technique. Moreover, symptom improvement has been found to favor intrusive symptoms, whereas avoidance and hyperarousal have been less affected. Additionally, there are several published reports documenting difficulties in implementing the treatment, ranging from client refusal, adverse reactions, and therapist inexperience. In this article we outline an alternative group form of exposure therapy, manualized trauma focus group therapy (TFGT), designed to overcome some of these implementation obstacles and to enhance the effects of imaginal exposure to include those chronic PTSD symptoms of avoidance and social isolation. We describe the cognitive behavioral and developmental models from which the approach was derived, present clinical guidelines and an illustrative session, discuss complications we have encountered in TFGT pilot studies, and offer suggestions for improving future implementation. (C) 1997 John Wiley & Sons, Inc. C1 Pepperdine Univ, Grad Sch Educ & Psychol, Culver City, CA 92030 USA. Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. RP Foy, DW (reprint author), Pepperdine Univ, Grad Sch Educ & Psychol, 400 Corp Pointe, Culver City, CA 92030 USA. NR 11 TC 13 Z9 13 U1 1 U2 5 PU JOHN WILEY & SONS INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 1077-2413 J9 IN SESSION-PSYCHOTH JI In Session-Psychother. Pract. PD WIN PY 1997 VL 3 IS 4 BP 59 EP 73 PG 15 WC Psychology, Clinical SC Psychology GA YN949 UT WOS:000071225000006 ER PT J AU Summers, KK Hardin, TC Gore, SJ Graybill, JR AF Summers, KK Hardin, TC Gore, SJ Graybill, JR TI Therapeutic drug monitoring of systemic antifungal therapy SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Review ID LIQUID-CHROMATOGRAPHIC DETERMINATION; AMPHOTERICIN-B; ITRACONAZOLE THERAPY; IMMUNOCOMPROMISED PATIENTS; PHARMACOKINETIC PROPERTIES; CRYPTOCOCCAL MENINGITIS; INVASIVE ASPERGILLOSIS; PLASMA-CONCENTRATIONS; ORAL ITRACONAZOLE; ENZYMATIC METHOD AB The use of systemic antifungal therapy has significantly increased in recent years. Individualization of antifungal therapy through the use of serum or plasma concentrations has been suggested, although no specific recommendations have been developed. The important criteria for therapeutic drug monitoring and which of these criteria are satisfied by systemic antifungal agents are presented in this review. No one antifungal is ideally suited for application of therapeutic drug monitoring, but, under certain circumstances, obtaining serum or plasma concentrations can be justified. In patients who are susceptible to flucytosine toxicity, serum flucytosine concentrations should be monitored in an effort to avoid untoward side-effects. In contrast, therapeutic drug monitoring of amphotericin B is not recommended in the clinical setting. Demonstrating that ketoconazole and itraconazole are reaching the systemic circulation by obtaining serum concentrations may be clinically useful due to the large variability in their absorption and issues of patient compliance which may be seen with these agents. The bioavailability of fluconazole is much less varied although validation of compliance is a situation where obtaining serum concentrations may provide additional information. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Hardin, TC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 59 TC 38 Z9 42 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD DEC PY 1997 VL 40 IS 6 BP 753 EP 764 DI 10.1093/jac/40.6.753 PG 12 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA YQ345 UT WOS:000071376000002 PM 9462426 ER PT J AU Katragadda, S Xie, AL Puleo, D Skatrud, JB Morgan, BJ AF Katragadda, S Xie, AL Puleo, D Skatrud, JB Morgan, BJ TI Neural mechanism of the pressor response to obstructive and nonobstructive apnea SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE sympathetic nervous system; arterial pressure; obstructive sleep apnea ID SYMPATHETIC-NERVE ACTIVITY; LEFT-VENTRICULAR HEMODYNAMICS; BLOOD-PRESSURE; NEUROCIRCULATORY CONSEQUENCES; VOLUNTARY APNEA; STROKE VOLUME; SLEEP STATE; HYPOXEMIA; RESPIRATION; HUMANS AB Obstructive and nonobstructive apneas elicit substantial increases in muscle sympathetic nerve activity and arterial pressure. The time course of change in these variables suggests a causal relationship; however, mechanical influences, such as release of negative intrathoracic pressure and reinflation of the lungs, are potential contributors to the arterial pressure rise. To test the hypothesis that apnea-induced presser responses are neurally mediated, we measured arterial pressure (photoelectric plethysmography), muscle sympathetic nerve activity (peroneal microneurography), arterial O-2 saturation (pulse oximeter), and end-tidal CO2 tension (gas analyzer) during sustained Mueller maneuvers, intermittent Mueller maneuvers, and simple breath holds in six healthy humans before, during, and after ganglionic blockade with trimethaphan (3-4 mg/min, titrated to produce complete disappearance of sympathetic bursts from the neurogram). Ganglionic blockade abolished the presser responses to sustained and intermittent Mueller maneuvers (-4 +/- 1 vs. +15 +/- 3 and 0 +/- 2 vs. +/- 15 +/- 5 mmHg) and breath holds (0 +/- 3 vs. +11 +/- 3, all P < 0.05). We conclude that the acute presser response to obstructive and nonobstructive voluntary apnea is sympathetically mediated. C1 UNIV WISCONSIN,DEPT SURG,MADISON,WI 53706. UNIV WISCONSIN,DEPT MED,MADISON,WI 53706. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI 53706. NR 23 TC 53 Z9 53 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD DEC PY 1997 VL 83 IS 6 BP 2048 EP 2054 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA YK807 UT WOS:A1997YK80700035 PM 9390980 ER PT J AU Hofgartner, WT Swanzy, SR Bacina, RM Condon, J Gupta, M Matlock, PE Bergeron, DL Plorde, JJ Fritsche, TR AF Hofgartner, WT Swanzy, SR Bacina, RM Condon, J Gupta, M Matlock, PE Bergeron, DL Plorde, JJ Fritsche, TR TI Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: Evaluation of four commercial immunoassay systems SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ENZYME-IMMUNOASSAY; PERFORMANCE; DIAGNOSIS; ASSAY AB A comparative evaluation of the following commercial immunoassays for the determination of antibodies to Toxoplasma gondii was performed: Behring Diagnostics OPUS Toxo G and Toro M, Abbott Diagnostics IMX Toxo-IgG 2.0 and Toxo-IgM, Sanofi Diagnostics Pasteur Platelia Toxo IgG and Toxo IgM, and bioMerieux Vitek VIDAS Toxo IgG and IgM. Of 676 specimens that were tested for Toxoplasma-specific immunoglobulin G (IgG) antibodies, 26% were reactive by all methods while 8% displayed some discrepancy. Of 718 specimens that were tested for Toxoplasma-specific IgM antibodies, 3% were reactive by all methods while 10% displayed some discrepancy. Analysis of discrepant specimens revealed performance shortcomings with all IgM-specific assays. The impact of such shortcomings is magnified in a population with a low prevalence of toxoplasmosis. C1 UNIV WASHINGTON,MED CTR,DEPT LAB MED,SEATTLE,WA 98195. VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. NR 13 TC 45 Z9 52 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 1997 VL 35 IS 12 BP 3313 EP 3315 PG 3 WC Microbiology SC Microbiology GA YG967 UT WOS:A1997YG96700059 PM 9399544 ER PT J AU Marder, SR Davis, JM Chouinard, G AF Marder, SR Davis, JM Chouinard, G TI The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID NEGATIVE SYNDROME SCALE; 5 FACTOR MODEL; SYMPTOMS; COMPONENT; PANSS AB Background: In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo. In the present study, combined data from the two trials were analyzed. Method: Patients were randomly assigned to receive placebo,fixed doses of risperidone (2, 6, 10, and 16 mg/day), or 20 mg/day of haloperidol for 8 weeks. Factor analysis of scores on the Positive and Negative Syndrome Scale (PANSS) produced five dimensions (negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, and anxiety/depression), similar to the five dimensions of previous factor-analytic studies of PANSS data. Results: Mean changes (symptom reductions) in PANSS factor scores from baseline to treatment Weeks 6 and 8 were significantly greater in patients receiving 6-16 mg/day of risperidone than in patients receiving placebo or haloperidol. The advantages of risperidone were greatest for negative symptoms, uncontrolled hostility/excitement, and anxiety/depression. Even at the lowest dose, 2 mg/day, risperidone was significantly (p less than or equal to .05) superior to haloperidol in reducing negative symptoms. The differences in outcomes between risperidone and haloperidol on PANSS scores were not related to extrapyramidal symptoms. Conclusion: Risperidone produced significantly (p less than or equal to .05) greater improvements than haloperidol on all five dimensions. The large between-group differences on negative symptoms, hostility/excitement, and anxiety/depression suggest that risperidone and other serotonin/dopamine antagonists have qualitatively different effects from those of conventional antipsychotic agents. C1 W Los Angeles Vet Affairs Med Ctr, Psychiat Serv 116A, Brentwood Div, Los Angeles, CA 90037 USA. Univ Illinois, Inst Psychiat, Chicago, IL USA. Hop Louis H Lafontaine, Quebec City, PQ, Canada. RP Marder, SR (reprint author), W Los Angeles Vet Affairs Med Ctr, Psychiat Serv 116A, Brentwood Div, 11301 Wilshire Blvd, Los Angeles, CA 90037 USA. NR 33 TC 453 Z9 462 U1 1 U2 9 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 1997 VL 58 IS 12 BP 538 EP 546 DI 10.4088/JCP.v58n1205 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA YQ930 UT WOS:000071438900005 PM 9448657 ER PT J AU Frueh, BC Henning, KR Pellegrin, KL Chobot, K AF Frueh, BC Henning, KR Pellegrin, KL Chobot, K TI Relationship between scores on anger measures and PTSD symptomatology, employment, and compensation-seeking status in combat veterans SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; HOSTILITY; DEPRESSION; VALIDITY AB The interrelationship between the theoretically related constructs of anger and posttraumatic stress disorder (PTSD) symptoms was examined in a group of 42 combat veterans with PTSD using a multimeasure assessment strategy. Scores on several anger measures were found to be guile high in this sample and were significantly correlated with PTSD symptomatology. Furthermore, anger measures were found to be related to employment status independent of PTSD severity, but were not related to disability compensation-seeking status. Clinicians are advised to be aware of the potential implications for physical health and interpersonal functioning. and to incorporate anger management strategies into treatment plans for this population. (C) 1997 John Wiley & Sons, Inc. C1 MED UNIV S CAROLINA,CHARLESTON,SC 29425. RP Frueh, BC (reprint author), RALPH H JOHNSON VET AFFAIRS MED CTR,MENTAL HLTH SERV 116,109 BEE ST,CHARLESTON,SC 29401, USA. NR 30 TC 33 Z9 34 U1 0 U2 1 PU CLINICAL PSYCHOLOGY PUBL CO PI BRANDON PA 4 CONANT SQUARE, BRANDON, VT 05733 SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD DEC PY 1997 VL 53 IS 8 BP 871 EP 878 PG 8 WC Psychology, Clinical SC Psychology GA YH741 UT WOS:A1997YH74100013 PM 9403390 ER PT J AU Ubel, PA Merz, JF Shea, J Asch, DA AF Ubel, PA Merz, JF Shea, J Asch, DA TI How preliminary data affect people's stated willingness to enter a hypothetical randomized controlled trial SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE randomized control trial; decision making; ethics; survey; equipoise; informed consent ID CONSENT AB Purpose: To explore how preliminary trial data affect the general public's stated willingness to enter a randomized clinical trial, Methods: We asked 165 prospective jurors to imagine that their physicians wanted them to enroll in a clinical trial, We then presented them with scenarios portraying preliminary trial results-for example, 9 out of 10 patients get better with drug A and 5 out of 10 get better with drug B-and asked after each scenario, whether they would choose to be part of the trial. We designed the scenarios to test how stated willingness to enter the trial would be influenced by: 1) the difference in effectiveness of the 2 treatments based on the patients enrolled thus far; and 2) by the chance that the difference in effectiveness was random tie, the P value), The subjects' willingness to enter the trial at various decision points was analyzed using logistic regression. Results: Fewer subjects were willing to enter the trial as preliminary data indicated either an increasing difference in the effectiveness of the two treatments or an increasing statistical significance of that difference, For example 75% of subjects were willing to enter the research trial before any preliminary data were presented, but this number fell to 49% when subjects were presented with preliminary data showing that 9 out of 10 patients improved with one treatment and 5 out of 10 with the other, Multivariable logistic regression revealed that higher P values (odds ratio = 4.29; P < 0.001; 95% CI: 2.22-8.28) and smaller differences in effectiveness (odds ratio = 0.02; P < 0.001; 95% CI: 0.00-0.07) implicit in preliminary data presented to subjects made subjects less likely to agree to enter clinical trials. After adjustment for other relevant variables, male gender was associated with increased willingness to enter the trial. Conclusion: A subjects' willingness to enter the hypothetical trial was influenced by preliminary data, Fewer subjects were willing to enter the trial as the differences in benefit between 2 treatment groups increased, However, the majority of subjects were willing to enter the hypothetical trial even when preliminary evidence strongly favored one treatment over another, Given the importance of informed consent in entering patients in clinical trials, these results should be confirmed in actual trial settings. C1 Univ Penn, Ctr Bioeth, Div Gen Internal Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Ubel, PA (reprint author), Univ Penn, Ctr Bioeth, Div Gen Internal Med, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA. NR 9 TC 18 Z9 18 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD DEC PY 1997 VL 45 IS 9 BP 561 EP 566 PG 6 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA YQ215 UT WOS:000071362200007 PM 9444883 ER PT J AU Wu, MJ Chen-Liu, LW Xiao, QN Phillips, ML Elovson, J Linton, MF Young, SG Schumaker, VN AF Wu, MJ Chen-Liu, LW Xiao, QN Phillips, ML Elovson, J Linton, MF Young, SG Schumaker, VN TI Secretion from cell culture of HDL and VLDL bearing apoB-33 with a large internal deletion SO JOURNAL OF LIPID RESEARCH LA English DT Article DE very low density lipoproteins; low density lipoproteins; lipoprotein biosynthesis; apolipoprotein B; microsomal triglyceride transfer proteins ID LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B-GENE; TRIGLYCERIDE-RICH LIPOPROTEINS; RAT-LIVER; FAMILIAL HYPOBETALIPOPROTEINEMIA; PLASMA-LIPOPROTEINS; 2-STEP MODEL; EXPRESSION; MUTATION; CONFORMATION AB Rat hepatoma McA-RH7777 cells synthesize and secrete two populations of apoB-containing lipoproteins: a larger, VLDL-sized population floating in the S-f 40-150 range and a smaller, LDL and HDL-sized population. Three permanently transfected cell lines of McA-RH7777 cells secreted (in addition to the endogenous lipoproteins) lipoproteins containing 1) a carboxyl-terminally truncated human apoB-53 (2377 amino acids in length); 2) a carboxyl-terminally truncated human apoB-31 (1420 amino acids in length); or 3) an internally deleted human apoB protein, apoB-18/95, containing a total of 1490 amino acid residues, equivalent in length to an apoB-33. The apoB-18/95 protein contained amino acid residues 1-782 joined to 708 residues near the C-terminus of apoB (residues 3636-4343). All three of the apoB peptides, apoB-53, apoB-31, and apoB-18/95, were present on smaller LDL-HCL-class lipoproteins, with buoyant densities in the HDL density range. The sizes of the HDL class lipoproteins agreed with prior observations that lipoprotein core circumference is directly proportional to apoB size. As HDL containing apoB-18/95 conformed to this rule, contiguous apoB amino acid sequence is not required for the rule to be obeyed. In addition, apoB-18/95, but not apoB-31, was also present on the VLDL-sized lipoproteins even in the absence of serum or oleate supplementation. As the latter two constructs encode equally sized apoB peptides, their particular amino acid sequences rather than just overall length must determine whether they can assemble into a VLDL particle. C1 Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif San Francisco, Dept Med, Inst Cardiovasc Res, Gladstone Fdn Labs Cardiovasc Dis, San Francisco, CA 94141 USA. RP Schumaker, VN (reprint author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA. FU NHLBI NIH HHS [HL-41633, HL-06172, HL-28481] NR 34 TC 4 Z9 4 U1 0 U2 0 PU LIPID RESEARCH INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD DEC PY 1997 VL 38 IS 12 BP 2473 EP 2482 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YP442 UT WOS:000071277200009 PM 9458271 ER PT J AU Chauhan, NB Lee, JM Siegel, GJ AF Chauhan, NB Lee, JM Siegel, GJ TI Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE in situ hybridization; mRNA; Northern blot; image analysis; beta-amyloid; superior frontal cortex; pyramidal neurons; cerebellum; Purkinje cell ID AMYLOID PRECURSOR PROTEIN; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; HUMAN-BRAIN; DIFFERENTIAL DISTRIBUTION; DIFFUSE PLAQUES; GENE-EXPRESSION; DOWNS-SYNDROME; ALPHA-ISOFORM; AGED HUMAN AB The expression of Na,K-ATPase alpha 1- and alpha 3-mRNAs was analyzed by in situ hybridization in the superior frontal cortex and cerebellum of brains from five Alzheimer's disease (AD), five nondemented age-matched, and three young control subjects. Brains with well-preserved RNA, tested by Northern hybridization of immobilized RNA with [P-32]-labeled human beta-actin riboprobe, were chosen for analysis. In situ hybridization was performed on formalin-fixed, 5 mu m-thick Paraplast sections with [S-35]-labeled riboprobes prepared by in vitro transcription of the respective linearized clones: a 537-bp EcoRI-PstI fragment of alpha 1-cDNA and a 342-bp PstI-EcoRI fragment of alpha 3-cDNA. In cortex, grains related to mRNA were measured by density per unit area in five cortical columns separated by 1.0-1.2 cm in each of two adjacent sections. Each cortical column of 180-mu m width was divided into four depths orthogonal to the pial surface between the pia and the white matter. Amyloid plaques were counted in the same regions of adjacent sections. In addition, alpha 3-mRNA grain clusters over individual pyramidal neurons within depth 4 were analyzed. We found the following significant changes (p < 0.05): 1. Increases in total alpha 1-mRNA by 13-19% in AD compared to young and by 7-12% in AD compared to age-matched controls,. 2. Decrease in total alpha 3-mRNA by 31-38% in AD compared to young and age-matched controls. 3. Decrease in alpha 3-mRNA content over individual pyramidal perikarya by 14% in normal aged brains without plaques compared to young controls, and by 44% in AD relative to young controls and by 35% compared to age-matched controls. No significant difference (p < 0.2) was found with respect to alpha 1- or alpha 3-mRNA in cerebellar cortex or individual Purkinje cells among any of the groups. In addition, there was a trend toward an inverse correlation between the levels of alpha 3-mRNA and of diffuse plaques, but not of neuritic plaques, in AD cases. In conclusion: 1. The increases in alpha 1-mRNA in AD may be related to an increased reactive gliosis. 2. The declines in alpha 3-mRNA per individual neuron found in normal aging occur prior to the formation of diffuse plaques and are greatly accelerated in AD. 3. The declines in alpha 3-mRNA per neuron found in normal aging may predispose to or potentiate AD pathogenesis. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Mol & Cellular Neurosci Lab, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Dept Neurol, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA. RP Siegel, GJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Mol & Cellular Neurosci Lab, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 57 TC 36 Z9 36 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD DEC PY 1997 VL 9 IS 3 BP 151 EP 166 DI 10.1007/BF02800498 PG 16 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA YU389 UT WOS:000071712200002 PM 9481617 ER PT J AU Sober, SJ Stark, JM Yamasaki, DS Lytton, WW AF Sober, SJ Stark, JM Yamasaki, DS Lytton, WW TI Receptive field changes after strokelike cortical ablation: A role for activation dynamics SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID MAP REORGANIZATION; CORTEX; PARVALBUMIN; NEURONS; IMMUNOREACTIVITY; RECOVERY; MONKEYS; MODEL; GABA AB The reorganization of neural activity that takes place after stroke is of paramount importance in producing functional recovery. Experimental stroke models have suggested that this reorganization may have two phases, but physiology alone cannot fully resolve what causes each phase. Computer modeling suggests that these phases might involve an initial change in dynamics occurring immediately, followed by synaptic plasticity. We combined physiological recording from macaque middle temporal cortex (area MT) with a neural network computer model to examine this first phase of altered cortical function after a small, experimentally induced cortical lesion. Major receptive field (RF) changes seen in the first few days postlesion included both expansion and contraction of receptive fields. Although only expansion could be reproduced in an initial model, addition of inhibitory interneuron loss in a ring around the primary ablation, suggested by immunohistochemical examination, permitted contraction to be replicated as well. We therefore predict that this immunochemical observation reflects an immediate extension of the lesion rather than a late response. Additionally our model successfully predicted a correlation between increased firing rate and RF size. Our model suggests that activation dynamics alone, without anatomic remodeling, can cause the large receptive field changes that allow the rapid behavioral recovery seen after middle temporal lesions. C1 Univ Wisconsin, Dept Neurol, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. Univ Wisconsin, Dept Anat, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. RP Lytton, WW (reprint author), Univ Wisconsin, Dept Neurol, William S Middleton Mem Vet Hosp, 1300 Univ Ave,MSC 1720, Madison, WI 53706 USA. NR 21 TC 25 Z9 25 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 1997 VL 78 IS 6 BP 3438 EP 3443 PG 6 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA YP840 UT WOS:000071320900055 PM 9405557 ER PT J AU George, MS Ketter, TA Parekh, PI Rosinsky, N Ring, HA Pazzaglia, PJ Marangell, LB Callahan, AM Post, RM AF George, MS Ketter, TA Parekh, PI Rosinsky, N Ring, HA Pazzaglia, PJ Marangell, LB Callahan, AM Post, RM TI Blunted left cingulate activation in mood disorder subjects during a response interference task (the stroop) SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID SLEEP-DEPRIVATION; EMISSION TOMOGRAPHY; GLUCOSE-METABOLISM; BLOOD-FLOW; DEPRESSION; PERFORMANCE; CORTEX; SPECT AB Functional neuroimaging studies have found abnormal anterior cingulate activity in depressed subjects, and other studies have shown that the cingulate gyrus becomes active in healthy subjects during interference tasks. The authors hypothesized that subjects with mood disorder might show blunted cingulate activation during the standard Stroop interference task or during a modified version involving sadness-laden wards. In contrast to 11 age- and sex-matched healthy control subjects who activated the left cingulate during the standard Stroop, 11 mood-disordered subjects activated the right anterior cingulate gyrus only slightly and instead showed increased activity in the left dorso-lateral prefrontal and visual cortex. This study supports theories of blunted limbic and paralimbic activation and abnormal cingulate activity in depression and adds to the growing knowledge of the functional neuroanatomy of depression. C1 MED UNIV S CAROLINA,DEPT PSYCHIAT,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT NEUROL,CHARLESTON,SC 29425. RALPH H JOHNSON VET AFFAIRS HOSP,DEPT PSYCHIAT,CHARLESTON,SC. NEUROL INST,RAYMOND WAY NEUROPSYCHIAT RES GRP,LONDON,ENGLAND. NIMH,BIOL PSYCHIAT BRANCH,NIH,BETHESDA,MD 20892. RP George, MS (reprint author), MED UNIV S CAROLINA,DEPT RADIOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA. RI Ring, Howard/G-6684-2011 NR 62 TC 188 Z9 193 U1 0 U2 10 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 1997 VL 9 IS 1 BP 55 EP 63 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA WD688 UT WOS:A1997WD68800007 PM 9017529 ER PT J AU Walter, CA Grabowski, DT Street, KA Conrad, CC Richardson, A AF Walter, CA Grabowski, DT Street, KA Conrad, CC Richardson, A TI Analysis and modulation of DNA repair in aging SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article; Proceedings Paper CT 1st International NILS Workshop on Longevity Sciences - The Role of Molecular Genetics in Longevity Sciences CY NOV 29, 1996 CL OBU, JAPAN SP Natl Inst Longev Sci DE DNA repair; transgenic mice; quantitative extended-length PCR; mitochondrial DNA damage; aging ID METALLOTHIONEIN-II GENES; BASAL-CELL CARCINOMA; MITOCHONDRIAL-DNA; HUMAN-LYMPHOCYTES; OXIDATIVE DAMAGE; WERNER SYNDROME; DIETARY RESTRICTION; CHROMOSOMAL-ABERRATIONS; IONIZING-RADIATION; ALKYLATING-AGENTS AB Nearly 40 years ago it was proposed that accumulation of mutations or increased levels of DNA damage might contribute to aging processes. Despite several correlative studies in this area, the answer as to whether genomic integrity contributes to aging has remained illusive. More recently it has been hypothesized that decreased mitochondrial DNA integrity plays a role in aging. To begin to test these hypotheses more directly we are developing transgenic mouse and cell culture model systems. For example, transgenic mice overexpressing the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) have been made and have a reduced spontaneous frequency of hepatocellular carcinoma. A lifespan study using the MGMT transgenic mice is in progress in an effort to determine whether cancer impacts on the median or maximal lifespan of a species. Second, a quantitative PCR technique is being used to measure mitochondrial DNA damage in mitotic and post-mitotic cells to determine if the level of damage and/or repair is different based on mitotic status. Finally, mice deficient in metallothionein-I and -II are being used in an effort to determine if the subcellular distribution of metals impact on oxidative damage with increased age. (C) 1997 Elsevier Science Ireland Ltd. C1 UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284. S TEXAS VET HLTH CARE SYST,CTR GERIATR RES EDUC & CLIN,SAN ANTONIO,TX 78284. RP Walter, CA (reprint author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA. FU NCI NIH HHS [CA61335]; NIA NIH HHS [AG 13560]; NIEHS NIH HHS [ES05798] NR 84 TC 31 Z9 33 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing. Dev. PD DEC PY 1997 VL 98 IS 3 BP 203 EP 222 DI 10.1016/S0047-6374(97)00108-5 PG 20 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA YB781 UT WOS:A1997YB78100003 PM 9352490 ER PT J AU Gurdal, H Seasholtz, TM Wang, HY Brown, RD Johnson, MD Friedman, E AF Gurdal, H Seasholtz, TM Wang, HY Brown, RD Johnson, MD Friedman, E TI Role of G(alpha q) or G(alpha o) proteins in alpha(1)-adrenoceptor subtype mediated responses in Fischer 344 rat aorta SO MOLECULAR PHARMACOLOGY LA English DT Article ID CARDIOVASCULAR-SYSTEM; PULMONARY-ARTERY; PERTUSSIS TOXIN; XENOPUS-OOCYTES; SMOOTH-MUSCLE; RECEPTOR; EXPRESSION; BINDING; IDENTIFICATION; CONTRACTIONS AB Previous studies showed that alpha-adrenoceptor (AR) stimulation with norepinephrine is more potent at eliciting contraction in aortas from 1-month-old Fischer 344 rats than from older rats and that this response is mediated by alpha(1b)- and alpha(1d)-AR subtypes in 1-month-old rats. We examined the G proteins responsible for alpha(1)-AR-mediated contractile response and inositol phosphate accumulation in the aortas of 1-month-old Fischer 344 rats. Pertussis toxin (PTX) treatment (2.5 mu g/ml for 4 hr) of aortic rings partially inhibited phenylephrine (PHE)-stimulated contraction and inositol phosphate accumulation, suggesting the involvement of PTX-sensitive and -insensitive G proteins. Specific antisera directed against G(alpha q) and G(alpha o) but not G(alpha s) and G(alpha i) precipitated specific alpha(1)-AR binding sites labeled with 2-[beta-(4-hydroxy-3-[I-125]iodophenyl)ethylaminomethyl]tetralone. The number of 2-[beta-(4-hydroxy-3-[I-125] iodophenyl)ethylaminomethyl]tetralone binding sites precipitated by G(alpha) proteins was increased by activating membrane alpha(1)-ARs with PHE. Moreover, PHE stimulated the palmitoylation of G(alpha q) and G(alpha o), and this response was blocked by the alpha(1)-AR antagonist prazosin. Characterization of the alpha(1)-AR subtypes that couple to G proteins indicates that although aortic alpha(1a)- alpha(1b)- and alpha(1d)-ARs were associated with G(alpha q), alpha(1b)-AR was also linked to G(alpha o). These results suggest that alpha(1)-ARs mediate the contractile response in rat aorta by coupling to both G(q) protein and the PTX-sensitive G(o) protein. C1 Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Div Mol Pharmacol, Philadelphia, PA 19129 USA. Ankara Univ, Sch Med, Dept Pharmacol, TR-06100 Ankara, Turkey. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. RP Friedman, E (reprint author), Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Div Mol Pharmacol, 3200 Henry Ave, Philadelphia, PA 19129 USA. RI Gurdal, Hakan/A-3570-2016 OI Gurdal, Hakan/0000-0003-4751-2372 FU NIA NIH HHS [AG07700, AG13282, AG14510] NR 26 TC 35 Z9 35 U1 1 U2 2 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD DEC PY 1997 VL 52 IS 6 BP 1064 EP 1070 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YM055 UT WOS:000071023400017 PM 9415716 ER PT J AU Barnes, JL AF Barnes, JL TI Platelets in glomerular disease SO NEPHRON LA English DT Review DE migration; proliferation; extracellular matrix; glomerular permeability ID SYSTEMIC LUPUS-ERYTHEMATOSUS; HUMAN MESANGIAL CELLS; HABU SNAKE-VENOM; IMMUNE-COMPLEX NEPHRITIS; GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; EXTRACELLULAR-MATRIX COMPONENTS; PLASMA SEROTONIN CONCENTRATIONS; NEPHROTOXIC SERUM NEPHRITIS; TUMOR-NECROSIS-FACTOR AB Platelets are viewed as inflammatory cells and play an important role in hemostasis and wound repair. During activation, platelets secrete a wide variety of products that have multiple effects on target cell behavior during tissue remodeling. Among these secretory products are chemotactins, growth factors and fibrogenic substances. This review examines evidence for a role of platelets in glomerular disease and discusses mechanisms of how platelet secretory products may alter permselectivity of the glomerular basement membrane, resulting in enhanced immune complex localization. Also, platelet secretory products may stimulate glomerular remodeling after injury through mechanisms involving cell migration, proliferation and extracellular matrix synthesis, ultimately distorting the normal glomerular architecture and function. C1 AUDIE L MURPHY MEM VET ADM MED CTR,MED RES SERV,SAN ANTONIO,TX 78284. RP Barnes, JL (reprint author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV NEPHROL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA. NR 185 TC 21 Z9 21 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-2766 J9 NEPHRON JI Nephron PD DEC PY 1997 VL 77 IS 4 BP 378 EP 393 PG 16 WC Urology & Nephrology SC Urology & Nephrology GA YK445 UT WOS:A1997YK44500002 PM 9434058 ER PT J AU Lai, EC Felice, KJ Festoff, BW Gawel, MJ Gelinas, DF Kratz, R Murphy, MF Natter, HM Norris, FH Rudnicki, SA AF Lai, EC Felice, KJ Festoff, BW Gawel, MJ Gelinas, DF Kratz, R Murphy, MF Natter, HM Norris, FH Rudnicki, SA CA N Amer ALS IGF I Study Grp TI Effect of recombinant human insulin-like growth factor-I on progression of ALS - A placebo-controlled study SO NEUROLOGY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; SICKNESS IMPACT PROFILE; NATURAL-HISTORY; SPINAL-CORD; DISORDERS; SYSTEM AB The objective of this study was to investigate the safety and efficacy of recombinant human insulinlike growth factor-I (rhIGF-I) in the treatment of sporadic ALS. A double-blind, placebo-controlled, randomized study of 266 patients was conducted at eight centers in North America. Placebo or rhIGF-I (0.05 mg/kg/day or 0.10 mg/kg/day) was administered for 9 months. The primary outcome measure was disease symptom progression, assessed by the rate of change (per patient slope) in the Appel ALS rating scale total score. The Sickness Impact Profile (STP), a patient-perceived, health-related quality of life assessment, was a secondary outcome variable. Progression of functional impairment in patients receiving high-dose (0.10 mg/kg/day) rhIGF-I was 26% slower than in patients receiving placebo (p = 0.01). The high-dose treatment group was less likely to terminate the study due to protocol-defined markers of disease symptom progression, and members in this group exhibited a slower decline in quality of life, as assessed by the SIP. Patients receiving 0.05 mg/kg/day of rhIGF-I exhibited trends similar to those associated with high-dose treatment, suggesting a dose-dependent response. The incidence of clinically significant adverse experiences was comparable among the three treatment groups. Recombinant human insulin-like growth factor-I slowed the progression of functional impairment and the decline in health-related quality of life in patients with ALS with no medically important adverse effects. C1 Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. Univ Connecticut, Sch Med, Dept Neurol, Farmington, CT USA. Univ Kansas, Sch Med, VA Med Ctr, Kansas City, MO USA. Calif Pacific Med Ctr, Forbes Norris ALS & Neuromuscular Res Ctr, San Francisco, CA USA. Georgetown Univ, Dept Neurol, Washington, DC USA. Cephalon Inc, W Chester, PA USA. Allegheny Univ Hlth Sci, Hahnemann Hosp, Philadelphia, PA 19102 USA. Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA. Univ Toronto Clin, Sunnybrook Hlth Sci Ctr, N York, ON, Canada. RP Lai, EC (reprint author), Baylor Coll Med, Dept Neurol, 6550 Fannin,Suite 1801, Houston, TX 77030 USA. NR 33 TC 269 Z9 274 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC PY 1997 VL 49 IS 6 BP 1621 EP 1630 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA YL495 UT WOS:000070961600024 PM 9409357 ER PT J AU Rutecki, PA Yang, Y AF Rutecki, PA Yang, Y TI Metabotropic glutamate receptor activation modulates epileptiform activity in the hippocampus SO NEUROSCIENCE LA English DT Article DE bicuculline; 4-aminopyridine; carbachol; isoproterenol; afterhyperpolarization; ACPD ID RAT HIPPOCAMPUS; SYNAPTIC INHIBITION; PYRAMIDAL NEURONS; HIGH POTASSIUM; GUINEA-PIG; TRANS-ACPD; SLICE; CA1; AGONISTS; INVITRO AB Synchronous neuronal activity that resembles interictal epileptiform discharges occurs in hippocampal slices if there is an imbalance of inhibitory and excitatory synaptic activity. Antagonists of the GABA(A) receptor and agonists of the ionotropic glutamate receptors are convulsants that produce epileptiform discharges in hippocampal slices. We evaluated the effects of activation of the metabotropic class of glutamate receptors on epileptiform activity produced by convulsants. The metabotropic glutamate agonist (+/-)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (ACPD, 30-100 mu M) accelerated the rate of interictal epileptiform discharges produced by either bicuculline methiodide or 4-aminopyridine and had minimal effects on discharges produced by high [K+](o). The increase in rate was associated with a significant decrease in the amplitude and duration of the afterhyperpolarization that follows the paroxysmal depolarizing shift, the intracellular correlate of the interictal epileptiform discharge. A modest increase in input resistance (similar to 10%) accompanied the rate increase. beta-adrenergic or muscarinic agonists, neurotransmitters that also decrease the afterhyperpolarization, acted synergistically with ACPD (100 mu M) to increase the control rate of bicuculline-induced interictal discharges by more than eight-fold. Antagonists of beta-adrenergic or muscarinic receptors reduced, but did not block, the acceleration of bicuculline-induced discharge rate produced by 30 mu M ACPD. The results show that metabotropic glutamate receptors enhance the rate of interictal epileptiform discharges produced by bicuculline or 4-aminopyridine. ACPD had no effect on interictal epileptiform activity induced by high [K+](o), a finding that may indicate that in high [K+](o) conditions the metabotropic receptor is activated or that the effects of high [K+](o) already reduced the effect of depolarizing currents that are enhanced by ACPD. The acceleration in interictal discharge rate was associated with a reduction in the afterhyperpolarization that follows the paroxysmal depolarizing shift and this action appears to be important in determining the synchronization of neurons and the rate of interictal epileptiform discharges. Furthermore, interaction between mGluR activation and either muscarinic or beta-adrenergic activation may be important for seizure generation. (C) 1997 IBRO. Published by Elsevier Science Ltd. C1 UNIV WISCONSIN,SCH MED,DEPT NEUROSURG,WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53705. UNIV WISCONSIN,SCH MED,NEUROSCI TRAINING PROGRAM,WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53705. RP Rutecki, PA (reprint author), UNIV WISCONSIN,SCH MED,DEPT NEUROL,WILLIAM S MIDDLETON MEM VET ADM HOSP,2500 OVERLOOK TR,MADISON,WI 53705, USA. FU NINDS NIH HHS [NS28580] NR 47 TC 20 Z9 20 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD DEC PY 1997 VL 81 IS 4 BP 927 EP 935 DI 10.1016/S0306-4522(97)00264-9 PG 9 WC Neurosciences SC Neurosciences & Neurology GA XY724 UT WOS:A1997XY72400003 PM 9330356 ER PT J AU Matthias, P Tashkin, DP MarquesMagallanes, JA Wilkins, JN Simmons, MS AF Matthias, P Tashkin, DP MarquesMagallanes, JA Wilkins, JN Simmons, MS TI Effects of varying marijuana potency on deposition of tar and Delta(9)-THC in the lung during smoking SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE marijuana; Delta(9)-tetrahydrocannabinol (THC); smoking topography; tar yield; tar deposition; lung; carboxyhemoglobin boost; ''high'' ID CIGARETTE; CO AB To determine whether smoking more, compared to less, potent marijuana (MJ) cigarettes to a desired lever of intoxication (''high'') reduces pulmonary exposure to noxious smoke components, in 10 habitual smokers of MJ, we measured respiratory delivery and deposition of tar and Delta(9)-tetrahydrocannabinol (THC), carboxyhemoglobin (COHb) boost, smoking topography, including cumulative puff volume (CPV) and breathholding time, change in heart rate (Delta HR) and ''high'' during ad lib smoking of 0, 1.77, and 3.95% MJ cigarettes on 3 separate days. At each session, subjects had access to only a single MJ cigarette. On average, smoking topography and COHb, boost did not differ across the different strengths of MJ, while THC delivery, as well as HR, were significantly greater (p < 0.01) and tar deposition significantly less (p < 0.03) for 3.95% than 1.77% MJ. Although individual adaptations in smoking topography for 3.95% compared to 1.77% MJ were highly variable, three subjects with the lowest 3.95% MJ:1.77% MJ ratios for CPV also displayed the lowest 3.95% MJ:1.77% MJ ratios for tar deposition. In vitro studies using a standardized smoking technique revealed a mean 25% lower tar yield from 3.95% than 1.77% MJ (p < 0.05), but no difference between 1.77% and 0% marijuana. Under the conditions of this study, we conclude that tar delivery is reduced relative to THC content in a minority of subjects, and this reduction appears to be due to a reduced intake of smoke (decreased CPV) and/or a reduced tar yield from the stronger Ma preparation. (C) 1997 Elsevier Science Inc. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DIV PULM & CRIT CARE MED,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,CLIN PSYCHOPHARMACOL UNIT,LOS ANGELES,CA 90073. FU NIDA NIH HHS [R01 DA03018] NR 16 TC 25 Z9 25 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD DEC PY 1997 VL 58 IS 4 BP 1145 EP 1150 DI 10.1016/S0091-3057(97)00328-6 PG 6 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA YH611 UT WOS:A1997YH61100044 PM 9408226 ER PT J AU Toomey, R Wallace, CJ Corrigan, PW Schuldberg, D Green, MF AF Toomey, R Wallace, CJ Corrigan, PW Schuldberg, D Green, MF TI Social processing correlates of nonverbal social perception in schizophrenia SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID AFFECTIVE-DISORDERS; RECOGNITION; EMOTION; JUDGMENT; ISSUES; SKILLS AB THIS study examines the relationship of nonverbal social perception to other areas of social functioning in schizophrenia, One model of interpersonal problem-solving skills presents a sequence of receiving, processing, and sending skills, Social perception skills best fit the first stage in this model: receiving skills, As expected, schizophrenic subjects (N = 29) were less skillful than normal subjects (N = 15) on measures of social problem solving, understanding of social sequences, and social judgment, In addition, performance on these tasks was significantly related to nonverbal social perception, but only for the schizophrenic group. Thus, deficits in nonverbal social perception are related to other measures of social functioning in schizophrenia. Implications of these findings for understanding and treating social deficits in schizophrenia are discussed. C1 HMS Brockton VAMC, Dept Psychiat 116A, Belmont, MA 02401 USA. Harvard Univ, Massachusetts Mental Hlth Ctr, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Chicago, Ctr Psychiat Rehabil, Chicago, IL 60637 USA. Univ Montana, Missoula, MT 59812 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Toomey, R (reprint author), HMS Brockton VAMC, Dept Psychiat 116A, 940 Belmont St, Belmont, MA 02401 USA. NR 31 TC 29 Z9 31 U1 0 U2 1 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0033-2747 J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PD WIN PY 1997 VL 60 IS 4 BP 292 EP 300 PG 9 WC Psychiatry SC Psychiatry GA YT249 UT WOS:000071580800003 PM 9460098 ER PT J AU Vaisanen, ML Matto, J Salminen, K Jousimies-Somer, H AF Vaisanen, ML Matto, J Salminen, K Jousimies-Somer, H TI In vitro activity of trovafloxacin against anaerobic bacteria SO REVIEWS IN MEDICAL MICROBIOLOGY LA English DT Article; Proceedings Paper CT 10th International Symposium of the Society-for-Anaerobic-Microbiology CY JUL 09-11, 1997 CL CHURCHILL COLL CAMBRIDGE, CAMBRIDGE, ENGLAND SP Soc Anaerob Microbiol HO CHURCHILL COLL CAMBRIDGE DE antimicrobial activity; trovafloxacin; azithromycin; cefoxitin; metronidazole; anaerobe C1 Natl Publ Hlth Inst, Helsinki, Finland. Univ Helsinki, Inst Dent, FIN-00014 Helsinki, Finland. Pfizer Finland, Espoo, Finland. RP Vaisanen, ML (reprint author), W Los Angeles Vet Affairs Med Ctr, Wadsworth Anaerob Bacteriol Lab, 11301 Wilshire Blvd,Mail Code 113J,Bldg 500,Room, Los Angeles, CA 90073 USA. NR 4 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0954-139X J9 REV MED MICROBIOL JI Rev. Med. Microbiol. PD DEC PY 1997 VL 8 SU 1 BP S81 EP S83 PG 3 WC Microbiology SC Microbiology GA YU761 UT WOS:000071751600045 ER PT J AU Asch, DA Shea, JA Jedrziewski, MK Bosk, CL AF Asch, DA Shea, JA Jedrziewski, MK Bosk, CL TI The limits of suffering: Critical care nurses' views of hospital care at the end of life SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE euthanasia; life-support; critical care nursing ID PHYSICIAN-ASSISTED SUICIDE; SUSTAINING TREATMENTS; VOLUNTARY EUTHANASIA; WASHINGTON-STATE; DECISION-MAKING; ATTITUDES; WITHDRAW; SUPPORT; ONCOLOGISTS; REQUESTS AB This study explores critical care nurses' beliefs, motivations, and experiences regarding end of life care. We performed a content analysis of the text comments provided by 468 U.S. critical care nurses in response to an anonymous mail survey about euthanasia. These comments reveal that these U.S. critical care nurses' feelings about issues surrounding the end of life are extremely complex. Eight themes emerged from 37 coded concepts, and the median number of themes volunteered per nurse was three. Among the most prevalent themes were patient concerns (53%), family concerns (33%), clinical circumstances (42%), the nurses' personal concerns (38%), and external or structural issues (68%). A profound sense of compassion and often conflicting forces were noted within and across themes. The nurses' comments offer a unique perspective on the care of critically ill patients and reveal much about that care that should be improved. In particular, (1) some nurses are frustrated about their limited role in the management of patients at the end of life, given their special understanding of these patients' experiences and wishes; (2) considerable confusion remains about the most appropriate way to care for these patients; and (3) the environment of some critical care settings may be unable to foster the compassion that many patients need. (C) 1997 Elsevier Science Ltd. C1 Univ Penn, Sch Med, Div Gen Internal Med, Ralston Penn Ctr 317, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. RP Asch, DA (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, Ralston Penn Ctr 317, 3615 Chestnut St, Philadelphia, PA 19104 USA. NR 41 TC 51 Z9 52 U1 3 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD DEC PY 1997 VL 45 IS 11 BP 1661 EP 1668 DI 10.1016/S0277-9536(97)00125-1 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA YM110 UT WOS:000071029500007 PM 9428086 ER PT J AU Margolis, ML Montoya, FJ Palma, WR AF Margolis, ML Montoya, FJ Palma, WR TI Pulmonary function tests: Comparison of 95th percentile-based and conventional criteria of normality SO SOUTHERN MEDICAL JOURNAL LA English DT Article ID VALUES AB Background. Although 95th percentile-based normal limits are recommended instead of conventional criteria of normality to guide pulmonary function test (PFT) readings, we have found no objective assessment of how the choice of normal limits mig]lt influence PFT interpretation. Methods. We did a retrospective comparison of PFT leadings referenced to conventional criteria of normality versus independent repeat assessments influenced by 95th percentile-based normal limits in 166 veterans. We also conducted a nationwide telephone survey of VA Hospital PFT laboratories. Results. Discordant readings occurred in only 7.2% of 616 individual PFTs; however, these discrepancies could potentially influence at least one component of the PFT report of 26.5% of our subjects. The 95th percentile-based normal limits were used by only 40% of VA PFT laboratories, without relationship to geography or hospital size. Conclusions. Discrepancies between 95th percentile-based and conventional normal limits can potentially influence PFT readings, and 95th percentile-based criteria are not used in the majority of VA PFT laboratories. C1 MED COLL PENN & HAHNEMANN UNIV,DEPT MED,PHILADELPHIA,PA. ALLEGHENY UNIV HLTH SCI,PHILADELPHIA,PA. RP Margolis, ML (reprint author), PHILADELPHIA VET AFFAIRS MED CTR,PULM SECT,UNIV & WOODLAND AVE,PHILADELPHIA,PA 19104, USA. NR 14 TC 9 Z9 9 U1 0 U2 0 PU SOUTHERN MEDICAL ASSN PI BIRMINGHAM PA 35 LAKESHORE DR PO BOX 190088, BIRMINGHAM, AL 35219 SN 0038-4348 J9 SOUTHERN MED J JI South.Med.J. PD DEC PY 1997 VL 90 IS 12 BP 1187 EP 1191 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA YL069 UT WOS:A1997YL06900005 PM 9404903 ER PT J AU Smith, CB AF Smith, CB TI The future of Veterans Affairs medical centers SO WESTERN JOURNAL OF MEDICINE LA English DT Article ID CARE AB In the past four years, the Department of Veterans Affairs (VA) has experienced unprecedented changes in the ways it provides medical care, trains medical residents, and supports its clinical research program, For the most part, these changes have improved the quality and efficiency of care provided to veterans, and they have improved the chances that the VA will survive in an increasingly competitive medical market place. While the changes in priorities for training medical residents and funding clinical research have been designed to be more consistent with the overall mission of the VA, these changes have been stressful for many of the VA/medical school affiliations. Our challenge is to understand and manage these changes so that the many benefits that have derived from more than fifty years of VA/medical school affiliations can be retained. C1 UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195. RP Smith, CB (reprint author), VA PUGET SOUND HLTH CARE SYST,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA. NR 10 TC 6 Z9 6 U1 0 U2 0 PU CARDEN JENNINGS PUBL CO LTD PI CHARLOTTESVILLE PA BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903 SN 0093-0415 J9 WESTERN J MED JI West. J. Med. PD DEC PY 1997 VL 167 IS 6 BP 420 EP 425 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA YL334 UT WOS:A1997YL33400007 PM 9426482 ER PT J AU Damon, SE Haugk, KL Swisshelm, K Quinn, LS AF Damon, SE Haugk, KL Swisshelm, K Quinn, LS TI Developmental regulation of mac25/insulin-like growth factor-binding protein-7 expression in skeletal myogenesis SO EXPERIMENTAL CELL RESEARCH LA English DT Article ID MAMMARY EPITHELIAL-CELLS; FOLLISTATIN-LIKE GENE; MYOBLAST DIFFERENTIATION; RETINOIC ACID; MUSCLE; MAC25; BETA; PROLIFERATION; CANCER AB Mac25 is a newly discovered member of the insulin-like growth factor-binding protein (IGFBP) family, recently assigned the name IGFBP-7. Mac25/IGFBP-7 is hypothesized to have growth-suppressing activity, since mac25/IGFBP-7 mRNA is down-regulated in several tumor cell lines and is highly expressed in senescent mammary epithelial cells. In this study, mac25/IGFBP-7 mRNA expression was characterized in the C2 skeletal myogenic cell line, which undergoes a transition from actively dividing, undifferentiated myoblasts to nondividing, differentiated myotubes, Mac25/IGFBP-7 mRNA levels were 2.5-fold higher in dividing C2 myoblasts than in nondividing myotubes. The inverse correlation between mac25/IGFBP-7 expression and myogenic differentiation was further examined by treating myogenic cultures with transforming growth factor-beta (TGF-beta) or insulin-like growth factor-I (IGF-I). TGF-beta inhibited myogenic differentiation by 98% and stimulated mac25/IGFBP-7 mRNA expression 2-fold. IGF-I stimulated differentiation by 50% and inhibited mac25/IGFBP-7 expression 2- to 3-fold. These findings indicate that, in contrast to other cell systems examined so far, expression of this new member of the IGFBP family is not always correlated with a nonproliferative state. (C) 1997 Academic Press. C1 Amer Lake Div, VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Quinn, LS (reprint author), Amer Lake Div, VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. NR 24 TC 22 Z9 23 U1 0 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD NOV 25 PY 1997 VL 237 IS 1 BP 192 EP 195 DI 10.1006/excr.1997.3787 PG 4 WC Oncology; Cell Biology SC Oncology; Cell Biology GA YN237 UT WOS:000071146800024 PM 9417882 ER PT J AU Black, HR Cohen, JD Kaplan, NM Ferdinand, KC Chobanian, AV Dustan, HP Gifford, RW Moser, M Sheps, SG Agodoa, L August, PA Bakris, GL Burt, V Busse, W Carter, BL Chesley, FD Cleeman, J Cohn, JN Cregler, LL Crespo, C Cushman, WC Cutler, J Darrow, MD DeQuattro, VL Devereux, RB Dworkin, LD Elliott, WJ Epstein, M Falkner, B Ferrario, CM Flack, JM Frishman, W Frohlich, ED Green, LA Grimm, RH Hagberg, JM Hall, WD Handler, J Havas, S Hill, MN Horan, MJ Hsueh, WA Hyman, BN Izzo, JL Jamerson, K Kiley, JP Kochar, MS Kolasa, KM Krakoff, LR Levy, D Lindheimer, MD Luepker, RV Malone, MEL Massie, B Materson, BJ Merchant, J Messerli, FH Miller, NH Moore, MA MustoneAlexander, L Oparil, S Perry, HM Pickering, TG Pratt, JH Ram, CVS Randall, OS Reed, JW Roberts, RW Roccella, EJ Rogus, SD Saunders, E Schron, E Schwartz, G Sibai, BM Snyder, D Sowers, JR Stamler, J Temple, R Textor, S Thom, T Vidt, DG Weber, M Weinberger, MH Weinshilboum, R Whelton, PK Whisnant, JP Wiebers, DO Winston, MC Wright, JT Lenfant, C Casser, L Colman, PJ Edwards, T Feeley, DM Gajewski, J Levine, D Manger, W Marshall, EC Nickey, WA Robert, RW Secrest, BG Singer, EH Whisnant, JP Wilson, GJ Young, JM Bachman, JW Campese, VM Carr, AA Hand, M Holden, DC Jamieson, MJ Julius, S Mensah, GA Prisant, M Sullivan, JM Wilson, DJ Morosco, G Anderson, DE Waugh, D AF Black, HR Cohen, JD Kaplan, NM Ferdinand, KC Chobanian, AV Dustan, HP Gifford, RW Moser, M Sheps, SG Agodoa, L August, PA Bakris, GL Burt, V Busse, W Carter, BL Chesley, FD Cleeman, J Cohn, JN Cregler, LL Crespo, C Cushman, WC Cutler, J Darrow, MD DeQuattro, VL Devereux, RB Dworkin, LD Elliott, WJ Epstein, M Falkner, B Ferrario, CM Flack, JM Frishman, W Frohlich, ED Green, LA Grimm, RH Hagberg, JM Hall, WD Handler, J Havas, S Hill, MN Horan, MJ Hsueh, WA Hyman, BN Izzo, JL Jamerson, K Kiley, JP Kochar, MS Kolasa, KM Krakoff, LR Levy, D Lindheimer, MD Luepker, RV Malone, MEL Massie, B Materson, BJ Merchant, J Messerli, FH Miller, NH Moore, MA MustoneAlexander, L Oparil, S Perry, HM Pickering, TG Pratt, JH Ram, CVS Randall, OS Reed, JW Roberts, RW Roccella, EJ Rogus, SD Saunders, E Schron, E Schwartz, G Sibai, BM Snyder, D Sowers, JR Stamler, J Temple, R Textor, S Thom, T Vidt, DG Weber, M Weinberger, MH Weinshilboum, R Whelton, PK Whisnant, JP Wiebers, DO Winston, MC Wright, JT Lenfant, C Casser, L Colman, PJ Edwards, T Feeley, DM Gajewski, J Levine, D Manger, W Marshall, EC Nickey, WA Robert, RW Secrest, BG Singer, EH Whisnant, JP Wilson, GJ Young, JM Bachman, JW Campese, VM Carr, AA Hand, M Holden, DC Jamieson, MJ Julius, S Mensah, GA Prisant, M Sullivan, JM Wilson, DJ Morosco, G Anderson, DE Waugh, D TI The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure SO ARCHIVES OF INTERNAL MEDICINE LA English DT Review ID CORONARY HEART-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; ISOLATED SYSTOLIC HYPERTENSION; CONVERTING ENZYME-INHIBITION; RANDOMIZED CONTROLLED TRIALS; ACUTE MYOCARDIAL-INFARCTION; STAGE RENAL-DISEASE; FOLLOW-UP PROGRAM; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR-DISEASE C1 NHLBI, INFORMAT CTR, NATL HIGH BLOOD PRESSURE EDUC PROGRAM, BETHESDA, MD 20894 USA. MAYO CLIN & MAYO FDN, MAYO MED SCH, ROCHESTER, MN 55905 USA. RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA. ST LOUIS UNIV, HLTH SCI CTR, ST LOUIS, MO 63103 USA. UNIV TEXAS, SW MED SCH, DALLAS, TX 75230 USA. HEARTBEATS LIFE CTR, NEW ORLEANS, LA USA. BOSTON UNIV, BOSTON, MA 02215 USA. UNIV VERMONT, COLL MED, BURLINGTON, VT 05405 USA. CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA. YALE UNIV, SCH MED, NEW HAVEN, CT 06520 USA. NIDDK, BETHESDA, MD USA. NEW YORK HOSP, NEW YORK, NY 10021 USA. NATL CTR HLTH STAT, HYATTSVILLE, MD 20782 USA. UNIV WISCONSIN, MADISON, WI 53706 USA. UNIV COLORADO, DENVER, CO 80202 USA. US DEPT HHS, AGCY HLTH CARE POLICY & RES, ROCKVILLE, MD 20852 USA. UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA. CUNY, SCH MED, NEW YORK, NY 10031 USA. UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA. E CAROLINA UNIV, SCH MED, GREENVILLE, NC 27858 USA. UNIV SO CALIF, MED CTR, LOS ANGELES, CA 90089 USA. CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA. RHODE ISL HOSP, PROVIDENCE, RI USA. UNIV MIAMI, SCH MED, MIAMI, FL USA. ALLEGHENY UNIV HLTH SCI, PHILADELPHIA, PA 19102 USA. WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA. MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA. ALTON OCHSNER MED FDN & OCHSNER CLIN, NEW ORLEANS, LA 70121 USA. UNIV MICHIGAN, ANN ARBOR, MI 48109 USA. UNIV MARYLAND, COLLEGE PK, MD 20742 USA. EMORY UNIV, ATLANTA, GA 30322 USA. KAISER PERMANENTE, ANAHEIM, CA USA. UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA. JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA. BAYLOR COLL MED, HOUSTON, TX 77030 USA. SUNY BUFFALO, BUFFALO, NY 14260 USA. MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA. E CAROLINA UNIV, SCH MED, GREENVILLE, NC 27858 USA. ENGLEWOOD HOSP, ENGLEWOOD, CO USA. NHLBI, FRAMINGHAM HEART STUDY, BETHESDA, MD 20894 USA. UNIV CHICAGO HOSP, CHICAGO, IL 60637 USA. JEFFERSON COMMUNITY COLL, LOUISVILLE, KY USA. UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA. HLTH CARE FINANCING ADM, WASHINGTON, DC USA. STANFORD CARDIAC REHABIL PROGRAM, PALO ALTO, CA USA. GEORGE WASHINGTON UNIV, SCH MED & HLTH SCI, WASHINGTON, DC 20052 USA. UNIV ALABAMA, BIRMINGHAM, AL USA. VET AFFAIRS MED CTR, WASHINGTON, DC 20422 USA. WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63130 USA. INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA. UNIV TEXAS, SW MED CTR, DALLAS, TX USA. HOWARD UNIV HOSP, WASHINGTON, DC USA. MOREHOUSE SCH MED, ATLANTA, GA 30310 USA. VENCOR, LOUISVILLE, KY USA. US HLTH RESOURCES & SERV ADM, ROCKVILLE, MD 20857 USA. WAYNE STATE UNIV, DETROIT, MI 48202 USA. NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA. US FDA, ROCKVILLE, MD 20857 USA. BROOKDALE HOSP, BROOKLYN, NY USA. TULANE UNIV, SCH PUBL HLTH & TROP MED, NEW ORLEANS, LA 70118 USA. AMER HEART ASSOC, DALLAS, TX USA. CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA. CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, ATLANTA, GA 30333 USA. AMER OPTOMETR ASSOC, ST LOUIS, MO USA. US DEPT HHS, AGCY HLTH CARE POLICY & RES, ROCKVILLE, MD 20852 USA. AMER COLL PHYSICIANS, PHILADELPHIA, PA USA. AMER PODIATR MED ASSOC, BETHESDA, MD USA. NATL KIDNEY FDN, NEW YORK, NY USA. AMER RED CROSS, WASHINGTON, DC 20006 USA. NHLBI, AD HOC COMM MINOR POPULAT, BETHESDA, MD 20894 USA. AMER COLL CARDIOL, BETHESDA, MD USA. AMER MED ASSOC, CHICAGO, IL 60610 USA. AMER ACAD FAMILY PHYS, KANSAS CITY, MO USA. AMER PUBL HLTH ASSOC, WASHINGTON, DC 20005 USA. AMER ACAD OPHTHALMOL, SAN FRANCISCO, CA USA. AMER NURSES ASSOC, WASHINGTON, DC 20024 USA. AMER ACAD PHYS ASSISTANTS, ALEXANDRIA, VA 22314 USA. AMER OSTEOPATH ASSOC, CHICAGO, IL 60611 USA. US DEPT VET AFFAIRS, WASHINGTON, DC USA. AMER PHARMACEUT ASSOC, WASHINGTON, DC USA. AMER DENT ASSOC, CHICAGO, IL 60611 USA. AMER COLL CHEST PHYS, NORTHBROOK, IL 60062 USA. AMER DIABET ASSOC, ALEXANDRIA, VA USA. AMER ACAD NEUROL, MINNEAPOLIS, MN USA. AMER DIETET ASSOC, CHICAGO, IL USA. AMER COLL OCCUPAT & ENVIRONM MED, ARLINGTON HTS, IL 60005 USA. AUGUSTA PREVENT CARDIOL, CIRCULATORY DIS CTR, AUGUSTA, GA USA. UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA. MED COLL GEORGIA, AUGUSTA, GA 30912 USA. ROW SCI INC, ROCKVILLE, MD USA. NR 252 TC 4448 Z9 4569 U1 5 U2 68 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 EI 1538-3679 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 24 PY 1997 VL 157 IS 21 BP 2413 EP 2446 PG 34 WC Medicine, General & Internal SC General & Internal Medicine GA YH222 UT WOS:A1997YH22200004 ER PT J AU Kowluru, A Metz, SA AF Kowluru, A Metz, SA TI Ceramide-activated protein phosphatase-2A activity in insulin-secreting cells SO FEBS LETTERS LA English DT Article DE pancreatic beta cell; protein phosphatase 2A; okadaic acid; ceramide; carboxyl methylation; apoptosis ID CAMP; 2A AB Okadaic acid (OKA)-sensitive phosphatase (PP2A) activity may modulate nutrient-induced insulin secretion front pancreatic beta cells [Kowluru et al., Endocrinology 137 (1996) 2315-2323]. Ceramides, a new class of lipid second messengers may regulate PP2A [Dobrowsky and Hannun, J. Biol, Chem, (1992) 267, 5048-5051], and might play a role in cytokine-mediated apoptosis in beta cells [Sjoholm, FEBS Lett. 367 (1995) 283-286]. Therefore, we investigated the regulation of PP2A-like activity by ceramides in isolated beta (HIT-T15 or INS-1) cells, Cell-permeable (C2, C6 or C18) ceramides stimulated OKA-sensitive (but not -insensitive) phosphatase activity in a concentration-dependent manner (0-12.5 mu M), with maximal stimulation (+50-100%) at < 12.5 mu M. C2-dihydroceramide (a biologically inactive analog of C2 ceramide) failed to augment PP2A-like activity, Stimulatory effects of ceramides do not appear to be mediated via activation of the carboxyl methylation of the catalytic subunit of protein phosphatase 2A, since no effects of ceramides (up to 25 mu M) mere demonstrable on this parameter, These data identify a ceramide-activated protein phosphatase as a possible locus at which ceramides might exert their effects on beta cells leading to altered insulin secretion, and decreased cell viability followed by apoptotic cell demise. (C) 1997 Federation of European Biochemical Societies. C1 WILLIAM S MIDDLETON MEM VET ADM MED CTR,RES SERV,MADISON,WI. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MED SERV,MADISON,WI. UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53717. UNIV WISCONSIN,SCH MED,ENDOCRINOL SECT,MADISON,WI 53717. FU NIDDK NIH HHS [DK 37312] NR 19 TC 39 Z9 39 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD NOV 24 PY 1997 VL 418 IS 1-2 BP 179 EP 182 DI 10.1016/S0014-5793(97)01379-3 PG 4 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA YJ818 UT WOS:A1997YJ81800041 PM 9414122 ER PT J AU Xian, H True, W Eisen, SA Scherrer, JF Madden, P Goldberg, J Lyons, M Tsuang, M AF Xian, H True, W Eisen, SA Scherrer, JF Madden, P Goldberg, J Lyons, M Tsuang, M TI Evidence for a common genetic contribution to nicotine dependence and alcohol dependence. SO AMERICAN JOURNAL OF MEDICAL GENETICS LA English DT Meeting Abstract C1 WASHINGTON UNIV,SCH MED,DIV GEN MED SCI,ST LOUIS,MO 63110. VAMC,MED SERV,ST LOUIS,MO 63106. VAMC,RES SERV,ST LOUIS,MO 63106. ST LOUIS UNIV,SCH PUBL HLTH,ST LOUIS,MO 63106. UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63106. US DEPT VET AFFAIRS,HSRD,COOPERAT STUDIES HLTH SERV,HINES,IL 60141. UNIV ILLINOIS,SCH PUBL HLTH,PROGRAM EPIDEMIOL,CHICAGO,IL 60680. BOSTON UNIV,DEPT PSYCHOL,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02401. RI Lyons, Michael/B-6119-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0148-7299 J9 AM J MED GENET JI Am. J. Med. Genet. PD NOV 21 PY 1997 VL 74 IS 6 BP 578 EP 578 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA YB414 UT WOS:A1997YB41400083 ER PT J AU Falek, A Jarvik, LF AF Falek, A Jarvik, LF TI Twin studies, heritability, and intelligence SO SCIENCE LA English DT Letter C1 DEPT VET AFFAIRS,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,W LOS ANGELES VET AFFAIRS MED CTR,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. RP Falek, A (reprint author), EMORY UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,ATLANTA,GA 30322, USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 SN 0036-8075 J9 SCIENCE JI Science PD NOV 21 PY 1997 VL 278 IS 5342 BP 1385 EP 1386 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA YG858 UT WOS:A1997YG85800005 PM 9411758 ER PT J AU Kowluru, A Li, GD Rabaglia, ME Segu, VB Hofmann, F Aktories, K Metz, SA AF Kowluru, A Li, GD Rabaglia, ME Segu, VB Hofmann, F Aktories, K Metz, SA TI Evidence for differential roles of the Rho subfamily of GTP-binding proteins in glucose- and calcium-induced insulin secretion from pancreatic beta cells SO BIOCHEMICAL PHARMACOLOGY LA English DT Article; Proceedings Paper CT 16th International-Diabetes-Federation Congress CY JUL 20-25, 1997 CL HELSINKI, FINLAND SP Int Diabet Federat DE Cdc42; Rho; Rap; Rac; C3 exoenzyme; insulin secretion; pancreatic beta cell; clostridial toxins ID DIFFICILE TOXIN-B; CLOSTRIDIUM-DIFFICILE; RAT ISLETS; PURIFICATION; INHIBITION; GLUCOSYLATION; MODULATION; CDC42 AB We utilized clostridial toxins (with known specificities for inhibition of GTPases) to ascertain the contribution of candidate GTPases in physiologic insulin secretion from beta cells. Exposure of normal rat islets or isolated beta (HIT-T15) cells to Clostridium difficile toxins A and B catalyzed the glucosylation (and thereby the inactivation) of Rac, Cdc42, and Rho endogenous to beta cells; concomitantly, either toxin reduced glucose-or potassium-induced insulin secretion from rat islets and HIT cells. Treatment of beta cells with Clostridium sordellii lethal toxin (LT; which modified only Ras, Rap, and Rac) also reduced glucose-or potassium-induced secretion. However, clostridial toxin C3-exoenzyme (which ADP-ribosylates and inactivates only Rho) was without any effect on either glucose-or potassium-induced insulin secretion. These data suggest that Cdc42, Rac, Ras, and/or Rap (but not Rho) may be needed for glucose-or potassium-mediated secretion. The effects of these toxins appear to be specific on stimulus-secretion coupling, since no difference in metabolic viability (assessed colorimetrically by quantitating the conversion of the tetrazolium salt into a formazan in a reduction reaction driven by nutrient metabolism) was demonstrable between control and toxin (A or LT)-treated beta cells. Toxin (A or LT) treatment also did not alter glucose-or potassium-mediated rises in cytosolic free calcium concentrations ([Ca2+](i)), suggesting that these GTPases are involved in steps distal to elevations in [Ca2+](i). Recent findings indicate that: the carboxyl methylation of Cdc42 is stimulated by only glucose, whereas that of Rap (Kowluru et al., J Clin Invest 98: 540-555, 1996) and Rac (present study) are regulated by glucose or potassium. Together, these findings provide direct evidence, for the first time, that the Rho subfamily of GTPases plays a key regulatory role(s) in insulin secretion, and they suggest that Cdc42 may be required for early steps in glucose stimulation of insulin release, whereas Rap and/or Rac may be required for a later step(s) in the stimulus-secretion coupling cascade (i.e. Ca2+-induced exocytosis of insulin). (C) 1997 Elsevier Science Inc. C1 WILLIAM S MIDDLETON MEM VET ADM MED CTR, MED SERV, MADISON, WI 53705 USA. WILLIAM S MIDDLETON MEM VET ADM MED CTR, RES SERV, MADISON, WI 53705 USA. NATL UNIV SINGAPORE, NATL MED INST, SINGAPORE 119260, SINGAPORE. UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, D-79104 FREIBURG, GERMANY. RP Kowluru, A (reprint author), UNIV WISCONSIN, CTR CLIN SCI,SCH MED,ENDOCRINOL SECT,H4-568, 600 HIGHLAND AVE, MADISON, WI 53792 USA. FU NIDDK NIH HHS [DK 37312] NR 31 TC 74 Z9 75 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0006-2952 J9 BIOCHEM PHARMACOL JI Biochem. Pharmacol. PD NOV 15 PY 1997 VL 54 IS 10 BP 1097 EP 1108 DI 10.1016/S0006-2952(97)00314-6 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YD492 UT WOS:A1997YD49200005 PM 9464452 ER PT J AU Alsina, M Gao, SJ Montalvo, EA Leach, CT Roodman, GD Jenson, HB AF Alsina, M Gao, SJ Montalvo, EA Leach, CT Roodman, GD Jenson, HB TI Increased prevalence of antibodies to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma SO BLOOD LA English DT Meeting Abstract C1 VET ADM MED CTR,SAN ANTONIO,TX. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. RI Gao, Shou-Jiang/B-8641-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 379 EP 379 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42400379 ER PT J AU Harris, K Arcasoy, M Forget, B Schultz, S AF Harris, K Arcasoy, M Forget, B Schultz, S TI The erythropoietin receptor distal cytoplasmic domain induces granulocytic differentiation in 32D cells. SO BLOOD LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,S TEXAS VET HLTH CARE SYST,DIV HEMATOL,SAN ANTONIO,TX. YALE UNIV,DIV HEMATOL,NEW HAVEN,CT. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 748 EP 748 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42400748 ER PT J AU Bauer, TR Schwartz, BR Liles, WC Ochs, HD Hickstein, DD AF Bauer, TR Schwartz, BR Liles, WC Ochs, HD Hickstein, DD TI Retroviral-mediated gene transfer of human CD18 into CD34(+) cells from a patient with leukocyte adherence deficiency: Implications for human gene therapy. SO BLOOD LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SEATTLE,WA 98195. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 1045 EP 1045 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42401045 ER PT J AU Kwiatkowski, BA Hickstein, DD AF Kwiatkowski, BA Hickstein, DD TI ETS family member Tel binds to Fli-1 and inhibits its transcription activity. SO BLOOD LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SCH MED,SEATTLE,WA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 1075 EP 1075 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42401075 ER PT J AU Kroning, R Nagami, G Weiss, D Solomon, A Lichtenstein, A AF Kroning, R Nagami, G Weiss, D Solomon, A Lichtenstein, A TI In vitro cytotoxicity to renal tubular epithelial cells is induced by nephrotoxic Bence Jones proteins and enhanced by interleukin-6. SO BLOOD LA English DT Meeting Abstract C1 UNIV TENNESSEE,MED CTR,KNOXVILLE,TN. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 1568 EP 1568 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42401564 ER PT J AU Alsina, M Choi, SJ Devlin, RD Cruz, JC Roodman, GD AF Alsina, M Choi, SJ Devlin, RD Cruz, JC Roodman, GD TI Assessment of the role of IL-1 beta in the pathogenesis of myeloma bone disease. SO BLOOD LA English DT Meeting Abstract C1 VET ADM MED CTR,SAN ANTONIO,TX. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 2346 EP 2346 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42402342 ER PT J AU Adler, HT Nallaseth, FS Walter, G Tkachuk, DC AF Adler, HT Nallaseth, FS Walter, G Tkachuk, DC TI Evidence that HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein set and protein phosphatase 2A. SO BLOOD LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE DIV,SEATTLE,WA. UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093. UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 2478 EP 2478 PN 1 PG 2 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42402474 ER PT J AU Berenson, J Rettig, M Heppner, K Vescio, R Ma, H Schiller, G Belson, D Savage, A Nishikubo, C Shintaku, I Koeffler, H Asou, H Pinkus, G Schrage, M Green, E Said, J AF Berenson, J Rettig, M Heppner, K Vescio, R Ma, H Schiller, G Belson, D Savage, A Nishikubo, C Shintaku, I Koeffler, H Asou, H Pinkus, G Schrage, M Green, E Said, J TI Bone marrow biopsies from bone multiple myeloma patients contain Kaposi's sarcoma-associated herpesvirus. SO BLOOD LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,SCH MED,W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90024. CEDARS SINAI MED CTR,LOS ANGELES,CA 90048. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 2612 EP 2612 PN 1 PG 1 WC Hematology SC Hematology GA YG424 UT WOS:A1997YG42402608 ER PT J AU Herbert, V AF Herbert, V TI Two steps to eliminate the chronic US blood donor shortage. 1. Add serum transferrin saturation to the routine blood screen on first doctor visit. 2. Give high iron blood to those who need blood. SO BLOOD LA English DT Meeting Abstract C1 MT SINAI MED CTR,NEW YORK,NY 10029. BRONX VET ADM MED CTR,NEW YORK,NY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 3306 EP 3306 PN 2 PG 1 WC Hematology SC Hematology GA YG425 UT WOS:A1997YG42500616 ER PT J AU Bastian, LS Kwiatkowski, B Danner, S Roth, G AF Bastian, LS Kwiatkowski, B Danner, S Roth, G TI Regulation of the megakaryocytic glycoprotein IX promoter by GATA-1 and Fli-1. SO BLOOD LA English DT Meeting Abstract C1 VET AFFAIRS PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SEATTLE,WA 98195. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 3404 EP 3404 PN 2 PG 1 WC Hematology SC Hematology GA YG425 UT WOS:A1997YG42500714 ER PT J AU Aiba, Y Ogawa, M AF Aiba, Y Ogawa, M TI Development of natural killer cells, B lymphocytes, macrophages, and mast cells from single hematopoietic progenitors in culture of murine fetal liver cells SO BLOOD LA English DT Article ID LYMPHOHEMATOPOIETIC PROGENITORS; MONOCLONAL-ANTIBODY; BONE-MARROW; STEM-CELLS; NK CELLS; LYMPHOID DIFFERENTIATION; NEGATIVE REGULATION; T-CELLS; C-KIT; MOUSE AB We have recently established a clonal culture system that supports the growth of immature natural killer (NK) cells from murine fetal thymocytes. We now describe a culture system for mixed NK cell colony formation from single lymphohematopoietic progenitors, When Sca-1(+)c-kit(+) fetal liver cells were cultured in methylcellulose media with interleukin (IL)-2, IL-7, IL-11, and steel factor (SF), we found mixed colonies consisting of diffuse small round cells characteristic of immature NK cells and other types of cells. The single cell origin of the mixed colonies was established by micromanipulation, Individual mixed colonies derived from single cells were characterized by flow cytometric analysis and May-Grunwald Giemsa staining. All mixed colonies contained Thy-1(+)B220(-) cells, which can differentiate to mature NK cells in fetal thymus organ culture. Most of the colonies contained B220(+) B-lineage cells and macrophages, and some contained mast cells. IL-1 alpha and IL-3, which have previously been shown to inhibit the T- and B-cell potentials of blast colonies, suppressed the formation of mixed NK cell colonies, The clonal culture assay presented here may be useful in analysis of the developmental pathway and commitment of NK cells from multipotential progenitors. (C) 1997 by The American Society of Hematology. C1 RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,CHARLESTON,SC 29401. MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC. FU NIDDK NIH HHS [DK/HL48714, DK32294] NR 37 TC 32 Z9 32 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 BP 3923 EP 3930 PG 8 WC Hematology SC Hematology GA YF299 UT WOS:A1997YF29900012 PM 9354659 ER PT J AU Chauncey, TR Thompson, AR Stewart, L Gooley, T McDonald, GB AF Chauncey, TR Thompson, AR Stewart, L Gooley, T McDonald, GB TI No association between activated protein C (APC) resistance and hepatic venoocclusive disease (VOD) following stem cell transplantation. SO BLOOD LA English DT Meeting Abstract C1 FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104. PUGET SOUND BLOOD CTR,VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA 98104. UNIV WASHINGTON,SCH MED,SEATTLE,WA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD NOV 15 PY 1997 VL 90 IS 10 SU 1 BP 4353 EP 4353 PN 2 PG 2 WC Hematology SC Hematology GA YG425 UT WOS:A1997YG42501662 ER PT J AU Newton, TF Khalsa-Denison, ME Gawin, FH AF Newton, TF Khalsa-Denison, ME Gawin, FH TI The face of craving? Facial muscle EMG and reported craving in abstinent and non-abstinent cocaine users SO PSYCHIATRY RESEARCH LA English DT Article DE cocaine; craving; EMG; facial expression ID AFFECTIVE IMAGERY AB We studied 12 subjects, half of whom were current cocaine users and half of whom were abstinent former users, using facial EMG before and after subjects completed questionnaires describing cocaine use, craving and mood. Changes in zygomatic EMG tone before and after cocaine questionnaire completion correlated with reported craving in current users. This preliminary study suggests that facial EMG correlates with cocaine craving in current users. (C) 1997 Elsevier Science Ireland Ltd. C1 W Los Angeles Vet Affairs Med Ctr, Dept Psychiat W116AC, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Drug Abuse Res Ctr, Los Angeles, CA USA. Mood & Addict Neurosci Fdn, W Hollywood, CA 90046 USA. RP Newton, TF (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Psychiat W116AC, Wilshire & Sawtelle Blvd, Los Angeles, CA 90073 USA. OI newton, thomas/0000-0002-3198-5901 FU NIDA NIH HHS [DA07699, DA08082, DA07200] NR 7 TC 3 Z9 3 U1 1 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD NOV 14 PY 1997 VL 73 IS 1-2 BP 115 EP 118 DI 10.1016/S0165-1781(97)00115-7 PG 4 WC Psychiatry SC Psychiatry GA YQ291 UT WOS:000071370600012 PM 9463845 ER PT J AU Shuster, E AF Shuster, E TI Fifty years later: The significance of the Nuremberg Code SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HUMAN-RIGHTS RP Shuster, E (reprint author), VET AFFAIRS MED CTR,UNIV & WOODLAND AVE,PHILADELPHIA,PA 19104, USA. NR 21 TC 124 Z9 128 U1 0 U2 16 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 13 PY 1997 VL 337 IS 20 BP 1436 EP 1440 DI 10.1056/NEJM199711133372006 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA YF253 UT WOS:A1997YF25300006 PM 9358142 ER PT J AU Farber, NJ Novack, DH OBrien, MK AF Farber, NJ Novack, DH OBrien, MK TI Love, boundaries, and the patient-physician relationship SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID SEXUAL CONTACT; EXPLOITATION; VIOLATIONS; PREVALENCE AB Physicians often use their relationships with patients to promote specific therapeutic goals. Because of their personal histories, values, and biases, patients may react to physicians in ways that inhibit or enhance the relationship. The feelings that are aroused may induce physicians to become overly distant, engendering patient and physician dissatisfaction, or to become overly involved emotionally, which can have serious psychological and clinical consequences. We explore how a balance between clinical objectivity and bonding with the patient is optimal and achievable. The nature and origin of personal boundaries are described. Boundary transgressions on the part of the patient are discussed, and the means of preventing transgressions by both patients and physicians through medical education, the process of self-awareness, and an exploration of family-of-origin issues are proposed. Through attention to communication with patients, the physician can maintain an empathetic yet objective relationship with the patient. C1 ALLEGHENY UNIV HLTH SCI,PHILADELPHIA,PA 19102. VET AFFAIRS MED CTR,DEPT MED,PHILADELPHIA,PA. NR 37 TC 35 Z9 35 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 10 PY 1997 VL 157 IS 20 BP 2291 EP 2294 DI 10.1001/archinte.157.20.2291 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA YE938 UT WOS:A1997YE93800001 PM 9361568 ER PT J AU Asch, DA Hershey, JC AF Asch, DA Hershey, JC TI The three-salesmen conundrum in medicine SO LANCET LA English DT Editorial Material ID UNCERTAINTY; REGRET C1 VET AFFAIRS MED CTR,PHILADELPHIA,PA. UNIV PENN,WHARTON SCH,DEPT OPERAT & INFORMAT MANAGEMENT,PHILADELPHIA,PA 19104. NR 3 TC 3 Z9 3 U1 1 U2 1 PU LANCET LTD PI LONDON PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL SN 0140-6736 J9 LANCET JI Lancet PD NOV 8 PY 1997 VL 350 IS 9088 BP 1393 EP 1394 DI 10.1016/S0140-6736(97)04204-9 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA YE872 UT WOS:A1997YE87200049 PM 9365467 ER PT J AU Adler, HT Nallaseth, FS Walter, G Tkachuk, DC AF Adler, HT Nallaseth, FS Walter, G Tkachuk, DC TI HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID COLD SHOCK DOMAINS; 11Q23 TRANSLOCATIONS; DNA-BINDING; ALL-1 GENE; MYELOID LEUKEMOGENESIS; DROSOPHILA-TRITHORAX; PUTATIVE ONCOGENE; POTENT INHIBITOR; CRUCIFORM DNA; OKADAIC ACID AB One of the most common chromosomal abnormalities in acute leukemia is a reciprocal translocation involving the HRX gene at chromosome locus 11q23, resulting in HRX fusion proteins. Using the yeast two-hybrid system, in vitro binding studies, and human cell culture coimmunoprecipitation experiments, we show here that a region of the HRX protein that is consistently retained in HRX leukemic fusion proteins interacts directly with SET, another protein implicated in leukemia. We have identified the binding sites on HRX for SET and show that these sequences are clustered near the A.T hooks that have been shown to bind DNA. We also show that carboxyl-terminal SET sequences, possibly the acidic tail of SET, bind to HRX. We have also found serine/threonine-specific protein phosphatase activity in anti-HRX coimmunoprecipitates. Using the phosphatase inhibitor okadaic acid and Western blotting, the phosphatase was identified as protein phosphatase 2A (PP2A). Mutation of a single amino acid in one of the SET binding sites of HRX resulted in lower amounts of both coimmunoprecipitated SET protein and coimmunoprecipitated PP2A. These results suggest that the leukemogenic effects of HRX fusion proteins may be related to interactions with SET and PP2A. C1 UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093. UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195. RP Adler, HT (reprint author), VA PUGET SOUND HLTH CARE SYST,SEATTLE DIV,1660 S COLUMBIAN WAY,RES MAIL STOP 151,SEATTLE,WA 98108, USA. NR 68 TC 84 Z9 86 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 7 PY 1997 VL 272 IS 45 BP 28407 EP 28414 DI 10.1074/jbc.272.45.28407 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YF219 UT WOS:A1997YF21900039 PM 9353299 ER PT J AU Asch, DA Ubel, PA AF Asch, DA Ubel, PA TI Rationing by any other name - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter RP Asch, DA (reprint author), PHILADELPHIA VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104, USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 6 PY 1997 VL 337 IS 19 BP 1396 EP 1396 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA YE446 UT WOS:A1997YE44600030 ER PT J AU Anzueto, A Jubran, A Ohar, JA Piquette, CA Rennard, SI Colice, G Pattishall, EN Barrett, J Engle, M Perret, KA Rubin, BK AF Anzueto, A Jubran, A Ohar, JA Piquette, CA Rennard, SI Colice, G Pattishall, EN Barrett, J Engle, M Perret, KA Rubin, BK TI Effects of aerosolized surfactant in patients with stable chronic bronchitis - A prospective randomized controlled trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID RECOMBINANT HUMAN DNASE; IODINATED GLYCEROL; PULMONARY-FUNCTION; CYSTIC-FIBROSIS; MUCUS; TRANSPORT; SPUTUM AB Context.-Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. Objective.-To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. Design.-A prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). Setting.-Four US teaching hospitals. Participants.-A total of 87 adult patients with the diagnosis of stable chronic bronchitis. Main Outcome Measures.-Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). Results.-A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline, In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4%; postbronchodilator FEV1 improved 10.4% by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2% by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. Conclusion.-Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis. C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. AUDIE L MURPHY MEM VET ADM MED CTR,S TEX VET HLTH CARE SYST,SAN ANTONIO,TX 78284. LOYOLA UNIV,HINES,IL. US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,HINES,IL 60141. ST LOUIS UNIV,HLTH SCI CTR,ST LOUIS,MO 63103. UNIV NEBRASKA,MED CTR,OMAHA,NE. 3M PHARMACEUT,ST PAUL,MN. GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709. E TENNESSEE PULM ASSOC,KNOXVILLE,TN. NR 32 TC 45 Z9 46 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 5 PY 1997 VL 278 IS 17 BP 1426 EP 1431 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA YC917 UT WOS:A1997YC91700029 PM 9356001 ER PT J AU Lehmann, KG vanSuylen, RJ Stibbe, J Slager, CJ Oomen, JA Maas, A diMario, C deFeyter, P Serruys, PW AF Lehmann, KG vanSuylen, RJ Stibbe, J Slager, CJ Oomen, JA Maas, A diMario, C deFeyter, P Serruys, PW TI Composition of human thrombus assessed by quantitative colorimetric angioscopic analysis SO CIRCULATION LA English DT Article DE thrombus; diagnosis; fibrin ID UNSTABLE ANGINA-PECTORIS; LEFT-VENTRICULAR THROMBI; MYOCARDIAL-INFARCTION; CORONARY ANGIOSCOPY; INTRACORONARY THROMBUS; ANGIOGRAPHIC DETECTION; ULTRASOUND; ISCHEMIA; ASPIRIN; OCCLUSION AB Background Angioscopy surpasses other diagnostic tools, such as angiography and intravascular ultrasound, in detecting arterial thrombus. This capability arises in part from the unique ability of angioscopy to assess true color during imaging. In practice, hardware-induced chromatic distortions and the subjectivity of human color perception substantially limit the theoretic potential of angioscopic color. We used a novel application of tristimulus colorimetry to quantify thrombus color to both aid in its detection and assess its composition. Methods and Results A series of human thrombus models were constructed in vitro. Spatial homogeneity was ensured by light and electron microscopy. Quantitative colorimetry angioscopic analysis demonstrated excellent measurement reproducibility (mean difference, 0.07% to 0.17%), unaffected by illuminating light intensity (coefficient of variation, 0.21% to 3.67%). Colorimetric parameters C-1 and C-2 were strongly correlated (r=.99, P<.0001) with thrombus erythrocyte concentration. Principal components analysis transformed these parameters into a single value, the thrombus erythrocyte index with little (0.06%) loss of content. Measured and predicted concentrations were similar (mean difference; 0.16 erythrocytes per 1 ng). Randomly ordered images were also subjected to visual analysis by three experienced angioscopists, with suboptimal levels of both intraobserver (mean (kappa=0.63) and interobserver (mean kappa=0.48) agreement. In addition, visual ranking resulted in a Kendall rank coefficient of 0.72 to 0.76 versus a perfect 1.00 from quantitative measurement. Conclusions Quantitative colorimetric angioscopic analysis provides a new, objective. and reproducible analytic tool for assessing angioscopic images of human thrombus. Even under ideal circumstances, experienced angioscopists do a poor job of assessing color (and therefore composition) of human thrombi. This technique can, for the first time, provide quantitative information of thrombus composition during routine diagnostic imaging. C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SCH MED,SEATTLE,WA. ERASMUS UNIV ROTTERDAM,THORAXCTR,NL-3000 DR ROTTERDAM,NETHERLANDS. NR 44 TC 11 Z9 12 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 4 PY 1997 VL 96 IS 9 BP 3030 EP 3041 PG 12 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YF295 UT WOS:A1997YF29500044 PM 9386172 ER PT J AU Gomez, AG Grimm, CT Yee, EFT Skootsky, SA AF Gomez, AG Grimm, CT Yee, EFT Skootsky, SA TI Preparing residents for managed care practice using an experience-based curriculum SO ACADEMIC MEDICINE LA English DT Article ID HEALTH-CARE; MEDICAL-EDUCATION; PHYSICIANS; SYSTEM AB Many U.S. residency graduates will practice in various types of managed care organizations, where they will be expected to arrive skilled in managed care activities such as prescribing with formularies and adhering to preauthorization processes for procedures, referrals, and hospital admissions. Residency programs must prepare their trainees to negotiate for their patients' needs within such systems. This article describes a University of California, Los Angeles, UCLA School of Medicine curriculum that teaches managed care skills to residents in two internal medicine residency training programs. The residents in one program participate in a commercial health maintenance organization plan via a group-model faculty practice. Managed care activities for residents in this program were gradually introduced beginning in 1990. This reflected previous years' gradual yet enforced introduction of managed care activities that occurred for this program's faculty and most group practice physicians in California. Residents in the other program train at a public hospital where managed care practice is simulated. Managed care activities were not required by this program's institution but were Voluntarily introduced for their educational value beginning in 1994. Responding to this program's trainee and faculty requests, these activities were rapidly implemented over two years with the goal of preparing residents for joining practices in a market with high managed care penetration. Since 1994, the centerpiece of the curriculum has been residents' participation in ambulatory utilization review and related activities. Residents learn managed care principles through problem-based learning, experiential exercises, and feedback on resource utilization. The curriculum has affected residents' attitudes toward managed care and changed their patterns of referrals and resource use. Residents trained with this curriculum perceive managed care practices as familiar and less intrusive. They submit fewer requests for referrals, perhaps with review in mind. However, precautions may be required to avoid undercare. The authors found that the reduction of referrals requested was greater than what they had expected. Residents may find scrutiny by colleagues intimidating. Also, this curriculum requires a substantial time commitment from residency training, with its already busy teaching agenda. The authors feel that initiating a managed care curriculum is an important investment in time for U.S. residency programs. Given thatmost graduates of residency programs will have their health care management decisions scrutinized while in practice, the authors feel it is important that residents' first exposure to managed care be while they are still in the supportive residency environment. They believe that early exposure will not only give residents the confidence to overcome the intimidation of colleague scrutiny, but may also give graduates the tools for involvement with the development of future managed care health policy. C1 SEPULVEDA VET HLTH ADM MED CTR,PRIMARY AMBULATORY CARE & EDUC PROGRAM,SEPULVEDA,CA. UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024. SEPULVEDA VET HLTH ADM MED CTR,UCLA SAN FERNANDO VALLEY PROGRAM,BEHAV MED PROGRAM,SEPULVEDA,CA. W LOS ANGELES VET AFFAIRS MED CTR,WOMENS LIFE CYCLE HLTH & EDUC CTR,LOS ANGELES,CA. SEPULVEDA VET HLTH ADM MED CTR,WOMENS LIFE CYCLE HLTH & EDUC CTR,SEPULVEDA,CA. W LOS ANGELES VET HLTH ADM MED CTR,WOMENS LIFE CYCLE HLTH & EDUC CTR,LOS ANGELES,CA. UNIV CALIF LOS ANGELES,CTR MANAGED CARE EDUC,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,DIV GEN INTERNAL MED & HLTH SERV RES,LOS ANGELES,CA 90024. NR 18 TC 14 Z9 14 U1 0 U2 2 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 SN 1040-2446 J9 ACAD MED JI Acad. Med. PD NOV PY 1997 VL 72 IS 11 BP 959 EP 965 DI 10.1097/00001888-199711000-00011 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA YG464 UT WOS:A1997YG46400012 PM 9387817 ER PT J AU Chiappelli, F Kung, MA Tio, DL Tritt, SH Yirmiya, R Taylor, AN AF Chiappelli, F Kung, MA Tio, DL Tritt, SH Yirmiya, R Taylor, AN TI Fetal alcohol exposure augments the blunting of tumor necrosis factor production in vitro resulting from in vivo priming with lipopolysaccharide in young adult male but not female rats SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE fetal alcohol exposure; lipopolysaccharide (LPS); tumor necrosis factor-alpha; peripheral blood mononuclear cells (PBMCs); primed PBMCs ID PROLIFERATIVE RESPONSE; ETHANOL INUTERO; IMMUNE; ALTERS; CELLS AB We previously reported altered responses of thymocytes and splenocytes to mitogen stimulation in fetal alcohol-exposed (FAE) male Sprague-Dawley rats. We also reported enhanced neuroendocrine responses to stressful stimuli in these animals. The experiments we describe herein aimed at testing whether young adult FAE rats manifest a notable dysregulation in the neuroendocrine-immune response to pathogen administration. We tested the effect of in vivo priming of the animal with a low dose of endotoxin [lipopolysaccharide (LPS), 5 mu g/kg], considered to be suboptimal from the perspective of mounting detectable levels of circulating monokines several hours after administration, upon the production of immunoreactive tumor necrosis factor (TNF-alpha) in response to a further in vitro challenge of peripheral blood mononuclear cells with 2.5 mu g/ml of LPS 90 min after priming. We show that the response to the LPS pathogen in vitro after priming is significantly blunted (p < 0.01) in male rats exposed prenatally to alcohol, compared with control male animals. FAE female rats and FAE ovariectomized female rats do not show significant differences in the priming response, compared with control animals. We also show that there is no correspondence between plasma corticosterone levels and TNF-alpha production after priming in any of the groups tested. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA 90095. UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095. UNIV CALIF LOS ANGELES,SCH DENT,LAB HUMAN ORAL & MOL IMMUNOL,LOS ANGELES,CA 90024. W LOS ANGELES DEPT VET AFFAIRS MED CTR,LOS ANGELES,CA. HEBREW UNIV JERUSALEM,DEPT PSYCHOL,IL-91905 JERUSALEM,ISRAEL. FU NIAAA NIH HHS [AA09850]; NIDA NIH HHS [DA07683] NR 18 TC 3 Z9 3 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD NOV PY 1997 VL 21 IS 8 BP 1542 EP 1546 PG 5 WC Substance Abuse SC Substance Abuse GA YG096 UT WOS:A1997YG09600028 PM 9394129 ER PT J AU Holloman, LC Marder, SR AF Holloman, LC Marder, SR TI Management of acute extrapyramidal effects induced by antipsychotic drugs SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Review DE akathisia; amantadine; antiparkinson agents; antipsychotic agents; basal ganglia diseases; benzodiazepines; dosage; dystonia; metoprolol; parasympatholytic agents; Parkinson's disease; propranolol; sympatholytic agents; toxicity ID NEUROLEPTIC-INDUCED AKATHISIA; CHRONIC-SCHIZOPHRENIC PATIENTS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND CROSSOVER; D2-DOPAMINE RECEPTOR OCCUPANCY; TARDIVE-DYSKINESIA; PARKINSONS-DISEASE; CLINICAL CHARACTERISTICS; BENZTROPINE MESYLATE; INDUCED DYSTONIA AB The management of acute extrapyramidal effect (EPEs) induced by antipsychotic drugs is reviewed. EPEs associated with antipsychotics include acute dystonias, pseudoparkinsonism, and akathisia. Acute dystonias consist of abnormal muscle spasms and postures and usually occur three to five days after antipsychotic therapy begins or the dosage is increased. Acute dystonias should be treated with anticholinergic medications or benzodiazepines. Antipsychotic-induced pseudoparkinsonism has the same clinical appearance as idiopathic parkinsonism. Symptoms generally appear within the first three months. Pseudoparkinsonism is managed by lowering the anti-psychotic dosage or by adding an anticholinergic agent or a mantadine; switching to a low-potency agent or an atypical antipsychotic may also help. Akathisia is characterized by subjective feelings of restlessness and anxiety and objective signs of motor activity, such as inability to sit still. This EPE appears days to weeks after antipsychotic exposure begins and can be difficult to manage. If reduction of the antipsychotic dosage or a switch to a less potent antipsychotic is not practical or effective, an anticholinergic, P-blocker, or benzodiazepine may be added. Lipophilic beta-blockers, especially propranolol and metoprolol, appear to be the most effective treatments. Anticholinergic agents are commonly given to prevent acute dystonias, especially in high-risk patients, but long-term prophylaxis is controversial. Atypical antipsychotics may have less potential to induce EPEs. Options in the management of antipsychotic associated EPEs include using the lowest effective dosage of antipsychotic, treating the reactions with medications, and changing the antipsychotic to one with less potential for inducing EPEs. C1 W LOS ANGELES VET AFFAIRS MED CTR,DEPT PHARM,LOS ANGELES,CA 90073. W LOS ANGELES VET AFFAIRS MED CTR,MENTAL HLTH SERV,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA. NR 160 TC 36 Z9 38 U1 1 U2 5 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD NOV 1 PY 1997 VL 54 IS 21 BP 2461 EP 2477 PG 17 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YF848 UT WOS:A1997YF84800015 PM 9359953 ER PT J AU Cody, JD Singer, FR Roodman, GD Otterund, B Lewis, TB Leppert, M Leach, RJ AF Cody, JD Singer, FR Roodman, GD Otterund, B Lewis, TB Leppert, M Leach, RJ TI Genetic linkage of Paget disease of the bone to chromosome 18q SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID FAMILIAL EXPANSILE OSTEOLYSIS; GIANT-CELL TUMOR; NUCLEAR INCLUSIONS; OSTEOCLASTS; FEATURES; REGION AB Paget disease is a common bone disease characterized by abnormal osteoclasts that are large, multinucleated, and overactive and that contain paramyxovirus-like nuclear inclusions. There is evidence for a major genetic component to Paget disease, with up to 40% of patients having affected first-degree relatives; however, the locus (loci) and-gene(s) involved are unknown. Another bone disorder, familial expansile osteolysis (FEO), although extremely rare, also is characterized by similar osteoclast abnormalities but has an earlier age at onset and a more aggressive clinical progression. The causative gene for FEO has been localized to a region of human chromosome 18q. On the basis of the presence of similar clinical findings and of viral-like nuclear inclusions in osteoclasts, we hypothesized that FEO and Paget disease are allelic versions of the same locus. Therefore, a large kindred with a high incidence of Paget disease was examined to determine if Paget disease was linked to genetic markers in the same region of chromosome 18 as that for FEO. Our analysis yielded a two-point LOD score of 3.40, with the genetic marker D18S42, a marker tightly linked to the FEO locus. This demonstrates that the gene(s) responsible for FEO and that for Paget disease are either closely linked or the same locus. C1 UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. VET ADM MED CTR,DEPT MED,SAN ANTONIO,TX. ST JOHNS HOSP,JOHN WAYNE CANC INST,SANTA MONICA,CA. UNIV UTAH,SCH MED,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT. INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46204. FU NIA NIH HHS [1P30AG1319]; NIAMS NIH HHS [P01AR39529] NR 33 TC 107 Z9 107 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637 SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD NOV PY 1997 VL 61 IS 5 BP 1117 EP 1122 DI 10.1086/301601 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA YH017 UT WOS:A1997YH01700017 PM 9345096 ER PT J AU Gelernter, J Kranzler, H Coccaro, E Siever, L New, A Mulgrew, CL AF Gelernter, J Kranzler, H Coccaro, E Siever, L New, A Mulgrew, CL TI D4 dopamine-receptor (DRD4) alleles and novelty seeking in substance-dependent, personality-disorder, and control subjects SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID STRUCTURED CLINICAL INTERVIEW; GENE; ASSOCIATION; ALCOHOLISM; POLYMORPHISM; POPULATION; CLOZAPINE; VARIANTS; AFRICANS; REPEAT AB Two reports have been published suggesting an association between the personality trait of novelty seeking and the DRD4*7R allele at the D4 dopamine-receptor locus (with heterozygotes or homozygotes for DRD4*7R having higher novelty seeking). We studied novelty seeking and four coding-sequence polymorphisms affecting protein structure in the D4 dopamine-receptor gene (DRD4) in a sample of 341 American subjects, of whom 224 are of primarily European ancestry and 117 are of primarily African ancestry. These subjects had diagnoses of substance dependence or personality disorder (PD) or were screened to exclude major psychiatric diagnosis. We found that, although the substance-dependent subjects had significantly higher novelty seeking than the control and PD subjects, they did not differ in DRD4*7R allele frequency. There was no association between any DRD4 polymorphism and novelty seeking in any population or diagnostic group, except for a significant association between the DRD4*7R allele and lower novelty seeking among European American females and African American substance abusers. The novelty seeking of subjects heterozygous for a null mutation did not differ from that of subjects with two functional alleles. We conclude that the most likely explanation of these results is that the DRD4 VNTR does not influence directly the trait of novelty seeking, in these samples. C1 YALE UNIV,SCH MED,DEPT PSYCHIAT,DIV MOL PSYCHIAT,W HAVEN,CT 06516. UNIV CONNECTICUT,CTR HLTH,DEPT PSYCHIAT,FARMINGTON,CT 06032. MED COLL PENN & HAHNEMANN UNIV,EASTERN PENN PSYCHIAT INST,PHILADELPHIA,PA 19129. MT SINAI SCH MED,NEW YORK,NY. BRONX VET ADM MED CTR,NEW YORK,NY. RP Gelernter, J (reprint author), VA CONNECTICUT HEALTHCARE SYST,PSYCHIAT 116A2,W HAVEN CAMPUS,950 CAMPBELL AVE,W HAVEN,CT 06516, USA. FU NIMH NIH HHS [K02-MH01387, K20-MH00931, R29-MH50859] NR 32 TC 137 Z9 142 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637 SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD NOV PY 1997 VL 61 IS 5 BP 1144 EP 1152 DI 10.1086/301595 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA YH017 UT WOS:A1997YH01700021 PM 9345090 ER PT J AU Stiens, SA Berkin, D AF Stiens, SA Berkin, D TI A clinical rehabilitation course for college undergraduates provides an introduction to biopsychosocial interventions that minimize disablement SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE rehabilitation; premedical student; medical student; consultation; education; resident ID TEACHER AB A two-credits per semester clinical medicine course was established in the Department of Physical Medicine and Rehabilitation (PM&R) in cooperation with the Johns Hopkins University undergraduate Human Biology faculty to present the variety of inpatient consultation personnel, units, patient diagnostic groups, and functional problems. College students spend 4 hr weekly on the PM&R consultation service as team members under resident supervision. The curriculum emphasizes student understanding of the roles of rehabilitation team members. Objectives include demonstration of working knowledge of the Biopsychosocial Model, the World Health Organization Model of disablement and interdisciplinary rehabilitation intervention. The course includes simulations of physical impairments, demonstrations of adaptive equipment, interactive chart reviews, readings, and audio lectures. A retrospective sequential review was made of the last 100 physical medicine and rehabilitation consultations with student attendance. The results confirm student exposure to many ward settings (surgery, 30%; neurology/neurosurgery, 28%; medicine, 24%; intensive care, 15%; oncology, 2%; and psychiatry, 1%), patient complexity (averaging 10 problems), and multiple ICD-9 diagnosis categories (circulatory, 36%; neurologic, 22%; musculoskeletal, 17%; neoplasms, 10%; injury, 5%; endocrine, 4%; infections, 3%; and others, 3%). The rehabilitation consultation service is particularly effective as an introduction to hospital-based medical practice due to the diagnostic variety of the patients, the functional approach of rehabilitation, and student exposure to multiple hospital settings. The Biopsychosocial Model of medical practice is demonstrated through multiple interdisciplinary perspectives of needs and interventions for patients with obvious functional deficits. This process develops a rudimentary understanding of the effect of illness on the person and the variety of medically effective therapeutic modalities. C1 Univ Washington, Sch Med, Dept Rehabil Med,Spinal Cord Injury Unit, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA. Braintree Rehabil, Braintree, MA USA. Sinai Johns Hopkins PM&R Residency Training Progr, Baltimore, MD USA. RP Stiens, SA (reprint author), Univ Washington, Sch Med, Dept Rehabil Med,Spinal Cord Injury Unit, VA Puget Sound Hlth Care Syst, BB 919 Hlth Sci Bldg, Seattle, WA 98195 USA. NR 38 TC 3 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV-DEC PY 1997 VL 76 IS 6 BP 462 EP 470 DI 10.1097/00002060-199711000-00006 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA YP029 UT WOS:000071234100005 PM 9431264 ER PT J AU Vadakekalam, J Rabaglia, ME Metz, SA AF Vadakekalam, J Rabaglia, ME Metz, SA TI Interleukin-1 beta inhibits phospholipase C and insulin secretion at sites apart from K-ATP channel SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE pancreatic islet; calcium; exocytosis; purine nucleotides ID PANCREATIC B-CELLS; PROTEIN-KINASE-C; NITRIC-OXIDE; PHOSPHOINOSITIDE HYDROLYSIS; RAT ISLETS; GUANYLYL CYCLASE; RELEASE; LANGERHANS; MECHANISM; MOUSE AB Although interleukin-1 beta (IL-1 beta) reduces pancreatic islet content of ATP and GTP, the distal events that mediate its inhibitory effects on insulin secretion remain poorly understood. Herein, the activation of phospholipase C (PLC) was quantified during islet perifusions. An 18-h exposure to IL-1 beta (100 pM) totally vitiated activation of PLC induced by glucose, an effect that requires ATP and GTP and closure of the ATF-dependent K+ (K-ATP) channel. Surprisingly, however, when islets were depolarized directly using either of two agonists, glyburide (which does not act via generation of purine nucleotides) or 40 mM K+ (which acts distal to K-ATP channel), PLC and insulin secretion were again obliterated by IL-1 beta. IL-1 beta also reduced the labeling of phosphoinositide substrates; however, this effect was insufficient to explain the inhibition of PLC, since the effects on substrate labeling, but not on PLC, were prevented by coprovision of guanosine or adenosine. Furthermore, when IL-1 beta-treated islets piers exposed to 100 mu M carbachol (which activates PLC partially independent of extracellular Ca2+), the effects were still obliterated by IL-1 beta. These data (together with the finding that IL-1 beta inhibited Ca2+-induced insulin release) suggest that, in addition to its effects on ATP synthesis and thereby on the K-ATP channel, IL-1 beta has at least two undescribed. distal effects to block both PLC as well as Ca2+-induced exocytosis. The latter correlated best with IL-1 beta's effect to impede phosphainositide synthesis, since it also was reversed by guanosine or adenosine. C1 UNIV WISCONSIN, SCH MED, DIV ENDOCRINOL & METAB, MADISON, WI 53792 USA. UNIV WISCONSIN, SCH MED, DEPT MED, MADISON, WI 53792 USA. WILLIAM S MIDDLETON MEM VET ADM MED CTR, ENDOCRINOL SECT, MADISON, WI 53705 USA. WILLIAM S MIDDLETON MEM VET ADM MED CTR, MED SERV, MADISON, WI 53705 USA. FU NIDDK NIH HHS [DK-37312] NR 30 TC 4 Z9 5 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD NOV PY 1997 VL 273 IS 5 BP E942 EP E950 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA YF556 UT WOS:A1997YF55600014 PM 9374680 ER PT J AU Klebanov, S Herlihy, JT Freeman, GL AF Klebanov, S Herlihy, JT Freeman, GL TI Effect of long-term food restriction on cardiac mechanics SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE isoproterenol; calcium; ventricular pressure; Langendorff preparation; diet ID SYSTOLIC PRESSURE-VOLUME; CALORIC RESTRICTION; RAT HEARTS; ELECTRICAL PERFORMANCE; FISCHER-344 RATS; METABOLIC-RATE; AGE; LONGEVITY; MYOSIN; ENERGY AB Food restriction (FR) is the only known intervention capable of increasing mammalian life span. It not only increases longevity, but reduces the incidence of a broad spectrum of age-related pathologies, including cardiomyopathy, and retards the physiological decline associated with aging. Previous work from this laboratory has shown that long-term FR affects the contractile machinery of the heart, shifting the cardiac myosin profile from the fast, V-1 isoform to the slow, V-3 isoform. The aim of the present study was to determine whether FR also induces changes in cardiac mechanics. Isolated, isovolumically beating hearts were examined from four groups of rats: 1) ad Libitum-fed rats killed at 10-13 mo of age, 2) FR rats offered only 60% of the calories consumed by ad libitum-fed rats and killed at the same age, 3) young ad Libitum-fed rats having the same heart weights as the FR rats, and 4) ad Libitum-fed rats subjected to short-term FR, i.e., for the last 3 wk of life, and also killed at 10-13 mo of age. Both short-and long-term FR profoundly and to approximately the same extent affected cardiac mechanics. Hearts from FR rats developed much higher pressures than hearts from the ad Libitum-fed rats under conditions of low-calcium perfusate. This difference disappeared, however, when contractility was enhanced by either calcium or isoproterenol. FR prolonged both contraction and relaxation times. Long-term ad libitum-fed rats (adult, 10-13 mo of age) had a lower isoproterenol sensitivity than the young ad Libitum-fed rats (10 wk of age). Both short-and long-term FR restored the sensitivity to isoproterenol. In summary, FR profoundly affects many aspects of cardiac mechanics, enhancing some age-related changes (prolongation of the contraction and relaxation times), attenuating another (increasing the isoproterenol sensitivity), and, finally, inducing some unique changes unrelated to age (increased pressure development under low-calcium perfusate). C1 Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Freeman, GL (reprint author), Med Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 42 TC 25 Z9 27 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD NOV PY 1997 VL 273 IS 5 BP H2333 EP H2342 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA YF553 UT WOS:A1997YF55300031 ER PT J AU Gross, NJ Veldhuizen, R Possmayer, F Dhand, R AF Gross, NJ Veldhuizen, R Possmayer, F Dhand, R TI Surfactant convertase action is not essential for surfactant film formation SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE surfactant subtype; surfactant conversion ID PULMONARY SURFACTANT; LUNG SURFACTANT; EXTRACELLULAR METABOLISM; SERINE-PROTEASE; LAMELLAR BODIES; TUBULAR MYELIN; SUBFRACTIONS; CONVERSION; SUBTYPES; INVITRO AB A serine-active enzyme, ''surfactant convertase,'' is required for the conversion of surfactant from the tubular myelin (TM) form to the small vesicular (SV) form. This transformation involves at least two steps, the conversion of TM to a surface-active film at the air-fluid interface and the reorientation of the film into the surface-inactive SV form; we asked if convertase was required for the first of these steps. Rat and mouse TMs were pretreated with diisopropyl fluorophosphate (DFP) to inactivate endogenous convertase activity or with vehicle and then were analyzed for their ability to lower surface tension in vitro as an index of the conversion of TM to a surface film. DFP pretreatment did not alter the ability of TM preparations to lower surface tension, as assessed by pulsating bubble, and it did not affect the behavior of TM in a surface balance. In an experiment designed to test the ability of TM to feed a surface film to exhaustion, TMs that had been pretreated with DFP or vehicle performed similarly. These experiments show that convertase activity is not required for the conversion of TM to a monolayer and suggest, instead, that convertase acts at a post surface film stage. C1 US DEPT VET AFFAIRS, VET AFFAIRS EDWARD HINES JR HOSP, MED SERV, HINES, IL 60141 USA. LOYOLA UNIV, STRITCH SCH MED, DEPT MED, MAYWOOD, IL 60153 USA. LOYOLA UNIV, STRITCH SCH MED, DEPT MOL & CELLULAR BIOCHEM, MAYWOOD, IL 60153 USA. UNIV WESTERN ONTARIO, LAWSON RES INST, DEPT MED, LONDON, ON N6A 5A5, CANADA. UNIV WESTERN ONTARIO, LAWSON RES INST, DEPT PHYSIOL, LONDON, ON N6A 5A5, CANADA. UNIV WESTERN ONTARIO, MRC, GRP FETAL & NEONATAL HLTH & DEV, DEPT OBSTET & GYNAECOL, LONDON, ON N6A 5A5, CANADA. UNIV WESTERN ONTARIO, MRC, GRP FETAL & NEONATAL HLTH & DEV, DEPT BIOCHEM, LONDON, ON N6A 5A5, CANADA. FU NHLBI NIH HHS [HL-45782-01] NR 18 TC 10 Z9 11 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD NOV PY 1997 VL 273 IS 5 BP L907 EP L912 PG 6 WC Physiology; Respiratory System SC Physiology; Respiratory System GA YF568 UT WOS:A1997YF56800001 PM 9374716 ER PT J AU Jacobson, L Mariano, AJ Chabal, C Chaney, EF AF Jacobson, L Mariano, AJ Chabal, C Chaney, EF TI Beyond the needle - Expanding the role of anesthesiologists in the management of chronic non-malignant pain SO ANESTHESIOLOGY LA English DT Article DE anesthesiology; biomedical model; biopsychosocial model; nerve blocks; pain Clinics; multidisciplinary; pain; intractable; regional anesthesia; somatization ID SIMULTANEOUS INTERVIEW TECHNIQUE; PATIENT-PHYSICIAN RELATIONSHIP; RANDOMIZED CONTROLLED TRIAL; LOW-BACK-PAIN; ROVENSTINE LECTURE; REFRACTORY HEAD; PERSISTENT PAIN; LUMBAR SPINE; NECK PAIN; MEDICINE C1 VA PUGET SOUND HLTH CARE SYST,DEPT MENTAL HLTH,SEATTLE DIV,SEATTLE,WA 98108. UNIV WASHINGTON,SEATTLE,WA 98195. RP Jacobson, L (reprint author), VA PUGET SOUND HLTH CARE SYST,ANESTHESIOL SERV 112A,SEATTLE DIV,DEPT ANESTHESIOL,SEATTLE,WA 98108, USA. NR 84 TC 11 Z9 11 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0003-3022 J9 ANESTHESIOLOGY JI Anesthesiology PD NOV PY 1997 VL 87 IS 5 BP 1210 EP 1218 DI 10.1097/00000542-199711000-00026 PG 9 WC Anesthesiology SC Anesthesiology GA YE499 UT WOS:A1997YE49900026 PM 9366474 ER PT J AU Schuster, MA Asch, SM McGlynn, EA Kerr, EA Hardy, AM Gifford, DS AF Schuster, MA Asch, SM McGlynn, EA Kerr, EA Hardy, AM Gifford, DS TI Development of a quality of care measurement system for children and adolescents - Methodological considerations and comparisons with a system for adult women SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID HEALTH-CARE; ASTHMA; APPROPRIATENESS; PHYSICIANS; KNOWLEDGE; REFORM; IMPACT; RATES AB Objectives: To describe the development of a pediatric quality of care measurement system designed to cover multiple clinical topics that could be applied to enrollees in managed care organizations and to compare the development of this system with the concurrent development of a similar system for adult women. Design: Indicators were developed for 21 pediatric (ages 0-18 years) clinical topics and 20 adult (ages 17-50 years) women's clinical topics. Indicators were classified by the strength of evidence supporting them. A modified Delphi method was used to obtain validity and feasibility ratings from a pediatric expert panel and an adult women's expert panel. Indicators were categorized by type of care (preventive, acute, or chronic), function (screening, diagnosis, treatment, or follow up), and modality (history, physical examination, laboratory/radiology study, medication, other intervention, or other contact). Results: Of 557 pediatric and 391 adult women's proposed indicators, 453 (81%) and 340 (87%), respectively, were retained by the 2 expert panels. A lower percentage of final pediatric indicators than adult indicators were based on randomized, controlled trials and other rigorous studies (18% vs 40%, P<.001). The expert panels were more likely to retain indicators based on rigorous studies (93% retained) than on descriptive studies and expert opinion (81% retained, P<.001). A higher percentage of pediatric indicators than women's indicators were for preventive care (30% vs 11%, P<.001) and a lower percentage were for acute care (36% vs 49%, P<.001) or chronic care (34% vs 41%, P=.06). Conclusions: This study contributes to the field of pediatric quality of care assessment by providing many more indicators than have been available previously and by documenting the strength of evidence supporting these indicators. Formal consensus methods are essential for the development of pediatric quality measures because the evidence base for pediatric care is more limited than for adult care. C1 UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,W LOS ANGELES VET ADM HOSP,LOS ANGELES,CA. UNIV MICHIGAN,DEPT MED,ANN ARBOR,MI 48109. BROWN UNIV,WOMEN & INFANTS HOSP,PROVIDENCE,RI. ANN ARBOR VET ADM MED CTR,HLTH SERV RES & DEV FIELD PROGRAM,ANN ARBOR,MI. RP Schuster, MA (reprint author), RAND CORP,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90407, USA. FU PHS HHS [18C-90315/9-02] NR 44 TC 50 Z9 52 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD NOV PY 1997 VL 151 IS 11 BP 1085 EP 1092 PG 8 WC Pediatrics SC Pediatrics GA YF122 UT WOS:A1997YF12200003 PM 9369869 ER PT J AU Tiwari, P Reddy, V Tiwari, PK Wong, FKM Cheng, YL Yu, AW Ing, TS AF Tiwari, P Reddy, V Tiwari, PK Wong, FKM Cheng, YL Yu, AW Ing, TS TI Acid-base values of single pass, batch system, bicarbonate based hemodialysate SO ASAIO JOURNAL LA English DT Article; Proceedings Paper CT 42nd Annual Conference of the American-Society-for-Artificial-Internal-Organs CY MAY 03-04, 1996 CL WASHINGTON, DC SP Amer Soc Artificial Internal Organs AB The bicarbonate, calcium, and magnesium values of a single pass, batch system, bicarbonate based hemodialysate were found to be stable during a period of 5 hours, whether the solution was extensively covered by a floating polystyrene lid or not. The pH and PCO2 of the dialysate that had been covered with a floating lid remained stable during the 5 hours, whereas the corresponding values of the dialysate that had not been so covered did show changes that were secondary to the loss of carbon dioxide. The changes were not marked enough to preclude the clinical use of the latter uncovered dialysate. C1 US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,DEPT RES,HINES,IL 60141. US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,DEPT MED,HINES,IL 60141. LOYOLA UNIV,STRITCH SCH MED,MAYWOOD,IL 60153. CHINESE UNIV HONG KONG,DEPT MED,HONG KONG,HONG KONG. NR 8 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1058-2916 J9 ASAIO J JI Asaio J. PD NOV-DEC PY 1997 VL 43 IS 6 BP 897 EP 899 DI 10.1097/00002480-199711000-00009 PG 3 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA YF563 UT WOS:A1997YF56300009 PM 9386839 ER PT J AU True, WR Xian, H Eisen, SA Goldberg, J Lyons, MJ Tsuang, MT AF True, WR Xian, H Eisen, SA Goldberg, J Lyons, MJ Tsuang, MT TI Multivariate analyses of posttraumatic stress disorder and alcohol and drug dependence in 3304 twin pair members of the Vietnam Era Twin Registry. SO BEHAVIOR GENETICS LA English DT Meeting Abstract C1 St Louis Univ, Sch Publ Hlth, St Louis, MO 63108 USA. St Louis VAMC, Res Serv, St Louis, MO 63106 USA. Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA. US Dept Vet Affairs, HSRD, Hines, IL 60141 USA. Univ Illinois, Sch Publ Hlth, Program Epidemiol, Chicago, IL 60680 USA. Boston Univ, Dept Psychol, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02401 USA. RI Lyons, Michael/B-6119-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 1997 VL 27 IS 6 BP 608 EP 608 PG 1 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA YV287 UT WOS:000071808100109 ER PT J AU Metz, SA Meredith, M AF Metz, SA Meredith, M TI Of mice and men (and rats): caveats in defining specific roles of GTP in the pancreatic islet SO BIOCHEMICAL JOURNAL LA English DT Letter ID INDUCED INSULIN-SECRETION; BETA-CELLS; GLUCOSE; STIMULATION; RODENT C1 WILLIAM S MIDDLETON MEM VET ADM MED CTR, MADISON, WI 53705 USA. RP Metz, SA (reprint author), UNIV WISCONSIN HOSP & CLIN, H4 568 CSC, 600 HIGHLAND AVE, MADISON, WI 53792 USA. NR 17 TC 3 Z9 3 U1 0 U2 0 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD NOV 1 PY 1997 VL 327 BP 931 EP 933 PN 3 PG 3 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA YF865 UT WOS:A1997YF86500042 PM 9599223 ER PT J AU Tsai, T Goodman, S Saez, R Schiller, G Adkins, D Callander, N Wolff, S Freytes, CO AF Tsai, T Goodman, S Saez, R Schiller, G Adkins, D Callander, N Wolff, S Freytes, CO TI Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation SO BONE MARROW TRANSPLANTATION LA English DT Article DE BMT; relapse; second transplant; lymphoma; leukemia ID NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA; COMBINATION CHEMOTHERAPY; FOLLOW-UP; DISEASE; THERAPY; CYCLOPHOSPHAMIDE; CARMUSTINE; CISPLATIN; LEUKEMIA AB Increasing numbers of patients have received autologous stem cell transplants (ASCT) for hematologic malignancies, Since only a fraction of these patients are cured, physicians are more frequently faced with the dilemma of how to manage relapse post-transplant. Potential advantages of allogeneic transplantation (alloBMT) over ASCT include lack of graft tumor contamination and presence of a graft-versus-tumor effect, For this reason, patients who relapse after ASCT are often considered candidates for allogeneic bone marrow transplantation. However, there is limited knowledge on the outcome of alloBMT in patients who relapse after ASCT, We retrospectively analyzed the outcome of 20 patients with malignant lymphoma (n = 14) and AML (n = 6) who underwent alloBMT after failing an ASCT, The median age was 30 (17-41) years and the interval from ASCT to alloBMT was 10.5 (2-25) months, Seventeen patients died between 0.3 to 11 months (median 2.0) after alloBMT, all due to BMT-related toxicities, Three patients remain alive and free of disease at 1.1, 1.2 and 2.5 years after alloBMT. Sixteen of the 18 evaluable patients (89%) developed grade II-IV acute GVHD, Patients undergoing alloBMT after ASCT have a very high treatment-related mortality and incidence of grade II-IV acute GVHD, Alternative treatments with salvage chemotherapy, radiation or investigational approaches should be considered in patients who relapse after ASCT. C1 S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX. NASHVILLE VET ADM MED CTR,NASHVILLE,TN. UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA CITY,OK. UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA. WASHINGTON UNIV,SCH MED,ST LOUIS,MO. RP Tsai, T (reprint author), UNIV TEXAS,HLTH SCI CTR,DIV HEMATOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA. NR 16 TC 77 Z9 78 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD NOV PY 1997 VL 20 IS 10 BP 859 EP 863 DI 10.1038/sj.bmt.1700989 PG 5 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA YG896 UT WOS:A1997YG89600008 PM 9404927 ER PT J AU Goldsmith, KT Dion, LD Garver, RI AF Goldsmith, KT Dion, LD Garver, RI TI Recombinant adenovirus replication in non-small cell lung cancer SO CANCER GENE THERAPY LA English DT Meeting Abstract C1 BIRMINGHAM VAMC,DEPT MED,DIV PULM & CRIT CARE MED,BIRMINGHAM,AL. UNIV ALABAMA,BIRMINGHAM,AL. NR 0 TC 0 Z9 0 U1 0 U2 0 PU APPLETON & LANGE PI E NORWALK PA 25 VAN ZANT ST, E NORWALK, CT 06855 SN 0929-1903 J9 CANCER GENE THER JI Cancer Gene Ther. PD NOV-DEC PY 1997 VL 4 IS 6 SU S BP O39 EP O39 PG 2 WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine GA YJ318 UT WOS:A1997YJ31800039 ER PT J AU Glickerman, DJ Hathaway, PB Hatsukami, T Daly, CP Althaus, S Kohler, TR AF Glickerman, DJ Hathaway, PB Hatsukami, T Daly, CP Althaus, S Kohler, TR TI Transluminal treatment of a celiac artery pseudoaneurysm with a stent graft occlusion device SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article DE stents and prostheses; arteries, therapeutic blockade; aneurysm, therapy ID ABDOMINAL AORTIC-ANEURYSMS; ENDOVASCULAR REPAIR; EMBOLIZATION; PLACEMENT; PANCREATITIS; MANAGEMENT; EXPERIENCE; COIL AB This report describes the transluminal placement of a stent graft occlusion device to treat a celiac bypass graft pseudoaneurysm which was causing biliary and duodenal obstruction. RP Glickerman, DJ (reprint author), VET AFFAIRS PUGET SOUND HLTH CARE SYST,RADIOL SERV 114,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA. NR 24 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0174-1551 J9 CARDIOVASC INTER RAD JI Cardiovasc. Interv. Radiol. PD NOV-DEC PY 1997 VL 20 IS 6 BP 466 EP 469 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA YF148 UT WOS:A1997YF14800011 PM 9354718 ER PT J AU Gudmundsson, A Ershler, WB Goodman, B Lent, SJ Barczi, S Carnes, M AF Gudmundsson, A Ershler, WB Goodman, B Lent, SJ Barczi, S Carnes, M TI Serum concentrations of interleukin-6 are increased when sampled through an indwelling venous catheter SO CLINICAL CHEMISTRY LA English DT Letter ID PITUITARY-ADRENAL AXIS; PLASMA-LEVELS; CYTOKINES; DISEASE; WOMEN; MEN C1 UNIV WISCONSIN,DEPT MED,MADISON,WI 53792. RP Gudmundsson, A (reprint author), WILLIAM S MIDDLETON MEM VET ADM MED CTR,EDUC & CLIN CTR,2500 OVERLOOK TERRACE,MADISON,WI 53705, USA. FU NCRR NIH HHS [RR03186, RR29-DK40759]; NIA NIH HHS [R01 AG-1071] NR 17 TC 26 Z9 26 U1 0 U2 1 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD NOV PY 1997 VL 43 IS 11 BP 2199 EP 2201 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA YE072 UT WOS:A1997YE07200033 PM 9365415 ER PT J AU vanDijk, G Donahey, JCK Thiele, TE Scheurink, AJW Steffens, AB Wilkinson, CW Tenenbaum, R Campfield, LA Burn, P Seeley, RJ Woods, SC AF vanDijk, G Donahey, JCK Thiele, TE Scheurink, AJW Steffens, AB Wilkinson, CW Tenenbaum, R Campfield, LA Burn, P Seeley, RJ Woods, SC TI Central leptin stimulates corticosterone secretion at the onset of the dark phase SO DIABETES LA English DT Article ID OBESE GENE; WEIGHT; HYPOTHALAMUS; HUMANS; SERUM; RNA AB Leptin, a hormone secreted by adipose tissue in proportion to body adiposity, is proposed to be involved in the central nervous regulation of food intake and body weight, In addition, evidence is emerging that leptin regulates neuroendocrine and metabolic functions as well, presumably via its action in the central nervous system (CNS), To investigate this regulatory effect of leptin, we infused 3.5 mu g of human leptin directly into the third cerebral ventricle (i3vt) of lean male Long-Evans rats, 90 min before the onset of their dark phase, Before and after infusion, blood samples were withdrawn through indwelling catheters for assessment of hormonal (plasma corticosterone, insulin, leptin), autonomic (plasma norepinephrine, epinephrine), and metabolic (plasma glucose) parameters, I3vt leptin caused an increase in plasma corticosterone and plasma leptin levels relative to the control condition, The effects of i3vt leptin on corticosterone secretion became particularly apparent after the onset of the dark phase, The results of the present study indicate that i3vt leptin stimulates the hypothalamo-pituitary-adrenal (HPA) axis, particularly when rats normally encounter their largest meals, These results are consistent with the possibility that high circulating leptin levels may underlie the increased activity of the HPA axis that is generally characteristic of human obesity and most animal models of obesity. C1 UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195. UNIV WASHINGTON,DEPT BEHAV NEUROSCI,SEATTLE,WA 98195. UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195. UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195. VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110. RP vanDijk, G (reprint author), UNIV GRONINGEN,CTR BIOL,DEPT ANIM PHYSIOL,POB 14,NL-9750 AA HAREN,NETHERLANDS. OI van Dijk, Gertjan/0000-0002-6565-4019 FU NIAAA NIH HHS [AA-07455]; NIDDK NIH HHS [DK-17844, DK-35816] NR 24 TC 64 Z9 64 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 SN 0012-1797 J9 DIABETES JI Diabetes PD NOV PY 1997 VL 46 IS 11 BP 1911 EP 1914 DI 10.2337/diabetes.46.11.1911 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YC480 UT WOS:A1997YC48000037 PM 9356047 ER PT J AU Jensen, DM Jutabha, R Machicado, GA Jensen, ME Cheng, S Gombein, J Hirabayashi, K Ohning, G Randall, G AF Jensen, DM Jutabha, R Machicado, GA Jensen, ME Cheng, S Gombein, J Hirabayashi, K Ohning, G Randall, G TI Prospective randomized comparative study of bipolar electrocoagulation versus heater probe for treatment of chronically bleeding internal hemorrhoids SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID OUTPATIENT TREATMENT; COAGULATION; DIATHERMY; LASER; TRIAL AB Background: Our purpose was to compare the efficacy, complications, failure rates, and crossovers of heater and bipolar probe treatments of chronically bleeding internal hemorrhoids. Methods: Eighty-one patients (31 female, 50 male) with mean age of 53 years had large (grade 2 to 3) internal hemorrhoids with bleeding for a mean of 12 years, had failed medical management, and were randomized in a prospective study of anoscopic treatments to heater versus bipolar probes. Failure was defined as a major complication or failure to reduce the size of all internal hemorrhoids with three or more treatments. Results: With similar background variables and no difference in treatment times, rectal bleeding and other symptoms were controlled in a shorter time with the heater probe than with the bipolar probe (77 versus 121 days). Five complications (fissures, bleeding, or rectal spasm) occurred with the bipolar probe, and two occurred with the heater probe. The heater probe caused more pain during treatments but had significantly fewer failures and crossovers. Conclusions: For patients who had failed medical management of chronically bleeding internal hemorrhoids, the techniques and complications of heater and bipolar probes were similar, but pain was more common, failures and crossovers were less frequent, and the time to symptom relief was shorter with the heater probe than with the bipolar probe. C1 NORTHRIDGE HOSP,LOS ANGELES,CA. RP Jensen, DM (reprint author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,CURE,W LOS ANGELES VA MED CTR,ROOM 44-138 CHS,LOS ANGELES,CA 90095, USA. FU NIDDK NIH HHS [DK41301] NR 15 TC 21 Z9 25 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD NOV PY 1997 VL 46 IS 5 BP 435 EP 443 DI 10.1016/S0016-5107(97)70037-3 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA YF762 UT WOS:A1997YF76200008 PM 9402118 ER PT J AU Fass, R Higa, L Kodner, A Mayer, EA AF Fass, R Higa, L Kodner, A Mayer, EA TI Stimulus and site specific induction of hiccups in the oesophagus of normal subjects SO GUT LA English DT Article; Proceedings Paper CT 96th Annual Meeting of the American-Gastroenterological-Association CY MAY 18-23, 1996 CL SAN FRANCISCO, CA SP Amer Gastroenterol Assoc DE hiccups; oesophageal mechanoreceptors; electronic distension device; phasic distension; ramp distension; perception thresholds ID GASTROESOPHAGEAL REFLUX; INTRACTABLE HICCUPS; ESOPHAGEAL AB Background-Hiccups that are induced by a large meal have been suggested to result from gastric overdistension. The role of the oesophagus in precipitating hiccups has never been defined. Aims-To determine the involvement of oesophageal mechanoreceptors in the hiccup reflex. Methods-Ten normal healthy subjects were prospectively evaluated at a university affiliated hospital. Controlled inflation of a polyethylene bag in the proximal and distal oesophagus was carried out using slow ramp and rapid phasic distensions, by an electronic distension device. Results-Hiccups were induced in four subjects only during rapid phasic distensions and only in the proximal oesophagus. The mean (SEM) minimal volume threshold for the hiccup reflex was 32.5 (4.8) ml, which was above the perception threshold. Hiccups appeared during inflation and resolved after deflation. Conclusions-Sudden rapid stretch of the mechanoreceptors in the proximal oesophagus can trigger the hiccup reflex in normal subjects. Only rapid distensions above a determined volume threshold will predictably induce hiccups in a given subject. This mechanism may play a role in the physiological induction of hiccups. C1 UNIV CALIF LOS ANGELES,DEPT MED,DIGEST DIS RES CTR,NEUROENTER BIOL GRP,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. RP Fass, R (reprint author), VET ADM MED CTR,SECT GASTROENTEROL 111G 1,3601 S 6TH AVE,TUCSON,AZ 85723, USA. NR 19 TC 21 Z9 21 U1 0 U2 1 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0017-5749 J9 GUT JI Gut PD NOV PY 1997 VL 41 IS 5 BP 590 EP 593 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA YD748 UT WOS:A1997YD74800003 PM 9414962 ER PT J AU Duerinckx, A Atkinson, DP AF Duerinckx, A Atkinson, DP TI Coronary MR angiography during peak-systole: Work in progress SO JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE cardiac MRI; heart; coronary vessels, MRI; coronary angiography, MRI; systole; diastole; image quality ID MAGNETIC-RESONANCE ANGIOGRAPHY; FLOOD FLOW VELOCITY; ARTERY BLOOD-FLOW; IN-VIVO; CONTRAST; DIAMETER; RESERVE; MOTION; QUANTIFICATION; ACCURACY AB The purpose of this study is to compare the quality of images of coronary arteries obtained with two-dimensional breath-hold coronary MR angiography during peak systole and mid diastole, Two-dimensional coronary MR angiography was performed in eight normal volunteers at peak systole and in mid diastole with a commercial 1.5-T MR imager, An ultrafast gradient-echo sequence with incremented flip angle series and k-space segmentation was used. The image quality grade, length, and proximal diameter of each visualized coronary artery were measured. The highest quality images in systole and diastole were compared. Coronary MR angiography provided high quality images in systole and diastole in 14 of 16 coronary vessels (87.5%), In 8 of 14 vessels (57%), there was no visible coronary MR angiogram image degradation when comparing peak systolic with mid-diastolic images. In 4 of 14 vessels (29%), there was mild MR image degradation. There was significant MR image degradation in only one case (7%). And in one case (7%), there was mild image improvement during systole. The width and length of the visualized coronary vessels did not change significantly from diastole to systole, Existing two-dimensional breath-hold coronary MR angiography provides MR images during peak systole and mid-diastole with little or no perceptible difference in quality. C1 W Los Angeles Vet Affairs Med Ctr, Serv Radiol, MRI, Los Angeles, CA 90073 USA. RP Duerinckx, A (reprint author), W Los Angeles Vet Affairs Med Ctr, Serv Radiol, MRI, Mail Rout W114,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Atkinson, Dennis/N-5238-2015 OI Atkinson, Dennis/0000-0001-7393-7505 NR 49 TC 21 Z9 21 U1 0 U2 0 PU SOC MAGNETIC RESONANCE IMAGING PI EASTON PA 1991 NORTHAMPTON ST, EASTON, PA 18042-3189 USA SN 1053-1807 J9 JMRI-J MAGN RESON IM JI JMRI-J. Magn. Reson. Imaging PD NOV-DEC PY 1997 VL 7 IS 6 BP 979 EP 986 DI 10.1002/jmri.1880070608 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 102UU UT WOS:000074944300006 PM 9400840 ER PT J AU Yang, ZW McLachlan, RI Bremner, WJ Wreford, NG AF Yang, ZW McLachlan, RI Bremner, WJ Wreford, NG TI Quantitative (stereological) study of normal spermatogenesis in the adult monkey (Macaca fascicularis) SO JOURNAL OF ANDROLOGY LA English DT Article DE Sertoli cell; spermiogenesis; stereology; testis ID FOLLICLE-STIMULATING-HORMONE; TESTIS; CELL; RAT; RENEWAL; SERTOLI; VOLUME; NUMBER; CYCLE AB Germ cell and Sertoli cell numbers were estimated in six normal adult monkeys (Macaca fascicularis) using a contemporary unbiased and efficient stereological method-the optical disector. The data was used to assess the efficiency of spermatogenesis from type B spermatogonia to elongated spermatids. Animals underwent orchidectomy, and the right testis (volume 17.5 +/- 1.7 cm(3) [mean +/- SEM], range 13.2-25.1 cm(3)) was fixed in Bouin's fluid. Blocks were embedded in methacrylate resin and germ cells were counted in thick (25 mu m) sections using the optical disector in conjunction with a systematic uniform random-sampling protocol. The total numbers of Sertoli cells an all germ cells per testis were 566 +/- 43 (419-683) million and 12.8 +/- 1.6 (9.0-20.2) billion, respectively. On average, one Sertoli cell supported 12.4 +/- 1.9 (range 8.2-18.4) step 1-12 spermatids. 3.1 +/- 0.4 (2.3-4.5) pachytene spermatocytes, and 23.7 +/- 4.1 (15.0-39.0) total germ cells. Sertoli cell number correlated poorly with both testicular size (correlation coefficient r = -0.12) and germ cell numbers (r = -0.35 with total germ cell number), However, testicular size had a consistent and significant correlation with germ cell numbers (r = 0.97 with total germ cell number). The conversion ratio of pachytene spermatocytes to step 1-12 spermatids was 3.94 +/- 0.19, which is close to the theoretical maximum of 4. Similarly, the conversion between other cell types was consistently close to the maximum theoretical value. We conclude that the efficiency of spermatogenesis in the adult monkey is high, with stepwise conversion being consistently close to the maximal values. The capacity of Sertoli cells to support a cohort of germ cells varies widely between monkeys. Although absolute number of cells per testis is always the preferred parameter, it cannot always be obtained in an experimental situation where cost and ethical constraints mean that biopsies, rather than whole testes, are collected. Thus, if absolute data on germ cell numbers are not available, experimental outcomes impacting on cells beyond preleptonene spermatocytes may be best expressed in terms of changes in germ cell conversion rather than the traditional germ cell:Sertoli cell ratio. C1 MONASH UNIV,DEPT ANAT,CLAYTON,VIC 3168,AUSTRALIA. PRINCE HENRYS INST MED RES,MELBOURNE,VIC,AUSTRALIA. UNIV WASHINGTON,VET AFFAIRS PUGET SOUND HLTH CARE SYST,DEPT MED,SEATTLE,WA 98195. MONASH UNIV,INST REPROD & DEV,CLAYTON,VIC 3168,AUSTRALIA. NR 20 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 SN 0196-3635 J9 J ANDROL JI J. Androl. PD NOV-DEC PY 1997 VL 18 IS 6 BP 681 EP 687 PG 7 WC Andrology SC Endocrinology & Metabolism GA YL445 UT WOS:A1997YL44500014 ER PT J AU Looker, AC Orwoll, ES Johnston, CC Lindsay, RL Wahner, HW Dunn, WL Calvo, MS Harris, TB Heyse, SP AF Looker, AC Orwoll, ES Johnston, CC Lindsay, RL Wahner, HW Dunn, WL Calvo, MS Harris, TB Heyse, SP TI Prevalence of low femoral bone density in older US adults from NHANES III SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article; Proceedings Paper CT 17th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 09-13, 1995 CL BALTIMORE, MD SP Amer Soc Bone & Mineral Res ID MEXICAN-AMERICAN WOMEN; HIP FRACTURE; MINERAL DENSITY; OSTEOPOROTIC FRACTURES; POSTMENOPAUSAL WOMEN; SEX-DIFFERENCES; SECULAR TRENDS; PREDICTION; MASS; RISK AB Most estimates of osteoporosis in older U.S. adults have been based on its occurrence in white women, even though it is known to affect men and minority women, In the present study, we used dual-energy X-ray absorptiometry measurements of femoral bone mineral density (BMD) from the third National Health and Nutrition Examination Survey (NHANES III, 1988-1994) to estimate the overall scope of the disease in the older U.S. population, Specifically, we estimate prevalences of low femoral BMD in women 50 years and older and explore different approaches for defining low BMD in older men ire that age range, Low BMD levels were defined in accordance with an approach proposed by an expert panel of the World Health Organization and used BMD data from 382 non-Hispanic white (NHW) men or 409 NHW women ages 20-29 years from the NHANES III dataset, For women, estimates indicate 13-18%, or 4-6 million, have osteoporosis (i.e., BMD >2.5 standard deviations [SD] below the mean of young NHW women) and 37-50%, or 13-17 million, have osteopenia (BMD between 1 and 2.5 SD below the mean of young NHW women), For men, these numbers depend on the gender of the reference group used to define cutoff values, When based on male cutoffs, 3-6% (1-2 million) of men have osteoporosis and 28-47% (8-13 million) have osteopenia; when based on female cutoffs, 1-4% (280,000-1 million) have osteoporosis and 15-33% (4-9 million) have osteopenia, Most of the older U.S. adults with low femur BMD are women, but, regardless of which cutoffs are used, the number of men is substantial. C1 OREGON HLTH SCI UNIV,PORTLAND,OR 97201. PORTLAND VA MED CTR,PORTLAND,OR. INDIANA UNIV,MED CTR,INDIANAPOLIS,IN. HELEN HAYES HOSP,REG BONE CTR,W HAVERSTRAW,NY. MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905. US FDA,CTR FOOD SAFETY & APPL NUTR,WASHINGTON,DC 20204. NIA,NIH,BETHESDA,MD 20892. NIAID,NIH,BETHESDA,MD 20892. RP Looker, AC (reprint author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,6525 BELCREST RD,ROOM 900,HYATTSVILLE,MD 20782, USA. OI Orwoll, Eric/0000-0002-8520-7355 NR 47 TC 674 Z9 698 U1 7 U2 20 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD NOV PY 1997 VL 12 IS 11 BP 1761 EP 1768 DI 10.1359/jbmr.1997.12.11.1761 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YE194 UT WOS:A1997YE19400001 PM 9383679 ER PT J AU Silva, JA Leong, GB Weinstock, R AF Silva, JA Leong, GB Weinstock, R TI Violent behaviors associate with the antichrist delusion SO JOURNAL OF FORENSIC SCIENCES LA English DT Article DE forensic science; antichrist delusion; delusional misidentification; psychosis; violence; aggression; forensic psychiatry ID MISIDENTIFICATION SYNDROMES; CAPGRAS SYNDROME; TOMOGRAPHY; ATROPHY AB Delusions involving the antichrist concept have been occasionally reported. Some cases of the antichrist delusion have been associated with violent behavior. In this article we describe the case of a man who suffered from a chronic antichrist delusion and who also displayed repeated and serious violent behaviors. We also discuss the role of the antichrist delusion as well as other psychotic symptoms in the genesis of violence in the present case. C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. OHIO STATE UNIV,COLL MED,COLUMBUS,OH 43210. VET AFFAIRS OUTPATIENT CLIN,COLUMBUS,OH. UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. RP Silva, JA (reprint author), S TEXAS VET HLTH CARE SYST,PSYCHIAT SERV 116A,PSYCHIAT RES UNIT,7400 MERTON MINTER BLVD,SAN ANTONIO,TX 78284, USA. NR 44 TC 6 Z9 8 U1 0 U2 2 PU AMER SOC TESTING MATERIALS PI W CONSHOHOCKEN PA 100 BARR HARBOR DR, W CONSHOHOCKEN, PA 19428-2959 SN 0022-1198 J9 J FORENSIC SCI JI J. Forensic Sci. PD NOV PY 1997 VL 42 IS 6 BP 1058 EP 1061 PG 4 WC Medicine, Legal SC Legal Medicine GA YF717 UT WOS:A1997YF71700013 PM 9397546 ER PT J AU Rossi, RA Every, NR AF Rossi, RA Every, NR TI A computerized intervention to decrease the use of calcium channel blockers in hypertension SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 02-03, 1997 CL WASHINGTON, DC SP Soc Gen Internal Med DE guidelines; physician's practice patterns; hypertension; calcium channel blockers ID RANDOMIZED CONTROLLED TRIAL; DRUG; MORTALITY; THERAPY; QUALITY; CARE AB OBJECTIVE: To determine whether a computer-assisted reminder would alter prescribing habits for the treatment of hypertension in accordance with current clinical guidelines in a general internal medicine clinic. DESIGN:A randomized trial. SETTING: The General Internal Medicine Clinic of the Veterans Affairs Puget Sound Health Care System, Seattle Division. PATIENTS/PARTICIPANTS: Clinic providers were randomized to a control group (n = 35) or intervention group (n = 36). We targeted the providers of patients being treated for hypertension with calcium channel blockers, a class of drug not recommended for initial therapy. INTERVENTION: An automated computer query identified eligible patients and their providers, A guideline reminder was placed in the charts of patients of intervention providers; the charts of patients of control providers received no reminder. MEASUREMENTS AND MAIN RESULTS: During the 5-month study period, 346 patients were seen by the 36 primary care providers (staff physicians, nurse practitioners, residents, and fellows) in the intervention group, and 373 patients were seen by the 35 providers in the control group, Intervention providers changed 39 patients (11.3%) to other medications during the study period, compared with 1 patient (<1.0%) of control providers (p < .0001). For patients whose therapy was unchanged, providers noted angina in 23.1%, indications other than those for hypertension in 9.5%, intolerable adverse effects with first-line therapy in 13.9%, and inadequate control with first-line therapy in 13.9%. Of those patients without provider-indicated contraindications, 23.6% were switched from calcium channel blockers to first-line agents during the intervention period. CONCLUSIONS: The use of a computerized, clinic-based intervention increased compliance with guidelines in the treatment of primary hypertension in general, and decreased the use of calcium channel blockers for the treatment of hypertension in particular. C1 VET AFFAIRS PUGET SOUND HLTH CARE SYST,HLTH SERV RES & DEV,SEATTLE,WA. NR 18 TC 51 Z9 51 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 1997 VL 12 IS 11 BP 672 EP 678 DI 10.1046/j.1525-1497.1997.07140.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA YF246 UT WOS:A1997YF24600003 PM 9383135 ER PT J AU Morrison, DA Barbiere, C AF Morrison, DA Barbiere, C TI Evolving picture of high risk coronary artery intervention SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REFRACTORY UNSTABLE ANGINA; CARDIOGENIC-SHOCK; SURGERY; IMMEDIATE RP Morrison, DA (reprint author), DENVER VAMC,CARDIOL SECT,1055 CLERMONT ST,DENVER,CO 80020, USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU HEALTH MANAGEMENT PUBLICATIONSINC PI WAYNE PA 950 WEST VALLEY RD, STE 2800, WAYNE, PA 19087 SN 1042-3931 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD NOV-DEC PY 1997 VL 9 IS 9 BP 593 EP 600 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA YJ090 UT WOS:A1997YJ09000007 ER PT J AU Marvizon, JCG Martinez, V Grady, EF Bunnett, NW Mayer, EA AF Marvizon, JCG Martinez, V Grady, EF Bunnett, NW Mayer, EA TI Neurokinin 1 receptor internalization in spinal cord slices induced by dorsal root stimulation is mediated by NMDA receptors SO JOURNAL OF NEUROSCIENCE LA English DT Article DE C-fibers; central sensitization; dorsal horn; glutamate receptor; internalization; LTP; NK1 receptor; NMDA receptor; slices; substance P ID LONG-TERM POTENTIATION; IMMUNOREACTIVE SUBSTANCE-P; HORN NOCICEPTIVE NEURONS; EXCITATORY AMINO-ACIDS; C-FIBER; RAT; GLUTAMATE; PHARMACOLOGY; ENDOCYTOSIS; TACHYKININS AB The excitability of spinal neurons that transmit pain is modulated by glutamate and substance P (SP). Glutamate is an excitatory neurotransmitter in the dorsal horn, and its effects are enhanced by SP acting on neurokinin 1 receptors (NK1Rs). We assessed activation of NK1Rs by studying their internalization in spinal cord slices. NK1Rs were localized in sections from the slices by using immunohistochemistry combined with fluorescence and confocal microscopy. Incubating the slices with SP induced internalization in most NK1R-positive neurons in laminae I, IIo, and X and in half of NK1R-positive neurons in laminae III-V. SP-induced internalization was abolished by the specific NK1R antagonist L-703,606 (1 mu M). Stimulating the dorsal root with long-duration (0.4 msec) pulses evoked EPSPs in dorsal horn neurons with latencies consistent with the conduction speed of A partial derivative- and C-fibers. High-frequency (100 Hz) stimulation of the dorsal root with these pulses induced NK1R internalization in neurons in laminae I-IIo of the stimulated side of the slice but not in the contralateral side or in other laminae. Stimulation at lower frequencies (1 and 10 Hz) failed to elicit significant internalization, suggesting that the release of SP is frequency-dependent. Internalization produced by the 100 Hz tetanus was mimicked by NMDA and blocked by an NMDA antagonist, 2-amino-5-phosphonopentanoic acid, but not by the AMPA and kainate antagonist CNQX. The NK1R antagonist L-703,606 abolished the internalization produced by 100 Hz stimulation or NMDA. Therefore, the release of SP in the dorsal horn appears to be controlled by NMDA receptors. C1 UNIV CALIF LOS ANGELES,DEPT PHYSIOL,LOS ANGELES,CA 90073. UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143. UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143. RP Marvizon, JCG (reprint author), UNIV CALIF LOS ANGELES,W LOS ANGELES VET ADM MED CTR,NEUROENTER DIS PROGRAM,DEPT MED,LOS ANGELES,CA 90073, USA. RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [DK40919, DK43207, DK48351] NR 43 TC 137 Z9 139 U1 1 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 1 PY 1997 VL 17 IS 21 BP 8129 EP 8136 PG 8 WC Neurosciences SC Neurosciences & Neurology GA YC947 UT WOS:A1997YC94700007 PM 9334388 ER PT J AU Schlesinger, N Baker, DG Schumacher, HR AF Schlesinger, N Baker, DG Schumacher, HR TI Serum urate during bouts of acute gouty arthritis SO JOURNAL OF RHEUMATOLOGY LA English DT Letter C1 VET AFFAIRS MED CTR,ARTHRITIS IMMUNOL CTR,PHILADELPHIA,PA. UNIV PENN,SCH MED,PHILADELPHIA,PA 19104. RP Schlesinger, N (reprint author), ALLEGHENY UNIV HOSP,PHILADELPHIA,PA, USA. NR 4 TC 34 Z9 34 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO ON M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD NOV PY 1997 VL 24 IS 11 BP 2265 EP 2266 PG 2 WC Rheumatology SC Rheumatology GA YD326 UT WOS:A1997YD32600042 PM 9375898 ER PT J AU Cornish, JW Metzger, D Woody, GE Wilson, D McLellan, AT Vandergrift, B O'Brien, CP AF Cornish, JW Metzger, D Woody, GE Wilson, D McLellan, AT Vandergrift, B O'Brien, CP TI Naltrexone pharmacotherapy for opioid dependent federal probationers SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE naltrexone; opioid dependence; parole; probation; substance dependence ID FOLLOW-UP; HEROIN; EXPERIENCE; EFFICACY AB Federal probationers or parolees with a history of opioid addiction were referred by them selves or their probation/parole officer for a naltrexone treatment study. Participation was voluntary and subjects could drop out of the study at any time without adverse consequences. Following orientation and informed consent, 51 volunteers were randomly assigned in a 2:1 ratio to a 6-month program of probation plus naltrexone and brief drug counseling, or probation plus counseling alone. Naltrexone subjects received medication and counseling twice a week; controls received counseling at similar intervals. All therapy and medication were administered in an office located adjacent to the federal probation department. Fifty-two percent of subjects in the naltrexone group continued for 6 months and 33% remained in the control group. Opioid use was significantly lower in the naltrexone group. The overall mean percent of opioid positive urine tests among the naltrexone subjects was 8%, versus 30% for control subjects (p < .05). Fifty-six percent of the controls and 26% of the naltrexone group (p <.05) had their probation status revoked within the 6-month study period and rearmed to prison. Treatment with naltrexone and brief drug counseling call be integrated into the Federal Probation/Parole system with favorable results on both opioid use and re-arrest rates. (C) 1997 Elsevier Science Inc. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. United State Probat Off, Philadelphia, PA 19106 USA. RP Cornish, JW (reprint author), Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. RI Metzger, David/D-9499-2012 FU NIDA NIH HHS [DA05186] NR 23 TC 118 Z9 125 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD NOV-DEC PY 1997 VL 14 IS 6 BP 529 EP 534 DI 10.1016/S0740-5472(97)00020-2 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA YP426 UT WOS:000071275600003 PM 9437624 ER PT J AU Rossen, RD AF Rossen, RD TI HMG-CoA reductase inhibitors: A new class of anti-inflammatory drugs? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID MEVALONATE PATHWAY; MACROPHAGES; CHOLESTEROL; RUPTURE; CELLS C1 BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030. BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030. RP Rossen, RD (reprint author), HOUSTON VET AFFAIRS MED CTR,ROOM 147,BLDG 109,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA. NR 8 TC 19 Z9 21 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 1 PY 1997 VL 30 IS 5 BP 1218 EP 1219 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA YD802 UT WOS:A1997YD80200011 PM 9350918 ER PT J AU Rooke, K BriquetLaugier, V Xia, YR Lusis, AJ Doolittle, MH AF Rooke, K BriquetLaugier, V Xia, YR Lusis, AJ Doolittle, MH TI Mapping of the gene for calreticulin (Calr) to mouse Chromosome 8 SO MAMMALIAN GENOME LA English DT Article ID MOLECULAR CHAPERONE; CALNEXIN; OLIGOSACCHARIDE; PROTEIN C1 UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095. W LOS ANGELES VET AFFAIRS MED CTR,LIPID RES LAB,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095. UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095. FU NHLBI NIH HHS [HL28481] NR 10 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PD NOV PY 1997 VL 8 IS 11 BP 870 EP 871 DI 10.1007/s003359900599 PG 2 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA YC460 UT WOS:A1997YC46000019 PM 9337407 ER PT J AU Barnes, CJ Hardman, WE Lee, MK Cameron, IL AF Barnes, CJ Hardman, WE Lee, MK Cameron, IL TI Histological structure and lymphoid cell types in the distal colon aggregate of lymphoid nodules of 4-month old and 22-month old rats SO MEDICAL SCIENCE RESEARCH LA English DT Article DE rat; colon; lymphoid nodules; age ID TISSUE; PROLIFERATION; CRYPTS AB This study had two goals (1) to determine the general histological characteristics of the rat distal colonic lymphoid nodules; and (2) to characterise the immunohistochemical localisation of proliferating cells, apoptotic cells, B lymphocytes and cytotoxic T lymphocytes within the colonic lymphoid aggregates in young (i.e., 4-month old and old (i.e., 22-month old) rats. The immunohistochemical staining described in the article revealed the distal aggregates of lymphoid nodules (ALN) of the rat to be quite similar in structure and cell types to previously described intestinal lymphoid aggregates. There were no major differences in the distribution pattern of proliferating cells, apoptotic cells, B cells or cytotoxic T cells between that of the distal lymphoid aggregate and that of small intestinal Peyer's patches or that of the rat proximal colon ALN. With the techniques and markers employed here, no apparent change with age was observed in the distal ALN. C1 UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284. VET AFFAIRS MED CTR,GASTROENTEROL SECT,SAN ANTONIO,TX 78284. RP Barnes, CJ (reprint author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU CHAPMAN HALL LTD PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN SN 0269-8951 J9 MED SCI RES JI Med. Sci. Res. PD NOV PY 1997 VL 25 IS 11 BP 787 EP 789 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA YH335 UT WOS:A1997YH33500020 ER PT J AU Giordano, M Castellino, P Solini, A Canessa, ML DeFronzo, RA AF Giordano, M Castellino, P Solini, A Canessa, ML DeFronzo, RA TI Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: Role of insulin resistance and antihypertensive treatment SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID SODIUM-LITHIUM COUNTERTRANSPORT; CONVERTING ENZYME-INHIBITION; GLUCOSE DISPOSAL; PROTON EXCHANGE; ANGIOTENSIN-II; RED-CELLS; NEPHROPATHY; NIDDM; ANTAGONISTS; HYPERTROPHY AB We measured erythrocyte Na+/Li+ and Na+/H+ countertransport: (CT) activity (millimoles per liter per cell per hour) in 10 healthy control subjects (age, 38 +/- 4 years; body mass index, 25 +/- 1 kg/m(2)) and in 26 hypertensive patients with non-insulin-dependent diabetes mellitus ([NIDDM] age, 49 +/- 3 years; body mass index, 29 +/- 1 kg/m(2); fasting plasma glucose, 157 +/- 12 mg/dL) 4 weeks after discontinuation of previous antihypertensive treatment. Na+/Li+ CT was significantly increased in hypertensive NIDDM patients compared with controls (0.56 +/- 0.04 v 0.30 +/- 0.03, P < .01), whereas Na+/H+ CT was similar to control levels (21 +/- 1 v 20 +/- 2). A positive correlation was found between Na+/H+ CT and the severity of insulin resistance (r = .69, P < .01), mean arterial pressure ([MAP] r = .64, P < .01), plasma triglyceride concentration (r = .46, P < .05), and plasma total cholesterol (r = .41, P < .05). An inverse correlation was found between Na+/Li+ CT activity and plasma insulin concentration (r = -.47, P < .05). No relationship was observed between Na+/Li+ CT activity and either creatinine clearance or proteinuria. Stepwise multiple regression analysis for all metabolic variables and blood pressure showed that only the severity of insulin resistance was positively correlated with increased Na+/Li+ CT activity. Na+/H+ and Na+/Li+ CT activity were not altered by 3 hours of euglycemic physiologic hyperinsulinemia (84 +/- 3 mu U/mL). Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin. After captopril, a reduction of Na+/H+ CT was observed (22 +/- 4 v 13 +/- 2, P < .05): Na+/Li+ CT decreased after doxazosin (0.56 +/- 0.06 v 0.45 +/- 0.05, P < .05) and nifedipine (0.52 +/- 0.06 v 0.42 +/- 0.05, P < .05). In conclusion, in hypertensive NIDDM subjects, (1) Na+/Li+ CT is increased and is correlated with the level of insulin resistance and the MAP; (21 acute physiologic hyperinsulinemia does not affect Na+/Li+ or Na+/H+ CT activity; and (3) Na+/H+ CT activity is reduced by captopril, and Na+/Li+ CT is decreased by doxazosin and nifedipine. Copyright (C) 1997 by W.B. Saunders Company. C1 UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIABET DIV,SAN ANTONIO,TX 78284. S TEXAS VET HEALTHCARE SYST,AUDIE L MURPHY DIV,SAN ANTONIO,TX. BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115. UNIV NAPLES 2,INST INTERNAL MED & NEPHROL,NAPLES,ITALY. RI Solini, Anna/K-4666-2016 OI Solini, Anna/0000-0002-7855-8253; CASTELLINO, Pietro/0000-0002-9014-2007 FU NCRR NIH HHS [M01-RR-01346]; NHLBI NIH HHS [HL-35664] NR 45 TC 13 Z9 16 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD NOV PY 1997 VL 46 IS 11 BP 1316 EP 1323 DI 10.1016/S0026-0495(97)90237-7 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YE074 UT WOS:A1997YE07400014 PM 9361692 ER PT J AU Bates, JA Abramova, ME Michalak, M Clark, RA Valente, AJ AF Bates, JA Abramova, ME Michalak, M Clark, RA Valente, AJ TI Regulation of calreticulin transcription in HeLa cells in response to calcium depletion SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX 78284. UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD NOV PY 1997 VL 8 SU S BP 172 EP 172 PG 1 WC Cell Biology SC Cell Biology GA YF096 UT WOS:A1997YF09600169 ER PT J AU Herrera, CR Lewin, A Fiddes, R Friedman, J Linn, W Baker, T Balanoff, D Beach, CL AF Herrera, CR Lewin, A Fiddes, R Friedman, J Linn, W Baker, T Balanoff, D Beach, CL TI Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population SO PHARMACOTHERAPY LA English DT Article ID ONCE-DAILY DILTIAZEM; NON-HISPANIC WHITES; HEALTH AB Study Objective. To evaluate the safety and effectiveness of diltiazem CD for reducing blood pressure in Mexican-American patients with mild to moderate hypertension. Design. Randomized, double-blind, placebo-controlled trial. Setting. Twelve clinical sites in the United States. Patients. Patients with baseline diastolic blood pressures between 95 and 115 mm Hg. Interventions. Patients were treated with an average daily dose of diltiazem CD 246 mg (60 patients) or placebo (58 patients) to achieve a trough diastolic blood pressure below 90 mm Hg. Measurements and Main Results. Diltiazem CD significantly reduced mean diastolic blood pressure compared with placebo, -8.2 versus -4.1 mm Hg, respectively (p=0.0025). Diastolic blood pressure below 90 mm Hg or a reduction of 10 mm Hg or more was achieved by 57% of diltiazem CD versus 28% of placebo recipients. Systolic blood pressure and heart rate were also reduced with diltiazem CD. Adverse events were mild, with similar frequency for diltiazem CD (15%) and placebo (19%). Conclusion. Diltiazem CD is safe and effective in hypertensive Mexican-Americans, and diastolic blood pressure reductions compare with those in non-Hispanic white patients. C1 NATL RES INST,LOS ANGELES,CA. SO CALIF RES INST,WHITTIER,CA. HLTH CARE PARTNERS MED GRP,LOS ANGELES,CA. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. HOECHST MARION ROUSSEL,US MED RES,KANSAS CITY,MO. RP Herrera, CR (reprint author), UNIV TEXAS,DEPT INTERNAL MED,64331 FANNIN ST,MSB 1-122,HOUSTON,TX 77030, USA. NR 13 TC 6 Z9 6 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER BOX 806 171 HARRISON AVE, BOSTON, MA 02111 SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD NOV-DEC PY 1997 VL 17 IS 6 BP 1254 EP 1259 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YG522 UT WOS:A1997YG52200011 PM 9399608 ER PT J AU Noel, PH Pugh, JA Larme, AC Marsh, G AF Noel, PH Pugh, JA Larme, AC Marsh, G TI The use of traditional plant medicines for non-insulin dependent diabetes mellitus in South Texas SO PHYTOTHERAPY RESEARCH LA English DT Article DE NIDDM; Opuntia streptacantha; Cnidoscolus chayamansa; Eriobotrya japonica; Aloe vera ID FOLK MEDICINE; OPUNTIA SP AB The use of traditional plant medicines, as well as the factors associated with their use, were documented in 662 outpatients with non-insulin dependent diabetes mellitus enrolled at six primary care clinics in South Texas. Forty-nine percent of the patients reported using alternative treatments for their diabetes, which included 61 different traditional plant medicines. The four most commonly reported were nopal (Opuntia streptacantha) or the prickly pear cactus, chaya (Cnidoscolus chayamansa), mispero (Eriobotrya japonica) or loquat, and savila (Aloe vera). Logistic regression was used to develop a multivariate model which indicated that alternative medicine use is positively associated with age and diabetes-related 'hassles', and was more likely among border residents and individuals who were born in Mexico. Disease severity was not associated with the use of alternative treatments when controlling for other variables. Users of alternative treatments also appeared just as likely to adhere to orthodox biomedical treatment recommendations as non-users. While preliminary reports ire the literature suggest that some of the identified plants have hypoglycaemic properties, information is limited or nonexistent for many of the other plants. Given their preponderance in this region, some of these plants should he targeted for further investigation to document their efficacy or to screen for toxicity. (C) 1997 John Wiley & Sons, Ltd. C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,ALMMVA,SAN ANTONIO,TX 78284. RP Noel, PH (reprint author), UNIV TEXAS,HLTH SCI CTR,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA. OI Pugh, Jacqueline/0000-0003-4933-141X NR 26 TC 22 Z9 25 U1 2 U2 12 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 0951-418X J9 PHYTOTHER RES JI Phytother. Res. PD NOV PY 1997 VL 11 IS 7 BP 512 EP 517 DI 10.1002/(SICI)1099-1573(199711)11:7<512::AID-PTR149>3.0.CO;2-H PG 6 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA YC979 UT WOS:A1997YC97900008 ER PT J AU Liberman, RP AF Liberman, RP TI Preventing aggression SO PSYCHIATRIC SERVICES LA English DT Letter C1 W LOS ANGELES VET AFFAIRS MED CTR,COMMUNITY & REHABILITAT PSYCHIAT SECT,LOS ANGELES,CA 90073. RP Liberman, RP (reprint author), UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024, USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 1075-2730 J9 PSYCHIATR SERV JI Psychiatr. Serv. PD NOV PY 1997 VL 48 IS 11 BP 1467 EP 1467 PG 1 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA YE213 UT WOS:A1997YE21300021 PM 9355178 ER PT J AU Rettig, MB Said, JW Berenson, JR AF Rettig, MB Said, JW Berenson, JR TI Multiple myeloma and Kaposi's sarcoma-associated herpesvirus - a paracrine model of tumorigenesis? Response SO TRENDS IN MICROBIOLOGY LA English DT Article ID DENDRITIC CELLS; INTERLEUKIN-6 RP Rettig, MB (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,DIV HEMATOL & ONCOL,11301 WILSHIRE BLVD,111-H,LOS ANGELES,CA 90073, USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0966-842X J9 TRENDS MICROBIOL JI Trends Microbiol. PD NOV PY 1997 VL 5 IS 11 BP 425 EP 426 DI 10.1016/S0966-842X(97)01148-7 PG 2 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA YF711 UT WOS:A1997YF71100003 ER PT J AU Optenberg, SA Clark, JY Brawer, MK Thompson, IM Stein, CR Friedrichs, P AF Optenberg, SA Clark, JY Brawer, MK Thompson, IM Stein, CR Friedrichs, P TI Development of a decision-making tool to predict risk of prostate cancer: The Cancer of the Prostate Risk Index (CAPRI) test SO UROLOGY LA English DT Article; Proceedings Paper CT 92nd Annual Meeting of the American-Urological-Association CY APR 12-17, 1997 CL NEW ORLEANS, LA SP Amer Urolog Assoc ID DIGITAL RECTAL EXAMINATION; REFERENCE RANGES; UNITED-STATES; ANTIGEN; MEN; CARCINOMA; DIAGNOSIS; BLACK; RACE; OLD AB Objectives. To provide a simple and reliable clinical prediction for an individual patient's overall risk of cancer at biopsy by deriving an easily implemented test based on a generalizable model. Four variables are analyzed for inclusion in the model: prostate-specific antigen (PSA) level, digital rectal examination (DRE) results, race, and age. Methods. Two populations were used to develop and validate the test: a model (n = 633) and an independent, geographically separate, external population (n = 766). Pathology records for patients who underwent prostate biopsy between 1991 and 1995 were reviewed and screened for the presence of PSA and DRE results. Records where age and race could be determined were extracted. Multiple logistic regression was used with an iterative approach to optimize each test factor. The Wald chi-square test, receiver operating characteristic (ROC) curve, and Hosmer-Lemingshaw test were used to evaluate the model's predictive capability in the two populations. Results. The model and external populations were significantly different for racial mix, PSA level, age, and biopsy detection rate, providing diverse populations to validate the test. Within a combined model, PSA, DRE, race, and age all demonstrated independent capability to predict cancer at biopsy. Predictive power of the overall test was high within the model population (ROC 80.8%), with minimal loss of power in the external population. The test demonstrated no significant lack of fit in either population. Conclusions. Within a combined test, PSA, DRE, race, and age all contribute significantly to prediction of prostate cancer at biopsy in an individual patient. The test depicts individual risk in an easily understood, visually provocative manner and should assist the clinician and patient in reaching a decision as to whether biopsy is appropriate. C1 WILFORD HALL USAF MED CTR,DEPT UROL,SAN ANTONIO,TX 78236. BROOKE ARMY MED CTR,DEPT SURG,FT SAM HOUSTON,TX 78234. VET AFFAIRS PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,DEPT UROL,SEATTLE,WA 98195. RP Optenberg, SA (reprint author), USA,MED DEPT CTR & SCH,CTR HEALTHCARE EDUC & STUDIES,1608 STANLEY RD,BLDG 2268,FT SAM HOUSTON,TX 78234, USA. OI Clark, Joseph/0000-0002-3817-4343 NR 22 TC 23 Z9 23 U1 0 U2 1 PU CAHNERS PUBL CO PI NEW YORK PA 249 WEST 17 STREET, NEW YORK, NY 10011 SN 0090-4295 J9 UROLOGY JI UROLOGY PD NOV PY 1997 VL 50 IS 5 BP 665 EP 672 DI 10.1016/S0090-4295(97)00451-2 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA YG346 UT WOS:A1997YG34600002 PM 9372872 ER PT J AU Moon, TD Hagen, L Heisey, DM AF Moon, TD Hagen, L Heisey, DM TI Urinary symptomatology in younger men SO UROLOGY LA English DT Article ID BENIGN PROSTATIC HYPERPLASIA; SYMPTOMS; AGE AB Objectives. We surveyed a ''population'' of younger men (20 to 49 years old) for lower urinary tract symptomatology and for symptomatology associated with prostatitis. Methods. A National Guard unit was surveyed by mail with a 58-question urinary symptom questionnaire. Surveys were returned anonymously by mail. Results. International Prostate Symptom Score (IPSS) of 8 or greater was seen in 5% of men in their 20s and rose to 15% of those in their 40s. Approximately 5% (0% to 7%) reported a history of prostatitis. Caffeine caused symptoms in 2% to 13%, while exercise and smoking were not associated with symptoms. Individual prostatitis symptoms were only seen occasionally across this age group. Conclusions. As measured by the IPSS, urinary symptoms increased during the 20 to 49-year age period. A history of prostatitis is much less common than most nonpopulation studies suggest. (C) 1997, Elsevier Science Inc. All rights reserved. C1 WILLIAM S MIDDLETON MEM VET ADM MED CTR,SURG SERV,MADISON,WI. RP Moon, TD (reprint author), UNIV WISCONSIN,DEPT SURG,DIV UROL,G5343 CSC,600 HIGHLAND AVE,MADISON,WI 53792, USA. NR 12 TC 48 Z9 49 U1 0 U2 0 PU CAHNERS PUBL CO PI NEW YORK PA 249 WEST 17 STREET, NEW YORK, NY 10011 SN 0090-4295 J9 UROLOGY JI UROLOGY PD NOV PY 1997 VL 50 IS 5 BP 700 EP 703 DI 10.1016/S0090-4295(97)00336-1 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA YG346 UT WOS:A1997YG34600010 PM 9372878 ER PT J AU Ghosh, PM Mott, GE GhoshChoudhury, N Radnik, RA Stapleton, ML Ghidoni, JJ Kreisberg, JI AF Ghosh, PM Mott, GE GhoshChoudhury, N Radnik, RA Stapleton, ML Ghidoni, JJ Kreisberg, JI TI Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH LA English DT Article DE mesangial cell; protein prenylation; RhoA; geranylgeraniol; farnesol; cytokinesis ID FOCAL ADHESION KINASE; GTP-BINDING PROTEINS; POSTTRANSLATIONAL MODIFICATIONS; TYROSINE PHOSPHORYLATION; COMPETITIVE INHIBITOR; STRESS FIBERS; RHO; GROWTH; REDUCTASE; GERANYLGERANYLATION AB Lovastatin, an inhibitor of protein prenylation, was reported to inhibit DNA synthesis and induce apoptosis in cultured cells. This report describes the morphological consequences of lovastatin treatment. Lovastatin (50 mu M) induced mesangial cell rounding and disassembly of actin stress fibers within 24 to 48 h. After 48 to 72 h of lovastatin treatment, the cells detached from the substratum and underwent apoptotic cell death as evidenced by condensed nuclear chromatin, nuclear fragmentation, cell blebbing and decrease in cell size. Time lapse cinematography revealed that lovastatin caused cell rounding by either inhibiting cytokinesis or cell spreading following cytokinesis. Lovastatin-induced cell rounding, detachment, and apoptosis were dependent upon cell proliferation. These effects were prevented by serum deprivation to inhibit cell proliferation or by plating cells at densities which resulted in contact inhibition of cell growth. Lovastatin-induced mesangial cell rounding and apoptosis were also prevented by the inclusion of the isoprenoids all-trans-farnesol or all-trans-geranylgeraniol in the incubation medium. These results indicate that the effects of lovastatin were mediated by inhibition of protein isoprenylation because exogenous all-trans-geranylgeraniol can be used only in protein prenylation. The small GTP-binding protein RhoA, which may be important for cell spreading and cytokinesis, accumulated in the cytosol following treatment with lovastatin, suggestive of its inactivation. This effect was also prevented by the inclusion of either farnesol or geranylgeraniol in the incubation medium. Thus, lovastatin-induced apoptosis in mesangial cells occurs by interfering with prenylation dependent mitotic and post-mitotic events. (C) 1997 Elsevier Science B.V. C1 UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284. S TEXAS VET HLTH CARE SYST,RES & DEV SERV,SAN ANTONIO,TX. NR 38 TC 58 Z9 63 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-4889 J9 BBA-MOL CELL RES JI Biochim. Biophys. Acta-Mol. Cell Res. PD OCT 30 PY 1997 VL 1359 IS 1 BP 13 EP 24 DI 10.1016/S0167-4889(97)00091-8 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA YG699 UT WOS:A1997YG69900002 PM 9398081 ER PT J AU Campbell, AJ Robertson, MC Gardner, MM Norton, RN Tilyard, MW Buchner, DM AF Campbell, AJ Robertson, MC Gardner, MM Norton, RN Tilyard, MW Buchner, DM TI Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women SO BRITISH MEDICAL JOURNAL LA English DT Article ID FICSIT TRIALS; OLDER ADULTS; RISK-FACTORS; TAI-CHI; COMMUNITY; BALANCE; INTERVENTION; STRENGTH AB Objective: To assess the effectiveness of a home exercise programme of strength and balance retraining exercises in reducing falls and injuries in elderly women. Design: Randomised controlled trial of an individually tailored programme of physical therapy in the home (exercise group, n=116) compared with the usual care and an equal number of social visits (control group, n=117). Setting 17 general practices in Dunedin, New Zealand. Subjects: Women aged 80 years and older living in the community and registered with a general practice in Dunedin. Main outcome measures: Number of falls and injuries related to falls and time between falls during one year of follow up; changes in muscle strength and balance measures after six months. Results: After one year there were 152 falls in the control group and 88 falls in the exercise group. The mean (SD) rate of falls was lower in the exercise than the control group (0.87 (1.29) v 1.34 (1.93) falls per year respectively; difference 0.47; 95% confidence interval 0.04 to 0.90). The relative hazard for the first four falls in the exercise group compared with the control group was 0.68 (0.52 to 0.90). The relative hazard for a first fall with injury in the exercise group compared with the control group was 0.61 (0.39 to 0.97). After six months, balance had improved in the exercise group (difference between groups in change in balance score 0.43 (0.21 to 0.65). Conclusions: An individual programme of strength and balance retraining exercises improved physical function and was effective in reducing falls and injuries in women 80 years and older. C1 UNIV AUCKLAND,SCH MED,INJURY PREVENT RES CTR,AUCKLAND,NEW ZEALAND. UNIV OTAGO SCH MED,DUNEDIN SCH MED,DEPT GEN PRACTICE,DUNEDIN,NEW ZEALAND. VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA 98108. RP Campbell, AJ (reprint author), UNIV OTAGO SCH MED,DUNEDIN SCH MED,DEPT MED,POB 913,DUNEDIN,NEW ZEALAND. RI Robertson, Mary Clare/A-3964-2009 NR 24 TC 517 Z9 537 U1 15 U2 54 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0959-8138 J9 BRIT MED J JI Br. Med. J. PD OCT 25 PY 1997 VL 315 IS 7115 BP 1065 EP 1069 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA YD445 UT WOS:A1997YD44500027 PM 9366737 ER PT J AU Belding, MA Iguchi, MY Morral, AR McLellan, AT AF Belding, MA Iguchi, MY Morral, AR McLellan, AT TI Assessing the helping alliance and its impact in the treatment of opiate dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE helping alliance; therapeutic alliance; heroin dependence; methadone maintenance; treatment ID THERAPEUTIC ALLIANCE; PSYCHOTHERAPY; DETOXIFICATION; DETERMINANTS; DEPRESSION; THERAPIST; COUNSELOR; PROGRAM; SUCCESS AB This study assesses the relationship between the patient-counselor helping alliance (HA) and progress in methadone maintenance treatment. Questionnaire measures of HA were administered to 57 patients 1 and 3 months after admission. Three-month HA measures (especially counselors' ratings) predicted reductions in drug use as measured by weekly urinalysis results and 6-month self-report data. HA was unrelated to treatment retention or improvement in psychiatric symptomatology. Moreover, controlling for urinalysis results in the previous month rendered insignificant the correlations between 3-month HA and subsequent drug use. Thus, this evaluation of the HA's unique contribution to the prediction of outcome suggests that the development of a positive HA may be more a marker of treatment progress than a necessary precursor of positive outcomes in the methadone maintenance treatment setting. (C) 1997 Elsevier Science Ireland Ltd. C1 ALLEGHENY UNIV HLTH SCI,MCP HAHNEMANN UNIV,SCH MED,DEPT PSYCHIAT,PHILADELPHIA,PA 19102. RP Belding, MA (reprint author), UNIV PENN,SCH MED,DEPT PSYCHIAT,CTR STUDIES ADDICT,PHILADELPHIA VET AFFAIRS MED CTR,BLDG 7,PHILADELPHIA,PA 19104, USA. RI Iguchi, Martin/A-7848-2009 FU NIDA NIH HHS [P50 DA07705, R01 DA06096] NR 21 TC 33 Z9 33 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 25 PY 1997 VL 48 IS 1 BP 51 EP 59 DI 10.1016/S0376-8716(97)00103-8 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA XY392 UT WOS:A1997XY39200007 PM 9330921 ER PT J AU Sager, PT AF Sager, PT TI Atrial fibrillation: Antiarrhythmic therapy versus rate control with antithrombotic therapy SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article; Proceedings Paper CT Symposium on Changing Trends in Antiarrhythmic Therapy - Worldwide Experience with Class III Agents CY NOV 10-10, 1996 CL NEW ORLEANS, LA SP UCLA Sch Med, Berlex Lab ID RADIOFREQUENCY CATHETER MODIFICATION; RAPID VENTRICULAR RESPONSE; RANDOMIZED CONTROL TRIALS; ADVANCED HEART-FAILURE; SINUS RHYTHM; DOUBLE-BLIND; SUPRAVENTRICULAR ARRHYTHMIAS; ELECTRICAL CARDIOVERSION; ATRIOVENTRICULAR NODE; MECHANICAL FUNCTION AB Atrial fibrillation is a major health problem in the United States, but the best strategies for treating it have not been rigorously determined in clinical studies. Specifically, there is a paucity of data comparing the approach of maintaining sinus rhythm using prophylactic antiarrhythmic drug therapy with the approach of controlling the ventricular response to atrial fibrillation while reducing embolic events with concomitant antithrombotic therapy. Until ongoing randomized trials are completed, which patients benefit most from a specific approach cannot be determined with certainty. In general, the most reasonable strategies include (1) the restoration of sinus rhythm (without prophylactic antiarrhythmic therapy) after the patient's first episode of atrial fibrillation; and (2) the maintenance of sinus rhythm (including the use of prophylactic antiarrhythmic therapy) in patients who remain symptomatic despite adequate rate control, and who are not at high risk for proarrhythmia and/or are unlikely to maintain sinus rhythm. The risks and benefits need to be carefully weighed in patients with truly asymptomatic atrial fibrillation. Many patients may require multiple attempts to maintain sinus rhythm. Current investigative treatment modalities (e.g., ablation techniques, atrial implantable cardioverter-defibrillators, new antiarrhythmic agents) are likely to alter the current approaches to atrial fibrillation. (C) 1997 by Excerpta Medica, Inc. C1 W LOS ANGELES VET AFFAIRS MED CTR, DEPT MED, LOS ANGELES, CA 90073 USA. UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA. RP Sager, PT (reprint author), W LOS ANGELES VET AFFAIRS MED CTR, DIV CARDIOL, WILSHIRE & SAWTELLE BLVD, LOS ANGELES, CA 90073 USA. NR 85 TC 4 Z9 5 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 23 PY 1997 VL 80 SI 8A BP G74 EP G81 DI 10.1016/S0002-9149(97)00716-9 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA YC886 UT WOS:A1997YC88600009 PM 9354414 ER PT J AU Singh, BN Breithardt, G AF Singh, BN Breithardt, G TI Changing trends in antiarrhythmic therapy: Worldwide experience with class III agents - Introduction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Editorial Material C1 W LOS ANGELES VET AFFAIRS MED CTR,DEPT MED,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024. RP Singh, BN (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,DIV CARDIOL 111E,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 23 PY 1997 VL 80 SI 8A BP G1 EP G3 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA YC886 UT WOS:A1997YC88600001 PM 9354406 ER PT J AU Singh, BN AF Singh, BN TI Controlling cardiac arrhythmias: An overview with a historical perspective SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article; Proceedings Paper CT Symposium on Changing Trends in Antiarrhythmic Therapy - Worldwide Experience with Class III Agents CY NOV 10, 1996 CL NEW ORLEANS, LA SP UCLA Sch Med, Berlex Lab ID CONGESTIVE-HEART-FAILURE; ACUTE MYOCARDIAL-INFARCTION; ANTIARRHYTHMIC DRUGS; VENTRICULAR TACHYARRHYTHMIAS; DOUBLE-BLIND; INTRAVENOUS AMIODARONE; SINUS RHYTHM; SUDDEN-DEATH; SOTALOL; ATRIAL AB During the past decade, several developments in our knowledge of antiarrhythmic drugs have had a major influence on our approach to their use. These developments may be summarized as follows: (1) it has become clear that arrhythmias merit treatment only for the relief of symptoms, with improved quality of life, and for prolongation of survival by reducing arrhythmic deaths; (2) suppression of arrhythmias-symptomatic or asymptomatic-may not necessarily decrease mortality, the net impact on mortality being agent-specific; (3) antiarrhythmic drugs have the propensity to decrease as well as to increase cardiac arrhythmias (producing proarrhythmias); (4) the most important determinant of arrhythmia mortality is the degree and nature of ventricular dysfunction; and (5) only controlled trials have the potential to establish the effect of treatment on mortality in patients with cardiac arrhythmias. To these considerations must be added the advances in nonpharmacologic approaches to controlling cardiac arrhythmias. These include catheter ablation of cardiac arrhythmias, certain surgical techniques that in selected patients offer prospects of cure, and the development of implantable ventricular and atrial cardioverter defibrillators, which allow rite evaluation of drugs versus placebo against the background of the defibrillator. This is particularly germane in the case of life-threatening symptomatic ventricular arrhythmias such as sustained ventricular tachycardia and ventricular fibrillation. Antiarrhythmic drugs and implantable devices in the control of arrhythmias cannot be considered in isolation. Their role in mortality reduction needs to be defined alone as well as in combination by controlled clinical trials. (C) 1997 by Excerpta Medica, Inc. C1 W LOS ANGELES VET AFFAIRS MED CTR,DEPT MED,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024. RP Singh, BN (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,DIV CARDIOL 111E,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA. NR 78 TC 11 Z9 11 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 23 PY 1997 VL 80 SI 8A BP G4 EP G15 DI 10.1016/S0002-9149(97)00709-1 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA YC886 UT WOS:A1997YC88600002 PM 9354407 ER PT J AU Larsen, GC McAnulty, JH Hallstrom, A Marchant, C Shein, M Akiyama, T Brodsky, M Baessler, C Pinski, SL Jennings, CA Morris, M AF Larsen, GC McAnulty, JH Hallstrom, A Marchant, C Shein, M Akiyama, T Brodsky, M Baessler, C Pinski, SL Jennings, CA Morris, M TI Hospitalization charges in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial: The AVID economic analysis study SO CIRCULATION LA English DT Meeting Abstract C1 PORTLAND VA MED CTR,PORTLAND,OR. OREGON HLTH SCI UNIV,PORTLAND,OR 97201. UNIV WASHINGTON,SEATTLE,WA 98195. US FDA,ROCKVILLE,MD 20857. UNIV ROCHESTER,ROCHESTER,NY. UNIV CALIF,ORANGE,CA. MED COLL PENN & HAHNEMANN UNIV,LIKOFF INST,PHILADELPHIA,PA. CLEVELAND CLIN FDN,CLEVELAND,OH 44195. NATL INST HLTH,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 424 EP 424 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88000423 ER PT J AU Wilkoff, BL Shih, HT Friedman, PL Page, RL Klein, RC Dalamagas, H Nora, M Larsen, GC Baessler, C Morris, M Jennings, C AF Wilkoff, BL Shih, HT Friedman, PL Page, RL Klein, RC Dalamagas, H Nora, M Larsen, GC Baessler, C Morris, M Jennings, C TI Multivariate predictors of hospital length of stay in patients with severe ventricular arrhythmias: Antiarrhythmics versus implantable defibrillators registry study SO CIRCULATION LA English DT Meeting Abstract C1 CLEVELAND CLIN FDN,CLEVELAND,OH 44195. UNIV TEXAS,HOUSTON,TX. HARVARD UNIV,BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. UNIV TEXAS,DALLAS,TX 75230. UNIV UTAH,SALT LAKE CITY,UT. ST FRANCIS HOSP & MED CTR,HARTFORD,OH. MIDWEST HEART SPECIALISTS,LOMBARD,IL. PORTLAND VA MED CTR,PORTLAND,OR. MED COLL PENN & HAHNEMANN UNIV,LIKOFF INST,PHILADELPHIA,PA. UNIV WASHINGTON,SEATTLE,WA 98195. NHLBI,WASHINGTON,DC. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 425 EP 425 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88000430 ER PT J AU Lehmann, KG Brown, BG Melkert, R AF Lehmann, KG Brown, BG Melkert, R TI Occult luminal narrowing in coronary artery disease: Severity, predictors, and impact on interventions SO CIRCULATION LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SEATTLE,WA 98195. CARDIALYSIS,ROTTERDAM,NETHERLANDS. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 429 EP 429 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88000428 ER PT J AU Wong, H Yang, D Nikazy, J Hill, JS Schotz, MC AF Wong, H Yang, D Nikazy, J Hill, JS Schotz, MC TI Lipoprotein lipase subunit orientation and domain interaction during lipolysis SO CIRCULATION LA English DT Meeting Abstract C1 W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 609 EP 609 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88000596 ER PT J AU Chlumsky, LJ KolibalPegher, SS Brady, CA Cohen, SA AF Chlumsky, LJ KolibalPegher, SS Brady, CA Cohen, SA TI Sodium channel subtype steady state mRNA levels may not predict functional protein expression SO CIRCULATION LA English DT Meeting Abstract C1 VET AFFAIRS MED CTR,PHILADELPHIA,PA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 675 EP 675 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88000662 ER PT J AU Halperin, BD Brodsky, MA Lancaster, S Raitt, M Kron, J Akiyama, T Englestein, ED Jodanath, R Mitchell, LB Daubert, JP AF Halperin, BD Brodsky, MA Lancaster, S Raitt, M Kron, J Akiyama, T Englestein, ED Jodanath, R Mitchell, LB Daubert, JP TI Prognostic value of baseline electrophysiology studies - The Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial SO CIRCULATION LA English DT Meeting Abstract C1 OREGON HLTH SCI UNIV,PORTLAND,OR 97201. UNIV CALIF,ORANGE,CA. AVID COORDINATING CTR,SEATTLE,WA. PORTLAND VA MED CTR,PORTLAND,OR. UNIV ROCHESTER,ROCHESTER,NY. KRANNERT INST,INDIANAPOLIS,IN. N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DIV BIOSTAT,MANHASSET,NY 11030. FOOTHILLS PROV GEN HOSP,CALGARY,AB T2N 2T9,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 1865 EP 1865 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88001856 ER PT J AU Gallik, DM Meissner, MD Communale, M Singer, I Hanin, L AF Gallik, DM Meissner, MD Communale, M Singer, I Hanin, L TI Favorable hemodynamic effects of Amio-Aqueous(R), a new formulation of intravenous amiodarone SO CIRCULATION LA English DT Meeting Abstract C1 W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. WAYNE STATE UNIV,HARPER HOSP,DETROIT,MI. BETH ISRAEL DEACONESS MED CTR,BOSTON,MA. UNIV LOUISVILLE HOSP,LOUISVILLE,KY. ACAD PHARMACEUT,CHICAGO,IL. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 2147 EP 2147 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88002138 ER PT J AU Koren, MJ Buda, C Henry, W Ellison, WT Milas, JM Morgan, M Sprinkle, L McGreevy, MJ Goldberg, RK Gerry, S Barrett, M Connolly, S Morrison, L Abrahamson, DC Somogyi, C Weiss, RJ Abisalih, DN Ridley, C Browne, KF McGowan, N Hariman, RJ Tully, M Bissett, J May, R Heywood, JT Fabbri, S Crawford, W Platt, M Bramlet, D Morgan, C Dillon, MC Roark, S Marquis, N Page, RL Canby, RC Horton, RP Ash, G Shettigar, UR Barbier, G Appunn, D Leonelli, F McFarland, T Rajkovich, K Pritchett, ELC Tormey, MA Walker, JL Carley, JE Tracy, DM Anderson, JL Karagounis, LA Summers, K Barker, AH Fowles, RE Preece, MJ Doran, EN Roy, D Talajic, M Dubuc, M Beaudoin, D Fujimura, O Aceron, D Onufer, J Barciano, R Cameron, D Weller, B Drehobl, M Brodkin, J Joswig, B Barker, M Schu, D Kremers, MS Whisnant, D Lurie, M Brinkley, A Pollak, SJ Nicholls, S Bloomfield, D DeStefano, M King, N Geris, B Green, M Tang, ASL Luce, M ElShahawy, M Wagner, M Rudge, J Steinberg, JS Tan, E Yee, R Klein, GJ Braney, M Backes, R Miller, K Branco, M Myers, D Suggs, T Shah, A Heus, B Trizzino, C Grossman, WJ Fletcher, K Loh, IK Smith, C DeGennaro, K Singer, I Cicic, A Langan, MN Gomes, JA Mehta, D Pe, E Sager, PT Ploss, D Attin, M Lueken, M Gray, RJ Chelliah, NN Hagen, K Carter, D Gray, C Curtis, AB Conti, JB Salvetti, L Sheldon, R Ritchie, D Ellenbogen, K Wood, MA Michaels, N Hall, JH Fausset, D Linden, P Schulman, C Gershengorn, K Saltz, S Kinsman, E Jacobson, K Littell, F Mossberg, J Dauw, K Karlsberg, RP Gerez, T Tobis, FM Rasmussen, E Carlson, M Walker, B Silverman, B Banasik, S Rubin, M Busch, J Hack, TC Criasia, M Florek, R Hamlin, M Friedman, J Dinning, A Misaljevic, Y Keller, M Trajillo, N Anderson, D Wagshal, A Rofino, K Motta, M Block, LS Wistran, DC Grogan, EW Sommerfeldt, B Rothrock, D Baron, S Stedfield, S Swenson, L Gilbert, B Bernstein, V Kerr, C MacDonald, K Mooney, S Bilsker, MS Kamerman, M Bradley, J Peacock, T Chen, PS Goodman, JS Peter, CT Schoenbaum, M Conte, S Curlee, P Booker, R DiCarlo, LA Kappler, JH Winston, SA Adolphson, M Henthorn, R Lipps, J Ibanez, K Johnson, WB Polich, M Martin, DT Woodhead, G Moore, SL Mishak, S Manholt, S Noll, HE Kelley, JG Perlman, R Guido, J Stambler, B Sargent, D Stein, J Willis, R Stoever, WW Cotham, P Mason, K Gaber, J Winters, SL Curwin, JH Banas, JS Enright, LJ Brodsky, M Chaim, S Carlson, H Furka, E Daubert, J Akiyama, T Flynn, D Ocampo, C Erdin, RA Heiges, TA Kadel, K Stucky, ED Rittenhouse, M McAnulty, J Timberg, J McNeer, JF Smith, B Murray, KT Norris, K Edgett, C Sorenson, JL Adelman, B Stoner, D Offenberg, H Arnow, L Thind, G Faughn, C Williams, D Hendricks, E Friedman, B Payne, W Fuenzalida, CE Washam, M Heinsimer, J Lentini, MG Weinberg, DM Fox, C McCown, R Cook, FS ODonoghue, S Fenton, J Chung, M Kidwell, GA Jaeger, FJ Holmes, DR Morant, VA Trohman, RG Wilkoff, BL Pinski, SL Tchou, PJ Holmes, D Kerin, NZ Faitel, K Stamato, NJ Whiting, D Bhalla, RK Hicks, T Bianchi, P Hamilton, W Chilson, D Baxter, J Contrafatto, DS Afshari, D Guarnieri, T Bolderman, K Margolis, PD Durham, J Martin, HM Wayand, CE McGrew, F Wilson, B Nademanee, K Smith, S Sharma, A ONeill, G Skadsen, A Ware, D Malmberg, G Wilson, M Bednarczyk, E Bateson, M Zinn, PD Robles, E Cullors, D Crossley, G DavisOBrien, K Frishman, WH Root, L Blanco, B Furia, S Goodman, L JonesLanier, S Kocheril, A Winecoff, A Packer, D Cosberg, K Barbey, JT HewettMeulman, J Wertheimer, J Fierstein, J Benene, C Hurwitz, J Alexander, L Wimberly, B Overweg, N Mejia, V Pacifico, A Farrell, M Steinman, R ValMejias, J Patterson, P Wilson, J Enright, L Dyckman, E Harris, B Raines, P Paul, T Blackman, T Porterfield, JG Porterfield, LM Roth, J Vagnoni, J AF Koren, MJ Buda, C Henry, W Ellison, WT Milas, JM Morgan, M Sprinkle, L McGreevy, MJ Goldberg, RK Gerry, S Barrett, M Connolly, S Morrison, L Abrahamson, DC Somogyi, C Weiss, RJ Abisalih, DN Ridley, C Browne, KF McGowan, N Hariman, RJ Tully, M Bissett, J May, R Heywood, JT Fabbri, S Crawford, W Platt, M Bramlet, D Morgan, C Dillon, MC Roark, S Marquis, N Page, RL Canby, RC Horton, RP Ash, G Shettigar, UR Barbier, G Appunn, D Leonelli, F McFarland, T Rajkovich, K Pritchett, ELC Tormey, MA Walker, JL Carley, JE Tracy, DM Anderson, JL Karagounis, LA Summers, K Barker, AH Fowles, RE Preece, MJ Doran, EN Roy, D Talajic, M Dubuc, M Beaudoin, D Fujimura, O Aceron, D Onufer, J Barciano, R Cameron, D Weller, B Drehobl, M Brodkin, J Joswig, B Barker, M Schu, D Kremers, MS Whisnant, D Lurie, M Brinkley, A Pollak, SJ Nicholls, S Bloomfield, D DeStefano, M King, N Geris, B Green, M Tang, ASL Luce, M ElShahawy, M Wagner, M Rudge, J Steinberg, JS Tan, E Yee, R Klein, GJ Braney, M Backes, R Miller, K Branco, M Myers, D Suggs, T Shah, A Heus, B Trizzino, C Grossman, WJ Fletcher, K Loh, IK Smith, C DeGennaro, K Singer, I Cicic, A Langan, MN Gomes, JA Mehta, D Pe, E Sager, PT Ploss, D Attin, M Lueken, M Gray, RJ Chelliah, NN Hagen, K Carter, D Gray, C Curtis, AB Conti, JB Salvetti, L Sheldon, R Ritchie, D Ellenbogen, K Wood, MA Michaels, N Hall, JH Fausset, D Linden, P Schulman, C Gershengorn, K Saltz, S Kinsman, E Jacobson, K Littell, F Mossberg, J Dauw, K Karlsberg, RP Gerez, T Tobis, FM Rasmussen, E Carlson, M Walker, B Silverman, B Banasik, S Rubin, M Busch, J Hack, TC Criasia, M Florek, R Hamlin, M Friedman, J Dinning, A Misaljevic, Y Keller, M Trajillo, N Anderson, D Wagshal, A Rofino, K Motta, M Block, LS Wistran, DC Grogan, EW Sommerfeldt, B Rothrock, D Baron, S Stedfield, S Swenson, L Gilbert, B Bernstein, V Kerr, C MacDonald, K Mooney, S Bilsker, MS Kamerman, M Bradley, J Peacock, T Chen, PS Goodman, JS Peter, CT Schoenbaum, M Conte, S Curlee, P Booker, R DiCarlo, LA Kappler, JH Winston, SA Adolphson, M Henthorn, R Lipps, J Ibanez, K Johnson, WB Polich, M Martin, DT Woodhead, G Moore, SL Mishak, S Manholt, S Noll, HE Kelley, JG Perlman, R Guido, J Stambler, B Sargent, D Stein, J Willis, R Stoever, WW Cotham, P Mason, K Gaber, J Winters, SL Curwin, JH Banas, JS Enright, LJ Brodsky, M Chaim, S Carlson, H Furka, E Daubert, J Akiyama, T Flynn, D Ocampo, C Erdin, RA Heiges, TA Kadel, K Stucky, ED Rittenhouse, M McAnulty, J Timberg, J McNeer, JF Smith, B Murray, KT Norris, K Edgett, C Sorenson, JL Adelman, B Stoner, D Offenberg, H Arnow, L Thind, G Faughn, C Williams, D Hendricks, E Friedman, B Payne, W Fuenzalida, CE Washam, M Heinsimer, J Lentini, MG Weinberg, DM Fox, C McCown, R Cook, FS ODonoghue, S Fenton, J Chung, M Kidwell, GA Jaeger, FJ Holmes, DR Morant, VA Trohman, RG Wilkoff, BL Pinski, SL Tchou, PJ Holmes, D Kerin, NZ Faitel, K Stamato, NJ Whiting, D Bhalla, RK Hicks, T Bianchi, P Hamilton, W Chilson, D Baxter, J Contrafatto, DS Afshari, D Guarnieri, T Bolderman, K Margolis, PD Durham, J Martin, HM Wayand, CE McGrew, F Wilson, B Nademanee, K Smith, S Sharma, A ONeill, G Skadsen, A Ware, D Malmberg, G Wilson, M Bednarczyk, E Bateson, M Zinn, PD Robles, E Cullors, D Crossley, G DavisOBrien, K Frishman, WH Root, L Blanco, B Furia, S Goodman, L JonesLanier, S Kocheril, A Winecoff, A Packer, D Cosberg, K Barbey, JT HewettMeulman, J Wertheimer, J Fierstein, J Benene, C Hurwitz, J Alexander, L Wimberly, B Overweg, N Mejia, V Pacifico, A Farrell, M Steinman, R ValMejias, J Patterson, P Wilson, J Enright, L Dyckman, E Harris, B Raines, P Paul, T Blackman, T Porterfield, JG Porterfield, LM Roth, J Vagnoni, J TI Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide SO CIRCULATION LA English DT Article DE antiarrhythmia agents; arrhythmia; fibrillation; tachycardia ID ANTIARRHYTHMIC AGENT; FLECAINIDE; SC-40230; THERAPY; PLACEBO AB Background Atrial fibrillation and paroxysmal supraventricular tachycardia are common disorders of the heart rhythm for which antiarrhythmic drug therapy is commonly prescribed. The Atrial Fibrillation Investigation with Bidisomide (AFIB) study was a randomized, placebo-controlled clinical trial designed to accomplish three goals in a single protocol: (1) to determine the efficacy of the antiarrhythmic drug bidisomide in the treatment of these two arrhythmias; (2) to establish the appropriate dose range for bidisomide; and (3) to detect an adverse mortality effect of bidisomide if one were present in patients with atrial fibrillation. Methods and Results In this clinical trial, 1227 patients with atrial fibrillation and 187 with paroxysmal supraventricular tachycardia were randomly assigned to bidisomide (200, 400, or 600 mg BID) or placebo; patient groups with each arrhythmia were analyzed separately. Symptomatic recurrences of atrial fibrillation and paroxysmal supraventricular tachycardia were documented with the use of transtelephonic ECG monitoring. The time to the first symptomatic arrhythmia recurrence was measured in each patient and compared among treatment groups. Among the atrial fibrillation patients, there was no significant difference in the time to first symptomatic recurrence between the placebo group and any of the three bidisomide treatment groups; the hazard ratios (placebo:treatment) were 1.19, 1.03, and 1.14 for bidisomide 200, 400, and 600 mg BID, respectively. Among paroxysmal supraventricular tachycardia patients, there was a similar lack of a significant treatment effect; the hazard ratios were 1.30, 1.93, and 1.59 for bidisomide 200, 400, and 600 mg BID, respectively. In the primary safety analysis of mortality, 3 of 493 patients taking placebo died, compared with 9 of 488 patients taking one of the two higher doses of bidisomide (P>.10). Conclusions Bidisomide in the doses tested did not have a clinically important antiarrhythmic effect. The AFIB study provided a novel clinical trial design to test antiarrhythmic drugs for both safety and efficacy. C1 DUKE UNIV,MED CTR,DUKE S HOSP,DURHAM,NC 27710. JACKSONVILLE CARDIOVASC CLIN,JACKSONVILLE,FL. UPSTATE CLIN RES INC,GREER,SC. CARDIOL MED GRP SAN DIEGO,LA MESA,CA. MCMASTER UNIV,HAMILTON,ON,CANADA. ORANGE CTY HEART INST,ORANGE,CA. ANDROSCOGGIN CARDIOL ASSOCIATES,AUBURN,ME. WATSON CLIN,LAKELAND,FL. EDWARD HINES JR VET ADM HOSP,HINES,IL 60141. UNIV ARKANSAS MED SCI,LITTLE ROCK,AR 72205. LOMA LINDA UNIV,JERRY L PETTIS MEM VET HOSP,LOMA LINDA,CA 92357. MONTGOMERY CARDIOVASC ASSOCIATES PA,MONTGOMERY,AL. CARDIOL CONSULTANTS RES,ST PETERSBURG,FL. CARDIOL ASSOCIATES GAINESVILLE,GAINESVILLE,FL. UNIV TEXAS,SW MED CTR,DALLAS,TX. VET ADM MED CTR,BAY PINES,FL. UNIV KENTUCKY,MED CTR,LEXINGTON,KY. UNIV UTAH,LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143. SALT LAKE CLIN RES FDN,SALT LAKE CITY,UT. MONTREAL HEART INST,MONTREAL,PQ H1T 1C8,CANADA. UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103. CARDIOVASC ASSOCIATES LTD,NORFOLK,VA. TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA. CTR HLTH CARE,SAN DIEGO,CA. PRESBYTERIAN HOSP HEART CTR,CHARLOTTE,NC. CENT FLORIDA CARDIOL GRP PA,ORLANDO,FL. ST VINCENTS MED CTR,STATEN ISL,NY. OTTAWA CIVIC HOSP,OTTAWA,ON K1Y 4E9,CANADA. ST LUKES ROOSEVELT HOSP,NEW YORK,NY. UNIV WESTERN ONTARIO,UNIV HOSP,LONDON,ON N6A 5A5,CANADA. N CENT HEART INST,SIOUX FALLS,SD. W FLORIDA MED CTR CLIN PA,PENSACOLA,FL. HCA LOS ROBLES MED CTR,VENTURA HEART INST,THOUSAND OAKS,CA. UNIV LOUISVILLE,LOUISVILLE,KY 40292. MT SINAI MED CTR,NEW YORK,NY 10029. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. UNIV N DAKOTA,UNITED HOSP,GRAND FORKS,ND 58201. UNIV FLORIDA,GAINESVILLE,FL. CALGARY GEN HOSP,CALGARY,AB,CANADA. VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298. MED RES CONSORTIUM,INDIANAPOLIS,IN. CARDIOL ASSOCIATES GREATER BOSTON,BROOKLINE,MA. OREGON RES GRP,EUGENE,OR. CARDIOVASC RES INST SO CALIF,BEVERLY HILLS,CA. CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,CLEVELAND,OH 44106. NORTHSIDE HOSP,ATLANTA,GA. LEE COAST RES CTR INC,FT MYERS,FL. GOOD SAMARITAN HOSP,PORTLAND,OR 97209. HEALTHCARE PARTNERS,LOS ANGELES,CA. VET ADM MED CTR,DENVER,CO 80220. UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA. CARDIOL PHYSICIANS INC,SALEM,MA. JACKSON FDN MED RES,MADISON,WI. ST PAUL RAMSEY MED CTR,ST PAUL,MN 55101. UNIV BRITISH COLUMBIA HOSP,VANCOUVER,BC,CANADA. UNIV MIAMI,CORAL GABLES,FL 33124. DOCTORS CLIN,VERO BEACH,FL. CEDARS SINAI MED CTR,LOS ANGELES,CA 90048. UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA. ST MARYS HOSP,GRAND JCT,CO. MICHIGAN HEART & VASC INST,YPSILANTI,MI. CHRIST HOSP,CARDIOVASC RES CTR,CINCINNATI,OH 45219. IOWA HEART CTR,DES MOINES,IA. LAHEY CLIN FDN,BURLINGTON,MA. N OHIO HEART CTR,ELYRIA,OH. SHARP REES STEALY MED CTR,SAN DIEGO,CA. PARTNERS MED RES,BALTIMORE,MD. MCGUIRE DEPT VET AFFAIRS MED CTR,RICHMOND,VA. MERCY HOSP,MED CTR,SAN DIEGO,CA. HEALTHCARE RES CONSULTANTS,TULSA,OK. MORRISTOWN MEM HOSP,MORRISTOWN,NJ 07962. UNIV CALIF IRVINE,IRVINE MED CTR,ORANGE,CA 92668. UNIV ROCHESTER,MED CTR,ROCHESTER,NY 14627. NORTHSIDE CARDIOL,SPOKANE,WA. OREGON HLTH SCI UNIV,PORTLAND,OR 97201. VANDERBILT UNIV,MED CTR,NASHVILLE,TN. SW MED GRP,LAS VEGAS,NV. HALIFAX CLIN RES CTR,DAYTONA BEACH,FL. UNIV LOUISVILLE,HLTH SCI CTR,LOUISVILLE,KY 40292. ATLANTIC INST CLIN RES,DAYTONA BEACH,FL. VET ADM MED CTR,MED RES SERV,KANSAS CITY,MO. WESTERN HEART SPECIALISTS PC,DENVER,CO. ST JOSEPH MERCY HOSP OAKLAND,PONTIAC,MI. CARDIOL ASSOCIATES MED GRP,ANAHEIM,CA. WASHINGTON HOSP CTR,WASHINGTON,DC 20010. CLEVELAND CLIN FDN,CLEVELAND,OH 44195. SINAI HOSP,DETROIT,MI 48235. INLAND CARDIOL ASSOCIATES PS,SPOKANE,WA. ST FRANCIS REG MED CTR,PITTSBURGH,PA. MIDATLANTIC CARDIOVASC CONSULTANTS PA,BALTIMORE,MD. OKLAHOMA HEART INC,TULSA,OK. TAMPA MED RES ASSOCIATES INC,TAMPA,FL. CARDIOL GRP MEMPHIS PA,MEMPHIS,TN. DENVER GEN HOSP,DENVER,CO. UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550. MILLARD FILLMORE HOSP,BUFFALO,NY 14209. CARDIOL CLIN SAN ANTONIO PA,SAN ANTONIO,TX. WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC. MONTEFIORE HOSP & MED CTR,ALBERT EINSTEIN COLL MED HOSP,BRONX,NY 10461. MEM MED CTR INC,SAVANNAH,GA. MED COLL GEORGIA,AUGUSTA,GA 30912. MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905. GEORGETOWN UNIV,WASHINGTON,DC. ALBERT EINSTEIN MED CTR,PHILADELPHIA,PA 19141. PRESBYTERIAN HEART INST,DALLAS,TX. EASTSIDE COMPREHENS MED SERV,NEW YORK,NY. TEXAS ARRHYTHMIA INST,HOUSTON,TX. ST JOHNS HOSP,DETROIT,MI. GALICHIA MED CTR,WICHITA,KS. GOOD SAMARITAN HOSP,CINCINNATI,OH. SE CLIN RESOURCES,ATLANTA,GA. CARDIOL ASSOCIATES LEXINGTON,LEXINGTON,KY. FUTURE HEALTHCARE,BIRMINGHAM,AL. ARRHYTHMIA CONSULTANTS,MEMPHIS,TN. MED COLL WISCONSIN,MILWAUKEE,WI 53226. RI Page, Richard/L-5501-2014 OI Page, Richard/0000-0001-5603-1330 NR 18 TC 17 Z9 17 U1 2 U2 12 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 BP 2625 EP 2632 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC671 UT WOS:A1997YC67100027 ER PT J AU Ritchie, JL Maynard, C Every, NR Chapko, MK Martin, DC AF Ritchie, JL Maynard, C Every, NR Chapko, MK Martin, DC TI Coronary angioplasty volumes and outcomes in the healthcare cost and utilization project SO CIRCULATION LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SEATTLE,WA 98195. SEATTLE VA,SEATTLE,WA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 2831 EP 2831 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88002813 ER PT J AU Lehmann, KG HeathLange, SJ Ferris, ST AF Lehmann, KG HeathLange, SJ Ferris, ST TI Randomized comparison of hemostasis techniques following invasive cardiovascular procedures SO CIRCULATION LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 2959 EP 2959 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88002941 ER PT J AU Rithcie, JL Maynard, C Every, NR Chapko, MK Martin, DC AF Rithcie, JL Maynard, C Every, NR Chapko, MK Martin, DC TI Coronary angioplasty volumes and outcomes in the health can cost and utilization project SO CIRCULATION LA English DT Meeting Abstract C1 VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA. UNIV WASHINGTON,SEATTLE,WA 98195. SEATTLE VA,SEATTLE,WA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 21 PY 1997 VL 96 IS 8 SU S BP 3145 EP 3145 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA YC880 UT WOS:A1997YC88003126 ER EF